-DOCSTART- -X- -X- O
   
Daidzein NN NN O
and NN NN O
genistein NN NN O
glucuronides NN NN O
in NN NN O
vitro NN NN O
are NN NN O
weakly NN NN O
estrogenic NN NN O
and NN NN O
activate NN NN O
human NN NN O
natural NN NN O
killer NN NN O
cells NN NN O
at NN NN O
nutritionally NN NN O
relevant NN NN O
concentrations NN NN O
. NN NN O
   
Daidzein NN NN O
and NN NN O
genistein NN NN O
glucuronides NN NN O
( NN NN O
DG NN NN O
and NN NN O
GG NN NN O
) NN NN O
, NN NN O
major NN NN O
isoflavone NN NN O
metabolites NN NN O
, NN NN O
may NN NN O
be NN NN O
partly NN NN O
responsible NN NN O
for NN NN O
biological NN NN O
effects NN NN O
of NN NN O
isoflavones NN NN O
, NN NN O
such NN NN O
as NN NN O
estrogen NN NN B-Protein
receptor NN NN I-Protein
binding NN NN O
and NN NN O
natural NN NN O
killer NN NN O
cell NN NN O
( NN NN O
NK NN NN O
) NN NN O
activation NN NN O
or NN NN O
inhibition NN NN O
. NN NN O
   
DG NN NN O
and NN NN O
GG NN NN O
were NN NN O
synthesized NN NN O
using NN NN O
3 NN NN O
- NN NN O
methylcholanthrene NN NN O
- NN NN O
induced NN NN O
rat NN NN O
liver NN NN O
microsomes NN NN O
. NN NN O
   
The NN NN O
Km NN NN O
and NN NN O
Vmax NN NN O
for NN NN O
daidzein NN NN O
and NN NN O
genistein NN NN O
were NN NN O
9 NN NN O
. NN NN O
0 NN NN O
and NN NN O
7 NN NN O
. NN NN O
7 NN NN O
micromol NN NN O
/ NN NN O
L NN NN O
, NN NN O
and NN NN O
0 NN NN O
. NN NN O
7 NN NN O
and NN NN O
1 NN NN O
. NN NN O
6 NN NN O
micromol NN NN O
/ NN NN O
( NN NN O
mg NN NN O
protein NN NN O
. NN NN O
min NN NN O
) NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
The NN NN O
absence NN NN O
of NN NN O
ultraviolet NN NN O
absorbance NN NN O
maxima NN NN O
shifts NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
sodium NN NN O
acetate NN NN O
confirmed NN NN O
that NN NN O
the NN NN O
synthesized NN NN O
products NN NN O
were NN NN O
7 NN NN O
- NN NN O
O NN NN O
- NN NN O
glucuronides NN NN O
. NN NN O
   
DG NN NN O
and NN NN O
GG NN NN O
were NN NN O
further NN NN O
purified NN NN O
by NN NN O
a NN NN O
Sephadex NN NN O
LH NN NN O
- NN NN O
20 NN NN O
column NN NN O
. NN NN O
   
DG NN NN O
and NN NN O
GG NN NN O
competed NN NN O
with NN NN O
the NN NN O
binding NN NN O
of NN NN O
17beta NN NN O
- NN NN O
( NN NN O
3H NN NN O
) NN NN O
estradiol NN NN O
to NN NN O
estrogen NN NN B-Protein
receptors NN NN I-Protein
of NN NN O
B6D2F1 NN NN O
mouse NN NN O
uterine NN NN O
cytosol NN NN O
. NN NN O
   
The NN NN O
concentrations NN NN O
required NN NN O
for NN NN O
50 NN NN O
% NN NN O
displacement NN NN O
of NN NN O
17beta NN NN O
- NN NN O
( NN NN O
3H NN NN O
) NN NN O
estradiol NN NN O
( NN NN O
CB50 NN NN O
) NN NN O
were NN NN O
: NN NN O
17beta NN NN O
- NN NN O
estradiol NN NN O
, NN NN O
1 NN NN O
. NN NN O
34 NN NN O
nmol NN NN O
/ NN NN O
L NN NN O
; NN NN O
diethylstilbestrol NN NN O
, NN NN O
1 NN NN O
. NN NN O
46 NN NN O
nmol NN NN O
/ NN NN O
L NN NN O
; NN NN O
daidzein NN NN O
, NN NN O
1 NN NN O
. NN NN O
6 NN NN O
micromol NN NN O
/ NN NN O
L NN NN O
; NN NN O
DG NN NN O
, NN NN O
14 NN NN O
. NN NN O
7 NN NN O
micromol NN NN O
/ NN NN O
L NN NN O
; NN NN O
genistein NN NN O
, NN NN O
0 NN NN O
. NN NN O
154 NN NN O
micromol NN NN O
/ NN NN O
L NN NN O
; NN NN O
GG NN NN O
, NN NN O
7 NN NN O
. NN NN O
27 NN NN O
micromol NN NN O
/ NN NN O
L NN NN O
. NN NN O
   
In NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
NK NN NN O
cells NN NN O
, NN NN O
genistein NN NN O
at NN NN O
< NN NN O
0 NN NN O
. NN NN O
5 NN NN O
micromol NN NN O
/ NN NN O
L NN NN O
and NN NN O
DG NN NN O
and NN NN O
GG NN NN O
at NN NN O
0 NN NN O
. NN NN O
1 NN NN O
- NN NN O
10 NN NN O
micromol NN NN O
/ NN NN O
L NN NN O
enhanced NN NN O
NK NN NN O
cell NN NN O
- NN NN O
mediated NN NN O
K562 NN NN O
cancer NN NN O
cell NN NN O
killing NN NN O
significantly NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
At NN NN O
> NN NN O
0 NN NN O
. NN NN O
5 NN NN O
micromol NN NN O
/ NN NN O
L NN NN O
, NN NN O
genistein NN NN O
inhibited NN NN O
NK NN NN O
cytotoxicity NN NN O
significantly NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
glucuronides NN NN O
only NN NN O
inhibited NN NN O
NK NN NN O
cytotoxicity NN NN O
at NN NN O
50 NN NN O
micromol NN NN O
/ NN NN O
L NN NN O
. NN NN O
   
Isoflavones NN NN O
, NN NN O
and NN NN O
especially NN NN O
the NN NN O
isoflavone NN NN O
glucuronides NN NN O
, NN NN O
enhanced NN NN O
activation NN NN O
of NN NN O
NK NN NN O
cells NN NN O
by NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
, NN NN O
additively NN NN O
. NN NN O
   
At NN NN O
physiological NN NN O
concentrations NN NN O
, NN NN O
DG NN NN O
and NN NN O
GG NN NN O
were NN NN O
weakly NN NN O
estrogenic NN NN O
, NN NN O
and NN NN O
they NN NN O
activated NN NN O
human NN NN O
NK NN NN O
cells NN NN O
in NN NN O
nutritionally NN NN O
relevant NN NN O
concentrations NN NN O
in NN NN O
vitro NN NN O
, NN NN O
probably NN NN O
at NN NN O
a NN NN O
site NN NN O
different NN NN O
from NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
action NN NN O
. NN NN O
   
Osteoclast NN NN O
markers NN NN O
accumulate NN NN O
on NN NN O
cells NN NN O
developing NN NN O
from NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
precursors NN NN O
. NN NN O
   
Recent NN NN O
studies NN NN O
show NN NN O
that NN NN O
human NN NN O
osteoclasts NN NN O
develop NN NN O
in NN NN O
vitro NN NN O
from NN NN O
hematopoietic NN NN O
cells NN NN O
; NN NN O
however NN NN O
, NN NN O
special NN NN O
cultures NN NN O
conditions NN NN O
and NN NN O
/ NN NN O
or NN NN O
cytokine NN NN O
mobilized NN NN O
peripheral NN NN O
blood NN NN O
are NN NN O
apparently NN NN O
required NN NN O
. NN NN O
   
Here NN NN O
, NN NN O
we NN NN O
report NN NN O
that NN NN O
cells NN NN O
expressing NN NN O
osteoclast NN NN O
markers NN NN O
differentiate NN NN O
from NN NN O
precursors NN NN O
present NN NN O
in NN NN O
nonmobilized NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
( NN NN O
PBMC NN NN O
) NN NN O
, NN NN O
without NN NN O
the NN NN O
addition NN NN O
of NN NN O
stromal NN NN O
cells NN NN O
, NN NN O
growth NN NN O
factors NN NN O
, NN NN O
cytokines NN NN O
or NN NN O
steroids NN NN O
; NN NN O
and NN NN O
characterize NN NN O
their NN NN O
phenotype NN NN O
. NN NN O
   
Three NN NN O
days NN NN O
after NN NN O
establishing NN NN O
high NN NN O
- NN NN O
density NN NN O
PBMC NN NN O
cultures NN NN O
( NN NN O
1 NN NN O
. NN NN O
5 NN NN O
x NN NN O
10 NN NN O
( NN NN O
6 NN NN O
) NN NN O
cells NN NN O
/ NN NN O
cm2 NN NN O
) NN NN O
, NN NN O
in NN NN O
serum NN NN O
- NN NN O
containing NN NN O
medium NN NN O
, NN NN O
small NN NN O
adherent NN NN O
colonies NN NN O
of NN NN O
tartrate NN NN O
resistant NN NN O
acid NN NN O
phosphatase NN NN O
positive NN NN O
( NN NN O
TRAP NN NN B-Protein
+ NN NN O
) NN NN O
cells NN NN O
emerge NN NN O
, NN NN O
amidst NN NN O
massive NN NN O
monocyte NN NN O
cell NN NN O
death NN NN O
. NN NN O
   
These NN NN O
adherent NN NN O
cells NN NN O
have NN NN O
an NN NN O
eccentrically NN NN O
placed NN NN O
, NN NN O
round NN NN O
nucleus NN NN O
, NN NN O
and NN NN O
express NN NN O
low NN NN O
levels NN NN O
of NN NN O
TRAP NN NN B-Protein
and NN NN O
sodium NN NN O
fluoride NN NN O
- NN NN O
resistant NN NN O
- NN NN O
alpha NN NN O
- NN NN O
naphthyl NN NN O
- NN NN O
acetate NN NN O
- NN NN O
esterase NN NN O
( NN NN O
NaF NN NN O
- NN NN O
R NN NN O
- NN NN O
NSE NN NN O
) NN NN O
. NN NN O
   
Over NN NN O
the NN NN O
next NN NN O
week NN NN O
, NN NN O
this NN NN O
cell NN NN O
population NN NN O
accumulates NN NN O
phenotypic NN NN O
markers NN NN O
of NN NN O
osteoclasts NN NN O
( NN NN O
vitronectin NN NN O
receptor NN NN O
[ NN NN O
VR NN NN O
] NN NN O
, NN NN O
calcitonin NN NN O
receptor NN NN O
, NN NN O
TRAP NN NN B-Protein
, NN NN O
cathepsin NN NN B-Protein
K NN NN I-Protein
protein NN NN O
, NN NN O
and NN NN O
mRNA NN NN O
) NN NN O
with NN NN O
increased NN NN O
nuclearity NN NN O
, NN NN O
covering NN NN O
the NN NN O
entire NN NN O
surface NN NN O
by NN NN O
15 NN NN O
days NN NN O
. NN NN O
   
When NN NN O
cultured NN NN O
on NN NN O
bone NN NN O
, NN NN O
VR NN NN O
+ NN NN O
, NN NN O
TRAP NN NN B-Protein
+ NN NN O
cells NN NN O
of NN NN O
low NN NN O
multinuclearity NN NN O
appear NN NN O
and NN NN O
cover NN NN O
up NN NN O
to NN NN O
50 NN NN O
% NN NN O
of NN NN O
the NN NN O
surface NN NN O
. NN NN O
   
Resorption NN NN O
lacunae NN NN O
can NN NN O
be NN NN O
observed NN NN O
by NN NN O
day NN NN O
22 NN NN O
. NN NN O
   
Although NN NN O
these NN NN O
pits NN NN O
are NN NN O
not NN NN O
nearly NN NN O
as NN NN O
numerous NN NN O
as NN NN O
the NN NN O
cells NN NN O
of NN NN O
preosteoclast NN NN O
phenotype NN NN O
, NN NN O
they NN NN O
do NN NN O
represent NN NN O
the NN NN O
activity NN NN O
of NN NN O
a NN NN O
subset NN NN O
of NN NN O
osteoclast NN NN O
- NN NN O
like NN NN O
cells NN NN O
that NN NN O
has NN NN O
achieved NN NN O
osteoclastic NN NN O
maturity NN NN O
under NN NN O
these NN NN O
culture NN NN O
conditions NN NN O
. NN NN O
   
Transcripts NN NN O
for NN NN O
osteoprotegerin NN NN B-Protein
ligand NN NN I-Protein
( NN NN O
OPGL NN NN B-Protein
) NN NN O
, NN NN O
an NN NN O
osteoclast NN NN O
differentiation NN NN O
factor NN NN O
( NN NN O
also NN NN O
known NN NN O
as NN NN O
RANKL NN NN B-Protein
and NN NN O
TRANCE NN NN B-Protein
) NN NN O
are NN NN O
expressed NN NN O
, NN NN O
likely NN NN O
by NN NN O
adherent NN NN O
cells NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
an NN NN O
adherent NN NN O
population NN NN O
of NN NN O
cells NN NN O
, NN NN O
with NN NN O
preosteoclast NN NN O
/ NN NN O
osteoclast NN NN O
phenotypic NN NN O
properties NN NN O
, NN NN O
arises NN NN O
selectively NN NN O
under NN NN O
simple NN NN O
culture NN NN O
conditions NN NN O
from NN NN O
normal NN NN O
PBMC NN NN O
. NN NN O
   
Further NN NN O
characterization NN NN O
of NN NN O
these NN NN O
cells NN NN O
should NN NN O
identify NN NN O
factors NN NN O
involved NN NN O
in NN NN O
the NN NN O
growth NN NN O
, NN NN O
terminal NN NN O
differentiation NN NN O
and NN NN O
activation NN NN O
of NN NN O
osteoclasts NN NN O
. NN NN O
   
Phenotypic NN NN O
and NN NN O
functional NN NN O
studies NN NN O
of NN NN O
leukocytes NN NN O
in NN NN O
human NN NN O
endometrium NN NN O
and NN NN O
endometriosis NN NN O
. NN NN O
   
The NN NN O
aetiology NN NN O
of NN NN O
endometriosis NN NN O
, NN NN O
a NN NN O
common NN NN O
and NN NN O
disabling NN NN O
disorder NN NN O
, NN NN O
is NN NN O
presently NN NN O
unknown NN NN O
, NN NN O
although NN NN O
immune NN NN O
dysfunction NN NN O
could NN NN O
allow NN NN O
ectopic NN NN O
endometrial NN NN O
fragments NN NN O
to NN NN O
survive NN NN O
outside NN NN O
the NN NN O
uterine NN NN O
cavity NN NN O
. NN NN O
   
These NN NN O
studies NN NN O
investigate NN NN O
the NN NN O
relationship NN NN O
between NN NN O
leukocyte NN NN O
populations NN NN O
, NN NN O
steroid NN NN O
hormone NN NN O
receptor NN NN O
expression NN NN O
, NN NN O
proliferative NN NN O
activity NN NN O
, NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
and NN NN O
apoptosis NN NN O
in NN NN O
eutopic NN NN O
and NN NN O
ectopic NN NN O
endometrium NN NN O
from NN NN O
women NN NN O
with NN NN O
endometriosis NN NN O
or NN NN O
adenomyosis NN NN O
at NN NN O
different NN NN O
phases NN NN O
of NN NN O
the NN NN O
menstrual NN NN O
cycle NN NN O
. NN NN O
   
Significantly NN NN O
increased NN NN O
oestrogen NN NN O
receptor NN NN O
expression NN NN O
, NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
and NN NN O
numbers NN NN O
of NN NN O
CD8 NN NN O
+ NN NN O
leukocytes NN NN O
were NN NN O
found NN NN O
in NN NN O
ectopic NN NN O
compared NN NN O
with NN NN O
eutopic NN NN O
endometrium NN NN O
in NN NN O
endometriosis NN NN O
, NN NN O
and NN NN O
CD56 NN NN B-Protein
+ NN NN O
endometrial NN NN O
granulated NN NN O
lymphocytes NN NN O
( NN NN O
eGLs NN NN O
) NN NN O
were NN NN O
significantly NN NN O
reduced NN NN O
in NN NN O
ectopic NN NN O
endometrium NN NN O
. NN NN O
   
Apoptotic NN NN O
cells NN NN O
were NN NN O
rarely NN NN O
found NN NN O
in NN NN O
control NN NN O
and NN NN O
subject NN NN O
endometria NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
with NN NN O
endometriosis NN NN O
, NN NN O
adenomyotic NN NN O
lesions NN NN O
showed NN NN O
identical NN NN O
steroid NN NN O
hormone NN NN O
receptor NN NN O
expression NN NN O
, NN NN O
proliferative NN NN O
activity NN NN O
, NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
and NN NN O
leukocyte NN NN O
subpopulations NN NN O
to NN NN O
eutopic NN NN O
endometrium NN NN O
, NN NN O
indicating NN NN O
different NN NN O
aetiologies NN NN O
for NN NN O
these NN NN O
disorders NN NN O
. NN NN O
   
The NN NN O
unusual NN NN O
CD56 NN NN B-Protein
+ NN NN O
CD16 NN NN B-Protein
- NN NN O
eGLs NN NN O
present NN NN O
in NN NN O
large NN NN O
numbers NN NN O
in NN NN O
late NN NN O
secretory NN NN O
phase NN NN O
eutopic NN NN O
endometrium NN NN O
were NN NN O
highly NN NN O
purified NN NN O
( NN NN O
> NN NN O
98 NN NN O
% NN NN O
) NN NN O
by NN NN O
immunomagnetic NN NN O
separation NN NN O
. NN NN O
   
Except NN NN O
for NN NN O
a NN NN O
negligible NN NN O
cytotoxic NN NN O
activity NN NN O
of NN NN O
eGLs NN NN O
from NN NN O
early NN NN O
proliferative NN NN O
samples NN NN O
, NN NN O
cytotoxic NN NN O
activity NN NN O
of NN NN O
eGLs NN NN O
from NN NN O
non NN NN O
- NN NN O
pregnant NN NN O
endometrium NN NN O
during NN NN O
the NN NN O
menstrual NN NN O
cycle NN NN O
was NN NN O
comparable NN NN O
with NN NN O
those NN NN O
in NN NN O
peripheral NN NN O
blood NN NN O
, NN NN O
predominantly NN NN O
CD56 NN NN B-Protein
+ NN NN O
CD16 NN NN B-Protein
+ NN NN O
natural NN NN O
killer NN NN O
cells NN NN O
. NN NN O
   
eGLs NN NN O
from NN NN O
non NN NN O
- NN NN O
pregnant NN NN O
endometrium NN NN O
and NN NN O
early NN NN O
pregnancy NN NN O
showed NN NN O
a NN NN O
variable NN NN O
proliferative NN NN O
response NN NN O
to NN NN O
5 NN NN O
and NN NN O
100 NN NN O
U NN NN O
/ NN NN O
ml NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
over NN NN O
48 NN NN O
- NN NN O
h NN NN O
and NN NN O
120 NN NN O
- NN NN O
h NN NN O
time NN NN O
courses NN NN O
. NN NN O
   
eGLs NN NN O
are NN NN O
evidently NN NN O
functionally NN NN O
important NN NN O
in NN NN O
the NN NN O
eutopic NN NN O
endometrium NN NN O
. NN NN O
   
Their NN NN O
absence NN NN O
in NN NN O
endometriotic NN NN O
lesions NN NN O
together NN NN O
with NN NN O
increased NN NN O
CD NN NN O
+ NN NN O
8 NN NN O
T NN NN O
- NN NN O
cell NN NN O
numbers NN NN O
and NN NN O
increased NN NN O
oestrogen NN NN O
receptor NN NN O
and NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
may NN NN O
have NN NN O
significant NN NN O
effects NN NN O
on NN NN O
the NN NN O
development NN NN O
and NN NN O
progression NN NN O
of NN NN O
endometriosis NN NN O
. NN NN O
   
Clonality NN NN O
of NN NN O
isolated NN NN O
eosinophils NN NN O
in NN NN O
the NN NN O
hypereosinophilic NN NN O
syndrome NN NN O
. NN NN O
   
The NN NN O
idiopathic NN NN O
hypereosinophilic NN NN O
syndrome NN NN O
( NN NN O
IHES NN NN O
) NN NN O
is NN NN O
a NN NN O
rare NN NN O
disorder NN NN O
characterized NN NN O
by NN NN O
unexplained NN NN O
, NN NN O
persistent NN NN O
eosinophilia NN NN O
associated NN NN O
with NN NN O
multiple NN NN O
organ NN NN O
dysfunction NN NN O
due NN NN O
to NN NN O
eosinophilic NN NN O
tissue NN NN O
infiltration NN NN O
. NN NN O
   
In NN NN O
the NN NN O
absence NN NN O
of NN NN O
karyotypic NN NN O
abnormalities NN NN O
, NN NN O
there NN NN O
is NN NN O
no NN NN O
specific NN NN O
test NN NN O
to NN NN O
detect NN NN O
clonal NN NN O
eosinophilia NN NN O
in NN NN O
IHES NN NN O
. NN NN O
   
Analysis NN NN O
of NN NN O
X NN NN O
- NN NN O
chromosome NN NN O
inactivation NN NN O
patterns NN NN O
can NN NN O
be NN NN O
used NN NN O
to NN NN O
determine NN NN O
whether NN NN O
proliferative NN NN O
disorders NN NN O
are NN NN O
clonal NN NN O
in NN NN O
origin NN NN O
. NN NN O
   
Methylation NN NN O
of NN NN O
HpaII NN NN O
and NN NN O
Hha NN NN O
I NN NN O
sites NN NN O
near NN NN O
the NN NN O
polymorphic NN NN O
trinucleotide NN NN O
repeat NN NN O
of NN NN O
the NN NN O
human NN NN B-Protein
androgen NN NN I-Protein
receptor NN NN I-Protein
gene NN NN O
( NN NN O
HUMARA NN NN B-Protein
) NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
correlate NN NN O
with NN NN O
X NN NN O
- NN NN O
inactivation NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
have NN NN O
used NN NN O
the NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
( NN NN O
PCR NN NN O
) NN NN O
with NN NN O
nested NN NN O
primers NN NN O
to NN NN O
analyze NN NN O
X NN NN O
- NN NN O
inactivation NN NN O
patterns NN NN O
of NN NN O
the NN NN O
HUMARA NN NN B-Protein
loci NN NN O
in NN NN O
purified NN NN O
eosinophils NN NN O
from NN NN O
female NN NN O
patients NN NN O
with NN NN O
eosinophilia NN NN O
. NN NN O
   
Peripheral NN NN O
blood NN NN O
eosinophils NN NN O
were NN NN O
isolated NN NN O
by NN NN O
their NN NN O
autofluoresence NN NN O
using NN NN O
flow NN NN O
cytometric NN NN O
sorting NN NN O
. NN NN O
   
Eosinophils NN NN O
purified NN NN O
from NN NN O
a NN NN O
female NN NN O
patient NN NN O
presenting NN NN O
with NN NN O
IHES NN NN O
were NN NN O
found NN NN O
to NN NN O
show NN NN O
a NN NN O
clonal NN NN O
pattern NN NN O
of NN NN O
X NN NN O
- NN NN O
inactivation NN NN O
. NN NN O
   
Eosinophil NN NN O
- NN NN O
depleted NN NN O
leukocytes NN NN O
from NN NN O
this NN NN O
patient NN NN O
were NN NN O
polyclonal NN NN O
by NN NN O
HUMARA NN NN B-Protein
analysis NN NN O
, NN NN O
thus NN NN O
excluding NN NN O
skewedness NN NN O
of NN NN O
random NN NN O
X NN NN O
- NN NN O
inactivation NN NN O
. NN NN O
   
After NN NN O
corticosteroid NN NN O
suppression NN NN O
of NN NN O
her NN NN O
blood NN NN O
eosinophilia NN NN O
, NN NN O
a NN NN O
clonal NN NN O
population NN NN O
of NN NN O
eosinophils NN NN O
could NN NN O
no NN NN O
longer NN NN O
be NN NN O
detected NN NN O
in NN NN O
purified NN NN O
eosinophils NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
eosinophils NN NN O
purified NN NN O
from NN NN O
a NN NN O
patient NN NN O
with NN NN O
Churg NN NN O
- NN NN O
Strauss NN NN O
syndrome NN NN O
and NN NN O
from NN NN O
six NN NN O
patients NN NN O
with NN NN O
reactive NN NN O
eosinophilias NN NN O
attributed NN NN O
to NN NN O
allergy NN NN O
, NN NN O
parasitic NN NN O
infection NN NN O
, NN NN O
or NN NN O
drug NN NN O
reaction NN NN O
showed NN NN O
a NN NN O
polyclonal NN NN O
pattern NN NN O
of NN NN O
X NN NN O
- NN NN O
inactivation NN NN O
by NN NN O
HUMARA NN NN B-Protein
analysis NN NN O
. NN NN O
   
The NN NN O
finding NN NN O
of NN NN O
clonal NN NN O
eosinophilia NN NN O
in NN NN O
a NN NN O
patient NN NN O
presenting NN NN O
with NN NN O
IHES NN NN O
indicates NN NN O
that NN NN O
such NN NN O
patients NN NN O
may NN NN O
have NN NN O
, NN NN O
in NN NN O
reality NN NN O
, NN NN O
a NN NN O
low NN NN O
- NN NN O
grade NN NN O
clonal NN NN O
disorder NN NN O
that NN NN O
can NN NN O
be NN NN O
distinguished NN NN O
from NN NN O
reactive NN NN O
eosinophilias NN NN O
by NN NN O
HUMARA NN NN B-Protein
analysis NN NN O
. NN NN O
   
Further NN NN O
, NN NN O
the NN NN O
method NN NN O
described NN NN O
can NN NN O
be NN NN O
used NN NN O
to NN NN O
monitor NN NN O
disease NN NN O
progression NN NN O
. NN NN O
   
Binding NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
to NN NN O
STAT5 NN NN O
target NN NN O
sequences NN NN O
in NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
- NN NN O
transformed NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
type NN NN O
I NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
( NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
) NN NN O
induces NN NN O
abnormal NN NN O
growth NN NN O
and NN NN O
subsequent NN NN O
transformation NN NN O
of NN NN O
T NN NN O
cells NN NN O
, NN NN O
which NN NN O
is NN NN O
associated NN NN O
with NN NN O
the NN NN O
development NN NN O
of NN NN O
an NN NN O
acute NN NN O
T NN NN O
- NN NN O
cell NN NN O
malignancy NN NN O
termed NN NN O
adult NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
. NN NN O
   
A NN NN O
characteristic NN NN O
of NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
- NN NN O
transformed NN NN O
T NN NN O
cells NN NN O
is NN NN O
the NN NN O
constitutive NN NN O
nuclear NN NN O
expression NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
/ NN NN O
Rel NN NN O
family NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
, NN NN O
which NN NN O
appears NN NN O
to NN NN O
be NN NN O
essential NN NN O
for NN NN O
the NN NN O
growth NN NN O
of NN NN O
these NN NN O
transformed NN NN O
cells NN NN O
. NN NN O
   
Although NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
/ NN NN O
Rel NN NN O
factors NN NN O
are NN NN O
known NN NN O
to NN NN O
induce NN NN O
the NN NN O
expression NN NN O
of NN NN O
T NN NN O
- NN NN O
cell NN NN O
growth NN NN O
factor NN NN O
interleukin NN NN B-Protein
( NN NN I-Protein
IL NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
it NN NN O
is NN NN O
unclear NN NN O
how NN NN O
they NN NN O
participate NN NN O
in NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
independent NN NN O
growth NN NN O
of NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
- NN NN O
transformed NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
certain NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
/ NN NN O
Rel NN NN O
members NN NN O
, NN NN O
predominantly NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
, NN NN O
interact NN NN O
with NN NN O
enhancer NN NN O
sequences NN NN O
for NN NN O
STAT5 NN NN O
, NN NN O
a NN NN O
key NN NN O
transcription NN NN O
factor NN NN O
mediating NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
induced NN NN O
T NN NN O
- NN NN O
cell NN NN O
proliferation NN NN O
. NN NN O
   
Reporter NN NN O
gene NN NN O
assays NN NN O
reveal NN NN O
that NN NN O
the NN NN O
binding NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
to NN NN O
the NN NN O
STAT5 NN NN O
site NN NN O
present NN NN O
in NN NN O
the NN NN O
Fc NN NN B-Protein
gammaR1 NN NN I-Protein
gene NN NN O
leads NN NN O
to NN NN O
potent NN NN O
transactivation NN NN O
of NN NN O
this NN NN O
enhancer NN NN O
. NN NN O
   
Binding NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
to NN NN O
the NN NN O
Fc NN NN B-Protein
gammaR1 NN NN I-Protein
STAT NN NN O
site NN NN O
also NN NN O
occurs NN NN O
in NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
T NN NN O
cells NN NN O
immortalized NN NN O
with NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
in NN NN O
vitro NN NN O
and NN NN O
is NN NN O
correlated NN NN O
with NN NN O
enhanced NN NN O
levels NN NN O
of NN NN O
proliferation NN NN O
of NN NN O
these NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
results NN NN O
raise NN NN O
the NN NN O
possibility NN NN O
that NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
/ NN NN O
Rel NN NN O
may NN NN O
participate NN NN O
in NN NN O
the NN NN O
growth NN NN O
control NN NN O
of NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
- NN NN O
transformed NN NN O
T NN NN O
cells NN NN O
by NN NN O
regulating NN NN O
genes NN NN O
driven NN NN O
by NN NN O
both NN NN O
kappaB NN NN O
and NN NN O
certain NN NN O
STAT NN NN O
enhancers NN NN O
. NN NN O
   
Alternative NN NN O
polyadenylation NN NN O
events NN NN O
contribute NN NN O
to NN NN O
the NN NN O
induction NN NN O
of NN NN O
NF NN NN O
- NN NN O
ATc NN NN O
in NN NN O
effector NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
ATc NN NN O
is NN NN O
synthesized NN NN O
in NN NN O
three NN NN O
prominent NN NN O
isoforms NN NN O
. NN NN O
   
These NN NN O
differ NN NN O
in NN NN O
the NN NN O
length NN NN O
of NN NN O
their NN NN O
C NN NN O
terminal NN NN O
peptides NN NN O
and NN NN O
mode NN NN O
of NN NN O
synthesis NN NN O
. NN NN O
   
Due NN NN O
to NN NN O
a NN NN O
switch NN NN O
from NN NN O
the NN NN O
use NN NN O
of NN NN O
a NN NN O
3 NN NN O
' NN NN O
polyA NN NN O
site NN NN O
to NN NN O
a NN NN O
more NN NN O
proximal NN NN O
polyA NN NN O
site NN NN O
, NN NN O
NF NN NN O
- NN NN O
ATc NN NN O
expression NN NN O
switches NN NN O
from NN NN O
the NN NN O
synthesis NN NN O
of NN NN O
the NN NN O
two NN NN O
longer NN NN O
isoforms NN NN O
in NN NN O
naive NN NN O
T NN NN O
cells NN NN O
to NN NN O
that NN NN O
of NN NN O
short NN NN O
isoform NN NN O
A NN NN O
in NN NN O
T NN NN O
effector NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
relative NN NN O
low NN NN O
binding NN NN O
affinity NN NN O
of NN NN O
cleavage NN NN O
stimulation NN NN O
factor NN NN O
CstF NN NN B-Protein
- NN NN I-Protein
64 NN NN I-Protein
to NN NN O
the NN NN O
proximal NN NN O
polyA NN NN O
site NN NN O
seems NN NN O
to NN NN O
contribute NN NN O
to NN NN O
its NN NN O
neglect NN NN O
in NN NN O
naive NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
alternative NN NN O
polyadenylation NN NN O
events NN NN O
ensure NN NN O
the NN NN O
rapid NN NN O
accumulation NN NN O
of NN NN O
high NN NN O
concentrations NN NN O
of NN NN O
NF NN NN O
- NN NN O
ATc NN NN O
necessary NN NN O
to NN NN O
exceed NN NN O
critical NN NN O
threshold NN NN O
levels NN NN O
of NN NN O
NF NN NN O
- NN NN O
ATc NN NN O
for NN NN O
gene NN NN O
induction NN NN O
in NN NN O
effector NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
A NN NN O
direct NN NN O
interaction NN NN O
between NN NN O
the NN NN O
adaptor NN NN O
protein NN NN O
Cbl NN NN B-Protein
- NN NN I-Protein
b NN NN I-Protein
and NN NN O
the NN NN O
kinase NN NN O
zap NN NN B-Protein
- NN NN I-Protein
70 NN NN I-Protein
induces NN NN O
a NN NN O
positive NN NN O
signal NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Engagement NN NN O
of NN NN O
the NN NN O
T NN NN O
- NN NN O
cell NN NN O
receptor NN NN O
( NN NN O
TCR NN NN O
) NN NN O
- NN NN O
CD3 NN NN O
complex NN NN O
induces NN NN O
a NN NN O
rapid NN NN O
increase NN NN O
in NN NN O
the NN NN O
activities NN NN O
of NN NN O
Src NN NN O
- NN NN O
family NN NN O
and NN NN O
Syk NN NN B-Protein
/ NN NN O
Zap NN NN B-Protein
- NN NN I-Protein
70 NN NN I-Protein
- NN NN O
family NN NN O
kinases NN NN O
[ NN NN O
1 NN NN O
] NN NN O
[ NN NN O
2 NN NN O
] NN NN O
. NN NN O
   
These NN NN O
activated NN NN O
kinases NN NN O
then NN NN O
induce NN NN O
the NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
multiple NN NN O
intracellular NN NN O
proteins NN NN O
, NN NN O
eventually NN NN O
leading NN NN O
to NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
One NN NN O
of NN NN O
the NN NN O
prominent NN NN O
substrates NN NN O
for NN NN O
these NN NN O
kinases NN NN O
is NN NN O
the NN NN O
adaptor NN NN O
protein NN NN O
Cbl NN NN O
[ NN NN O
3 NN NN O
] NN NN O
and NN NN O
recent NN NN O
studies NN NN O
suggest NN NN O
that NN NN O
Cbl NN NN O
negatively NN NN O
regulates NN NN O
upstream NN NN O
kinases NN NN O
such NN NN O
as NN NN O
Syk NN NN B-Protein
and NN NN O
Zap NN NN B-Protein
- NN NN I-Protein
70 NN NN I-Protein
[ NN NN O
4 NN NN O
] NN NN O
[ NN NN O
5 NN NN O
] NN NN O
. NN NN O
   
Cbl NN NN B-Protein
- NN NN I-Protein
b NN NN I-Protein
, NN NN O
a NN NN O
homologue NN NN O
of NN NN O
Cbl NN NN O
, NN NN O
is NN NN O
widely NN NN O
expressed NN NN O
in NN NN O
many NN NN O
tissues NN NN O
and NN NN O
cells NN NN O
including NN NN O
hematopoietic NN NN O
cells NN NN O
[ NN NN O
6 NN NN O
] NN NN O
[ NN NN O
7 NN NN O
] NN NN O
. NN NN O
   
Cbl NN NN B-Protein
- NN NN I-Protein
b NN NN I-Protein
undergoes NN NN O
rapid NN NN O
tyrosine NN NN O
phosphorylation NN NN O
upon NN NN O
stimulation NN NN O
of NN NN O
the NN NN O
TCR NN NN O
and NN NN O
cytokine NN NN O
receptors NN NN O
[ NN NN O
8 NN NN O
] NN NN O
[ NN NN O
9 NN NN O
] NN NN O
. NN NN O
   
The NN NN O
role NN NN O
of NN NN O
Cbl NN NN B-Protein
- NN NN I-Protein
b NN NN I-Protein
is NN NN O
unclear NN NN O
, NN NN O
however NN NN O
. NN NN O
   
Here NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
overexpression NN NN O
of NN NN O
Cbl NN NN B-Protein
- NN NN I-Protein
b NN NN I-Protein
in NN NN O
T NN NN O
cells NN NN O
induced NN NN O
the NN NN O
constitutive NN NN O
activation NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
( NN NN O
NFAT NN NN O
) NN NN O
. NN NN O
   
A NN NN O
loss NN NN O
- NN NN O
of NN NN O
- NN NN O
function NN NN O
mutation NN NN O
in NN NN O
Cbl NN NN B-Protein
- NN NN I-Protein
b NN NN I-Protein
disrupted NN NN O
the NN NN O
interaction NN NN O
between NN NN O
Cbl NN NN B-Protein
- NN NN I-Protein
b NN NN I-Protein
and NN NN O
Zap NN NN B-Protein
- NN NN I-Protein
70 NN NN I-Protein
and NN NN O
nearly NN NN O
completely NN NN O
abrogated NN NN O
the NN NN O
Cbl NN NN B-Protein
- NN NN I-Protein
b NN NN I-Protein
- NN NN O
mediated NN NN O
activation NN NN O
of NN NN O
NFAT NN NN O
. NN NN O
   
Unlike NN NN O
the NN NN O
proposed NN NN O
role NN NN O
of NN NN O
Cbl NN NN O
as NN NN O
a NN NN O
negative NN NN O
regulator NN NN O
, NN NN O
our NN NN O
results NN NN O
suggest NN NN O
that NN NN O
the NN NN O
Cbl NN NN O
homologue NN NN O
Cbl NN NN B-Protein
- NN NN I-Protein
b NN NN I-Protein
has NN NN O
a NN NN O
positive NN NN O
role NN NN O
in NN NN O
T NN NN O
- NN NN O
cell NN NN O
signaling NN NN O
, NN NN O
most NN NN O
likely NN NN O
via NN NN O
a NN NN O
direct NN NN O
interaction NN NN O
with NN NN O
the NN NN O
upstream NN NN O
kinase NN NN O
Zap NN NN B-Protein
- NN NN I-Protein
70 NN NN I-Protein
. NN NN O
   
Detection NN NN O
of NN NN O
intracellular NN NN O
phosphorylated NN NN O
STAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
by NN NN O
flow NN NN O
cytometry NN NN O
. NN NN O
   
We NN NN O
have NN NN O
applied NN NN O
flow NN NN O
cytometry NN NN O
to NN NN O
the NN NN O
investigation NN NN O
of NN NN O
interferon NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
activation NN NN O
of NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
This NN NN O
approach NN NN O
uses NN NN O
monoclonal NN NN O
antibodies NN NN O
that NN NN O
distinguish NN NN O
between NN NN O
the NN NN O
native NN NN O
and NN NN O
phosphorylated NN NN O
forms NN NN O
of NN NN O
STAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
It NN NN O
enables NN NN O
rapid NN NN O
and NN NN O
quantitative NN NN O
assessment NN NN O
of NN NN O
STAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
phosphorylation NN NN O
on NN NN O
a NN NN O
discrete NN NN O
cell NN NN O
basis NN NN O
and NN NN O
is NN NN O
both NN NN O
more NN NN O
sensitive NN NN O
and NN NN O
less NN NN O
time NN NN O
consuming NN NN O
than NN NN O
immunoblotting NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
it NN NN O
allows NN NN O
for NN NN O
discrimination NN NN O
between NN NN O
a NN NN O
mixture NN NN O
of NN NN O
cells NN NN O
that NN NN O
differ NN NN O
in NN NN O
their NN NN O
response NN NN O
to NN NN O
interferon NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
. NN NN O
   
This NN NN O
approach NN NN O
should NN NN O
allow NN NN O
for NN NN O
the NN NN O
evaluation NN NN O
of NN NN O
different NN NN O
intracellular NN NN O
signaling NN NN O
pathways NN NN O
using NN NN O
a NN NN O
combination NN NN O
of NN NN O
monoclonal NN NN O
reagents NN NN O
that NN NN O
are NN NN O
specific NN NN O
for NN NN O
native NN NN O
and NN NN O
activation NN NN O
modified NN NN O
proteins NN NN O
. NN NN O
   
Application NN NN O
of NN NN O
this NN NN O
form NN NN O
of NN NN O
testing NN NN O
should NN NN O
prove NN NN O
valuable NN NN O
in NN NN O
screening NN NN O
for NN NN O
signaling NN NN O
defects NN NN O
in NN NN O
selected NN NN O
patients NN NN O
with NN NN O
recurrent NN NN O
infections NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
this NN NN O
technique NN NN O
should NN NN O
permit NN NN O
dissection NN NN O
of NN NN O
a NN NN O
full NN NN O
range NN NN O
of NN NN O
cellular NN NN O
signaling NN NN O
pathways NN NN O
at NN NN O
the NN NN O
protein NN NN O
level NN NN O
. NN NN O
   
Glucocorticoid NN NN O
hormone NN NN O
suppression NN NN O
of NN NN O
human NN NN O
neutrophil NN NN O
- NN NN O
mediated NN NN O
tumor NN NN O
cell NN NN O
cytostasis NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
study NN NN O
, NN NN O
we NN NN O
have NN NN O
investigated NN NN O
the NN NN O
effect NN NN O
of NN NN O
glucocorticoid NN NN O
hormones NN NN O
on NN NN O
neutrophil NN NN O
- NN NN O
mediated NN NN O
tumor NN NN O
cell NN NN O
cytostasis NN NN O
and NN NN O
found NN NN O
that NN NN O
hydrocortisone NN NN O
and NN NN O
a NN NN O
synthetic NN NN O
hormone NN NN O
, NN NN O
dexamethasone NN NN O
( NN NN O
Dex NN NN O
) NN NN O
, NN NN O
inhibited NN NN O
cytostasis NN NN O
in NN NN O
the NN NN O
presence NN NN O
or NN NN O
absence NN NN O
of NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
Dex NN NN O
was NN NN O
completely NN NN O
reversed NN NN O
by NN NN O
a NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
antagonist NN NN O
, NN NN O
RU38486 NN NN O
. NN NN O
   
To NN NN O
clarify NN NN O
the NN NN O
underlying NN NN O
mechanisms NN NN O
, NN NN O
we NN NN O
examined NN NN O
effects NN NN O
of NN NN O
Dex NN NN O
on NN NN O
the NN NN O
binding NN NN O
avidity NN NN O
of NN NN O
beta2 NN NN B-Protein
integrin NN NN I-Protein
on NN NN O
the NN NN O
neutrophil NN NN O
surface NN NN O
and NN NN O
how NN NN O
these NN NN O
might NN NN O
in NN NN O
turn NN NN O
affect NN NN O
neutrophil NN NN O
- NN NN O
to NN NN O
- NN NN O
tumor NN NN O
cell NN NN O
binding NN NN O
. NN NN O
   
Dex NN NN O
was NN NN O
found NN NN O
to NN NN O
inhibit NN NN O
these NN NN O
neutrophil NN NN O
properties NN NN O
, NN NN O
and NN NN O
RU38486 NN NN O
completely NN NN O
suppressed NN NN O
both NN NN O
forms NN NN O
of NN NN O
Dex NN NN O
inhibition NN NN O
. NN NN O
   
Taken NN NN O
together NN NN O
, NN NN O
our NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
glucocorticoid NN NN O
hormone NN NN O
inhibition NN NN O
of NN NN O
neutrophil NN NN O
- NN NN O
mediated NN NN O
tumor NN NN O
cell NN NN O
cytostasis NN NN O
is NN NN O
at NN NN O
least NN NN O
partially NN NN O
due NN NN O
to NN NN O
a NN NN O
lowering NN NN O
of NN NN O
the NN NN O
ligand NN NN O
binding NN NN O
avidity NN NN O
of NN NN O
beta2 NN NN B-Protein
integrin NN NN I-Protein
on NN NN O
the NN NN O
neutrophil NN NN O
surface NN NN O
. NN NN O
   
Abnormalities NN NN O
of NN NN O
cyclic NN NN O
adenosine NN NN O
monophosphate NN NN O
signaling NN NN O
in NN NN O
platelets NN NN O
from NN NN O
untreated NN NN O
patients NN NN O
with NN NN O
bipolar NN NN O
disorder NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Abnormalities NN NN O
in NN NN O
the NN NN O
cyclic NN NN O
adenosine NN NN O
monophosphate NN NN O
( NN NN O
cAMP NN NN O
) NN NN O
- NN NN O
dependent NN NN O
phosphorylation NN NN O
system NN NN O
have NN NN O
been NN NN O
recently NN NN O
reported NN NN O
in NN NN O
patients NN NN O
with NN NN O
bipolar NN NN O
disorder NN NN O
. NN NN O
   
We NN NN O
evaluated NN NN O
the NN NN O
immunoreactivity NN NN O
of NN NN O
the NN NN O
regulatory NN NN O
and NN NN O
catalytic NN NN O
subunits NN NN O
of NN NN O
cAMP NN NN O
- NN NN O
dependent NN NN O
protein NN NN O
kinase NN NN O
( NN NN O
protein NN NN O
kinase NN NN O
A NN NN O
) NN NN O
and NN NN O
1 NN NN O
of NN NN O
its NN NN O
substrates NN NN O
, NN NN O
Rap1 NN NN B-Protein
, NN NN O
in NN NN O
platelets NN NN O
from NN NN O
untreated NN NN O
euthymic NN NN O
, NN NN O
manic NN NN O
, NN NN O
and NN NN O
depressed NN NN O
patients NN NN O
with NN NN O
bipolar NN NN O
disorder NN NN O
and NN NN O
healthy NN NN O
subjects NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Platelets NN NN O
were NN NN O
collected NN NN O
from NN NN O
112 NN NN O
drug NN NN O
- NN NN O
free NN NN O
patients NN NN O
with NN NN O
bipolar NN NN O
disorder NN NN O
( NN NN O
52 NN NN O
euthymic NN NN O
, NN NN O
29 NN NN O
depressed NN NN O
, NN NN O
and NN NN O
31 NN NN O
manic NN NN O
) NN NN O
and NN NN O
62 NN NN O
healthy NN NN O
subjects NN NN O
. NN NN O
   
The NN NN O
levels NN NN O
of NN NN O
cAMP NN NN O
- NN NN O
dependent NN NN O
protein NN NN O
kinase NN NN O
and NN NN O
Rap1 NN NN B-Protein
were NN NN O
assessed NN NN O
by NN NN O
Western NN NN O
blot NN NN O
analysis NN NN O
, NN NN O
immunostaining NN NN O
, NN NN O
and NN NN O
computer NN NN O
- NN NN O
assisted NN NN O
imaging NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
immunolabeling NN NN O
of NN NN O
the NN NN O
catalytic NN NN O
subunit NN NN O
of NN NN O
cAMP NN NN O
- NN NN O
dependent NN NN O
protein NN NN O
kinase NN NN O
was NN NN O
significantly NN NN O
different NN NN O
among NN NN O
groups NN NN O
( NN NN O
P NN NN O
< NN NN O
. NN NN O
001 NN NN O
) NN NN O
, NN NN O
with NN NN O
higher NN NN O
values NN NN O
in NN NN O
untreated NN NN O
depressed NN NN O
and NN NN O
manic NN NN O
patients NN NN O
with NN NN O
bipolar NN NN O
disorder NN NN O
compared NN NN O
with NN NN O
untreated NN NN O
euthymic NN NN O
patients NN NN O
with NN NN O
bipolar NN NN O
disorder NN NN O
and NN NN O
healthy NN NN O
subjects NN NN O
. NN NN O
   
No NN NN O
significant NN NN O
differences NN NN O
were NN NN O
found NN NN O
in NN NN O
the NN NN O
immunolabeling NN NN O
of NN NN O
the NN NN O
regulatory NN NN O
subunits NN NN O
( NN NN O
type NN NN O
I NN NN O
and NN NN O
type NN NN O
II NN NN O
) NN NN O
of NN NN O
cAMP NN NN O
- NN NN O
dependent NN NN O
protein NN NN O
kinase NN NN O
. NN NN O
   
The NN NN O
immunolabeling NN NN O
of NN NN O
Rap1 NN NN B-Protein
was NN NN O
significantly NN NN O
higher NN NN O
( NN NN O
P NN NN O
< NN NN O
. NN NN O
001 NN NN O
) NN NN O
in NN NN O
untreated NN NN O
euthymic NN NN O
, NN NN O
depressed NN NN O
, NN NN O
and NN NN O
manic NN NN O
patients NN NN O
than NN NN O
in NN NN O
healthy NN NN O
persons NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Levels NN NN O
of NN NN O
Rap1 NN NN B-Protein
and NN NN O
the NN NN O
catalytic NN NN O
subunit NN NN O
of NN NN O
cAMP NN NN O
- NN NN O
dependent NN NN O
protein NN NN O
kinase NN NN O
are NN NN O
altered NN NN O
in NN NN O
the NN NN O
platelets NN NN O
of NN NN O
bipolar NN NN O
patients NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
may NN NN O
provide NN NN O
clues NN NN O
toward NN NN O
understanding NN NN O
the NN NN O
involvement NN NN O
of NN NN O
cAMP NN NN O
signaling NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
bipolar NN NN O
disorder NN NN O
. NN NN O
   
Lineage NN NN O
- NN NN O
specific NN NN O
activation NN NN O
of NN NN O
STAT3 NN NN B-Protein
by NN NN O
interferon NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
in NN NN O
human NN NN O
neutrophils NN NN O
. NN NN O
   
Binding NN NN O
of NN NN O
interferon NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
( NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
) NN NN O
to NN NN O
its NN NN O
heterodimeric NN NN O
receptor NN NN O
induces NN NN O
activation NN NN O
of NN NN O
the NN NN O
tyrosine NN NN O
kinases NN NN O
JAK1 NN NN B-Protein
and NN NN O
JAK2 NN NN B-Protein
followed NN NN O
by NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
STAT1alpha NN NN B-Protein
. NN NN O
   
Selective NN NN O
activation NN NN O
of NN NN O
STAT1alpha NN NN B-Protein
at NN NN O
the NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
receptor NN NN O
is NN NN O
achieved NN NN O
by NN NN O
specific NN NN O
interaction NN NN O
between NN NN O
a NN NN O
cytosolic NN NN O
tyrosine NN NN O
motif NN NN O
including NN NN O
Y440 NN NN O
in NN NN O
the NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
- NN NN I-Protein
chain NN NN I-Protein
and NN NN O
the NN NN O
SH2 NN NN O
domain NN NN O
of NN NN O
STAT1alpha NN NN B-Protein
. NN NN O
   
We NN NN O
demonstrate NN NN O
that NN NN O
, NN NN O
in NN NN O
addition NN NN O
to NN NN O
STAT1alpha NN NN B-Protein
, NN NN O
STAT3 NN NN B-Protein
is NN NN O
also NN NN O
activated NN NN O
by NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
in NN NN O
human NN NN O
neutrophils NN NN O
. NN NN O
   
The NN NN O
activation NN NN O
of NN NN O
STAT3 NN NN B-Protein
was NN NN O
not NN NN O
found NN NN O
in NN NN O
human NN NN O
eosinophils NN NN O
, NN NN O
monocytes NN NN O
, NN NN O
and NN NN O
HL NN NN O
- NN NN O
60 NN NN O
cells NN NN O
, NN NN O
although NN NN O
the NN NN O
STAT3 NN NN B-Protein
protein NN NN O
was NN NN O
expressed NN NN O
in NN NN O
these NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
cell NN NN O
type NN NN O
- NN NN O
specific NN NN O
activation NN NN O
of NN NN O
STAT3 NN NN B-Protein
by NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
was NN NN O
also NN NN O
observed NN NN O
in NN NN O
neutrophils NN NN O
that NN NN O
are NN NN O
differentiated NN NN O
in NN NN O
vitro NN NN O
from NN NN O
human NN NN O
CD34 NN NN B-Protein
+ NN NN O
hematopoietic NN NN O
stem NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
a NN NN O
single NN NN O
cytokine NN NN O
receptor NN NN O
can NN NN O
activate NN NN O
different NN NN O
STAT NN NN O
family NN NN O
members NN NN O
in NN NN O
a NN NN O
cell NN NN O
- NN NN O
specific NN NN O
manner NN NN O
, NN NN O
which NN NN O
might NN NN O
result NN NN O
in NN NN O
cell NN NN O
- NN NN O
specific NN NN O
gene NN NN O
transcription NN NN O
. NN NN O
   
Analysis NN NN O
of NN NN O
the NN NN O
modulation NN NN O
of NN NN O
transcriptional NN NN O
activity NN NN O
in NN NN O
myelopoiesis NN NN O
and NN NN O
leukemogenesis NN NN O
. NN NN O
   
Acute NN NN O
myeloid NN NN O
leukemia NN NN O
( NN NN O
AML NN NN O
) NN NN O
is NN NN O
still NN NN O
associated NN NN O
with NN NN O
a NN NN O
mortality NN NN O
of NN NN O
60 NN NN O
to NN NN O
80 NN NN O
% NN NN O
. NN NN O
   
AML NN NN O
is NN NN O
characterized NN NN O
by NN NN O
a NN NN O
block NN NN O
in NN NN O
myeloid NN NN O
differentiation NN NN O
. NN NN O
   
The NN NN O
transcription NN NN O
factors NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
and NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBPalpha NN NN I-Protein
are NN NN O
responsible NN NN O
for NN NN O
normal NN NN O
myeloid NN NN O
differentiation NN NN O
from NN NN O
stem NN NN O
cells NN NN O
to NN NN O
monocytes NN NN O
or NN NN O
granulocytes NN NN O
. NN NN O
   
In NN NN O
particular NN NN O
, NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
induces NN NN O
expression NN NN O
of NN NN O
the NN NN O
macrophage NN NN B-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
( NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
) NN NN O
receptor NN NN O
and NN NN O
the NN NN O
development NN NN O
of NN NN O
monocytes NN NN O
, NN NN O
whereas NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBPalpha NN NN I-Protein
increases NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
granulocyte NN NN B-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
( NN NN I-Protein
G NN NN I-Protein
- NN NN I-Protein
CSF NN NN I-Protein
) NN NN I-Protein
receptor NN NN I-Protein
and NN NN O
leads NN NN O
to NN NN O
mature NN NN O
granulocytes NN NN O
. NN NN O
   
In NN NN O
AML NN NN O
, NN NN O
chromosomal NN NN O
aberrations NN NN O
result NN NN O
in NN NN O
oncoproteins NN NN O
such NN NN O
as NN NN O
AML1 NN NN B-Protein
/ NN NN O
ETO NN NN O
, NN NN O
PML NN NN B-Protein
/ NN NN O
RARalpha NN NN B-Protein
, NN NN O
or NN NN O
activated NN NN O
Ras NN NN O
, NN NN O
which NN NN O
can NN NN O
deregulate NN NN O
genes NN NN O
important NN NN O
for NN NN O
normal NN NN O
myelopoiesis NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
AML1 NN NN B-Protein
/ NN NN O
ETO NN NN O
can NN NN O
bind NN NN O
to NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBPalpha NN NN I-Protein
, NN NN O
inhibit NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBPalpha NN NN I-Protein
- NN NN O
dependent NN NN O
transcription NN NN O
, NN NN O
and NN NN O
block NN NN O
granulocytic NN NN O
differentiation NN NN O
. NN NN O
   
However NN NN O
, NN NN O
AML1 NN NN B-Protein
/ NN NN O
ETO NN NN O
can NN NN O
also NN NN O
synergize NN NN O
with NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
AML1 NN NN B-Protein
to NN NN O
enhance NN NN O
the NN NN O
activity NN NN O
of NN NN O
the NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
receptor NN NN O
promoter NN NN O
. NN NN O
   
On NN NN O
the NN NN O
other NN NN O
hand NN NN O
, NN NN O
the NN NN O
PML NN NN B-Protein
/ NN NN O
RARalpha NN NN B-Protein
fusion NN NN O
protein NN NN O
causes NN NN O
transcriptional NN NN O
repression NN NN O
by NN NN O
recruiting NN NN O
the NN NN O
nuclear NN NN O
corepressor NN NN O
( NN NN O
N NN NN O
- NN NN O
CoR NN NN O
) NN NN O
histone NN NN O
deacetylase NN NN O
complex NN NN O
to NN NN O
the NN NN O
DNA NN NN O
, NN NN O
which NN NN O
results NN NN O
in NN NN O
decreased NN NN O
histone NN NN O
acetylation NN NN O
and NN NN O
a NN NN O
repressive NN NN O
chromatin NN NN O
organization NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
describe NN NN O
methods NN NN O
to NN NN O
investigate NN NN O
whether NN NN O
and NN NN O
how NN NN O
signaling NN NN O
agonists NN NN O
induce NN NN O
myeloid NN NN O
differentiation NN NN O
and NN NN O
how NN NN O
oncoproteins NN NN O
might NN NN O
cause NN NN O
AML NN NN O
by NN NN O
modulating NN NN O
the NN NN O
activity NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
that NN NN O
are NN NN O
pivotal NN NN O
for NN NN O
normal NN NN O
myeloid NN NN O
development NN NN O
. NN NN O
   
Copyright NN NN O
1999 NN NN O
Academic NN NN O
Press NN NN O
. NN NN O
   
Impaired NN NN O
binding NN NN O
of NN NN O
a NN NN O
DQ2 NN NN B-Protein
and NN NN O
DQ8 NN NN B-Protein
- NN NN O
binding NN NN O
HSV NN NN O
VP16 NN NN O
peptide NN NN O
to NN NN O
a NN NN O
DQA1 NN NN O
* NN NN O
0501 NN NN O
/ NN NN O
DQB1 NN NN O
* NN NN O
0302 NN NN O
trans NN NN O
class NN NN O
II NN NN O
heterodimer NN NN O
. NN NN O
   
DQalpha NN NN B-Protein
and NN NN O
DQbeta NN NN B-Protein
trans NN NN O
heterodimeric NN NN O
HLA NN NN O
- NN NN O
DQ NN NN O
molecules NN NN O
form NN NN O
in NN NN O
individuals NN NN O
heterozygous NN NN O
for NN NN O
the NN NN O
DQ2 NN NN O
and NN NN O
DQ8 NN NN O
specificities NN NN O
. NN NN O
   
Unique NN NN O
functions NN NN O
and NN NN O
disease NN NN O
associations NN NN O
have NN NN O
been NN NN O
postulated NN NN O
for NN NN O
such NN NN O
trans NN NN O
- NN NN O
dimers NN NN O
, NN NN O
which NN NN O
may NN NN O
be NN NN O
different NN NN O
from NN NN O
cis NN NN O
- NN NN O
encoded NN NN O
DQ NN NN O
molecules NN NN O
encoded NN NN O
by NN NN O
the NN NN O
corresponding NN NN O
haplotypes NN NN O
. NN NN O
   
We NN NN O
analyzed NN NN O
the NN NN O
ability NN NN O
of NN NN O
the NN NN O
trans NN NN O
- NN NN O
dimer NN NN O
encoded NN NN O
by NN NN O
HLA NN NN O
- NN NN O
DQA1 NN NN O
* NN NN O
0501 NN NN O
/ NN NN O
DQB1 NN NN O
* NN NN O
0302 NN NN O
to NN NN O
bind NN NN O
a NN NN O
peptide NN NN O
antigen NN NN O
which NN NN O
interacts NN NN O
with NN NN O
DQ NN NN O
molecules NN NN O
encoded NN NN O
by NN NN O
both NN NN O
parental NN NN O
haplotypes NN NN O
. NN NN O
   
Markedly NN NN O
impaired NN NN O
binding NN NN O
was NN NN O
observed NN NN O
, NN NN O
consistent NN NN O
with NN NN O
both NN NN O
the NN NN O
use NN NN O
of NN NN O
different NN NN O
anchor NN NN O
residues NN NN O
and NN NN O
with NN NN O
changes NN NN O
in NN NN O
levels NN NN O
of NN NN O
DQ NN NN O
cis NN NN O
- NN NN O
dimer NN NN O
availability NN NN O
for NN NN O
peptide NN NN O
binding NN NN O
interactions NN NN O
. NN NN O
   
MDS1 NN NN B-Protein
/ NN NN O
EVI1 NN NN B-Protein
enhances NN NN O
TGF NN NN B-Protein
- NN NN I-Protein
beta1 NN NN I-Protein
signaling NN NN O
and NN NN O
strengthens NN NN O
its NN NN O
growth NN NN O
- NN NN O
inhibitory NN NN O
effect NN NN O
but NN NN O
the NN NN O
leukemia NN NN O
- NN NN O
associated NN NN O
fusion NN NN O
protein NN NN O
AML1 NN NN B-Protein
/ NN NN O
MDS1 NN NN B-Protein
/ NN NN O
EVI1 NN NN B-Protein
, NN NN O
product NN NN O
of NN NN O
the NN NN O
t NN NN O
( NN NN O
3 NN NN O
; NN NN O
21 NN NN O
) NN NN O
, NN NN O
abrogates NN NN O
growth NN NN O
- NN NN O
inhibition NN NN O
in NN NN O
response NN NN O
to NN NN O
TGF NN NN B-Protein
- NN NN I-Protein
beta1 NN NN I-Protein
. NN NN O
   
MDS1 NN NN B-Protein
/ NN NN O
EVI1 NN NN B-Protein
, NN NN O
located NN NN O
on NN NN O
chromosome NN NN O
3 NN NN O
band NN NN O
q26 NN NN O
, NN NN O
encodes NN NN O
a NN NN O
zinc NN NN O
- NN NN O
finger NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
transcription NN NN O
activator NN NN O
not NN NN O
detected NN NN O
in NN NN O
normal NN NN O
hematopoietic NN NN O
cells NN NN O
but NN NN O
expressed NN NN O
in NN NN O
several NN NN O
normal NN NN O
tissues NN NN O
. NN NN O
   
MDS1 NN NN B-Protein
/ NN NN O
EVI1 NN NN B-Protein
is NN NN O
inappropriately NN NN O
activated NN NN O
in NN NN O
myeloid NN NN O
leukemias NN NN O
following NN NN O
chromosomal NN NN O
rearrangements NN NN O
involving NN NN O
band NN NN O
3q26 NN NN O
. NN NN O
   
The NN NN O
rearrangements NN NN O
lead NN NN O
either NN NN O
to NN NN O
gene NN NN O
truncation NN NN O
, NN NN O
and NN NN O
to NN NN O
expression NN NN O
of NN NN O
the NN NN O
transcription NN NN O
repressor NN NN O
EVI1 NN NN B-Protein
, NN NN O
as NN NN O
seen NN NN O
in NN NN O
the NN NN O
t NN NN O
( NN NN O
3 NN NN O
; NN NN O
3 NN NN O
) NN NN O
( NN NN O
q21 NN NN O
; NN NN O
q26 NN NN O
) NN NN O
and NN NN O
inv NN NN O
( NN NN O
3 NN NN O
) NN NN O
( NN NN O
q21q26 NN NN O
) NN NN O
, NN NN O
or NN NN O
to NN NN O
gene NN NN O
fusion NN NN O
, NN NN O
as NN NN O
seen NN NN O
in NN NN O
the NN NN O
t NN NN O
( NN NN O
3 NN NN O
; NN NN O
21 NN NN O
) NN NN O
( NN NN O
q26 NN NN O
; NN NN O
q22 NN NN O
) NN NN O
which NN NN O
results NN NN O
in NN NN O
the NN NN O
fusion NN NN O
protein NN NN O
AML1 NN NN B-Protein
/ NN NN O
MDS1 NN NN B-Protein
/ NN NN O
EVI1 NN NN B-Protein
. NN NN O
   
This NN NN O
fusion NN NN O
protein NN NN O
contains NN NN O
the NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
domain NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
AML1 NN NN B-Protein
fused NN NN O
in NN NN O
- NN NN O
frame NN NN O
to NN NN O
the NN NN O
entire NN NN O
MDS1 NN NN B-Protein
/ NN NN O
EVI1 NN NN B-Protein
with NN NN O
the NN NN O
exclusion NN NN O
of NN NN O
its NN NN O
first NN NN O
12 NN NN O
amino NN NN O
acids NN NN O
. NN NN O
   
In NN NN O
this NN NN O
report NN NN O
, NN NN O
we NN NN O
have NN NN O
analyzed NN NN O
the NN NN O
response NN NN O
of NN NN O
the NN NN O
hematopoietic NN NN O
precursor NN NN O
cell NN NN O
line NN NN O
32Dcl3 NN NN O
, NN NN O
expressing NN NN O
either NN NN O
the NN NN O
normal NN NN O
protein NN NN O
MDS1 NN NN B-Protein
/ NN NN O
EVI1 NN NN B-Protein
or NN NN O
the NN NN O
fusion NN NN O
protein NN NN O
AML1 NN NN B-Protein
/ NN NN O
MDS1 NN NN B-Protein
/ NN NN O
EVI1 NN NN B-Protein
, NN NN O
to NN NN O
factors NN NN O
that NN NN O
control NN NN O
cell NN NN O
differentiation NN NN O
or NN NN O
cell NN NN O
replication NN NN O
. NN NN O
   
The NN NN O
32Dcl3 NN NN O
cells NN NN O
are NN NN O
IL NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
- NN NN O
dependent NN NN O
for NN NN O
growth NN NN O
and NN NN O
they NN NN O
differentiate NN NN O
into NN NN O
granulocytes NN NN O
when NN NN O
exposed NN NN O
to NN NN O
G NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
. NN NN O
   
They NN NN O
are NN NN O
growth NN NN O
- NN NN O
inhibited NN NN O
by NN NN O
TGF NN NN B-Protein
- NN NN I-Protein
beta1 NN NN I-Protein
. NN NN O
   
We NN NN O
show NN NN O
that NN NN O
whereas NN NN O
the NN NN O
expression NN NN O
of NN NN O
MDS1 NN NN B-Protein
/ NN NN O
EVI1 NN NN B-Protein
has NN NN O
no NN NN O
effect NN NN O
on NN NN O
granulocytic NN NN O
differentiation NN NN O
induced NN NN O
by NN NN O
G NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
, NN NN O
expression NN NN O
of NN NN O
AML1 NN NN B-Protein
/ NN NN O
MDS1 NN NN B-Protein
/ NN NN O
EVI1 NN NN B-Protein
blocks NN NN O
differentiation NN NN O
resulting NN NN O
in NN NN O
cell NN NN O
death NN NN O
. NN NN O
   
This NN NN O
effect NN NN O
is NN NN O
similar NN NN O
to NN NN O
that NN NN O
previously NN NN O
described NN NN O
by NN NN O
others NN NN O
for NN NN O
32Dcl3 NN NN O
cells NN NN O
that NN NN O
express NN NN O
transgenic NN NN O
Evil NN NN B-Protein
. NN NN O
   
Furthermore NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
whereas NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
fusion NN NN O
protein NN NN O
AML1 NN NN B-Protein
/ NN NN O
MDS1 NN NN B-Protein
/ NN NN O
EVI1 NN NN B-Protein
completely NN NN O
abrogates NN NN O
the NN NN O
growth NN NN O
- NN NN O
inhibitory NN NN O
effect NN NN O
of NN NN O
TGF NN NN B-Protein
- NN NN I-Protein
beta1 NN NN I-Protein
and NN NN O
allows NN NN O
32Dcl3 NN NN O
cells NN NN O
to NN NN O
proliferate NN NN O
, NN NN O
expression NN NN O
of NN NN O
the NN NN O
normal NN NN O
protein NN NN O
MDS1 NN NN B-Protein
/ NN NN O
EVI1 NN NN B-Protein
has NN NN O
the NN NN O
opposite NN NN O
effect NN NN O
, NN NN O
and NN NN O
it NN NN O
strengthens NN NN O
the NN NN O
response NN NN O
of NN NN O
cells NN NN O
to NN NN O
the NN NN O
growth NN NN O
- NN NN O
inhibitory NN NN O
effect NN NN O
of NN NN O
TGF NN NN B-Protein
- NN NN I-Protein
beta1 NN NN I-Protein
. NN NN O
   
By NN NN O
using NN NN O
the NN NN O
yeast NN NN O
two NN NN O
- NN NN O
hybrid NN NN O
system NN NN O
, NN NN O
we NN NN O
also NN NN O
show NN NN O
that NN NN O
EVI1 NN NN B-Protein
( NN NN O
contained NN NN O
in NN NN O
its NN NN O
entirety NN NN O
in NN NN O
MDS1 NN NN B-Protein
/ NN NN O
EVI1 NN NN B-Protein
and NN NN O
AML1 NN NN B-Protein
/ NN NN O
MDS1 NN NN B-Protein
/ NN NN O
EVI1 NN NN B-Protein
) NN NN O
physically NN NN O
interacts NN NN O
with NN NN O
SMAD3 NN NN B-Protein
, NN NN O
which NN NN O
is NN NN O
an NN NN O
intracellular NN NN O
mediator NN NN O
of NN NN O
TGF NN NN B-Protein
- NN NN I-Protein
beta1 NN NN I-Protein
signaling NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
we NN NN O
have NN NN O
correlated NN NN O
the NN NN O
response NN NN O
of NN NN O
the NN NN O
cells NN NN O
to NN NN O
G NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
or NN NN O
TGF NN NN B-Protein
- NN NN I-Protein
beta1 NN NN I-Protein
with NN NN O
the NN NN O
ability NN NN O
of NN NN O
the NN NN O
normal NN NN O
and NN NN O
fusion NN NN O
proteins NN NN O
to NN NN O
activate NN NN O
or NN NN O
repress NN NN O
promoters NN NN O
which NN NN O
they NN NN O
can NN NN O
directly NN NN O
regulate NN NN O
by NN NN O
binding NN NN O
to NN NN O
the NN NN O
promoter NN NN O
site NN NN O
. NN NN O
   
We NN NN O
propose NN NN O
that NN NN O
mutations NN NN O
of NN NN O
MDS1 NN NN B-Protein
/ NN NN O
EVI1 NN NN B-Protein
either NN NN O
by NN NN O
gene NN NN O
truncation NN NN O
resulting NN NN O
in NN NN O
the NN NN O
transcription NN NN O
repressor NN NN O
EVI1 NN NN B-Protein
or NN NN O
by NN NN O
gene NN NN O
fusion NN NN O
to NN NN O
AML1 NN NN B-Protein
lead NN NN O
to NN NN O
an NN NN O
altered NN NN O
cellular NN NN O
response NN NN O
to NN NN O
growth NN NN O
and NN NN O
differentiation NN NN O
factors NN NN O
that NN NN O
could NN NN O
result NN NN O
in NN NN O
leukemic NN NN O
transformation NN NN O
. NN NN O
   
The NN NN O
different NN NN O
response NN NN O
of NN NN O
myeloid NN NN O
cells NN NN O
ectopically NN NN O
expressing NN NN O
the NN NN O
normal NN NN O
or NN NN O
the NN NN O
fusion NN NN O
protein NN NN O
to NN NN O
G NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
and NN NN O
TGF NN NN B-Protein
- NN NN I-Protein
beta1 NN NN I-Protein
could NN NN O
depend NN NN O
on NN NN O
the NN NN O
different NN NN O
transactivation NN NN O
properties NN NN O
of NN NN O
these NN NN O
proteins NN NN O
resulting NN NN O
in NN NN O
divergent NN NN O
expression NN NN O
of NN NN O
downstream NN NN O
genes NN NN O
regulated NN NN O
by NN NN O
the NN NN O
two NN NN O
proteins NN NN O
. NN NN O
   
Interferon NN NN O
- NN NN O
alpha NN NN O
induction NN NN O
of NN NN O
STATs1 NN NN B-Protein
, NN NN O
- NN NN B-Protein
3 NN NN I-Protein
DNA NN NN O
binding NN NN O
and NN NN O
growth NN NN O
arrest NN NN O
is NN NN O
independent NN NN O
of NN NN O
Lck NN NN B-Protein
and NN NN O
active NN NN O
mitogen NN NN O
- NN NN O
activated NN NN O
kinase NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Type NN NN O
I NN NN O
interferons NN NN O
( NN NN O
IFNs NN NN O
) NN NN O
are NN NN O
a NN NN O
family NN NN O
of NN NN O
cytokines NN NN O
that NN NN O
have NN NN O
antiviral NN NN O
and NN NN O
antiproliferative NN NN O
effects NN NN O
. NN NN O
   
Data NN NN O
regarding NN NN O
the NN NN O
processes NN NN O
by NN NN O
which NN NN O
these NN NN O
cytokines NN NN O
transduce NN NN O
signals NN NN O
from NN NN O
the NN NN O
cell NN NN O
membrane NN NN O
to NN NN O
the NN NN O
nucleus NN NN O
are NN NN O
becoming NN NN O
increasingly NN NN O
complex NN NN O
. NN NN O
   
The NN NN O
most NN NN O
characterized NN NN O
pathway NN NN O
is NN NN O
via NN NN O
JAK NN NN O
- NN NN O
STAT NN NN O
signaling NN NN O
. NN NN O
   
Previous NN NN O
studies NN NN O
established NN NN O
a NN NN O
potential NN NN O
role NN NN O
for NN NN O
the NN NN O
Src NN NN O
- NN NN O
family NN NN O
kinase NN NN O
Lck NN NN B-Protein
in NN NN O
JAK NN NN O
- NN NN O
STAT NN NN O
signaling NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
this NN NN O
study NN NN O
was NN NN O
designed NN NN O
to NN NN O
analyze NN NN O
the NN NN O
role NN NN O
of NN NN O
Lck NN NN B-Protein
in NN NN O
IFN NN NN O
- NN NN O
alpha NN NN O
signaling NN NN O
by NN NN O
using NN NN O
the NN NN O
Jurkat NN NN O
, NN NN O
JCam NN NN O
( NN NN O
an NN NN O
Lck NN NN B-Protein
- NN NN O
defective NN NN O
cell NN NN O
line NN NN O
derived NN NN O
from NN NN O
Jurkat NN NN O
) NN NN O
, NN NN O
and NN NN O
JCam NN NN O
/ NN NN O
Lck NN NN B-Protein
( NN NN O
JCam NN NN O
cells NN NN O
with NN NN O
Lck NN NN B-Protein
restored NN NN O
) NN NN O
. NN NN O
   
The NN NN O
results NN NN O
show NN NN O
that NN NN O
IFN NN NN O
- NN NN O
alpha NN NN O
can NN NN O
induce NN NN O
MAPK NN NN O
activity NN NN O
, NN NN O
but NN NN O
only NN NN O
in NN NN O
cells NN NN O
containing NN NN O
Lck NN NN B-Protein
. NN NN O
   
Furthermore NN NN O
, NN NN O
STATs1 NN NN B-Protein
and NN NN O
- NN NN B-Protein
3 NN NN I-Protein
are NN NN O
effectively NN NN O
phosphorylated NN NN O
and NN NN O
activated NN NN O
to NN NN O
bind NN NN O
DNA NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
Lck NN NN B-Protein
expression NN NN O
in NN NN O
IFN NN NN O
- NN NN O
alpha NN NN O
- NN NN O
treated NN NN O
cells NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
the NN NN O
results NN NN O
demonstrate NN NN O
that NN NN O
IFN NN NN O
- NN NN O
alpha NN NN O
exerts NN NN O
an NN NN O
antiproliferative NN NN O
effect NN NN O
in NN NN O
all NN NN O
three NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
These NN NN O
data NN NN O
indicate NN NN O
that NN NN O
Lck NN NN B-Protein
and NN NN O
active NN NN O
MAPK NN NN O
do NN NN O
not NN NN O
affect NN NN O
IFN NN NN O
- NN NN O
alpha NN NN O
- NN NN O
induced NN NN O
growth NN NN O
arrest NN NN O
or NN NN O
induction NN NN O
of NN NN O
STAT1s1 NN NN O
and NN NN O
- NN NN O
3 NN NN O
DNA NN NN O
binding NN NN O
ability NN NN O
. NN NN O
   
Copyright NN NN O
1999 NN NN O
Academic NN NN O
Press NN NN O
. NN NN O
   
T NN NN O
helper NN NN O
differentiation NN NN O
proceeds NN NN O
through NN NN O
Stat1 NN NN B-Protein
- NN NN O
dependent NN NN O
, NN NN O
Stat4 NN NN B-Protein
- NN NN O
dependent NN NN O
and NN NN O
Stat4 NN NN B-Protein
- NN NN O
independent NN NN O
phases NN NN O
. NN NN O
   
Much NN NN O
of NN NN O
our NN NN O
focus NN NN O
in NN NN O
understanding NN NN O
Th1 NN NN O
/ NN NN O
Th2 NN NN O
development NN NN O
has NN NN O
been NN NN O
on NN NN O
the NN NN O
signals NN NN O
delivered NN NN O
by NN NN O
IL NN NN O
- NN NN O
12 NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
as NN NN O
final NN NN O
determinants NN NN O
of NN NN O
terminal NN NN O
T NN NN O
cell NN NN O
differentiation NN NN O
. NN NN O
   
Because NN NN O
extinction NN NN O
of NN NN O
IL NN NN O
- NN NN O
12 NN NN O
signaling NN NN O
in NN NN O
early NN NN O
Th2 NN NN O
development NN NN O
could NN NN O
potentially NN NN O
be NN NN O
important NN NN O
in NN NN O
imprinting NN NN O
a NN NN O
more NN NN O
permanent NN NN O
Th2 NN NN O
phenotype NN NN O
on NN NN O
a NN NN O
population NN NN O
of NN NN O
T NN NN O
cells NN NN O
, NN NN O
we NN NN O
have NN NN O
also NN NN O
examined NN NN O
various NN NN O
parameters NN NN O
regulating NN NN O
the NN NN O
IL NN NN O
- NN NN O
12 NN NN O
signaling NN NN O
pathway NN NN O
. NN NN O
   
Whereas NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
appears NN NN O
to NN NN O
repress NN NN O
functional NN NN O
IL NN NN O
- NN NN O
12 NN NN O
signaling NN NN O
through NN NN O
inhibition NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
12R NN NN I-Protein
beta NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
, NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
in NN NN O
the NN NN O
mouse NN NN O
, NN NN O
and NN NN O
IFN NN NN O
- NN NN O
alpha NN NN O
in NN NN O
the NN NN O
human NN NN O
appear NN NN O
to NN NN O
induce NN NN O
IL NN NN B-Protein
- NN NN I-Protein
12R NN NN I-Protein
beta NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
and NN NN O
promote NN NN O
IL NN NN O
- NN NN O
12 NN NN O
responsiveness NN NN O
. NN NN O
   
We NN NN O
propose NN NN O
that NN NN O
Th1 NN NN O
development NN NN O
can NN NN O
be NN NN O
considered NN NN O
in NN NN O
two NN NN O
stages NN NN O
, NN NN O
capacitance NN NN O
and NN NN O
development NN NN O
. NN NN O
   
Capacitance NN NN O
would NN NN O
simply NN NN O
involve NN NN O
expression NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
12R NN NN I-Protein
beta NN NN I-Protein
1 NN NN I-Protein
and NN NN O
beta NN NN B-Protein
2 NN NN I-Protein
subunits NN NN O
, NN NN O
regulated NN NN O
by NN NN O
TCR NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
and NN NN O
IFNs NN NN O
. NN NN O
   
The NN NN O
second NN NN O
stage NN NN O
, NN NN O
development NN NN O
, NN NN O
we NN NN O
propose NN NN O
is NN NN O
the NN NN O
true NN NN O
IL NN NN O
- NN NN O
12 NN NN O
induced NN NN O
developmental NN NN O
stage NN NN O
, NN NN O
involving NN NN O
expression NN NN O
of NN NN O
Stat4 NN NN B-Protein
inducible NN NN O
proteins NN NN O
. NN NN O
   
In NN NN O
the NN NN O
human NN NN O
, NN NN O
this NN NN O
may NN NN O
also NN NN O
occur NN NN O
via NN NN O
IFN NN NN O
- NN NN O
alpha NN NN O
, NN NN O
which NN NN O
is NN NN O
able NN NN O
to NN NN O
activate NN NN O
Stat4 NN NN B-Protein
. NN NN O
   
It NN NN O
is NN NN O
perhaps NN NN O
possible NN NN O
that NN NN O
all NN NN O
of NN NN O
Stat4 NN NN B-Protein
actions NN NN O
on NN NN O
Th1 NN NN O
development NN NN O
may NN NN O
be NN NN O
exert NN NN O
directly NN NN O
by NN NN O
Stat4 NN NN B-Protein
at NN NN O
the NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
gene NN NN O
, NN NN O
however NN NN O
we NN NN O
suggest NN NN O
that NN NN O
, NN NN O
more NN NN O
likely NN NN O
, NN NN O
Stat4 NN NN B-Protein
may NN NN O
act NN NN O
to NN NN O
induce NN NN O
Th1 NN NN O
development NN NN O
through NN NN O
the NN NN O
induction NN NN O
of NN NN O
other NN NN O
non NN NN O
- NN NN O
cytokine NN NN O
genes NN NN O
, NN NN O
whose NN NN O
stable NN NN O
expression NN NN O
maintains NN NN O
the NN NN O
transcriptional NN NN O
state NN NN O
of NN NN O
a NN NN O
Th1 NN NN O
cell NN NN O
. NN NN O
   
1 NN NN O
, NN NN O
25 NN NN O
- NN NN O
Dihydroxyvitamin NN NN O
D3 NN NN O
induces NN NN O
differentiation NN NN O
of NN NN O
a NN NN O
retinoic NN NN O
acid NN NN O
- NN NN O
resistant NN NN O
acute NN NN O
promyelocytic NN NN O
leukemia NN NN O
cell NN NN O
line NN NN O
( NN NN O
UF NN NN O
- NN NN O
1 NN NN O
) NN NN O
associated NN NN O
with NN NN O
expression NN NN O
of NN NN O
p21 NN NN B-Protein
( NN NN O
WAF1 NN NN B-Protein
/ NN NN O
CIP1 NN NN B-Protein
) NN NN O
and NN NN O
p27 NN NN B-Protein
( NN NN O
KIP1 NN NN B-Protein
) NN NN O
. NN NN O
   
Retinoic NN NN O
acid NN NN O
( NN NN O
RA NN NN O
) NN NN O
resistance NN NN O
is NN NN O
a NN NN O
serious NN NN O
problem NN NN O
for NN NN O
patients NN NN O
with NN NN O
acute NN NN O
promyelocytic NN NN O
leukemia NN NN O
( NN NN O
APL NN NN O
) NN NN O
who NN NN O
are NN NN O
receiving NN NN O
all NN NN O
- NN NN O
trans NN NN O
RA NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
mechanisms NN NN O
and NN NN O
strategies NN NN O
to NN NN O
overcome NN NN O
RA NN NN O
resistance NN NN O
by NN NN O
APL NN NN O
cells NN NN O
are NN NN O
still NN NN O
unclear NN NN O
. NN NN O
   
The NN NN O
biologic NN NN O
effects NN NN O
of NN NN O
RA NN NN O
are NN NN O
mediated NN NN O
by NN NN O
two NN NN O
distinct NN NN O
families NN NN O
of NN NN O
transcriptional NN NN O
factors NN NN O
: NN NN O
RA NN NN O
receptors NN NN O
( NN NN O
RARs NN NN O
) NN NN O
and NN NN O
retinoid NN NN O
X NN NN O
receptors NN NN O
( NN NN O
RXRs NN NN O
) NN NN O
. NN NN O
   
RXRs NN NN O
heterodimerize NN NN O
with NN NN O
1 NN NN B-Protein
, NN NN I-Protein
25 NN NN I-Protein
- NN NN I-Protein
dihydroxyvitamin NN NN I-Protein
D3 NN NN I-Protein
[ NN NN I-Protein
1 NN NN I-Protein
, NN NN I-Protein
25 NN NN I-Protein
( NN NN I-Protein
OH NN NN I-Protein
) NN NN I-Protein
2D3 NN NN I-Protein
] NN NN I-Protein
receptor NN NN I-Protein
( NN NN O
VDR NN NN B-Protein
) NN NN O
, NN NN O
enabling NN NN O
their NN NN O
efficient NN NN O
transcriptional NN NN O
activation NN NN O
. NN NN O
   
The NN NN O
cyclin NN NN O
- NN NN O
dependent NN NN O
kinase NN NN O
( NN NN O
cdk NN NN O
) NN NN O
inhibitor NN NN O
p21 NN NN B-Protein
( NN NN O
WAF1 NN NN B-Protein
/ NN NN O
CIP1 NN NN B-Protein
) NN NN O
has NN NN O
a NN NN O
vitamin NN NN O
D3 NN NN O
- NN NN O
responsive NN NN O
element NN NN O
( NN NN O
VDRE NN NN O
) NN NN O
in NN NN O
its NN NN O
promoter NN NN O
, NN NN O
and NN NN O
1 NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
enhances NN NN O
the NN NN O
expression NN NN O
of NN NN O
p21 NN NN B-Protein
( NN NN O
WAF1 NN NN B-Protein
/ NN NN O
CIP1 NN NN B-Protein
) NN NN O
and NN NN O
induces NN NN O
differentiation NN NN O
of NN NN O
selected NN NN O
myeloid NN NN O
leukemic NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
We NN NN O
have NN NN O
recently NN NN O
established NN NN O
a NN NN O
novel NN NN O
APL NN NN O
cell NN NN O
line NN NN O
( NN NN O
UF NN NN O
- NN NN O
1 NN NN O
) NN NN O
with NN NN O
features NN NN O
of NN NN O
RA NN NN O
resistance NN NN O
. NN NN O
   
1 NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
can NN NN O
induce NN NN O
growth NN NN O
inhibition NN NN O
and NN NN O
G1 NN NN O
arrest NN NN O
of NN NN O
UF NN NN O
- NN NN O
1 NN NN O
cells NN NN O
, NN NN O
resulting NN NN O
in NN NN O
differentiation NN NN O
of NN NN O
these NN NN O
cells NN NN O
toward NN NN O
granulocytes NN NN O
. NN NN O
   
This NN NN O
1 NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
- NN NN O
induced NN NN O
G1 NN NN O
arrest NN NN O
is NN NN O
enhanced NN NN O
by NN NN O
all NN NN O
- NN NN O
trans NN NN O
RA NN NN O
. NN NN O
   
Also NN NN O
, NN NN O
1 NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
( NN NN O
10 NN NN O
( NN NN O
- NN NN O
10 NN NN O
) NN NN O
to NN NN O
10 NN NN O
( NN NN O
- NN NN O
7 NN NN O
) NN NN O
mol NN NN O
/ NN NN O
L NN NN O
) NN NN O
in NN NN O
combination NN NN O
with NN NN O
RA NN NN O
markedly NN NN O
inhibits NN NN O
cellular NN NN O
proliferation NN NN O
in NN NN O
a NN NN O
dose NN NN O
- NN NN O
and NN NN O
time NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
. NN NN O
   
Associated NN NN O
with NN NN O
these NN NN O
findings NN NN O
, NN NN O
the NN NN O
levels NN NN O
of NN NN O
p21 NN NN B-Protein
( NN NN O
WAF1 NN NN B-Protein
/ NN NN O
CIP1 NN NN B-Protein
) NN NN O
and NN NN O
p27 NN NN B-Protein
( NN NN O
KIP1 NN NN B-Protein
) NN NN O
mRNA NN NN O
and NN NN O
protein NN NN O
increased NN NN O
in NN NN O
these NN NN O
cells NN NN O
. NN NN O
   
Northern NN NN O
blot NN NN O
analysis NN NN O
showed NN NN O
that NN NN O
p21 NN NN B-Protein
( NN NN O
WAF1 NN NN B-Protein
/ NN NN O
CIP1 NN NN B-Protein
) NN NN O
and NN NN O
p27 NN NN B-Protein
( NN NN O
KIP1 NN NN B-Protein
) NN NN O
mRNA NN NN O
and NN NN O
protein NN NN O
increased NN NN O
in NN NN O
these NN NN O
cells NN NN O
. NN NN O
   
Northern NN NN O
blot NN NN O
analysis NN NN O
showed NN NN O
that NN NN O
p21 NN NN B-Protein
( NN NN O
WAF1 NN NN B-Protein
/ NN NN O
CIP1 NN NN B-Protein
) NN NN O
and NN NN O
p27 NN NN B-Protein
( NN NN O
KIP1 NN NN B-Protein
) NN NN O
transcripts NN NN O
were NN NN O
induced NN NN O
after NN NN O
6 NN NN O
hours NN NN O
' NN NN O
exposure NN NN O
to NN NN O
1 NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
and NN NN O
then NN NN O
decreased NN NN O
to NN NN O
basal NN NN O
levels NN NN O
over NN NN O
48 NN NN O
hours NN NN O
. NN NN O
   
Western NN NN O
blot NN NN O
experiments NN NN O
showed NN NN O
that NN NN O
p21 NN NN B-Protein
( NN NN O
WAF1 NN NN B-Protein
/ NN NN O
CIP1 NN NN B-Protein
) NN NN O
protein NN NN O
levels NN NN O
increased NN NN O
and NN NN O
became NN NN O
detectable NN NN O
after NN NN O
12 NN NN O
hours NN NN O
of NN NN O
1 NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
treatment NN NN O
and NN NN O
induction NN NN O
of NN NN O
p27 NN NN B-Protein
( NN NN O
KIP1 NN NN B-Protein
) NN NN O
protein NN NN O
was NN NN O
much NN NN O
more NN NN O
gradual NN NN O
and NN NN O
sustained NN NN O
in NN NN O
UF NN NN O
- NN NN O
1 NN NN O
cells NN NN O
. NN NN O
   
Interestingly NN NN O
, NN NN O
the NN NN O
combination NN NN O
of NN NN O
1 NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
and NN NN O
RA NN NN O
markedly NN NN O
enhanced NN NN O
the NN NN O
levels NN NN O
of NN NN O
p27 NN NN B-Protein
( NN NN O
KIP1 NN NN B-Protein
) NN NN O
transcript NN NN O
and NN NN O
protein NN NN O
as NN NN O
compared NN NN O
with NN NN O
levels NN NN O
induced NN NN O
by NN NN O
1 NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
alone NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
exogenous NN NN O
p27 NN NN B-Protein
( NN NN O
KIP1 NN NN B-Protein
) NN NN O
expression NN NN O
can NN NN O
enhance NN NN O
the NN NN O
level NN NN O
of NN NN O
CD11b NN NN B-Protein
antigen NN NN O
in NN NN O
myeloid NN NN O
leukemic NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
RA NN NN O
alone NN NN O
can NN NN O
induce NN NN O
G1 NN NN O
arrest NN NN O
of NN NN O
UF NN NN O
- NN NN O
1 NN NN O
cells NN NN O
; NN NN O
however NN NN O
, NN NN O
it NN NN O
did NN NN O
not NN NN O
result NN NN O
in NN NN O
an NN NN O
increase NN NN O
of NN NN O
p21 NN NN B-Protein
( NN NN O
WAF1 NN NN B-Protein
/ NN NN O
CIP1 NN NN B-Protein
) NN NN O
and NN NN O
p27 NN NN B-Protein
( NN NN O
KIP1 NN NN B-Protein
) NN NN O
transcript NN NN O
and NN NN O
protein NN NN O
expression NN NN O
in NN NN O
RA NN NN O
- NN NN O
resistant NN NN O
cells NN NN O
. NN NN O
   
Taken NN NN O
together NN NN O
, NN NN O
we NN NN O
conclude NN NN O
that NN NN O
1 NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
induces NN NN O
increased NN NN O
expression NN NN O
of NN NN O
cdk NN NN O
inhibitors NN NN O
, NN NN O
which NN NN O
mediates NN NN O
a NN NN O
G1 NN NN O
arrest NN NN O
, NN NN O
and NN NN O
this NN NN O
may NN NN O
be NN NN O
associated NN NN O
with NN NN O
differentiation NN NN O
of NN NN O
RA NN NN O
- NN NN O
resistant NN NN O
UF NN NN O
- NN NN O
1 NN NN O
cells NN NN O
toward NN NN O
mature NN NN O
granulocytes NN NN O
. NN NN O
   
Human NN NN O
immunodeficiency NN NN O
virus NN NN O
- NN NN O
associated NN NN O
Hodgkin NN NN O
' NN NN O
s NN NN O
disease NN NN O
derives NN NN O
from NN NN O
post NN NN O
- NN NN O
germinal NN NN O
center NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
Human NN NN O
immunodeficiency NN NN O
virus NN NN O
- NN NN O
associated NN NN O
Hodgkin NN NN O
' NN NN O
s NN NN O
disease NN NN O
( NN NN O
HIV NN NN O
- NN NN O
HD NN NN O
) NN NN O
displays NN NN O
several NN NN O
peculiarities NN NN O
when NN NN O
compared NN NN O
with NN NN O
HD NN NN O
of NN NN O
the NN NN O
general NN NN O
population NN NN O
. NN NN O
   
These NN NN O
include NN NN O
overrepresentation NN NN O
of NN NN O
clinically NN NN O
aggressive NN NN O
histologic NN NN O
types NN NN O
and NN NN O
frequent NN NN O
infection NN NN O
of NN NN O
Reed NN NN O
- NN NN O
Sternberg NN NN O
( NN NN O
RS NN NN O
) NN NN O
cells NN NN O
by NN NN O
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
( NN NN O
EBV NN NN O
) NN NN O
. NN NN O
   
Recently NN NN O
, NN NN O
we NN NN O
have NN NN O
reported NN NN O
that NN NN O
the NN NN O
histogenesis NN NN O
of NN NN O
HD NN NN O
of NN NN O
the NN NN O
general NN NN O
population NN NN O
may NN NN O
be NN NN O
assessed NN NN O
by NN NN O
monitoring NN NN O
the NN NN O
expression NN NN O
pattern NN NN O
of NN NN O
BCL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
, NN NN O
a NN NN O
transcription NN NN O
factor NN NN O
expressed NN NN O
in NN NN O
germinal NN NN O
center NN NN O
( NN NN O
GC NN NN O
) NN NN O
B NN NN O
cells NN NN O
, NN NN O
and NN NN O
of NN NN O
CD138 NN NN B-Protein
/ NN NN O
syndecan NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
syn NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
, NN NN O
a NN NN O
proteoglycan NN NN O
associated NN NN O
with NN NN O
post NN NN O
- NN NN O
GC NN NN O
, NN NN O
terminal NN NN O
B NN NN O
- NN NN O
cell NN NN O
differentiation NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
have NN NN O
applied NN NN O
these NN NN O
two NN NN O
markers NN NN O
to NN NN O
the NN NN O
study NN NN O
of NN NN O
HIV NN NN O
- NN NN O
HD NN NN O
histogenesis NN NN O
and NN NN O
correlated NN NN O
their NN NN O
expression NN NN O
status NN NN O
to NN NN O
the NN NN O
virologic NN NN O
features NN NN O
of NN NN O
this NN NN O
disease NN NN O
. NN NN O
   
We NN NN O
have NN NN O
found NN NN O
that NN NN O
RS NN NN O
cells NN NN O
of NN NN O
all NN NN O
histologic NN NN O
categories NN NN O
of NN NN O
HIV NN NN O
- NN NN O
HD NN NN O
consistently NN NN O
display NN NN O
the NN NN O
BCL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
( NN NN O
- NN NN O
) NN NN O
/ NN NN O
syn NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
+ NN NN O
) NN NN O
phenotype NN NN O
and NN NN O
thus NN NN O
reflect NN NN O
post NN NN O
- NN NN O
GC NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
Although NN NN O
BCL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
( NN NN O
- NN NN O
) NN NN O
/ NN NN O
syn NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
+ NN NN O
) NN NN O
RS NN NN O
cells NN NN O
of NN NN O
HIV NN NN O
- NN NN O
HD NN NN O
express NN NN O
CD40 NN NN B-Protein
, NN NN O
they NN NN O
are NN NN O
not NN NN O
surrounded NN NN O
by NN NN O
CD40 NN NN B-Protein
ligand NN NN I-Protein
- NN NN O
positive NN NN O
( NN NN O
CD40L NN NN B-Protein
+ NN NN O
) NN NN O
reactive NN NN O
T NN NN O
lymphocytes NN NN O
, NN NN O
which NN NN O
, NN NN O
in NN NN O
HD NN NN O
of NN NN O
the NN NN O
general NN NN O
population NN NN O
, NN NN O
are NN NN O
thought NN NN O
to NN NN O
regulate NN NN O
the NN NN O
disease NN NN O
phenotype NN NN O
through NN NN O
CD40 NN NN B-Protein
/ NN NN O
CD40L NN NN B-Protein
interactions NN NN O
. NN NN O
   
Conversely NN NN O
, NN NN O
RS NN NN O
cells NN NN O
of NN NN O
virtually NN NN O
all NN NN O
HIV NN NN O
- NN NN O
HD NN NN O
express NN NN O
the NN NN O
EBV NN NN O
- NN NN O
encoded NN NN O
latent NN NN B-Protein
membrane NN NN I-Protein
protein NN NN I-Protein
1 NN NN I-Protein
( NN NN O
LMP1 NN NN B-Protein
) NN NN O
, NN NN O
which NN NN O
, NN NN O
being NN NN O
functionally NN NN O
homologous NN NN O
to NN NN O
CD40 NN NN B-Protein
, NN NN O
may NN NN O
contribute NN NN O
, NN NN O
at NN NN O
least NN NN O
in NN NN O
part NN NN O
, NN NN O
to NN NN O
the NN NN O
modulation NN NN O
of NN NN O
the NN NN O
HIV NN NN O
- NN NN O
HD NN NN O
phenotype NN NN O
. NN NN O
   
Interferon NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
mediates NN NN O
stromal NN NN O
cell NN NN O
rescue NN NN O
of NN NN O
T NN NN O
cells NN NN O
from NN NN O
apoptosis NN NN O
. NN NN O
   
The NN NN O
resolution NN NN O
of NN NN O
immune NN NN O
responses NN NN O
is NN NN O
characterized NN NN O
by NN NN O
extensive NN NN O
apoptosis NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
However NN NN O
, NN NN O
to NN NN O
generate NN NN O
and NN NN O
maintain NN NN O
immunological NN NN O
memory NN NN O
, NN NN O
some NN NN O
antigen NN NN O
- NN NN O
specific NN NN O
T NN NN O
cells NN NN O
must NN NN O
survive NN NN O
and NN NN O
revert NN NN O
to NN NN O
a NN NN O
resting NN NN O
G0 NN NN O
/ NN NN O
G1 NN NN O
state NN NN O
. NN NN O
   
Cytokines NN NN O
that NN NN O
bind NN NN O
to NN NN O
the NN NN O
common NN NN O
gamma NN NN O
chain NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
receptor NN NN O
promote NN NN O
the NN NN O
survival NN NN O
of NN NN O
T NN NN O
cell NN NN O
blasts NN NN O
, NN NN O
but NN NN O
also NN NN O
induce NN NN O
proliferation NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
soluble NN NN O
factors NN NN O
secreted NN NN O
by NN NN O
stromal NN NN O
cells NN NN O
induce NN NN O
Tcell NN NN O
survival NN NN O
in NN NN O
a NN NN O
resting NN NN O
G0 NN NN O
/ NN NN O
G1 NN NN O
state NN NN O
. NN NN O
   
We NN NN O
now NN NN O
report NN NN O
that NN NN O
interferon NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
is NN NN O
the NN NN O
principal NN NN O
mediator NN NN O
of NN NN O
stromal NN NN O
cell NN NN O
- NN NN O
mediated NN NN O
Tcell NN NN O
rescue NN NN O
from NN NN O
apoptosis NN NN O
. NN NN O
   
Interferon NN NN O
- NN NN O
alpha NN NN O
and NN NN O
- NN NN O
beta NN NN O
promote NN NN O
the NN NN O
reversion NN NN O
of NN NN O
blast NN NN O
Tcells NN NN O
to NN NN O
a NN NN O
resting NN NN O
G0 NN NN O
/ NN NN O
G1 NN NN O
configuration NN NN O
with NN NN O
all NN NN O
the NN NN O
characteristic NN NN O
features NN NN O
of NN NN O
stromal NN NN O
cell NN NN O
rescue NN NN O
; NN NN O
such NN NN O
as NN NN O
high NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
XL NN NN I-Protein
expression NN NN O
and NN NN O
low NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
Type NN NN O
I NN NN O
interferons NN NN O
and NN NN O
stromal NN NN O
cells NN NN O
stimulate NN NN O
apparently NN NN O
identical NN NN O
signaling NN NN O
pathways NN NN O
, NN NN O
leading NN NN O
to NN NN O
STAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
activation NN NN O
. NN NN O
   
We NN NN O
also NN NN O
show NN NN O
that NN NN O
this NN NN O
mechanism NN NN O
may NN NN O
play NN NN O
a NN NN O
fundamental NN NN O
role NN NN O
in NN NN O
the NN NN O
persistence NN NN O
of NN NN O
T NN NN O
cells NN NN O
at NN NN O
sites NN NN O
of NN NN O
chronic NN NN O
inflammation NN NN O
; NN NN O
suggesting NN NN O
that NN NN O
chronic NN NN O
inflammation NN NN O
is NN NN O
an NN NN O
aberrant NN NN O
consequence NN NN O
of NN NN O
immunological NN NN O
memory NN NN O
. NN NN O
   
Glucocorticoids NN NN O
promote NN NN O
nonphlogistic NN NN O
phagocytosis NN NN O
of NN NN O
apoptotic NN NN O
leukocytes NN NN O
. NN NN O
   
Phagocyte NN NN O
recognition NN NN O
, NN NN O
uptake NN NN O
, NN NN O
and NN NN O
nonphlogistic NN NN O
degradation NN NN O
of NN NN O
neutrophils NN NN O
and NN NN O
other NN NN O
leukocytes NN NN O
undergoing NN NN O
apoptosis NN NN O
promote NN NN O
the NN NN O
resolution NN NN O
of NN NN O
inflammation NN NN O
. NN NN O
   
This NN NN O
study NN NN O
assessed NN NN O
the NN NN O
effects NN NN O
of NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
glucocorticoids NN NN O
on NN NN O
this NN NN O
leukocyte NN NN O
clearance NN NN O
mechanism NN NN O
. NN NN O
   
Pretreatment NN NN O
of NN NN O
"""""""" NN NN O
semimature NN NN O
"""""""" NN NN O
5 NN NN O
- NN NN O
day NN NN O
human NN NN O
monocyte NN NN O
- NN NN O
derived NN NN O
macrophages NN NN O
( NN NN O
M NN NN O
phi NN NN O
) NN NN O
for NN NN O
24 NN NN O
h NN NN O
with NN NN O
methylprednisolone NN NN O
, NN NN O
dexamethasone NN NN O
, NN NN O
and NN NN O
hydrocortisone NN NN O
, NN NN O
but NN NN O
not NN NN O
the NN NN O
nonglucocorticoid NN NN O
steroids NN NN O
aldosterone NN NN O
, NN NN O
estradiol NN NN O
, NN NN O
and NN NN O
progesterone NN NN O
, NN NN O
potentiated NN NN O
phagocytosis NN NN O
of NN NN O
apoptotic NN NN O
neutrophils NN NN O
. NN NN O
   
These NN NN O
effects NN NN O
were NN NN O
specific NN NN O
in NN NN O
that NN NN O
the NN NN O
potentiated NN NN O
phagocytosis NN NN O
of NN NN O
apoptotic NN NN O
neutrophils NN NN O
was NN NN O
completely NN NN O
blocked NN NN O
by NN NN O
the NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
antagonist NN NN O
RU38486 NN NN O
, NN NN O
and NN NN O
glucocorticoids NN NN O
did NN NN O
not NN NN O
promote NN NN O
5 NN NN O
- NN NN O
day NN NN O
M NN NN O
phi NN NN O
ingestion NN NN O
of NN NN O
opsonized NN NN O
erythrocytes NN NN O
. NN NN O
   
Similar NN NN O
glucocorticoid NN NN O
- NN NN O
mediated NN NN O
potentiation NN NN O
was NN NN O
observed NN NN O
with NN NN O
5 NN NN O
- NN NN O
day NN NN O
M NN NN O
phi NN NN O
uptake NN NN O
of NN NN O
alternative NN NN O
apoptotic NN NN O
"""""""" NN NN O
targets NN NN O
"""""""" NN NN O
( NN NN O
eosinophils NN NN O
and NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
) NN NN O
and NN NN O
in NN NN O
uptake NN NN O
of NN NN O
apoptotic NN NN O
neutrophils NN NN O
by NN NN O
alternative NN NN O
phagocytes NN NN O
( NN NN O
human NN NN O
glomerular NN NN O
mesangial NN NN O
cells NN NN O
and NN NN O
murine NN NN O
M NN NN O
phi NN NN O
elicited NN NN O
into NN NN O
the NN NN O
peritoneum NN NN O
or NN NN O
derived NN NN O
from NN NN O
bone NN NN O
marrow NN NN O
) NN NN O
. NN NN O
   
Importantly NN NN O
, NN NN O
methylprednisolone NN NN O
- NN NN O
mediated NN NN O
enhancement NN NN O
of NN NN O
the NN NN O
uptake NN NN O
of NN NN O
apoptotic NN NN O
neutrophils NN NN O
did NN NN O
not NN NN O
trigger NN NN O
the NN NN O
release NN NN O
of NN NN O
the NN NN O
chemokines NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
and NN NN O
monocyte NN NN B-Protein
chemoattractant NN NN I-Protein
protein NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
Furthermore NN NN O
, NN NN O
longer NN NN O
- NN NN O
term NN NN O
potentiation NN NN O
by NN NN O
methylprednisolone NN NN O
was NN NN O
observed NN NN O
in NN NN O
maturing NN NN O
human NN NN O
monocyte NN NN O
- NN NN O
derived NN NN O
M NN NN O
phi NN NN O
, NN NN O
with NN NN O
greater NN NN O
increases NN NN O
in NN NN O
5 NN NN O
- NN NN O
day NN NN O
M NN NN O
phi NN NN O
uptake NN NN O
of NN NN O
apoptotic NN NN O
cells NN NN O
being NN NN O
observed NN NN O
the NN NN O
earlier NN NN O
glucocorticoids NN NN O
were NN NN O
added NN NN O
during NN NN O
monocyte NN NN O
maturation NN NN O
into NN NN O
M NN NN O
phi NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
potentiation NN NN O
of NN NN O
nonphlogistic NN NN O
clearance NN NN O
of NN NN O
apoptotic NN NN O
leukocytes NN NN O
by NN NN O
phagocytes NN NN O
is NN NN O
a NN NN O
hitherto NN NN O
unrecognized NN NN O
property NN NN O
of NN NN O
glucocorticoids NN NN O
that NN NN O
has NN NN O
potential NN NN O
implications NN NN O
for NN NN O
therapies NN NN O
aimed NN NN O
at NN NN O
promoting NN NN O
the NN NN O
resolution NN NN O
of NN NN O
inflammatory NN NN O
diseases NN NN O
. NN NN O
   
Glucocorticoid NN NN O
- NN NN O
induced NN NN O
cell NN NN O
death NN NN O
requires NN NN O
autoinduction NN NN O
of NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
expression NN NN O
in NN NN O
human NN NN O
leukemic NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
to NN NN O
the NN NN O
negative NN NN O
autoregulation NN NN O
of NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
( NN NN O
GR NN NN B-Protein
) NN NN O
expression NN NN O
seen NN NN O
in NN NN O
most NN NN O
cells NN NN O
and NN NN O
tissues NN NN O
, NN NN O
GR NN NN B-Protein
expression NN NN O
is NN NN O
positively NN NN O
autoregulated NN NN O
in NN NN O
human NN NN O
leukemic NN NN O
T NN NN O
cells NN NN O
and NN NN O
in NN NN O
other NN NN O
cells NN NN O
sensitive NN NN O
to NN NN O
glucocorticoid NN NN O
- NN NN O
induced NN NN O
cell NN NN O
death NN NN O
. NN NN O
   
To NN NN O
determine NN NN O
whether NN NN O
positive NN NN O
autoregulation NN NN O
is NN NN O
a NN NN O
necessary NN NN O
component NN NN O
of NN NN O
glucocorticoid NN NN O
- NN NN O
induced NN NN O
cell NN NN O
death NN NN O
, NN NN O
a NN NN O
wild NN NN O
- NN NN O
type NN NN O
GR NN NN B-Protein
gene NN NN O
under NN NN O
the NN NN O
control NN NN O
of NN NN O
a NN NN O
tetracycline NN NN O
- NN NN O
regulated NN NN O
promoter NN NN O
was NN NN O
stably NN NN O
transfected NN NN O
into NN NN O
glucocorticoid NN NN O
- NN NN O
resistant NN NN O
cells NN NN O
lacking NN NN O
endogenous NN NN O
functional NN NN O
receptor NN NN O
. NN NN O
   
Transfectants NN NN O
grown NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
tetracycline NN NN O
contained NN NN O
about NN NN O
15 NN NN O
, NN NN O
000 NN NN O
receptors NN NN O
/ NN NN O
cell NN NN O
, NN NN O
a NN NN O
value NN NN O
approximately NN NN O
equal NN NN O
to NN NN O
basal NN NN O
level NN NN O
GR NN NN B-Protein
expression NN NN O
in NN NN O
glucocorticoid NN NN O
- NN NN O
sensitive NN NN O
6TG1 NN NN O
. NN NN O
1 NN NN O
cells NN NN O
before NN NN O
steroid NN NN O
treatment NN NN O
. NN NN O
   
Under NN NN O
these NN NN O
conditions NN NN O
, NN NN O
dexamethasone NN NN O
had NN NN O
a NN NN O
minimal NN NN O
effect NN NN O
on NN NN O
cell NN NN O
growth NN NN O
, NN NN O
elicited NN NN O
little NN NN O
internucleosomal NN NN O
DNA NN NN O
fragmentation NN NN O
, NN NN O
and NN NN O
induced NN NN O
no NN NN O
cell NN NN O
cycle NN NN O
perturbation NN NN O
. NN NN O
   
In NN NN O
the NN NN O
absence NN NN O
of NN NN O
tetracycline NN NN O
, NN NN O
GR NN NN B-Protein
mRNA NN NN O
and NN NN O
protein NN NN O
expression NN NN O
increased NN NN O
2 NN NN O
- NN NN O
3 NN NN O
- NN NN O
fold NN NN O
, NN NN O
and NN NN O
cells NN NN O
expressed NN NN O
48 NN NN O
, NN NN O
000 NN NN O
receptors NN NN O
, NN NN O
a NN NN O
level NN NN O
nearly NN NN O
equivalent NN NN O
to NN NN O
that NN NN O
present NN NN O
in NN NN O
6TG1 NN NN O
. NN NN O
1 NN NN O
cells NN NN O
after NN NN O
18 NN NN O
h NN NN O
of NN NN O
autoinduction NN NN O
. NN NN O
   
Under NN NN O
these NN NN O
conditions NN NN O
, NN NN O
dexamethasone NN NN O
markedly NN NN O
inhibited NN NN O
cell NN NN O
growth NN NN O
, NN NN O
caused NN NN O
G1 NN NN O
arrest NN NN O
, NN NN O
and NN NN O
induced NN NN O
significant NN NN O
internucleosomal NN NN O
DNA NN NN O
fragmentation NN NN O
. NN NN O
   
These NN NN O
studies NN NN O
therefore NN NN O
suggest NN NN O
that NN NN O
basal NN NN O
level NN NN O
GR NN NN B-Protein
expression NN NN O
is NN NN O
inadequate NN NN O
to NN NN O
mediate NN NN O
glucocorticoid NN NN O
- NN NN O
induced NN NN O
apoptosis NN NN O
in NN NN O
glucocorticoid NN NN O
- NN NN O
sensitive NN NN O
T NN NN O
cells NN NN O
and NN NN O
that NN NN O
positive NN NN O
autoregulation NN NN O
is NN NN O
a NN NN O
necessary NN NN O
component NN NN O
of NN NN O
this NN NN O
process NN NN O
. NN NN O
   
Jeg NN NN O
- NN NN O
3 NN NN O
human NN NN O
choriocarcinoma NN NN O
- NN NN O
induced NN NN O
immunosuppression NN NN O
: NN NN O
downregulation NN NN O
of NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
- NN NN I-Protein
chain NN NN I-Protein
, NN NN O
and NN NN O
its NN NN O
Jak NN NN O
/ NN NN O
Stat NN NN O
signaling NN NN O
pathway NN NN O
. NN NN O
   
PROBLEM NN NN O
: NN NN O
The NN NN O
mechanisms NN NN O
of NN NN O
the NN NN O
immunosuppressive NN NN O
and NN NN O
immunosuppression NN NN O
- NN NN O
inducing NN NN O
capacities NN NN O
of NN NN O
Jeg NN NN O
- NN NN O
3 NN NN O
human NN NN O
choriocarcinoma NN NN O
cell NN NN O
line NN NN O
supernatants NN NN O
( NN NN O
HCSs NN NN O
) NN NN O
are NN NN O
not NN NN O
yet NN NN O
completely NN NN O
understood NN NN O
. NN NN O
   
The NN NN O
influence NN NN O
on NN NN O
interleukin NN NN B-Protein
( NN NN I-Protein
IL NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
and NN NN O
interferon NN NN B-Protein
( NN NN I-Protein
IFN NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
gamma NN NN I-Protein
production NN NN O
; NN NN O
IL NN NN O
- NN NN O
2 NN NN O
receptor NN NN O
( NN NN O
IL NN NN O
- NN NN O
2R NN NN O
) NN NN O
alpha NN NN O
- NN NN O
, NN NN O
beta NN NN O
- NN NN O
, NN NN O
and NN NN O
gamma NN NN O
- NN NN O
chain NN NN O
; NN NN O
and NN NN O
the NN NN O
signaling NN NN O
pathway NN NN O
molecules NN NN O
Janus NN NN B-Protein
kinase NN NN I-Protein
( NN NN I-Protein
Jak NN NN I-Protein
) NN NN I-Protein
1 NN NN I-Protein
, NN NN O
Jak3 NN NN B-Protein
, NN NN O
signal NN NN B-Protein
transducers NN NN I-Protein
and NN NN I-Protein
activators NN NN I-Protein
of NN NN I-Protein
transcription NN NN I-Protein
( NN NN I-Protein
Stat NN NN I-Protein
) NN NN I-Protein
1 NN NN I-Protein
, NN NN O
Stat3 NN NN B-Protein
, NN NN O
and NN NN O
Stat5 NN NN B-Protein
should NN NN O
be NN NN O
investigated NN NN O
. NN NN O
   
METHOD NN NN O
OF NN NN O
STUDY NN NN O
: NN NN O
For NN NN O
assessment NN NN O
of NN NN O
IL NN NN O
production NN NN O
, NN NN O
whole NN NN O
peripheral NN NN O
venous NN NN O
blood NN NN O
from NN NN O
healthy NN NN O
donors NN NN O
was NN NN O
stimulated NN NN O
with NN NN O
phorbol NN NN O
- NN NN O
myristate NN NN O
- NN NN O
acetate NN NN O
and NN NN O
ionomycine NN NN O
. NN NN O
   
Secretion NN NN O
of NN NN O
ILs NN NN O
was NN NN O
blocked NN NN O
with NN NN O
monensine NN NN O
. NN NN O
   
Intracellular NN NN O
ILs NN NN O
were NN NN O
analyzed NN NN O
by NN NN O
flow NN NN O
cytometry NN NN O
. NN NN O
   
For NN NN O
IL NN NN O
- NN NN O
2R NN NN O
and NN NN O
signaling NN NN O
pathway NN NN O
molecule NN NN O
analysis NN NN O
, NN NN O
peripheral NN NN O
blood NN NN O
lymphocytes NN NN O
were NN NN O
stimulated NN NN O
with NN NN O
phytohemagglutinin NN NN B-Protein
( NN NN O
PHA NN NN B-Protein
) NN NN O
. NN NN O
   
IL NN NN O
- NN NN O
2R NN NN O
chains NN NN O
were NN NN O
measured NN NN O
by NN NN O
flow NN NN O
cytometry NN NN O
, NN NN O
and NN NN O
Jaks NN NN O
/ NN NN O
Stats NN NN O
by NN NN O
sodium NN NN O
dodecyl NN NN O
sulfate NN NN O
polyacrylamide NN NN O
gel NN NN O
electrophoresis NN NN O
( NN NN O
SDS NN NN O
- NN NN O
PAGE NN NN O
) NN NN O
and NN NN O
Western NN NN O
blot NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Phorbol NN NN O
- NN NN O
myristate NN NN O
- NN NN O
acetate NN NN O
and NN NN O
ionomycine NN NN O
strongly NN NN O
increase NN NN O
the NN NN O
percent NN NN O
- NN NN O
age NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
+ NN NN O
cells NN NN O
; NN NN O
an NN NN O
additional NN NN O
50 NN NN O
% NN NN O
HCSs NN NN O
significantly NN NN O
suppresses NN NN O
the NN NN O
percentage NN NN O
to NN NN O
, NN NN O
or NN NN O
below NN NN O
the NN NN O
level NN NN O
of NN NN O
unstimulated NN NN O
cells NN NN O
. NN NN O
   
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
production NN NN O
is NN NN O
strongly NN NN O
decreased NN NN O
by NN NN O
HCSs NN NN O
in NN NN O
some NN NN O
cases NN NN O
, NN NN O
but NN NN O
not NN NN O
in NN NN O
others NN NN O
. NN NN O
   
PHA NN NN B-Protein
stimulates NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
- NN NN I-Protein
, NN NN O
beta NN NN B-Protein
- NN NN I-Protein
, NN NN O
and NN NN O
gamma NN NN B-Protein
- NN NN I-Protein
chain NN NN I-Protein
expression NN NN O
and NN NN O
their NN NN O
signaling NN NN O
pathway NN NN O
molecules NN NN O
Jak1 NN NN B-Protein
, NN NN O
Jak3 NN NN B-Protein
, NN NN O
Stat1 NN NN B-Protein
, NN NN O
Stat3 NN NN B-Protein
, NN NN O
and NN NN O
Stat5 NN NN B-Protein
. NN NN O
   
50 NN NN O
% NN NN O
HCS NN NN O
downregulates NN NN O
the NN NN O
alpha NN NN O
- NN NN O
chain NN NN O
and NN NN O
slightly NN NN O
upregulates NN NN O
the NN NN O
beta NN NN O
- NN NN O
chain NN NN O
. NN NN O
   
Jak1 NN NN B-Protein
, NN NN O
Jak3 NN NN B-Protein
, NN NN O
Stat1 NN NN B-Protein
, NN NN O
Stat3 NN NN B-Protein
, NN NN O
and NN NN O
Stat5 NN NN B-Protein
expression NN NN O
is NN NN O
suppressed NN NN O
approximately NN NN O
to NN NN O
, NN NN O
or NN NN O
below NN NN O
the NN NN O
level NN NN O
of NN NN O
unstimulated NN NN O
cells NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
HCS NN NN O
forcefully NN NN O
blocks NN NN O
the NN NN O
production NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
; NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
- NN NN I-Protein
chain NN NN I-Protein
; NN NN O
and NN NN O
Jak1 NN NN B-Protein
, NN NN O
Jak3 NN NN B-Protein
, NN NN O
Stat1 NN NN B-Protein
, NN NN O
Stat3 NN NN B-Protein
, NN NN O
and NN NN O
Stat5 NN NN B-Protein
expression NN NN O
. NN NN O
   
The NN NN O
observed NN NN O
phenomena NN NN O
might NN NN O
be NN NN O
caused NN NN O
by NN NN O
downregulation NN NN O
of NN NN O
an NN NN O
IL NN NN O
- NN NN O
2R NN NN O
regulation NN NN O
gene NN NN O
, NN NN O
and NN NN O
might NN NN O
play NN NN O
a NN NN O
key NN NN O
role NN NN O
in NN NN O
the NN NN O
expansion NN NN O
of NN NN O
choriocarcinoma NN NN O
, NN NN O
and NN NN O
possibly NN NN O
in NN NN O
the NN NN O
survival NN NN O
of NN NN O
the NN NN O
fetal NN NN O
allograft NN NN O
. NN NN O
   
Vitamin NN NN B-Protein
D NN NN I-Protein
receptor NN NN I-Protein
3 NN NN O
' NN NN O
- NN NN O
untranslated NN NN O
region NN NN O
polymorphisms NN NN O
: NN NN O
lack NN NN O
of NN NN O
effect NN NN O
on NN NN O
mRNA NN NN O
stability NN NN O
. NN NN O
   
Allelic NN NN O
variation NN NN O
at NN NN O
the NN NN O
3 NN NN O
' NN NN O
- NN NN O
end NN NN O
of NN NN O
the NN NN O
vitamin NN NN B-Protein
D NN NN I-Protein
receptor NN NN I-Protein
( NN NN O
VDR NN NN B-Protein
) NN NN O
gene NN NN O
has NN NN O
been NN NN O
associated NN NN O
with NN NN O
a NN NN O
3 NN NN O
- NN NN O
5 NN NN O
- NN NN O
fold NN NN O
increased NN NN O
risk NN NN O
of NN NN O
developing NN NN O
prostate NN NN O
cancer NN NN O
and NN NN O
with NN NN O
differences NN NN O
in NN NN O
bone NN NN O
mineralization NN NN O
. NN NN O
   
This NN NN O
genetic NN NN O
diversity NN NN O
does NN NN O
not NN NN O
alter NN NN O
the NN NN O
VDR NN NN B-Protein
protein NN NN O
structurally NN NN O
, NN NN O
but NN NN O
instead NN NN O
may NN NN O
be NN NN O
a NN NN O
marker NN NN O
( NN NN O
s NN NN O
) NN NN O
of NN NN O
other NN NN O
, NN NN O
nearby NN NN O
polymorphisms NN NN O
that NN NN O
influence NN NN O
message NN NN O
stability NN NN O
or NN NN O
translation NN NN O
. NN NN O
   
The NN NN O
work NN NN O
reported NN NN O
here NN NN O
was NN NN O
instigated NN NN O
to NN NN O
identify NN NN O
additional NN NN O
VDR NN NN B-Protein
3 NN NN O
' NN NN O
- NN NN O
UTR NN NN O
polymorphisms NN NN O
that NN NN O
may NN NN O
have NN NN O
functional NN NN O
significance NN NN O
and NN NN O
to NN NN O
then NN NN O
test NN NN O
whether NN NN O
these NN NN O
genetic NN NN O
variants NN NN O
alter NN NN O
message NN NN O
stability NN NN O
. NN NN O
   
Initially NN NN O
, NN NN O
four NN NN O
novel NN NN O
, NN NN O
frequently NN NN O
occurring NN NN O
sequence NN NN O
variants NN NN O
were NN NN O
identified NN NN O
that NN NN O
associated NN NN O
with NN NN O
two NN NN O
common NN NN O
haplotypes NN NN O
that NN NN O
were NN NN O
described NN NN O
previously NN NN O
. NN NN O
   
These NN NN O
common NN NN O
sequence NN NN O
variants NN NN O
were NN NN O
not NN NN O
found NN NN O
within NN NN O
three NN NN O
message NN NN O
- NN NN O
destabilizing NN NN O
elements NN NN O
that NN NN O
we NN NN O
mapped NN NN O
within NN NN O
the NN NN O
3 NN NN O
' NN NN O
- NN NN O
UTR NN NN O
of NN NN O
the NN NN O
vitamin NN NN B-Protein
D NN NN I-Protein
receptor NN NN I-Protein
mRNA NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
the NN NN O
two NN NN O
VDR NN NN B-Protein
3 NN NN O
' NN NN O
- NN NN O
UTR NN NN O
haplotypes NN NN O
conferred NN NN O
an NN NN O
identical NN NN O
half NN NN O
- NN NN O
life NN NN O
on NN NN O
a NN NN O
heterologous NN NN O
beta NN NN O
- NN NN O
globin NN NN O
reporter NN NN O
gene NN NN O
, NN NN O
in NN NN O
an NN NN O
in NN NN O
vitro NN NN O
assay NN NN O
. NN NN O
   
We NN NN O
therefore NN NN O
conclude NN NN O
that NN NN O
common NN NN O
polymorphisms NN NN O
within NN NN O
the NN NN O
VDR NN NN B-Protein
3 NN NN O
' NN NN O
- NN NN O
UTR NN NN O
do NN NN O
not NN NN O
influence NN NN O
message NN NN O
stability NN NN O
. NN NN O
   
[ NN NN O
Induction NN NN O
of NN NN O
apoptosis NN NN O
in NN NN O
lymphocytes NN NN O
by NN NN O
glucocorticoids NN NN O
: NN NN O
between NN NN O
physiology NN NN O
and NN NN O
pharmacology NN NN O
] NN NN O
   
Glucocorticoids NN NN O
are NN NN O
physiological NN NN O
molecules NN NN O
that NN NN O
are NN NN O
also NN NN O
extensively NN NN O
used NN NN O
in NN NN O
clinics NN NN O
as NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
, NN NN O
immunosuppressive NN NN O
or NN NN O
anti NN NN O
- NN NN O
tumoral NN NN O
agents NN NN O
. NN NN O
   
Glucocorticoids NN NN O
can NN NN O
induce NN NN O
apoptosis NN NN O
on NN NN O
normal NN NN O
lymphoid NN NN O
cells NN NN O
and NN NN O
play NN NN O
a NN NN O
key NN NN O
role NN NN O
in NN NN O
the NN NN O
physiology NN NN O
of NN NN O
thymic NN NN O
selection NN NN O
. NN NN O
   
In NN NN O
clinics NN NN O
these NN NN O
molecules NN NN O
are NN NN O
also NN NN O
used NN NN O
for NN NN O
their NN NN O
potencies NN NN O
in NN NN O
inducing NN NN O
apoptosis NN NN O
of NN NN O
malignant NN NN O
lymphoid NN NN O
cells NN NN O
. NN NN O
   
Glucocorticoids NN NN O
are NN NN O
mediating NN NN O
their NN NN O
effects NN NN O
after NN NN O
binding NN NN O
to NN NN O
an NN NN O
intracellular NN NN O
receptor NN NN O
belonging NN NN O
to NN NN O
the NN NN O
steroid NN NN O
receptor NN NN O
superfamily NN NN O
: NN NN O
the NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
( NN NN O
GR NN NN B-Protein
) NN NN O
. NN NN O
   
Once NN NN O
activated NN NN O
, NN NN O
the NN NN O
GR NN NN B-Protein
, NN NN O
can NN NN O
mediate NN NN O
his NN NN O
effects NN NN O
through NN NN O
direct NN NN O
binding NN NN O
on NN NN O
the NN NN O
DNA NN NN O
or NN NN O
via NN NN O
protein NN NN O
/ NN NN O
protein NN NN O
interactions NN NN O
with NN NN O
transcription NN NN O
factors NN NN O
. NN NN O
   
Depending NN NN O
on NN NN O
the NN NN O
type NN NN O
of NN NN O
lymphocytes NN NN O
, NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
apoptosis NN NN O
induced NN NN O
by NN NN O
glucocorticoids NN NN O
fall NN NN O
roughly NN NN O
in NN NN O
two NN NN O
categories NN NN O
: NN NN O
induction NN NN O
of NN NN O
"""""""" NN NN O
death NN NN O
genes NN NN O
"""""""" NN NN O
by NN NN O
the NN NN O
activated NN NN O
GR NN NN B-Protein
( NN NN O
I NN NN O
kappa NN NN O
B NN NN O
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
) NN NN O
or NN NN O
repression NN NN O
of NN NN O
survival NN NN O
factors NN NN O
( NN NN O
AP NN NN O
- NN NN O
1 NN NN O
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
Myc NN NN I-Protein
) NN NN O
. NN NN O
   
In NN NN O
the NN NN O
case NN NN O
of NN NN O
thymic NN NN O
selection NN NN O
the NN NN O
mechanism NN NN O
is NN NN O
more NN NN O
subtle NN NN O
depending NN NN O
on NN NN O
the NN NN O
mutual NN NN O
repression NN NN O
of NN NN O
Nur77 NN NN B-Protein
and NN NN O
GR NN NN B-Protein
. NN NN O
   
Cleavage NN NN O
of NN NN O
transcription NN NN O
factor NN NN O
SP1 NN NN B-Protein
by NN NN O
caspases NN NN O
during NN NN O
anti NN NN O
- NN NN O
IgM NN NN O
- NN NN O
induced NN NN O
B NN NN O
- NN NN O
cell NN NN O
apoptosis NN NN O
. NN NN O
   
Apoptosis NN NN O
is NN NN O
instrumental NN NN O
in NN NN O
the NN NN O
processes NN NN O
generating NN NN O
the NN NN O
diversity NN NN O
of NN NN O
the NN NN O
B NN NN O
- NN NN O
cell NN NN O
repertoire NN NN O
. NN NN O
   
Autoreactive NN NN O
B NN NN O
- NN NN O
cells NN NN O
are NN NN O
eliminated NN NN O
by NN NN O
anti NN NN O
- NN NN O
IgM NN NN O
crosslinking NN NN O
after NN NN O
encountering NN NN O
self NN NN O
- NN NN O
antigens NN NN O
, NN NN O
but NN NN O
precise NN NN O
mechanisms NN NN O
leading NN NN O
to NN NN O
B NN NN O
- NN NN O
cell NN NN O
apoptosis NN NN O
are NN NN O
still NN NN O
not NN NN O
well NN NN O
understood NN NN O
. NN NN O
   
We NN NN O
report NN NN O
here NN NN O
the NN NN O
cleavage NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
SP1 NN NN B-Protein
in NN NN O
the NN NN O
human NN NN O
Burkitt NN NN O
lymphoma NN NN O
cell NN NN O
line NN NN O
BL60 NN NN O
during NN NN O
anti NN NN O
- NN NN O
IgM NN NN O
- NN NN O
induced NN NN O
apoptosis NN NN O
. NN NN O
   
Western NN NN O
blot NN NN O
analysis NN NN O
revealed NN NN O
two NN NN O
cleavage NN NN O
products NN NN O
of NN NN O
approximately NN NN O
68 NN NN O
kDa NN NN O
and NN NN O
45 NN NN O
kDa NN NN O
after NN NN O
induction NN NN O
of NN NN O
apoptosis NN NN O
. NN NN O
   
Cleavage NN NN O
could NN NN O
be NN NN O
completely NN NN O
inhibited NN NN O
by NN NN O
zDEVD NN NN O
- NN NN O
fmk NN NN O
, NN NN O
an NN NN O
inhibitor NN NN O
specific NN NN O
for NN NN O
caspase NN NN O
3 NN NN O
- NN NN O
like NN NN O
proteases NN NN O
. NN NN O
   
In NN NN O
- NN NN O
vitro NN NN O
cleavage NN NN O
of NN NN O
recombinant NN NN O
SP1 NN NN B-Protein
by NN NN O
recombinant NN NN O
caspase NN NN B-Protein
3 NN NN I-Protein
( NN NN O
CPP32 NN NN B-Protein
) NN NN O
or NN NN O
caspase NN NN B-Protein
7 NN NN I-Protein
( NN NN O
Mch NN NN B-Protein
3 NN NN I-Protein
) NN NN O
results NN NN O
in NN NN O
similar NN NN O
cleavage NN NN O
products NN NN O
as NN NN O
those NN NN O
observed NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
Recombinant NN NN O
caspase NN NN B-Protein
6 NN NN I-Protein
( NN NN O
Mch NN NN B-Protein
2 NN NN I-Protein
) NN NN O
primarily NN NN O
generates NN NN O
a NN NN O
68 NN NN O
- NN NN O
kDa NN NN O
cleavage NN NN O
product NN NN O
, NN NN O
as NN NN O
observed NN NN O
after NN NN O
calcium NN NN O
ionophore NN NN O
( NN NN O
CaI NN NN O
) NN NN O
induced NN NN O
B NN NN O
- NN NN O
cell NN NN O
apoptosis NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
caspase NN NN B-Protein
1 NN NN I-Protein
( NN NN O
ICE NN NN B-Protein
) NN NN O
did NN NN O
not NN NN O
cleave NN NN O
SP1 NN NN B-Protein
in NN NN O
vitro NN NN O
. NN NN O
   
The NN NN O
time NN NN O
course NN NN O
of NN NN O
SP1 NN NN B-Protein
cleavage NN NN O
during NN NN O
anti NN NN O
- NN NN O
IgM NN NN O
- NN NN O
induced NN NN O
apoptosis NN NN O
is NN NN O
paralleled NN NN O
by NN NN O
an NN NN O
increase NN NN O
of NN NN O
caspase NN NN O
activity NN NN O
measured NN NN O
by NN NN O
DEVD NN NN O
- NN NN O
p NN NN O
- NN NN O
nitroanilide NN NN O
( NN NN O
DEVD NN NN O
- NN NN O
pNA NN NN O
) NN NN O
cleavage NN NN O
. NN NN O
   
DNA NN NN O
band NN NN O
- NN NN O
shift NN NN O
assays NN NN O
revealed NN NN O
a NN NN O
decrease NN NN O
in NN NN O
the NN NN O
intensity NN NN O
of NN NN O
the NN NN O
full NN NN O
length NN NN O
SP1 NN NN B-Protein
/ NN NN O
DNA NN NN O
complex NN NN O
and NN NN O
an NN NN O
increase NN NN O
in NN NN O
the NN NN O
intensity NN NN O
of NN NN O
a NN NN O
smaller NN NN O
complex NN NN O
due NN NN O
to NN NN O
the NN NN O
binding NN NN O
of NN NN O
one NN NN O
SP1 NN NN B-Protein
cleavage NN NN O
product NN NN O
. NN NN O
   
By NN NN O
Edman NN NN O
sequencing NN NN O
we NN NN O
could NN NN O
identify NN NN O
a NN NN O
caspase NN NN B-Protein
3 NN NN I-Protein
cleavage NN NN O
site NN NN O
after NN NN O
Asp584 NN NN O
( NN NN O
D584AQPQAGR NN NN O
) NN NN O
, NN NN O
generating NN NN O
a NN NN O
22 NN NN O
- NN NN O
kDa NN NN O
C NN NN O
- NN NN O
terminal NN NN O
SP1 NN NN B-Protein
protein NN NN O
fragment NN NN O
which NN NN O
still NN NN O
contains NN NN O
the NN NN O
DNA NN NN O
binding NN NN O
site NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
show NN NN O
the NN NN O
cleavage NN NN O
of NN NN O
the NN NN O
human NN NN O
transcription NN NN O
factor NN NN O
SP1 NN NN B-Protein
in NN NN O
vivo NN NN O
and NN NN O
in NN NN O
vitro NN NN O
, NN NN O
underlining NN NN O
the NN NN O
central NN NN O
role NN NN O
of NN NN O
caspase NN NN B-Protein
3 NN NN I-Protein
- NN NN O
like NN NN O
proteases NN NN O
during NN NN O
the NN NN O
process NN NN O
of NN NN O
anti NN NN O
- NN NN O
IgM NN NN O
- NN NN O
induced NN NN O
apoptosis NN NN O
. NN NN O
   
Spi NN NN B-Protein
- NN NN I-Protein
C NN NN I-Protein
, NN NN O
a NN NN O
novel NN NN O
Ets NN NN O
protein NN NN O
that NN NN O
is NN NN O
temporally NN NN O
regulated NN NN O
during NN NN O
B NN NN O
lymphocyte NN NN O
development NN NN O
. NN NN O
   
A NN NN O
novel NN NN O
Ets NN NN O
protein NN NN O
was NN NN O
isolated NN NN O
by NN NN O
yeast NN NN O
one NN NN O
- NN NN O
hybrid NN NN O
screening NN NN O
of NN NN O
a NN NN O
cDNA NN NN O
library NN NN O
made NN NN O
from NN NN O
lipopolysaccharide NN NN O
- NN NN O
stimulated NN NN O
mouse NN NN O
splenic NN NN O
B NN NN O
cells NN NN O
, NN NN O
using NN NN O
the NN NN O
SP6 NN NN O
kappa NN NN O
promoter NN NN O
kappaY NN NN O
element NN NN O
as NN NN O
a NN NN O
bait NN NN O
. NN NN O
   
The NN NN O
novel NN NN O
Ets NN NN O
protein NN NN O
was NN NN O
most NN NN O
closely NN NN O
related NN NN O
to NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
and NN NN O
Spi NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
within NN NN O
the NN NN O
DNA NN NN O
binding NN NN O
Ets NN NN O
domain NN NN O
and NN NN O
was NN NN O
therefore NN NN O
named NN NN O
Spi NN NN B-Protein
- NN NN I-Protein
C NN NN I-Protein
. NN NN O
   
However NN NN O
, NN NN O
Spi NN NN B-Protein
- NN NN I-Protein
C NN NN I-Protein
may NN NN O
represent NN NN O
a NN NN O
novel NN NN O
subgroup NN NN O
within NN NN O
the NN NN O
Ets NN NN O
protein NN NN O
family NN NN O
, NN NN O
as NN NN O
it NN NN O
differed NN NN O
significantly NN NN O
from NN NN O
Spi NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
and NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
within NN NN O
helix NN NN O
1 NN NN O
of NN NN O
the NN NN O
Ets NN NN O
domain NN NN O
. NN NN O
   
Spi NN NN B-Protein
- NN NN I-Protein
C NN NN I-Protein
was NN NN O
encoded NN NN O
by NN NN O
a NN NN O
single NN NN O
- NN NN O
copy NN NN O
gene NN NN O
that NN NN O
was NN NN O
mapped NN NN O
to NN NN O
chromosome NN NN O
10 NN NN O
, NN NN O
region NN NN O
C NN NN O
. NN NN O
   
Spi NN NN B-Protein
- NN NN I-Protein
C NN NN I-Protein
interacted NN NN O
with NN NN O
DNA NN NN O
similarly NN NN O
to NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
as NN NN O
judged NN NN O
by NN NN O
methylation NN NN O
interference NN NN O
, NN NN O
band NN NN O
- NN NN O
shift NN NN O
and NN NN O
site NN NN O
selection NN NN O
analysis NN NN O
, NN NN O
and NN NN O
activated NN NN O
transcription NN NN O
of NN NN O
a NN NN O
kappaY NN NN O
element NN NN O
reporter NN NN O
gene NN NN O
upon NN NN O
co NN NN O
- NN NN O
transfection NN NN O
of NN NN O
HeLa NN NN O
cells NN NN O
. NN NN O
   
Spi NN NN B-Protein
- NN NN I-Protein
C NN NN I-Protein
RNA NN NN O
was NN NN O
expressed NN NN O
in NN NN O
mature NN NN O
B NN NN O
lymphocytes NN NN O
and NN NN O
at NN NN O
lower NN NN O
levels NN NN O
in NN NN O
macrophages NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
pre NN NN O
- NN NN O
B NN NN O
cell NN NN O
and NN NN O
plasma NN NN O
cell NN NN O
lines NN NN O
were NN NN O
Spi NN NN B-Protein
- NN NN I-Protein
C NN NN I-Protein
- NN NN O
negative NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
Spi NN NN B-Protein
- NN NN I-Protein
C NN NN I-Protein
might NN NN O
be NN NN O
a NN NN O
regulatory NN NN O
molecule NN NN O
during NN NN O
a NN NN O
specific NN NN O
phase NN NN O
of NN NN O
B NN NN O
lymphoid NN NN O
development NN NN O
. NN NN O
   
Evidence NN NN O
for NN NN O
a NN NN O
polyclonal NN NN O
etiology NN NN O
of NN NN O
palmar NN NN O
fibromatosis NN NN O
. NN NN O
   
X NN NN O
chromosome NN NN O
inactivation NN NN O
patterns NN NN O
at NN NN O
the NN NN O
androgen NN NN B-Protein
receptor NN NN I-Protein
locus NN NN O
were NN NN O
evaluated NN NN O
to NN NN O
determine NN NN O
clonality NN NN O
in NN NN O
microdissected NN NN O
lesional NN NN O
tissue NN NN O
and NN NN O
in NN NN O
leukocytes NN NN O
from NN NN O
2 NN NN O
women NN NN O
with NN NN O
Dupuytren NN NN O
' NN NN O
s NN NN O
disease NN NN O
. NN NN O
   
The NN NN O
tissue NN NN O
from NN NN O
both NN NN O
patients NN NN O
generated NN NN O
a NN NN O
polyclonal NN NN O
pattern NN NN O
of NN NN O
X NN NN O
chromosome NN NN O
inactivation NN NN O
of NN NN O
the NN NN O
human NN NN O
androgen NN NN B-Protein
receptor NN NN I-Protein
gene NN NN O
. NN NN O
   
This NN NN O
finding NN NN O
supports NN NN O
a NN NN O
polyclonal NN NN O
reactive NN NN O
process NN NN O
as NN NN O
the NN NN O
underlying NN NN O
etiology NN NN O
for NN NN O
palmar NN NN O
fibromatosis NN NN O
. NN NN O
   
Transient NN NN O
pseudo NN NN O
- NN NN O
hypoaldosteronism NN NN O
following NN NN O
resection NN NN O
of NN NN O
the NN NN O
ileum NN NN O
: NN NN O
normal NN NN O
level NN NN O
of NN NN O
lymphocytic NN NN O
aldosterone NN NN B-Protein
receptors NN NN I-Protein
outside NN NN O
the NN NN O
acute NN NN O
phase NN NN O
. NN NN O
   
Pseudo NN NN O
- NN NN O
hypoaldosteronism NN NN O
( NN NN O
PHA NN NN O
) NN NN O
is NN NN O
due NN NN O
to NN NN O
mineralocorticoid NN NN O
resistance NN NN O
and NN NN O
manifests NN NN O
as NN NN O
hyponatremia NN NN O
and NN NN O
hyperkalemia NN NN O
with NN NN O
increased NN NN O
plasma NN NN O
aldosterone NN NN O
levels NN NN O
. NN NN O
   
It NN NN O
may NN NN O
be NN NN O
familial NN NN O
or NN NN O
secondary NN NN O
to NN NN O
abnormal NN NN O
renal NN NN O
sodium NN NN O
handling NN NN O
. NN NN O
   
We NN NN O
report NN NN O
the NN NN O
case NN NN O
of NN NN O
a NN NN O
54 NN NN O
- NN NN O
year NN NN O
- NN NN O
old NN NN O
woman NN NN O
with NN NN O
multifocal NN NN O
cancer NN NN O
of NN NN O
the NN NN O
colon NN NN O
, NN NN O
who NN NN O
developed NN NN O
PHA NN NN O
after NN NN O
subtotal NN NN O
colectomy NN NN O
, NN NN O
ileal NN NN O
resection NN NN O
and NN NN O
jejunostomy NN NN O
. NN NN O
   
She NN NN O
was NN NN O
treated NN NN O
with NN NN O
6 NN NN O
g NN NN O
of NN NN O
salt NN NN O
daily NN NN O
to NN NN O
prevent NN NN O
dehydration NN NN O
, NN NN O
which NN NN O
she NN NN O
stopped NN NN O
herself NN NN O
because NN NN O
of NN NN O
reduced NN NN O
fecal NN NN O
losses NN NN O
. NN NN O
   
One NN NN O
month NN NN O
later NN NN O
she NN NN O
was NN NN O
admitted NN NN O
with NN NN O
signs NN NN O
of NN NN O
acute NN NN O
adrenal NN NN O
failure NN NN O
, NN NN O
i NN NN O
. NN NN O
e NN NN O
. NN NN O
fatigue NN NN O
, NN NN O
severe NN NN O
nausea NN NN O
, NN NN O
blood NN NN O
pressure NN NN O
of NN NN O
80 NN NN O
/ NN NN O
60 NN NN O
mmHg NN NN O
, NN NN O
extracellular NN NN O
dehydration NN NN O
, NN NN O
hyponatremia NN NN O
( NN NN O
118 NN NN O
mmol NN NN O
/ NN NN O
l NN NN O
) NN NN O
; NN NN O
hyperkalemia NN NN O
( NN NN O
7 NN NN O
. NN NN O
6 NN NN O
mmol NN NN O
/ NN NN O
l NN NN O
) NN NN O
, NN NN O
increased NN NN O
blood NN NN O
urea NN NN O
nitrogen NN NN O
( NN NN O
BUN NN NN O
) NN NN O
( NN NN O
200 NN NN O
mg NN NN O
/ NN NN O
dl NN NN O
) NN NN O
and NN NN O
creatininemia NN NN O
( NN NN O
2 NN NN O
. NN NN O
5 NN NN O
mg NN NN O
/ NN NN O
dl NN NN O
) NN NN O
, NN NN O
and NN NN O
decreased NN NN O
plasma NN NN O
bicarbonates NN NN O
level NN NN O
( NN NN O
HCO3 NN NN O
- NN NN O
: NN NN O
16 NN NN O
mmol NN NN O
/ NN NN O
l NN NN O
; NN NN O
N NN NN O
: NN NN O
27 NN NN O
- NN NN O
30 NN NN O
) NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
plasma NN NN O
cortisol NN NN O
was NN NN O
high NN NN O
( NN NN O
66 NN NN O
microg NN NN O
/ NN NN O
100 NN NN O
ml NN NN O
at NN NN O
10 NN NN O
: NN NN O
00 NN NN O
h NN NN O
; NN NN O
N NN NN O
: NN NN O
8 NN NN O
- NN NN O
15 NN NN O
) NN NN O
and NN NN O
the NN NN O
ACTH NN NN O
was NN NN O
normal NN NN O
( NN NN O
13 NN NN O
pg NN NN O
/ NN NN O
ml NN NN O
, NN NN O
N NN NN O
: NN NN O
10 NN NN O
- NN NN O
60 NN NN O
) NN NN O
; NN NN O
there NN NN O
was NN NN O
a NN NN O
marked NN NN O
increase NN NN O
in NN NN O
plasma NN NN O
renin NN NN B-Protein
activity NN NN O
( NN NN O
> NN NN O
37 NN NN O
ng NN NN O
/ NN NN O
ml NN NN O
/ NN NN O
h NN NN O
; NN NN O
N NN NN O
supine NN NN O
< NN NN O
3 NN NN O
) NN NN O
, NN NN O
active NN NN O
renin NN NN B-Protein
( NN NN O
869 NN NN O
pg NN NN O
/ NN NN O
ml NN NN O
; NN NN O
N NN NN O
supine NN NN O
: NN NN O
1 NN NN O
. NN NN O
120 NN NN O
) NN NN O
, NN NN O
aldosterone NN NN O
( NN NN O
> NN NN O
2000 NN NN O
pg NN NN O
/ NN NN O
ml NN NN O
; NN NN O
N NN NN O
supine NN NN O
< NN NN O
150 NN NN O
) NN NN O
and NN NN O
plasma NN NN O
AVP NN NN O
( NN NN O
20 NN NN O
pmol NN NN O
/ NN NN O
l NN NN O
; NN NN O
N NN NN O
: NN NN O
0 NN NN O
. NN NN O
5 NN NN O
- NN NN O
2 NN NN O
. NN NN O
5 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
plasma NN NN O
ANH NN NN O
level NN NN O
was NN NN O
38 NN NN O
pmol NN NN O
/ NN NN O
l NN NN O
( NN NN O
N NN NN O
supine NN NN O
: NN NN O
5 NN NN O
- NN NN O
25 NN NN O
) NN NN O
. NN NN O
   
A NN NN O
urinary NN NN O
steroidogram NN NN O
resulted NN NN O
in NN NN O
highly NN NN O
elevated NN NN O
tetrahydrocortisol NN NN O
( NN NN O
THF NN NN O
: NN NN O
13 NN NN O
. NN NN O
3 NN NN O
mg NN NN O
/ NN NN O
24h NN NN O
; NN NN O
N NN NN O
: NN NN O
1 NN NN O
. NN NN O
4 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
8 NN NN O
) NN NN O
with NN NN O
no NN NN O
increase NN NN O
in NN NN O
tetrahydrocortisone NN NN O
( NN NN O
THE NN NN O
: NN NN O
3 NN NN O
. NN NN O
16 NN NN O
mg NN NN O
/ NN NN O
24h NN NN O
; NN NN O
N NN NN O
: NN NN O
2 NN NN O
. NN NN O
7 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
. NN NN O
0 NN NN O
) NN NN O
excretion NN NN O
, NN NN O
and NN NN O
with NN NN O
low NN NN O
THE NN NN O
/ NN NN O
THF NN NN O
( NN NN O
0 NN NN O
. NN NN O
24 NN NN O
; NN NN O
N NN NN O
: NN NN O
1 NN NN O
. NN NN O
87 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
36 NN NN O
) NN NN O
and NN NN O
alpha NN NN O
THF NN NN O
/ NN NN O
THF NN NN O
( NN NN O
0 NN NN O
. NN NN O
35 NN NN O
; NN NN O
N NN NN O
: NN NN O
0 NN NN O
. NN NN O
92 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
42 NN NN O
) NN NN O
ratios NN NN O
. NN NN O
   
The NN NN O
number NN NN O
of NN NN O
mineralocorticoid NN NN B-Protein
receptors NN NN I-Protein
in NN NN O
mononuclear NN NN O
leukocytes NN NN O
was NN NN O
in NN NN O
the NN NN O
lower NN NN O
normal NN NN O
range NN NN O
for NN NN O
age NN NN O
, NN NN O
while NN NN O
the NN NN O
number NN NN O
of NN NN O
glucocorticoid NN NN B-Protein
receptors NN NN I-Protein
was NN NN O
reduced NN NN O
. NN NN O
   
Small NN NN O
- NN NN O
bowel NN NN O
resection NN NN O
in NN NN O
ileostomized NN NN O
patients NN NN O
causes NN NN O
excessive NN NN O
fecal NN NN O
sodium NN NN O
losses NN NN O
and NN NN O
results NN NN O
in NN NN O
chronic NN NN O
sodium NN NN O
depletion NN NN O
with NN NN O
contraction NN NN O
of NN NN O
the NN NN O
plasma NN NN O
volume NN NN O
and NN NN O
severe NN NN O
secondary NN NN O
hyperaldosteronism NN NN O
. NN NN O
   
Nevertheless NN NN O
, NN NN O
this NN NN O
hyperaldosteronism NN NN O
may NN NN O
be NN NN O
associated NN NN O
with NN NN O
hyponatremia NN NN O
and NN NN O
hyperkalemia NN NN O
suggesting NN NN O
PHA NN NN O
related NN NN O
to NN NN O
the NN NN O
major NN NN O
importance NN NN O
of NN NN O
the NN NN O
colon NN NN O
for NN NN O
the NN NN O
absorption NN NN O
of NN NN O
sodium NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
this NN NN O
case NN NN O
report NN NN O
emphasizes NN NN O
1 NN NN O
) NN NN O
the NN NN O
possibility NN NN O
of NN NN O
a NN NN O
syndrome NN NN O
of NN NN O
acquired NN NN O
PHA NN NN O
with NN NN O
severe NN NN O
hyperkalemia NN NN O
after NN NN O
resection NN NN O
of NN NN O
the NN NN O
ileum NN NN O
and NN NN O
colon NN NN O
responding NN NN O
to NN NN O
oral NN NN O
salt NN NN O
supplementation NN NN O
; NN NN O
2 NN NN O
) NN NN O
the NN NN O
major NN NN O
increase NN NN O
in NN NN O
AVP NN NN O
and NN NN O
the NN NN O
small NN NN O
increase NN NN O
in NN NN O
ANH NN NN O
; NN NN O
3 NN NN O
) NN NN O
the NN NN O
strong NN NN O
increase NN NN O
in NN NN O
urinary NN NN O
THF NN NN O
with NN NN O
low NN NN O
THE NN NN O
/ NN NN O
THF NN NN O
and NN NN O
alpha NN NN O
THF NN NN O
/ NN NN O
THF NN NN O
ratios NN NN O
; NN NN O
4 NN NN O
) NN NN O
the NN NN O
normal NN NN O
number NN NN O
of NN NN O
lymphocytic NN NN O
mineralocorticoid NN NN B-Protein
receptors NN NN I-Protein
outside NN NN O
the NN NN O
acute NN NN O
episode NN NN O
. NN NN O
   
In NN NN O
vivo NN NN O
modulation NN NN O
of NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
mRNA NN NN O
by NN NN O
inhaled NN NN O
fluticasone NN NN O
propionate NN NN O
in NN NN O
bronchial NN NN O
mucosa NN NN O
and NN NN O
blood NN NN O
lymphocytes NN NN O
in NN NN O
subjects NN NN O
with NN NN O
mild NN NN O
asthma NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
In NN NN O
vivo NN NN O
regulation NN NN O
of NN NN O
the NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
( NN NN O
GR NN NN B-Protein
) NN NN O
by NN NN O
glucocorticoids NN NN O
provides NN NN O
a NN NN O
means NN NN O
of NN NN O
modulating NN NN O
sensitivity NN NN O
of NN NN O
targeted NN NN O
cells NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
We NN NN O
sought NN NN O
to NN NN O
determine NN NN O
the NN NN O
in NN NN O
vivo NN NN O
modulation NN NN O
of NN NN O
GR NN NN B-Protein
mRNA NN NN O
expression NN NN O
by NN NN O
fluticasone NN NN O
propionate NN NN O
( NN NN O
FP NN NN O
) NN NN O
in NN NN O
subjects NN NN O
with NN NN O
mild NN NN O
asthma NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Ten NN NN O
atopic NN NN O
asthmatic NN NN O
subjects NN NN O
were NN NN O
treated NN NN O
with NN NN O
FP NN NN O
250 NN NN O
microg NN NN O
twice NN NN O
daily NN NN O
for NN NN O
4 NN NN O
weeks NN NN O
. NN NN O
   
Before NN NN O
and NN NN O
after NN NN O
treatment NN NN O
, NN NN O
the NN NN O
patients NN NN O
underwent NN NN O
fiberoptic NN NN O
bronchoscopy NN NN O
with NN NN O
endobronchial NN NN O
biopsy NN NN O
and NN NN O
sampling NN NN O
of NN NN O
venous NN NN O
blood NN NN O
for NN NN O
measurements NN NN O
of NN NN O
GR NN NN B-Protein
mRNA NN NN O
levels NN NN O
. NN NN O
   
A NN NN O
solution NN NN O
hybridization NN NN O
assay NN NN O
was NN NN O
used NN NN O
for NN NN O
quantitative NN NN O
analysis NN NN O
of NN NN O
GR NN NN B-Protein
mRNA NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
a NN NN O
24 NN NN O
- NN NN O
hour NN NN O
urinary NN NN O
cortisol NN NN O
excretion NN NN O
and NN NN O
an NN NN O
adrenocorticotropic NN NN B-Protein
hormone NN NN I-Protein
test NN NN O
before NN NN O
and NN NN O
after NN NN O
treatment NN NN O
with NN NN O
FP NN NN O
were NN NN O
performed NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
A NN NN O
high NN NN O
interindividual NN NN O
variation NN NN O
in NN NN O
GR NN NN B-Protein
mRNA NN NN O
expression NN NN O
was NN NN O
seen NN NN O
. NN NN O
   
However NN NN O
, NN NN O
we NN NN O
detected NN NN O
a NN NN O
significant NN NN O
reduction NN NN O
of NN NN O
the NN NN O
GR NN NN B-Protein
mRNA NN NN O
levels NN NN O
in NN NN O
the NN NN O
endobronchial NN NN O
biopsy NN NN O
specimens NN NN O
after NN NN O
FP NN NN O
treatment NN NN O
( NN NN O
36 NN NN O
. NN NN O
6 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
23 NN NN O
. NN NN O
1 NN NN O
and NN NN O
25 NN NN O
. NN NN O
0 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
10 NN NN O
. NN NN O
9 NN NN O
amol NN NN O
GR NN NN B-Protein
mRNA NN NN O
/ NN NN O
microg NN NN O
RNA NN NN O
, NN NN O
respectively NN NN O
; NN NN O
P NN NN O
< NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
In NN NN O
the NN NN O
peripheral NN NN O
blood NN NN O
lymphocytes NN NN O
an NN NN O
even NN NN O
more NN NN O
striking NN NN O
downregulation NN NN O
of NN NN O
the NN NN O
GR NN NN B-Protein
by NN NN O
its NN NN O
cognate NN NN O
ligand NN NN O
was NN NN O
documented NN NN O
( NN NN O
30 NN NN O
. NN NN O
3 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
26 NN NN O
. NN NN O
5 NN NN O
and NN NN O
8 NN NN O
. NN NN O
8 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
5 NN NN O
amol NN NN O
GR NN NN B-Protein
mRNA NN NN O
/ NN NN O
microg NN NN O
RNA NN NN O
, NN NN O
respectively NN NN O
; NN NN O
P NN NN O
< NN NN O
. NN NN O
001 NN NN O
) NN NN O
, NN NN O
possibly NN NN O
reflecting NN NN O
differences NN NN O
in NN NN O
glucocorticoid NN NN O
sensitivity NN NN O
between NN NN O
tissues NN NN O
. NN NN O
   
A NN NN O
small NN NN O
but NN NN O
significant NN NN O
reduction NN NN O
of NN NN O
the NN NN O
24 NN NN O
- NN NN O
hour NN NN O
urinary NN NN O
cortisol NN NN O
excretion NN NN O
was NN NN O
observed NN NN O
( NN NN O
233 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
109 NN NN O
and NN NN O
157 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
66 NN NN O
nmol NN NN O
/ NN NN O
L NN NN O
, NN NN O
respectively NN NN O
; NN NN O
P NN NN O
< NN NN O
. NN NN O
01 NN NN O
) NN NN O
, NN NN O
whereas NN NN O
the NN NN O
feedback NN NN O
regulation NN NN O
of NN NN O
glucocorticoid NN NN O
synthesis NN NN O
by NN NN O
means NN NN O
of NN NN O
the NN NN O
hypothalamic NN NN O
- NN NN O
pituitary NN NN O
- NN NN O
adrenal NN NN O
axis NN NN O
as NN NN O
assessed NN NN O
by NN NN O
the NN NN O
adrenocorticotropic NN NN B-Protein
hormone NN NN I-Protein
test NN NN O
remained NN NN O
normal NN NN O
after NN NN O
treatment NN NN O
with NN NN O
FP NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
The NN NN O
results NN NN O
in NN NN O
this NN NN O
study NN NN O
confirm NN NN O
the NN NN O
potency NN NN O
of NN NN O
the NN NN O
inhaled NN NN O
corticosteroid NN NN O
FP NN NN O
and NN NN O
provide NN NN O
evidence NN NN O
for NN NN O
a NN NN O
considerable NN NN O
tissue NN NN O
- NN NN O
specific NN NN O
interindividual NN NN O
variation NN NN O
in NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
GR NN NN B-Protein
. NN NN O
   
p38 NN NN O
mitogen NN NN O
- NN NN O
activated NN NN O
protein NN NN O
kinase NN NN O
mediates NN NN O
signal NN NN O
integration NN NN O
of NN NN O
TCR NN NN O
/ NN NN O
CD28 NN NN B-Protein
costimulation NN NN O
in NN NN O
primary NN NN O
murine NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Optimal NN NN O
T NN NN O
cell NN NN O
activation NN NN O
requires NN NN O
two NN NN O
signals NN NN O
, NN NN O
one NN NN O
generated NN NN O
by NN NN O
TCR NN NN O
and NN NN O
another NN NN O
by NN NN O
the NN NN O
CD28 NN NN B-Protein
costimulatory NN NN I-Protein
receptor NN NN I-Protein
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
investigated NN NN O
the NN NN O
regulation NN NN O
of NN NN O
costimulation NN NN O
- NN NN O
induced NN NN O
mitogen NN NN O
- NN NN O
activated NN NN O
protein NN NN O
kinase NN NN O
( NN NN O
MAPK NN NN O
) NN NN O
activation NN NN O
in NN NN O
primary NN NN O
mouse NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
to NN NN O
that NN NN O
reported NN NN O
for NN NN O
human NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
, NN NN O
we NN NN O
found NN NN O
that NN NN O
p38 NN NN O
MAPK NN NN O
, NN NN O
but NN NN O
not NN NN O
Jun NN NN O
NH2 NN NN O
- NN NN O
terminal NN NN O
kinase NN NN O
( NN NN O
JNK NN NN O
) NN NN O
, NN NN O
is NN NN O
weakly NN NN O
activated NN NN O
upon NN NN O
stimulation NN NN O
with NN NN O
either NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
or NN NN O
anti NN NN O
- NN NN O
CD28 NN NN B-Protein
in NN NN O
murine NN NN O
thymocytes NN NN O
and NN NN O
splenic NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
However NN NN O
, NN NN O
p38 NN NN O
MAPK NN NN O
is NN NN O
activated NN NN O
strongly NN NN O
and NN NN O
synergistically NN NN O
by NN NN O
either NN NN O
CD3 NN NN O
/ NN NN O
CD28 NN NN B-Protein
coligation NN NN O
or NN NN O
PMA NN NN O
/ NN NN O
Ca2 NN NN O
+ NN NN O
ionophore NN NN O
stimulation NN NN O
, NN NN O
which NN NN O
mimics NN NN O
TCR NN NN O
- NN NN O
CD3 NN NN O
/ NN NN O
CD28 NN NN B-Protein
- NN NN O
mediated NN NN O
signaling NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
p38 NN NN O
MAPK NN NN O
correlates NN NN O
closely NN NN O
with NN NN O
the NN NN O
stimulation NN NN O
of NN NN O
T NN NN O
cell NN NN O
proliferation NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
PMA NN NN O
- NN NN O
induced NN NN O
JNK NN NN O
activation NN NN O
is NN NN O
inhibited NN NN O
by NN NN O
Ca2 NN NN O
+ NN NN O
ionophore NN NN O
. NN NN O
   
T NN NN O
cell NN NN O
proliferation NN NN O
and NN NN O
production NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
, NN NN O
and NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
induced NN NN O
by NN NN O
both NN NN O
CD3 NN NN O
and NN NN O
CD3 NN NN O
/ NN NN O
CD28 NN NN B-Protein
ligation NN NN O
and NN NN O
the NN NN O
nuclear NN NN O
expression NN NN O
of NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
and NN NN O
ATF NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
proteins NN NN O
are NN NN O
each NN NN O
blocked NN NN O
by NN NN O
the NN NN O
p38 NN NN O
MAPK NN NN O
inhibitor NN NN O
SB203580 NN NN O
. NN NN O
   
Our NN NN O
findings NN NN O
demonstrate NN NN O
that NN NN O
p38 NN NN O
MAPK NN NN O
1 NN NN O
) NN NN O
plays NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
signal NN NN O
integration NN NN O
during NN NN O
costimulation NN NN O
of NN NN O
primary NN NN O
mouse NN NN O
T NN NN O
cells NN NN O
, NN NN O
2 NN NN O
) NN NN O
may NN NN O
be NN NN O
involved NN NN O
in NN NN O
the NN NN O
induction NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
activation NN NN O
and NN NN O
augmentation NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
transcriptional NN NN O
activity NN NN O
, NN NN O
and NN NN O
3 NN NN O
) NN NN O
regulates NN NN O
whether NN NN O
T NN NN O
cells NN NN O
enter NN NN O
a NN NN O
state NN NN O
of NN NN O
functional NN NN O
unresponsiveness NN NN O
. NN NN O
   
The NN NN O
functional NN NN O
synergy NN NN O
between NN NN O
IL NN NN O
- NN NN O
12 NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
involves NN NN O
p38 NN NN O
mitogen NN NN O
- NN NN O
activated NN NN O
protein NN NN O
kinase NN NN O
and NN NN O
is NN NN O
associated NN NN O
with NN NN O
the NN NN O
augmentation NN NN O
of NN NN O
STAT NN NN O
serine NN NN O
phosphorylation NN NN O
. NN NN O
   
IL NN NN O
- NN NN O
12 NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
can NN NN O
stimulate NN NN O
mitogen NN NN O
- NN NN O
or NN NN O
CD3 NN NN O
- NN NN O
activated NN NN O
T NN NN O
cells NN NN O
to NN NN O
proliferate NN NN O
, NN NN O
produce NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
, NN NN O
and NN NN O
kill NN NN O
tumor NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
magnitude NN NN O
of NN NN O
these NN NN O
functional NN NN O
responses NN NN O
is NN NN O
greatly NN NN O
augmented NN NN O
when NN NN O
T NN NN O
cells NN NN O
are NN NN O
activated NN NN O
by NN NN O
the NN NN O
combination NN NN O
of NN NN O
IL NN NN O
- NN NN O
12 NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
Although NN NN O
peripheral NN NN O
blood NN NN O
T NN NN O
cells NN NN O
are NN NN O
largely NN NN O
unresponsive NN NN O
to NN NN O
these NN NN O
cytokines NN NN O
without NN NN O
prior NN NN O
activation NN NN O
, NN NN O
a NN NN O
small NN NN O
subset NN NN O
of NN NN O
CD8 NN NN B-Protein
+ NN NN O
T NN NN O
cells NN NN O
( NN NN O
CD8 NN NN B-Protein
+ NN NN O
CD18bright NN NN O
) NN NN O
is NN NN O
strongly NN NN O
activated NN NN O
by NN NN O
the NN NN O
combination NN NN O
of NN NN O
IL NN NN O
- NN NN O
12 NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
In NN NN O
this NN NN O
report NN NN O
we NN NN O
show NN NN O
that NN NN O
the NN NN O
functional NN NN O
synergy NN NN O
between NN NN O
IL NN NN O
- NN NN O
12 NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
in NN NN O
CD8 NN NN B-Protein
+ NN NN O
CD18bright NN NN O
T NN NN O
cells NN NN O
correlates NN NN O
with NN NN O
the NN NN O
activation NN NN O
of NN NN O
the NN NN O
stress NN NN O
kinases NN NN O
, NN NN O
p38 NN NN O
mitogen NN NN O
- NN NN O
activated NN NN O
protein NN NN O
( NN NN O
MAP NN NN O
) NN NN O
kinase NN NN O
and NN NN O
stress NN NN O
- NN NN O
activated NN NN O
protein NN NN O
kinase NN NN O
( NN NN O
SAPK NN NN O
) NN NN O
/ NN NN O
Jun NN NN O
N NN NN O
- NN NN O
terminal NN NN O
kinase NN NN O
, NN NN O
but NN NN O
not NN NN O
with NN NN O
the NN NN O
activation NN NN O
of NN NN O
the NN NN O
extracellular NN NN O
signal NN NN O
- NN NN O
regulated NN NN O
kinases NN NN O
. NN NN O
   
The NN NN O
functional NN NN O
synergy NN NN O
between NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
IL NN NN O
- NN NN O
12 NN NN O
is NN NN O
also NN NN O
associated NN NN O
with NN NN O
a NN NN O
prominent NN NN O
increase NN NN O
in NN NN O
STAT1 NN NN B-Protein
and NN NN O
STAT3 NN NN B-Protein
serine NN NN O
phosphorylation NN NN O
over NN NN O
that NN NN O
observed NN NN O
with NN NN O
IL NN NN O
- NN NN O
12 NN NN O
or NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
alone NN NN O
. NN NN O
   
By NN NN O
contrast NN NN O
, NN NN O
STAT NN NN O
tyrosine NN NN O
phosphorylation NN NN O
is NN NN O
not NN NN O
augmented NN NN O
over NN NN O
that NN NN O
seen NN NN O
with NN NN O
either NN NN O
cytokine NN NN O
alone NN NN O
. NN NN O
   
A NN NN O
specific NN NN O
inhibitor NN NN O
of NN NN O
p38 NN NN O
MAP NN NN O
kinase NN NN O
completely NN NN O
inhibits NN NN O
the NN NN O
serine NN NN O
phosphorylation NN NN O
of NN NN O
STAT1 NN NN B-Protein
and NN NN O
STAT3 NN NN B-Protein
induced NN NN O
by NN NN O
IL NN NN O
- NN NN O
12 NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
abrogates NN NN O
the NN NN O
functional NN NN O
synergy NN NN O
between NN NN O
IL NN NN O
- NN NN O
12 NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
without NN NN O
affecting NN NN O
STAT NN NN O
tyrosine NN NN O
phosphorylation NN NN O
. NN NN O
   
This NN NN O
suggests NN NN O
that NN NN O
p38 NN NN O
MAP NN NN O
kinase NN NN O
may NN NN O
play NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
regulating NN NN O
STAT NN NN O
serine NN NN O
phosphorylation NN NN O
in NN NN O
response NN NN O
to NN NN O
the NN NN O
combination NN NN O
of NN NN O
IL NN NN O
- NN NN O
12 NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
Furthermore NN NN O
, NN NN O
these NN NN O
findings NN NN O
indicate NN NN O
that NN NN O
the NN NN O
optimal NN NN O
activation NN NN O
of NN NN O
T NN NN O
cells NN NN O
by NN NN O
IL NN NN O
- NN NN O
12 NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
may NN NN O
depend NN NN O
on NN NN O
an NN NN O
interaction NN NN O
between NN NN O
the NN NN O
p38 NN NN O
MAP NN NN O
kinase NN NN O
and NN NN O
Janus NN NN O
kinase NN NN O
/ NN NN O
STAT NN NN O
signaling NN NN O
pathways NN NN O
. NN NN O
   
Modulation NN NN O
of NN NN O
E2F NN NN O
complexes NN NN O
during NN NN O
G0 NN NN O
to NN NN O
S NN NN O
phase NN NN O
transition NN NN O
in NN NN O
human NN NN O
primary NN NN O
B NN NN O
- NN NN O
lymphocytes NN NN O
. NN NN O
   
The NN NN O
pocket NN NN O
protein NN NN O
- NN NN O
E2F NN NN O
complexes NN NN O
are NN NN O
convergence NN NN O
points NN NN O
for NN NN O
cell NN NN O
cycle NN NN O
signaling NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
report NN NN O
, NN NN O
we NN NN O
identified NN NN O
and NN NN O
monitored NN NN O
the NN NN O
pocket NN NN O
protein NN NN O
- NN NN O
E2F NN NN O
complexes NN NN O
in NN NN O
human NN NN O
primary NN NN O
B NN NN O
- NN NN O
lymphocytes NN NN O
after NN NN O
activation NN NN O
by NN NN O
phorbol NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
. NN NN O
   
Consistent NN NN O
with NN NN O
previous NN NN O
data NN NN O
from NN NN O
human NN NN O
and NN NN O
mouse NN NN O
fibroblasts NN NN O
and NN NN O
T NN NN O
- NN NN O
lymphocytes NN NN O
, NN NN O
E2F4 NN NN B-Protein
and NN NN O
DP1 NN NN B-Protein
form NN NN O
the NN NN O
predominant NN NN O
E2F NN NN O
heterodimers NN NN O
both NN NN O
in NN NN O
G0 NN NN O
and NN NN O
G1 NN NN O
phases NN NN O
of NN NN O
the NN NN O
human NN NN O
B NN NN O
- NN NN O
lymphocyte NN NN O
cell NN NN O
cycle NN NN O
, NN NN O
whereas NN NN O
E2F1 NN NN B-Protein
and NN NN O
- NN NN B-Protein
3 NN NN I-Protein
are NN NN O
first NN NN O
detected NN NN O
in NN NN O
late NN NN O
G1 NN NN O
, NN NN O
and NN NN O
their NN NN O
expression NN NN O
levels NN NN O
increase NN NN O
towards NN NN O
S NN NN O
phase NN NN O
. NN NN O
   
Intriguingly NN NN O
, NN NN O
the NN NN O
major NN NN O
E2F NN NN O
complex NN NN O
that NN NN O
we NN NN O
detected NN NN O
in NN NN O
quiescent NN NN O
human NN NN O
B NN NN O
- NN NN O
lymphocytes NN NN O
is NN NN O
consisted NN NN O
of NN NN O
pRB NN NN B-Protein
, NN NN O
E2F4 NN NN B-Protein
, NN NN O
and NN NN O
DP1 NN NN B-Protein
. NN NN O
   
Though NN NN O
the NN NN O
levels NN NN O
of NN NN O
DP1 NN NN B-Protein
and NN NN O
- NN NN B-Protein
2 NN NN I-Protein
increase NN NN O
when NN NN O
cells NN NN O
progress NN NN O
from NN NN O
G0 NN NN O
to NN NN O
S NN NN O
, NN NN O
the NN NN O
proportion NN NN O
of NN NN O
DP1 NN NN B-Protein
to NN NN O
DP2 NN NN B-Protein
remains NN NN O
relatively NN NN O
constant NN NN O
during NN NN O
the NN NN O
cell NN NN O
cycle NN NN O
. NN NN O
   
We NN NN O
also NN NN O
observed NN NN O
an NN NN O
increase NN NN O
in NN NN O
electrophoretic NN NN O
mobility NN NN O
of NN NN O
the NN NN O
predominant NN NN O
E2F NN NN O
components NN NN O
, NN NN O
DP1 NN NN B-Protein
and NN NN O
E2F4 NN NN B-Protein
, NN NN O
as NN NN O
B NN NN O
- NN NN O
lymphocytes NN NN O
progressed NN NN O
from NN NN O
G0 NN NN O
into NN NN O
early NN NN O
G1 NN NN O
. NN NN O
   
This NN NN O
increase NN NN O
in NN NN O
mobility NN NN O
was NN NN O
attributable NN NN O
to NN NN O
dephosphorylation NN NN O
, NN NN O
as NN NN O
lambda NN NN O
phosphatase NN NN O
treatment NN NN O
could NN NN O
convert NN NN O
the NN NN O
slower NN NN O
migrating NN NN O
forms NN NN O
into NN NN O
the NN NN O
corresponding NN NN O
faster NN NN O
mobility NN NN O
forms NN NN O
. NN NN O
   
We NN NN O
further NN NN O
demonstrated NN NN O
that NN NN O
this NN NN O
change NN NN O
in NN NN O
phosphorylation NN NN O
status NN NN O
correlates NN NN O
with NN NN O
a NN NN O
decrease NN NN O
in NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
. NN NN O
   
This NN NN O
modulation NN NN O
of NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
mediated NN NN O
through NN NN O
the NN NN O
dephosphorylation NN NN O
of NN NN O
DP1 NN NN B-Protein
and NN NN O
E2F4 NN NN B-Protein
could NN NN O
help NN NN O
to NN NN O
explain NN NN O
the NN NN O
lack NN NN O
of NN NN O
in NN NN O
vivo NN NN O
DNA NN NN O
footprinting NN NN O
in NN NN O
late NN NN O
G1 NN NN O
and NN NN O
S NN NN O
phases NN NN O
of NN NN O
gene NN NN O
promoters NN NN O
negatively NN NN O
regulated NN NN O
through NN NN O
E2F NN NN O
sites NN NN O
and NN NN O
suggests NN NN O
a NN NN O
novel NN NN O
mechanism NN NN O
for NN NN O
controlling NN NN O
E2F NN NN O
transcriptional NN NN O
activity NN NN O
during NN NN O
the NN NN O
transition NN NN O
from NN NN O
quiescence NN NN O
to NN NN O
proliferation NN NN O
. NN NN O
   
Retinoid NN NN O
X NN NN O
receptor NN NN O
( NN NN O
RXR NN NN O
) NN NN O
agonist NN NN O
- NN NN O
induced NN NN O
activation NN NN O
of NN NN O
dominant NN NN O
- NN NN O
negative NN NN O
RXR NN NN O
- NN NN O
retinoic NN NN B-Protein
acid NN NN I-Protein
receptor NN NN I-Protein
alpha403 NN NN I-Protein
heterodimers NN NN O
is NN NN O
developmentally NN NN O
regulated NN NN O
during NN NN O
myeloid NN NN O
differentiation NN NN O
. NN NN O
   
The NN NN O
multiple NN NN O
biologic NN NN O
activities NN NN O
of NN NN O
retinoic NN NN O
acid NN NN O
( NN NN O
RA NN NN O
) NN NN O
are NN NN O
mediated NN NN O
through NN NN O
RAR NN NN O
and NN NN O
retinoid NN NN O
X NN NN O
receptor NN NN O
( NN NN O
RXR NN NN O
) NN NN O
nuclear NN NN O
receptors NN NN O
that NN NN O
interact NN NN O
with NN NN O
specific NN NN O
DNA NN NN O
target NN NN O
sequences NN NN O
as NN NN O
heterodimers NN NN O
( NN NN O
RXR NN NN O
- NN NN O
RAR NN NN O
) NN NN O
or NN NN O
homodimers NN NN O
( NN NN O
RXR NN NN O
- NN NN O
RXR NN NN O
) NN NN O
. NN NN O
   
RA NN NN O
receptor NN NN O
activation NN NN O
appears NN NN O
critical NN NN O
to NN NN O
regulating NN NN O
important NN NN O
aspects NN NN O
of NN NN O
hematopoiesis NN NN O
, NN NN O
since NN NN O
transducing NN NN O
a NN NN O
COOH NN NN O
- NN NN O
terminally NN NN O
truncated NN NN O
RARalpha NN NN B-Protein
exhibiting NN NN O
dominant NN NN O
- NN NN O
negative NN NN O
activity NN NN O
( NN NN O
RARalpha403 NN NN B-Protein
) NN NN O
into NN NN O
normal NN NN O
mouse NN NN O
bone NN NN O
marrow NN NN O
generates NN NN O
hematopoietic NN NN O
growth NN NN O
factor NN NN O
- NN NN O
dependent NN NN O
cell NN NN O
lines NN NN O
frozen NN NN O
at NN NN O
the NN NN O
multipotent NN NN O
progenitor NN NN O
( NN NN O
EML NN NN O
) NN NN O
or NN NN O
committed NN NN O
promyelocyte NN NN O
( NN NN O
MPRO NN NN O
) NN NN O
stages NN NN O
. NN NN O
   
Nevertheless NN NN O
, NN NN O
relatively NN NN O
high NN NN O
, NN NN O
pharmacological NN NN O
concentrations NN NN O
of NN NN O
RA NN NN O
( NN NN O
1 NN NN O
to NN NN O
10 NN NN O
& NN NN O
mgr NN NN O
; NN NN O
M NN NN O
) NN NN O
overcome NN NN O
these NN NN O
differentiation NN NN O
blocks NN NN O
and NN NN O
induce NN NN O
terminal NN NN O
granulocytic NN NN O
differentiation NN NN O
of NN NN O
the NN NN O
MPRO NN NN O
promyelocytes NN NN O
while NN NN O
potentiating NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
) NN NN O
- NN NN O
induced NN NN O
commitment NN NN O
of NN NN O
EML NN NN O
cells NN NN O
to NN NN O
the NN NN O
granulocyte NN NN O
/ NN NN O
monocyte NN NN O
lineage NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
study NN NN O
, NN NN O
we NN NN O
utilized NN NN O
RXR NN NN O
- NN NN O
and NN NN O
RAR NN NN O
- NN NN O
specific NN NN O
agonists NN NN O
and NN NN O
antagonists NN NN O
to NN NN O
determine NN NN O
how NN NN O
RA NN NN O
overcomes NN NN O
the NN NN O
dominant NN NN O
- NN NN O
negative NN NN O
activity NN NN O
of NN NN O
the NN NN O
truncated NN NN O
RARalpha NN NN B-Protein
in NN NN O
these NN NN O
different NN NN O
myeloid NN NN O
developmental NN NN O
stages NN NN O
. NN NN O
   
Unexpectedly NN NN O
, NN NN O
we NN NN O
observed NN NN O
that NN NN O
an NN NN O
RXR NN NN O
- NN NN O
specific NN NN O
, NN NN O
rather NN NN O
than NN NN O
an NN NN O
RAR NN NN O
- NN NN O
specific NN NN O
, NN NN O
agonist NN NN O
induces NN NN O
terminal NN NN O
granulocytic NN NN O
differentiation NN NN O
of NN NN O
MPRO NN NN O
promyelocytes NN NN O
, NN NN O
and NN NN O
this NN NN O
differentiation NN NN O
is NN NN O
associated NN NN O
with NN NN O
activation NN NN O
of NN NN O
DNA NN NN O
response NN NN O
elements NN NN O
corresponding NN NN O
to NN NN O
RAR NN NN O
- NN NN O
RXR NN NN O
heterodimers NN NN O
rather NN NN O
than NN NN O
RXR NN NN O
- NN NN O
RXR NN NN O
homodimers NN NN O
. NN NN O
   
This NN NN O
RXR NN NN O
agonist NN NN O
activity NN NN O
is NN NN O
blocked NN NN O
by NN NN O
RAR NN NN O
- NN NN O
specific NN NN O
antagonists NN NN O
, NN NN O
suggesting NN NN O
extensive NN NN O
cross NN NN O
- NN NN O
talk NN NN O
between NN NN O
the NN NN O
partners NN NN O
of NN NN O
the NN NN O
RXR NN NN O
- NN NN O
RARalpha403 NN NN B-Protein
heterodimer NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
in NN NN O
the NN NN O
more NN NN O
immature NN NN O
, NN NN O
multipotent NN NN O
EML NN NN O
cells NN NN O
we NN NN O
observed NN NN O
that NN NN O
this NN NN O
RXR NN NN O
- NN NN O
specific NN NN O
agonist NN NN O
is NN NN O
inactive NN NN O
either NN NN O
in NN NN O
potentiating NN NN O
IL NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
- NN NN O
mediated NN NN O
commitment NN NN O
of NN NN O
EML NN NN O
cells NN NN O
to NN NN O
the NN NN O
granulocyte NN NN O
lineage NN NN O
or NN NN O
in NN NN O
transactivating NN NN O
RAR NN NN O
- NN NN O
RXR NN NN O
response NN NN O
elements NN NN O
. NN NN O
   
RA NN NN O
- NN NN O
triggered NN NN O
GALdbd NN NN O
- NN NN O
RARalpha NN NN B-Protein
hybrid NN NN O
activity NN NN O
in NN NN O
these NN NN O
cells NN NN O
indicates NN NN O
that NN NN O
the NN NN O
multipotent NN NN O
EML NN NN O
cells NN NN O
harbor NN NN O
substantial NN NN O
nuclear NN NN O
hormone NN NN O
receptor NN NN O
coactivator NN NN O
activity NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
histone NN NN O
deacetylase NN NN O
( NN NN O
HDAC NN NN O
) NN NN O
inhibitor NN NN O
trichostatin NN NN O
A NN NN O
readily NN NN O
activates NN NN O
an NN NN O
RXR NN NN O
- NN NN O
RAR NN NN O
reporter NN NN O
construct NN NN O
in NN NN O
the NN NN O
multipotent NN NN O
EML NN NN O
cells NN NN O
but NN NN O
not NN NN O
in NN NN O
the NN NN O
committed NN NN O
MPRO NN NN O
promyelocytes NN NN O
, NN NN O
indicating NN NN O
that NN NN O
differences NN NN O
in NN NN O
HDAC NN NN O
- NN NN O
containing NN NN O
repressor NN NN O
complexes NN NN O
in NN NN O
these NN NN O
two NN NN O
closely NN NN O
related NN NN O
but NN NN O
distinct NN NN O
hematopoietic NN NN O
lineages NN NN O
might NN NN O
account NN NN O
for NN NN O
the NN NN O
differential NN NN O
activation NN NN O
of NN NN O
the NN NN O
RXR NN NN O
- NN NN O
RARalpha403 NN NN B-Protein
heterodimers NN NN O
that NN NN O
we NN NN O
observed NN NN O
at NN NN O
these NN NN O
different NN NN O
stages NN NN O
of NN NN O
myeloid NN NN O
development NN NN O
. NN NN O
   
Bcl NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
expression NN NN O
in NN NN O
reactive NN NN O
follicular NN NN O
hyperplasia NN NN O
, NN NN O
follicular NN NN O
lymphoma NN NN O
, NN NN O
and NN NN O
angioimmunoblastic NN NN O
T NN NN O
- NN NN O
cell NN NN O
lymphoma NN NN O
with NN NN O
hyperplastic NN NN O
germinal NN NN O
centers NN NN O
: NN NN O
heterogeneity NN NN O
of NN NN O
intrafollicular NN NN O
T NN NN O
- NN NN O
cells NN NN O
and NN NN O
their NN NN O
altered NN NN O
distribution NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
angioimmunoblastic NN NN O
T NN NN O
- NN NN O
cell NN NN O
lymphoma NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
The NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
gene NN NN O
product NN NN O
, NN NN O
a NN NN O
nuclear NN NN O
phosphoprotein NN NN O
, NN NN O
is NN NN O
expressed NN NN O
independently NN NN O
of NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
gene NN NN O
rearrangement NN NN O
. NN NN O
   
In NN NN O
lymph NN NN O
nodes NN NN O
, NN NN O
expression NN NN O
of NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
protein NN NN O
is NN NN O
restricted NN NN O
to NN NN O
germinal NN NN O
center NN NN O
( NN NN O
GC NN NN O
) NN NN O
B NN NN O
- NN NN O
cells NN NN O
and NN NN O
10 NN NN O
% NN NN O
to NN NN O
15 NN NN O
% NN NN O
of NN NN O
CD3 NN NN O
/ NN NN O
CD4 NN NN B-Protein
+ NN NN O
intrafollicular NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Interfollicular NN NN O
cells NN NN O
are NN NN O
negative NN NN O
for NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
protein NN NN O
, NN NN O
except NN NN O
for NN NN O
rare NN NN O
CD3 NN NN O
+ NN NN O
/ NN NN O
CD4 NN NN B-Protein
+ NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Recently NN NN O
, NN NN O
we NN NN O
reported NN NN O
cases NN NN O
of NN NN O
angioimmunoblastic NN NN O
T NN NN O
- NN NN O
cell NN NN O
lymphoma NN NN O
( NN NN O
AITL NN NN O
) NN NN O
with NN NN O
hyperplastic NN NN O
GCs NN NN O
( NN NN O
AITL NN NN O
/ NN NN O
GC NN NN O
) NN NN O
, NN NN O
and NN NN O
observed NN NN O
that NN NN O
borders NN NN O
of NN NN O
enlarged NN NN O
GCs NN NN O
were NN NN O
ill NN NN O
defined NN NN O
, NN NN O
with NN NN O
features NN NN O
suggestive NN NN O
of NN NN O
an NN NN O
outward NN NN O
migration NN NN O
of NN NN O
GC NN NN O
cells NN NN O
to NN NN O
surrounding NN NN O
interfollicular NN NN O
zones NN NN O
. NN NN O
   
This NN NN O
prompted NN NN O
a NN NN O
study NN NN O
of NN NN O
follicular NN NN O
borders NN NN O
with NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
staining NN NN O
in NN NN O
reactive NN NN O
follicular NN NN O
hyperplasias NN NN O
and NN NN O
follicular NN NN O
lymphomas NN NN O
to NN NN O
compare NN NN O
with NN NN O
AITL NN NN O
/ NN NN O
GC NN NN O
. NN NN O
   
MATERIALS NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
Formalin NN NN O
- NN NN O
fixed NN NN O
paraffin NN NN O
sections NN NN O
were NN NN O
used NN NN O
for NN NN O
immunostaining NN NN O
of NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
. NN NN O
   
Six NN NN O
cases NN NN O
of NN NN O
AITL NN NN O
/ NN NN O
GC NN NN O
, NN NN O
12 NN NN O
nonspecific NN NN O
reactive NN NN O
follicular NN NN O
hyperplasia NN NN O
( NN NN O
FH NN NN O
) NN NN O
, NN NN O
7 NN NN O
HIV NN NN O
adenopathy NN NN O
, NN NN O
10 NN NN O
follicular NN NN O
lymphoma NN NN O
( NN NN O
FL NN NN O
) NN NN O
, NN NN O
and NN NN O
8 NN NN O
typical NN NN O
AITL NN NN O
( NN NN O
ie NN NN O
, NN NN O
AITL NN NN O
without NN NN O
GC NN NN O
) NN NN O
were NN NN O
studied NN NN O
. NN NN O
   
Double NN NN O
staining NN NN O
for NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
/ NN NN O
CD20 NN NN B-Protein
, NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
/ NN NN O
CD3 NN NN O
, NN NN O
and NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
/ NN NN O
CD57 NN NN B-Protein
was NN NN O
performed NN NN O
in NN NN O
selected NN NN O
cases NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
In NN NN O
FH NN NN O
and NN NN O
HIV NN NN O
adenopathy NN NN O
, NN NN O
staining NN NN O
for NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
revealed NN NN O
densely NN NN O
populated NN NN O
GCs NN NN O
with NN NN O
well NN NN O
- NN NN O
defined NN NN O
and NN NN O
regular NN NN O
GC NN NN O
borders NN NN O
, NN NN O
whereas NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
+ NN NN O
cells NN NN O
were NN NN O
rare NN NN O
in NN NN O
the NN NN O
interfollicular NN NN O
areas NN NN O
. NN NN O
   
An NN NN O
occasional NN NN O
GC NN NN O
with NN NN O
an NN NN O
ill NN NN O
- NN NN O
defined NN NN O
border NN NN O
was NN NN O
invariably NN NN O
surrounded NN NN O
by NN NN O
a NN NN O
broad NN NN O
mantle NN NN O
zone NN NN O
; NN NN O
those NN NN O
with NN NN O
indistinct NN NN O
mantle NN NN O
zones NN NN O
had NN NN O
well NN NN O
- NN NN O
defined NN NN O
, NN NN O
regular NN NN O
borders NN NN O
. NN NN O
   
In NN NN O
FL NN NN O
, NN NN O
follicles NN NN O
were NN NN O
densely NN NN O
populated NN NN O
, NN NN O
and NN NN O
their NN NN O
borders NN NN O
were NN NN O
irregular NN NN O
, NN NN O
with NN NN O
some NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
+ NN NN O
cells NN NN O
in NN NN O
the NN NN O
interfollicular NN NN O
zones NN NN O
. NN NN O
   
In NN NN O
AITL NN NN O
/ NN NN O
GC NN NN O
, NN NN O
GCs NN NN O
were NN NN O
less NN NN O
dense NN NN O
, NN NN O
GC NN NN O
borders NN NN O
were NN NN O
ill NN NN O
defined NN NN O
and NN NN O
irregular NN NN O
, NN NN O
and NN NN O
the NN NN O
number NN NN O
of NN NN O
interfollicular NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
+ NN NN O
cells NN NN O
was NN NN O
markedly NN NN O
increased NN NN O
. NN NN O
   
Double NN NN O
staining NN NN O
revealed NN NN O
that NN NN O
these NN NN O
interfollicular NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
+ NN NN O
cells NN NN O
in NN NN O
AITL NN NN O
/ NN NN O
GC NN NN O
were NN NN O
Bcl6 NN NN B-Protein
+ NN NN O
/ NN NN O
CD3 NN NN O
+ NN NN O
/ NN NN O
CD20 NN NN B-Protein
- NN NN O
/ NN NN O
CD57 NN NN B-Protein
- NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
CD3 NN NN O
+ NN NN O
intrafollicular NN NN O
T NN NN O
cells NN NN O
were NN NN O
depleted NN NN O
in NN NN O
AITL NN NN O
/ NN NN O
GC NN NN O
, NN NN O
whereas NN NN O
they NN NN O
were NN NN O
abundant NN NN O
in NN NN O
FH NN NN O
. NN NN O
   
Intrafollicular NN NN O
CD57 NN NN B-Protein
+ NN NN O
cells NN NN O
did NN NN O
not NN NN O
stain NN NN O
for NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
, NN NN O
and NN NN O
were NN NN O
also NN NN O
depleted NN NN O
in NN NN O
AITL NN NN O
/ NN NN O
GC NN NN O
. NN NN O
   
In NN NN O
typical NN NN O
AITL NN NN O
, NN NN O
some NN NN O
neoplastic NN NN O
cells NN NN O
were NN NN O
positive NN NN O
for NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
, NN NN O
showing NN NN O
variable NN NN O
degrees NN NN O
of NN NN O
staining NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
( NN NN O
1 NN NN O
) NN NN O
GCs NN NN O
of NN NN O
AITL NN NN O
/ NN NN O
GC NN NN O
differed NN NN O
from NN NN O
those NN NN O
of NN NN O
other NN NN O
reactive NN NN O
follicular NN NN O
hyperplasias NN NN O
and NN NN O
follicular NN NN O
lymphomas NN NN O
, NN NN O
and NN NN O
staining NN NN O
for NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
was NN NN O
useful NN NN O
to NN NN O
discern NN NN O
them NN NN O
. NN NN O
   
( NN NN O
2 NN NN O
) NN NN O
Intrafollicular NN NN O
CD3 NN NN O
+ NN NN O
T NN NN O
cells NN NN O
, NN NN O
many NN NN O
of NN NN O
which NN NN O
were NN NN O
also NN NN O
positive NN NN O
for NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
, NN NN O
were NN NN O
markedly NN NN O
depleted NN NN O
in NN NN O
AITL NN NN O
/ NN NN O
GC NN NN O
, NN NN O
with NN NN O
increased NN NN O
interfollicular NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
+ NN NN O
/ NN NN O
CD3 NN NN O
+ NN NN O
cells NN NN O
, NN NN O
suggesting NN NN O
an NN NN O
outward NN NN O
migration NN NN O
of NN NN O
intrafollicular NN NN O
T NN NN O
cells NN NN O
in NN NN O
this NN NN O
condition NN NN O
. NN NN O
   
( NN NN O
3 NN NN O
) NN NN O
Interfollicular NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
+ NN NN O
/ NN NN O
CD3 NN NN O
+ NN NN O
cells NN NN O
in NN NN O
AITL NN NN O
/ NN NN O
GC NN NN O
were NN NN O
too NN NN O
numerous NN NN O
to NN NN O
be NN NN O
accounted NN NN O
for NN NN O
by NN NN O
migration NN NN O
alone NN NN O
, NN NN O
suggesting NN NN O
local NN NN O
proliferation NN NN O
. NN NN O
   
( NN NN O
4 NN NN O
) NN NN O
Intrafollicular NN NN O
CD57 NN NN B-Protein
+ NN NN O
cells NN NN O
were NN NN O
negative NN NN O
for NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
, NN NN O
indicating NN NN O
heterogeneity NN NN O
of NN NN O
the NN NN O
intrafollicular NN NN O
T NN NN O
- NN NN O
cell NN NN O
population NN NN O
. NN NN O
   
( NN NN O
5 NN NN O
) NN NN O
Some NN NN O
neoplastic NN NN O
cells NN NN O
in NN NN O
AITL NN NN O
stained NN NN O
for NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
, NN NN O
suggesting NN NN O
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
expression NN NN O
in NN NN O
this NN NN O
tumor NN NN O
. NN NN O
   
Differential NN NN O
inhibition NN NN O
of NN NN O
Smad6 NN NN B-Protein
and NN NN O
Smad7 NN NN B-Protein
on NN NN O
bone NN NN O
morphogenetic NN NN O
protein NN NN O
- NN NN O
and NN NN O
activin NN NN O
- NN NN O
mediated NN NN O
growth NN NN O
arrest NN NN O
and NN NN O
apoptosis NN NN O
in NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
Smad6 NN NN B-Protein
and NN NN O
Smad7 NN NN B-Protein
prevent NN NN O
ligand NN NN O
- NN NN O
induced NN NN O
activation NN NN O
of NN NN O
signal NN NN O
- NN NN O
transducing NN NN O
Smad NN NN O
proteins NN NN O
in NN NN O
the NN NN O
transforming NN NN O
growth NN NN O
factor NN NN O
- NN NN O
beta NN NN O
family NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
both NN NN O
Smad6 NN NN B-Protein
and NN NN O
Smad7 NN NN B-Protein
are NN NN O
human NN NN B-Protein
bone NN NN I-Protein
morphogenetic NN NN I-Protein
protein NN NN I-Protein
- NN NN I-Protein
2 NN NN I-Protein
( NN NN O
hBMP NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
- NN NN O
inducible NN NN O
antagonists NN NN O
of NN NN O
hBMP NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
induced NN NN O
growth NN NN O
arrest NN NN O
and NN NN O
apoptosis NN NN O
in NN NN O
mouse NN NN O
B NN NN O
cell NN NN O
hybridoma NN NN O
HS NN NN O
- NN NN O
72 NN NN O
cells NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
we NN NN O
confirmed NN NN O
that NN NN O
the NN NN O
ectopic NN NN O
expressions NN NN O
of NN NN O
Smad6 NN NN B-Protein
and NN NN O
Smad7 NN NN B-Protein
inhibited NN NN O
the NN NN O
hBMP NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
induced NN NN O
Smad1 NN NN B-Protein
/ NN NN O
Smad5 NN NN B-Protein
phosphorylation NN NN O
. NN NN O
   
We NN NN O
previously NN NN O
reported NN NN O
that NN NN O
Smad7 NN NN B-Protein
is NN NN O
an NN NN O
activin NN NN B-Protein
A NN NN I-Protein
- NN NN O
inducible NN NN O
antagonist NN NN O
of NN NN O
activin NN NN B-Protein
A NN NN I-Protein
- NN NN O
induced NN NN O
growth NN NN O
arrest NN NN O
and NN NN O
apoptosis NN NN O
in NN NN O
HS NN NN O
- NN NN O
72 NN NN O
cells NN NN O
. NN NN O
   
Interestingly NN NN O
, NN NN O
although NN NN O
mRNA NN NN O
expression NN NN O
of NN NN O
Smad6 NN NN B-Protein
was NN NN O
induced NN NN O
by NN NN O
activin NN NN B-Protein
A NN NN I-Protein
in NN NN O
HS NN NN O
- NN NN O
72 NN NN O
cells NN NN O
, NN NN O
Smad6 NN NN B-Protein
showed NN NN O
no NN NN O
antagonistic NN NN O
effect NN NN O
on NN NN O
activin NN NN B-Protein
A NN NN I-Protein
- NN NN O
induced NN NN O
growth NN NN O
arrest NN NN O
and NN NN O
apoptosis NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
we NN NN O
found NN NN O
that NN NN O
the NN NN O
ectopic NN NN O
expression NN NN O
of NN NN O
Smad7 NN NN B-Protein
, NN NN O
but NN NN O
not NN NN O
Smad6 NN NN B-Protein
, NN NN O
inhibited NN NN O
the NN NN O
activin NN NN B-Protein
A NN NN I-Protein
- NN NN O
induced NN NN O
Smad2 NN NN B-Protein
phosphorylation NN NN O
in NN NN O
HS NN NN O
- NN NN O
72 NN NN O
cells NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
Smad6 NN NN B-Protein
and NN NN O
Smad7 NN NN B-Protein
exhibit NN NN O
differential NN NN O
inhibitory NN NN O
effects NN NN O
in NN NN O
bone NN NN B-Protein
morphogenetic NN NN I-Protein
protein NN NN I-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
and NN NN O
activin NN NN B-Protein
A NN NN I-Protein
- NN NN O
mediated NN NN O
signaling NN NN O
in NN NN O
B NN NN O
lineage NN NN O
cells NN NN O
. NN NN O
   
Transcription NN NN O
factors NN NN O
Sp1 NN NN B-Protein
and NN NN O
AP NN NN O
- NN NN O
2 NN NN O
mediate NN NN O
induction NN NN O
of NN NN O
acid NN NN O
sphingomyelinase NN NN O
during NN NN O
monocytic NN NN O
differentiation NN NN O
. NN NN O
   
Cells NN NN O
from NN NN O
the NN NN O
human NN NN O
monocytic NN NN O
leukemia NN NN O
cell NN NN O
line NN NN O
THP NN NN O
- NN NN O
1 NN NN O
differentiate NN NN O
towards NN NN O
a NN NN O
macrophage NN NN O
- NN NN O
like NN NN O
phenotype NN NN O
when NN NN O
stimulated NN NN O
with NN NN O
phorbol NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
- NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
( NN NN O
PMA NN NN O
) NN NN O
, NN NN O
1 NN NN O
, NN NN O
25 NN NN O
- NN NN O
dihydroxy NN NN O
- NN NN O
vitamin NN NN O
D3 NN NN O
, NN NN O
and NN NN O
various NN NN O
other NN NN O
agents NN NN O
. NN NN O
   
We NN NN O
demonstrate NN NN O
here NN NN O
that NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
lysosomal NN NN O
enzyme NN NN O
acid NN NN O
sphingomyelinase NN NN O
( NN NN O
ASM NN NN O
; NN NN O
E NN NN O
. NN NN O
C NN NN O
. NN NN O
3 NN NN O
. NN NN O
1 NN NN O
. NN NN O
4 NN NN O
. NN NN O
12 NN NN O
) NN NN O
is NN NN O
induced NN NN O
during NN NN O
this NN NN O
process NN NN O
and NN NN O
is NN NN O
strongly NN NN O
elevated NN NN O
in NN NN O
differentiated NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cells NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
in NN NN O
differentiated NN NN O
human NN NN O
mononuclear NN NN O
phagocytes NN NN O
. NN NN O
   
Using NN NN O
Northern NN NN O
blotting NN NN O
, NN NN O
RNase NN NN O
protection NN NN O
assay NN NN O
, NN NN O
and NN NN O
nuclear NN NN O
run NN NN O
- NN NN O
on NN NN O
analyses NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
the NN NN O
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
ASM NN NN O
expression NN NN O
is NN NN O
regulated NN NN O
mainly NN NN O
at NN NN O
the NN NN O
level NN NN O
of NN NN O
transcription NN NN O
and NN NN O
that NN NN O
new NN NN O
protein NN NN O
synthesis NN NN O
is NN NN O
required NN NN O
for NN NN O
enhanced NN NN O
ASM NN NN O
activity NN NN O
. NN NN O
   
This NN NN O
cell NN NN O
- NN NN O
type NN NN O
specific NN NN O
induction NN NN O
by NN NN O
PMA NN NN O
treatment NN NN O
was NN NN O
further NN NN O
investigated NN NN O
with NN NN O
respect NN NN O
to NN NN O
transcriptional NN NN O
control NN NN O
. NN NN O
   
A NN NN O
series NN NN O
of NN NN O
5 NN NN O
' NN NN O
deletion NN NN O
derivatives NN NN O
of NN NN O
the NN NN O
upstream NN NN O
regulatory NN NN O
region NN NN O
were NN NN O
used NN NN O
in NN NN O
transient NN NN O
transfection NN NN O
assays NN NN O
to NN NN O
identify NN NN O
promoter NN NN O
elements NN NN O
required NN NN O
for NN NN O
basal NN NN O
and NN NN O
inducible NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
A NN NN O
PMA NN NN O
responsive NN NN O
element NN NN O
was NN NN O
localized NN NN O
to NN NN O
a NN NN O
region NN NN O
between NN NN O
- NN NN O
319 NN NN O
and NN NN O
- NN NN O
219 NN NN O
bp NN NN O
upstream NN NN O
of NN NN O
the NN NN O
initiation NN NN O
codon NN NN O
and NN NN O
co NN NN O
- NN NN O
transfections NN NN O
with NN NN O
transcription NN NN O
factor NN NN O
expression NN NN O
plasmids NN NN O
for NN NN O
AP NN NN O
- NN NN O
2 NN NN O
and NN NN O
Sp1 NN NN B-Protein
resulted NN NN O
in NN NN O
augmented NN NN O
ASM NN NN O
promoter NN NN O
activity NN NN O
, NN NN O
which NN NN O
was NN NN O
abolished NN NN O
when NN NN O
the NN NN O
binding NN NN O
sites NN NN O
for NN NN O
these NN NN O
two NN NN O
factors NN NN O
were NN NN O
deleted NN NN O
. NN NN O
   
Using NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
and NN NN O
supershift NN NN O
assays NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
this NN NN O
region NN NN O
is NN NN O
specifically NN NN O
bound NN NN O
by NN NN O
Sp1 NN NN B-Protein
and NN NN O
AP NN NN O
- NN NN O
2 NN NN O
. NN NN O
   
These NN NN O
factors NN NN O
are NN NN O
present NN NN O
in NN NN O
nuclear NN NN O
extracts NN NN O
prepared NN NN O
from NN NN O
both NN NN O
induced NN NN O
and NN NN O
uninduced NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cells NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
intensity NN NN O
of NN NN O
the NN NN O
complex NN NN O
formed NN NN O
appeared NN NN O
to NN NN O
increase NN NN O
when NN NN O
nuclear NN NN O
extracts NN NN O
from NN NN O
PMA NN NN O
- NN NN O
treated NN NN O
cells NN NN O
were NN NN O
used NN NN O
. NN NN O
   
From NN NN O
these NN NN O
studies NN NN O
, NN NN O
we NN NN O
conclude NN NN O
that NN NN O
a NN NN O
concerted NN NN O
action NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factors NN NN O
AP NN NN O
- NN NN O
2 NN NN O
and NN NN O
Sp1 NN NN B-Protein
is NN NN O
essential NN NN O
for NN NN O
the NN NN O
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
ASM NN NN O
expression NN NN O
during NN NN O
the NN NN O
process NN NN O
of NN NN O
macrophage NN NN O
differentiation NN NN O
. NN NN O
   
Estrogen NN NN O
and NN NN O
progesterone NN NN O
induction NN NN O
of NN NN O
survival NN NN O
of NN NN O
monoblastoid NN NN O
cells NN NN O
undergoing NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
induced NN NN O
apoptosis NN NN O
. NN NN O
   
Induction NN NN O
of NN NN O
apoptosis NN NN O
of NN NN O
mononucleated NN NN O
cells NN NN O
is NN NN O
a NN NN O
physiological NN NN O
process NN NN O
for NN NN O
regulating NN NN O
the NN NN O
intensity NN NN O
of NN NN O
the NN NN O
immune NN NN O
response NN NN O
. NN NN O
   
The NN NN O
female NN NN O
steroid NN NN O
hormones NN NN O
estrogen NN NN O
( NN NN O
E2 NN NN O
) NN NN O
and NN NN O
progesterone NN NN O
( NN NN O
Prog NN NN O
) NN NN O
are NN NN O
known NN NN O
to NN NN O
modulate NN NN O
the NN NN O
reactivity NN NN O
of NN NN O
the NN NN O
immune NN NN O
system NN NN O
; NN NN O
recently NN NN O
it NN NN O
has NN NN O
been NN NN O
demonstrated NN NN O
that NN NN O
they NN NN O
can NN NN O
regulate NN NN O
induction NN NN O
of NN NN O
apoptosis NN NN O
of NN NN O
endothelial NN NN O
cells NN NN O
and NN NN O
osteoblasts NN NN O
. NN NN O
   
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
mediated NN NN O
induction NN NN O
of NN NN O
apoptosis NN NN O
has NN NN O
been NN NN O
well NN NN O
characterized NN NN O
in NN NN O
myeloid NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
investigated NN NN O
whether NN NN O
E2 NN NN O
and NN NN O
Prog NN NN O
could NN NN O
interfere NN NN O
with NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
induced NN NN O
apoptosis NN NN O
of NN NN O
the NN NN O
monoblastoid NN NN O
U937 NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
Treatment NN NN O
with NN NN O
E2 NN NN O
or NN NN O
Prog NN NN O
increased NN NN O
survival NN NN O
and NN NN O
prevented NN NN O
apoptosis NN NN O
induced NN NN O
by NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
in NN NN O
both NN NN O
undifferentiated NN NN O
and NN NN O
macrophage NN NN O
- NN NN O
like NN NN O
PMA NN NN O
- NN NN O
differentiated NN NN O
U937 NN NN O
cells NN NN O
, NN NN O
as NN NN O
assessed NN NN O
by NN NN O
trypan NN NN O
blue NN NN O
exclusion NN NN O
cell NN NN O
counting NN NN O
, NN NN O
thymidine NN NN O
incorporation NN NN O
, NN NN O
AnnexinV NN NN O
labeling NN NN O
, NN NN O
followed NN NN O
by NN NN O
flow NN NN O
cytometry NN NN O
and NN NN O
DNA NN NN O
fragmentation NN NN O
studies NN NN O
. NN NN O
   
This NN NN O
effect NN NN O
can NN NN O
be NN NN O
associated NN NN O
with NN NN O
the NN NN O
activation NN NN O
of NN NN O
specific NN NN O
hormone NN NN O
receptors NN NN O
, NN NN O
since NN NN O
we NN NN O
observed NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
estrogen NN NN O
receptor NN NN O
alpha NN NN O
( NN NN O
ER NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
, NN NN O
ER NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
, NN NN O
and NN NN O
progesterone NN NN B-Protein
receptor NN NN I-Protein
( NN NN O
PR NN NN B-Protein
) NN NN O
mRNAs NN NN O
; NN NN O
the NN NN O
ER NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
protein NN NN O
expression NN NN O
was NN NN O
confirmed NN NN O
by NN NN O
immunocytochemical NN NN O
analysis NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
hormone NN NN O
- NN NN O
mediated NN NN O
survival NN NN O
against NN NN O
apoptosis NN NN O
was NN NN O
concentration NN NN O
dependent NN NN O
, NN NN O
reaching NN NN O
the NN NN O
half NN NN O
- NN NN O
maximal NN NN O
effect NN NN O
at NN NN O
10 NN NN O
nM NN NN O
and NN NN O
blocked NN NN O
by NN NN O
the NN NN O
ER NN NN O
antagonist NN NN O
ICI NN NN O
182 NN NN O
, NN NN O
780 NN NN O
in NN NN O
undifferentiated NN NN O
cells NN NN O
, NN NN O
further NN NN O
supporting NN NN O
a NN NN O
receptor NN NN O
- NN NN O
mediated NN NN O
mechanism NN NN O
of NN NN O
cell NN NN O
survival NN NN O
. NN NN O
   
Other NN NN O
steroid NN NN O
receptor NN NN O
drugs NN NN O
such NN NN O
as NN NN O
Raloxifene NN NN O
, NN NN O
RU486 NN NN O
, NN NN O
or NN NN O
the NN NN O
ICI NN NN O
182 NN NN O
, NN NN O
780 NN NN O
in NN NN O
PMA NN NN O
- NN NN O
differentiated NN NN O
cells NN NN O
displayed NN NN O
agonist NN NN O
activity NN NN O
by NN NN O
preventing NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
induced NN NN O
apoptosis NN NN O
as NN NN O
efficiently NN NN O
as NN NN O
the NN NN O
hormones NN NN O
alone NN NN O
, NN NN O
providing NN NN O
further NN NN O
evidence NN NN O
to NN NN O
the NN NN O
notion NN NN O
that NN NN O
steroid NN NN O
receptor NN NN O
drugs NN NN O
may NN NN O
manifest NN NN O
agonist NN NN O
or NN NN O
antagonist NN NN O
activities NN NN O
depending NN NN O
on NN NN O
the NN NN O
cellular NN NN O
context NN NN O
in NN NN O
which NN NN O
they NN NN O
are NN NN O
studied NN NN O
. NN NN O
   
Treatment NN NN O
with NN NN O
E2 NN NN O
was NN NN O
also NN NN O
associated NN NN O
with NN NN O
a NN NN O
time NN NN O
- NN NN O
dependent NN NN O
decrease NN NN O
in NN NN O
the NN NN O
mRNA NN NN O
level NN NN O
of NN NN O
the NN NN O
proapoptotic NN NN O
Nip NN NN O
- NN NN O
2 NN NN O
protein NN NN O
, NN NN O
supporting NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
hormone NN NN O
responsiveness NN NN O
of NN NN O
U937 NN NN O
cells NN NN O
is NN NN O
mediated NN NN O
by NN NN O
target NN NN O
gene NN NN O
transcription NN NN O
. NN NN O
   
Together NN NN O
, NN NN O
these NN NN O
results NN NN O
demonstrate NN NN O
that NN NN O
ER NN NN O
and NN NN O
PR NN NN B-Protein
can NN NN O
be NN NN O
activated NN NN O
by NN NN O
endogenous NN NN O
or NN NN O
exogenous NN NN O
ligands NN NN O
to NN NN O
induce NN NN O
a NN NN O
genetic NN NN O
response NN NN O
that NN NN O
impairs NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
induced NN NN O
apoptosis NN NN O
in NN NN O
U937 NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
data NN NN O
presented NN NN O
here NN NN O
suggest NN NN O
that NN NN O
the NN NN O
female NN NN O
steroid NN NN O
receptors NN NN O
play NN NN O
a NN NN O
role NN NN O
in NN NN O
regulation NN NN O
of NN NN O
the NN NN O
immune NN NN O
response NN NN O
by NN NN O
preventing NN NN O
apoptosis NN NN O
of NN NN O
monoblastoid NN NN O
cells NN NN O
; NN NN O
this NN NN O
effect NN NN O
might NN NN O
have NN NN O
important NN NN O
consequences NN NN O
in NN NN O
the NN NN O
clinical NN NN O
use NN NN O
of NN NN O
steroid NN NN O
receptor NN NN O
drugs NN NN O
. NN NN O
   
- NN NN O
- NN NN O
Vegeto NN NN O
, NN NN O
E NN NN O
. NN NN O
, NN NN O
Pollio NN NN O
, NN NN O
G NN NN O
. NN NN O
, NN NN O
Pellicciari NN NN O
, NN NN O
C NN NN O
. NN NN O
, NN NN O
Maggi NN NN O
, NN NN O
A NN NN O
. NN NN O
   
Estrogen NN NN O
and NN NN O
progesterone NN NN O
induction NN NN O
of NN NN O
survival NN NN O
of NN NN O
monoblastoid NN NN O
cells NN NN O
undergoing NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
inuced NN NN O
apoptosis NN NN O
. NN NN O
   
Grf40 NN NN B-Protein
, NN NN O
A NN NN O
novel NN NN O
Grb2 NN NN O
family NN NN O
member NN NN O
, NN NN O
is NN NN O
involved NN NN O
in NN NN O
T NN NN O
cell NN NN O
signaling NN NN O
through NN NN O
interaction NN NN O
with NN NN O
SLP NN NN B-Protein
- NN NN I-Protein
76 NN NN I-Protein
and NN NN O
LAT NN NN B-Protein
. NN NN O
   
We NN NN O
molecularly NN NN O
cloned NN NN O
a NN NN O
new NN NN O
Grb2 NN NN O
family NN NN O
member NN NN O
, NN NN O
named NN NN O
Grf40 NN NN B-Protein
, NN NN O
containing NN NN O
the NN NN O
common NN NN O
SH3 NN NN O
- NN NN O
SH2 NN NN O
- NN NN O
SH3 NN NN O
motif NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
Grf40 NN NN B-Protein
is NN NN O
predominant NN NN O
in NN NN O
hematopoietic NN NN O
cells NN NN O
, NN NN O
particularly NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Grf40 NN NN B-Protein
binds NN NN O
to NN NN O
the NN NN O
SH2 NN NN B-Protein
domain NN NN I-Protein
- NN NN I-Protein
containing NN NN I-Protein
leukocyte NN NN I-Protein
protein NN NN I-Protein
of NN NN I-Protein
76 NN NN I-Protein
kD NN NN I-Protein
( NN NN O
SLP NN NN B-Protein
- NN NN I-Protein
76 NN NN I-Protein
) NN NN O
via NN NN O
its NN NN O
SH3 NN NN O
domain NN NN O
more NN NN O
tightly NN NN O
than NN NN O
Grb2 NN NN B-Protein
. NN NN O
   
Incidentally NN NN O
, NN NN O
Grf40 NN NN B-Protein
binds NN NN O
to NN NN O
linker NN NN B-Protein
for NN NN I-Protein
activation NN NN I-Protein
of NN NN I-Protein
T NN NN I-Protein
cells NN NN I-Protein
( NN NN O
LAT NN NN B-Protein
) NN NN O
possibly NN NN O
via NN NN O
its NN NN O
SH2 NN NN O
domain NN NN O
. NN NN O
   
Overexpression NN NN O
of NN NN O
wild NN NN O
- NN NN O
type NN NN O
Grf40 NN NN B-Protein
in NN NN O
Jurkat NN NN O
cells NN NN O
induced NN NN O
a NN NN O
significant NN NN O
increase NN NN O
of NN NN O
SLP NN NN B-Protein
- NN NN I-Protein
76 NN NN I-Protein
- NN NN O
dependent NN NN O
interleukin NN NN B-Protein
( NN NN I-Protein
IL NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
and NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cell NN NN O
( NN NN O
NF NN NN O
- NN NN O
AT NN NN O
) NN NN O
activation NN NN O
upon NN NN O
T NN NN O
cell NN NN O
receptor NN NN O
( NN NN O
TCR NN NN O
) NN NN O
stimulation NN NN O
, NN NN O
whereas NN NN O
the NN NN O
COOH NN NN O
- NN NN O
terminal NN NN O
SH3 NN NN O
- NN NN O
deleted NN NN O
Grf40 NN NN B-Protein
mutant NN NN O
lacked NN NN O
any NN NN O
recognizable NN NN O
increase NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
activity NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
the NN NN O
SH2 NN NN O
- NN NN O
deleted NN NN O
Grf40 NN NN B-Protein
mutant NN NN O
led NN NN O
to NN NN O
a NN NN O
marked NN NN O
inhibition NN NN O
of NN NN O
these NN NN O
regulatory NN NN O
activities NN NN O
, NN NN O
the NN NN O
effect NN NN O
of NN NN O
which NN NN O
is NN NN O
apparently NN NN O
stronger NN NN O
than NN NN O
that NN NN O
of NN NN O
the NN NN O
SH2 NN NN O
- NN NN O
deleted NN NN O
Grb2 NN NN B-Protein
mutant NN NN O
. NN NN O
   
Our NN NN O
data NN NN O
suggest NN NN O
that NN NN O
Grf40 NN NN B-Protein
is NN NN O
an NN NN O
adaptor NN NN O
molecule NN NN O
involved NN NN O
in NN NN O
TCR NN NN O
- NN NN O
mediated NN NN O
signaling NN NN O
through NN NN O
a NN NN O
more NN NN O
efficient NN NN O
interaction NN NN O
than NN NN O
Grb2 NN NN B-Protein
with NN NN O
SLP NN NN B-Protein
- NN NN I-Protein
76 NN NN I-Protein
and NN NN O
LAT NN NN B-Protein
. NN NN O
   
Signal NN NN O
transduction NN NN O
through NN NN O
interferon NN NN O
- NN NN O
gamma NN NN O
receptor NN NN O
on NN NN O
human NN NN O
eosinophils NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
We NN NN O
reported NN NN O
on NN NN O
the NN NN O
constitutive NN NN O
interferon NN NN O
- NN NN O
gamma NN NN O
receptor NN NN O
( NN NN O
IFN NN NN O
- NN NN O
gammaR NN NN O
) NN NN O
expression NN NN O
on NN NN O
eosinophils NN NN O
. NN NN O
   
But NN NN O
signal NN NN O
transduction NN NN O
through NN NN O
IFN NN NN O
- NN NN O
gammaR NN NN O
on NN NN O
eosinophils NN NN O
remains NN NN O
to NN NN O
be NN NN O
elucidated NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
examined NN NN O
the NN NN O
involvement NN NN O
of NN NN O
the NN NN O
Jak NN NN O
/ NN NN O
Stat NN NN O
pathway NN NN O
in NN NN O
the NN NN O
signaling NN NN O
of NN NN O
eosinophils NN NN O
after NN NN O
IFN NN NN O
- NN NN O
gammaR NN NN O
conjugation NN NN O
by NN NN O
the NN NN O
ligand NN NN O
binding NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Purified NN NN O
peripheral NN NN O
eosinophils NN NN O
were NN NN O
stimulated NN NN O
with NN NN O
IFN NN NN O
- NN NN O
gamma NN NN O
at NN NN O
37 NN NN O
degrees NN NN O
C NN NN O
for NN NN O
1 NN NN O
- NN NN O
60 NN NN O
min NN NN O
. NN NN O
   
Tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
IFN NN NN O
- NN NN O
gammaR NN NN O
, NN NN O
Jak1 NN NN B-Protein
, NN NN O
Jak2 NN NN B-Protein
, NN NN O
and NN NN O
Stat1alpha NN NN B-Protein
was NN NN O
examined NN NN O
by NN NN O
immunoblotting NN NN O
. NN NN O
   
Gel NN NN O
- NN NN O
shift NN NN O
assay NN NN O
was NN NN O
also NN NN O
examined NN NN O
to NN NN O
show NN NN O
the NN NN O
formation NN NN O
of NN NN O
Stat1alpha NN NN B-Protein
- NN NN O
DNA NN NN O
complexes NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
We NN NN O
show NN NN O
that NN NN O
binding NN NN O
of NN NN O
IFN NN NN O
- NN NN O
gamma NN NN O
to NN NN O
human NN NN O
eosinophils NN NN O
initiated NN NN O
a NN NN O
series NN NN O
of NN NN O
events NN NN O
that NN NN O
resulted NN NN O
in NN NN O
the NN NN O
rapid NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
not NN NN O
only NN NN O
the NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gammaRalpha NN NN I-Protein
chain NN NN I-Protein
but NN NN O
also NN NN O
Jak1 NN NN B-Protein
, NN NN O
Jak2 NN NN B-Protein
, NN NN O
and NN NN O
Stat1alpha NN NN B-Protein
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
IFN NN NN O
- NN NN O
gamma NN NN O
enhanced NN NN O
the NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
of NN NN O
Stat1alpha NN NN B-Protein
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
These NN NN O
data NN NN O
indicate NN NN O
that NN NN O
IFN NN NN O
- NN NN O
gamma NN NN O
affects NN NN O
eosinophils NN NN O
through NN NN O
its NN NN O
specific NN NN O
receptor NN NN O
and NN NN O
utilizes NN NN O
the NN NN O
Jak NN NN O
/ NN NN O
Stat NN NN O
pathway NN NN O
as NN NN O
its NN NN O
mode NN NN O
of NN NN O
signaling NN NN O
. NN NN O
   
Constitutive NN NN O
activation NN NN O
of NN NN O
an NN NN O
epithelial NN NN O
signal NN NN O
transducer NN NN O
and NN NN O
activator NN NN O
of NN NN O
transcription NN NN O
( NN NN O
STAT NN NN O
) NN NN O
pathway NN NN O
in NN NN O
asthma NN NN O
. NN NN O
   
Cytokine NN NN O
effects NN NN O
on NN NN O
immunity NN NN O
and NN NN O
inflammation NN NN O
often NN NN O
depend NN NN O
on NN NN O
the NN NN O
transcription NN NN O
factors NN NN O
termed NN NN O
signal NN NN O
transducers NN NN O
and NN NN O
activators NN NN O
of NN NN O
transcription NN NN O
( NN NN O
STATs NN NN O
) NN NN O
, NN NN O
so NN NN O
STAT NN NN O
signaling NN NN O
pathways NN NN O
are NN NN O
candidates NN NN O
for NN NN O
influencing NN NN O
inflammatory NN NN O
disease NN NN O
. NN NN O
   
We NN NN O
reasoned NN NN O
that NN NN O
selective NN NN O
IFN NN NN O
responsiveness NN NN O
of NN NN O
the NN NN O
first NN NN O
STAT NN NN O
family NN NN O
member NN NN O
( NN NN O
Stat1 NN NN B-Protein
) NN NN O
and NN NN O
Stat1 NN NN B-Protein
- NN NN O
dependent NN NN O
immune NN NN O
- NN NN O
response NN NN O
genes NN NN O
such NN NN O
as NN NN O
intercellular NN NN B-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
, NN NN O
IFN NN NN B-Protein
regulatory NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
, NN NN O
and NN NN O
Stat1 NN NN B-Protein
itself NN NN O
in NN NN O
airway NN NN O
epithelial NN NN O
cells NN NN O
provides NN NN O
a NN NN O
basis NN NN O
for NN NN O
detecting NN NN O
cytokine NN NN O
signaling NN NN O
abnormalities NN NN O
in NN NN O
inflammatory NN NN O
airway NN NN O
disease NN NN O
. NN NN O
   
On NN NN O
the NN NN O
basis NN NN O
of NN NN O
nuclear NN NN O
localization NN NN O
and NN NN O
phosphorylation NN NN O
, NN NN O
we NN NN O
found NN NN O
that NN NN O
epithelial NN NN O
Stat1 NN NN B-Protein
( NN NN O
but NN NN O
not NN NN O
other NN NN O
control NN NN O
transcription NN NN O
factors NN NN O
) NN NN O
was NN NN O
invariably NN NN O
activated NN NN O
in NN NN O
asthmatic NN NN O
compared NN NN O
with NN NN O
normal NN NN O
control NN NN O
or NN NN O
chronic NN NN O
bronchitis NN NN O
subjects NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
epithelial NN NN O
levels NN NN O
of NN NN O
activated NN NN O
Stat1 NN NN B-Protein
correlated NN NN O
with NN NN O
levels NN NN O
of NN NN O
expression NN NN O
for NN NN O
epithelial NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
and NN NN O
Stat1 NN NN B-Protein
, NN NN O
and NN NN O
in NN NN O
turn NN NN O
, NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
levels NN NN O
correlated NN NN O
with NN NN O
T NN NN O
- NN NN O
cell NN NN O
accumulation NN NN O
in NN NN O
tissue NN NN O
. NN NN O
   
However NN NN O
, NN NN O
only NN NN O
low NN NN O
levels NN NN O
of NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
or NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
- NN NN O
producing NN NN O
cells NN NN O
were NN NN O
detected NN NN O
in NN NN O
airway NN NN O
tissue NN NN O
in NN NN O
all NN NN O
subjects NN NN O
. NN NN O
   
The NN NN O
results NN NN O
therefore NN NN O
provide NN NN O
initial NN NN O
evidence NN NN O
linking NN NN O
abnormal NN NN O
behavior NN NN O
of NN NN O
STAT NN NN O
pathways NN NN O
for NN NN O
cytokine NN NN O
signaling NN NN O
to NN NN O
the NN NN O
development NN NN O
of NN NN O
an NN NN O
inflammatory NN NN O
disease NN NN O
. NN NN O
   
In NN NN O
that NN NN O
context NN NN O
, NN NN O
the NN NN O
results NN NN O
also NN NN O
change NN NN O
the NN NN O
current NN NN O
scheme NN NN O
for NN NN O
asthma NN NN O
pathogenesis NN NN O
to NN NN O
one NN NN O
that NN NN O
must NN NN O
include NN NN O
a NN NN O
localized NN NN O
gain NN NN O
in NN NN O
transcriptional NN NN O
signal NN NN O
ordinarily NN NN O
used NN NN O
for NN NN O
a NN NN O
T NN NN O
helper NN NN O
1 NN NN O
- NN NN O
type NN NN O
cytokine NN NN O
( NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
) NN NN O
in NN NN O
combination NN NN O
with NN NN O
allergy NN NN O
- NN NN O
driven NN NN O
overproduction NN NN O
of NN NN O
T NN NN O
helper NN NN O
2 NN NN O
- NN NN O
type NN NN O
cytokines NN NN O
. NN NN O
   
HLA NN NN O
class NN NN O
I NN NN O
- NN NN O
mediated NN NN O
induction NN NN O
of NN NN O
cell NN NN O
proliferation NN NN O
involves NN NN O
cyclin NN NN O
E NN NN O
- NN NN O
mediated NN NN O
inactivation NN NN O
of NN NN O
Rb NN NN B-Protein
function NN NN O
and NN NN O
induction NN NN O
of NN NN O
E2F NN NN O
activity NN NN O
. NN NN O
   
Chronic NN NN O
rejection NN NN O
of NN NN O
transplanted NN NN O
organs NN NN O
is NN NN O
manifested NN NN O
as NN NN O
atherosclerosis NN NN O
of NN NN O
the NN NN O
blood NN NN O
vessels NN NN O
of NN NN O
the NN NN O
allograft NN NN O
. NN NN O
   
HLA NN NN O
class NN NN O
I NN NN O
Ags NN NN O
have NN NN O
been NN NN O
implicated NN NN O
to NN NN O
play NN NN O
a NN NN O
major NN NN O
role NN NN O
in NN NN O
this NN NN O
process NN NN O
, NN NN O
since NN NN O
signaling NN NN O
via NN NN O
HLA NN NN O
class NN NN O
I NN NN O
molecules NN NN O
can NN NN O
induce NN NN O
the NN NN O
proliferation NN NN O
of NN NN O
aortic NN NN O
endothelial NN NN O
as NN NN O
well NN NN O
as NN NN O
smooth NN NN O
muscle NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
HLA NN NN O
class NN NN O
I NN NN O
- NN NN O
mediated NN NN O
induction NN NN O
of NN NN O
cell NN NN O
proliferation NN NN O
correlates NN NN O
with NN NN O
inactivation NN NN O
of NN NN O
the NN NN O
Rb NN NN B-Protein
protein NN NN O
in NN NN O
the NN NN O
T NN NN O
cell NN NN O
line NN NN O
Jurkat NN NN O
as NN NN O
well NN NN O
as NN NN O
human NN NN O
aortic NN NN O
endothelial NN NN O
cells NN NN O
. NN NN O
   
HLA NN NN O
class NN NN O
I NN NN O
- NN NN O
mediated NN NN O
inactivation NN NN O
of NN NN O
Rb NN NN B-Protein
can NN NN O
be NN NN O
inhibited NN NN O
specifically NN NN O
by NN NN O
neutralizing NN NN O
Abs NN NN O
to NN NN O
basic NN NN O
fibroblast NN NN O
growth NN NN O
factor NN NN O
( NN NN O
bFGF NN NN O
) NN NN O
, NN NN O
suggesting NN NN O
a NN NN O
role NN NN O
for NN NN O
FGF NN NN O
receptors NN NN O
in NN NN O
the NN NN O
signaling NN NN O
process NN NN O
. NN NN O
   
Signaling NN NN O
through NN NN O
HLA NN NN O
class NN NN O
I NN NN O
molecules NN NN O
induced NN NN O
cyclin NN NN O
E NN NN O
- NN NN O
associated NN NN O
kinase NN NN O
activity NN NN O
within NN NN O
4 NN NN O
h NN NN O
in NN NN O
quiescent NN NN O
endothelial NN NN O
cells NN NN O
, NN NN O
and NN NN O
appeared NN NN O
to NN NN O
mediate NN NN O
the NN NN O
inactivation NN NN O
of NN NN O
Rb NN NN B-Protein
. NN NN O
   
A NN NN O
cdk2 NN NN B-Protein
inhibitor NN NN O
, NN NN O
Olomoucine NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
a NN NN O
dominant NN NN O
- NN NN O
negative NN NN O
cdk2 NN NN B-Protein
construct NN NN O
prevented NN NN O
HLA NN NN O
class NN NN O
I NN NN O
- NN NN O
mediated NN NN O
inactivation NN NN O
of NN NN O
Rb NN NN B-Protein
; NN NN O
in NN NN O
contrast NN NN O
, NN NN O
dominant NN NN O
- NN NN O
negative NN NN O
cdk4 NN NN B-Protein
and NN NN O
cdk6 NN NN B-Protein
constructs NN NN O
had NN NN O
no NN NN O
effect NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
there NN NN O
was NN NN O
no NN NN O
increase NN NN O
in NN NN O
cyclin NN NN O
D NN NN O
- NN NN O
associated NN NN O
kinase NN NN O
activity NN NN O
upon NN NN O
HLA NN NN O
class NN NN O
I NN NN O
ligation NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
cyclin NN NN O
E NN NN O
- NN NN O
dependent NN NN O
kinase NN NN O
activity NN NN O
mediates NN NN O
Rb NN NN B-Protein
inactivation NN NN O
, NN NN O
leading NN NN O
to NN NN O
E2F NN NN O
activation NN NN O
and NN NN O
cell NN NN O
proliferation NN NN O
. NN NN O
   
Increased NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
beta NN NN I-Protein
in NN NN O
airway NN NN O
cells NN NN O
of NN NN O
glucocorticoid NN NN O
- NN NN O
insensitive NN NN O
asthma NN NN O
. NN NN O
   
Glucocorticoid NN NN O
( NN NN O
GC NN NN O
) NN NN O
- NN NN O
insensitive NN NN O
asthma NN NN O
is NN NN O
a NN NN O
challenging NN NN O
clinical NN NN O
problem NN NN O
that NN NN O
can NN NN O
be NN NN O
associated NN NN O
with NN NN O
life NN NN O
- NN NN O
threatening NN NN O
disease NN NN O
progression NN NN O
. NN NN O
   
The NN NN O
molecular NN NN O
basis NN NN O
of NN NN O
GC NN NN O
insensitivity NN NN O
is NN NN O
unknown NN NN O
. NN NN O
   
Alternative NN NN O
splicing NN NN O
of NN NN O
the NN NN O
GC NN NN B-Protein
receptor NN NN I-Protein
( NN NN O
GCR NN NN B-Protein
) NN NN O
pre NN NN O
- NN NN O
mRNA NN NN O
generates NN NN O
a NN NN O
second NN NN O
GCR NN NN O
, NN NN O
termed NN NN O
GCRbeta NN NN B-Protein
, NN NN O
which NN NN O
does NN NN O
not NN NN O
bind NN NN O
GC NN NN O
but NN NN O
antagonizes NN NN O
the NN NN O
transactivating NN NN O
activity NN NN O
of NN NN O
the NN NN O
classic NN NN O
GCR NN NN B-Protein
. NN NN O
   
Thus NN NN O
increased NN NN O
expression NN NN O
of NN NN O
GCRbeta NN NN B-Protein
could NN NN O
account NN NN O
for NN NN O
glucocorticoid NN NN O
insensitivity NN NN O
. NN NN O
   
Bronchoalveolar NN NN O
lavage NN NN O
( NN NN O
BAL NN NN O
) NN NN O
cells NN NN O
and NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
( NN NN O
PBMC NN NN O
) NN NN O
were NN NN O
examined NN NN O
for NN NN O
GCRbeta NN NN B-Protein
immunoreactivity NN NN O
using NN NN O
a NN NN O
GCRbeta NN NN B-Protein
- NN NN O
specific NN NN O
antibody NN NN O
by NN NN O
immunohistochemical NN NN O
staining NN NN O
. NN NN O
   
Cell NN NN O
localization NN NN O
of NN NN O
GCRbeta NN NN B-Protein
expression NN NN O
was NN NN O
performed NN NN O
using NN NN O
a NN NN O
double NN NN O
immunostaining NN NN O
technique NN NN O
. NN NN O
   
Patients NN NN O
with NN NN O
GC NN NN O
- NN NN O
insensitive NN NN O
asthma NN NN O
expressed NN NN O
a NN NN O
significantly NN NN O
higher NN NN O
number NN NN O
of NN NN O
GCRbeta NN NN B-Protein
- NN NN O
immunoreactive NN NN O
cells NN NN O
in NN NN O
their NN NN O
BAL NN NN O
and NN NN O
peripheral NN NN O
blood NN NN O
than NN NN O
GC NN NN O
- NN NN O
sensitive NN NN O
asthmatics NN NN O
or NN NN O
normal NN NN O
control NN NN O
subjects NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
GCRbeta NN NN B-Protein
expression NN NN O
in NN NN O
GC NN NN O
- NN NN O
insensitive NN NN O
asthma NN NN O
was NN NN O
particularly NN NN O
high NN NN O
in NN NN O
airway NN NN O
T NN NN O
cells NN NN O
, NN NN O
which NN NN O
are NN NN O
thought NN NN O
to NN NN O
play NN NN O
a NN NN O
major NN NN O
role NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
asthma NN NN O
. NN NN O
   
We NN NN O
also NN NN O
examined NN NN O
the NN NN O
expression NN NN O
of NN NN O
GCRbeta NN NN B-Protein
in NN NN O
specimens NN NN O
from NN NN O
the NN NN O
airways NN NN O
of NN NN O
patients NN NN O
with NN NN O
chronic NN NN O
bronchitis NN NN O
. NN NN O
   
In NN NN O
chronic NN NN O
bronchitis NN NN O
, NN NN O
few NN NN O
cells NN NN O
were NN NN O
GCRbeta NN NN B-Protein
- NN NN O
positive NN NN O
and NN NN O
their NN NN O
numbers NN NN O
did NN NN O
not NN NN O
differ NN NN O
significantly NN NN O
from NN NN O
normal NN NN O
control NN NN O
subjects NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
GC NN NN O
- NN NN O
insensitive NN NN O
asthma NN NN O
is NN NN O
associated NN NN O
with NN NN O
increased NN NN O
expression NN NN O
of NN NN O
GCRbeta NN NN B-Protein
in NN NN O
airway NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Differences NN NN O
in NN NN O
phosphorylation NN NN O
of NN NN O
the NN NN O
IL NN NN O
- NN NN O
2R NN NN O
associated NN NN O
JAK NN NN O
/ NN NN O
STAT NN NN O
proteins NN NN O
between NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
( NN NN O
+ NN NN O
) NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
independent NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
dependent NN NN O
cell NN NN O
lines NN NN O
and NN NN O
uncultured NN NN O
leukemic NN NN O
cells NN NN O
from NN NN O
patients NN NN O
with NN NN O
adult NN NN O
T NN NN O
- NN NN O
cell NN NN O
lymphoma NN NN O
/ NN NN O
leukemia NN NN O
. NN NN O
   
To NN NN O
determine NN NN O
activation NN NN O
status NN NN O
of NN NN O
the NN NN O
IL NN NN O
- NN NN O
2R NN NN O
- NN NN O
associated NN NN O
( NN NN O
Jak NN NN O
/ NN NN O
STAT NN NN O
) NN NN O
pathway NN NN O
in NN NN O
the NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
infected NN NN O
cells NN NN O
, NN NN O
we NN NN O
examined NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
Jak3 NN NN B-Protein
, NN NN O
STAT3 NN NN B-Protein
, NN NN O
and NN NN O
STAT5 NN NN O
in NN NN O
several NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
( NN NN O
+ NN NN O
) NN NN O
T NN NN O
- NN NN O
cell NN NN O
lines NN NN O
and NN NN O
in NN NN O
uncultured NN NN O
leukemic NN NN O
T NN NN O
cells NN NN O
isolated NN NN O
from NN NN O
patients NN NN O
with NN NN O
adult NN NN O
T NN NN O
- NN NN O
cell NN NN O
lymphoma NN NN O
/ NN NN O
leukemia NN NN O
( NN NN O
ATLL NN NN O
) NN NN O
. NN NN O
   
Constitutive NN NN O
basal NN NN O
phosphorylation NN NN O
of NN NN O
Jak3 NN NN B-Protein
and NN NN O
, NN NN O
usually NN NN O
, NN NN O
STAT3 NN NN B-Protein
and NN NN O
STAT5 NN NN O
was NN NN O
detected NN NN O
in NN NN O
all NN NN O
four NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
independent NN NN O
cell NN NN O
lines NN NN O
tested NN NN O
, NN NN O
but NN NN O
in NN NN O
none NN NN O
of NN NN O
the NN NN O
three NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
dependent NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Similarly NN NN O
, NN NN O
there NN NN O
was NN NN O
no NN NN O
detectable NN NN O
basal NN NN O
phosphorylation NN NN O
of NN NN O
Jak3 NN NN B-Protein
and NN NN O
STAT5 NN NN O
in NN NN O
the NN NN O
leukemic NN NN O
cells NN NN O
from NN NN O
ATLL NN NN O
patients NN NN O
( NN NN O
0 NN NN O
/ NN NN O
8 NN NN O
and NN NN O
0 NN NN O
/ NN NN O
3 NN NN O
, NN NN O
respectively NN NN O
) NN NN O
. NN NN O
   
However NN NN O
, NN NN O
stimulation NN NN O
with NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
resulted NN NN O
in NN NN O
Jak3 NN NN B-Protein
and NN NN O
STAT5 NN NN O
phosphorylation NN NN O
in NN NN O
both NN NN O
leukemic NN NN O
ATLL NN NN O
cells NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
dependent NN NN O
lines NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
expression NN NN O
of NN NN O
SHP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
phosphatase NN NN I-Protein
which NN NN O
is NN NN O
a NN NN O
negative NN NN O
regulator NN NN O
of NN NN O
cytokine NN NN O
receptor NN NN O
signaling NN NN O
, NN NN O
was NN NN O
lost NN NN O
in NN NN O
most NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
independent NN NN O
cell NN NN O
lines NN NN O
( NN NN O
3 NN NN O
/ NN NN O
4 NN NN O
) NN NN O
but NN NN O
not NN NN O
in NN NN O
the NN NN O
leukemic NN NN O
ATLL NN NN O
cells NN NN O
( NN NN O
0 NN NN O
/ NN NN O
3 NN NN O
) NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
the NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
( NN NN O
+ NN NN O
) NN NN O
T NN NN O
- NN NN O
cell NN NN O
lines NN NN O
( NN NN O
313 NN NN O
) NN NN O
but NN NN O
not NN NN O
the NN NN O
control NN NN O
, NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
( NN NN O
- NN NN O
) NN NN O
T NN NN O
- NN NN O
cell NN NN O
lines NN NN O
were NN NN O
resistant NN NN O
to NN NN O
rapamycin NN NN O
and NN NN O
its NN NN O
novel NN NN O
analog NN NN O
RAD NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
( NN NN O
1 NN NN O
) NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
infection NN NN O
per NN NN O
se NN NN O
does NN NN O
not NN NN O
result NN NN O
in NN NN O
a NN NN O
constitutive NN NN O
phosphorylation NN NN O
of NN NN O
the NN NN O
Jak3 NN NN B-Protein
, NN NN O
STAT3 NN NN B-Protein
, NN NN O
and NN NN O
STAT5 NN NN O
proteins NN NN O
; NN NN O
( NN NN O
2 NN NN O
) NN NN O
malignant NN NN O
transformation NN NN O
in NN NN O
at NN NN O
least NN NN O
some NN NN O
cases NN NN O
of NN NN O
ATLL NN NN O
does NN NN O
not NN NN O
require NN NN O
the NN NN O
constitutive NN NN O
, NN NN O
but NN NN O
may NN NN O
require NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
induced NN NN O
, NN NN O
activation NN NN O
of NN NN O
the NN NN O
IL NN NN O
- NN NN O
2R NN NN O
Jak NN NN O
/ NN NN O
STAT NN NN O
pathway NN NN O
; NN NN O
and NN NN O
( NN NN O
3 NN NN O
) NN NN O
there NN NN O
are NN NN O
major NN NN O
differences NN NN O
in NN NN O
T NN NN O
- NN NN O
cell NN NN O
immortalization NN NN O
mechanism NN NN O
( NN NN O
s NN NN O
) NN NN O
which NN NN O
appear NN NN O
to NN NN O
involve NN NN O
SHP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
target NN NN O
molecules NN NN O
for NN NN O
rapamycin NN NN O
and NN NN O
RAD NN NN O
. NN NN O
   
USF NN NN O
/ NN NN O
c NN NN B-Protein
- NN NN I-Protein
Myc NN NN I-Protein
enhances NN NN O
, NN NN O
while NN NN O
Yin NN NN B-Protein
- NN NN I-Protein
Yang NN NN I-Protein
1 NN NN I-Protein
suppresses NN NN O
, NN NN O
the NN NN O
promoter NN NN O
activity NN NN O
of NN NN O
CXCR4 NN NN B-Protein
, NN NN O
a NN NN O
coreceptor NN NN O
for NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
entry NN NN O
. NN NN O
   
Transcription NN NN O
factors NN NN O
USF1 NN NN B-Protein
and NN NN O
USF2 NN NN B-Protein
up NN NN O
- NN NN O
regulate NN NN O
gene NN NN O
expression NN NN O
( NN NN O
i NN NN O
. NN NN O
e NN NN O
. NN NN O
, NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
long NN NN O
terminal NN NN O
repeats NN NN O
) NN NN O
via NN NN O
interaction NN NN O
with NN NN O
an NN NN O
E NN NN O
box NN NN O
on NN NN O
their NN NN O
target NN NN O
promoters NN NN O
, NN NN O
which NN NN O
is NN NN O
also NN NN O
a NN NN O
binding NN NN O
site NN NN O
for NN NN O
c NN NN B-Protein
- NN NN I-Protein
Myc NN NN I-Protein
. NN NN O
   
The NN NN O
c NN NN B-Protein
- NN NN I-Protein
Myc NN NN I-Protein
oncoprotein NN NN O
is NN NN O
important NN NN O
in NN NN O
control NN NN O
of NN NN O
cellular NN NN O
proliferation NN NN O
and NN NN O
differentiation NN NN O
, NN NN O
while NN NN O
Yin NN NN B-Protein
- NN NN I-Protein
Yang NN NN I-Protein
1 NN NN I-Protein
( NN NN O
YY1 NN NN B-Protein
) NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
control NN NN O
the NN NN O
expression NN NN O
of NN NN O
a NN NN O
number NN NN O
of NN NN O
cellular NN NN O
and NN NN O
viral NN NN O
genes NN NN O
. NN NN O
   
These NN NN O
two NN NN O
proteins NN NN O
physically NN NN O
interact NN NN O
with NN NN O
each NN NN O
other NN NN O
and NN NN O
mutually NN NN O
inhibit NN NN O
their NN NN O
respective NN NN O
biological NN NN O
functions NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
USF NN NN O
/ NN NN O
c NN NN B-Protein
- NN NN I-Protein
Myc NN NN I-Protein
up NN NN O
- NN NN O
regulates NN NN O
, NN NN O
while NN NN O
YY1 NN NN B-Protein
down NN NN O
- NN NN O
regulates NN NN O
the NN NN O
promoter NN NN O
activity NN NN O
of NN NN O
CXCR4 NN NN B-Protein
, NN NN O
a NN NN O
coreceptor NN NN O
for NN NN O
T NN NN O
cell NN NN O
- NN NN O
tropic NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
entry NN NN O
. NN NN O
   
We NN NN O
have NN NN O
identified NN NN O
an NN NN O
E NN NN O
box NN NN O
around NN NN O
- NN NN O
260 NN NN O
and NN NN O
a NN NN O
YY1 NN NN B-Protein
binding NN NN O
site NN NN O
around NN NN O
- NN NN O
300 NN NN O
relative NN NN O
to NN NN O
the NN NN O
transcription NN NN O
start NN NN O
site NN NN O
. NN NN O
   
Mutation NN NN O
of NN NN O
the NN NN O
E NN NN O
box NN NN O
abolished NN NN O
USF NN NN O
/ NN NN O
c NN NN B-Protein
- NN NN I-Protein
Myc NN NN I-Protein
- NN NN O
mediated NN NN O
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
CXCR4 NN NN B-Protein
promoter NN NN O
activity NN NN O
, NN NN O
and NN NN O
mutation NN NN O
of NN NN O
the NN NN O
YY1 NN NN B-Protein
binding NN NN O
site NN NN O
was NN NN O
associated NN NN O
with NN NN O
unresponsiveness NN NN O
to NN NN O
YY1 NN NN B-Protein
- NN NN O
mediated NN NN O
inhibition NN NN O
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
USF NN NN O
/ NN NN O
c NN NN B-Protein
- NN NN I-Protein
Myc NN NN I-Protein
and NN NN O
YY1 NN NN B-Protein
may NN NN O
play NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
- NN NN O
replicative NN NN O
cycle NN NN O
, NN NN O
by NN NN O
modulating NN NN O
both NN NN O
the NN NN O
viral NN NN O
fusion NN NN O
/ NN NN O
entry NN NN O
process NN NN O
and NN NN O
viral NN NN O
expression NN NN O
. NN NN O
   
Glucocorticoid NN NN B-Protein
receptors NN NN I-Protein
are NN NN O
down NN NN O
- NN NN O
regulated NN NN O
in NN NN O
inflamed NN NN O
colonic NN NN O
mucosa NN NN O
but NN NN O
not NN NN O
in NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
from NN NN O
patients NN NN O
with NN NN O
inflammatory NN NN O
bowel NN NN O
disease NN NN O
[ NN NN O
see NN NN O
comments NN NN O
] NN NN O
   
BACKGROUND NN NN O
: NN NN O
Growing NN NN O
evidence NN NN O
indicates NN NN O
that NN NN O
the NN NN O
immune NN NN O
system NN NN O
and NN NN O
the NN NN O
hypothalamic NN NN O
- NN NN O
pituitary NN NN O
- NN NN O
adrenal NN NN O
system NN NN O
are NN NN O
linked NN NN O
by NN NN O
several NN NN O
mechanisms NN NN O
, NN NN O
for NN NN O
example NN NN O
intracellular NN NN O
glucocorticoid NN NN B-Protein
receptors NN NN I-Protein
( NN NN O
hGR NN NN B-Protein
) NN NN O
. NN NN O
   
Glucocorticoids NN NN O
are NN NN O
the NN NN O
standard NN NN O
treatment NN NN O
of NN NN O
acute NN NN O
attacks NN NN O
of NN NN O
inflammatory NN NN O
bowel NN NN O
disease NN NN O
( NN NN O
IBD NN NN O
) NN NN O
. NN NN O
   
Binding NN NN O
of NN NN O
glucocorticoids NN NN O
to NN NN O
hGR NN NN B-Protein
down NN NN O
- NN NN O
regulates NN NN O
the NN NN O
transcription NN NN O
of NN NN O
inflammatory NN NN O
genes NN NN O
that NN NN O
can NN NN O
propagate NN NN O
IBD NN NN O
. NN NN O
   
PATIENTS NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
IBD NN NN O
patients NN NN O
were NN NN O
either NN NN O
treated NN NN O
with NN NN O
5 NN NN O
- NN NN O
60 NN NN O
mg NN NN O
of NN NN O
prednisolone NN NN O
for NN NN O
more NN NN O
than NN NN O
1 NN NN O
week NN NN O
or NN NN O
were NN NN O
without NN NN O
glucocorticoid NN NN O
treatment NN NN O
for NN NN O
more NN NN O
than NN NN O
4 NN NN O
weeks NN NN O
. NN NN O
   
hGR NN NN B-Protein
levels NN NN O
were NN NN O
determined NN NN O
from NN NN O
isolated NN NN O
cytosol NN NN O
of NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
( NN NN O
PBMCs NN NN O
) NN NN O
or NN NN O
mucosal NN NN O
biopsies NN NN O
using NN NN O
a NN NN O
radioassay NN NN O
with NN NN O
[ NN NN O
3H NN NN O
] NN NN O
- NN NN O
dexamethasone NN NN O
. NN NN O
   
Interleukin NN NN B-Protein
( NN NN I-Protein
IL NN NN I-Protein
) NN NN I-Protein
6 NN NN I-Protein
levels NN NN O
were NN NN O
determined NN NN O
by NN NN O
enzyme NN NN O
- NN NN O
linked NN NN O
immunosorbent NN NN O
assay NN NN O
( NN NN O
ELISA NN NN O
) NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
systemic NN NN O
( NN NN O
PBMC NN NN O
) NN NN O
hGR NN NN B-Protein
levels NN NN O
of NN NN O
corticosteroid NN NN O
- NN NN O
treated NN NN O
IBD NN NN O
patients NN NN O
were NN NN O
significantly NN NN O
lower NN NN O
than NN NN O
those NN NN O
of NN NN O
control NN NN O
subjects NN NN O
( NN NN O
59 NN NN O
. NN NN O
6 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
57 NN NN O
. NN NN O
1 NN NN O
dpm NN NN O
mg NN NN O
- NN NN O
1 NN NN O
cytosol NN NN O
protein NN NN O
vs NN NN O
. NN NN O
227 NN NN O
. NN NN O
0 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
90 NN NN O
. NN NN O
8 NN NN O
dpm NN NN O
mg NN NN O
- NN NN O
1 NN NN O
cytosol NN NN O
protein NN NN O
, NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
007 NN NN O
) NN NN O
and NN NN O
IBD NN NN O
patients NN NN O
not NN NN O
receiving NN NN O
glucocorticoid NN NN O
treatment NN NN O
( NN NN O
179 NN NN O
. NN NN O
7 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
171 NN NN O
. NN NN O
3 NN NN O
dpm NN NN O
mg NN NN O
- NN NN O
1 NN NN O
cytosol NN NN O
protein NN NN O
, NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
002 NN NN O
) NN NN O
. NN NN O
   
Systemic NN NN O
hGR NN NN B-Protein
levels NN NN O
in NN NN O
untreated NN NN O
IBD NN NN O
patients NN NN O
did NN NN O
not NN NN O
differ NN NN O
significantly NN NN O
from NN NN O
those NN NN O
in NN NN O
control NN NN O
subjects NN NN O
. NN NN O
   
In NN NN O
patients NN NN O
with NN NN O
connective NN NN O
tissue NN NN O
diseases NN NN O
, NN NN O
systemic NN NN O
hGR NN NN B-Protein
levels NN NN O
were NN NN O
also NN NN O
found NN NN O
to NN NN O
be NN NN O
decreased NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
glucocorticoid NN NN O
treatment NN NN O
. NN NN O
   
Systemic NN NN O
hGR NN NN B-Protein
levels NN NN O
in NN NN O
patients NN NN O
with NN NN O
Crohn NN NN O
' NN NN O
s NN NN O
disease NN NN O
( NN NN O
CD NN NN O
) NN NN O
treated NN NN O
with NN NN O
steroids NN NN O
( NN NN O
66 NN NN O
. NN NN O
6 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
61 NN NN O
. NN NN O
0 NN NN O
dpm NN NN O
mg NN NN O
- NN NN O
1 NN NN O
cytosol NN NN O
protein NN NN O
) NN NN O
were NN NN O
not NN NN O
different NN NN O
from NN NN O
those NN NN O
in NN NN O
patients NN NN O
with NN NN O
ulcerative NN NN O
colitis NN NN O
( NN NN O
UC NN NN O
) NN NN O
( NN NN O
56 NN NN O
. NN NN O
1 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
51 NN NN O
. NN NN O
6 NN NN O
dpm NN NN O
mg NN NN O
- NN NN O
1 NN NN O
cytosol NN NN O
protein NN NN O
) NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
to NN NN O
these NN NN O
findings NN NN O
, NN NN O
mucosal NN NN O
hGR NN NN B-Protein
levels NN NN O
were NN NN O
significantly NN NN O
decreased NN NN O
in NN NN O
both NN NN O
steroid NN NN O
- NN NN O
treated NN NN O
( NN NN O
18 NN NN O
. NN NN O
0 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
15 NN NN O
. NN NN O
5 NN NN O
) NN NN O
and NN NN O
not NN NN O
steroid NN NN O
- NN NN O
treated NN NN O
( NN NN O
37 NN NN O
. NN NN O
8 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
30 NN NN O
. NN NN O
5 NN NN O
) NN NN O
patients NN NN O
compared NN NN O
with NN NN O
control NN NN O
subjects NN NN O
( NN NN O
125 NN NN O
. NN NN O
6 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
97 NN NN O
. NN NN O
1 NN NN O
; NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
00009 NN NN O
and NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
0008 NN NN O
respectively NN NN O
) NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
levels NN NN O
in NN NN O
all NN NN O
IBD NN NN O
groups NN NN O
with NN NN O
and NN NN O
without NN NN O
steroids NN NN O
were NN NN O
significantly NN NN O
different NN NN O
from NN NN O
those NN NN O
in NN NN O
control NN NN O
subjects NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
In NN NN O
IBD NN NN O
there NN NN O
is NN NN O
no NN NN O
difference NN NN O
in NN NN O
systemic NN NN O
hGR NN NN B-Protein
levels NN NN O
between NN NN O
not NN NN O
steroid NN NN O
- NN NN O
treated NN NN O
patients NN NN O
and NN NN O
control NN NN O
subjects NN NN O
, NN NN O
in NN NN O
spite NN NN O
of NN NN O
inflammatory NN NN O
activity NN NN O
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
) NN NN O
. NN NN O
   
Mucosal NN NN O
hGR NN NN B-Protein
levels NN NN O
were NN NN O
decreased NN NN O
independently NN NN O
of NN NN O
treatment NN NN O
, NN NN O
probably NN NN O
leading NN NN O
to NN NN O
a NN NN O
decreased NN NN O
protection NN NN O
against NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
action NN NN O
in NN NN O
the NN NN O
intestinal NN NN O
mucosa NN NN O
. NN NN O
   
Bacterial NN NN O
peptidoglycan NN NN O
induces NN NN O
CD14 NN NN B-Protein
- NN NN O
dependent NN NN O
activation NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
CREB NN NN O
/ NN NN O
ATF NN NN O
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
Peptidoglycan NN NN O
( NN NN O
PGN NN NN O
) NN NN O
, NN NN O
the NN NN O
major NN NN O
cell NN NN O
wall NN NN O
component NN NN O
of NN NN O
Gram NN NN O
- NN NN O
positive NN NN O
bacteria NN NN O
, NN NN O
induces NN NN O
secretion NN NN O
of NN NN O
cytokines NN NN O
in NN NN O
macrophages NN NN O
through NN NN O
CD14 NN NN B-Protein
, NN NN O
the NN NN O
pattern NN NN O
recognition NN NN O
receptor NN NN O
that NN NN O
binds NN NN O
lipopolysaccharide NN NN O
and NN NN O
other NN NN O
microbial NN NN O
products NN NN O
. NN NN O
   
To NN NN O
begin NN NN O
to NN NN O
elucidate NN NN O
the NN NN O
mechanisms NN NN O
that NN NN O
regulate NN NN O
the NN NN O
transcription NN NN O
of NN NN O
cytokine NN NN O
genes NN NN O
, NN NN O
we NN NN O
wanted NN NN O
to NN NN O
determine NN NN O
which NN NN O
transcription NN NN O
factors NN NN O
are NN NN O
activated NN NN O
by NN NN O
PGN NN NN O
in NN NN O
mouse NN NN O
RAW264 NN NN O
. NN NN O
7 NN NN O
and NN NN O
human NN NN O
THP NN NN O
- NN NN O
1 NN NN O
macrophage NN NN O
cells NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
demonstrated NN NN O
that NN NN O
: NN NN O
( NN NN O
i NN NN O
) NN NN O
PGN NN NN O
induced NN NN O
phosphorylation NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factors NN NN O
ATF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
CREB NN NN B-Protein
; NN NN O
( NN NN O
ii NN NN O
) NN NN O
ATF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
CREB NN NN B-Protein
bound NN NN O
DNA NN NN O
as NN NN O
a NN NN O
dimer NN NN O
and NN NN O
induced NN NN O
transcriptional NN NN O
activation NN NN O
of NN NN O
a NN NN O
CRE NN NN O
reporter NN NN O
plasmid NN NN O
, NN NN O
which NN NN O
was NN NN O
inhibited NN NN O
by NN NN O
dominant NN NN O
negative NN NN O
CREB NN NN B-Protein
and NN NN O
ATF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
; NN NN O
( NN NN O
iii NN NN O
) NN NN O
PGN NN NN O
induced NN NN O
phosphorylation NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
, NN NN O
protein NN NN O
synthesis NN NN O
of NN NN O
JunB NN NN B-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
, NN NN O
and NN NN O
transcriptional NN NN O
activation NN NN O
of NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
reporter NN NN O
plasmid NN NN O
, NN NN O
which NN NN O
was NN NN O
inhibited NN NN O
by NN NN O
dominant NN NN O
negative NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
; NN NN O
and NN NN O
( NN NN O
iv NN NN O
) NN NN O
PGN NN NN O
- NN NN O
induced NN NN O
activation NN NN O
of NN NN O
CREB NN NN O
/ NN NN O
ATF NN NN O
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
was NN NN O
mediated NN NN O
through NN NN O
CD14 NN NN B-Protein
. NN NN O
   
This NN NN O
is NN NN O
the NN NN O
first NN NN O
study NN NN O
to NN NN O
demonstrate NN NN O
activation NN NN O
of NN NN O
CREB NN NN O
/ NN NN O
ATF NN NN O
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
transcription NN NN O
factors NN NN O
by NN NN O
PGN NN NN O
or NN NN O
by NN NN O
any NN NN O
other NN NN O
component NN NN O
of NN NN O
Gram NN NN O
- NN NN O
positive NN NN O
bacteria NN NN O
. NN NN O
   
Nuclear NN NN B-Protein
factor NN NN I-Protein
- NN NN I-Protein
90 NN NN I-Protein
of NN NN I-Protein
activated NN NN I-Protein
T NN NN I-Protein
- NN NN I-Protein
cells NN NN I-Protein
: NN NN O
A NN NN O
double NN NN O
- NN NN O
stranded NN NN O
RNA NN NN O
- NN NN O
binding NN NN O
protein NN NN O
and NN NN O
substrate NN NN O
for NN NN O
the NN NN O
double NN NN O
- NN NN O
stranded NN NN O
RNA NN NN O
- NN NN O
dependent NN NN O
protein NN NN O
kinase NN NN O
, NN NN O
PKR NN NN B-Protein
. NN NN O
   
NFAT NN NN O
transcription NN NN O
factors NN NN O
play NN NN O
a NN NN O
central NN NN O
role NN NN O
in NN NN O
initiating NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
through NN NN O
the NN NN O
induction NN NN O
of NN NN O
immediate NN NN O
- NN NN O
early NN NN O
T NN NN O
- NN NN O
cell NN NN O
specific NN NN O
genes NN NN O
including NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
. NN NN O
   
NFAT NN NN O
transcription NN NN O
factors NN NN O
bind NN NN O
to NN NN O
a NN NN O
sequence NN NN O
in NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
enhancer NN NN O
known NN NN O
as NN NN O
the NN NN O
antigen NN NN O
receptor NN NN O
response NN NN O
element NN NN O
2 NN NN O
( NN NN O
ARRE NN NN O
- NN NN O
2 NN NN O
) NN NN O
. NN NN O
   
Multiple NN NN O
proteins NN NN O
exhibiting NN NN O
ARRE NN NN O
- NN NN O
2 NN NN O
binding NN NN O
activity NN NN O
have NN NN O
been NN NN O
isolated NN NN O
, NN NN O
including NN NN O
a NN NN O
heterodimer NN NN O
from NN NN O
stimulated NN NN O
T NN NN O
- NN NN O
cell NN NN O
nuclear NN NN O
extracts NN NN O
consisting NN NN O
of NN NN O
Mr NN NN O
= NN NN O
90 NN NN O
000 NN NN O
( NN NN O
NF90 NN NN B-Protein
) NN NN O
and NN NN O
Mr NN NN O
= NN NN O
45 NN NN O
000 NN NN O
( NN NN O
NF45 NN NN B-Protein
) NN NN O
subunits NN NN O
. NN NN O
   
The NN NN O
subunits NN NN O
of NN NN O
this NN NN O
heterodimer NN NN O
have NN NN O
been NN NN O
cloned NN NN O
, NN NN O
and NN NN O
NF90 NN NN B-Protein
was NN NN O
found NN NN O
to NN NN O
encode NN NN O
a NN NN O
protein NN NN O
containing NN NN O
two NN NN O
domains NN NN O
that NN NN O
are NN NN O
predicted NN NN O
to NN NN O
form NN NN O
motifs NN NN O
capable NN NN O
of NN NN O
binding NN NN O
to NN NN O
double NN NN O
- NN NN O
stranded NN NN O
RNA NN NN O
. NN NN O
   
Using NN NN O
in NN NN O
vitro NN NN O
translated NN NN O
polypeptides NN NN O
, NN NN O
we NN NN O
have NN NN O
demonstrated NN NN O
that NN NN O
NF90 NN NN B-Protein
specifically NN NN O
binds NN NN O
to NN NN O
double NN NN O
- NN NN O
stranded NN NN O
RNA NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
NF90 NN NN B-Protein
was NN NN O
phosphorylated NN NN O
in NN NN O
a NN NN O
double NN NN O
- NN NN O
stranded NN NN O
RNA NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
likely NN NN O
by NN NN O
the NN NN O
interferon NN NN B-Protein
- NN NN I-Protein
induced NN NN I-Protein
, NN NN I-Protein
double NN NN I-Protein
- NN NN I-Protein
stranded NN NN I-Protein
RNA NN NN I-Protein
- NN NN I-Protein
dependent NN NN I-Protein
protein NN NN I-Protein
kinase NN NN I-Protein
, NN NN O
PKR NN NN B-Protein
. NN NN O
   
The NN NN O
NF90 NN NN B-Protein
protein NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
expressed NN NN O
not NN NN O
only NN NN O
in NN NN O
T NN NN O
- NN NN O
cells NN NN O
, NN NN O
but NN NN O
also NN NN O
in NN NN O
nonimmune NN NN O
HeLa NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
HeLa NN NN O
cells NN NN O
, NN NN O
the NN NN O
protein NN NN O
was NN NN O
almost NN NN O
exclusively NN NN O
localized NN NN O
to NN NN O
the NN NN O
ribosome NN NN O
salt NN NN O
wash NN NN O
fraction NN NN O
of NN NN O
cell NN NN O
lysates NN NN O
. NN NN O
   
c NN NN B-Protein
- NN NN I-Protein
Myc NN NN I-Protein
and NN NN O
E1A NN NN B-Protein
induced NN NN O
cellular NN NN O
sensitivity NN NN O
to NN NN O
activated NN NN O
NK NN NN O
cells NN NN O
involves NN NN O
cytotoxic NN NN O
granules NN NN O
as NN NN O
death NN NN O
effectors NN NN O
. NN NN O
   
The NN NN O
contact NN NN O
of NN NN O
natural NN NN O
killer NN NN O
( NN NN O
NK NN NN O
) NN NN O
cells NN NN O
with NN NN O
foreign NN NN O
cells NN NN O
and NN NN O
with NN NN O
certain NN NN O
virus NN NN O
- NN NN O
infected NN NN O
or NN NN O
tumor NN NN O
cells NN NN O
triggers NN NN O
the NN NN O
cytolytic NN NN O
machinery NN NN O
of NN NN O
NK NN NN O
cells NN NN O
. NN NN O
   
This NN NN O
triggering NN NN O
leads NN NN O
to NN NN O
exocytosis NN NN O
of NN NN O
the NN NN O
cytotoxic NN NN O
NK NN NN O
cell NN NN O
granules NN NN O
. NN NN O
   
The NN NN O
oncoproteins NN NN O
c NN NN B-Protein
- NN NN I-Protein
Myc NN NN I-Protein
and NN NN O
E1A NN NN B-Protein
render NN NN O
cells NN NN O
vulnerable NN NN O
to NN NN O
NK NN NN O
cell NN NN O
mediated NN NN O
cytolysis NN NN O
yet NN NN O
the NN NN O
mechanisms NN NN O
of NN NN O
sensitization NN NN O
are NN NN O
not NN NN O
well NN NN O
understood NN NN O
. NN NN O
   
In NN NN O
a NN NN O
model NN NN O
where NN NN O
foreign NN NN O
cells NN NN O
( NN NN O
rat NN NN O
fibroblasts NN NN O
) NN NN O
were NN NN O
cocultured NN NN O
with NN NN O
human NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
activated NN NN O
NK NN NN O
cells NN NN O
, NN NN O
we NN NN O
observed NN NN O
that NN NN O
NK NN NN O
cells NN NN O
were NN NN O
capable NN NN O
of NN NN O
efficiently NN NN O
killing NN NN O
their NN NN O
targets NN NN O
only NN NN O
if NN NN O
the NN NN O
cells NN NN O
overexpressed NN NN O
the NN NN O
oncogene NN NN O
c NN NN B-Protein
- NN NN I-Protein
Myc NN NN I-Protein
or NN NN O
E1A NN NN B-Protein
. NN NN O
   
Both NN NN O
the NN NN O
parental NN NN O
and NN NN O
the NN NN O
oncogene NN NN O
expressing NN NN O
fibroblasts NN NN O
similarly NN NN O
triggered NN NN O
phosphoinositide NN NN O
hydrolysis NN NN O
in NN NN O
the NN NN O
bound NN NN O
NK NN NN O
cells NN NN O
, NN NN O
demonstrating NN NN O
that NN NN O
NK NN NN O
cells NN NN O
were NN NN O
cytolytically NN NN O
activated NN NN O
in NN NN O
contact NN NN O
with NN NN O
both NN NN O
resistant NN NN O
parental NN NN O
and NN NN O
oncogene NN NN O
expressing NN NN O
sensitive NN NN O
target NN NN O
fibroblasts NN NN O
. NN NN O
   
The NN NN O
cell NN NN O
death NN NN O
was NN NN O
independent NN NN O
of NN NN O
wild NN NN O
- NN NN O
type NN NN O
p53 NN NN B-Protein
and NN NN O
was NN NN O
not NN NN O
inhibited NN NN O
by NN NN O
an NN NN O
anti NN NN O
- NN NN O
apoptotic NN NN O
protein NN NN O
EIB19K NN NN B-Protein
. NN NN O
   
These NN NN O
results NN NN O
provided NN NN O
evidence NN NN O
that NN NN O
c NN NN B-Protein
- NN NN I-Protein
Myc NN NN I-Protein
and NN NN O
E1A NN NN B-Protein
activated NN NN O
the NN NN O
NK NN NN O
cell NN NN O
induced NN NN O
cytolysis NN NN O
at NN NN O
a NN NN O
post NN NN O
- NN NN O
triggering NN NN O
stage NN NN O
of NN NN O
NK NN NN O
cell NN NN O
- NN NN O
target NN NN O
cell NN NN O
interaction NN NN O
. NN NN O
   
In NN NN O
consistence NN NN O
, NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
Myc NN NN I-Protein
and NN NN O
E1A NN NN B-Protein
overexpressing NN NN O
fibroblasts NN NN O
were NN NN O
more NN NN O
sensitive NN NN O
to NN NN O
the NN NN O
cytolytic NN NN O
effects NN NN O
of NN NN O
isolated NN NN O
NK NN NN O
cell NN NN O
- NN NN O
derived NN NN O
granules NN NN O
than NN NN O
parental NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
data NN NN O
indicate NN NN O
that NN NN O
oncogenes NN NN O
activate NN NN O
the NN NN O
cytotoxicity NN NN O
of NN NN O
NK NN NN O
cell NN NN O
granules NN NN O
. NN NN O
   
This NN NN O
mechanism NN NN O
can NN NN O
have NN NN O
a NN NN O
role NN NN O
in NN NN O
directing NN NN O
the NN NN O
cytolytic NN NN O
action NN NN O
of NN NN O
NK NN NN O
cells NN NN O
towards NN NN O
the NN NN O
virus NN NN O
- NN NN O
infected NN NN O
and NN NN O
cancer NN NN O
cells NN NN O
. NN NN O
   
Apoptosis NN NN O
and NN NN O
growth NN NN O
inhibition NN NN O
in NN NN O
malignant NN NN O
lymphocytes NN NN O
after NN NN O
treatment NN NN O
with NN NN O
arsenic NN NN O
trioxide NN NN O
at NN NN O
clinically NN NN O
achievable NN NN O
concentrations NN NN O
[ NN NN O
see NN NN O
comments NN NN O
] NN NN O
   
BACKGROUND NN NN O
: NN NN O
Arsenic NN NN O
trioxide NN NN O
( NN NN O
As2O3 NN NN O
) NN NN O
can NN NN O
induce NN NN O
clinical NN NN O
remission NN NN O
in NN NN O
patients NN NN O
with NN NN O
acute NN NN O
promyelocytic NN NN O
leukemia NN NN O
via NN NN O
induction NN NN O
of NN NN O
differentiation NN NN O
and NN NN O
programmed NN NN O
cell NN NN O
death NN NN O
( NN NN O
apoptosis NN NN O
) NN NN O
. NN NN O
   
We NN NN O
investigated NN NN O
the NN NN O
effects NN NN O
of NN NN O
As2O3 NN NN O
on NN NN O
a NN NN O
panel NN NN O
of NN NN O
malignant NN NN O
lymphocytes NN NN O
to NN NN O
determine NN NN O
whether NN NN O
growth NN NN O
- NN NN O
inhibitory NN NN O
and NN NN O
apoptotic NN NN O
effects NN NN O
of NN NN O
As2O3 NN NN O
can NN NN O
be NN NN O
observed NN NN O
in NN NN O
these NN NN O
cells NN NN O
at NN NN O
clinically NN NN O
achievable NN NN O
concentrations NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Eight NN NN O
malignant NN NN O
lymphocytic NN NN O
cell NN NN O
lines NN NN O
and NN NN O
primary NN NN O
cultures NN NN O
of NN NN O
lymphocytic NN NN O
leukemia NN NN O
and NN NN O
lymphoma NN NN O
cells NN NN O
were NN NN O
treated NN NN O
with NN NN O
As2O3 NN NN O
, NN NN O
with NN NN O
or NN NN O
without NN NN O
dithiothreitol NN NN O
( NN NN O
DTT NN NN O
) NN NN O
or NN NN O
buthionine NN NN O
sulfoximine NN NN O
( NN NN O
BSO NN NN O
) NN NN O
( NN NN O
an NN NN O
inhibitor NN NN O
of NN NN O
glutathione NN NN O
synthesis NN NN O
) NN NN O
. NN NN O
   
Apoptosis NN NN O
was NN NN O
assessed NN NN O
by NN NN O
cell NN NN O
morphology NN NN O
, NN NN O
flow NN NN O
cytometry NN NN O
, NN NN O
annexin NN NN B-Protein
V NN NN I-Protein
protein NN NN O
level NN NN O
, NN NN O
and NN NN O
terminal NN NN B-Protein
deoxynucleotidyl NN NN I-Protein
transferase NN NN I-Protein
labeling NN NN O
of NN NN O
DNA NN NN O
fragments NN NN O
. NN NN O
   
Cellular NN NN O
proliferation NN NN O
was NN NN O
determined NN NN O
by NN NN O
5 NN NN O
- NN NN O
bromo NN NN O
- NN NN O
2 NN NN O
' NN NN O
- NN NN O
deoxyuridine NN NN O
incorporation NN NN O
into NN NN O
DNA NN NN O
and NN NN O
flow NN NN O
cytometry NN NN O
and NN NN O
by NN NN O
use NN NN O
of NN NN O
a NN NN O
mitotic NN NN O
arrest NN NN O
assay NN NN O
. NN NN O
   
Mitochondrial NN NN O
transmembrane NN NN O
potential NN NN O
( NN NN O
delta NN NN O
psi NN NN O
( NN NN O
m NN NN O
) NN NN O
) NN NN O
was NN NN O
measured NN NN O
by NN NN O
means NN NN O
of NN NN O
rhodamine NN NN O
123 NN NN O
staining NN NN O
and NN NN O
flow NN NN O
cytometry NN NN O
. NN NN O
   
Protein NN NN O
expression NN NN O
was NN NN O
assessed NN NN O
by NN NN O
western NN NN O
blot NN NN O
analysis NN NN O
or NN NN O
immunofluorescence NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Therapeutic NN NN O
concentrations NN NN O
of NN NN O
As2O3 NN NN O
( NN NN O
1 NN NN O
- NN NN O
2 NN NN O
microM NN NN O
) NN NN O
had NN NN O
dual NN NN O
effects NN NN O
on NN NN O
malignant NN NN O
lymphocytes NN NN O
: NN NN O
1 NN NN O
) NN NN O
inhibition NN NN O
of NN NN O
growth NN NN O
through NN NN O
adenosine NN NN O
triphosphate NN NN O
( NN NN O
ATP NN NN O
) NN NN O
depletion NN NN O
and NN NN O
prolongation NN NN O
of NN NN O
cell NN NN O
cycle NN NN O
time NN NN O
and NN NN O
2 NN NN O
) NN NN O
induction NN NN O
of NN NN O
apoptosis NN NN O
. NN NN O
   
As2O3 NN NN O
- NN NN O
induced NN NN O
apoptosis NN NN O
was NN NN O
preceded NN NN O
by NN NN O
delta NN NN O
psi NN NN O
( NN NN O
m NN NN O
) NN NN O
collapse NN NN O
. NN NN O
   
DTT NN NN O
antagonized NN NN O
and NN NN O
BSO NN NN O
enhanced NN NN O
As2O3 NN NN O
- NN NN O
induced NN NN O
ATP NN NN O
depletion NN NN O
, NN NN O
delta NN NN O
psi NN NN O
( NN NN O
m NN NN O
) NN NN O
collapse NN NN O
, NN NN O
and NN NN O
apoptosis NN NN O
. NN NN O
   
Caspase NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
activation NN NN O
, NN NN O
usually NN NN O
resulting NN NN O
from NN NN O
delta NN NN O
psi NN NN O
( NN NN O
m NN NN O
) NN NN O
collapse NN NN O
, NN NN O
was NN NN O
not NN NN O
always NN NN O
associated NN NN O
with NN NN O
As2O3 NN NN O
- NN NN O
induced NN NN O
apoptosis NN NN O
. NN NN O
   
As2O3 NN NN O
induced NN NN O
PML NN NN B-Protein
( NN NN O
promyelocytic NN NN O
leukemia NN NN O
) NN NN O
protein NN NN O
degradation NN NN O
but NN NN O
did NN NN O
not NN NN O
modulate NN NN O
expression NN NN O
of NN NN O
cell NN NN O
cycle NN NN O
- NN NN O
related NN NN O
proteins NN NN O
, NN NN O
including NN NN O
c NN NN B-Protein
- NN NN I-Protein
myc NN NN I-Protein
, NN NN O
retinoblastoma NN NN B-Protein
protein NN NN I-Protein
, NN NN O
cyclin NN NN B-Protein
- NN NN I-Protein
dependent NN NN I-Protein
kinase NN NN I-Protein
4 NN NN I-Protein
, NN NN O
cyclin NN NN B-Protein
D1 NN NN I-Protein
, NN NN O
and NN NN O
p53 NN NN B-Protein
, NN NN O
or NN NN O
expression NN NN O
of NN NN O
differentiation NN NN O
- NN NN O
related NN NN O
antigens NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Substantial NN NN O
growth NN NN O
inhibition NN NN O
and NN NN O
apoptosis NN NN O
without NN NN O
evidence NN NN O
of NN NN O
differentiation NN NN O
were NN NN O
induced NN NN O
in NN NN O
most NN NN O
malignant NN NN O
lymphocytic NN NN O
cells NN NN O
treated NN NN O
with NN NN O
1 NN NN O
- NN NN O
2 NN NN O
microM NN NN O
As2O3 NN NN O
. NN NN O
   
As2O3 NN NN O
may NN NN O
prove NN NN O
useful NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
malignant NN NN O
lymphoproliferative NN NN O
disorders NN NN O
. NN NN O
   
A NN NN O
role NN NN O
for NN NN O
RanBP1 NN NN B-Protein
in NN NN O
the NN NN O
release NN NN O
of NN NN O
CRM1 NN NN B-Protein
from NN NN O
the NN NN O
nuclear NN NN O
pore NN NN O
complex NN NN O
in NN NN O
a NN NN O
terminal NN NN O
step NN NN O
of NN NN O
nuclear NN NN O
export NN NN O
. NN NN O
   
We NN NN O
recently NN NN O
developed NN NN O
an NN NN O
assay NN NN O
in NN NN O
which NN NN O
nuclear NN NN O
export NN NN O
of NN NN O
the NN NN O
shuttling NN NN O
transcription NN NN O
factor NN NN O
NFAT NN NN O
( NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
) NN NN O
can NN NN O
be NN NN O
reconstituted NN NN O
in NN NN O
permeabilized NN NN O
cells NN NN O
with NN NN O
the NN NN O
GTPase NN NN O
Ran NN NN B-Protein
and NN NN O
the NN NN O
nuclear NN NN O
export NN NN O
receptor NN NN O
CRM1 NN NN B-Protein
. NN NN O
   
We NN NN O
have NN NN O
now NN NN O
used NN NN O
this NN NN O
assay NN NN O
to NN NN O
identify NN NN O
another NN NN O
export NN NN O
factor NN NN O
. NN NN O
   
After NN NN O
preincubation NN NN O
of NN NN O
permeabilized NN NN O
cells NN NN O
with NN NN O
a NN NN O
Ran NN NN B-Protein
mutant NN NN O
that NN NN O
cannot NN NN O
hydrolyze NN NN O
GTP NN NN O
( NN NN O
RanQ69L NN NN O
) NN NN O
, NN NN O
cytosol NN NN O
supports NN NN O
NFAT NN NN O
export NN NN O
, NN NN O
but NN NN O
CRM1 NN NN B-Protein
and NN NN O
Ran NN NN B-Protein
alone NN NN O
do NN NN O
not NN NN O
. NN NN O
   
The NN NN O
RanQ69L NN NN O
preincubation NN NN O
leads NN NN O
to NN NN O
accumulation NN NN O
of NN NN O
CRM1 NN NN B-Protein
at NN NN O
the NN NN O
cytoplasmic NN NN O
periphery NN NN O
of NN NN O
the NN NN O
nuclear NN NN O
pore NN NN O
complex NN NN O
( NN NN O
NPC NN NN O
) NN NN O
in NN NN O
association NN NN O
with NN NN O
the NN NN O
p62 NN NN B-Protein
complex NN NN O
and NN NN O
Can NN NN B-Protein
/ NN NN O
Nup214 NN NN B-Protein
. NN NN O
   
RanGTP NN NN O
- NN NN O
dependent NN NN O
association NN NN O
of NN NN O
CRM1 NN NN B-Protein
with NN NN O
these NN NN O
nucleoporins NN NN O
was NN NN O
reconstituted NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
By NN NN O
biochemical NN NN O
fractionation NN NN O
and NN NN O
reconstitution NN NN O
, NN NN O
we NN NN O
showed NN NN O
that NN NN O
RanBP1 NN NN B-Protein
restores NN NN O
nuclear NN NN O
export NN NN O
after NN NN O
the NN NN O
RanQ69L NN NN O
preincubation NN NN O
. NN NN O
   
It NN NN O
also NN NN O
stimulates NN NN O
nuclear NN NN O
export NN NN O
in NN NN O
cells NN NN O
that NN NN O
have NN NN O
not NN NN O
been NN NN O
preincubated NN NN O
with NN NN O
RanQ69L NN NN O
. NN NN O
   
RanBP1 NN NN B-Protein
as NN NN O
well NN NN O
as NN NN O
Ran NN NN B-Protein
- NN NN O
binding NN NN O
domains NN NN O
of NN NN O
the NN NN O
cytoplasmic NN NN O
nucleoporin NN NN O
RanBP2 NN NN B-Protein
promote NN NN O
the NN NN O
release NN NN O
of NN NN O
CRM1 NN NN B-Protein
from NN NN O
the NN NN O
NPC NN NN O
. NN NN O
   
Taken NN NN O
together NN NN O
, NN NN O
our NN NN O
results NN NN O
indicate NN NN O
that NN NN O
RanGTP NN NN O
is NN NN O
important NN NN O
for NN NN O
the NN NN O
targeting NN NN O
of NN NN O
export NN NN O
complexes NN NN O
to NN NN O
the NN NN O
cytoplasmic NN NN O
side NN NN O
of NN NN O
the NN NN O
NPC NN NN O
and NN NN O
that NN NN O
RanBP1 NN NN B-Protein
and NN NN O
probably NN NN O
RanBP2 NN NN B-Protein
are NN NN O
involved NN NN O
in NN NN O
the NN NN O
dissociation NN NN O
of NN NN O
nuclear NN NN O
export NN NN O
complexes NN NN O
from NN NN O
the NN NN O
NPC NN NN O
in NN NN O
a NN NN O
terminal NN NN O
step NN NN O
of NN NN O
transport NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
Th1 NN NN O
and NN NN O
Th2 NN NN O
type NN NN O
cytokines NN NN O
responding NN NN O
to NN NN O
HBsAg NN NN B-Protein
and NN NN O
HBxAg NN NN B-Protein
in NN NN O
chronic NN NN O
hepatitis NN NN O
B NN NN O
patients NN NN O
. NN NN O
   
The NN NN O
cytokine NN NN O
pattern NN NN O
on NN NN O
viral NN NN O
antigen NN NN O
recognition NN NN O
is NN NN O
believed NN NN O
to NN NN O
exert NN NN O
a NN NN O
profound NN NN O
influence NN NN O
on NN NN O
the NN NN O
resolution NN NN O
of NN NN O
viral NN NN O
infections NN NN O
and NN NN O
viral NN NN O
clearance NN NN O
. NN NN O
   
This NN NN O
study NN NN O
was NN NN O
initiated NN NN O
to NN NN O
investigate NN NN O
whether NN NN O
a NN NN O
cytokine NN NN O
imbalance NN NN O
oriented NN NN O
toward NN NN O
Th2 NN NN O
type NN NN O
response NN NN O
plays NN NN O
a NN NN O
role NN NN O
in NN NN O
chronic NN NN O
hepatitis NN NN O
B NN NN O
. NN NN O
   
Cytokine NN NN O
profiles NN NN O
of NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
associated NN NN O
with NN NN O
chronic NN NN O
hepatitis NN NN O
B NN NN O
were NN NN O
analysed NN NN O
by NN NN O
RT NN NN O
- NN NN O
PCR NN NN O
. NN NN O
   
Upon NN NN O
HBsAg NN NN B-Protein
stimulation NN NN O
, NN NN O
expression NN NN O
of NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
, NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
was NN NN O
detected NN NN O
in NN NN O
41 NN NN O
% NN NN O
, NN NN O
8 NN NN O
% NN NN O
, NN NN O
41 NN NN O
% NN NN O
, NN NN O
and NN NN O
50 NN NN O
% NN NN O
of NN NN O
the NN NN O
patients NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Among NN NN O
these NN NN O
cytokines NN NN O
, NN NN O
the NN NN O
expression NN NN O
of NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
was NN NN O
associated NN NN O
with NN NN O
high NN NN O
levels NN NN O
of NN NN O
serum NN NN O
AST NN NN O
/ NN NN O
ALT NN NN O
. NN NN O
   
However NN NN O
, NN NN O
we NN NN O
could NN NN O
not NN NN O
prove NN NN O
that NN NN O
Th2 NN NN O
type NN NN O
cytokines NN NN O
had NN NN O
a NN NN O
protective NN NN O
effect NN NN O
on NN NN O
hepatocytes NN NN O
. NN NN O
   
Upon NN NN O
HBxAg NN NN B-Protein
stimulation NN NN O
, NN NN O
there NN NN O
was NN NN O
no NN NN O
recognizable NN NN O
association NN NN O
of NN NN O
cytokine NN NN O
patterns NN NN O
with NN NN O
AST NN NN O
/ NN NN O
ALT NN NN O
levels NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
production NN NN O
of NN NN O
a NN NN O
Th1 NN NN O
cytokine NN NN O
, NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
, NN NN O
by NN NN O
HBsAg NN NN B-Protein
- NN NN O
reactive NN NN O
cells NN NN O
was NN NN O
associated NN NN O
with NN NN O
hepatocyte NN NN O
damage NN NN O
in NN NN O
chronic NN NN O
hepatitis NN NN O
B NN NN O
, NN NN O
while NN NN O
no NN NN O
counteracting NN NN O
effect NN NN O
of NN NN O
Th2 NN NN O
cytokines NN NN O
produced NN NN O
by NN NN O
those NN NN O
cells NN NN O
was NN NN O
observed NN NN O
. NN NN O
   
Protein NN NN B-Protein
kinase NN NN I-Protein
B NN NN I-Protein
( NN NN O
c NN NN B-Protein
- NN NN I-Protein
Akt NN NN I-Protein
) NN NN O
, NN NN O
phosphatidylinositol NN NN O
3 NN NN O
- NN NN O
kinase NN NN O
, NN NN O
and NN NN O
STAT5 NN NN B-Protein
are NN NN O
activated NN NN O
by NN NN O
erythropoietin NN NN B-Protein
( NN NN O
EPO NN NN B-Protein
) NN NN O
in NN NN O
HCD57 NN NN O
erythroid NN NN O
cells NN NN O
but NN NN O
are NN NN O
constitutively NN NN O
active NN NN O
in NN NN O
an NN NN O
EPO NN NN B-Protein
- NN NN O
independent NN NN O
, NN NN O
apoptosis NN NN O
- NN NN O
resistant NN NN O
subclone NN NN O
( NN NN O
HCD57 NN NN O
- NN NN O
SREI NN NN O
cells NN NN O
) NN NN O
. NN NN O
   
We NN NN O
found NN NN O
that NN NN O
erythropoietin NN NN B-Protein
( NN NN O
EPO NN NN B-Protein
) NN NN O
and NN NN O
stem NN NN B-Protein
cell NN NN I-Protein
factor NN NN I-Protein
( NN NN O
SCF NN NN B-Protein
) NN NN O
activated NN NN O
protein NN NN B-Protein
kinase NN NN I-Protein
B NN NN I-Protein
( NN NN O
PKB NN NN B-Protein
/ NN NN O
Akt NN NN B-Protein
) NN NN O
in NN NN O
EPO NN NN B-Protein
- NN NN O
dependent NN NN O
HCD57 NN NN O
erythroid NN NN O
cells NN NN O
. NN NN O
   
To NN NN O
better NN NN O
understand NN NN O
signals NN NN O
controlling NN NN O
proliferation NN NN O
and NN NN O
viability NN NN O
, NN NN O
erythroid NN NN O
cells NN NN O
that NN NN O
resist NN NN O
apoptosis NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
EPO NN NN B-Protein
were NN NN O
subcloned NN NN O
and NN NN O
characterized NN NN O
( NN NN O
HCD57 NN NN O
- NN NN O
SREI NN NN O
cells NN NN O
) NN NN O
. NN NN O
   
Constitutive NN NN O
activations NN NN O
of NN NN O
PKB NN NN B-Protein
/ NN NN O
Akt NN NN B-Protein
, NN NN O
STAT5a NN NN B-Protein
, NN NN O
and NN NN O
STAT5b NN NN B-Protein
were NN NN O
noted NN NN O
in NN NN O
these NN NN O
EPO NN NN B-Protein
- NN NN O
independent NN NN O
cells NN NN O
. NN NN O
   
PI3 NN NN O
- NN NN O
kinase NN NN O
activity NN NN O
was NN NN O
an NN NN O
upstream NN NN O
activator NN NN O
of NN NN O
PKB NN NN B-Protein
/ NN NN O
Akt NN NN B-Protein
because NN NN O
the NN NN O
PI3 NN NN O
- NN NN O
kinase NN NN O
inhibitor NN NN O
LY294002 NN NN O
blocked NN NN O
both NN NN O
constitutive NN NN O
PKB NN NN B-Protein
/ NN NN O
Akt NN NN B-Protein
and NN NN O
factor NN NN O
- NN NN O
dependent NN NN O
PKB NN NN B-Protein
/ NN NN O
Akt NN NN B-Protein
activity NN NN O
. NN NN O
   
The NN NN O
LY294002 NN NN O
study NN NN O
showed NN NN O
that NN NN O
proliferation NN NN O
and NN NN O
viability NN NN O
of NN NN O
both NN NN O
HCD57 NN NN O
- NN NN O
SREI NN NN O
and NN NN O
HCD57 NN NN O
cells NN NN O
correlated NN NN O
with NN NN O
the NN NN O
activity NN NN O
of NN NN O
PKB NN NN B-Protein
/ NN NN O
Akt NN NN B-Protein
; NN NN O
however NN NN O
, NN NN O
PKB NN NN B-Protein
/ NN NN O
Akt NN NN B-Protein
activity NN NN O
alone NN NN O
did NN NN O
not NN NN O
protect NN NN O
these NN NN O
cells NN NN O
from NN NN O
apoptosis NN NN O
. NN NN O
   
Treatment NN NN O
of NN NN O
HCD57 NN NN O
cells NN NN O
with NN NN O
SCF NN NN B-Protein
also NN NN O
activated NN NN O
PKB NN NN B-Protein
/ NN NN O
Akt NN NN B-Protein
, NN NN O
but NN NN O
did NN NN O
not NN NN O
protect NN NN O
from NN NN O
apoptosis NN NN O
. NN NN O
   
This NN NN O
result NN NN O
suggested NN NN O
that NN NN O
PKB NN NN B-Protein
/ NN NN O
PI3 NN NN O
- NN NN O
kinase NN NN O
activity NN NN O
is NN NN O
necessary NN NN O
but NN NN O
not NN NN O
sufficient NN NN O
to NN NN O
promote NN NN O
viability NN NN O
and NN NN O
/ NN NN O
or NN NN O
proliferation NN NN O
. NN NN O
   
Constitutive NN NN O
STAT5 NN NN B-Protein
activity NN NN O
, NN NN O
activated NN NN O
through NN NN O
an NN NN O
unknown NN NN O
pathway NN NN O
not NN NN O
including NN NN O
JAK2 NN NN B-Protein
or NN NN O
EPOR NN NN B-Protein
, NN NN O
may NN NN O
act NN NN O
in NN NN O
concert NN NN O
with NN NN O
the NN NN O
constitutive NN NN O
PI3 NN NN O
- NN NN O
kinase NN NN O
/ NN NN O
PKB NN NN B-Protein
/ NN NN O
Akt NN NN B-Protein
pathway NN NN O
to NN NN O
protect NN NN O
the NN NN O
EPO NN NN B-Protein
- NN NN O
independent NN NN O
HCD57 NN NN O
- NN NN O
SREI NN NN O
cells NN NN O
from NN NN O
apoptosis NN NN O
and NN NN O
promote NN NN O
limited NN NN O
proliferation NN NN O
. NN NN O
   
Human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
1 NN NN O
Tax NN NN B-Protein
protein NN NN O
induces NN NN O
the NN NN O
expression NN NN O
of NN NN O
STAT1 NN NN B-Protein
and NN NN O
STAT5 NN NN B-Protein
genes NN NN O
in NN NN O
T NN NN O
- NN NN O
cells NN NN O
. NN NN O
   
Human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
) NN NN O
Tax NN NN B-Protein
transforms NN NN O
normal NN NN O
T NN NN O
- NN NN O
cells NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
interleukin NN NN B-Protein
( NN NN I-Protein
IL NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
2 NN NN I-Protein
in NN NN O
vitro NN NN O
. NN NN O
   
STAT NN NN O
is NN NN O
a NN NN O
family NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
that NN NN O
play NN NN O
a NN NN O
pivotal NN NN O
role NN NN O
in NN NN O
cytokine NN NN O
- NN NN O
induced NN NN O
functions NN NN O
of NN NN O
a NN NN O
various NN NN O
type NN NN O
of NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
investigated NN NN O
the NN NN O
involvement NN NN O
of NN NN O
STATs NN NN O
in NN NN O
the NN NN O
transformation NN NN O
of NN NN O
T NN NN O
- NN NN O
cells NN NN O
by NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
HTLV NN NN O
- NN NN O
1 NN NN O
- NN NN O
transformed NN NN O
T NN NN O
- NN NN O
cell NN NN O
lines NN NN O
expressed NN NN O
higher NN NN O
amounts NN NN O
of NN NN O
STAT1 NN NN B-Protein
, NN NN O
STAT3 NN NN B-Protein
and NN NN O
STAT5 NN NN B-Protein
RNA NN NN O
and NN NN O
proteins NN NN O
than NN NN O
virus NN NN O
- NN NN O
negative NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
expression NN NN O
of NN NN O
STAT1 NN NN B-Protein
and NN NN O
STAT5 NN NN B-Protein
in NN NN O
a NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
line NN NN O
was NN NN O
induced NN NN O
by NN NN O
Tax NN NN B-Protein
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
induced NN NN O
the NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
of NN NN O
STAT3 NN NN B-Protein
and NN NN O
STAT5 NN NN B-Protein
of NN NN O
a NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
- NN NN O
transformed NN NN O
cell NN NN O
line NN NN O
and NN NN O
then NN NN O
stimulated NN NN O
its NN NN O
proliferation NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
did NN NN O
neither NN NN O
in NN NN O
a NN NN O
cell NN NN O
line NN NN O
lacking NN NN O
STAT3 NN NN B-Protein
and NN NN O
STAT5 NN NN B-Protein
. NN NN O
   
The NN NN O
expression NN NN O
of NN NN O
STAT1 NN NN B-Protein
, NN NN O
STAT3 NN NN B-Protein
and NN NN O
STAT5 NN NN B-Protein
mRNAs NN NN O
were NN NN O
also NN NN O
induced NN NN O
by NN NN O
a NN NN O
T NN NN O
- NN NN O
cell NN NN O
mitogen NN NN O
in NN NN O
normal NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
suggest NN NN O
that NN NN O
the NN NN O
induction NN NN O
of NN NN O
STAT1 NN NN B-Protein
and NN NN O
STAT5 NN NN B-Protein
by NN NN O
Tax NN NN B-Protein
enhances NN NN O
cytokine NN NN O
- NN NN O
induced NN NN O
functions NN NN O
of NN NN O
virus NN NN O
- NN NN O
infected NN NN O
T NN NN O
- NN NN O
cells NN NN O
, NN NN O
hence NN NN O
the NN NN O
induction NN NN O
may NN NN O
play NN NN O
a NN NN O
role NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
dependent NN NN O
transformation NN NN O
steps NN NN O
of NN NN O
T NN NN O
- NN NN O
cells NN NN O
by NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
Modulation NN NN O
of NN NN O
CD28 NN NN B-Protein
expression NN NN O
: NN NN O
distinct NN NN O
regulatory NN NN O
pathways NN NN O
during NN NN O
activation NN NN O
and NN NN O
replicative NN NN O
senescence NN NN O
. NN NN O
   
The NN NN O
costimulatory NN NN O
molecule NN NN O
CD28 NN NN B-Protein
has NN NN O
a NN NN O
restricted NN NN O
tissue NN NN O
distribution NN NN O
and NN NN O
is NN NN O
expressed NN NN O
on NN NN O
T NN NN O
cells NN NN O
and NN NN O
some NN NN O
plasmacytoma NN NN O
cells NN NN O
. NN NN O
   
Although NN NN O
CD28 NN NN B-Protein
is NN NN O
constitutively NN NN O
expressed NN NN O
, NN NN O
its NN NN O
expression NN NN O
is NN NN O
transiently NN NN O
down NN NN O
- NN NN O
regulated NN NN O
following NN NN O
T NN NN O
cell NN NN O
activation NN NN O
and NN NN O
declines NN NN O
progressively NN NN O
with NN NN O
in NN NN O
vitro NN NN O
senescence NN NN O
. NN NN O
   
In NN NN O
vivo NN NN O
, NN NN O
CD8 NN NN O
+ NN NN O
T NN NN O
cells NN NN O
and NN NN O
, NN NN O
less NN NN O
frequently NN NN O
, NN NN O
CD4 NN NN O
+ NN NN O
T NN NN O
cells NN NN O
may NN NN O
completely NN NN O
lose NN NN O
CD28 NN NN B-Protein
surface NN NN O
expression NN NN O
during NN NN O
chronic NN NN O
infections NN NN O
and NN NN O
with NN NN O
aging NN NN O
. NN NN O
   
This NN NN O
correlates NN NN O
with NN NN O
changes NN NN O
of NN NN O
nuclear NN NN O
protein NN NN O
- NN NN O
binding NN NN O
activities NN NN O
to NN NN O
two NN NN O
motifs NN NN O
, NN NN O
site NN NN O
alpha NN NN O
and NN NN O
beta NN NN O
, NN NN O
within NN NN O
the NN NN O
CD28 NN NN B-Protein
minimal NN NN O
promoter NN NN O
. NN NN O
   
Both NN NN O
alpha NN NN O
- NN NN O
and NN NN O
beta NN NN O
- NN NN O
bound NN NN O
complexes NN NN O
are NN NN O
found NN NN O
only NN NN O
in NN NN O
lymphoid NN NN O
tissues NN NN O
, NN NN O
in NN NN O
CD28 NN NN B-Protein
+ NN NN O
T NN NN O
cells NN NN O
, NN NN O
and NN NN O
in NN NN O
some NN NN O
transformed NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
complexes NN NN O
are NN NN O
coordinately NN NN O
expressed NN NN O
except NN NN O
during NN NN O
replicative NN NN O
senescence NN NN O
, NN NN O
which NN NN O
is NN NN O
characterized NN NN O
by NN NN O
the NN NN O
down NN NN O
- NN NN O
modulation NN NN O
of NN NN O
site NN NN O
beta NN NN O
- NN NN O
but NN NN O
not NN NN O
site NN NN O
alpha NN NN O
- NN NN O
binding NN NN O
activities NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
T NN NN O
cell NN NN O
activation NN NN O
induces NN NN O
a NN NN O
parallel NN NN O
decline NN NN O
in NN NN O
both NN NN O
site NN NN O
alpha NN NN O
- NN NN O
and NN NN O
beta NN NN O
- NN NN O
binding NN NN O
activities NN NN O
. NN NN O
   
CD4 NN NN B-Protein
+ NN NN O
and NN NN O
CD8 NN NN O
+ NN NN O
T NN NN O
cells NN NN O
differ NN NN O
in NN NN O
their NN NN O
beta NN NN O
- NN NN O
binding NN NN O
profiles NN NN O
, NN NN O
which NN NN O
may NN NN O
explain NN NN O
the NN NN O
more NN NN O
pronounced NN NN O
down NN NN O
- NN NN O
regulation NN NN O
of NN NN O
CD28 NN NN B-Protein
in NN NN O
senescent NN NN O
CD8 NN NN O
+ NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
vivo NN NN O
expanded NN NN O
CD4 NN NN B-Protein
+ NN NN O
CD28null NN NN B-Protein
and NN NN O
CD8 NN NN O
+ NN NN O
CD28null NN NN B-Protein
T NN NN O
cells NN NN O
uniformly NN NN O
lack NN NN O
alpha NN NN O
- NN NN O
and NN NN O
beta NN NN O
- NN NN O
bound NN NN O
complexes NN NN O
, NN NN O
resembling NN NN O
the NN NN O
pattern NN NN O
seen NN NN O
in NN NN O
chronically NN NN O
activated NN NN O
cells NN NN O
and NN NN O
not NN NN O
of NN NN O
senescent NN NN O
cells NN NN O
. NN NN O
   
Glucocorticoid NN NN B-Protein
receptors NN NN I-Protein
in NN NN O
anorexia NN NN O
nervosa NN NN O
and NN NN O
Cushing NN NN O
' NN NN O
s NN NN O
disease NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Patients NN NN O
with NN NN O
anorexia NN NN O
nervosa NN NN O
do NN NN O
not NN NN O
display NN NN O
cushingoid NN NN O
features NN NN O
in NN NN O
spite NN NN O
of NN NN O
elevated NN NN O
cortisol NN NN O
plasma NN NN O
levels NN NN O
. NN NN O
   
Whether NN NN O
a NN NN O
cortisol NN NN O
resistance NN NN O
or NN NN O
a NN NN O
reduced NN NN O
availability NN NN O
of NN NN O
the NN NN O
metabolic NN NN O
substrates NN NN O
necessary NN NN O
to NN NN O
develop NN NN O
the NN NN O
effect NN NN O
of NN NN O
glucocorticoids NN NN O
is NN NN O
responsible NN NN O
for NN NN O
this NN NN O
has NN NN O
not NN NN O
been NN NN O
established NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Twenty NN NN O
- NN NN O
two NN NN O
patients NN NN O
with NN NN O
severe NN NN O
restrictive NN NN O
anorexia NN NN O
nervosa NN NN O
, NN NN O
10 NN NN O
patients NN NN O
with NN NN O
active NN NN O
Cushing NN NN O
' NN NN O
s NN NN O
disease NN NN O
, NN NN O
and NN NN O
24 NN NN O
healthy NN NN O
volunteers NN NN O
without NN NN O
psychiatric NN NN O
disorders NN NN O
or NN NN O
mood NN NN O
alterations NN NN O
were NN NN O
investigated NN NN O
. NN NN O
   
Glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
characteristics NN NN O
were NN NN O
examined NN NN O
on NN NN O
mononuclear NN NN O
leukocytes NN NN O
by NN NN O
measuring NN NN O
[ NN NN O
3H NN NN O
] NN NN O
dexamethasone NN NN O
binding NN NN O
and NN NN O
the NN NN O
effect NN NN O
of NN NN O
dexamethasone NN NN O
on NN NN O
[ NN NN O
3H NN NN O
] NN NN O
thymidine NN NN O
incorporation NN NN O
, NN NN O
which NN NN O
represents NN NN O
an NN NN O
index NN NN O
of NN NN O
DNA NN NN O
synthesis NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
The NN NN O
number NN NN O
of NN NN O
glucocorticoid NN NN B-Protein
receptors NN NN I-Protein
on NN NN O
mononuclear NN NN O
leukocytes NN NN O
( NN NN O
MNL NN NN O
) NN NN O
was NN NN O
comparable NN NN O
in NN NN O
patients NN NN O
with NN NN O
anorexia NN NN O
nervosa NN NN O
, NN NN O
patients NN NN O
with NN NN O
active NN NN O
Cushing NN NN O
' NN NN O
s NN NN O
disease NN NN O
, NN NN O
and NN NN O
normal NN NN O
subjects NN NN O
( NN NN O
binding NN NN O
capacity NN NN O
3 NN NN O
. NN NN O
3 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
23 NN NN O
vs NN NN O
. NN NN O
3 NN NN O
. NN NN O
7 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
30 NN NN O
and NN NN O
3 NN NN O
. NN NN O
5 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
20 NN NN O
fmol NN NN O
/ NN NN O
10 NN NN O
( NN NN O
6 NN NN O
) NN NN O
cells NN NN O
) NN NN O
. NN NN O
   
Conversely NN NN O
, NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
affinity NN NN O
was NN NN O
significantly NN NN O
decreased NN NN O
in NN NN O
anorexia NN NN O
nervosa NN NN O
as NN NN O
well NN NN O
as NN NN O
in NN NN O
Cushing NN NN O
' NN NN O
s NN NN O
patients NN NN O
compared NN NN O
to NN NN O
control NN NN O
subjects NN NN O
( NN NN O
dissociation NN NN O
constant NN NN O
4 NN NN O
. NN NN O
0 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
31 NN NN O
and NN NN O
4 NN NN O
. NN NN O
1 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
34 NN NN O
vs NN NN O
. NN NN O
2 NN NN O
. NN NN O
9 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
29 NN NN O
nmol NN NN O
/ NN NN O
L NN NN O
, NN NN O
p NN NN O
< NN NN O
. NN NN O
001 NN NN O
) NN NN O
and NN NN O
inversely NN NN O
correlated NN NN O
with NN NN O
the NN NN O
levels NN NN O
of NN NN O
urinary NN NN O
free NN NN O
cortisol NN NN O
in NN NN O
both NN NN O
groups NN NN O
of NN NN O
patients NN NN O
. NN NN O
   
Basal NN NN O
[ NN NN O
3H NN NN O
] NN NN O
thymidine NN NN O
incorporation NN NN O
in NN NN O
MNL NN NN O
was NN NN O
significantly NN NN O
reduced NN NN O
in NN NN O
anorexia NN NN O
nervosa NN NN O
as NN NN O
well NN NN O
as NN NN O
in NN NN O
Cushing NN NN O
' NN NN O
s NN NN O
patients NN NN O
compared NN NN O
to NN NN O
control NN NN O
subjects NN NN O
( NN NN O
p NN NN O
< NN NN O
. NN NN O
001 NN NN O
) NN NN O
and NN NN O
was NN NN O
diminished NN NN O
by NN NN O
dexamethasone NN NN O
to NN NN O
an NN NN O
extent NN NN O
similar NN NN O
to NN NN O
control NN NN O
subjects NN NN O
in NN NN O
patients NN NN O
with NN NN O
anorexia NN NN O
nervosa NN NN O
, NN NN O
but NN NN O
significantly NN NN O
( NN NN O
p NN NN O
< NN NN O
. NN NN O
001 NN NN O
) NN NN O
less NN NN O
in NN NN O
those NN NN O
with NN NN O
Cushing NN NN O
' NN NN O
s NN NN O
disease NN NN O
. NN NN O
   
In NN NN O
patients NN NN O
with NN NN O
anorexia NN NN O
nervosa NN NN O
, NN NN O
the NN NN O
incorporation NN NN O
of NN NN O
[ NN NN O
3H NN NN O
] NN NN O
thymidine NN NN O
into NN NN O
the NN NN O
MNL NN NN O
was NN NN O
inversely NN NN O
correlated NN NN O
with NN NN O
urinary NN NN O
free NN NN O
cortisol NN NN O
levels NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
These NN NN O
data NN NN O
indicate NN NN O
that NN NN O
the NN NN O
lack NN NN O
of NN NN O
cushingoid NN NN O
features NN NN O
in NN NN O
patients NN NN O
with NN NN O
anorexia NN NN O
nervosa NN NN O
is NN NN O
not NN NN O
ascribable NN NN O
to NN NN O
a NN NN O
reduced NN NN O
sensitivity NN NN O
to NN NN O
glucocorticoids NN NN O
but NN NN O
is NN NN O
more NN NN O
likely NN NN O
due NN NN O
to NN NN O
the NN NN O
paucity NN NN O
of NN NN O
metabolic NN NN O
substrates NN NN O
. NN NN O
   
Latent NN NN B-Protein
membrane NN NN I-Protein
protein NN NN I-Protein
1 NN NN I-Protein
of NN NN O
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
interacts NN NN O
with NN NN O
JAK3 NN NN B-Protein
and NN NN O
activates NN NN O
STAT NN NN O
proteins NN NN O
. NN NN O
   
Latent NN NN B-Protein
membrane NN NN I-Protein
protein NN NN I-Protein
1 NN NN I-Protein
( NN NN O
LMP1 NN NN B-Protein
) NN NN O
acts NN NN O
like NN NN O
a NN NN O
permanently NN NN O
activated NN NN O
receptor NN NN O
of NN NN O
the NN NN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
( NN NN O
TNF NN NN O
) NN NN O
- NN NN O
receptor NN NN O
superfamily NN NN O
and NN NN O
is NN NN O
absolutely NN NN O
required NN NN O
for NN NN O
B NN NN O
cell NN NN O
immortalization NN NN O
by NN NN O
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
. NN NN O
   
Molecular NN NN O
and NN NN O
biochemical NN NN O
approaches NN NN O
demonstrated NN NN O
that NN NN O
LMP1 NN NN B-Protein
usurps NN NN O
cellular NN NN O
signaling NN NN O
pathways NN NN O
resulting NN NN O
in NN NN O
the NN NN O
induction NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
via NN NN O
two NN NN O
C NN NN O
- NN NN O
terminal NN NN O
activating NN NN O
regions NN NN O
. NN NN O
   
We NN NN O
demonstrate NN NN O
here NN NN O
that NN NN O
a NN NN O
third NN NN O
region NN NN O
encompassing NN NN O
a NN NN O
proline NN NN O
rich NN NN O
sequence NN NN O
within NN NN O
the NN NN O
33 NN NN O
bp NN NN O
repetitive NN NN O
stretch NN NN O
of NN NN O
LMP1 NN NN B-Protein
' NN NN O
s NN NN O
C NN NN O
- NN NN O
terminus NN NN O
is NN NN O
required NN NN O
for NN NN O
the NN NN O
activation NN NN O
of NN NN O
Janus NN NN B-Protein
kinase NN NN I-Protein
3 NN NN I-Protein
( NN NN O
JAK3 NN NN B-Protein
) NN NN O
. NN NN O
   
The NN NN O
interaction NN NN O
of NN NN O
LMP1 NN NN B-Protein
and NN NN O
JAK3 NN NN B-Protein
leads NN NN O
to NN NN O
the NN NN O
enhanced NN NN O
tyrosine NN NN O
auto NN NN O
/ NN NN O
transphosphorylation NN NN O
of NN NN O
JAK3 NN NN B-Protein
within NN NN O
minutes NN NN O
after NN NN O
crosslinking NN NN O
of NN NN O
a NN NN O
conditional NN NN O
NGF NN NN B-Protein
- NN NN I-Protein
R NN NN I-Protein
: NN NN O
LMP1 NN NN B-Protein
chimera NN NN O
and NN NN O
is NN NN O
a NN NN O
prerequisite NN NN O
for NN NN O
the NN NN O
activation NN NN O
of NN NN O
STAT NN NN O
transcription NN NN O
factors NN NN O
. NN NN O
   
These NN NN O
results NN NN O
reveal NN NN O
a NN NN O
novel NN NN O
activating NN NN O
region NN NN O
in NN NN O
the NN NN O
LMP1 NN NN B-Protein
C NN NN O
- NN NN O
terminus NN NN O
and NN NN O
identify NN NN O
the NN NN O
JAK NN NN O
/ NN NN O
STAT NN NN O
pathway NN NN O
as NN NN O
a NN NN O
target NN NN O
of NN NN O
this NN NN O
viral NN NN O
integral NN NN O
membrane NN NN O
protein NN NN O
in NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
20 NN NN O
- NN NN O
Epi NN NN O
analogues NN NN O
of NN NN O
1 NN NN O
, NN NN O
25 NN NN O
- NN NN O
dihydroxyvitamin NN NN O
D3 NN NN O
are NN NN O
highly NN NN O
potent NN NN O
inducers NN NN O
of NN NN O
DRIP NN NN O
coactivator NN NN O
complex NN NN O
binding NN NN O
to NN NN O
the NN NN O
vitamin NN NN B-Protein
D3 NN NN I-Protein
receptor NN NN I-Protein
. NN NN O
   
1 NN NN O
, NN NN O
25 NN NN O
- NN NN O
Dihydroxyvitamin NN NN O
D3 NN NN O
( NN NN O
1 NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
) NN NN O
plays NN NN O
a NN NN O
major NN NN O
role NN NN O
in NN NN O
the NN NN O
stimulation NN NN O
of NN NN O
bone NN NN O
growth NN NN O
, NN NN O
mineralization NN NN O
, NN NN O
and NN NN O
intestinal NN NN O
calcium NN NN O
and NN NN O
phosphate NN NN O
absorption NN NN O
; NN NN O
it NN NN O
also NN NN O
acts NN NN O
as NN NN O
a NN NN O
general NN NN O
inhibitor NN NN O
of NN NN O
cellular NN NN O
proliferation NN NN O
. NN NN O
   
Several NN NN O
new NN NN O
, NN NN O
clinically NN NN O
relevant NN NN O
compounds NN NN O
dissociate NN NN O
antiproliferative NN NN O
and NN NN O
calcemic NN NN O
activities NN NN O
of NN NN O
1 NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
, NN NN O
but NN NN O
the NN NN O
molecular NN NN O
basis NN NN O
for NN NN O
this NN NN O
has NN NN O
not NN NN O
been NN NN O
clearly NN NN O
elucidated NN NN O
. NN NN O
   
Here NN NN O
, NN NN O
we NN NN O
tested NN NN O
whether NN NN O
the NN NN O
potency NN NN O
of NN NN O
one NN NN O
class NN NN O
of NN NN O
compounds NN NN O
, NN NN O
20 NN NN O
- NN NN O
epi NN NN O
analogues NN NN O
, NN NN O
to NN NN O
induce NN NN O
myeloid NN NN O
cell NN NN O
differentiation NN NN O
, NN NN O
is NN NN O
because NN NN O
of NN NN O
direct NN NN O
molecular NN NN O
effects NN NN O
on NN NN O
vitamin NN NN B-Protein
D NN NN I-Protein
receptor NN NN I-Protein
( NN NN O
VDR NN NN B-Protein
) NN NN O
. NN NN O
   
We NN NN O
report NN NN O
that NN NN O
two NN NN O
20 NN NN O
- NN NN O
epi NN NN O
analogues NN NN O
, NN NN O
MC1627 NN NN O
and NN NN O
MC1288 NN NN O
, NN NN O
induced NN NN O
differentiation NN NN O
and NN NN O
transcription NN NN O
of NN NN O
p21 NN NN B-Protein
( NN NN O
Waf1 NN NN B-Protein
, NN NN O
Cip1 NN NN B-Protein
) NN NN O
, NN NN O
a NN NN O
key NN NN O
VDR NN NN B-Protein
target NN NN O
gene NN NN O
involved NN NN O
in NN NN O
growth NN NN O
inhibition NN NN O
, NN NN O
at NN NN O
a NN NN O
concentration NN NN O
100 NN NN O
- NN NN O
fold NN NN O
lower NN NN O
than NN NN O
that NN NN O
of NN NN O
1 NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
. NN NN O
   
We NN NN O
compared NN NN O
this NN NN O
sensitivity NN NN O
to NN NN O
analogue NN NN O
effects NN NN O
on NN NN O
VDR NN NN B-Protein
interacting NN NN O
proteins NN NN O
: NN NN O
RXR NN NN O
, NN NN O
GRIP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
and NN NN O
DRIP205 NN NN B-Protein
, NN NN O
a NN NN O
subunit NN NN O
of NN NN O
the NN NN O
DRIP NN NN O
coactivator NN NN O
complex NN NN O
. NN NN O
   
Compared NN NN O
with NN NN O
the NN NN O
interaction NN NN O
of NN NN O
VDR NN NN B-Protein
with NN NN O
RXR NN NN O
or NN NN O
GRIP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
the NN NN O
differentiation NN NN O
dose NN NN O
- NN NN O
response NN NN O
most NN NN O
closely NN NN O
correlated NN NN O
to NN NN O
the NN NN O
ligand NN NN O
- NN NN O
dependent NN NN O
recruitment NN NN O
of NN NN O
the NN NN O
DRIP NN NN O
coactivator NN NN O
complex NN NN O
to NN NN O
VDR NN NN B-Protein
and NN NN O
to NN NN O
the NN NN O
ability NN NN O
of NN NN O
the NN NN O
receptor NN NN O
to NN NN O
activate NN NN O
transcription NN NN O
in NN NN O
a NN NN O
cell NN NN O
- NN NN O
free NN NN O
system NN NN O
. NN NN O
   
These NN NN O
results NN NN O
provide NN NN O
compelling NN NN O
links NN NN O
between NN NN O
the NN NN O
efficiency NN NN O
of NN NN O
the NN NN O
20 NN NN O
- NN NN O
epi NN NN O
analogue NN NN O
in NN NN O
inducing NN NN O
VDR NN NN B-Protein
/ NN NN O
DRIP NN NN O
interactions NN NN O
, NN NN O
transactivation NN NN O
in NN NN O
vitro NN NN O
, NN NN O
and NN NN O
its NN NN O
enhanced NN NN O
ability NN NN O
to NN NN O
induce NN NN O
cellular NN NN O
differentiation NN NN O
. NN NN O
   
Multiple NN NN O
NF NN NN B-Protein
- NN NN I-Protein
ATc NN NN I-Protein
isoforms NN NN O
with NN NN O
individual NN NN O
transcriptional NN NN O
properties NN NN O
are NN NN O
synthesized NN NN O
in NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
The NN NN O
transcription NN NN O
factor NN NN O
NF NN NN B-Protein
- NN NN I-Protein
ATc NN NN I-Protein
that NN NN O
controls NN NN O
gene NN NN O
expression NN NN O
in NN NN O
T NN NN O
lymphocytes NN NN O
and NN NN O
embryonic NN NN O
cardiac NN NN O
cells NN NN O
is NN NN O
expressed NN NN O
in NN NN O
three NN NN O
prominent NN NN O
isoforms NN NN O
. NN NN O
   
This NN NN O
is NN NN O
due NN NN O
to NN NN O
alternative NN NN O
splice NN NN O
/ NN NN O
polyadenylation NN NN O
events NN NN O
that NN NN O
lead NN NN O
to NN NN O
the NN NN O
predominant NN NN O
synthesis NN NN O
of NN NN O
two NN NN O
long NN NN O
isoforms NN NN O
in NN NN O
naive NN NN O
T NN NN O
cells NN NN O
and NN NN O
a NN NN O
shorter NN NN O
NF NN NN B-Protein
- NN NN I-Protein
ATc NN NN I-Protein
isoform NN NN O
in NN NN O
effector NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Whereas NN NN O
the NN NN O
previously NN NN O
described NN NN O
isoform NN NN O
NF NN NN B-Protein
- NN NN I-Protein
ATc NN NN I-Protein
/ NN NN O
A NN NN O
contains NN NN O
a NN NN O
relatively NN NN O
short NN NN O
C NN NN O
terminus NN NN O
, NN NN O
the NN NN O
longer NN NN O
isoforms NN NN O
, NN NN O
B NN NN O
and NN NN O
C NN NN O
, NN NN O
span NN NN O
extra NN NN O
C NN NN O
- NN NN O
terminal NN NN O
peptides NN NN O
of NN NN O
128 NN NN O
and NN NN O
246 NN NN O
aa NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
We NN NN O
show NN NN O
here NN NN O
that NN NN O
in NN NN O
addition NN NN O
to NN NN O
the NN NN O
strong NN NN O
N NN NN O
- NN NN O
terminal NN NN O
trans NN NN O
- NN NN O
activation NN NN O
domain NN NN O
, NN NN O
TAD NN NN O
- NN NN O
A NN NN O
, NN NN O
which NN NN O
is NN NN O
common NN NN O
to NN NN O
all NN NN O
three NN NN O
NF NN NN B-Protein
- NN NN I-Protein
ATc NN NN I-Protein
isoforms NN NN O
, NN NN O
NF NN NN B-Protein
- NN NN I-Protein
ATc NN NN I-Protein
/ NN NN O
C NN NN O
contains NN NN O
a NN NN O
second NN NN O
trans NN NN O
- NN NN O
activation NN NN O
domain NN NN O
, NN NN O
TAD NN NN O
- NN NN O
B NN NN O
, NN NN O
in NN NN O
its NN NN O
C NN NN O
- NN NN O
terminal NN NN O
peptide NN NN O
. NN NN O
   
Various NN NN O
stimuli NN NN O
of NN NN O
T NN NN O
cells NN NN O
that NN NN O
induce NN NN O
the NN NN O
activity NN NN O
of NN NN O
TAD NN NN O
- NN NN O
A NN NN O
also NN NN O
enhance NN NN O
the NN NN O
activity NN NN O
of NN NN O
TAD NN NN O
- NN NN O
B NN NN O
, NN NN O
but NN NN O
, NN NN O
unlike NN NN O
TAD NN NN O
- NN NN O
A NN NN O
, NN NN O
TAD NN NN O
- NN NN O
B NN NN O
remains NN NN O
unphosphorylated NN NN O
by NN NN O
protein NN NN O
from NN NN O
12 NN NN O
- NN NN O
O NN NN O
- NN NN O
tetradecanoyl NN NN O
12 NN NN O
- NN NN O
phorbol NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
- NN NN O
stimulated NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
shorter NN NN O
C NN NN O
- NN NN O
terminal NN NN O
peptide NN NN O
of NN NN O
isoform NN NN O
NF NN NN B-Protein
- NN NN I-Protein
ATc NN NN I-Protein
/ NN NN O
B NN NN O
exerts NN NN O
a NN NN O
suppressive NN NN O
transcriptional NN NN O
effect NN NN O
. NN NN O
   
These NN NN O
properties NN NN O
of NN NN O
NF NN NN B-Protein
- NN NN I-Protein
ATc NN NN I-Protein
/ NN NN O
B NN NN O
and NN NN O
- NN NN O
C NN NN O
might NN NN O
be NN NN O
of NN NN O
importance NN NN O
for NN NN O
gene NN NN O
regulation NN NN O
in NN NN O
naive NN NN O
T NN NN O
lymphocytes NN NN O
in NN NN O
which NN NN O
NF NN NN B-Protein
- NN NN I-Protein
ATc NN NN I-Protein
/ NN NN O
B NN NN O
and NN NN O
- NN NN O
C NN NN O
are NN NN O
predominantly NN NN O
synthesized NN NN O
. NN NN O
   
Phorbol NN NN O
ester NN NN O
- NN NN O
induced NN NN O
mononuclear NN NN O
cell NN NN O
differentiation NN NN O
is NN NN O
blocked NN NN O
by NN NN O
the NN NN O
mitogen NN NN O
- NN NN O
activated NN NN O
protein NN NN O
kinase NN NN O
kinase NN NN O
( NN NN O
MEK NN NN O
) NN NN O
inhibitor NN NN O
PD98059 NN NN O
. NN NN O
   
The NN NN O
purpose NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
evaluate NN NN O
whether NN NN O
the NN NN O
mitogen NN NN O
- NN NN O
activated NN NN O
protein NN NN O
kinase NN NN O
( NN NN O
MAPK NN NN O
) NN NN O
signaling NN NN O
pathway NN NN O
contributes NN NN O
to NN NN O
12 NN NN O
- NN NN O
O NN NN O
- NN NN O
tetradecanoylphorbol NN NN O
- NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
( NN NN O
TPA NN NN O
) NN NN O
- NN NN O
induced NN NN O
mononuclear NN NN O
differentiation NN NN O
in NN NN O
the NN NN O
human NN NN O
myeloblastic NN NN O
leukemia NN NN O
ML NN NN O
- NN NN O
1 NN NN O
cells NN NN O
. NN NN O
   
Upon NN NN O
TPA NN NN O
treatment NN NN O
, NN NN O
the NN NN O
activity NN NN O
of NN NN O
ERK1 NN NN B-Protein
and NN NN O
ERK2 NN NN B-Protein
rapidly NN NN O
increased NN NN O
, NN NN O
with NN NN O
maximal NN NN O
induction NN NN O
between NN NN O
1 NN NN O
and NN NN O
3 NN NN O
h NN NN O
, NN NN O
while NN NN O
ERK2 NN NN B-Protein
protein NN NN O
levels NN NN O
remained NN NN O
constant NN NN O
. NN NN O
   
The NN NN O
activity NN NN O
of NN NN O
JNK1 NN NN B-Protein
was NN NN O
also NN NN O
significantly NN NN O
induced NN NN O
, NN NN O
with NN NN O
JNK1 NN NN B-Protein
protein NN NN O
levels NN NN O
increasing NN NN O
moderately NN NN O
during NN NN O
exposure NN NN O
to NN NN O
TPA NN NN O
. NN NN O
   
Treatment NN NN O
of NN NN O
cells NN NN O
with NN NN O
PD98059 NN NN O
, NN NN O
a NN NN O
specific NN NN O
inhibitor NN NN O
of NN NN O
mitogen NN NN O
- NN NN O
activated NN NN O
protein NN NN O
kinase NN NN O
kinase NN NN O
( NN NN O
MEK NN NN O
) NN NN O
, NN NN O
inhibited NN NN O
TPA NN NN O
- NN NN O
induced NN NN O
ERK2 NN NN B-Protein
activity NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
PD98059 NN NN O
completely NN NN O
blocked NN NN O
the NN NN O
TPA NN NN O
- NN NN O
induced NN NN O
differentiation NN NN O
of NN NN O
ML NN NN O
- NN NN O
1 NN NN O
cells NN NN O
, NN NN O
as NN NN O
assessed NN NN O
by NN NN O
a NN NN O
number NN NN O
of NN NN O
features NN NN O
associated NN NN O
with NN NN O
mononuclear NN NN O
differentiation NN NN O
including NN NN O
changes NN NN O
in NN NN O
morphology NN NN O
, NN NN O
nonspecific NN NN O
esterase NN NN O
activity NN NN O
, NN NN O
phagocytic NN NN O
ability NN NN O
, NN NN O
NADPH NN NN O
oxidase NN NN O
activity NN NN O
, NN NN O
mitochondrial NN NN O
respiration NN NN O
, NN NN O
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
mRNA NN NN O
inducibility NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
activation NN NN O
of NN NN O
the NN NN O
MEK NN NN O
/ NN NN O
ERK NN NN O
signaling NN NN O
pathway NN NN O
is NN NN O
necessary NN NN O
for NN NN O
TPA NN NN O
- NN NN O
induced NN NN O
mononuclear NN NN O
cell NN NN O
differentiation NN NN O
. NN NN O
   
Immune NN NN O
functions NN NN O
, NN NN O
clinical NN NN O
parameters NN NN O
and NN NN O
hormone NN NN O
receptor NN NN O
status NN NN O
in NN NN O
breast NN NN O
cancer NN NN O
patients NN NN O
. NN NN O
   
We NN NN O
have NN NN O
carried NN NN O
out NN NN O
a NN NN O
detailed NN NN O
analysis NN NN O
of NN NN O
the NN NN O
cellular NN NN O
immune NN NN O
functions NN NN O
of NN NN O
breast NN NN O
cancer NN NN O
patients NN NN O
in NN NN O
comparison NN NN O
with NN NN O
healthy NN NN O
controls NN NN O
. NN NN O
   
A NN NN O
possible NN NN O
correlation NN NN O
between NN NN O
immune NN NN O
and NN NN O
clinical NN NN O
parameters NN NN O
was NN NN O
analysed NN NN O
in NN NN O
50 NN NN O
breast NN NN O
cancer NN NN O
patients NN NN O
. NN NN O
   
Immune NN NN O
parameters NN NN O
, NN NN O
natural NN NN O
killer NN NN O
cell NN NN O
and NN NN O
T NN NN O
lymphocyte NN NN O
functions NN NN O
and NN NN O
the NN NN O
numbers NN NN O
of NN NN O
circulating NN NN O
T NN NN O
lymphocytes NN NN O
were NN NN O
analysed NN NN O
against NN NN O
the NN NN O
clinical NN NN O
parameters NN NN O
comprising NN NN O
the NN NN O
tumour NN NN O
burden NN NN O
, NN NN O
the NN NN O
stage NN NN O
of NN NN O
the NN NN O
disease NN NN O
and NN NN O
the NN NN O
expression NN NN O
of NN NN O
hormone NN NN O
receptors NN NN O
on NN NN O
the NN NN O
tumour NN NN O
. NN NN O
   
In NN NN O
order NN NN O
to NN NN O
analyse NN NN O
the NN NN O
immune NN NN O
function NN NN O
data NN NN O
effectively NN NN O
, NN NN O
low NN NN O
responders NN NN O
were NN NN O
identified NN NN O
with NN NN O
stringent NN NN O
cut NN NN O
- NN NN O
off NN NN O
values NN NN O
. NN NN O
   
Considerably NN NN O
higher NN NN O
proportions NN NN O
of NN NN O
low NN NN O
responders NN NN O
were NN NN O
found NN NN O
among NN NN O
the NN NN O
patient NN NN O
population NN NN O
. NN NN O
   
Elevated NN NN O
numbers NN NN O
of NN NN O
circulating NN NN O
T NN NN O
lymphocytes NN NN O
and NN NN O
CD3 NN NN O
- NN NN O
directed NN NN O
cytolysis NN NN O
correlated NN NN O
with NN NN O
the NN NN O
expression NN NN O
of NN NN O
oestrogen NN NN B-Protein
receptors NN NN I-Protein
independently NN NN O
of NN NN O
the NN NN O
clinical NN NN O
/ NN NN O
histological NN NN O
parameters NN NN O
. NN NN O
   
UV NN NN O
- NN NN O
induced NN NN O
CYP1A1 NN NN B-Protein
gene NN NN O
expression NN NN O
in NN NN O
human NN NN O
cells NN NN O
is NN NN O
mediated NN NN O
by NN NN O
tryptophan NN NN O
. NN NN O
   
Induction NN NN O
of NN NN O
cytochrome NN NN B-Protein
P NN NN I-Protein
- NN NN I-Protein
4501A1 NN NN I-Protein
( NN NN O
CYP1A1 NN NN B-Protein
) NN NN O
activity NN NN O
by NN NN O
UV NN NN O
has NN NN O
been NN NN O
observed NN NN O
earlier NN NN O
in NN NN O
animal NN NN O
studies NN NN O
via NN NN O
a NN NN O
mechanism NN NN O
that NN NN O
has NN NN O
not NN NN O
yet NN NN O
been NN NN O
resolved NN NN O
. NN NN O
   
Our NN NN O
previous NN NN O
data NN NN O
have NN NN O
indicated NN NN O
that NN NN O
formylated NN NN O
indolocarbazoles NN NN O
which NN NN O
are NN NN O
formed NN NN O
by NN NN O
UV NN NN O
irradiation NN NN O
of NN NN O
tryptophan NN NN O
solutions NN NN O
are NN NN O
very NN NN O
potent NN NN O
Ah NN NN B-Protein
- NN NN I-Protein
receptor NN NN I-Protein
agonists NN NN O
. NN NN O
   
To NN NN O
evaluate NN NN O
the NN NN O
effect NN NN O
of NN NN O
UV NN NN O
light NN NN O
on NN NN O
cytochrome NN NN B-Protein
P4501A1 NN NN I-Protein
gene NN NN O
expression NN NN O
, NN NN O
we NN NN O
studied NN NN O
the NN NN O
induction NN NN O
of NN NN O
CYP1A1 NN NN B-Protein
mRNA NN NN O
by NN NN O
UV NN NN O
irradiation NN NN O
of NN NN O
cultured NN NN O
human NN NN O
keratinocytes NN NN O
( NN NN O
HaCaT NN NN O
cell NN NN O
line NN NN O
) NN NN O
, NN NN O
primary NN NN O
human NN NN O
blood NN NN O
lymphocytes NN NN O
and NN NN O
mouse NN NN O
Hepa NN NN O
- NN NN O
1 NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
cells NN NN O
were NN NN O
exposed NN NN O
to NN NN O
UV NN NN O
light NN NN O
delivered NN NN O
by NN NN O
a NN NN O
bank NN NN O
of NN NN O
6 NN NN O
Philips NN NN O
TL20 NN NN O
/ NN NN O
12RS NN NN O
sun NN NN O
lamps NN NN O
emitting NN NN O
primarily NN NN O
in NN NN O
the NN NN O
UVB NN NN O
range NN NN O
in NN NN O
the NN NN O
absence NN NN O
and NN NN O
presence NN NN O
of NN NN O
tryptophan NN NN O
. NN NN O
   
A NN NN O
semiquantitative NN NN O
reverse NN NN O
transcriptase NN NN O
- NN NN O
linked NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
( NN NN O
RT NN NN O
- NN NN O
PCR NN NN O
) NN NN O
was NN NN O
used NN NN O
for NN NN O
analysis NN NN O
of NN NN O
gene NN NN O
expression NN NN O
in NN NN O
the NN NN O
treated NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
results NN NN O
show NN NN O
that NN NN O
the NN NN O
CYP1A1 NN NN B-Protein
mRNA NN NN O
level NN NN O
induced NN NN O
by NN NN O
UV NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
tryptophan NN NN O
was NN NN O
higher NN NN O
than NN NN O
that NN NN O
induced NN NN O
by NN NN O
UV NN NN O
alone NN NN O
in NN NN O
both NN NN O
HaCaT NN NN O
cells NN NN O
and NN NN O
lymphocytes NN NN O
after NN NN O
3 NN NN O
h NN NN O
of NN NN O
incubation NN NN O
post NN NN O
- NN NN O
UV NN NN O
irradiation NN NN O
. NN NN O
   
To NN NN O
find NN NN O
out NN NN O
if NN NN O
the NN NN O
induction NN NN O
by NN NN O
UV NN NN O
light NN NN O
is NN NN O
caused NN NN O
by NN NN O
the NN NN O
formation NN NN O
of NN NN O
an NN NN O
Ah NN NN B-Protein
receptor NN NN I-Protein
ligand NN NN O
, NN NN O
Hepa NN NN O
- NN NN O
1 NN NN O
wild NN NN O
- NN NN O
type NN NN O
and NN NN O
Ah NN NN B-Protein
receptor NN NN I-Protein
deficient NN NN O
c12 NN NN O
cell NN NN O
lines NN NN O
were NN NN O
applied NN NN O
. NN NN O
   
Wild NN NN O
- NN NN O
type NN NN O
( NN NN O
wt NN NN O
) NN NN O
cells NN NN O
were NN NN O
inducible NN NN O
either NN NN O
by NN NN O
the NN NN O
tryptophan NN NN O
photoproduct NN NN O
6 NN NN O
- NN NN O
formylindolo NN NN O
[ NN NN O
3 NN NN O
, NN NN O
2 NN NN O
- NN NN O
b NN NN O
] NN NN O
carbazole NN NN O
( NN NN O
FICZ NN NN O
) NN NN O
or NN NN O
by NN NN O
UV NN NN O
- NN NN O
irradiation NN NN O
but NN NN O
very NN NN O
low NN NN O
or NN NN O
undetectable NN NN O
levels NN NN O
were NN NN O
observed NN NN O
in NN NN O
the NN NN O
c12 NN NN O
cells NN NN O
. NN NN O
   
This NN NN O
shows NN NN O
that NN NN O
the NN NN O
induction NN NN O
of NN NN O
gene NN NN O
expression NN NN O
by NN NN O
FICZ NN NN O
and NN NN O
UV NN NN O
is NN NN O
Ah NN NN B-Protein
receptor NN NN I-Protein
dependent NN NN O
. NN NN O
   
Together NN NN O
, NN NN O
these NN NN O
results NN NN O
indicate NN NN O
that NN NN O
UV NN NN O
- NN NN O
induced NN NN O
CYP1A1 NN NN B-Protein
gene NN NN O
expression NN NN O
in NN NN O
mammalian NN NN O
cells NN NN O
is NN NN O
mediated NN NN O
by NN NN O
an NN NN O
Ah NN NN B-Protein
receptor NN NN I-Protein
ligand NN NN O
formed NN NN O
from NN NN O
tryptophan NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
the NN NN O
photoproducts NN NN O
of NN NN O
tryptophan NN NN O
are NN NN O
suggested NN NN O
to NN NN O
be NN NN O
mediators NN NN O
of NN NN O
light NN NN O
via NN NN O
binding NN NN O
to NN NN O
the NN NN O
Ah NN NN B-Protein
receptor NN NN I-Protein
and NN NN O
as NN NN O
such NN NN O
also NN NN O
could NN NN O
have NN NN O
a NN NN O
role NN NN O
in NN NN O
light NN NN O
- NN NN O
regulated NN NN O
biological NN NN O
rhythms NN NN O
. NN NN O
   
Effects NN NN O
of NN NN O
diesel NN NN O
organic NN NN O
extracts NN NN O
on NN NN O
chemokine NN NN O
production NN NN O
by NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Polyaromatic NN NN O
hydrocarbons NN NN O
( NN NN O
PAHs NN NN O
) NN NN O
associated NN NN O
with NN NN O
diesel NN NN O
exhaust NN NN O
particles NN NN O
( NN NN O
DEPs NN NN O
) NN NN O
are NN NN O
found NN NN O
in NN NN O
the NN NN O
atmospheric NN NN O
urban NN NN O
pollution NN NN O
. NN NN O
   
Such NN NN O
compounds NN NN O
have NN NN O
been NN NN O
shown NN NN O
to NN NN O
favor NN NN O
IgE NN NN O
production NN NN O
, NN NN O
bronchial NN NN O
hyperresponsiveness NN NN O
, NN NN O
and NN NN O
airway NN NN O
inflammation NN NN O
. NN NN O
   
Chemokines NN NN O
are NN NN O
a NN NN O
group NN NN O
of NN NN O
chemotactic NN NN O
cytokines NN NN O
involved NN NN O
in NN NN O
the NN NN O
recruitment NN NN O
of NN NN O
inflammatory NN NN O
cells NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
We NN NN O
investigated NN NN O
the NN NN O
effect NN NN O
of NN NN O
DEP NN NN O
- NN NN O
PAHs NN NN O
on NN NN O
the NN NN O
release NN NN O
and NN NN O
mRNA NN NN O
expression NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
, NN NN O
MCP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
and NN NN O
RANTES NN NN B-Protein
by NN NN O
PBMCs NN NN O
obtained NN NN O
from NN NN O
healthy NN NN O
subjects NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Protein NN NN O
production NN NN O
in NN NN O
supernatants NN NN O
was NN NN O
assessed NN NN O
by NN NN O
ELISA NN NN O
, NN NN O
and NN NN O
mRNA NN NN O
expression NN NN O
was NN NN O
evaluated NN NN O
by NN NN O
semiquantitative NN NN O
RT NN NN O
- NN NN O
PCR NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Secretion NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
and NN NN O
RANTES NN NN B-Protein
increased NN NN O
in NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
with NN NN O
increasing NN NN O
concentrations NN NN O
of NN NN O
DEP NN NN O
- NN NN O
PAHs NN NN O
( NN NN O
range NN NN O
, NN NN O
0 NN NN O
. NN NN O
5 NN NN O
ng NN NN O
to NN NN O
50 NN NN O
ng NN NN O
/ NN NN O
mL NN NN O
) NN NN O
. NN NN O
   
On NN NN O
the NN NN O
contrary NN NN O
, NN NN O
the NN NN O
release NN NN O
of NN NN O
MCP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
was NN NN O
significantly NN NN O
inhibited NN NN O
, NN NN O
also NN NN O
in NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
. NN NN O
   
Messenger NN NN O
RNA NN NN O
production NN NN O
coding NN NN O
for NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
, NN NN O
RANTES NN NN B-Protein
, NN NN O
and NN NN O
MCP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
showed NN NN O
parallel NN NN O
variations NN NN O
to NN NN O
the NN NN O
production NN NN O
of NN NN O
the NN NN O
correspondent NN NN O
proteins NN NN O
. NN NN O
   
Effects NN NN O
of NN NN O
DEP NN NN O
- NN NN O
PAHs NN NN O
became NN NN O
significant NN NN O
at NN NN O
7 NN NN O
hours NN NN O
and NN NN O
up NN NN O
to NN NN O
48 NN NN O
hours NN NN O
time NN NN O
culture NN NN O
for NN NN O
MCP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
and NN NN O
up NN NN O
to NN NN O
24 NN NN O
hours NN NN O
time NN NN O
culture NN NN O
for NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
and NN NN O
RANTES NN NN B-Protein
. NN NN O
   
Moreover NN NN O
, NN NN O
supernatants NN NN O
from NN NN O
DEP NN NN O
- NN NN O
PAH NN NN O
- NN NN O
activated NN NN O
cells NN NN O
, NN NN O
compared NN NN O
with NN NN O
those NN NN O
of NN NN O
controls NN NN O
, NN NN O
exhibited NN NN O
a NN NN O
significantly NN NN O
enhanced NN NN O
chemotactic NN NN O
activity NN NN O
for NN NN O
neutrophils NN NN O
and NN NN O
eosinophils NN NN O
, NN NN O
which NN NN O
was NN NN O
significantly NN NN O
inhibited NN NN O
by NN NN O
pretreatment NN NN O
with NN NN O
anti NN NN O
- NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
and NN NN O
anti NN NN O
- NN NN O
RANTES NN NN B-Protein
neutralizing NN NN O
antibodies NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
the NN NN O
chemokine NN NN O
pathways NN NN O
are NN NN O
modulated NN NN O
by NN NN O
DEP NN NN O
- NN NN O
PAHs NN NN O
at NN NN O
the NN NN O
transcriptional NN NN O
level NN NN O
, NN NN O
reinforcing NN NN O
the NN NN O
idea NN NN O
that NN NN O
the NN NN O
development NN NN O
of NN NN O
inflammatory NN NN O
reactions NN NN O
might NN NN O
be NN NN O
affected NN NN O
by NN NN O
diesel NN NN O
exhaust NN NN O
emission NN NN O
. NN NN O
   
Oxidative NN NN O
stress NN NN O
triggers NN NN O
STAT3 NN NN B-Protein
tyrosine NN NN O
phosphorylation NN NN O
and NN NN O
nuclear NN NN O
translocation NN NN O
in NN NN O
human NN NN O
lymphocytes NN NN O
. NN NN O
   
Oxidizing NN NN O
agents NN NN O
are NN NN O
powerful NN NN O
activators NN NN O
of NN NN O
factors NN NN O
responsible NN NN O
for NN NN O
the NN NN O
transcriptional NN NN O
activation NN NN O
of NN NN O
cytokine NN NN O
- NN NN O
encoding NN NN O
genes NN NN O
involved NN NN O
in NN NN O
tissue NN NN O
injury NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
we NN NN O
show NN NN O
evidence NN NN O
that NN NN O
STAT3 NN NN B-Protein
is NN NN O
a NN NN O
transcription NN NN O
factor NN NN O
whose NN NN O
activity NN NN O
is NN NN O
modulated NN NN O
by NN NN O
H2O2 NN NN O
in NN NN O
human NN NN O
lymphocytes NN NN O
, NN NN O
in NN NN O
which NN NN O
endogenous NN NN O
catalase NN NN O
had NN NN O
previously NN NN O
been NN NN O
inhibited NN NN O
. NN NN O
   
H2O2 NN NN O
- NN NN O
induced NN NN O
nuclear NN NN O
translocation NN NN O
of NN NN O
STAT3 NN NN B-Protein
to NN NN O
form NN NN O
sequence NN NN O
- NN NN O
specific NN NN O
DNA NN NN O
- NN NN O
bound NN NN O
complexes NN NN O
was NN NN O
evidenced NN NN O
by NN NN O
immunoblotting NN NN O
of NN NN O
nuclear NN NN O
fractions NN NN O
and NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
, NN NN O
and NN NN O
vanadate NN NN O
was NN NN O
found NN NN O
to NN NN O
strongly NN NN O
synergize NN NN O
with NN NN O
H2O2 NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
anti NN NN O
- NN NN O
STAT3 NN NN B-Protein
antibodies NN NN O
specifically NN NN O
precipitated NN NN O
a NN NN O
protein NN NN O
of NN NN O
92 NN NN O
kDa NN NN O
that NN NN O
becomes NN NN O
phosphorylated NN NN O
on NN NN O
tyrosine NN NN O
upon NN NN O
lymphocyte NN NN O
treatment NN NN O
with NN NN O
H2O2 NN NN O
. NN NN O
   
Phenylarsine NN NN O
oxide NN NN O
, NN NN O
a NN NN O
tyrosine NN NN O
phosphatase NN NN O
inhibitor NN NN O
, NN NN O
and NN NN O
genistein NN NN O
, NN NN O
a NN NN O
tyrosine NN NN O
kinase NN NN O
inhibitor NN NN O
, NN NN O
cooperated NN NN O
and NN NN O
cancelled NN NN O
, NN NN O
respectively NN NN O
, NN NN O
the NN NN O
H2O2 NN NN O
- NN NN O
promoted NN NN O
STAT3 NN NN B-Protein
nuclear NN NN O
translocation NN NN O
. NN NN O
   
Evidence NN NN O
is NN NN O
also NN NN O
presented NN NN O
, NN NN O
using NN NN O
Fe2 NN NN O
+ NN NN O
/ NN NN O
Cu2 NN NN O
+ NN NN O
ions NN NN O
, NN NN O
that NN NN O
. NN NN O
OH NN NN O
generated NN NN O
from NN NN O
H2O2 NN NN O
through NN NN O
Fenton NN NN O
reactions NN NN O
could NN NN O
be NN NN O
a NN NN O
candidate NN NN O
oxygen NN NN O
reactive NN NN O
species NN NN O
to NN NN O
directly NN NN O
activate NN NN O
STAT3 NN NN B-Protein
. NN NN O
   
Present NN NN O
data NN NN O
suggest NN NN O
that NN NN O
H2O2 NN NN O
and NN NN O
vanadate NN NN O
are NN NN O
likely NN NN O
to NN NN O
inhibit NN NN O
the NN NN O
activity NN NN O
of NN NN O
intracellular NN NN O
tyrosine NN NN O
phosphatase NN NN O
( NN NN O
s NN NN O
) NN NN O
, NN NN O
leading NN NN O
to NN NN O
enhanced NN NN O
STAT3 NN NN B-Protein
tyrosine NN NN O
phosphorylation NN NN O
and NN NN O
hence NN NN O
its NN NN O
translocation NN NN O
to NN NN O
the NN NN O
nucleus NN NN O
. NN NN O
   
These NN NN O
results NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
of NN NN O
STAT3 NN NN B-Protein
can NN NN O
be NN NN O
modulated NN NN O
by NN NN O
oxidizing NN NN O
agents NN NN O
and NN NN O
provide NN NN O
a NN NN O
framework NN NN O
to NN NN O
understand NN NN O
the NN NN O
effects NN NN O
of NN NN O
oxidative NN NN O
stress NN NN O
on NN NN O
the NN NN O
JAK NN NN O
- NN NN O
STAT NN NN O
signaling NN NN O
pathway NN NN O
. NN NN O
   
Binding NN NN O
characteristics NN NN O
of NN NN O
the NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
in NN NN O
peripheral NN NN O
blood NN NN O
lymphocytes NN NN O
in NN NN O
multiple NN NN O
sclerosis NN NN O
. NN NN O
   
Although NN NN O
the NN NN O
exact NN NN O
etiology NN NN O
of NN NN O
multiple NN NN O
sclerosis NN NN O
( NN NN O
MS NN NN O
) NN NN O
remains NN NN O
unresolved NN NN O
, NN NN O
immune NN NN O
reactions NN NN O
are NN NN O
believed NN NN O
to NN NN O
be NN NN O
the NN NN O
central NN NN O
pathogenic NN NN O
mechanisms NN NN O
. NN NN O
   
Endogenous NN NN O
and NN NN O
therapeutic NN NN O
steroid NN NN O
hormones NN NN O
affect NN NN O
the NN NN O
immune NN NN O
system NN NN O
, NN NN O
and NN NN O
inflammatory NN NN O
diseases NN NN O
are NN NN O
associated NN NN O
with NN NN O
activation NN NN O
of NN NN O
the NN NN O
hypothalamic NN NN O
- NN NN O
pituitary NN NN O
- NN NN O
adrenal NN NN O
axis NN NN O
, NN NN O
providing NN NN O
evidence NN NN O
of NN NN O
an NN NN O
immune NN NN O
- NN NN O
endocrine NN NN O
interplay NN NN O
. NN NN O
   
Function NN NN O
tests NN NN O
in NN NN O
MS NN NN O
have NN NN O
revealed NN NN O
dysregulation NN NN O
of NN NN O
the NN NN O
hypothalamic NN NN O
- NN NN O
pituitary NN NN O
- NN NN O
adrenal NN NN O
system NN NN O
in NN NN O
a NN NN O
substantial NN NN O
proportion NN NN O
of NN NN O
patients NN NN O
. NN NN O
   
We NN NN O
characterized NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
( NN NN O
GR NN NN B-Protein
) NN NN O
binding NN NN O
in NN NN O
peripheral NN NN O
blood NN NN O
lymphocytes NN NN O
from NN NN O
39 NN NN O
MS NN NN O
patients NN NN O
and NN NN O
14 NN NN O
age NN NN O
- NN NN O
and NN NN O
sex NN NN O
- NN NN O
matched NN NN O
controls NN NN O
with NN NN O
respect NN NN O
to NN NN O
dissociation NN NN O
constant NN NN O
and NN NN O
binding NN NN O
capacity NN NN O
, NN NN O
using NN NN O
a NN NN O
whole NN NN O
- NN NN O
cell NN NN O
binding NN NN O
assay NN NN O
with NN NN O
[ NN NN O
3H NN NN O
] NN NN O
dexamethasone NN NN O
as NN NN O
the NN NN O
ligand NN NN O
. NN NN O
   
GR NN NN B-Protein
binding NN NN O
parameters NN NN O
did NN NN O
not NN NN O
differ NN NN O
significantly NN NN O
between NN NN O
patients NN NN O
( NN NN O
Kd NN NN O
8 NN NN O
. NN NN O
98 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
07 NN NN O
nM NN NN O
, NN NN O
Bmax NN NN O
183 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
29 NN NN O
. NN NN O
8 NN NN O
fmol NN NN O
/ NN NN O
mg NN NN O
) NN NN O
and NN NN O
controls NN NN O
( NN NN O
Kd NN NN O
9 NN NN O
. NN NN O
36 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
17 NN NN O
nM NN NN O
, NN NN O
Bmax NN NN O
158 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
16 NN NN O
fmol NN NN O
/ NN NN O
mg NN NN O
) NN NN O
. NN NN O
   
No NN NN O
effect NN NN O
of NN NN O
age NN NN O
, NN NN O
sex NN NN O
, NN NN O
course NN NN O
, NN NN O
duration NN NN O
or NN NN O
severity NN NN O
of NN NN O
disease NN NN O
, NN NN O
or NN NN O
prior NN NN O
steroid NN NN O
treatments NN NN O
was NN NN O
detected NN NN O
. NN NN O
   
GR NN NN B-Protein
binding NN NN O
parameters NN NN O
were NN NN O
analyzed NN NN O
in NN NN O
relation NN NN O
to NN NN O
the NN NN O
results NN NN O
of NN NN O
the NN NN O
combined NN NN O
dexamethasone NN NN O
- NN NN O
CRH NN NN B-Protein
test NN NN O
, NN NN O
which NN NN O
reflects NN NN O
corticosteroid NN NN O
receptor NN NN O
function NN NN O
at NN NN O
the NN NN O
hypothalamus NN NN O
, NN NN O
in NN NN O
30 NN NN O
patients NN NN O
and NN NN O
9 NN NN O
controls NN NN O
. NN NN O
   
While NN NN O
controls NN NN O
showed NN NN O
a NN NN O
moderate NN NN O
correlation NN NN O
between NN NN O
binding NN NN O
affinity NN NN O
of NN NN O
the NN NN O
GR NN NN B-Protein
in NN NN O
lymphocytes NN NN O
and NN NN O
regulatory NN NN O
function NN NN O
at NN NN O
the NN NN O
hypothalamic NN NN O
level NN NN O
, NN NN O
the NN NN O
patients NN NN O
did NN NN O
not NN NN O
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
the NN NN O
physiological NN NN O
relationship NN NN O
between NN NN O
binding NN NN O
and NN NN O
function NN NN O
of NN NN O
the NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
is NN NN O
disturbed NN NN O
in NN NN O
MS NN NN O
. NN NN O
   
CBP NN NN B-Protein
/ NN NN O
p300 NN NN B-Protein
integrates NN NN O
Raf NN NN O
/ NN NN O
Rac NN NN O
- NN NN O
signaling NN NN O
pathways NN NN O
in NN NN O
the NN NN O
transcriptional NN NN O
induction NN NN O
of NN NN O
NF NN NN B-Protein
- NN NN I-Protein
ATc NN NN I-Protein
during NN NN O
T NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
NF NN NN B-Protein
- NN NN I-Protein
ATc NN NN I-Protein
, NN NN O
an NN NN O
inducibly NN NN O
expressed NN NN O
transcription NN NN O
factor NN NN O
, NN NN O
controls NN NN O
gene NN NN O
expression NN NN O
in NN NN O
T NN NN O
lymphocytes NN NN O
and NN NN O
cardiomyocytes NN NN O
. NN NN O
   
We NN NN O
show NN NN O
here NN NN O
that NN NN O
the NN NN O
transcriptional NN NN O
co NN NN O
- NN NN O
activators NN NN O
CBP NN NN B-Protein
/ NN NN O
p300 NN NN B-Protein
bind NN NN O
to NN NN O
and NN NN O
control NN NN O
the NN NN O
activity NN NN O
of NN NN O
the NN NN O
inducible NN NN O
N NN NN O
- NN NN O
terminal NN NN O
transactivation NN NN O
domain NN NN O
of NN NN O
NF NN NN B-Protein
- NN NN I-Protein
ATc NN NN I-Protein
, NN NN O
TAD NN NN O
- NN NN O
A NN NN O
. NN NN O
   
Similar NN NN O
to NN NN O
the NN NN O
N NN NN O
terminal NN NN O
transactivation NN NN O
domain NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
, NN NN O
TAD NN NN O
- NN NN O
A NN NN O
is NN NN O
inducibly NN NN O
phosphorylated NN NN O
, NN NN O
but NN NN O
this NN NN O
phosphorylation NN NN O
is NN NN O
dispensable NN NN O
for NN NN O
the NN NN O
interaction NN NN O
with NN NN O
CBP NN NN B-Protein
/ NN NN O
p300 NN NN B-Protein
. NN NN O
   
Constitutive NN NN O
active NN NN O
versions NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Raf NN NN I-Protein
and NN NN O
Rac NN NN O
synergistically NN NN O
enhance NN NN O
the NN NN O
CBP NN NN B-Protein
/ NN NN O
p300 NN NN B-Protein
- NN NN O
mediated NN NN O
increase NN NN O
of NN NN O
TAD NN NN O
- NN NN O
A NN NN O
activity NN NN O
, NN NN O
indicating NN NN O
the NN NN O
important NN NN O
role NN NN O
CBP NN NN B-Protein
/ NN NN O
p300 NN NN B-Protein
plays NN NN O
in NN NN O
the NN NN O
integration NN NN O
of NN NN O
T NN NN O
cell NN NN O
activation NN NN O
signals NN NN O
. NN NN O
   
Since NN NN O
a NN NN O
mutation NN NN O
of NN NN O
CBP NN NN B-Protein
abolishing NN NN O
HAT NN NN O
activity NN NN O
is NN NN O
almost NN NN O
as NN NN O
active NN NN O
as NN NN O
wild NN NN O
- NN NN O
type NN NN O
CBP NN NN B-Protein
in NN NN O
T NN NN O
cells NN NN O
, NN NN O
functions NN NN O
of NN NN O
CBP NN NN B-Protein
/ NN NN O
p300 NN NN B-Protein
other NN NN O
than NN NN O
histone NN NN O
acetylation NN NN O
appear NN NN O
to NN NN O
control NN NN O
the NN NN O
NF NN NN O
- NN NN O
AT NN NN O
- NN NN O
dependent NN NN O
transcription NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Association NN NN O
of NN NN O
the NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
chain NN NN I-Protein
with NN NN O
p47phox NN NN B-Protein
, NN NN O
an NN NN O
activator NN NN O
of NN NN O
the NN NN O
phagocyte NN NN O
NADPH NN NN O
oxidase NN NN O
in NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
Interleukin NN NN B-Protein
( NN NN I-Protein
IL NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
4 NN NN I-Protein
plays NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
IgE NN NN O
synthesis NN NN O
in NN NN O
B NN NN O
cells NN NN O
and NN NN O
in NN NN O
Th2 NN NN O
differentiation NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
conducts NN NN O
its NN NN O
biological NN NN O
activities NN NN O
through NN NN O
binding NN NN O
to NN NN O
the NN NN O
IL NN NN O
- NN NN O
4 NN NN O
receptor NN NN O
( NN NN O
IL NN NN O
- NN NN O
4R NN NN O
) NN NN O
on NN NN O
the NN NN O
surface NN NN O
of NN NN O
target NN NN O
cells NN NN O
. NN NN O
   
IL NN NN O
- NN NN O
4R NN NN O
are NN NN O
thought NN NN O
to NN NN O
be NN NN O
composed NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4R NN NN I-Protein
alpha NN NN I-Protein
chain NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4R NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
and NN NN O
either NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
gamma NN NN I-Protein
chain NN NN I-Protein
or NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13R NN NN I-Protein
alpha NN NN I-Protein
chain NN NN I-Protein
. NN NN O
   
We NN NN O
have NN NN O
previously NN NN O
shown NN NN O
that NN NN O
the NN NN O
membrane NN NN O
- NN NN O
proximal NN NN O
portion NN NN O
in NN NN O
the NN NN O
cytoplasmic NN NN O
domain NN NN O
of NN NN O
the NN NN O
human NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4R NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
hIL NN NN B-Protein
- NN NN I-Protein
4R NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
is NN NN O
critical NN NN O
for NN NN O
proliferation NN NN O
, NN NN O
generation NN NN O
of NN NN O
germline NN NN O
epsilon NN NN O
transcript NN NN O
, NN NN O
and NN NN O
activation NN NN O
of NN NN O
STAT6 NN NN B-Protein
, NN NN O
based NN NN O
on NN NN O
analyses NN NN O
of NN NN O
truncated NN NN O
hIL NN NN B-Protein
- NN NN I-Protein
4R NN NN I-Protein
alphas NN NN I-Protein
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
found NN NN O
that NN NN O
p47phox NN NN B-Protein
, NN NN O
an NN NN O
activator NN NN O
of NN NN O
the NN NN O
phagocyte NN NN O
NADPH NN NN O
oxidase NN NN O
, NN NN O
binds NN NN O
to NN NN O
this NN NN O
portion NN NN O
by NN NN O
the NN NN O
two NN NN O
- NN NN O
hybrid NN NN O
system NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
we NN NN O
observed NN NN O
the NN NN O
association NN NN O
of NN NN O
p47phox NN NN B-Protein
with NN NN O
the NN NN O
hIL NN NN B-Protein
- NN NN I-Protein
4R NN NN I-Protein
alpha NN NN I-Protein
in NN NN O
B NN NN O
cells NN NN O
derived NN NN O
from NN NN O
a NN NN O
normal NN NN O
donor NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
p47phox NN NN B-Protein
is NN NN O
involved NN NN O
in NN NN O
the NN NN O
signal NN NN O
transduction NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
in NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
However NN NN O
, NN NN O
activation NN NN O
of NN NN O
STAT6 NN NN B-Protein
, NN NN O
CD23 NN NN B-Protein
expression NN NN O
, NN NN O
and NN NN O
IgE NN NN O
synthesis NN NN O
induced NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
were NN NN O
not NN NN O
affected NN NN O
in NN NN O
p47phox NN NN B-Protein
- NN NN O
deficient NN NN O
patients NN NN O
, NN NN O
which NN NN O
raises NN NN O
the NN NN O
possibility NN NN O
that NN NN O
p47phox NN NN B-Protein
may NN NN O
be NN NN O
important NN NN O
in NN NN O
other NN NN O
signaling NN NN O
activities NN NN O
as NN NN O
well NN NN O
in NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
Aiolos NN NN B-Protein
transcription NN NN O
factor NN NN O
controls NN NN O
cell NN NN O
death NN NN O
in NN NN O
T NN NN O
cells NN NN O
by NN NN O
regulating NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
and NN NN O
its NN NN O
cellular NN NN O
localization NN NN O
. NN NN O
   
We NN NN O
searched NN NN O
for NN NN O
proteins NN NN O
that NN NN O
interact NN NN O
with NN NN O
Ras NN NN O
in NN NN O
interleukin NN NN B-Protein
( NN NN I-Protein
IL NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
stimulated NN NN O
or NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
deprived NN NN O
cells NN NN O
, NN NN O
and NN NN O
found NN NN O
that NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
Aiolos NN NN B-Protein
interacts NN NN O
with NN NN O
Ras NN NN O
. NN NN O
   
The NN NN O
Ras NN NN O
- NN NN O
Aiolos NN NN B-Protein
interaction NN NN O
was NN NN O
confirmed NN NN O
in NN NN O
vitro NN NN O
and NN NN O
in NN NN O
vivo NN NN O
by NN NN O
co NN NN O
- NN NN O
immunoprecipitation NN NN O
. NN NN O
   
Indirect NN NN O
immunofluorescence NN NN O
shows NN NN O
that NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
controls NN NN O
the NN NN O
cellular NN NN O
distribution NN NN O
of NN NN O
Aiolos NN NN B-Protein
and NN NN O
induces NN NN O
its NN NN O
tyrosine NN NN O
phosphorylation NN NN O
, NN NN O
required NN NN O
for NN NN O
dissociation NN NN O
from NN NN O
Ras NN NN O
. NN NN O
   
We NN NN O
also NN NN O
identified NN NN O
functional NN NN O
Aiolos NN NN B-Protein
- NN NN O
binding NN NN O
sites NN NN O
in NN NN O
the NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
, NN NN O
which NN NN O
are NN NN O
able NN NN O
to NN NN O
activate NN NN O
the NN NN O
luciferase NN NN B-Protein
reporter NN NN O
gene NN NN O
. NN NN O
   
Mutation NN NN O
of NN NN O
Aiolos NN NN B-Protein
- NN NN O
binding NN NN O
sites NN NN O
within NN NN O
the NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
inhibits NN NN O
transactivation NN NN O
of NN NN O
the NN NN O
reporter NN NN O
gene NN NN O
luciferase NN NN B-Protein
, NN NN O
suggesting NN NN O
direct NN NN O
control NN NN O
of NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
by NN NN O
Aiolos NN NN B-Protein
. NN NN O
   
Co NN NN O
- NN NN O
transfection NN NN O
experiments NN NN O
confirm NN NN O
that NN NN O
Aiolos NN NN B-Protein
induces NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
and NN NN O
prevents NN NN O
apoptosis NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
deprived NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
propose NN NN O
a NN NN O
model NN NN O
for NN NN O
the NN NN O
regulation NN NN O
of NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
via NN NN O
Aiolos NN NN B-Protein
. NN NN O
   
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
beta NN NN I-Protein
in NN NN O
rheumatoid NN NN O
arthritis NN NN O
: NN NN O
correlation NN NN O
with NN NN O
inflammation NN NN O
, NN NN O
not NN NN O
disease NN NN O
specificity NN NN O
. NN NN O
   
Rheumatoid NN NN O
arthritis NN NN O
synovial NN NN O
tissue NN NN O
was NN NN O
examined NN NN O
and NN NN O
compared NN NN O
with NN NN O
osteoarthritis NN NN O
tissue NN NN O
for NN NN O
the NN NN O
presence NN NN O
of NN NN O
the NN NN O
nuclear NN NN O
transcription NN NN O
factor NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
beta NN NN I-Protein
( NN NN O
NF NN NN B-Protein
- NN NN I-Protein
IL NN NN I-Protein
- NN NN I-Protein
6 NN NN I-Protein
) NN NN O
. NN NN O
   
The NN NN O
region NN NN O
( NN NN O
lining NN NN O
or NN NN O
sublining NN NN O
) NN NN O
, NN NN O
cell NN NN O
type NN NN O
, NN NN O
and NN NN O
subcellular NN NN O
distribution NN NN O
( NN NN O
cytoplasmic NN NN O
or NN NN O
nuclear NN NN O
) NN NN O
of NN NN O
the NN NN O
expression NN NN O
of NN NN O
C NN NN O
/ NN NN O
EBP NN NN O
beta NN NN O
was NN NN O
characterized NN NN O
. NN NN O
   
Rheumatoid NN NN O
arthritis NN NN O
synovial NN NN O
fluid NN NN O
and NN NN O
blood NN NN O
and NN NN O
normal NN NN O
peripheral NN NN O
blood NN NN O
were NN NN O
also NN NN O
examined NN NN O
. NN NN O
   
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
beta NN NN I-Protein
was NN NN O
detected NN NN O
in NN NN O
the NN NN O
synovial NN NN O
lining NN NN O
and NN NN O
in NN NN O
sublining NN NN O
cells NN NN O
of NN NN O
synovial NN NN O
tissue NN NN O
from NN NN O
patients NN NN O
with NN NN O
both NN NN O
rheumatoid NN NN O
and NN NN O
osteoarthritis NN NN O
. NN NN O
   
A NN NN O
significant NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
and NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
, NN NN O
respectively NN NN O
) NN NN O
increase NN NN O
in NN NN O
the NN NN O
percentage NN NN O
of NN NN O
cells NN NN O
with NN NN O
nuclear NN NN O
staining NN NN O
was NN NN O
seen NN NN O
in NN NN O
the NN NN O
lining NN NN O
layer NN NN O
, NN NN O
compared NN NN O
to NN NN O
cells NN NN O
in NN NN O
the NN NN O
sublining NN NN O
region NN NN O
, NN NN O
in NN NN O
rheumatoid NN NN O
and NN NN O
osteoarthritis NN NN O
. NN NN O
   
In NN NN O
both NN NN O
diseases NN NN O
a NN NN O
strong NN NN O
correlation NN NN O
( NN NN O
r NN NN O
= NN NN O
0 NN NN O
. NN NN O
79 NN NN O
, NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
was NN NN O
observed NN NN O
between NN NN O
the NN NN O
percentage NN NN O
of NN NN O
cells NN NN O
in NN NN O
the NN NN O
synovial NN NN O
lining NN NN O
that NN NN O
were NN NN O
positive NN NN O
for NN NN O
nuclear NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
beta NN NN I-Protein
and NN NN O
lining NN NN O
cell NN NN O
depth NN NN O
. NN NN O
   
Two NN NN O
- NN NN O
color NN NN O
immunohistochemistry NN NN O
demonstrated NN NN O
that NN NN O
both NN NN O
macrophages NN NN O
and NN NN O
fibroblast NN NN O
- NN NN O
like NN NN O
synoviocytes NN NN O
were NN NN O
positive NN NN O
for NN NN O
nuclear NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
beta NN NN I-Protein
. NN NN O
   
The NN NN O
presence NN NN O
of NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
beta NN NN I-Protein
was NN NN O
confirmed NN NN O
by NN NN O
immunohistochemistry NN NN O
and NN NN O
Western NN NN O
blot NN NN O
analysis NN NN O
with NN NN O
isolated NN NN O
synovial NN NN O
fibroblasts NN NN O
. NN NN O
   
Nuclear NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
beta NN NN I-Protein
was NN NN O
also NN NN O
detected NN NN O
in NN NN O
rheumatoid NN NN O
synovial NN NN O
fluid NN NN O
monocytes NN NN O
/ NN NN O
macrophages NN NN O
, NN NN O
but NN NN O
not NN NN O
in NN NN O
lymphocytes NN NN O
or NN NN O
neutrophils NN NN O
. NN NN O
   
Western NN NN O
blot NN NN O
analysis NN NN O
confirmed NN NN O
the NN NN O
presence NN NN O
of NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
beta NN NN I-Protein
in NN NN O
these NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
intensity NN NN O
of NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
beta NN NN I-Protein
staining NN NN O
was NN NN O
greater NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
in NN NN O
synovial NN NN O
fluid NN NN O
monocytes NN NN O
than NN NN O
in NN NN O
those NN NN O
from NN NN O
normal NN NN O
or NN NN O
rheumatoid NN NN O
peripheral NN NN O
blood NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
the NN NN O
enhanced NN NN O
nuclear NN NN O
staining NN NN O
for NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
beta NN NN I-Protein
in NN NN O
the NN NN O
synovial NN NN O
lining NN NN O
, NN NN O
compared NN NN O
to NN NN O
the NN NN O
sublining NN NN O
, NN NN O
suggesting NN NN O
activation NN NN O
in NN NN O
the NN NN O
lining NN NN O
, NN NN O
and NN NN O
the NN NN O
positive NN NN O
correlation NN NN O
of NN NN O
lining NN NN O
layer NN NN O
depth NN NN O
with NN NN O
the NN NN O
percentage NN NN O
of NN NN O
cells NN NN O
in NN NN O
the NN NN O
lining NN NN O
positive NN NN O
for NN NN O
nuclear NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
beta NN NN I-Protein
, NN NN O
suggest NN NN O
a NN NN O
potential NN NN O
role NN NN O
for NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
beta NN NN I-Protein
in NN NN O
chronic NN NN O
inflammation NN NN O
. NN NN O
   
The NN NN O
regulation NN NN O
of NN NN O
the NN NN O
production NN NN O
or NN NN O
activity NN NN O
of NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
beta NN NN I-Protein
, NN NN O
to NN NN O
inhibit NN NN O
inflammatory NN NN O
mediator NN NN O
expression NN NN O
by NN NN O
synovial NN NN O
macrophages NN NN O
and NN NN O
fibroblasts NN NN O
, NN NN O
offers NN NN O
a NN NN O
novel NN NN O
approach NN NN O
to NN NN O
therapeutic NN NN O
intervention NN NN O
. NN NN O
   
p70 NN NN B-Protein
( NN NN I-Protein
s6k NN NN I-Protein
) NN NN I-Protein
integrates NN NN O
phosphatidylinositol NN NN O
3 NN NN O
- NN NN O
kinase NN NN O
and NN NN O
rapamycin NN NN O
- NN NN O
regulated NN NN O
signals NN NN O
for NN NN O
E2F NN NN O
regulation NN NN O
in NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
In NN NN O
T NN NN O
lymphocytes NN NN O
, NN NN O
the NN NN O
hematopoietic NN NN O
cytokine NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
uses NN NN O
phosphatidylinositol NN NN O
3 NN NN O
- NN NN O
kinase NN NN O
( NN NN O
PI NN NN O
3 NN NN O
- NN NN O
kinase NN NN O
) NN NN O
- NN NN O
induced NN NN O
signaling NN NN O
pathways NN NN O
to NN NN O
regulate NN NN O
E2F NN NN O
transcriptional NN NN O
activity NN NN O
, NN NN O
a NN NN O
critical NN NN O
cell NN NN O
cycle NN NN O
checkpoint NN NN O
. NN NN O
   
PI NN NN O
3 NN NN O
- NN NN O
kinase NN NN O
also NN NN O
regulates NN NN O
the NN NN O
activity NN NN O
of NN NN O
p70 NN NN B-Protein
( NN NN I-Protein
s6k NN NN I-Protein
) NN NN I-Protein
, NN NN O
the NN NN O
40S NN NN O
ribosomal NN NN O
protein NN NN O
S6 NN NN O
kinase NN NN O
, NN NN O
a NN NN O
response NN NN O
that NN NN O
is NN NN O
abrogated NN NN O
by NN NN O
the NN NN O
macrolide NN NN O
rapamycin NN NN O
. NN NN O
   
This NN NN O
immunosuppressive NN NN O
drug NN NN O
is NN NN O
known NN NN O
to NN NN O
prevent NN NN O
T NN NN O
- NN NN O
cell NN NN O
proliferation NN NN O
, NN NN O
but NN NN O
the NN NN O
precise NN NN O
point NN NN O
at NN NN O
which NN NN O
rapamycin NN NN O
regulates NN NN O
T NN NN O
- NN NN O
cell NN NN O
cycle NN NN O
progression NN NN O
has NN NN O
yet NN NN O
to NN NN O
be NN NN O
elucidated NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
the NN NN O
effects NN NN O
of NN NN O
rapamycin NN NN O
on NN NN O
, NN NN O
and NN NN O
the NN NN O
role NN NN O
of NN NN O
p70 NN NN B-Protein
( NN NN I-Protein
s6k NN NN I-Protein
) NN NN I-Protein
in NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
PI NN NN O
3 NN NN O
- NN NN O
kinase NN NN O
activation NN NN O
of NN NN O
E2Fs NN NN O
have NN NN O
not NN NN O
been NN NN O
characterized NN NN O
. NN NN O
   
Our NN NN O
present NN NN O
results NN NN O
show NN NN O
that NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
and NN NN O
PI NN NN O
3 NN NN O
- NN NN O
kinase NN NN O
- NN NN O
induced NN NN O
pathways NN NN O
for NN NN O
the NN NN O
regulation NN NN O
of NN NN O
E2F NN NN O
transcriptional NN NN O
activity NN NN O
include NN NN O
both NN NN O
rapamycin NN NN O
- NN NN O
resistant NN NN O
and NN NN O
rapamycin NN NN O
- NN NN O
sensitive NN NN O
components NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
a NN NN O
rapamycin NN NN O
- NN NN O
resistant NN NN O
mutant NN NN O
of NN NN O
p70 NN NN B-Protein
( NN NN I-Protein
s6k NN NN I-Protein
) NN NN I-Protein
in NN NN O
T NN NN O
cells NN NN O
could NN NN O
restore NN NN O
rapamycin NN NN O
- NN NN O
suppressed NN NN O
E2F NN NN O
responses NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
the NN NN O
rapamycin NN NN O
- NN NN O
controlled NN NN O
processes NN NN O
involved NN NN O
in NN NN O
E2F NN NN O
regulation NN NN O
appear NN NN O
to NN NN O
be NN NN O
mediated NN NN O
by NN NN O
p70 NN NN B-Protein
( NN NN I-Protein
s6k NN NN I-Protein
) NN NN I-Protein
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
rapamycin NN NN O
- NN NN O
resistant NN NN O
p70 NN NN B-Protein
( NN NN I-Protein
s6k NN NN I-Protein
) NN NN I-Protein
could NN NN O
not NN NN O
rescue NN NN O
rapamycin NN NN O
inhibition NN NN O
of NN NN O
T NN NN O
- NN NN O
cell NN NN O
cycle NN NN O
entry NN NN O
, NN NN O
consistent NN NN O
with NN NN O
the NN NN O
involvement NN NN O
of NN NN O
additional NN NN O
, NN NN O
rapamycin NN NN O
- NN NN O
sensitive NN NN O
pathways NN NN O
in NN NN O
the NN NN O
control NN NN O
of NN NN O
T NN NN O
- NN NN O
cell NN NN O
cycle NN NN O
progression NN NN O
. NN NN O
   
The NN NN O
present NN NN O
results NN NN O
thus NN NN O
show NN NN O
that NN NN O
p70 NN NN B-Protein
( NN NN I-Protein
s6k NN NN I-Protein
) NN NN I-Protein
is NN NN O
able NN NN O
to NN NN O
regulate NN NN O
E2F NN NN O
transcriptional NN NN O
activity NN NN O
and NN NN O
provide NN NN O
direct NN NN O
evidence NN NN O
for NN NN O
the NN NN O
first NN NN O
time NN NN O
for NN NN O
a NN NN O
link NN NN O
between NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
receptors NN NN O
, NN NN O
PI NN NN O
3 NN NN O
- NN NN O
kinase NN NN O
, NN NN O
and NN NN O
p70 NN NN B-Protein
( NN NN I-Protein
s6k NN NN I-Protein
) NN NN I-Protein
that NN NN O
regulates NN NN O
a NN NN O
crucial NN NN O
G1 NN NN O
checkpoint NN NN O
in NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
SOCS NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
is NN NN O
tyrosine NN NN O
phosphorylated NN NN O
in NN NN O
response NN NN O
to NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
suppresses NN NN O
STAT5 NN NN B-Protein
phosphorylation NN NN O
and NN NN O
lymphocyte NN NN O
proliferation NN NN O
. NN NN O
   
Members NN NN O
of NN NN O
the NN NN O
recently NN NN O
discovered NN NN O
SOCS NN NN O
/ NN NN O
CIS NN NN O
/ NN NN O
SSI NN NN O
family NN NN O
have NN NN O
been NN NN O
proposed NN NN O
as NN NN O
regulators NN NN O
of NN NN O
cytokine NN NN O
signaling NN NN O
, NN NN O
and NN NN O
while NN NN O
targets NN NN O
and NN NN O
mechanisms NN NN O
have NN NN O
been NN NN O
suggested NN NN O
for NN NN O
some NN NN O
family NN NN O
members NN NN O
, NN NN O
the NN NN O
precise NN NN O
role NN NN O
of NN NN O
these NN NN O
proteins NN NN O
remains NN NN O
to NN NN O
be NN NN O
defined NN NN O
. NN NN O
   
To NN NN O
date NN NN O
no NN NN O
SOCS NN NN O
proteins NN NN O
have NN NN O
been NN NN O
specifically NN NN O
implicated NN NN O
in NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
signaling NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
report NN NN O
SOCS NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
expression NN NN O
in NN NN O
response NN NN O
to NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
in NN NN O
both NN NN O
T NN NN O
- NN NN O
cell NN NN O
lines NN NN O
and NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
lymphocytes NN NN O
. NN NN O
   
SOCS NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
protein NN NN O
was NN NN O
detectable NN NN O
as NN NN O
early NN NN O
as NN NN O
30 NN NN O
min NN NN O
following NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
stimulation NN NN O
, NN NN O
while NN NN O
CIS NN NN B-Protein
was NN NN O
seen NN NN O
only NN NN O
at NN NN O
low NN NN O
levels NN NN O
after NN NN O
2 NN NN O
h NN NN O
. NN NN O
   
Unlike NN NN O
CIS NN NN B-Protein
, NN NN O
SOCS NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
was NN NN O
rapidly NN NN O
tyrosine NN NN O
phosphorylated NN NN O
in NN NN O
response NN NN O
to NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
Tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
SOCS NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
was NN NN O
observed NN NN O
upon NN NN O
coexpression NN NN O
with NN NN O
Jak1 NN NN B-Protein
and NN NN O
Jak2 NN NN B-Protein
but NN NN O
only NN NN O
weakly NN NN O
with NN NN O
Jak3 NN NN B-Protein
. NN NN O
   
In NN NN O
these NN NN O
experiments NN NN O
, NN NN O
SOCS NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
associated NN NN O
with NN NN O
Jak1 NN NN B-Protein
and NN NN O
inhibited NN NN O
Jak1 NN NN B-Protein
phosphorylation NN NN O
, NN NN O
and NN NN O
this NN NN O
inhibition NN NN O
was NN NN O
markedly NN NN O
enhanced NN NN O
by NN NN O
the NN NN O
presence NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
receptor NN NN I-Protein
beta NN NN I-Protein
chain NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2Rbeta NN NN I-Protein
) NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
following NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
stimulation NN NN O
of NN NN O
T NN NN O
cells NN NN O
, NN NN O
SOCS NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
was NN NN O
able NN NN O
to NN NN O
interact NN NN O
with NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
receptor NN NN O
complex NN NN O
, NN NN O
and NN NN O
in NN NN O
particular NN NN O
tyrosine NN NN O
phosphorylated NN NN O
Jak1 NN NN B-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2Rbeta NN NN I-Protein
. NN NN O
   
Additionally NN NN O
, NN NN O
in NN NN O
lymphocytes NN NN O
expressing NN NN O
SOCS NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
but NN NN O
not NN NN O
CIS NN NN B-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
induced NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
STAT5b NN NN B-Protein
was NN NN O
markedly NN NN O
reduced NN NN O
, NN NN O
while NN NN O
there NN NN O
was NN NN O
only NN NN O
a NN NN O
weak NN NN O
effect NN NN O
on NN NN O
IL NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
- NN NN O
mediated NN NN O
STAT5b NN NN B-Protein
tyrosine NN NN O
phosphorylation NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
proliferation NN NN O
induced NN NN O
by NN NN O
both NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
was NN NN O
significantly NN NN O
inhibited NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
SOCS NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
. NN NN O
   
The NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
when NN NN O
SOCS NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
is NN NN O
rapidly NN NN O
induced NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
in NN NN O
T NN NN O
cells NN NN O
, NN NN O
it NN NN O
acts NN NN O
to NN NN O
inhibit NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
responses NN NN O
in NN NN O
a NN NN O
classical NN NN O
negative NN NN O
feedback NN NN O
loop NN NN O
. NN NN O
   
The NN NN O
role NN NN O
of NN NN O
gamma NN NN O
/ NN NN O
delta NN NN O
T NN NN O
cell NN NN O
receptor NN NN O
positive NN NN O
cells NN NN O
in NN NN O
pregnancy NN NN O
. NN NN O
   
PROBLEM NN NN O
: NN NN O
Due NN NN O
to NN NN O
the NN NN O
lack NN NN O
of NN NN O
classical NN NN O
HLA NN NN O
antigens NN NN O
on NN NN O
the NN NN O
trophoblast NN NN O
, NN NN O
fetal NN NN O
antigens NN NN O
are NN NN O
possibly NN NN O
presented NN NN O
in NN NN O
a NN NN O
non NN NN O
major NN NN O
histocompatibility NN NN O
complex NN NN O
( NN NN O
MHC NN NN O
) NN NN O
restricted NN NN O
way NN NN O
. NN NN O
   
Decidual NN NN O
gammadelta NN NN O
T NN NN O
cells NN NN O
, NN NN O
which NN NN O
significantly NN NN O
increase NN NN O
in NN NN O
number NN NN O
during NN NN O
pregnancy NN NN O
, NN NN O
might NN NN O
play NN NN O
a NN NN O
role NN NN O
in NN NN O
recognition NN NN O
of NN NN O
fetal NN NN O
antigens NN NN O
and NN NN O
also NN NN O
in NN NN O
determining NN NN O
the NN NN O
quality NN NN O
of NN NN O
the NN NN O
response NN NN O
to NN NN O
these NN NN O
antigens NN NN O
. NN NN O
   
Our NN NN O
study NN NN O
was NN NN O
aimed NN NN O
at NN NN O
investigating NN NN O
the NN NN O
role NN NN O
of NN NN O
this NN NN O
cell NN NN O
population NN NN O
in NN NN O
progesterone NN NN O
- NN NN O
dependent NN NN O
immunomodulation NN NN O
. NN NN O
   
METHOD NN NN O
OF NN NN O
STUDY NN NN O
: NN NN O
Peripheral NN NN O
lymphocytes NN NN O
from NN NN O
healthy NN NN O
pregnant NN NN O
women NN NN O
and NN NN O
from NN NN O
habitual NN NN O
aborters NN NN O
were NN NN O
tested NN NN O
by NN NN O
immunocytochemistry NN NN O
for NN NN O
the NN NN O
presence NN NN O
of NN NN O
gamma NN NN O
/ NN NN O
delta NN NN O
T NN NN O
cell NN NN O
receptor NN NN O
( NN NN O
TCR NN NN O
) NN NN O
and NN NN O
progesterone NN NN B-Protein
receptor NN NN I-Protein
. NN NN O
   
To NN NN O
investigate NN NN O
the NN NN O
effect NN NN O
of NN NN O
treatment NN NN O
with NN NN O
a NN NN O
pan NN NN O
anti NN NN O
gamma NN NN O
/ NN NN O
delta NN NN O
antibody NN NN O
, NN NN O
lymphocytes NN NN O
were NN NN O
incubated NN NN O
for NN NN O
3 NN NN O
hr NN NN O
with NN NN O
the NN NN O
antibody NN NN O
, NN NN O
and NN NN O
then NN NN O
interleukin NN NN B-Protein
( NN NN I-Protein
IL NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
10 NN NN I-Protein
, NN NN O
IL NN NN O
- NN NN O
12 NN NN O
and NN NN O
progesterone NN NN B-Protein
- NN NN I-Protein
induced NN NN I-Protein
blocking NN NN I-Protein
factor NN NN I-Protein
( NN NN O
PIBF NN NN B-Protein
) NN NN O
expression NN NN O
( NN NN O
by NN NN O
immuno NN NN O
- NN NN O
cytochemistry NN NN O
) NN NN O
as NN NN O
well NN NN O
as NN NN O
natural NN NN O
killer NN NN O
( NN NN O
NK NN NN O
) NN NN O
cell NN NN O
activity NN NN O
were NN NN O
determined NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
In NN NN O
peripheral NN NN O
blood NN NN O
of NN NN O
healthy NN NN O
pregnant NN NN O
women NN NN O
the NN NN O
percentage NN NN O
of NN NN O
gamma NN NN O
/ NN NN O
delta NN NN O
TCR NN NN O
+ NN NN O
cells NN NN O
was NN NN O
significantly NN NN O
higher NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
than NN NN O
in NN NN O
that NN NN O
of NN NN O
recurrent NN NN O
aborters NN NN O
or NN NN O
of NN NN O
non NN NN O
- NN NN O
pregnant NN NN O
individuals NN NN O
. NN NN O
   
Ninety NN NN O
- NN NN O
seven NN NN O
percent NN NN O
of NN NN O
gamma NN NN O
/ NN NN O
delta NN NN O
TCR NN NN O
+ NN NN O
pregnancy NN NN O
lymphocytes NN NN O
expressed NN NN O
progesterone NN NN B-Protein
receptor NN NN I-Protein
. NN NN O
   
Binding NN NN O
of NN NN O
a NN NN O
specific NN NN O
antibody NN NN O
to NN NN O
the NN NN O
gamma NN NN O
/ NN NN O
delta NN NN O
TCR NN NN O
inhibited NN NN O
PIBF NN NN B-Protein
- NN NN O
as NN NN O
well NN NN O
as NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
production NN NN O
, NN NN O
whereas NN NN O
it NN NN O
increased NN NN O
NK NN NN O
activity NN NN O
and NN NN O
IL NN NN O
- NN NN O
12 NN NN O
expression NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
These NN NN O
data NN NN O
suggest NN NN O
the NN NN O
role NN NN O
of NN NN O
gamma NN NN O
/ NN NN O
delta NN NN O
TCR NN NN O
- NN NN O
bearing NN NN O
lymphocytes NN NN O
in NN NN O
progesterone NN NN O
- NN NN O
dependent NN NN O
immunomodulation NN NN O
. NN NN O
   
Expression NN NN O
and NN NN O
role NN NN O
of NN NN O
PML NN NN B-Protein
gene NN NN O
in NN NN O
normal NN NN O
adult NN NN O
hematopoiesis NN NN O
: NN NN O
functional NN NN O
interaction NN NN O
between NN NN O
PML NN NN B-Protein
and NN NN O
Rb NN NN B-Protein
proteins NN NN O
in NN NN O
erythropoiesis NN NN O
. NN NN O
   
The NN NN O
expression NN NN O
of NN NN O
the NN NN O
PML NN NN B-Protein
gene NN NN O
was NN NN O
investigated NN NN O
in NN NN O
purified NN NN O
early NN NN O
hematopoietic NN NN O
progenitor NN NN O
cells NN NN O
( NN NN O
HPCs NN NN O
) NN NN O
induced NN NN O
to NN NN O
unilineage NN NN O
erythroid NN NN O
or NN NN O
granulocytic NN NN O
differentiation NN NN O
. NN NN O
   
PML NN NN B-Protein
mRNA NN NN O
and NN NN O
protein NN NN O
, NN NN O
while NN NN O
barely NN NN O
detectable NN NN O
in NN NN O
quiescent NN NN O
HPCs NN NN O
, NN NN O
are NN NN O
consistently NN NN O
induced NN NN O
by NN NN O
growth NN NN O
factor NN NN O
stimulation NN NN O
through NN NN O
the NN NN O
erythroid NN NN O
or NN NN O
granulocytic NN NN O
lineage NN NN O
. NN NN O
   
Thereafter NN NN O
, NN NN O
PML NN NN B-Protein
is NN NN O
downmodulated NN NN O
in NN NN O
late NN NN O
granulocytic NN NN O
maturation NN NN O
, NN NN O
whereas NN NN O
it NN NN O
is NN NN O
sustainably NN NN O
expressed NN NN O
through NN NN O
the NN NN O
erythroid NN NN O
pathway NN NN O
. NN NN O
   
In NN NN O
functional NN NN O
studies NN NN O
, NN NN O
PML NN NN B-Protein
expression NN NN O
was NN NN O
inhibited NN NN O
by NN NN O
addition NN NN O
of NN NN O
antisense NN NN O
oligomers NN NN O
targeting NN NN O
PML NN NN B-Protein
mRNA NN NN O
( NN NN O
alpha NN NN O
- NN NN O
PML NN NN O
) NN NN O
. NN NN O
   
Interestingly NN NN O
, NN NN O
early NN NN O
treatment NN NN O
( NN NN O
day NN NN O
0 NN NN O
HPCs NN NN O
) NN NN O
with NN NN O
alpha NN NN O
- NN NN O
PML NN NN O
reduced NN NN O
the NN NN O
number NN NN O
of NN NN O
both NN NN O
erythroid NN NN O
and NN NN O
granulocytic NN NN O
colonies NN NN O
, NN NN O
whereas NN NN O
late NN NN O
treatment NN NN O
( NN NN O
day NN NN O
5 NN NN O
culture NN NN O
) NN NN O
reduced NN NN O
erythroid NN NN O
, NN NN O
but NN NN O
not NN NN O
granulocytic NN NN O
, NN NN O
clonogenesis NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
PML NN NN B-Protein
is NN NN O
required NN NN O
for NN NN O
early NN NN O
hematopoiesis NN NN O
and NN NN O
erythroid NN NN O
, NN NN O
but NN NN O
not NN NN O
granulocytic NN NN O
maturation NN NN O
. NN NN O
   
The NN NN O
pattern NN NN O
of NN NN O
PML NN NN B-Protein
expression NN NN O
in NN NN O
normal NN NN O
hematopoiesis NN NN O
mimics NN NN O
that NN NN O
of NN NN O
retinoblastoma NN NN O
pRb NN NN B-Protein
105 NN NN I-Protein
. NN NN O
   
Combined NN NN O
treatment NN NN O
of NN NN O
HPCs NN NN O
with NN NN O
alpha NN NN O
- NN NN O
PML NN NN O
and NN NN O
alpha NN NN O
- NN NN O
Rb NN NN O
oligomers NN NN O
inhibited NN NN O
both NN NN O
PML NN NN B-Protein
and NN NN O
Rb NN NN B-Protein
protein NN NN O
expression NN NN O
and NN NN O
completely NN NN O
blocked NN NN O
erythroid NN NN O
colony NN NN O
development NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
PML NN NN B-Protein
and NN NN O
pRb NN NN B-Protein
105 NN NN I-Protein
were NN NN O
co NN NN O
- NN NN O
immunoprecipitated NN NN O
in NN NN O
cellular NN NN O
lysates NN NN O
derived NN NN O
from NN NN O
erythroid NN NN O
precursors NN NN O
indicating NN NN O
that NN NN O
this NN NN O
functional NN NN O
interaction NN NN O
may NN NN O
have NN NN O
a NN NN O
biochemical NN NN O
basis NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
a NN NN O
key NN NN O
functional NN NN O
role NN NN O
of NN NN O
PML NN NN B-Protein
in NN NN O
early NN NN O
hematopoiesis NN NN O
and NN NN O
late NN NN O
erythropoiesis NN NN O
: NN NN O
the NN NN O
latter NN NN O
phenomenon NN NN O
may NN NN O
be NN NN O
related NN NN O
to NN NN O
the NN NN O
molecular NN NN O
and NN NN O
functional NN NN O
interaction NN NN O
of NN NN O
PML NN NN B-Protein
with NN NN O
pRb NN NN B-Protein
105 NN NN I-Protein
. NN NN O
   
Signal NN NN O
transduction NN NN O
pathways NN NN O
in NN NN O
normal NN NN O
human NN NN O
monocytes NN NN O
stimulated NN NN O
by NN NN O
cytokines NN NN O
and NN NN O
mediators NN NN O
: NN NN O
comparative NN NN O
study NN NN O
with NN NN O
normal NN NN O
human NN NN O
neutrophils NN NN O
or NN NN O
transformed NN NN O
cells NN NN O
and NN NN O
the NN NN O
putative NN NN O
roles NN NN O
in NN NN O
functionality NN NN O
and NN NN O
cell NN NN O
biology NN NN O
. NN NN O
   
Granulocyte NN NN B-Protein
- NN NN I-Protein
macrophage NN NN I-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
( NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
) NN NN O
and NN NN O
interleukin NN NN B-Protein
( NN NN I-Protein
IL NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
3 NN NN I-Protein
induced NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
92 NN NN O
- NN NN O
kDa NN NN O
protein NN NN O
in NN NN O
normal NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
We NN NN O
identified NN NN O
this NN NN O
92 NN NN O
- NN NN O
kDa NN NN O
protein NN NN O
as NN NN O
STAT5 NN NN B-Protein
, NN NN O
but NN NN O
not NN NN O
as NN NN O
STATs1 NN NN B-Protein
, NN NN O
3 NN NN B-Protein
, NN NN O
and NN NN O
6 NN NN B-Protein
nor NN NN O
c NN NN B-Protein
- NN NN I-Protein
fes NN NN I-Protein
and NN NN O
vav NN NN B-Protein
protooncogene NN NN O
products NN NN O
, NN NN O
and NN NN O
demonstrated NN NN O
its NN NN O
translocation NN NN O
to NN NN O
the NN NN O
nucleus NN NN O
, NN NN O
enhancement NN NN O
of NN NN O
specific NN NN O
DNA NN NN O
binding NN NN O
capacity NN NN O
, NN NN O
and NN NN O
potentiation NN NN O
of NN NN O
trancriptional NN NN O
activity NN NN O
by NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
. NN NN O
   
N NN NN O
- NN NN O
formyl NN NN O
- NN NN O
methionyl NN NN O
- NN NN O
leucyl NN NN O
- NN NN O
phenylalanine NN NN O
( NN NN O
FMLP NN NN O
) NN NN O
and NN NN O
phorbol NN NN O
myristate NN NN O
acetate NN NN O
( NN NN O
PMA NN NN O
) NN NN O
induced NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
42 NN NN O
- NN NN O
and NN NN O
44 NN NN O
- NN NN O
kDa NN NN O
proteins NN NN O
, NN NN O
which NN NN O
were NN NN O
identified NN NN O
as NN NN O
extracellular NN NN O
signal NN NN O
- NN NN O
regulated NN NN O
kinase NN NN O
( NN NN O
ERK NN NN O
) NN NN O
, NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
In NN NN O
marked NN NN O
contrast NN NN O
to NN NN O
neutrophils NN NN O
and NN NN O
MO7e NN NN O
cells NN NN O
, NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
did NN NN O
not NN NN O
induce NN NN O
tyrosine NN NN O
phosphorylation NN NN O
and NN NN O
activation NN NN O
of NN NN O
ERK NN NN O
in NN NN O
monocytes NN NN O
. NN NN O
   
Among NN NN O
upstream NN NN O
signaling NN NN O
molecules NN NN O
of NN NN O
ERK NN NN O
, NN NN O
Shc NN NN B-Protein
was NN NN O
constitutively NN NN O
associated NN NN O
with NN NN O
Grb2 NN NN B-Protein
and NN NN O
was NN NN O
not NN NN O
tyrosine NN NN O
- NN NN O
phosphorylated NN NN O
by NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
and NN NN O
FMLP NN NN O
, NN NN O
and NN NN O
Sos1 NN NN B-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
Raf NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
were NN NN O
not NN NN O
phosphorylated NN NN O
by NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
, NN NN O
TNF NN NN B-Protein
, NN NN O
and NN NN O
FMLP NN NN O
in NN NN O
monocytes NN NN O
, NN NN O
whereas NN NN O
all NN NN O
these NN NN O
signaling NN NN O
molecules NN NN O
were NN NN O
affected NN NN O
and NN NN O
/ NN NN O
or NN NN O
utilized NN NN O
by NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
in NN NN O
MO7e NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
to NN NN O
neutrophils NN NN O
, NN NN O
p38 NN NN O
was NN NN O
constitutively NN NN O
phosphorylated NN NN O
and NN NN O
agonist NN NN O
- NN NN O
dependent NN NN O
phosphorylation NN NN O
and NN NN O
activation NN NN O
was NN NN O
not NN NN O
detected NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
Superoxide NN NN O
release NN NN O
stimulated NN NN O
by NN NN O
FMLP NN NN O
was NN NN O
inhibited NN NN O
partially NN NN O
by NN NN O
PD98059 NN NN O
or NN NN O
SB203580 NN NN O
, NN NN O
a NN NN O
specific NN NN O
inhibitor NN NN O
of NN NN O
ERK NN NN O
or NN NN O
p38 NN NN O
pathway NN NN O
, NN NN O
and NN NN O
was NN NN O
almost NN NN O
completely NN NN O
inhibited NN NN O
by NN NN O
the NN NN O
combination NN NN O
of NN NN O
both NN NN O
inhibitors NN NN O
, NN NN O
whereas NN NN O
PMA NN NN O
- NN NN O
induced NN NN O
superoxide NN NN O
release NN NN O
was NN NN O
resistant NN NN O
to NN NN O
these NN NN O
two NN NN O
inhibitors NN NN O
in NN NN O
monocytes NN NN O
. NN NN O
   
PD98059 NN NN O
inhibited NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
- NN NN O
dependent NN NN O
proliferation NN NN O
of NN NN O
MO7e NN NN O
cells NN NN O
. NN NN O
   
Present NN NN O
results NN NN O
indicate NN NN O
trancriptional NN NN O
roles NN NN O
of NN NN O
STAT5 NN NN B-Protein
and NN NN O
functional NN NN O
roles NN NN O
of NN NN O
ERK NN NN O
and NN NN O
/ NN NN O
or NN NN O
p38 NN NN O
in NN NN O
normal NN NN O
human NN NN O
monocytes NN NN O
stimulated NN NN O
by NN NN O
physiological NN NN O
receptor NN NN O
- NN NN O
mediated NN NN O
agonists NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
and NN NN O
FMLP NN NN O
. NN NN O
   
Possible NN NN O
roles NN NN O
of NN NN O
ERK NN NN O
in NN NN O
proliferation NN NN O
of NN NN O
transformed NN NN O
cells NN NN O
were NN NN O
also NN NN O
suggested NN NN O
. NN NN O
   
Tyrphostin NN NN O
AG NN NN O
- NN NN O
490 NN NN O
inhibits NN NN O
cytokine NN NN O
- NN NN O
mediated NN NN O
JAK3 NN NN B-Protein
/ NN NN O
STAT5a NN NN B-Protein
/ NN NN O
b NN NN B-Protein
signal NN NN O
transduction NN NN O
and NN NN O
cellular NN NN O
proliferation NN NN O
of NN NN O
antigen NN NN O
- NN NN O
activated NN NN O
human NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Janus NN NN B-Protein
kinase NN NN I-Protein
3 NN NN I-Protein
( NN NN O
JAK3 NN NN B-Protein
) NN NN O
is NN NN O
a NN NN O
cytoplasmic NN NN O
tyrosine NN NN O
kinase NN NN O
required NN NN O
for NN NN O
T NN NN O
cell NN NN O
development NN NN O
and NN NN O
activated NN NN O
by NN NN O
cytokines NN NN O
that NN NN O
utilize NN NN O
the NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
( NN NN I-Protein
IL NN NN I-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN I-Protein
receptor NN NN I-Protein
common NN NN I-Protein
gamma NN NN I-Protein
chain NN NN I-Protein
( NN NN O
gamma NN NN B-Protein
( NN NN I-Protein
c NN NN I-Protein
) NN NN I-Protein
) NN NN O
. NN NN O
   
Genetic NN NN O
inactivation NN NN O
of NN NN O
JAK3 NN NN B-Protein
is NN NN O
manifested NN NN O
as NN NN O
severe NN NN O
combined NN NN O
immunodeficiency NN NN O
disease NN NN O
( NN NN O
SCID NN NN O
) NN NN O
in NN NN O
humans NN NN O
and NN NN O
mice NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
have NN NN O
suggested NN NN O
that NN NN O
JAK3 NN NN B-Protein
represents NN NN O
a NN NN O
pharmacological NN NN O
target NN NN O
to NN NN O
control NN NN O
certain NN NN O
lymphoid NN NN O
- NN NN O
derived NN NN O
diseases NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
provide NN NN O
novel NN NN O
evidence NN NN O
that NN NN O
AG NN NN O
- NN NN O
490 NN NN O
potently NN NN O
inhibits NN NN O
the NN NN O
autokinase NN NN O
activity NN NN O
of NN NN O
JAK3 NN NN B-Protein
and NN NN O
tyrosine NN NN O
phosphorylation NN NN O
and NN NN O
DNA NN NN O
binding NN NN O
of NN NN O
signal NN NN B-Protein
transducer NN NN I-Protein
and NN NN I-Protein
activator NN NN I-Protein
of NN NN I-Protein
transcription NN NN I-Protein
5a NN NN I-Protein
and NN NN O
5b NN NN B-Protein
( NN NN O
STAT5a NN NN B-Protein
/ NN NN O
b NN NN B-Protein
) NN NN O
. NN NN O
   
Similar NN NN O
inhibitory NN NN O
effects NN NN O
were NN NN O
observed NN NN O
with NN NN O
other NN NN O
cytokines NN NN O
that NN NN O
use NN NN O
gamma NN NN B-Protein
( NN NN I-Protein
c NN NN I-Protein
) NN NN I-Protein
. NN NN O
   
AG NN NN O
- NN NN O
490 NN NN O
also NN NN O
inhibited NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
mediated NN NN O
proliferative NN NN O
growth NN NN O
in NN NN O
human NN NN O
T NN NN O
cells NN NN O
with NN NN O
an NN NN O
IC50 NN NN O
) NN NN O
= NN NN O
25 NN NN O
microM NN NN O
that NN NN O
was NN NN O
partially NN NN O
recoverable NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
this NN NN O
inhibitor NN NN O
prevented NN NN O
tetanus NN NN O
toxoid NN NN O
antigen NN NN O
- NN NN O
specific NN NN O
T NN NN O
cell NN NN O
proliferation NN NN O
and NN NN O
expansion NN NN O
but NN NN O
failed NN NN O
to NN NN O
block NN NN O
activation NN NN O
of NN NN O
Zap70 NN NN B-Protein
or NN NN O
p56Lck NN NN B-Protein
after NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
stimulation NN NN O
of NN NN O
human NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Taken NN NN O
together NN NN O
, NN NN O
these NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
AG NN NN O
- NN NN O
490 NN NN O
inhibits NN NN O
the NN NN O
JAK3 NN NN B-Protein
- NN NN O
mediated NN NN O
Type NN NN O
II NN NN O
signaling NN NN O
pathway NN NN O
but NN NN O
not NN NN O
the NN NN O
T NN NN O
cell NN NN O
receptor NN NN O
- NN NN O
derived NN NN O
Type NN NN O
I NN NN O
pathway NN NN O
and NN NN O
possesses NN NN O
therapeutic NN NN O
potential NN NN O
for NN NN O
T NN NN O
cell NN NN O
- NN NN O
derived NN NN O
pathologies NN NN O
such NN NN O
as NN NN O
graft NN NN O
- NN NN O
versus NN NN O
- NN NN O
host NN NN O
disease NN NN O
, NN NN O
allergy NN NN O
, NN NN O
and NN NN O
autoimmune NN NN O
disorders NN NN O
. NN NN O
   
Genetic NN NN O
evidence NN NN O
for NN NN O
an NN NN O
additional NN NN O
factor NN NN O
required NN NN O
for NN NN O
erythropoietin NN NN B-Protein
- NN NN O
induced NN NN O
signal NN NN O
transduction NN NN O
. NN NN O
   
Erythropoietin NN NN B-Protein
( NN NN O
EPO NN NN B-Protein
) NN NN O
and NN NN O
its NN NN O
receptor NN NN O
( NN NN O
EPOR NN NN B-Protein
) NN NN O
are NN NN O
required NN NN O
for NN NN O
the NN NN O
development NN NN O
of NN NN O
mature NN NN O
erythrocytes NN NN O
. NN NN O
   
After NN NN O
binding NN NN O
of NN NN O
ligand NN NN O
, NN NN O
the NN NN O
EPOR NN NN B-Protein
activates NN NN O
a NN NN O
variety NN NN O
of NN NN O
signaling NN NN O
pathways NN NN O
that NN NN O
ultimately NN NN O
control NN NN O
cellular NN NN O
proliferation NN NN O
, NN NN O
survival NN NN O
, NN NN O
and NN NN O
specific NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
Although NN NN O
erythroid NN NN O
progenitors NN NN O
appear NN NN O
to NN NN O
be NN NN O
the NN NN O
principal NN NN O
EPO NN NN B-Protein
- NN NN O
responsive NN NN O
cell NN NN O
type NN NN O
in NN NN O
vivo NN NN O
due NN NN O
to NN NN O
the NN NN O
restricted NN NN O
expression NN NN O
of NN NN O
the NN NN O
EPOR NN NN B-Protein
, NN NN O
many NN NN O
growth NN NN O
factor NN NN O
- NN NN O
dependent NN NN O
cell NN NN O
lines NN NN O
expressing NN NN O
the NN NN O
EPOR NN NN B-Protein
can NN NN O
respond NN NN O
to NN NN O
EPO NN NN B-Protein
by NN NN O
activating NN NN O
many NN NN O
or NN NN O
all NN NN O
of NN NN O
these NN NN O
pathways NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
study NN NN O
, NN NN O
we NN NN O
have NN NN O
identified NN NN O
a NN NN O
cellular NN NN O
context NN NN O
( NN NN O
the NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
[ NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
] NN NN O
- NN NN O
dependent NN NN O
HT NN NN O
- NN NN O
2 NN NN O
line NN NN O
) NN NN O
in NN NN O
which NN NN O
the NN NN O
EPO NN NN B-Protein
stimulation NN NN O
of NN NN O
the NN NN O
EPOR NN NN B-Protein
fails NN NN O
to NN NN O
support NN NN O
cellular NN NN O
proliferation NN NN O
, NN NN O
STAT NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
induction NN NN O
, NN NN O
or NN NN O
MAPK NN NN O
activation NN NN O
, NN NN O
despite NN NN O
efficient NN NN O
phosphorylation NN NN O
of NN NN O
the NN NN O
EPOR NN NN B-Protein
and NN NN O
JAK2 NN NN B-Protein
and NN NN O
inhibition NN NN O
of NN NN O
apoptosis NN NN O
after NN NN O
withdrawal NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
Interestingly NN NN O
, NN NN O
when NN NN O
we NN NN O
fused NN NN O
HT NN NN O
- NN NN O
2 NN NN O
cells NN NN O
expressing NN NN O
the NN NN O
EPOR NN NN B-Protein
with NN NN O
Ba NN NN O
/ NN NN O
F3 NN NN O
cells NN NN O
in NN NN O
a NN NN O
complementation NN NN O
assay NN NN O
, NN NN O
the NN NN O
resulting NN NN O
hybridomas NN NN O
proliferated NN NN O
and NN NN O
potently NN NN O
activated NN NN O
STAT NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
and NN NN O
MAPK NN NN O
in NN NN O
response NN NN O
to NN NN O
EPO NN NN B-Protein
. NN NN O
   
These NN NN O
data NN NN O
indicate NN NN O
that NN NN O
an NN NN O
unidentified NN NN O
cellular NN NN O
factor NN NN O
is NN NN O
needed NN NN O
to NN NN O
mediate NN NN O
signaling NN NN O
by NN NN O
the NN NN O
EPOR NN NN B-Protein
. NN NN O
   
Moreover NN NN O
, NN NN O
Ba NN NN O
/ NN NN O
F3 NN NN O
cells NN NN O
apparently NN NN O
express NN NN O
this NN NN O
factor NN NN O
( NN NN O
s NN NN O
) NN NN O
and NN NN O
somatic NN NN O
fusions NN NN O
can NN NN O
, NN NN O
therefore NN NN O
, NN NN O
confer NN NN O
EPO NN NN B-Protein
- NN NN O
responsiveness NN NN O
to NN NN O
HT NN NN O
- NN NN O
2 NN NN O
cells NN NN O
that NN NN O
lack NN NN O
this NN NN O
factor NN NN O
. NN NN O
   
Cutting NN NN O
edge NN NN O
: NN NN O
expression NN NN O
of NN NN O
the NN NN O
NF NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
in NN NN O
eosinophils NN NN O
: NN NN O
regulation NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
. NN NN O
   
We NN NN O
report NN NN O
that NN NN O
NF NN NN B-Protein
- NN NN I-Protein
AT1 NN NN I-Protein
and NN NN O
NF NN NN B-Protein
- NN NN I-Protein
AT4 NN NN I-Protein
are NN NN O
expressed NN NN O
cytoplasmically NN NN O
in NN NN O
resting NN NN O
eosinophils NN NN O
, NN NN O
whereas NN NN O
NF NN NN B-Protein
- NN NN I-Protein
AT2 NN NN I-Protein
and NN NN O
NF NN NN B-Protein
- NN NN I-Protein
AT3 NN NN I-Protein
have NN NN O
not NN NN O
been NN NN O
seen NN NN O
. NN NN O
   
Likewise NN NN O
, NN NN O
NF NN NN B-Protein
- NN NN I-Protein
AT1 NN NN I-Protein
mRNA NN NN O
and NN NN O
NF NN NN B-Protein
- NN NN I-Protein
AT4 NN NN I-Protein
mRNA NN NN O
have NN NN O
been NN NN O
detected NN NN O
in NN NN O
resting NN NN O
eosinophils NN NN O
, NN NN O
and NN NN O
their NN NN O
levels NN NN O
can NN NN O
be NN NN O
significantly NN NN O
up NN NN O
- NN NN O
regulated NN NN O
by NN NN O
the NN NN O
Th2 NN NN O
- NN NN O
associated NN NN O
cytokines NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
. NN NN O
   
There NN NN O
is NN NN O
no NN NN O
detectable NN NN O
NF NN NN O
- NN NN O
AT NN NN O
protein NN NN O
expression NN NN O
in NN NN O
the NN NN O
nuclei NN NN O
of NN NN O
resting NN NN O
eosinophils NN NN O
. NN NN O
   
However NN NN O
NF NN NN O
- NN NN O
ATs NN NN O
appear NN NN O
in NN NN O
the NN NN O
nuclei NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
- NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
- NN NN O
, NN NN O
or NN NN O
ionomycin NN NN O
- NN NN O
stimulated NN NN O
eosinophils NN NN O
. NN NN O
   
Only NN NN O
NF NN NN B-Protein
- NN NN I-Protein
AT1 NN NN I-Protein
and NN NN O
NF NN NN B-Protein
- NN NN I-Protein
AT4 NN NN I-Protein
, NN NN O
but NN NN O
not NN NN O
NF NN NN B-Protein
- NN NN I-Protein
AT2 NN NN I-Protein
and NN NN O
NF NN NN B-Protein
- NN NN I-Protein
AT3 NN NN I-Protein
, NN NN O
have NN NN O
translocated NN NN O
into NN NN O
the NN NN O
nuclei NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
- NN NN O
or NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
- NN NN O
stimulated NN NN O
eosinophils NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
delineate NN NN O
a NN NN O
novel NN NN O
pathway NN NN O
in NN NN O
the NN NN O
cytokine NN NN O
network NN NN O
in NN NN O
which NN NN O
Th2 NN NN O
lymphocytes NN NN O
"""""""" NN NN O
control NN NN O
"""""""" NN NN O
eosinophils NN NN O
via NN NN O
the NN NN O
release NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
, NN NN O
and NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
AT NN NN O
in NN NN O
eosinophils NN NN O
. NN NN O
   
The NN NN O
findings NN NN O
also NN NN O
suggest NN NN O
that NN NN O
a NN NN O
later NN NN O
feedback NN NN O
"""""""" NN NN O
talking NN NN O
"""""""" NN NN O
may NN NN O
exist NN NN O
between NN NN O
eosinophils NN NN O
and NN NN O
Th2 NN NN O
lymphocytes NN NN O
. NN NN O
   
Altered NN NN O
memory NN NN O
T NN NN O
cell NN NN O
differentiation NN NN O
in NN NN O
patients NN NN O
with NN NN O
early NN NN O
rheumatoid NN NN O
arthritis NN NN O
. NN NN O
   
The NN NN O
chronic NN NN O
immune NN NN O
response NN NN O
in NN NN O
rheumatoid NN NN O
arthritis NN NN O
( NN NN O
RA NN NN O
) NN NN O
might NN NN O
be NN NN O
driven NN NN O
by NN NN O
activated NN NN O
Th1 NN NN O
cells NN NN O
without NN NN O
sufficient NN NN O
Th2 NN NN O
cell NN NN O
differentiation NN NN O
to NN NN O
down NN NN O
- NN NN O
modulate NN NN O
inflammation NN NN O
. NN NN O
   
To NN NN O
test NN NN O
whether NN NN O
disordered NN NN O
memory NN NN O
T NN NN O
cell NN NN O
differentiation NN NN O
contributes NN NN O
to NN NN O
the NN NN O
typical NN NN O
Th1 NN NN O
- NN NN O
dominated NN NN O
chronic NN NN O
inflammation NN NN O
in NN NN O
RA NN NN O
we NN NN O
investigated NN NN O
differentiation NN NN O
of NN NN O
resting NN NN O
CD4 NN NN O
+ NN NN O
memory NN NN O
T NN NN O
cells NN NN O
in NN NN O
patients NN NN O
with NN NN O
early NN NN O
( NN NN O
6 NN NN O
wk NN NN O
to NN NN O
12 NN NN O
mo NN NN O
) NN NN O
untreated NN NN O
RA NN NN O
and NN NN O
in NN NN O
age NN NN O
- NN NN O
and NN NN O
sex NN NN O
- NN NN O
matched NN NN O
healthy NN NN O
controls NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
No NN NN O
difference NN NN O
in NN NN O
cytokine NN NN O
secretion NN NN O
profiles NN NN O
of NN NN O
freshly NN NN O
isolated NN NN O
memory NN NN O
T NN NN O
cells NN NN O
was NN NN O
detected NN NN O
between NN NN O
patients NN NN O
and NN NN O
controls NN NN O
. NN NN O
   
A NN NN O
cell NN NN O
culture NN NN O
system NN NN O
was NN NN O
then NN NN O
employed NN NN O
that NN NN O
permitted NN NN O
the NN NN O
differentiation NN NN O
of NN NN O
Th NN NN O
effectors NN NN O
from NN NN O
resting NN NN O
memory NN NN O
T NN NN O
cells NN NN O
by NN NN O
short NN NN O
term NN NN O
priming NN NN O
. NN NN O
   
Marked NN NN O
differences NN NN O
were NN NN O
found NN NN O
in NN NN O
response NN NN O
to NN NN O
priming NN NN O
. NN NN O
   
Th2 NN NN O
cells NN NN O
could NN NN O
be NN NN O
induced NN NN O
in NN NN O
all NN NN O
healthy NN NN O
controls NN NN O
by NN NN O
priming NN NN O
with NN NN O
anti NN NN O
- NN NN O
CD28 NN NN B-Protein
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
TCR NN NN O
ligation NN NN O
. NN NN O
   
By NN NN O
contrast NN NN O
, NN NN O
priming NN NN O
under NN NN O
those NN NN O
conditions NN NN O
resulted NN NN O
in NN NN O
Th2 NN NN O
differentiation NN NN O
in NN NN O
only NN NN O
9 NN NN O
of NN NN O
24 NN NN O
RA NN NN O
patients NN NN O
. NN NN O
   
Exogenous NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
could NN NN O
overcome NN NN O
the NN NN O
apparent NN NN O
Th2 NN NN O
differentiation NN NN O
defect NN NN O
in NN NN O
seven NN NN O
patients NN NN O
but NN NN O
was NN NN O
without NN NN O
effect NN NN O
in NN NN O
the NN NN O
remaining NN NN O
eight NN NN O
patients NN NN O
. NN NN O
   
In NN NN O
all NN NN O
patients NN NN O
a NN NN O
marked NN NN O
decrease NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
producing NN NN O
cells NN NN O
and NN NN O
a NN NN O
significant NN NN O
increase NN NN O
in NN NN O
well NN NN O
- NN NN O
differentiated NN NN O
Th1 NN NN O
cells NN NN O
that NN NN O
produced NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
but NN NN O
not NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
were NN NN O
evident NN NN O
after NN NN O
priming NN NN O
with NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
and NN NN O
anti NN NN O
- NN NN O
CD28 NN NN B-Protein
. NN NN O
   
The NN NN O
data NN NN O
suggest NN NN O
that NN NN O
CD4 NN NN B-Protein
+ NN NN O
memory NN NN O
T NN NN O
cells NN NN O
from NN NN O
patients NN NN O
with NN NN O
early NN NN O
untreated NN NN O
RA NN NN O
manifest NN NN O
an NN NN O
intrinsic NN NN O
abnormality NN NN O
in NN NN O
their NN NN O
ability NN NN O
to NN NN O
differentiate NN NN O
into NN NN O
specific NN NN O
cytokine NN NN O
- NN NN O
producing NN NN O
effector NN NN O
cells NN NN O
that NN NN O
might NN NN O
contribute NN NN O
to NN NN O
the NN NN O
characteristic NN NN O
Th1 NN NN O
- NN NN O
dominated NN NN O
chronic NN NN O
( NN NN O
auto NN NN O
) NN NN O
immune NN NN O
inflammation NN NN O
in NN NN O
RA NN NN O
. NN NN O
   
ICSAT NN NN B-Protein
overexpression NN NN O
is NN NN O
not NN NN O
sufficient NN NN O
to NN NN O
cause NN NN O
adult NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
or NN NN O
multiple NN NN O
myeloma NN NN O
. NN NN O
   
ICSAT NN NN B-Protein
( NN NN O
Interferon NN NN B-Protein
Consensus NN NN I-Protein
Sequence NN NN I-Protein
binding NN NN I-Protein
protein NN NN I-Protein
for NN NN I-Protein
Activated NN NN I-Protein
T NN NN I-Protein
cells NN NN I-Protein
) NN NN O
is NN NN O
a NN NN O
lymphocyte NN NN O
- NN NN O
specific NN NN O
member NN NN O
of NN NN O
the NN NN O
interferon NN NN O
regulatory NN NN O
factor NN NN O
( NN NN O
IRF NN NN O
) NN NN O
family NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
, NN NN O
originally NN NN O
identified NN NN O
through NN NN O
Southwestern NN NN O
screening NN NN O
of NN NN O
the NN NN O
ATL NN NN O
( NN NN O
Adult NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
) NN NN O
- NN NN O
16T NN NN O
expression NN NN O
library NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
created NN NN O
transgenic NN NN O
mice NN NN O
overexpressing NN NN O
ICSAT NN NN B-Protein
in NN NN O
lymphocytes NN NN O
. NN NN O
   
Although NN NN O
spontaneous NN NN O
tumorigenesis NN NN O
was NN NN O
not NN NN O
observed NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
production NN NN O
with NN NN O
Concanavalin NN NN O
A NN NN O
stimulation NN NN O
was NN NN O
significantly NN NN O
increased NN NN O
in NN NN O
transgenic NN NN O
mice NN NN O
overexpressing NN NN O
ICSAT NN NN B-Protein
. NN NN O
   
ICSAT NN NN B-Protein
overexpression NN NN O
in NN NN O
lymphocytes NN NN O
seems NN NN O
insufficient NN NN O
for NN NN O
the NN NN O
leukemogenesis NN NN O
of NN NN O
ATL NN NN O
or NN NN O
multiple NN NN O
myeloma NN NN O
( NN NN O
MM NN NN O
) NN NN O
, NN NN O
however NN NN O
, NN NN O
it NN NN O
may NN NN O
regulate NN NN O
T NN NN O
cell NN NN O
activation NN NN O
and NN NN O
its NN NN O
overexpression NN NN O
may NN NN O
lead NN NN O
to NN NN O
leukemogenesis NN NN O
via NN NN O
controlling NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
production NN NN O
. NN NN O
   
Copyright NN NN O
1999 NN NN O
Academic NN NN O
Press NN NN O
. NN NN O
   
Extracellular NN NN B-Protein
signal NN NN I-Protein
- NN NN I-Protein
regulated NN NN I-Protein
protein NN NN I-Protein
kinase NN NN I-Protein
( NN NN O
ERK NN NN B-Protein
) NN NN O
- NN NN O
dependent NN NN O
and NN NN O
ERK NN NN B-Protein
- NN NN O
independent NN NN O
pathways NN NN O
target NN NN O
STAT3 NN NN B-Protein
on NN NN O
serine NN NN O
- NN NN O
727 NN NN O
in NN NN O
human NN NN O
neutrophils NN NN O
stimulated NN NN O
by NN NN O
chemotactic NN NN O
factors NN NN O
and NN NN O
cytokines NN NN O
. NN NN O
   
STAT3 NN NN B-Protein
( NN NN O
signal NN NN B-Protein
transducer NN NN I-Protein
and NN NN I-Protein
activator NN NN I-Protein
of NN NN I-Protein
transcription NN NN I-Protein
3 NN NN I-Protein
) NN NN O
is NN NN O
a NN NN O
latent NN NN O
transcription NN NN O
factor NN NN O
that NN NN O
is NN NN O
activated NN NN O
by NN NN O
tyrosine NN NN O
phosphorylation NN NN O
( NN NN O
Tyr NN NN O
- NN NN O
705 NN NN O
) NN NN O
in NN NN O
cells NN NN O
stimulated NN NN O
with NN NN O
cytokines NN NN O
or NN NN O
growth NN NN O
factors NN NN O
. NN NN O
   
Recent NN NN O
studies NN NN O
suggest NN NN O
that NN NN O
one NN NN O
or NN NN O
more NN NN O
cytoplasmic NN NN O
serine NN NN O
kinases NN NN O
also NN NN O
phosphorylate NN NN O
STAT3 NN NN B-Protein
and NN NN O
are NN NN O
necessary NN NN O
for NN NN O
maximal NN NN O
gene NN NN O
activation NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
demonstrate NN NN O
, NN NN O
with NN NN O
a NN NN O
site NN NN O
- NN NN O
specific NN NN O
antibody NN NN O
, NN NN O
that NN NN O
STAT3 NN NN B-Protein
is NN NN O
phosphorylated NN NN O
on NN NN O
Ser NN NN O
- NN NN O
727 NN NN O
in NN NN O
human NN NN O
neutrophils NN NN O
stimulated NN NN O
with NN NN O
chemotactic NN NN O
factors NN NN O
( NN NN O
N NN NN O
- NN NN O
formyl NN NN O
- NN NN O
methionyl NN NN O
- NN NN O
leucyl NN NN O
- NN NN O
phenylalanine NN NN O
and NN NN O
complement NN NN O
C5a NN NN O
) NN NN O
, NN NN O
cytokines NN NN O
[ NN NN O
granulocyte NN NN B-Protein
/ NN NN I-Protein
macrophage NN NN I-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
( NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
) NN NN O
and NN NN O
granulocyte NN NN B-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
( NN NN O
G NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
) NN NN O
] NN NN O
, NN NN O
or NN NN O
a NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
activator NN NN O
( NN NN O
PMA NN NN O
) NN NN O
. NN NN O
   
( NN NN O
2 NN NN O
- NN NN O
Amino NN NN O
- NN NN O
3 NN NN O
' NN NN O
- NN NN O
methoxyphenyl NN NN O
) NN NN O
oxanaphthalen NN NN O
- NN NN O
4 NN NN O
- NN NN O
one NN NN O
( NN NN O
PD NN NN O
98059 NN NN O
) NN NN O
, NN NN O
an NN NN O
inhibitor NN NN O
of NN NN O
extracellular NN NN B-Protein
signal NN NN I-Protein
- NN NN I-Protein
regulated NN NN I-Protein
protein NN NN I-Protein
kinase NN NN I-Protein
( NN NN O
ERK NN NN B-Protein
) NN NN O
activation NN NN O
, NN NN O
blocked NN NN O
the NN NN O
serine NN NN O
phosphorylation NN NN O
of NN NN O
STAT3 NN NN B-Protein
induced NN NN O
by NN NN O
chemotactic NN NN O
factors NN NN O
or NN NN O
PMA NN NN O
. NN NN O
   
The NN NN O
drug NN NN O
was NN NN O
less NN NN O
effective NN NN O
on NN NN O
cytokines NN NN O
: NN NN O
it NN NN O
virtually NN NN O
abolished NN NN O
the NN NN O
response NN NN O
to NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
that NN NN O
occurred NN NN O
5 NN NN O
min NN NN O
after NN NN O
stimulation NN NN O
but NN NN O
only NN NN O
partly NN NN O
decreased NN NN O
those NN NN O
at NN NN O
15 NN NN O
- NN NN O
30 NN NN O
min NN NN O
and NN NN O
did NN NN O
not NN NN O
appreciably NN NN O
alter NN NN O
responses NN NN O
to NN NN O
G NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
regardless NN NN O
of NN NN O
incubation NN NN O
time NN NN O
. NN NN O
   
1 NN NN O
- NN NN O
( NN NN O
5 NN NN O
- NN NN O
Isoquinolinylsulphonyl NN NN O
) NN NN O
- NN NN O
2 NN NN O
- NN NN O
methylpiperazine NN NN O
dihydrochloride NN NN O
( NN NN O
H7 NN NN O
) NN NN O
, NN NN O
an NN NN O
inhibitor NN NN O
of NN NN O
a NN NN O
putative NN NN O
STAT3 NN NN B-Protein
serine NN NN O
kinase NN NN O
, NN NN O
and NN NN O
4 NN NN O
- NN NN O
( NN NN O
4 NN NN O
- NN NN O
fluorophenyl NN NN O
) NN NN O
- NN NN O
2 NN NN O
- NN NN O
( NN NN O
4 NN NN O
- NN NN O
methylsulphinylphenyl NN NN O
) NN NN O
- NN NN O
5 NN NN O
- NN NN O
( NN NN O
4 NN NN O
- NN NN O
pyridyl NN NN O
) NN NN O
1H NN NN O
- NN NN O
imidazole NN NN O
( NN NN O
SB NN NN O
203580 NN NN O
) NN NN O
, NN NN O
an NN NN O
inhibitor NN NN O
of NN NN O
p38 NN NN O
mitogen NN NN O
- NN NN O
activated NN NN O
protein NN NN O
( NN NN O
MAP NN NN O
) NN NN O
kinase NN NN O
, NN NN O
did NN NN O
not NN NN O
dampen NN NN O
any NN NN O
of NN NN O
these NN NN O
serine NN NN O
phosphorylation NN NN O
responses NN NN O
. NN NN O
   
We NN NN O
propose NN NN O
that NN NN O
neutrophils NN NN O
use NN NN O
both NN NN O
ERK NN NN B-Protein
- NN NN O
dependent NN NN O
and NN NN O
ERK NN NN B-Protein
- NN NN O
independent NN NN O
pathways NN NN O
to NN NN O
phosphorylate NN NN O
Ser NN NN O
- NN NN O
727 NN NN O
on NN NN O
STAT3 NN NN B-Protein
. NN NN O
   
The NN NN O
former NN NN O
pathway NN NN O
is NN NN O
recruited NN NN O
by NN NN O
all NN NN O
ERK NN NN B-Protein
- NN NN O
activating NN NN O
stimuli NN NN O
, NN NN O
whereas NN NN O
the NN NN O
latter NN NN O
pathway NN NN O
uses NN NN O
an NN NN O
undefined NN NN O
serine NN NN O
kinase NN NN O
and NN NN O
is NN NN O
recruited NN NN O
selectively NN NN O
by NN NN O
cytokines NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
STAT5 NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
relies NN NN O
on NN NN O
Janus NN NN O
kinase NN NN O
function NN NN O
but NN NN O
not NN NN O
on NN NN O
receptor NN NN O
tyrosine NN NN O
phosphorylation NN NN O
, NN NN O
and NN NN O
can NN NN O
contribute NN NN O
to NN NN O
both NN NN O
cell NN NN O
proliferation NN NN O
and NN NN O
gene NN NN O
regulation NN NN O
. NN NN O
   
We NN NN O
have NN NN O
investigated NN NN O
mechanisms NN NN O
and NN NN O
consequences NN NN O
of NN NN O
STAT5 NN NN O
activation NN NN O
through NN NN O
the NN NN O
human NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
receptor NN NN O
( NN NN O
IL NN NN O
- NN NN O
4R NN NN O
) NN NN O
. NN NN O
   
By NN NN O
functionally NN NN O
expressing NN NN O
receptor NN NN O
mutants NN NN O
in NN NN O
the NN NN O
murine NN NN O
pro NN NN O
- NN NN O
B NN NN O
cell NN NN O
line NN NN O
Ba NN NN O
/ NN NN O
F3 NN NN O
, NN NN O
we NN NN O
could NN NN O
show NN NN O
that NN NN O
phosphorylated NN NN O
tyrosine NN NN O
residues NN NN O
within NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4R NN NN I-Protein
alpha NN NN I-Protein
chain NN NN I-Protein
are NN NN O
dispensable NN NN O
for NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
- NN NN O
induced NN NN O
STAT5 NN NN O
activity NN NN O
. NN NN O
   
However NN NN O
, NN NN O
disruption NN NN O
of NN NN O
a NN NN O
membrane NN NN O
- NN NN O
proximal NN NN O
proline NN NN O
- NN NN O
rich NN NN O
sequence NN NN O
motif NN NN O
( NN NN O
' NN NN O
box1 NN NN O
' NN NN O
) NN NN O
in NN NN O
either NN NN O
subunit NN NN O
of NN NN O
the NN NN O
bipartite NN NN O
IL NN NN O
- NN NN O
4R NN NN O
abolished NN NN O
not NN NN O
only NN NN O
ligand NN NN O
- NN NN O
induced NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
Janus NN NN O
kinases NN NN O
JAK1 NN NN B-Protein
and NN NN O
JAK3 NN NN B-Protein
, NN NN O
but NN NN O
also NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
- NN NN O
triggered NN NN O
activation NN NN O
of NN NN O
STAT5 NN NN O
and NN NN O
concomitant NN NN O
cell NN NN O
proliferation NN NN O
. NN NN O
   
A NN NN O
dominant NN NN O
- NN NN O
negative NN NN O
version NN NN O
of NN NN O
STAT5b NN NN B-Protein
, NN NN O
but NN NN O
not NN NN O
of NN NN O
STAT5a NN NN B-Protein
, NN NN O
interfered NN NN O
with NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
- NN NN O
induced NN NN O
DNA NN NN O
synthesis NN NN O
in NN NN O
Ba NN NN O
/ NN NN O
F3 NN NN O
cells NN NN O
, NN NN O
suggesting NN NN O
an NN NN O
involvement NN NN O
of NN NN O
STAT5b NN NN B-Protein
in NN NN O
the NN NN O
control NN NN O
of NN NN O
cell NN NN O
proliferation NN NN O
through NN NN O
IL NN NN O
- NN NN O
4R NN NN O
. NN NN O
   
Reporter NN NN O
gene NN NN O
experiments NN NN O
finally NN NN O
showed NN NN O
that NN NN O
transcription NN NN O
from NN NN O
promoters NN NN O
of NN NN O
STAT5 NN NN O
target NN NN O
genes NN NN O
can NN NN O
be NN NN O
specifically NN NN O
induced NN NN O
by NN NN O
challenging NN NN O
cells NN NN O
with NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
, NN NN O
and NN NN O
that NN NN O
both NN NN O
STAT5a NN NN B-Protein
and NN NN O
STAT5b NN NN B-Protein
can NN NN O
contribute NN NN O
to NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
- NN NN O
triggered NN NN O
transcriptional NN NN O
control NN NN O
. NN NN O
   
Diminished NN NN O
responses NN NN O
to NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13 NN NN I-Protein
by NN NN O
human NN NN O
monocytes NN NN O
differentiated NN NN O
in NN NN O
vitro NN NN O
: NN NN O
role NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13Ralpha1 NN NN I-Protein
chain NN NN I-Protein
and NN NN O
STAT6 NN NN B-Protein
. NN NN O
   
The NN NN O
primary NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13 NN NN I-Protein
receptor NN NN O
complex NN NN O
on NN NN O
human NN NN O
monocytes NN NN O
is NN NN O
believed NN NN O
to NN NN O
be NN NN O
a NN NN O
heterodimer NN NN O
comprised NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4R NN NN I-Protein
alpha NN NN I-Protein
chain NN NN I-Protein
and NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
gamma NN NN I-Protein
chain NN NN I-Protein
( NN NN O
gamma NN NN O
( NN NN O
c NN NN O
) NN NN O
) NN NN O
- NN NN O
like NN NN O
molecule NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13R NN NN I-Protein
alpha1 NN NN I-Protein
. NN NN O
   
mRNA NN NN O
levels NN NN O
for NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13R NN NN I-Protein
alpha1 NN NN I-Protein
, NN NN O
but NN NN O
not NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4R NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
were NN NN O
markedly NN NN O
decreased NN NN O
in NN NN O
in NN NN O
vitro NN NN O
monocyte NN NN O
- NN NN O
derived NN NN O
macrophages NN NN O
( NN NN O
MDMac NN NN O
) NN NN O
, NN NN O
and NN NN O
with NN NN O
increasing NN NN O
time NN NN O
of NN NN O
monocytes NN NN O
in NN NN O
culture NN NN O
correlated NN NN O
with NN NN O
the NN NN O
loss NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13 NN NN I-Protein
regulation NN NN O
of NN NN O
lipopolysaccharide NN NN O
- NN NN O
induced NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
production NN NN O
. NN NN O
   
Analysis NN NN O
of NN NN O
cell NN NN O
lines NN NN O
Daudi NN NN O
and NN NN O
THP NN NN O
- NN NN O
1 NN NN O
that NN NN O
differentially NN NN O
express NN NN O
gamma NN NN O
( NN NN O
c NN NN O
) NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13R NN NN I-Protein
alpha1 NN NN I-Protein
showed NN NN O
that NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13 NN NN I-Protein
can NN NN O
activate NN NN O
STAT6 NN NN B-Protein
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13R NN NN I-Protein
alpha1 NN NN I-Protein
- NN NN O
positive NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cells NN NN O
but NN NN O
not NN NN O
in NN NN O
gamma NN NN O
( NN NN O
c NN NN O
) NN NN O
- NN NN O
positive NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13R NN NN I-Protein
alpha1 NN NN I-Protein
- NN NN O
negative NN NN O
Daudi NN NN O
cells NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
13 NN NN I-Protein
activation NN NN O
of NN NN O
STAT6 NN NN B-Protein
was NN NN O
reduced NN NN O
in NN NN O
MDMac NN NN O
which NN NN O
was NN NN O
associated NN NN O
with NN NN O
diminished NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13 NN NN I-Protein
- NN NN O
induced NN NN O
expression NN NN O
of NN NN O
CD23 NN NN B-Protein
and NN NN O
MHC NN NN O
class NN NN O
II NN NN O
. NN NN O
   
However NN NN O
, NN NN O
with NN NN O
reduced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13R NN NN I-Protein
alpha1 NN NN I-Protein
expression NN NN O
and NN NN O
low NN NN O
nuclear NN NN O
STAT6 NN NN B-Protein
activity NN NN O
, NN NN O
some NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13 NN NN I-Protein
- NN NN O
induced NN NN O
responses NN NN O
were NN NN O
unaltered NN NN O
in NN NN O
magnitude NN NN O
in NN NN O
MDMac NN NN O
. NN NN O
   
In NN NN O
the NN NN O
absence NN NN O
of NN NN O
functional NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13R NN NN I-Protein
alpha1 NN NN I-Protein
and NN NN O
gamma NN NN O
( NN NN O
c NN NN O
) NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13 NN NN I-Protein
must NN NN O
signal NN NN O
through NN NN O
an NN NN O
alternative NN NN O
receptor NN NN O
complex NN NN O
on NN NN O
MDMac NN NN O
. NN NN O
   
Experiments NN NN O
with NN NN O
a NN NN O
blocking NN NN O
antibody NN NN O
to NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4R NN NN I-Protein
alpha NN NN I-Protein
showed NN NN O
that NN NN O
this NN NN O
chain NN NN O
remains NN NN O
an NN NN O
essential NN NN O
component NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13 NN NN I-Protein
receptor NN NN O
complex NN NN O
on NN NN O
MDMac NN NN O
. NN NN O
   
Monoallelic NN NN O
expression NN NN O
of NN NN O
Pax5 NN NN B-Protein
: NN NN O
a NN NN O
paradigm NN NN O
for NN NN O
the NN NN O
haploinsufficiency NN NN O
of NN NN O
mammalian NN NN O
Pax NN NN O
genes NN NN O
? NN NN O
   
It NN NN O
is NN NN O
generally NN NN O
assumed NN NN O
that NN NN O
most NN NN O
mammalian NN NN O
genes NN NN O
are NN NN O
transcribed NN NN O
from NN NN O
both NN NN O
alleles NN NN O
. NN NN O
   
Hence NN NN O
, NN NN O
the NN NN O
diploid NN NN O
state NN NN O
of NN NN O
the NN NN O
genome NN NN O
offers NN NN O
the NN NN O
advantage NN NN O
that NN NN O
a NN NN O
loss NN NN O
- NN NN O
of NN NN O
- NN NN O
function NN NN O
mutation NN NN O
in NN NN O
one NN NN O
allele NN NN O
can NN NN O
be NN NN O
compensated NN NN O
for NN NN O
by NN NN O
the NN NN O
remaining NN NN O
wild NN NN O
- NN NN O
type NN NN O
allele NN NN O
of NN NN O
the NN NN O
same NN NN O
gene NN NN O
. NN NN O
   
Indeed NN NN O
, NN NN O
the NN NN O
vast NN NN O
majority NN NN O
of NN NN O
human NN NN O
disease NN NN O
syndromes NN NN O
and NN NN O
engineered NN NN O
mutations NN NN O
in NN NN O
the NN NN O
mouse NN NN O
genome NN NN O
are NN NN O
recessive NN NN O
, NN NN O
indicating NN NN O
that NN NN O
recessiveness NN NN O
is NN NN O
the NN NN O
' NN NN O
default NN NN O
' NN NN O
state NN NN O
. NN NN O
   
However NN NN O
, NN NN O
a NN NN O
minority NN NN O
of NN NN O
genes NN NN O
are NN NN O
semi NN NN O
- NN NN O
dominant NN NN O
, NN NN O
as NN NN O
heterozygous NN NN O
loss NN NN O
- NN NN O
of NN NN O
- NN NN O
function NN NN O
mutation NN NN O
in NN NN O
these NN NN O
genes NN NN O
leads NN NN O
to NN NN O
phenotypic NN NN O
abnormalities NN NN O
. NN NN O
   
This NN NN O
condition NN NN O
, NN NN O
known NN NN O
as NN NN O
haploinsufficiency NN NN O
, NN NN O
has NN NN O
been NN NN O
described NN NN O
for NN NN O
five NN NN O
of NN NN O
the NN NN O
nine NN NN O
mammalian NN NN O
Pax NN NN O
genes NN NN O
, NN NN O
which NN NN O
are NN NN O
associated NN NN O
with NN NN O
mouse NN NN O
developmental NN NN O
mutants NN NN O
and NN NN O
human NN NN O
disease NN NN O
syndromes NN NN O
. NN NN O
   
Recently NN NN O
we NN NN O
have NN NN O
reported NN NN O
that NN NN O
the NN NN O
Pax5 NN NN B-Protein
gene NN NN O
is NN NN O
subject NN NN O
to NN NN O
allele NN NN O
- NN NN O
specific NN NN O
regulation NN NN O
during NN NN O
B NN NN O
cell NN NN O
development NN NN O
. NN NN O
   
Pax5 NN NN B-Protein
is NN NN O
predominantly NN NN O
transcribed NN NN O
from NN NN O
only NN NN O
one NN NN O
of NN NN O
its NN NN O
two NN NN O
alleles NN NN O
in NN NN O
early NN NN O
B NN NN O
- NN NN O
lymphoid NN NN O
progenitors NN NN O
and NN NN O
mature NN NN O
B NN NN O
cells NN NN O
, NN NN O
while NN NN O
it NN NN O
transiently NN NN O
switches NN NN O
to NN NN O
a NN NN O
biallelic NN NN O
mode NN NN O
of NN NN O
transcription NN NN O
in NN NN O
pre NN NN O
- NN NN O
B NN NN O
and NN NN O
immature NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
As NN NN O
a NN NN O
consequence NN NN O
, NN NN O
B NN NN O
- NN NN O
lymphoid NN NN O
tissues NN NN O
are NN NN O
mosaic NN NN O
with NN NN O
regard NN NN O
to NN NN O
the NN NN O
transcribed NN NN O
allele NN NN O
, NN NN O
and NN NN O
heterozygous NN NN O
mutation NN NN O
of NN NN O
Pax5 NN NN B-Protein
therefore NN NN O
results NN NN O
in NN NN O
deletion NN NN O
of NN NN O
B NN NN O
lymphocytes NN NN O
expressing NN NN O
only NN NN O
the NN NN O
mutant NN NN O
allele NN NN O
. NN NN O
   
The NN NN O
allele NN NN O
- NN NN O
specific NN NN O
regulation NN NN O
of NN NN O
Pax5 NN NN B-Protein
raises NN NN O
the NN NN O
intriguing NN NN O
possibility NN NN O
that NN NN O
monoallelic NN NN O
expression NN NN O
may NN NN O
also NN NN O
be NN NN O
the NN NN O
mechanism NN NN O
causing NN NN O
the NN NN O
haploinsufficiency NN NN O
of NN NN O
other NN NN O
Pax NN NN O
genes NN NN O
. NN NN O
   
In NN NN O
this NN NN O
review NN NN O
, NN NN O
we NN NN O
discuss NN NN O
different NN NN O
models NN NN O
accounting NN NN O
for NN NN O
the NN NN O
haploinsufficiency NN NN O
of NN NN O
mammalian NN NN O
Pax NN NN O
genes NN NN O
, NN NN O
provide NN NN O
further NN NN O
evidence NN NN O
in NN NN O
support NN NN O
of NN NN O
the NN NN O
allele NN NN O
- NN NN O
specific NN NN O
regulation NN NN O
of NN NN O
Pax5 NN NN B-Protein
and NN NN O
discuss NN NN O
the NN NN O
implication NN NN O
of NN NN O
these NN NN O
findings NN NN O
in NN NN O
the NN NN O
context NN NN O
of NN NN O
the NN NN O
recent NN NN O
literature NN NN O
describing NN NN O
the NN NN O
stochastic NN NN O
and NN NN O
monoallelic NN NN O
activation NN NN O
of NN NN O
other NN NN O
hematopoietic NN NN O
genes NN NN O
. NN NN O
   
The NN NN O
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
latency NN NN O
BamHI NN NN O
- NN NN O
Q NN NN O
promoter NN NN O
is NN NN O
positively NN NN O
regulated NN NN O
by NN NN O
STATs NN NN O
and NN NN O
Zta NN NN B-Protein
interference NN NN O
with NN NN O
JAK NN NN O
/ NN NN O
STAT NN NN O
activation NN NN O
leads NN NN O
to NN NN O
loss NN NN O
of NN NN O
BamHI NN NN O
- NN NN O
Q NN NN O
promoter NN NN O
activity NN NN O
. NN NN O
   
In NN NN O
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
( NN NN O
EBV NN NN O
) NN NN O
- NN NN O
associated NN NN O
tumors NN NN O
in NN NN O
nonimmunocompromised NN NN O
patients NN NN O
, NN NN O
EBV NN NN O
gene NN NN O
expression NN NN O
is NN NN O
highly NN NN O
restricted NN NN O
. NN NN O
   
EBV NN NN B-Protein
- NN NN I-Protein
encoded NN NN I-Protein
nuclear NN NN I-Protein
antigen NN NN I-Protein
( NN NN I-Protein
EBNA NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
is NN NN O
expressed NN NN O
, NN NN O
whereas NN NN O
the NN NN O
immunogenic NN NN O
and NN NN O
proliferative NN NN O
EBNAs NN NN O
are NN NN O
not NN NN O
. NN NN O
   
This NN NN O
pattern NN NN O
of NN NN O
EBNA NN NN O
expression NN NN O
is NN NN O
generated NN NN O
by NN NN O
usage NN NN O
of NN NN O
the NN NN O
BamHI NN NN O
- NN NN O
Q NN NN O
promoter NN NN O
( NN NN O
Qp NN NN O
) NN NN O
. NN NN O
   
We NN NN O
have NN NN O
determined NN NN O
that NN NN O
the NN NN O
JAK NN NN O
/ NN NN O
STAT NN NN O
pathway NN NN O
positively NN NN O
regulates NN NN O
Qp NN NN O
activity NN NN O
. NN NN O
   
In NN NN O
transient NN NN O
- NN NN O
transfection NN NN O
assays NN NN O
, NN NN O
a NN NN O
Qp NN NN O
- NN NN O
CAT NN NN O
reporter NN NN O
was NN NN O
activated NN NN O
by NN NN O
cotransfected NN NN O
JAK NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
by NN NN O
treatment NN NN O
of NN NN O
cells NN NN O
with NN NN O
the NN NN O
cytokine NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
. NN NN O
   
The NN NN O
ability NN NN O
of NN NN O
Qp NN NN O
to NN NN O
bind NN NN O
signal NN NN O
transducer NN NN O
and NN NN O
activator NN NN O
of NN NN O
transcription NN NN O
( NN NN O
STAT NN NN O
) NN NN O
proteins NN NN O
was NN NN O
directly NN NN O
demonstrated NN NN O
by NN NN O
electrophoretic NN NN O
mobility NN NN O
- NN NN O
shift NN NN O
assay NN NN O
, NN NN O
and NN NN O
mutation NN NN O
of NN NN O
potential NN NN O
STAT NN NN O
- NN NN O
binding NN NN O
sites NN NN O
reduced NN NN O
Qp NN NN O
responsiveness NN NN O
to NN NN O
Janus NN NN B-Protein
kinase NN NN I-Protein
( NN NN I-Protein
JAK NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
Consistent NN NN O
with NN NN O
a NN NN O
role NN NN O
for NN NN O
STATs NN NN O
in NN NN O
Qp NN NN O
function NN NN O
, NN NN O
Qp NN NN O
using NN NN O
Burkitt NN NN O
' NN NN O
s NN NN O
lymphoma NN NN O
Rael NN NN O
cells NN NN O
and NN NN O
cultured NN NN O
nasopharyngeal NN NN O
carcinoma NN NN O
( NN NN O
NPC NN NN O
) NN NN O
cells NN NN O
contained NN NN O
nuclear NN NN O
STAT NN NN O
protein NN NN O
. NN NN O
   
We NN NN O
investigated NN NN O
whether NN NN O
the NN NN O
inability NN NN O
to NN NN O
maintain NN NN O
EBV NN NN O
- NN NN O
positive NN NN O
NPC NN NN O
cell NN NN O
lines NN NN O
in NN NN O
culture NN NN O
was NN NN O
related NN NN O
to NN NN O
Qp NN NN O
activity NN NN O
. NN NN O
   
Passaging NN NN O
of NN NN O
the NN NN O
NPC NN NN O
cell NN NN O
line NN NN O
HK666 NN NN O
led NN NN O
to NN NN O
activation NN NN O
of NN NN O
expression NN NN O
of NN NN O
BZLF1 NN NN B-Protein
, NN NN O
which NN NN O
encodes NN NN O
Zta NN NN B-Protein
and NN NN O
loss NN NN O
of NN NN O
Qp NN NN O
function NN NN O
. NN NN O
   
Transient NN NN O
expression NN NN O
assays NN NN O
linked NN NN O
Zta NN NN B-Protein
expression NN NN O
to NN NN O
the NN NN O
down NN NN O
- NN NN O
regulation NN NN O
of NN NN O
Qp NN NN O
. NN NN O
   
Cotransfection NN NN O
of NN NN O
Zta NN NN B-Protein
reduced NN NN O
Qp NN NN O
activity NN NN O
in NN NN O
reporter NN NN O
assays NN NN O
. NN NN O
   
This NN NN O
negative NN NN O
regulation NN NN O
required NN NN O
Zta NN NN B-Protein
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
. NN NN O
   
We NN NN O
provide NN NN O
evidence NN NN O
that NN NN O
Zta NN NN B-Protein
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
p53 NN NN B-Protein
leads NN NN O
to NN NN O
p53 NN NN B-Protein
- NN NN O
mediated NN NN O
interference NN NN O
with NN NN O
JAK NN NN O
/ NN NN O
STAT NN NN O
activation NN NN O
of NN NN O
Qp NN NN O
. NN NN O
   
The NN NN O
data NN NN O
imply NN NN O
that NN NN O
JAK NN NN O
/ NN NN O
STAT NN NN O
signaling NN NN O
has NN NN O
a NN NN O
role NN NN O
in NN NN O
EBV NN NN O
- NN NN O
associated NN NN O
malignancies NN NN O
. NN NN O
   
Selective NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
of NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
- NN NN O
stimulated NN NN O
STAT NN NN O
molecules NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
It NN NN O
has NN NN O
been NN NN O
demonstrated NN NN O
that NN NN O
interferon NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
( NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
) NN NN O
and NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
) NN NN O
have NN NN O
various NN NN O
reverse NN NN O
effects NN NN O
on NN NN O
macrophages NN NN O
; NN NN O
however NN NN O
, NN NN O
the NN NN O
molecular NN NN O
mechanism NN NN O
of NN NN O
this NN NN O
difference NN NN O
has NN NN O
not NN NN O
been NN NN O
fully NN NN O
understood NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
analyzed NN NN O
the NN NN O
binding NN NN O
activity NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
- NN NN O
and NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
- NN NN O
activated NN NN O
STAT NN NN O
molecules NN NN O
to NN NN O
two NN NN O
kinds NN NN O
of NN NN O
GAS NN NN O
- NN NN O
motif NN NN O
sequences NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
- NN NN O
activated NN NN O
STAT1 NN NN B-Protein
could NN NN O
bind NN NN O
to NN NN O
the NN NN O
GAS NN NN O
- NN NN O
motif NN NN O
sequence NN NN O
in NN NN O
the NN NN O
promoter NN NN O
region NN NN O
of NN NN O
the NN NN O
Fcgamma NN NN O
receptor NN NN O
, NN NN O
but NN NN O
not NN NN O
to NN NN O
that NN NN O
in NN NN O
the NN NN O
promoter NN NN O
region NN NN O
of NN NN O
the NN NN O
COX NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
, NN NN O
whereas NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
- NN NN O
activated NN NN O
STAT1 NN NN B-Protein
and NN NN O
STAT5 NN NN B-Protein
could NN NN O
bind NN NN O
to NN NN O
both NN NN O
sequences NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
inhibited NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
- NN NN O
induced NN NN O
STAT NN NN O
activation NN NN O
without NN NN O
newly NN NN O
synthesized NN NN O
protein NN NN O
. NN NN O
   
We NN NN O
further NN NN O
demonstrated NN NN O
that NN NN O
aspirin NN NN O
, NN NN O
but NN NN O
not NN NN O
dexamethasone NN NN O
, NN NN O
suppressed NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
- NN NN O
induced NN NN O
STAT NN NN O
activation NN NN O
. NN NN O
   
Taken NN NN O
together NN NN O
, NN NN O
these NN NN O
results NN NN O
suggest NN NN O
that NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
- NN NN O
activated NN NN O
STAT1 NN NN B-Protein
has NN NN O
a NN NN O
specificity NN NN O
in NN NN O
binding NN NN O
to NN NN O
the NN NN O
GAS NN NN O
- NN NN O
motif NN NN O
sequences NN NN O
, NN NN O
whereas NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
- NN NN O
activated NN NN O
STAT1 NN NN B-Protein
and NN NN O
STAT5 NN NN B-Protein
have NN NN O
a NN NN O
broader NN NN O
spectrum NN NN O
in NN NN O
binding NN NN O
to NN NN O
the NN NN O
GAS NN NN O
- NN NN O
motif NN NN O
sequences NN NN O
. NN NN O
   
This NN NN O
may NN NN O
explain NN NN O
the NN NN O
difference NN NN O
between NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
and NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
in NN NN O
biological NN NN O
activity NN NN O
, NN NN O
and NN NN O
the NN NN O
inhibitory NN NN O
effect NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
on NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
activities NN NN O
. NN NN O
   
Block NN NN O
of NN NN O
granulocytic NN NN O
differentiation NN NN O
of NN NN O
32Dcl3 NN NN O
cells NN NN O
by NN NN O
AML1 NN NN O
/ NN NN O
ETO NN NN O
( NN NN O
MTG8 NN NN O
) NN NN O
but NN NN O
not NN NN O
by NN NN O
highly NN NN O
expressed NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
The NN NN O
chimeric NN NN O
gene NN NN O
, NN NN O
AML1 NN NN O
/ NN NN O
ETO NN NN O
( NN NN O
MTG8 NN NN O
) NN NN O
, NN NN O
generated NN NN O
in NN NN O
t NN NN O
( NN NN O
8 NN NN O
; NN NN O
21 NN NN O
) NN NN O
acute NN NN O
myeloid NN NN O
leukemia NN NN O
enhances NN NN O
the NN NN O
expression NN NN O
of NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
To NN NN O
evaluate NN NN O
whether NN NN O
this NN NN O
enhancement NN NN O
is NN NN O
the NN NN O
primary NN NN O
role NN NN O
of NN NN O
AML1 NN NN O
/ NN NN O
ETO NN NN O
in NN NN O
leukemogenesis NN NN O
, NN NN O
effects NN NN O
of NN NN O
over NN NN O
- NN NN O
expression NN NN O
of NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
in NN NN O
the NN NN O
murine NN NN O
myeloid NN NN O
precursor NN NN O
cell NN NN O
line NN NN O
, NN NN O
32Dcl3 NN NN O
, NN NN O
were NN NN O
examined NN NN O
. NN NN O
   
When NN NN O
32Dcl3 NN NN O
cells NN NN O
expressing NN NN O
exogenous NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
were NN NN O
induced NN NN O
to NN NN O
differentiate NN NN O
, NN NN O
the NN NN O
onset NN NN O
of NN NN O
morphological NN NN O
differentiation NN NN O
was NN NN O
delayed NN NN O
. NN NN O
   
However NN NN O
, NN NN O
even NN NN O
the NN NN O
cells NN NN O
expressing NN NN O
very NN NN O
high NN NN O
levels NN NN O
of NN NN O
exogenous NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
eventually NN NN O
underwent NN NN O
differentiation NN NN O
without NN NN O
a NN NN O
significant NN NN O
decrease NN NN O
in NN NN O
the NN NN O
synthesis NN NN O
of NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
On NN NN O
the NN NN O
contrary NN NN O
, NN NN O
32Dcl3 NN NN O
cells NN NN O
stably NN NN O
expressing NN NN O
AML1 NN NN O
/ NN NN O
ETO NN NN O
were NN NN O
completely NN NN O
resistant NN NN O
to NN NN O
differentiation NN NN O
and NN NN O
continued NN NN O
to NN NN O
grow NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
G NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
. NN NN O
   
These NN NN O
results NN NN O
are NN NN O
consistent NN NN O
with NN NN O
the NN NN O
interpretation NN NN O
that NN NN O
stimulation NN NN O
of NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
is NN NN O
not NN NN O
the NN NN O
primary NN NN O
target NN NN O
of NN NN O
AML1 NN NN O
/ NN NN O
ETO NN NN O
. NN NN O
   
The NN NN O
Legionella NN NN O
pneumophila NN NN O
rpoS NN NN B-Protein
gene NN NN O
is NN NN O
required NN NN O
for NN NN O
growth NN NN O
within NN NN O
Acanthamoeba NN NN O
castellanii NN NN O
. NN NN O
   
To NN NN O
investigate NN NN O
regulatory NN NN O
networks NN NN O
in NN NN O
Legionella NN NN O
pneumophila NN NN O
, NN NN O
the NN NN O
gene NN NN O
encoding NN NN O
the NN NN O
homolog NN NN O
of NN NN O
the NN NN O
Escherichia NN NN O
coli NN NN O
stress NN NN O
and NN NN O
stationary NN NN O
- NN NN O
phase NN NN O
sigma NN NN O
factor NN NN O
RpoS NN NN B-Protein
was NN NN O
identified NN NN O
by NN NN O
complementation NN NN O
of NN NN O
an NN NN O
E NN NN O
. NN NN O
coli NN NN O
rpoS NN NN B-Protein
mutation NN NN O
. NN NN O
   
An NN NN O
open NN NN O
reading NN NN O
frame NN NN O
that NN NN O
is NN NN O
approximately NN NN O
60 NN NN O
% NN NN O
identical NN NN O
to NN NN O
the NN NN O
E NN NN O
. NN NN O
coli NN NN O
rpoS NN NN B-Protein
gene NN NN O
was NN NN O
identified NN NN O
. NN NN O
   
Western NN NN O
blot NN NN O
analysis NN NN O
showed NN NN O
that NN NN O
the NN NN O
level NN NN O
of NN NN O
L NN NN O
. NN NN O
pneumophila NN NN O
RpoS NN NN B-Protein
increased NN NN O
in NN NN O
stationary NN NN O
phase NN NN O
. NN NN O
   
An NN NN O
insertion NN NN O
mutation NN NN O
was NN NN O
constructed NN NN O
in NN NN O
the NN NN O
rpoS NN NN B-Protein
gene NN NN O
on NN NN O
the NN NN O
chromosome NN NN O
of NN NN O
L NN NN O
. NN NN O
pneumophila NN NN O
, NN NN O
and NN NN O
the NN NN O
ability NN NN O
of NN NN O
this NN NN O
mutant NN NN O
strain NN NN O
to NN NN O
survive NN NN O
various NN NN O
stress NN NN O
conditions NN NN O
was NN NN O
assayed NN NN O
and NN NN O
compared NN NN O
with NN NN O
results NN NN O
for NN NN O
the NN NN O
wild NN NN O
- NN NN O
type NN NN O
strain NN NN O
. NN NN O
   
Both NN NN O
the NN NN O
mutant NN NN O
and NN NN O
wild NN NN O
- NN NN O
type NN NN O
strains NN NN O
were NN NN O
more NN NN O
resistant NN NN O
to NN NN O
stress NN NN O
when NN NN O
in NN NN O
stationary NN NN O
phase NN NN O
than NN NN O
when NN NN O
in NN NN O
the NN NN O
logarithmic NN NN O
phase NN NN O
of NN NN O
growth NN NN O
. NN NN O
   
This NN NN O
finding NN NN O
indicates NN NN O
that NN NN O
L NN NN O
. NN NN O
pneumophila NN NN O
RpoS NN NN B-Protein
is NN NN O
not NN NN O
required NN NN O
for NN NN O
a NN NN O
stationary NN NN O
- NN NN O
phase NN NN O
- NN NN O
dependent NN NN O
resistance NN NN O
to NN NN O
stress NN NN O
. NN NN O
   
Although NN NN O
the NN NN O
mutant NN NN O
strain NN NN O
was NN NN O
able NN NN O
to NN NN O
kill NN NN O
HL NN NN O
- NN NN O
60 NN NN O
- NN NN O
and NN NN O
THP NN NN O
- NN NN O
1 NN NN O
- NN NN O
derived NN NN O
macrophages NN NN O
, NN NN O
it NN NN O
could NN NN O
not NN NN O
replicate NN NN O
within NN NN O
a NN NN O
protozoan NN NN O
host NN NN O
, NN NN O
Acanthamoeba NN NN O
castellanii NN NN O
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
L NN NN O
. NN NN O
pneumophila NN NN O
possesses NN NN O
a NN NN O
growth NN NN O
phase NN NN O
- NN NN O
dependent NN NN O
resistance NN NN O
to NN NN O
stress NN NN O
that NN NN O
is NN NN O
independent NN NN O
of NN NN O
RpoS NN NN B-Protein
control NN NN O
and NN NN O
that NN NN O
RpoS NN NN B-Protein
likely NN NN O
regulates NN NN O
genes NN NN O
that NN NN O
enable NN NN O
it NN NN O
to NN NN O
survive NN NN O
in NN NN O
the NN NN O
environment NN NN O
within NN NN O
protozoa NN NN O
. NN NN O
   
Our NN NN O
data NN NN O
indicate NN NN O
that NN NN O
the NN NN O
role NN NN O
of NN NN O
rpoS NN NN B-Protein
in NN NN O
L NN NN O
. NN NN O
pneumophila NN NN O
is NN NN O
very NN NN O
different NN NN O
from NN NN O
what NN NN O
has NN NN O
previously NN NN O
been NN NN O
reported NN NN O
for NN NN O
E NN NN O
. NN NN O
coli NN NN O
rpoS NN NN B-Protein
. NN NN O
   
Cutting NN NN O
edge NN NN O
: NN NN O
TCR NN NN O
stimulation NN NN O
by NN NN O
antibody NN NN O
and NN NN O
bacterial NN NN O
superantigen NN NN O
induces NN NN O
Stat3 NN NN B-Protein
activation NN NN O
in NN NN O
human NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Recent NN NN O
data NN NN O
show NN NN O
that NN NN O
TCR NN NN O
/ NN NN O
CD3 NN NN O
stimulation NN NN O
induces NN NN O
activation NN NN O
of NN NN O
Stat5 NN NN B-Protein
in NN NN O
murine NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Here NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
CD3 NN NN O
ligation NN NN O
by NN NN O
mAb NN NN O
and NN NN O
Staphylococcal NN NN O
enterotoxin NN NN O
( NN NN O
SE NN NN O
) NN NN O
induce NN NN O
a NN NN O
rapid NN NN O
, NN NN O
gradually NN NN O
accumulating NN NN O
, NN NN O
long NN NN O
- NN NN O
lasting NN NN O
tyrosine NN NN O
, NN NN O
and NN NN O
serine NN NN O
phosphorylation NN NN O
of NN NN O
Stat3 NN NN B-Protein
( NN NN O
but NN NN O
not NN NN O
Stat5 NN NN B-Protein
) NN NN O
in NN NN O
allogen NN NN O
- NN NN O
specific NN NN O
human NN NN O
CD4 NN NN O
+ NN NN O
T NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
induces NN NN O
a NN NN O
rapid NN NN O
and NN NN O
transient NN NN O
tyrosine NN NN O
and NN NN O
serine NN NN O
phosphorylation NN NN O
of NN NN O
Stat3 NN NN B-Protein
. NN NN O
   
Compared NN NN O
with NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
CD3 NN NN B-Protein
ligation NN NN O
induces NN NN O
a NN NN O
delayed NN NN O
Stat3 NN NN B-Protein
binding NN NN O
to NN NN O
oligonucleotide NN NN O
probes NN NN O
from NN NN O
the NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
promoter NN NN O
. NN NN O
   
CD3 NN NN B-Protein
- NN NN O
mediated NN NN O
activation NN NN O
of NN NN O
Stat3 NN NN B-Protein
is NN NN O
almost NN NN O
completely NN NN O
inhibited NN NN O
by NN NN O
a NN NN O
Src NN NN O
kinase NN NN O
inhibitor NN NN O
( NN NN O
PP1 NN NN O
) NN NN O
, NN NN O
whereas NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
induced NN NN O
Stat3 NN NN B-Protein
activation NN NN O
is NN NN O
unaffected NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
CD3 NN NN B-Protein
ligation NN NN O
by NN NN O
mAb NN NN O
and NN NN O
SE NN NN O
triggers NN NN O
a NN NN O
rapid NN NN O
, NN NN O
PP1 NN NN O
- NN NN O
sensitive NN NN O
tyrosine NN NN O
and NN NN O
serine NN NN O
phosphorylation NN NN O
of NN NN O
Stat3 NN NN B-Protein
in NN NN O
human NN NN O
CD4 NN NN O
+ NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
we NN NN O
provide NN NN O
evidence NN NN O
that NN NN O
TCR NN NN O
/ NN NN O
CD3 NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
induce NN NN O
Stat3 NN NN B-Protein
activation NN NN O
via NN NN O
distinct NN NN O
signaling NN NN O
pathways NN NN O
. NN NN O
   
[ NN NN O
Hormonal NN NN O
metabolic NN NN O
status NN NN O
in NN NN O
breast NN NN O
cancer NN NN O
patients NN NN O
after NN NN O
conservative NN NN O
surgery NN NN O
: NN NN O
comparison NN NN O
with NN NN O
known NN NN O
prognostic NN NN O
criteria NN NN O
] NN NN O
   
Body NN NN O
weight NN NN O
, NN NN O
body NN NN O
mass NN NN O
index NN NN O
, NN NN O
body NN NN O
fat NN NN O
, NN NN O
lean NN NN O
body NN NN O
mass NN NN O
, NN NN O
blood NN NN O
- NN NN O
glucose NN NN O
, NN NN O
cholesterol NN NN O
, NN NN O
HDL NN NN O
- NN NN O
cholesterol NN NN O
, NN NN O
triglyceride NN NN O
, NN NN O
beta NN NN O
- NN NN O
lipoproteins NN NN O
, NN NN O
insulin NN NN O
, NN NN O
gonadotropin NN NN O
, NN NN O
estradiol NN NN O
, NN NN O
testosterone NN NN O
, NN NN O
SHBG NN NN B-Protein
, NN NN O
T3 NN NN O
, NN NN O
T4 NN NN O
and NN NN O
TSH NN NN O
levels NN NN O
as NN NN O
well NN NN O
as NN NN O
estradiol NN NN B-Protein
and NN NN O
progesterone NN NN B-Protein
receptor NN NN I-Protein
levels NN NN O
in NN NN O
excised NN NN O
tumor NN NN O
were NN NN O
studied NN NN O
in NN NN O
40 NN NN O
patients NN NN O
with NN NN O
breast NN NN O
cancer NN NN O
prior NN NN O
to NN NN O
conservative NN NN O
treatment NN NN O
. NN NN O
   
Said NN NN O
anthropometric NN NN O
, NN NN O
metabolic NN NN O
and NN NN O
hormonal NN NN O
parameters NN NN O
were NN NN O
compared NN NN O
with NN NN O
the NN NN O
index NN NN O
of NN NN O
lymphocytic NN NN O
infiltration NN NN O
of NN NN O
tumor NN NN O
selected NN NN O
as NN NN O
a NN NN O
prognostic NN NN O
factor NN NN O
. NN NN O
   
A NN NN O
significant NN NN O
correlation NN NN O
between NN NN O
high NN NN O
lymphocytic NN NN O
infiltration NN NN O
( NN NN O
2 NN NN O
. NN NN O
5 NN NN O
points NN NN O
) NN NN O
, NN NN O
low NN NN O
body NN NN O
mass NN NN O
and NN NN O
fat NN NN O
was NN NN O
identified NN NN O
. NN NN O
   
Also NN NN O
, NN NN O
smoking NN NN O
contributed NN NN O
to NN NN O
loss NN NN O
of NN NN O
body NN NN O
mass NN NN O
and NN NN O
fat NN NN O
; NN NN O
however NN NN O
, NN NN O
it NN NN O
caused NN NN O
lymphocytic NN NN O
infiltration NN NN O
to NN NN O
rise NN NN O
. NN NN O
   
Moderate NN NN O
body NN NN O
mass NN NN O
, NN NN O
relatively NN NN O
low NN NN O
fat NN NN O
level NN NN O
and NN NN O
positive NN NN O
receptor NN NN O
status NN NN O
are NN NN O
among NN NN O
factors NN NN O
of NN NN O
good NN NN O
prognosis NN NN O
in NN NN O
breast NN NN O
cancer NN NN O
of NN NN O
early NN NN O
stages NN NN O
. NN NN O
   
Tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
decreases NN NN O
, NN NN O
and NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
increases NN NN O
, NN NN O
the NN NN O
sensitivity NN NN O
of NN NN O
human NN NN O
monocytes NN NN O
to NN NN O
dexamethasone NN NN O
: NN NN O
potential NN NN O
regulation NN NN O
of NN NN O
the NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
. NN NN O
   
Resistance NN NN O
to NN NN O
glucocorticoid NN NN O
therapy NN NN O
has NN NN O
been NN NN O
observed NN NN O
in NN NN O
patients NN NN O
with NN NN O
autoimmune NN NN O
/ NN NN O
inflammatory NN NN O
diseases NN NN O
and NN NN O
may NN NN O
be NN NN O
related NN NN O
to NN NN O
the NN NN O
inflammatory NN NN O
process NN NN O
itself NN NN O
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
examine NN NN O
the NN NN O
ability NN NN O
of NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNFalpha NN NN B-Protein
, NN NN O
a NN NN O
proinflammatory NN NN O
cytokine NN NN O
) NN NN O
and NN NN O
interleukin NN NN B-Protein
( NN NN I-Protein
IL NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
10 NN NN I-Protein
( NN NN O
an NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
cytokine NN NN O
) NN NN O
to NN NN O
differentially NN NN O
regulate NN NN O
the NN NN O
sensitivity NN NN O
of NN NN O
human NN NN O
monocytes NN NN O
/ NN NN O
macrophages NN NN O
to NN NN O
glucocorticoids NN NN O
. NN NN O
   
To NN NN O
accomplish NN NN O
this NN NN O
, NN NN O
we NN NN O
first NN NN O
analyzed NN NN O
the NN NN O
pattern NN NN O
of NN NN O
TNFalpha NN NN B-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
inhibition NN NN O
by NN NN O
dexamethasone NN NN O
in NN NN O
LPS NN NN O
- NN NN O
stimulated NN NN O
whole NN NN O
- NN NN O
blood NN NN O
cell NN NN O
cultures NN NN O
. NN NN O
   
Second NN NN O
, NN NN O
we NN NN O
studied NN NN O
the NN NN O
modulation NN NN O
of NN NN O
the NN NN O
sensitivity NN NN O
of NN NN O
these NN NN O
cells NN NN O
to NN NN O
dexamethasone NN NN O
by NN NN O
preincubation NN NN O
with NN NN O
TNFalpha NN NN B-Protein
or NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
and NN NN O
measurement NN NN O
of NN NN O
LPS NN NN O
- NN NN O
stimulated NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
secretion NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
we NN NN O
evaluated NN NN O
the NN NN O
effect NN NN O
of NN NN O
dexamethasone NN NN O
on NN NN O
phorbolmyristate NN NN O
- NN NN O
acetate NN NN O
- NN NN O
stimulated NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
receptor NN NN I-Protein
antagonist NN NN I-Protein
secretion NN NN O
by NN NN O
the NN NN O
human NN NN O
monocytic NN NN O
cell NN NN O
line NN NN O
U937 NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
we NN NN O
investigated NN NN O
whether NN NN O
the NN NN O
modulation NN NN O
of NN NN O
corticosensitivity NN NN O
in NN NN O
TNFalpha NN NN B-Protein
- NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
- NN NN O
pretreated NN NN O
U937 NN NN O
cells NN NN O
was NN NN O
related NN NN O
to NN NN O
a NN NN O
change NN NN O
of NN NN O
the NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
concentration NN NN O
and NN NN O
affinity NN NN O
. NN NN O
   
Dexamethasone NN NN O
had NN NN O
different NN NN O
effects NN NN O
on NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
TNFalpha NN NN B-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
secretion NN NN O
; NN NN O
whereas NN NN O
it NN NN O
suppressed NN NN O
TNFalpha NN NN B-Protein
in NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
fashion NN NN O
, NN NN O
its NN NN O
effect NN NN O
on NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
secretion NN NN O
was NN NN O
biphasic NN NN O
, NN NN O
producing NN NN O
stimulation NN NN O
at NN NN O
lower NN NN O
, NN NN O
and NN NN O
inhibition NN NN O
at NN NN O
higher NN NN O
doses NN NN O
. NN NN O
   
The NN NN O
concentration NN NN O
of NN NN O
LPS NN NN O
employed NN NN O
influenced NN NN O
the NN NN O
effect NN NN O
of NN NN O
dexamethasone NN NN O
on NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
secretion NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
Pretreatment NN NN O
with NN NN O
TNFalpha NN NN B-Protein
diminished NN NN O
, NN NN O
and NN NN O
with NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
improved NN NN O
, NN NN O
the NN NN O
ability NN NN O
of NN NN O
dexamethasone NN NN O
to NN NN O
suppress NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
secretion NN NN O
in NN NN O
whole NN NN O
- NN NN O
blood NN NN O
cell NN NN O
cultures NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
for NN NN O
both NN NN O
) NN NN O
and NN NN O
to NN NN O
enhance NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
receptor NN NN I-Protein
antagonist NN NN I-Protein
secretion NN NN O
by NN NN O
U937 NN NN O
cells NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
for NN NN O
both NN NN O
) NN NN O
. NN NN O
   
TNFalpha NN NN B-Protein
decreased NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
, NN NN O
while NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
increased NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
, NN NN O
the NN NN O
concentration NN NN O
of NN NN O
dexamethasone NN NN O
binding NN NN O
sites NN NN O
in NN NN O
these NN NN O
cells NN NN O
, NN NN O
with NN NN O
no NN NN O
discernible NN NN O
effect NN NN O
on NN NN O
their NN NN O
binding NN NN O
affinity NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
glucocorticoids NN NN O
differentially NN NN O
modulate NN NN O
TNFalpha NN NN B-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
secretion NN NN O
by NN NN O
human NN NN O
monocytes NN NN O
in NN NN O
a NN NN O
LPS NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
fashion NN NN O
and NN NN O
that NN NN O
the NN NN O
sensitivity NN NN O
of NN NN O
these NN NN O
cells NN NN O
to NN NN O
glucocorticoids NN NN O
is NN NN O
altered NN NN O
by NN NN O
TNFalpha NN NN B-Protein
or NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
pretreatment NN NN O
; NN NN O
TNFalpha NN NN B-Protein
blocks NN NN O
their NN NN O
effects NN NN O
, NN NN O
whereas NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
acts NN NN O
synergistically NN NN O
with NN NN O
glucocorticoids NN NN O
. NN NN O
   
This NN NN O
is NN NN O
accompanied NN NN O
by NN NN O
opposite NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
changes NN NN O
, NN NN O
respectively NN NN O
opposing NN NN O
and NN NN O
favoring NN NN O
glucocorticoid NN NN O
actions NN NN O
. NN NN O
   
This NN NN O
study NN NN O
suggests NN NN O
that NN NN O
the NN NN O
pattern NN NN O
of NN NN O
pro NN NN O
- NN NN O
/ NN NN O
antiinflammatory NN NN O
cytokine NN NN O
secretion NN NN O
may NN NN O
alter NN NN O
the NN NN O
response NN NN O
of NN NN O
patients NN NN O
to NN NN O
glucocorticoid NN NN O
therapy NN NN O
. NN NN O
   
Modulation NN NN O
of NN NN O
normal NN NN O
erythroid NN NN O
differentiation NN NN O
by NN NN O
the NN NN O
endogenous NN NN O
thyroid NN NN O
hormone NN NN O
and NN NN O
retinoic NN NN O
acid NN NN O
receptors NN NN O
: NN NN O
a NN NN O
possible NN NN O
target NN NN O
for NN NN O
v NN NN B-Protein
- NN NN I-Protein
erbA NN NN I-Protein
oncogene NN NN O
action NN NN O
. NN NN O
   
The NN NN O
v NN NN B-Protein
- NN NN I-Protein
erbA NN NN I-Protein
oncogene NN NN O
, NN NN O
a NN NN O
mutated NN NN O
version NN NN O
of NN NN O
the NN NN O
thyroid NN NN B-Protein
hormone NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
c NN NN B-Protein
- NN NN I-Protein
erbA NN NN I-Protein
/ NN NN O
TR NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
, NN NN O
inhibits NN NN O
erythroid NN NN O
differentiation NN NN O
and NN NN O
constitutively NN NN O
represses NN NN O
transcription NN NN O
of NN NN O
certain NN NN O
erythrocyte NN NN O
genes NN NN O
, NN NN O
suggesting NN NN O
a NN NN O
normal NN NN O
function NN NN O
of NN NN O
the NN NN O
proto NN NN O
- NN NN O
oncogene NN NN O
c NN NN B-Protein
- NN NN I-Protein
erbA NN NN I-Protein
in NN NN O
erythropoiesis NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
endogenous NN NN O
thyroid NN NN B-Protein
hormone NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
c NN NN B-Protein
- NN NN I-Protein
erbA NN NN I-Protein
/ NN NN O
TR NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
and NN NN O
the NN NN O
closely NN NN O
related NN NN O
retinoic NN NN B-Protein
acid NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
RAR NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
play NN NN O
a NN NN O
role NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
normal NN NN O
erythroid NN NN O
differentiation NN NN O
. NN NN O
   
Retinoic NN NN O
acid NN NN O
( NN NN O
RA NN NN O
) NN NN O
distinctly NN NN O
modulated NN NN O
the NN NN O
erythroid NN NN O
differentiation NN NN O
program NN NN O
of NN NN O
normal NN NN O
erythroid NN NN O
progenitors NN NN O
and NN NN O
erythroblasts NN NN O
reversibly NN NN O
transformed NN NN O
by NN NN O
a NN NN O
conditional NN NN O
tyrosine NN NN O
kinase NN NN O
oncogene NN NN O
. NN NN O
   
When NN NN O
added NN NN O
pulsewise NN NN O
to NN NN O
immature NN NN O
cells NN NN O
, NN NN O
differentiation NN NN O
was NN NN O
accelerated NN NN O
while NN NN O
more NN NN O
mature NN NN O
cells NN NN O
underwent NN NN O
premature NN NN O
cell NN NN O
death NN NN O
. NN NN O
   
Thyroid NN NN O
hormone NN NN O
( NN NN O
T3 NN NN O
) NN NN O
alone NN NN O
caused NN NN O
similar NN NN O
but NN NN O
weaker NN NN O
effects NN NN O
. NN NN O
   
Interestingly NN NN O
, NN NN O
T3 NN NN O
strongly NN NN O
enhanced NN NN O
the NN NN O
action NN NN O
of NN NN O
RA NN NN O
, NN NN O
suggesting NN NN O
cooperative NN NN O
action NN NN O
of NN NN O
the NN NN O
two NN NN O
receptors NN NN O
in NN NN O
modulating NN NN O
erythroid NN NN O
differentiation NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
the NN NN O
human NN NN O
RAR NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
in NN NN O
receptor NN NN O
- NN NN O
negative NN NN O
erythroblasts NN NN O
conferred NN NN O
RA NN NN O
- NN NN O
induced NN NN O
regulation NN NN O
of NN NN O
differentiation NN NN O
to NN NN O
the NN NN O
otherwise NN NN O
unresponsive NN NN O
cells NN NN O
, NN NN O
thus NN NN O
showing NN NN O
that NN NN O
the NN NN O
RAR NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
is NN NN O
essential NN NN O
for NN NN O
the NN NN O
RA NN NN O
effect NN NN O
. NN NN O
   
Likewise NN NN O
, NN NN O
enhanced NN NN O
expression NN NN O
of NN NN O
exogenous NN NN O
c NN NN B-Protein
- NN NN I-Protein
erbA NN NN I-Protein
/ NN NN O
TR NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
in NN NN O
erythroblasts NN NN O
rendered NN NN O
them NN NN O
susceptible NN NN O
to NN NN O
modulation NN NN O
of NN NN O
differentiation NN NN O
by NN NN O
T3 NN NN O
, NN NN O
suggesting NN NN O
a NN NN O
similar NN NN O
function NN NN O
of NN NN O
both NN NN O
receptors NN NN O
. NN NN O
   
Glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
in NN NN O
patients NN NN O
with NN NN O
lupus NN NN O
nephritis NN NN O
: NN NN O
relationship NN NN O
between NN NN O
receptor NN NN O
levels NN NN O
in NN NN O
mononuclear NN NN O
leukocytes NN NN O
and NN NN O
effect NN NN O
of NN NN O
glucocorticoid NN NN O
therapy NN NN O
. NN NN O
   
We NN NN O
investigated NN NN O
the NN NN O
clinical NN NN O
significance NN NN O
of NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
determination NN NN O
in NN NN O
20 NN NN O
patients NN NN O
with NN NN O
systemic NN NN O
lupus NN NN O
erythematosus NN NN O
( NN NN O
SLE NN NN O
) NN NN O
who NN NN O
afterwards NN NN O
developed NN NN O
nephrotic NN NN O
syndrome NN NN O
. NN NN O
   
Glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
concentrations NN NN O
in NN NN O
mononuclear NN NN O
leukocytes NN NN O
( NN NN O
MNL NN NN O
) NN NN O
in NN NN O
these NN NN O
patients NN NN O
were NN NN O
comparable NN NN O
with NN NN O
those NN NN O
in NN NN O
both NN NN O
other NN NN O
patients NN NN O
with NN NN O
SLE NN NN O
and NN NN O
healthy NN NN O
persons NN NN O
. NN NN O
   
Improvement NN NN O
in NN NN O
urinary NN NN O
protein NN NN O
excretion NN NN O
and NN NN O
in NN NN O
disease NN NN O
activity NN NN O
, NN NN O
which NN NN O
was NN NN O
scored NN NN O
according NN NN O
to NN NN O
the NN NN O
SLE NN NN O
Disease NN NN O
Activity NN NN O
Index NN NN O
system NN NN O
of NN NN O
the NN NN O
University NN NN O
of NN NN O
Toronto NN NN O
, NN NN O
closely NN NN O
related NN NN O
to NN NN O
the NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
concentrations NN NN O
in NN NN O
MNL NN NN O
isolated NN NN O
from NN NN O
the NN NN O
corresponding NN NN O
patients NN NN O
. NN NN O
   
In NN NN O
summary NN NN O
, NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
determination NN NN O
in NN NN O
patients NN NN O
with NN NN O
lupus NN NN O
nephritis NN NN O
may NN NN O
be NN NN O
a NN NN O
predictive NN NN O
clue NN NN O
for NN NN O
assessing NN NN O
responsiveness NN NN O
to NN NN O
glucocorticoid NN NN O
therapy NN NN O
. NN NN O
   
A NN NN O
microtitre NN NN O
assay NN NN O
system NN NN O
for NN NN O
glucocorticoid NN NN B-Protein
receptors NN NN I-Protein
: NN NN O
decreased NN NN O
receptor NN NN O
concentration NN NN O
in NN NN O
myocardial NN NN O
infarction NN NN O
. NN NN O
   
A NN NN O
major NN NN O
difficulty NN NN O
in NN NN O
determination NN NN O
of NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
sites NN NN O
is NN NN O
the NN NN O
very NN NN O
complicated NN NN O
assay NN NN O
procedure NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
we NN NN O
describe NN NN O
a NN NN O
microtitre NN NN O
assay NN NN O
system NN NN O
for NN NN O
glucocorticoid NN NN B-Protein
receptors NN NN I-Protein
which NN NN O
is NN NN O
a NN NN O
whole NN NN O
- NN NN O
cell NN NN O
competitive NN NN O
binding NN NN O
radioassay NN NN O
using NN NN O
[ NN NN O
3H NN NN O
] NN NN O
- NN NN O
dexamethasone NN NN O
as NN NN O
radioligand NN NN O
. NN NN O
   
This NN NN O
modification NN NN O
of NN NN O
a NN NN O
previously NN NN O
described NN NN O
protocol NN NN O
simplifies NN NN O
and NN NN O
reduces NN NN O
laboratory NN NN O
work NN NN O
and NN NN O
allows NN NN O
assay NN NN O
reproducibility NN NN O
to NN NN O
be NN NN O
controlled NN NN O
more NN NN O
reliably NN NN O
. NN NN O
   
Thus NN NN O
enabled NN NN O
to NN NN O
perform NN NN O
the NN NN O
test NN NN O
on NN NN O
multiple NN NN O
blood NN NN O
samples NN NN O
in NN NN O
parallel NN NN O
, NN NN O
we NN NN O
investigated NN NN O
cardiac NN NN O
infarction NN NN O
patients NN NN O
over NN NN O
a NN NN O
12 NN NN O
- NN NN O
day NN NN O
period NN NN O
to NN NN O
test NN NN O
if NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
binding NN NN O
is NN NN O
altered NN NN O
in NN NN O
this NN NN O
' NN NN O
stressful NN NN O
' NN NN O
disease NN NN O
. NN NN O
   
On NN NN O
the NN NN O
first NN NN O
day NN NN O
of NN NN O
the NN NN O
disease NN NN O
, NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
capacity NN NN O
was NN NN O
significantly NN NN O
decreased NN NN O
without NN NN O
alteration NN NN O
of NN NN O
the NN NN O
receptor NN NN O
- NN NN O
ligand NN NN O
affinity NN NN O
, NN NN O
whereas NN NN O
on NN NN O
days NN NN O
4 NN NN O
and NN NN O
12 NN NN O
the NN NN O
number NN NN O
of NN NN O
receptor NN NN O
sites NN NN O
was NN NN O
normal NN NN O
again NN NN O
. NN NN O
   
This NN NN O
result NN NN O
fits NN NN O
well NN NN O
into NN NN O
the NN NN O
general NN NN O
observation NN NN O
of NN NN O
stress NN NN O
- NN NN O
induced NN NN O
down NN NN O
- NN NN O
regulation NN NN O
of NN NN O
immune NN NN O
responses NN NN O
. NN NN O
   
Single NN NN O
point NN NN O
estimation NN NN O
of NN NN O
glucocorticoid NN NN B-Protein
receptors NN NN I-Protein
in NN NN O
lymphocytes NN NN O
of NN NN O
normal NN NN O
subjects NN NN O
and NN NN O
of NN NN O
children NN NN O
under NN NN O
long NN NN O
term NN NN O
glucocorticoid NN NN O
treatment NN NN O
. NN NN O
   
A NN NN O
single NN NN O
point NN NN O
assay NN NN O
of NN NN O
glucocorticoid NN NN B-Protein
receptors NN NN I-Protein
( NN NN O
GR NN NN B-Protein
) NN NN O
in NN NN O
human NN NN O
lymphocytes NN NN O
based NN NN O
on NN NN O
the NN NN O
measurement NN NN O
of NN NN O
specific NN NN O
dexamethasone NN NN O
binding NN NN O
has NN NN O
been NN NN O
developed NN NN O
and NN NN O
compared NN NN O
with NN NN O
a NN NN O
common NN NN O
multi NN NN O
- NN NN O
point NN NN O
Scatchard NN NN O
analysis NN NN O
. NN NN O
   
The NN NN O
assay NN NN O
conditions NN NN O
- NN NN O
concentration NN NN O
of NN NN O
the NN NN O
ligand NN NN O
20 NN NN O
nmol NN NN O
/ NN NN O
l NN NN O
, NN NN O
incubation NN NN O
time NN NN O
2 NN NN O
h NN NN O
and NN NN O
the NN NN O
cell NN NN O
count NN NN O
2 NN NN O
- NN NN O
6 NN NN O
mil NN NN O
. NN NN O
   
cells NN NN O
/ NN NN O
tube NN NN O
in NN NN O
the NN NN O
assay NN NN O
volume NN NN O
0 NN NN O
. NN NN O
25 NN NN O
ml NN NN O
were NN NN O
found NN NN O
to NN NN O
be NN NN O
optimal NN NN O
. NN NN O
   
An NN NN O
attempt NN NN O
was NN NN O
also NN NN O
undertaken NN NN O
to NN NN O
use NN NN O
a NN NN O
cell NN NN O
harvester NN NN O
for NN NN O
the NN NN O
separation NN NN O
of NN NN O
cells NN NN O
from NN NN O
unbound NN NN O
ligand NN NN O
. NN NN O
   
Though NN NN O
specifically NN NN O
bound NN NN O
dexamethasone NN NN O
measured NN NN O
by NN NN O
whole NN NN O
- NN NN O
cell NN NN O
assay NN NN O
and NN NN O
that NN NN O
using NN NN O
cell NN NN O
harvester NN NN O
correlated NN NN O
well NN NN O
, NN NN O
almost NN NN O
by NN NN O
one NN NN O
order NN NN O
lower NN NN O
values NN NN O
obtained NN NN O
with NN NN O
the NN NN O
latter NN NN O
method NN NN O
render NN NN O
it NN NN O
non NN NN O
- NN NN O
applicable NN NN O
for NN NN O
receptor NN NN O
quantitation NN NN O
. NN NN O
   
The NN NN O
results NN NN O
from NN NN O
9 NN NN O
healthy NN NN O
volunteers NN NN O
( NN NN O
average NN NN O
GR NN NN B-Protein
concentration NN NN O
7131 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1256 NN NN O
sites NN NN O
/ NN NN O
cell NN NN O
) NN NN O
correlated NN NN O
excellently NN NN O
with NN NN O
those NN NN O
obtained NN NN O
by NN NN O
the NN NN O
Scatchard NN NN O
analysis NN NN O
. NN NN O
   
The NN NN O
single NN NN O
point NN NN O
assay NN NN O
has NN NN O
been NN NN O
also NN NN O
applied NN NN O
for NN NN O
determination NN NN O
of NN NN O
GH NN NN O
in NN NN O
10 NN NN O
children NN NN O
treated NN NN O
with NN NN O
large NN NN O
doses NN NN O
of NN NN O
prednisone NN NN O
. NN NN O
   
The NN NN O
average NN NN O
values NN NN O
from NN NN O
healthy NN NN O
volunteers NN NN O
did NN NN O
not NN NN O
differ NN NN O
significantly NN NN O
from NN NN O
those NN NN O
found NN NN O
in NN NN O
these NN NN O
children NN NN O
, NN NN O
though NN NN O
much NN NN O
broader NN NN O
range NN NN O
was NN NN O
found NN NN O
in NN NN O
patients NN NN O
. NN NN O
   
A NN NN O
novel NN NN O
B NN NN O
cell NN NN O
- NN NN O
derived NN NN O
coactivator NN NN O
potentiates NN NN O
the NN NN O
activation NN NN O
of NN NN O
immunoglobulin NN NN O
promoters NN NN O
by NN NN O
octamer NN NN O
- NN NN O
binding NN NN O
transcription NN NN O
factors NN NN O
. NN NN O
   
A NN NN O
novel NN NN O
B NN NN O
cell NN NN O
- NN NN O
restricted NN NN O
activity NN NN O
, NN NN O
required NN NN O
for NN NN O
high NN NN O
levels NN NN O
of NN NN O
octamer NN NN O
/ NN NN O
Oct NN NN O
- NN NN O
dependent NN NN O
transcription NN NN O
from NN NN O
an NN NN O
immunoglobulin NN NN O
heavy NN NN O
chain NN NN O
( NN NN O
IgH NN NN O
) NN NN O
promoter NN NN O
, NN NN O
was NN NN O
detected NN NN O
in NN NN O
an NN NN O
in NN NN O
vitro NN NN O
system NN NN O
consisting NN NN O
of NN NN O
HeLa NN NN O
cell NN NN O
- NN NN O
derived NN NN O
extracts NN NN O
complemented NN NN O
with NN NN O
fractionated NN NN O
B NN NN O
cell NN NN O
nuclear NN NN O
proteins NN NN O
. NN NN O
   
The NN NN O
factor NN NN O
responsible NN NN O
for NN NN O
this NN NN O
activity NN NN O
was NN NN O
designated NN NN O
Oct NN NN O
coactivator NN NN O
from NN NN O
B NN NN O
cells NN NN O
( NN NN O
OCA NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
) NN NN O
. NN NN O
   
OCA NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
stimulates NN NN O
the NN NN O
transcription NN NN O
from NN NN O
an NN NN O
IgH NN NN O
promoter NN NN O
in NN NN O
conjunction NN NN O
with NN NN O
either NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
or NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
but NN NN O
shows NN NN O
no NN NN O
significant NN NN O
effect NN NN O
on NN NN O
the NN NN O
octamer NN NN O
/ NN NN O
Oct NN NN O
- NN NN O
dependent NN NN O
transcription NN NN O
of NN NN O
the NN NN O
ubiquitously NN NN O
expressed NN NN O
histone NN NN O
H2B NN NN O
promoter NN NN O
and NN NN O
the NN NN O
transcription NN NN O
of NN NN O
USF NN NN B-Protein
- NN NN O
and NN NN O
Sp1 NN NN B-Protein
- NN NN O
regulated NN NN O
promoters NN NN O
. NN NN O
   
Taken NN NN O
together NN NN O
, NN NN O
our NN NN O
results NN NN O
suggest NN NN O
that NN NN O
OCA NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
is NN NN O
a NN NN O
tissue NN NN O
- NN NN O
, NN NN O
promoter NN NN O
- NN NN O
, NN NN O
and NN NN O
factor NN NN O
- NN NN O
specific NN NN O
coactivator NN NN O
and NN NN O
that NN NN O
OCA NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
may NN NN O
be NN NN O
a NN NN O
major NN NN O
determinant NN NN O
for NN NN O
B NN NN O
cell NN NN O
- NN NN O
specific NN NN O
activation NN NN O
of NN NN O
immunoglobulin NN NN O
promoters NN NN O
. NN NN O
   
In NN NN O
light NN NN O
of NN NN O
the NN NN O
evidence NN NN O
showing NN NN O
physical NN NN O
and NN NN O
functional NN NN O
interactions NN NN O
between NN NN O
Oct NN NN O
factors NN NN O
and NN NN O
OCA NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
, NN NN O
we NN NN O
propose NN NN O
a NN NN O
mechanism NN NN O
of NN NN O
action NN NN O
for NN NN O
OCA NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
and NN NN O
discuss NN NN O
the NN NN O
implications NN NN O
of NN NN O
OCA NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
for NN NN O
the NN NN O
transcriptional NN NN O
regulation NN NN O
of NN NN O
other NN NN O
tissue NN NN O
- NN NN O
specific NN NN O
promoters NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
and NN NN O
jun NN NN B-Protein
B NN NN I-Protein
in NN NN O
peripheral NN NN O
blood NN NN O
lymphocytes NN NN O
from NN NN O
young NN NN O
and NN NN O
elderly NN NN O
adults NN NN O
. NN NN O
   
The NN NN O
expression NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
and NN NN O
jun NN NN B-Protein
B NN NN I-Protein
proto NN NN O
- NN NN O
oncogenes NN NN O
was NN NN O
studied NN NN O
in NN NN O
phytohemagglutinin NN NN B-Protein
( NN NN O
PHA NN NN B-Protein
) NN NN O
activated NN NN O
peripheral NN NN O
blood NN NN O
lymphocytes NN NN O
( NN NN O
PBL NN NN O
) NN NN O
from NN NN O
young NN NN O
and NN NN O
aged NN NN O
humans NN NN O
. NN NN O
   
Specific NN NN O
mRNAs NN NN O
for NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
were NN NN O
detectable NN NN O
within NN NN O
30 NN NN O
min NN NN O
after NN NN O
cell NN NN O
activation NN NN O
and NN NN O
reached NN NN O
maximal NN NN O
levels NN NN O
within NN NN O
2 NN NN O
h NN NN O
. NN NN O
   
Both NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
and NN NN O
jun NN NN B-Protein
B NN NN I-Protein
mRNAs NN NN O
decreased NN NN O
to NN NN O
pre NN NN O
- NN NN O
activation NN NN O
levels NN NN O
within NN NN O
6 NN NN O
h NN NN O
, NN NN O
while NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
mRNA NN NN O
remained NN NN O
elevated NN NN O
. NN NN O
   
In NN NN O
PHA NN NN B-Protein
- NN NN O
activated NN NN O
PBL NN NN O
, NN NN O
no NN NN O
age NN NN O
- NN NN O
related NN NN O
differences NN NN O
were NN NN O
observed NN NN O
in NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
or NN NN O
jun NN NN B-Protein
B NN NN I-Protein
mRNA NN NN O
expression NN NN O
. NN NN O
   
However NN NN O
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
mRNA NN NN O
levels NN NN O
decreased NN NN O
significantly NN NN O
( NN NN O
1 NN NN O
. NN NN O
73 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
08 NN NN O
vs NN NN O
. NN NN O
1 NN NN O
. NN NN O
16 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
09 NN NN O
arbitrary NN NN O
units NN NN O
, NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
, NN NN O
young NN NN O
vs NN NN O
. NN NN O
old NN NN O
) NN NN O
in NN NN O
PBL NN NN O
from NN NN O
elderly NN NN O
individuals NN NN O
activated NN NN O
with NN NN O
PHA NN NN B-Protein
. NN NN O
   
Because NN NN O
previous NN NN O
work NN NN O
has NN NN O
demonstrated NN NN O
that NN NN O
T NN NN O
cells NN NN O
from NN NN O
elderly NN NN O
individuals NN NN O
may NN NN O
display NN NN O
normal NN NN O
proliferative NN NN O
responses NN NN O
when NN NN O
activated NN NN O
via NN NN O
the NN NN O
anti NN NN O
- NN NN O
CD2 NN NN B-Protein
pathway NN NN O
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
and NN NN O
jun NN NN B-Protein
B NN NN I-Protein
mRNA NN NN O
expression NN NN O
was NN NN O
also NN NN O
studied NN NN O
in NN NN O
anti NN NN O
- NN NN O
CD2 NN NN B-Protein
- NN NN O
activated NN NN O
purified NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
No NN NN O
age NN NN O
- NN NN O
related NN NN O
differences NN NN O
were NN NN O
found NN NN O
in NN NN O
the NN NN O
expression NN NN O
of NN NN O
either NN NN O
of NN NN O
these NN NN O
two NN NN O
proto NN NN O
- NN NN O
oncogenes NN NN O
by NN NN O
anti NN NN O
- NN NN O
CD2 NN NN B-Protein
activated NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
the NN NN O
decreased NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
production NN NN O
and NN NN O
proliferative NN NN O
response NN NN O
displayed NN NN O
by NN NN O
PHA NN NN B-Protein
- NN NN O
activated NN NN O
PBL NN NN O
from NN NN O
elderly NN NN O
adults NN NN O
may NN NN O
be NN NN O
related NN NN O
to NN NN O
age NN NN O
- NN NN O
related NN NN O
changes NN NN O
in NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
mRNA NN NN O
expression NN NN O
and NN NN O
in NN NN O
the NN NN O
ratio NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
to NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
mRNA NN NN O
. NN NN O
   
SCL NN NN B-Protein
and NN NN O
related NN NN O
hemopoietic NN NN O
helix NN NN O
- NN NN O
loop NN NN O
- NN NN O
helix NN NN O
transcription NN NN O
factors NN NN O
. NN NN O
   
The NN NN O
helix NN NN O
- NN NN O
loop NN NN O
- NN NN O
helix NN NN O
( NN NN O
HLH NN NN O
) NN NN O
proteins NN NN O
are NN NN O
a NN NN O
family NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
that NN NN O
include NN NN O
proteins NN NN O
critical NN NN O
to NN NN O
differentiation NN NN O
and NN NN O
development NN NN O
in NN NN O
species NN NN O
ranging NN NN O
from NN NN O
plants NN NN O
to NN NN O
mammals NN NN O
. NN NN O
   
Five NN NN O
members NN NN O
of NN NN O
this NN NN O
family NN NN O
( NN NN O
MYC NN NN O
, NN NN O
SCL NN NN B-Protein
, NN NN O
TAL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
LYL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
E2A NN NN B-Protein
) NN NN O
are NN NN O
implicated NN NN O
in NN NN O
oncogenic NN NN O
events NN NN O
in NN NN O
human NN NN O
lymphoid NN NN O
tumors NN NN O
because NN NN O
of NN NN O
their NN NN O
consistent NN NN O
involvement NN NN O
in NN NN O
chromosomal NN NN O
translocations NN NN O
. NN NN O
   
Although NN NN O
activated NN NN O
in NN NN O
T NN NN O
cell NN NN O
leukemias NN NN O
, NN NN O
expression NN NN O
of NN NN O
SCL NN NN B-Protein
and NN NN O
LYL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
is NN NN O
low NN NN O
or NN NN O
undetectable NN NN O
in NN NN O
normal NN NN O
T NN NN O
cell NN NN O
populations NN NN O
. NN NN O
   
SCL NN NN B-Protein
is NN NN O
expressed NN NN O
in NN NN O
erythroid NN NN O
, NN NN O
megakaryocyte NN NN O
and NN NN O
mast NN NN O
cell NN NN O
populations NN NN O
( NN NN O
the NN NN O
same NN NN O
cell NN NN O
lineages NN NN O
as NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
a NN NN O
zinc NN NN O
- NN NN O
finger NN NN O
transcription NN NN O
factor NN NN O
) NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
both NN NN O
SCL NN NN B-Protein
and NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
undergo NN NN O
coordinate NN NN O
modulation NN NN O
during NN NN O
chemically NN NN O
induced NN NN O
erythroid NN NN O
differentiation NN NN O
of NN NN O
mouse NN NN O
erythroleukemia NN NN O
cells NN NN O
and NN NN O
are NN NN O
down NN NN O
- NN NN O
modulated NN NN O
during NN NN O
myeloid NN NN O
differentiation NN NN O
of NN NN O
human NN NN O
K562 NN NN O
cells NN NN O
, NN NN O
thus NN NN O
implying NN NN O
a NN NN O
role NN NN O
for NN NN O
SCL NN NN B-Protein
in NN NN O
erythroid NN NN O
differentiation NN NN O
events NN NN O
. NN NN O
   
However NN NN O
, NN NN O
in NN NN O
contrast NN NN O
to NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
SCL NN NN B-Protein
is NN NN O
expressed NN NN O
in NN NN O
the NN NN O
developing NN NN O
brain NN NN O
. NN NN O
   
Studies NN NN O
of NN NN O
the NN NN O
function NN NN O
of NN NN O
SCL NN NN B-Protein
suggest NN NN O
it NN NN O
is NN NN O
also NN NN O
important NN NN O
in NN NN O
proliferation NN NN O
and NN NN O
self NN NN O
- NN NN O
renewal NN NN O
events NN NN O
in NN NN O
erythroid NN NN O
cells NN NN O
. NN NN O
   
Mutations NN NN O
in NN NN O
the NN NN O
Pit NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
in NN NN O
children NN NN O
with NN NN O
combined NN NN O
pituitary NN NN O
hormone NN NN O
deficiency NN NN O
. NN NN O
   
Pit NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
is NN NN O
a NN NN O
pituitary NN NN O
- NN NN O
specific NN NN O
transcription NN NN O
factor NN NN O
that NN NN O
binds NN NN O
to NN NN O
and NN NN O
transactivates NN NN O
promoters NN NN O
of NN NN O
growth NN NN O
hormone NN NN O
and NN NN O
prolactin NN NN O
genes NN NN O
. NN NN O
   
In NN NN O
three NN NN O
unrelated NN NN O
Japanese NN NN O
children NN NN O
with NN NN O
combined NN NN O
pituitary NN NN O
hormone NN NN O
deficiency NN NN O
, NN NN O
we NN NN O
identified NN NN O
three NN NN O
point NN NN O
mutations NN NN O
in NN NN O
the NN NN O
Pit NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
, NN NN O
Pro24Leu NN NN O
, NN NN O
Arg143Gln NN NN O
, NN NN O
and NN NN O
Arg271Trp NN NN O
, NN NN O
located NN NN O
on NN NN O
the NN NN O
major NN NN O
transactivation NN NN O
region NN NN O
, NN NN O
POU NN NN O
- NN NN O
specific NN NN O
domain NN NN O
, NN NN O
and NN NN O
POU NN NN O
- NN NN O
homeodomain NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Cell NN NN O
cycle NN NN O
- NN NN O
dependent NN NN O
initiation NN NN O
and NN NN O
lineage NN NN O
- NN NN O
dependent NN NN O
abrogation NN NN O
of NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
in NN NN O
pure NN NN O
differentiating NN NN O
hematopoietic NN NN O
progenitors NN NN O
. NN NN O
   
The NN NN O
programmed NN NN O
activation NN NN O
/ NN NN O
repression NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
in NN NN O
early NN NN O
hematopoietic NN NN O
differentiation NN NN O
has NN NN O
not NN NN O
yet NN NN O
been NN NN O
explored NN NN O
. NN NN O
   
The NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
protein NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
is NN NN O
required NN NN O
for NN NN O
normal NN NN O
erythroid NN NN O
development NN NN O
and NN NN O
regulates NN NN O
erythroid NN NN O
- NN NN O
expressed NN NN O
genes NN NN O
in NN NN O
maturing NN NN O
erythroblasts NN NN O
. NN NN O
   
We NN NN O
analyzed NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
in NN NN O
early NN NN O
human NN NN O
adult NN NN O
hematopoiesis NN NN O
by NN NN O
using NN NN O
an NN NN O
in NN NN O
vitro NN NN O
system NN NN O
in NN NN O
which NN NN O
"""""""" NN NN O
pure NN NN O
"""""""" NN NN O
early NN NN O
hematopoietic NN NN O
progenitors NN NN O
are NN NN O
induced NN NN O
to NN NN O
gradual NN NN O
and NN NN O
synchronized NN NN O
differentiation NN NN O
selectively NN NN O
along NN NN O
the NN NN O
erythroid NN NN O
or NN NN O
granulocyte NN NN O
- NN NN O
macrophage NN NN O
pathway NN NN O
by NN NN O
differential NN NN O
treatment NN NN O
with NN NN O
hematopoietic NN NN O
growth NN NN O
factors NN NN O
. NN NN O
   
The NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
, NN NN O
though NN NN O
virtually NN NN O
silent NN NN O
in NN NN O
quiescent NN NN O
progenitors NN NN O
, NN NN O
is NN NN O
activated NN NN O
after NN NN O
entrance NN NN O
into NN NN O
the NN NN O
cell NN NN O
cycle NN NN O
upon NN NN O
stimulation NN NN O
with NN NN O
hematopoietic NN NN O
growth NN NN O
factors NN NN O
. NN NN O
   
Subsequently NN NN O
, NN NN O
increasing NN NN O
expression NN NN O
along NN NN O
the NN NN O
erythroid NN NN O
pathway NN NN O
contrasts NN NN O
with NN NN O
an NN NN O
abrupt NN NN O
downregulation NN NN O
in NN NN O
the NN NN O
granulocyte NN NN O
- NN NN O
macrophage NN NN O
lineage NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
a NN NN O
microenvironment NN NN O
- NN NN O
directed NN NN O
, NN NN O
two NN NN O
- NN NN O
step NN NN O
model NN NN O
for NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
in NN NN O
differentiating NN NN O
hematopoietic NN NN O
progenitors NN NN O
that NN NN O
involves NN NN O
( NN NN O
i NN NN O
) NN NN O
cycle NN NN O
- NN NN O
dependent NN NN O
initiation NN NN O
and NN NN O
( NN NN O
ii NN NN O
) NN NN O
lineage NN NN O
- NN NN O
dependent NN NN O
maintenance NN NN O
or NN NN O
suppression NN NN O
. NN NN O
   
Hypothetically NN NN O
, NN NN O
on NN NN O
/ NN NN O
off NN NN O
switches NN NN O
of NN NN O
lineage NN NN O
- NN NN O
restricted NN NN O
transactivators NN NN O
may NN NN O
underlie NN NN O
the NN NN O
binary NN NN O
fate NN NN O
decisions NN NN O
of NN NN O
hematopoietic NN NN O
progenitors NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
human NN NN O
CD4 NN NN B-Protein
T NN NN O
lymphocytes NN NN O
. NN NN O
   
Interaction NN NN O
of NN NN O
fibronectin NN NN B-Protein
with NN NN O
VLA NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
receptor NN NN I-Protein
on NN NN O
CD4 NN NN B-Protein
cells NN NN O
induces NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
transcription NN NN O
factor NN NN O
. NN NN O
   
Fibronectin NN NN B-Protein
synergized NN NN O
with NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
antibody NN NN O
to NN NN O
promote NN NN O
CD4 NN NN B-Protein
cell NN NN O
proliferation NN NN O
in NN NN O
a NN NN O
serum NN NN O
- NN NN O
free NN NN O
culture NN NN O
system NN NN O
whereas NN NN O
no NN NN O
proliferation NN NN O
was NN NN O
observed NN NN O
when NN NN O
CD4 NN NN B-Protein
cells NN NN O
were NN NN O
cultured NN NN O
with NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
alone NN NN O
or NN NN O
fibronectin NN NN B-Protein
alone NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
anti NN NN O
- NN NN O
CD29 NN NN B-Protein
( NN NN O
integrin NN NN B-Protein
beta NN NN I-Protein
1 NN NN I-Protein
) NN NN O
as NN NN O
well NN NN O
as NN NN O
anti NN NN O
- NN NN O
VLA NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
( NN NN O
human NN NN O
fibronectin NN NN O
receptor NN NN O
) NN NN O
antibodies NN NN O
blocked NN NN O
this NN NN O
CD4 NN NN B-Protein
cell NN NN O
activation NN NN O
in NN NN O
this NN NN O
system NN NN O
. NN NN O
   
Although NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
alone NN NN O
or NN NN O
fibronectin NN NN B-Protein
alone NN NN O
cannot NN NN O
induce NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
message NN NN O
by NN NN O
CD4 NN NN B-Protein
cells NN NN O
, NN NN O
the NN NN O
combination NN NN O
of NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
plus NN NN O
fibronectin NN NN B-Protein
induced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
message NN NN O
by NN NN O
CD4 NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
an NN NN O
analysis NN NN O
of NN NN O
the NN NN O
molecular NN NN O
mechanism NN NN O
by NN NN O
which NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
message NN NN O
was NN NN O
generated NN NN O
, NN NN O
we NN NN O
showed NN NN O
that NN NN O
a NN NN O
fibronectin NN NN B-Protein
- NN NN O
VLA NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
fibronectin NN NN B-Protein
receptor NN NN O
interaction NN NN O
may NN NN O
contribute NN NN O
an NN NN O
independent NN NN O
signal NN NN O
distinct NN NN O
from NN NN O
the NN NN O
CD3 NN NN O
pathway NN NN O
of NN NN O
activation NN NN O
by NN NN O
the NN NN O
induction NN NN O
of NN NN O
an NN NN O
AP NN NN O
- NN NN O
1 NN NN O
transcriptional NN NN O
factor NN NN O
. NN NN O
   
Thus NN NN O
the NN NN O
VLA NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
fibronectin NN NN I-Protein
receptor NN NN I-Protein
on NN NN O
CD4 NN NN B-Protein
cells NN NN O
can NN NN O
play NN NN O
a NN NN O
complementary NN NN O
role NN NN O
in NN NN O
CD3 NN NN O
- NN NN O
TCR NN NN O
- NN NN O
mediated NN NN O
signal NN NN O
transduction NN NN O
through NN NN O
its NN NN O
interaction NN NN O
with NN NN O
fibronectin NN NN B-Protein
. NN NN O
   
1 NN NN B-Protein
, NN NN I-Protein
25 NN NN I-Protein
- NN NN I-Protein
Dihydroxyvitamin NN NN I-Protein
D3 NN NN I-Protein
receptor NN NN I-Protein
RNA NN NN O
: NN NN O
expression NN NN O
in NN NN O
hematopoietic NN NN O
cells NN NN O
. NN NN O
   
1 NN NN O
, NN NN O
25 NN NN O
- NN NN O
Dihydroxyvitamin NN NN O
D3 NN NN O
[ NN NN O
1 NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
] NN NN O
induces NN NN O
differentiation NN NN O
and NN NN O
inhibits NN NN O
proliferation NN NN O
of NN NN O
myeloid NN NN O
leukemic NN NN O
cells NN NN O
from NN NN O
various NN NN O
lines NN NN O
and NN NN O
patients NN NN O
; NN NN O
these NN NN O
effects NN NN O
are NN NN O
probably NN NN O
mediated NN NN O
through NN NN O
the NN NN O
1 NN NN B-Protein
, NN NN I-Protein
25 NN NN I-Protein
( NN NN I-Protein
OH NN NN I-Protein
) NN NN I-Protein
2D3 NN NN I-Protein
receptor NN NN I-Protein
. NN NN O
   
Little NN NN O
is NN NN O
known NN NN O
of NN NN O
expression NN NN O
of NN NN O
1 NN NN B-Protein
, NN NN I-Protein
25 NN NN I-Protein
( NN NN I-Protein
OH NN NN I-Protein
) NN NN I-Protein
2D3 NN NN I-Protein
receptor NN NN I-Protein
RNA NN NN O
in NN NN O
hematopoietic NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
examined NN NN O
the NN NN O
expression NN NN O
and NN NN O
modulation NN NN O
of NN NN O
expression NN NN O
of NN NN O
1 NN NN B-Protein
, NN NN I-Protein
25 NN NN I-Protein
( NN NN I-Protein
OH NN NN I-Protein
) NN NN I-Protein
2D3 NN NN I-Protein
receptor NN NN I-Protein
RNA NN NN O
in NN NN O
various NN NN O
proliferating NN NN O
and NN NN O
nonproliferating NN NN O
hematopoietic NN NN O
cells NN NN O
. NN NN O
   
Constitutive NN NN O
expression NN NN O
of NN NN O
1 NN NN B-Protein
, NN NN I-Protein
25 NN NN I-Protein
( NN NN I-Protein
OH NN NN I-Protein
) NN NN I-Protein
2D3 NN NN I-Protein
receptor NN NN I-Protein
RNA NN NN O
was NN NN O
detected NN NN O
in NN NN O
various NN NN O
kinds NN NN O
of NN NN O
hematopoietic NN NN O
cells NN NN O
, NN NN O
including NN NN O
macrophages NN NN O
and NN NN O
activated NN NN O
T NN NN O
lymphocytes NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
in NN NN O
cell NN NN O
lines NN NN O
KG NN NN O
- NN NN O
1 NN NN O
( NN NN O
myeloblasts NN NN O
) NN NN O
, NN NN O
HL NN NN O
- NN NN O
60 NN NN O
( NN NN O
promyelocytes NN NN O
) NN NN O
, NN NN O
ML NN NN O
- NN NN O
3 NN NN O
( NN NN O
myelomonoblasts NN NN O
) NN NN O
, NN NN O
U937 NN NN O
, NN NN O
THP NN NN O
- NN NN O
1 NN NN O
( NN NN O
monoblasts NN NN O
) NN NN O
, NN NN O
K562 NN NN O
( NN NN O
erythroblasts NN NN O
) NN NN O
, NN NN O
and NN NN O
S NN NN O
- NN NN O
LB1 NN NN O
( NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
- NN NN O
transfected NN NN O
T NN NN O
lymphocytes NN NN O
) NN NN O
. NN NN O
   
Receptor NN NN O
transcripts NN NN O
were NN NN O
4 NN NN O
. NN NN O
6 NN NN O
kilobases NN NN O
( NN NN O
kb NN NN O
) NN NN O
, NN NN O
and NN NN O
no NN NN O
variant NN NN O
sizes NN NN O
were NN NN O
observed NN NN O
. NN NN O
   
All NN NN O
cell NN NN O
lines NN NN O
examined NN NN O
in NN NN O
this NN NN O
group NN NN O
also NN NN O
expressed NN NN O
1 NN NN B-Protein
, NN NN I-Protein
25 NN NN I-Protein
( NN NN I-Protein
OH NN NN I-Protein
) NN NN I-Protein
2D3 NN NN I-Protein
receptors NN NN I-Protein
. NN NN O
   
Most NN NN O
B NN NN O
lymphocyte NN NN O
lines NN NN O
expressed NN NN O
negligible NN NN O
levels NN NN O
of NN NN O
1 NN NN B-Protein
, NN NN I-Protein
25 NN NN I-Protein
( NN NN I-Protein
OH NN NN I-Protein
) NN NN I-Protein
2D3 NN NN I-Protein
receptor NN NN I-Protein
RNA NN NN O
and NN NN O
protein NN NN O
; NN NN O
however NN NN O
; NN NN O
analysis NN NN O
of NN NN O
a NN NN O
lymphoid NN NN O
/ NN NN O
myeloid NN NN O
somatic NN NN O
hybrid NN NN O
suggested NN NN O
that NN NN O
suppression NN NN O
of NN NN O
expression NN NN O
of NN NN O
1 NN NN B-Protein
, NN NN I-Protein
25 NN NN I-Protein
( NN NN I-Protein
OH NN NN I-Protein
) NN NN I-Protein
2D3 NN NN I-Protein
receptor NN NN I-Protein
RNA NN NN O
in NN NN O
B NN NN O
lymphocytes NN NN O
may NN NN O
be NN NN O
a NN NN O
dominant NN NN O
characteristic NN NN O
. NN NN O
   
HL NN NN O
- NN NN O
60 NN NN O
cells NN NN O
were NN NN O
cultured NN NN O
with NN NN O
10 NN NN O
( NN NN O
- NN NN O
7 NN NN O
) NN NN O
mol NN NN O
/ NN NN O
L NN NN O
1 NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
for NN NN O
24 NN NN O
to NN NN O
72 NN NN O
hours NN NN O
, NN NN O
and NN NN O
levels NN NN O
of NN NN O
expression NN NN O
of NN NN O
1 NN NN B-Protein
, NN NN I-Protein
25 NN NN I-Protein
( NN NN I-Protein
OH NN NN I-Protein
) NN NN I-Protein
2D3 NN NN I-Protein
receptor NN NN I-Protein
and NN NN O
its NN NN O
RNA NN NN O
were NN NN O
examined NN NN O
. NN NN O
   
Levels NN NN O
of NN NN O
RNA NN NN O
coding NN NN O
for NN NN O
the NN NN O
receptor NN NN O
were NN NN O
not NN NN O
modulated NN NN O
by NN NN O
exposure NN NN O
to NN NN O
high NN NN O
levels NN NN O
of NN NN O
ligand NN NN O
. NN NN O
   
Levels NN NN O
of NN NN O
occupied NN NN O
1 NN NN B-Protein
, NN NN I-Protein
25 NN NN I-Protein
( NN NN I-Protein
OH NN NN I-Protein
) NN NN I-Protein
2D3 NN NN I-Protein
receptor NN NN I-Protein
protein NN NN O
increased NN NN O
in NN NN O
these NN NN O
HL NN NN O
- NN NN O
60 NN NN O
cells NN NN O
; NN NN O
but NN NN O
the NN NN O
total NN NN O
number NN NN O
of NN NN O
1 NN NN B-Protein
, NN NN I-Protein
25 NN NN I-Protein
( NN NN I-Protein
OH NN NN I-Protein
) NN NN I-Protein
2D3 NN NN I-Protein
receptors NN NN I-Protein
decreased NN NN O
about NN NN O
50 NN NN O
% NN NN O
at NN NN O
24 NN NN O
hours NN NN O
and NN NN O
returned NN NN O
toward NN NN O
normal NN NN O
at NN NN O
72 NN NN O
hours NN NN O
. NN NN O
   
Steady NN NN O
- NN NN O
state NN NN O
levels NN NN O
of NN NN O
1 NN NN B-Protein
, NN NN I-Protein
25 NN NN I-Protein
( NN NN I-Protein
OH NN NN I-Protein
) NN NN I-Protein
2D3 NN NN I-Protein
receptor NN NN I-Protein
RNA NN NN O
were NN NN O
not NN NN O
affected NN NN O
by NN NN O
terminal NN NN O
differentiation NN NN O
of NN NN O
HL NN NN O
- NN NN O
60 NN NN O
toward NN NN O
either NN NN O
granulocytes NN NN O
or NN NN O
macrophages NN NN O
. NN NN O
   
Nondividing NN NN O
macrophages NN NN O
from NN NN O
normal NN NN O
individuals NN NN O
also NN NN O
expressed NN NN O
1 NN NN B-Protein
, NN NN I-Protein
25 NN NN I-Protein
( NN NN I-Protein
OH NN NN I-Protein
) NN NN I-Protein
2D3 NN NN I-Protein
receptor NN NN I-Protein
RNA NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
nondividing NN NN O
peripheral NN NN O
blood NN NN O
lymphocytes NN NN O
from NN NN O
normal NN NN O
individuals NN NN O
did NN NN O
not NN NN O
express NN NN O
1 NN NN B-Protein
, NN NN I-Protein
25 NN NN I-Protein
( NN NN I-Protein
OH NN NN I-Protein
) NN NN I-Protein
2D3 NN NN I-Protein
receptor NN NN I-Protein
RNA NN NN O
; NN NN O
with NN NN O
stimulation NN NN O
of NN NN O
proliferation NN NN O
of NN NN O
these NN NN O
cells NN NN O
, NN NN O
accumulation NN NN O
of NN NN O
1 NN NN B-Protein
, NN NN I-Protein
25 NN NN I-Protein
( NN NN I-Protein
OH NN NN I-Protein
) NN NN I-Protein
2D3 NN NN I-Protein
receptor NN NN I-Protein
RNA NN NN O
increased NN NN O
markedly NN NN O
. NN NN O
   
Half NN NN O
- NN NN O
life NN NN O
( NN NN O
t1 NN NN O
/ NN NN O
2 NN NN O
) NN NN O
of NN NN O
1 NN NN B-Protein
, NN NN I-Protein
25 NN NN I-Protein
( NN NN I-Protein
OH NN NN I-Protein
) NN NN I-Protein
2D3 NN NN I-Protein
receptor NN NN I-Protein
RNA NN NN O
in NN NN O
T NN NN O
lymphocytes NN NN O
was NN NN O
short NN NN O
( NN NN O
1 NN NN O
hour NN NN O
) NN NN O
as NN NN O
determined NN NN O
by NN NN O
measuring NN NN O
decay NN NN O
of NN NN O
the NN NN O
message NN NN O
after NN NN O
addition NN NN O
of NN NN O
actinomycin NN NN O
D NN NN O
. NN NN O
   
Consistent NN NN O
with NN NN O
this NN NN O
short NN NN O
t1 NN NN O
/ NN NN O
2 NN NN O
, NN NN O
accumulation NN NN O
of NN NN O
1 NN NN B-Protein
, NN NN I-Protein
25 NN NN I-Protein
( NN NN I-Protein
OH NN NN I-Protein
) NN NN I-Protein
2D3 NN NN I-Protein
receptor NN NN I-Protein
RNA NN NN O
increased NN NN O
in NN NN O
cells NN NN O
as NN NN O
their NN NN O
protein NN NN O
synthesis NN NN O
was NN NN O
inhibited NN NN O
. NN NN O
   
Further NN NN O
studies NN NN O
are NN NN O
required NN NN O
to NN NN O
understand NN NN O
the NN NN O
physiologic NN NN O
role NN NN O
of NN NN O
1 NN NN B-Protein
, NN NN I-Protein
25 NN NN I-Protein
( NN NN I-Protein
OH NN NN I-Protein
) NN NN I-Protein
2D3 NN NN I-Protein
receptors NN NN I-Protein
in NN NN O
myeloid NN NN O
cells NN NN O
and NN NN O
proliferating NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
Charybdotoxin NN NN O
- NN NN O
sensitive NN NN O
, NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
- NN NN O
dependent NN NN O
membrane NN NN O
potential NN NN O
changes NN NN O
are NN NN O
not NN NN O
involved NN NN O
in NN NN O
human NN NN O
T NN NN O
or NN NN O
B NN NN O
cell NN NN O
activation NN NN O
and NN NN O
proliferation NN NN O
. NN NN O
   
The NN NN O
involvement NN NN O
of NN NN O
ion NN NN O
channels NN NN O
in NN NN O
B NN NN O
and NN NN O
T NN NN O
lymphocyte NN NN O
activation NN NN O
is NN NN O
supported NN NN O
by NN NN O
many NN NN O
reports NN NN O
of NN NN O
changes NN NN O
in NN NN O
ion NN NN O
fluxes NN NN O
and NN NN O
membrane NN NN O
potential NN NN O
after NN NN O
mitogen NN NN O
binding NN NN O
. NN NN O
   
Human NN NN O
T NN NN O
and NN NN O
B NN NN O
lymphocytes NN NN O
demonstrate NN NN O
an NN NN O
early NN NN O
and NN NN O
transient NN NN O
hyperpolarization NN NN O
after NN NN O
ligand NN NN O
binding NN NN O
. NN NN O
   
Inasmuch NN NN O
as NN NN O
the NN NN O
change NN NN O
in NN NN O
membrane NN NN O
potential NN NN O
is NN NN O
dependent NN NN O
on NN NN O
elevation NN NN O
of NN NN O
free NN NN O
cytosolic NN NN O
calcium NN NN O
, NN NN O
the NN NN O
hyperpolarization NN NN O
is NN NN O
presumably NN NN O
through NN NN O
opening NN NN O
of NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
- NN NN O
stimulated NN NN O
K NN NN O
+ NN NN O
channels NN NN O
. NN NN O
   
We NN NN O
have NN NN O
used NN NN O
charybdotoxin NN NN O
, NN NN O
a NN NN O
known NN NN O
inhibitor NN NN O
of NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
- NN NN O
dependent NN NN O
K NN NN O
+ NN NN O
channels NN NN O
, NN NN O
to NN NN O
study NN NN O
the NN NN O
role NN NN O
of NN NN O
these NN NN O
channels NN NN O
in NN NN O
lymphocyte NN NN O
activation NN NN O
and NN NN O
mitogenesis NN NN O
. NN NN O
   
We NN NN O
demonstrate NN NN O
that NN NN O
charybdotoxin NN NN O
inhibits NN NN O
the NN NN O
ligand NN NN O
- NN NN O
induced NN NN O
transient NN NN O
membrane NN NN O
hyperpolarization NN NN O
in NN NN O
B NN NN O
and NN NN O
T NN NN O
cells NN NN O
in NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
fashion NN NN O
, NN NN O
without NN NN O
affecting NN NN O
changes NN NN O
in NN NN O
cytosolic NN NN O
Ca2 NN NN O
+ NN NN O
. NN NN O
   
However NN NN O
, NN NN O
blockade NN NN O
of NN NN O
the NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
- NN NN O
activated NN NN O
K NN NN O
+ NN NN O
channel NN NN O
is NN NN O
not NN NN O
associated NN NN O
with NN NN O
changes NN NN O
in NN NN O
cell NN NN O
- NN NN O
cycle NN NN O
gene NN NN O
activation NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
production NN NN O
, NN NN O
IL NN NN O
- NN NN O
2R NN NN O
expression NN NN O
or NN NN O
B NN NN O
and NN NN O
T NN NN O
cell NN NN O
mitogenesis NN NN O
. NN NN O
   
These NN NN O
results NN NN O
imply NN NN O
that NN NN O
membrane NN NN O
potential NN NN O
changes NN NN O
secondary NN NN O
to NN NN O
the NN NN O
ligand NN NN O
- NN NN O
dependent NN NN O
opening NN NN O
of NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
- NN NN O
activated NN NN O
K NN NN O
+ NN NN O
channels NN NN O
are NN NN O
not NN NN O
involved NN NN O
in NN NN O
B NN NN O
and NN NN O
T NN NN O
lymphocyte NN NN O
activation NN NN O
and NN NN O
mitogenesis NN NN O
. NN NN O
   
Cloning NN NN O
of NN NN O
murine NN NN O
TCF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
a NN NN O
T NN NN O
cell NN NN O
- NN NN O
specific NN NN O
transcription NN NN O
factor NN NN O
interacting NN NN O
with NN NN O
functional NN NN O
motifs NN NN O
in NN NN O
the NN NN O
CD3 NN NN O
- NN NN O
epsilon NN NN O
and NN NN O
T NN NN O
cell NN NN O
receptor NN NN O
alpha NN NN O
enhancers NN NN O
. NN NN O
   
CD3 NN NN B-Protein
- NN NN I-Protein
epsilon NN NN I-Protein
gene NN NN O
expression NN NN O
is NN NN O
confined NN NN O
to NN NN O
the NN NN O
T NN NN O
cell NN NN O
lineage NN NN O
. NN NN O
   
We NN NN O
have NN NN O
recently NN NN O
identified NN NN O
and NN NN O
cloned NN NN O
a NN NN O
human NN NN O
transcription NN NN O
factor NN NN O
, NN NN O
TCF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
that NN NN O
binds NN NN O
to NN NN O
a NN NN O
functional NN NN O
element NN NN O
in NN NN O
the NN NN O
T NN NN O
lymphocyte NN NN O
- NN NN O
specific NN NN O
enhancer NN NN O
of NN NN O
CD3 NN NN B-Protein
- NN NN I-Protein
epsilon NN NN I-Protein
. NN NN O
   
In NN NN O
a NN NN O
panel NN NN O
of NN NN O
human NN NN O
cell NN NN O
lines NN NN O
, NN NN O
TCF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
was NN NN O
restricted NN NN O
to NN NN O
T NN NN O
lineage NN NN O
cells NN NN O
. NN NN O
   
TCF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
belonged NN NN O
to NN NN O
a NN NN O
novel NN NN O
family NN NN O
of NN NN O
genes NN NN O
that NN NN O
contain NN NN O
the NN NN O
so NN NN O
- NN NN O
called NN NN O
high NN NN O
mobility NN NN O
group NN NN O
1 NN NN O
( NN NN O
HMG NN NN O
) NN NN O
box NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
report NN NN O
the NN NN O
cloning NN NN O
of NN NN O
murine NN NN O
TCF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
Two NN NN O
splice NN NN O
alternatives NN NN O
were NN NN O
identified NN NN O
that NN NN O
were NN NN O
not NN NN O
previously NN NN O
observed NN NN O
in NN NN O
human NN NN O
TCF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
Murine NN NN O
and NN NN O
human NN NN O
TCF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
displayed NN NN O
a NN NN O
95 NN NN O
. NN NN O
5 NN NN O
% NN NN O
overall NN NN O
amino NN NN O
acid NN NN O
homology NN NN O
. NN NN O
   
Recombinant NN NN O
murine NN NN O
and NN NN O
human NN NN O
TCF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
recognized NN NN O
the NN NN O
same NN NN O
sequence NN NN O
motif NN NN O
in NN NN O
the NN NN O
CD3 NN NN O
- NN NN O
epsilon NN NN O
enhancer NN NN O
as NN NN O
judged NN NN O
by NN NN O
gel NN NN O
retardation NN NN O
and NN NN O
methylation NN NN O
interference NN NN O
assays NN NN O
. NN NN O
   
With NN NN O
the NN NN O
murine NN NN O
cDNA NN NN O
clones NN NN O
several NN NN O
aspects NN NN O
of NN NN O
TCF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
were NN NN O
analyzed NN NN O
. NN NN O
   
First NN NN O
, NN NN O
deletion NN NN O
analysis NN NN O
revealed NN NN O
that NN NN O
a NN NN O
region NN NN O
of NN NN O
TCF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
containing NN NN O
the NN NN O
HMG NN NN O
box NN NN O
was NN NN O
sufficient NN NN O
for NN NN O
sequence NN NN O
- NN NN O
specific NN NN O
binding NN NN O
. NN NN O
   
Second NN NN O
, NN NN O
by NN NN O
high NN NN O
stringency NN NN O
Northern NN NN O
blotting NN NN O
and NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
, NN NN O
TCF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
was NN NN O
shown NN NN O
to NN NN O
be NN NN O
confined NN NN O
to NN NN O
the NN NN O
thymus NN NN O
and NN NN O
to NN NN O
the NN NN O
T NN NN O
cell NN NN O
areas NN NN O
of NN NN O
the NN NN O
spleen NN NN O
. NN NN O
   
Third NN NN O
, NN NN O
TCF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
bound NN NN O
specifically NN NN O
to NN NN O
a NN NN O
functional NN NN O
T NN NN O
cell NN NN O
- NN NN O
specific NN NN O
element NN NN O
in NN NN O
the NN NN O
T NN NN B-Protein
cell NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TCR NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
enhancer NN NN O
. NN NN O
   
The NN NN O
T NN NN O
lineage NN NN O
- NN NN O
specific NN NN O
expression NN NN O
and NN NN O
the NN NN O
affinity NN NN O
for NN NN O
functional NN NN O
motifs NN NN O
in NN NN O
the NN NN O
TCR NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
CD3 NN NN B-Protein
- NN NN I-Protein
epsilon NN NN I-Protein
enhancers NN NN O
imply NN NN O
an NN NN O
important NN NN O
role NN NN O
for NN NN O
TCF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
in NN NN O
the NN NN O
establishment NN NN O
of NN NN O
the NN NN O
mature NN NN O
T NN NN O
cell NN NN O
phenotype NN NN O
. NN NN O
   
HTLV NN NN O
- NN NN O
1 NN NN O
Tax NN NN B-Protein
induces NN NN O
expression NN NN O
of NN NN O
various NN NN O
immediate NN NN O
early NN NN O
serum NN NN O
responsive NN NN O
genes NN NN O
. NN NN O
   
Human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
) NN NN O
is NN NN O
an NN NN O
etiological NN NN O
agent NN NN O
of NN NN O
adult NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
( NN NN O
ATL NN NN O
) NN NN O
. NN NN O
   
We NN NN O
showed NN NN O
here NN NN O
by NN NN O
mobility NN NN O
- NN NN O
shift NN NN O
assay NN NN O
that NN NN O
T NN NN O
- NN NN O
cell NN NN O
lines NN NN O
transformed NN NN O
with NN NN O
the NN NN O
virus NN NN O
contained NN NN O
high NN NN O
levels NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
activities NN NN O
. NN NN O
   
Consistent NN NN O
with NN NN O
this NN NN O
result NN NN O
, NN NN O
these NN NN O
cell NN NN O
lines NN NN O
expressed NN NN O
increased NN NN O
levels NN NN O
of NN NN O
mRNAs NN NN O
encoding NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
proteins NN NN O
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
, NN NN O
Fra NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
, NN NN O
JunB NN NN B-Protein
, NN NN O
and NN NN O
JunD NN NN B-Protein
. NN NN O
   
Previously NN NN O
, NN NN O
transcription NN NN O
of NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
gene NN NN O
has NN NN O
been NN NN O
reported NN NN O
to NN NN O
be NN NN O
transactivated NN NN O
by NN NN O
the NN NN O
viral NN NN O
transcription NN NN O
factor NN NN O
, NN NN O
Tax1 NN NN B-Protein
. NN NN O
   
By NN NN O
using NN NN O
the NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
line NN NN O
( NN NN O
JPX NN NN O
- NN NN O
9 NN NN O
) NN NN O
, NN NN O
in NN NN O
which NN NN O
expression NN NN O
of NN NN O
the NN NN O
Tax1 NN NN B-Protein
is NN NN O
inducible NN NN O
, NN NN O
we NN NN O
showed NN NN O
that NN NN O
expression NN NN O
of NN NN O
mRNAs NN NN O
for NN NN O
Fra NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
, NN NN O
and NN NN O
JunD NN NN B-Protein
was NN NN O
also NN NN O
transactivated NN NN O
by NN NN O
Tax1 NN NN B-Protein
. NN NN O
   
Moreover NN NN O
, NN NN O
Tax1 NN NN B-Protein
activated NN NN O
expression NN NN O
of NN NN O
two NN NN O
other NN NN O
transcription NN NN O
factors NN NN O
having NN NN O
zinc NN NN O
finger NN NN O
motifs NN NN O
, NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
in NN NN O
the NN NN O
same NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
Tax1 NN NN B-Protein
- NN NN O
inducible NN NN O
transcription NN NN O
factors NN NN O
identified NN NN O
here NN NN O
are NN NN O
encoded NN NN O
by NN NN O
the NN NN O
members NN NN O
of NN NN O
immediate NN NN O
early NN NN O
genes NN NN O
under NN NN O
the NN NN O
control NN NN O
of NN NN O
growth NN NN O
signals NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
Tax1 NN NN B-Protein
was NN NN O
suggested NN NN O
to NN NN O
replace NN NN O
growth NN NN O
signals NN NN O
, NN NN O
at NN NN O
least NN NN O
in NN NN O
part NN NN O
, NN NN O
by NN NN O
this NN NN O
mechanism NN NN O
. NN NN O
   
Tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
mRNA NN NN O
accumulation NN NN O
in NN NN O
human NN NN O
myelomonocytic NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Role NN NN O
of NN NN O
transcriptional NN NN O
regulation NN NN O
by NN NN O
DNA NN NN O
sequence NN NN O
motifs NN NN O
and NN NN O
mRNA NN NN O
stabilization NN NN O
. NN NN O
   
The NN NN O
cytokine NN NN O
TNF NN NN B-Protein
mediates NN NN O
many NN NN O
of NN NN O
the NN NN O
pathologic NN NN O
signs NN NN O
of NN NN O
cachexia NN NN O
, NN NN O
inflammation NN NN O
, NN NN O
and NN NN O
sepsis NN NN O
. NN NN O
   
The NN NN O
current NN NN O
work NN NN O
describes NN NN O
the NN NN O
regulation NN NN O
of NN NN O
TNF NN NN B-Protein
in NN NN O
human NN NN O
myelomonocytic NN NN O
cell NN NN O
lines NN NN O
after NN NN O
PMA NN NN O
stimulation NN NN O
. NN NN O
   
The NN NN O
cell NN NN O
lines NN NN O
exhibit NN NN O
a NN NN O
low NN NN O
level NN NN O
of NN NN O
constitutive NN NN O
TNF NN NN B-Protein
mRNA NN NN O
expression NN NN O
. NN NN O
   
Within NN NN O
2 NN NN O
to NN NN O
4 NN NN O
h NN NN O
of NN NN O
PMA NN NN O
exposure NN NN O
, NN NN O
steady NN NN O
state NN NN O
levels NN NN O
of NN NN O
TNF NN NN B-Protein
mRNA NN NN O
are NN NN O
markedly NN NN O
elevated NN NN O
in NN NN O
all NN NN O
myelomonocytic NN NN O
cell NN NN O
lines NN NN O
studied NN NN O
. NN NN O
   
This NN NN O
rise NN NN O
is NN NN O
due NN NN O
to NN NN O
increased NN NN O
mRNA NN NN O
stability NN NN O
, NN NN O
which NN NN O
increased NN NN O
by NN NN O
almost NN NN O
twofold NN NN O
, NN NN O
and NN NN O
to NN NN O
an NN NN O
overall NN NN O
increase NN NN O
in NN NN O
transcription NN NN O
, NN NN O
which NN NN O
rises NN NN O
by NN NN O
more NN NN O
than NN NN O
sixfold NN NN O
. NN NN O
   
At NN NN O
the NN NN O
level NN NN O
of NN NN O
the NN NN O
genomic NN NN O
TNF NN NN B-Protein
gene NN NN O
, NN NN O
a NN NN O
DNase NN NN O
I NN NN O
hypersensitive NN NN O
site NN NN O
is NN NN O
detected NN NN O
within NN NN O
the NN NN O
TNF NN NN B-Protein
promoter NN NN O
between NN NN O
- NN NN O
200 NN NN O
to NN NN O
- NN NN O
100 NN NN O
bp NN NN O
relative NN NN O
to NN NN O
the NN NN O
transcription NN NN O
initiation NN NN O
site NN NN O
. NN NN O
   
Although NN NN O
absent NN NN O
in NN NN O
nonexpressing NN NN O
erythroleukemia NN NN O
cell NN NN O
lines NN NN O
, NN NN O
the NN NN O
DNase NN NN O
I NN NN O
site NN NN O
is NN NN O
present NN NN O
in NN NN O
uninduced NN NN O
myelomonocytic NN NN O
cell NN NN O
lines NN NN O
and NN NN O
is NN NN O
not NN NN O
changed NN NN O
after NN NN O
PMA NN NN O
induction NN NN O
. NN NN O
   
The NN NN O
PMA NN NN O
induction NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
mRNA NN NN O
correlated NN NN O
well NN NN O
with NN NN O
TNF NN NN B-Protein
gene NN NN O
induction NN NN O
; NN NN O
expression NN NN O
of NN NN O
genes NN NN O
encoding NN NN O
other NN NN O
proteins NN NN O
in NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
complex NN NN O
( NN NN O
junB NN NN B-Protein
and NN NN O
junD NN NN B-Protein
) NN NN O
were NN NN O
also NN NN O
induced NN NN O
by NN NN O
PMA NN NN O
. NN NN O
   
The NN NN O
nuclear NN NN O
extracts NN NN O
from NN NN O
resting NN NN O
and NN NN O
induced NN NN O
ML NN NN O
- NN NN O
1 NN NN O
cells NN NN O
contain NN NN O
proteins NN NN O
binding NN NN O
specifically NN NN O
to NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
, NN NN O
AP NN NN O
- NN NN O
2 NN NN O
, NN NN O
and NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
sequence NN NN O
located NN NN O
within NN NN O
the NN NN O
TNF NN NN B-Protein
promoter NN NN O
. NN NN O
   
PMA NN NN O
induction NN NN O
increases NN NN O
the NN NN O
level NN NN O
of NN NN O
a NN NN O
number NN NN O
of NN NN O
specific NN NN O
binding NN NN O
complexes NN NN O
relative NN NN O
to NN NN O
the NN NN O
resting NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
regulatory NN NN O
mechanisms NN NN O
of NN NN O
the NN NN O
human NN NN O
and NN NN O
murine NN NN O
TNF NN NN B-Protein
genes NN NN O
are NN NN O
discussed NN NN O
. NN NN O
   
The NN NN O
rhombotin NN NN O
family NN NN O
of NN NN O
cysteine NN NN O
- NN NN O
rich NN NN O
LIM NN NN O
- NN NN O
domain NN NN O
oncogenes NN NN O
: NN NN O
distinct NN NN O
members NN NN O
are NN NN O
involved NN NN O
in NN NN O
T NN NN O
- NN NN O
cell NN NN O
translocations NN NN O
to NN NN O
human NN NN O
chromosomes NN NN O
11p15 NN NN O
and NN NN O
11p13 NN NN O
. NN NN O
   
A NN NN O
chromosomal NN NN O
translocation NN NN O
in NN NN O
a NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
involving NN NN O
the NN NN O
short NN NN O
arm NN NN O
of NN NN O
human NN NN O
chromosome NN NN O
11 NN NN O
at NN NN O
band NN NN O
11p15 NN NN O
disrupts NN NN O
the NN NN O
rhombotin NN NN B-Protein
gene NN NN O
. NN NN O
   
This NN NN O
gene NN NN O
encodes NN NN O
a NN NN O
protein NN NN O
with NN NN O
duplicated NN NN O
cysteine NN NN O
- NN NN O
rich NN NN O
regions NN NN O
called NN NN O
LIM NN NN O
domains NN NN O
, NN NN O
which NN NN O
show NN NN O
homology NN NN O
to NN NN O
zinc NN NN O
- NN NN O
binding NN NN O
proteins NN NN O
and NN NN O
to NN NN O
iron NN NN O
- NN NN O
sulfur NN NN O
centers NN NN O
of NN NN O
ferredoxins NN NN O
. NN NN O
   
Two NN NN O
homologues NN NN O
of NN NN O
the NN NN O
rhombotin NN NN B-Protein
gene NN NN O
have NN NN O
now NN NN O
been NN NN O
isolated NN NN O
. NN NN O
   
One NN NN O
of NN NN O
these NN NN O
, NN NN O
designated NN NN O
Rhom NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
is NN NN O
located NN NN O
on NN NN O
human NN NN O
chromosome NN NN O
11 NN NN O
at NN NN O
band NN NN O
11p13 NN NN O
, NN NN O
where NN NN O
a NN NN O
cluster NN NN O
of NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
- NN NN O
specific NN NN O
translocations NN NN O
occur NN NN O
; NN NN O
all NN NN O
translocation NN NN O
breakpoints NN NN O
at NN NN O
11p13 NN NN O
are NN NN O
upstream NN NN O
of NN NN O
the NN NN O
Rhom NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
. NN NN O
   
Human NN NN O
and NN NN O
mouse NN NN O
Rhom NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
are NN NN O
highly NN NN O
conserved NN NN O
and NN NN O
, NN NN O
like NN NN O
rhombotin NN NN B-Protein
, NN NN O
encode NN NN O
two NN NN O
tandem NN NN O
cysteine NN NN O
- NN NN O
rich NN NN O
LIM NN NN O
domains NN NN O
. NN NN O
   
Rhom NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
mRNA NN NN O
is NN NN O
expressed NN NN O
in NN NN O
early NN NN O
mouse NN NN O
development NN NN O
in NN NN O
central NN NN O
nervous NN NN O
system NN NN O
, NN NN O
lung NN NN O
, NN NN O
kidney NN NN O
, NN NN O
liver NN NN O
, NN NN O
and NN NN O
spleen NN NN O
but NN NN O
only NN NN O
very NN NN O
low NN NN O
levels NN NN O
occur NN NN O
in NN NN O
thymus NN NN O
. NN NN O
   
The NN NN O
other NN NN O
gene NN NN O
, NN NN O
designated NN NN O
Rhom NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
, NN NN O
is NN NN O
not NN NN O
on NN NN O
chromosome NN NN O
11 NN NN O
but NN NN O
also NN NN O
retains NN NN O
homology NN NN O
to NN NN O
the NN NN O
LIM NN NN O
domain NN NN O
of NN NN O
rhombotin NN NN B-Protein
. NN NN O
   
Since NN NN O
the NN NN O
Rhom NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
is NN NN O
such NN NN O
a NN NN O
common NN NN O
site NN NN O
of NN NN O
chromosomal NN NN O
damage NN NN O
in NN NN O
T NN NN O
- NN NN O
cell NN NN O
tumors NN NN O
, NN NN O
the NN NN O
consistency NN NN O
of NN NN O
translocations NN NN O
near NN NN O
the NN NN O
rhombotin NN NN B-Protein
gene NN NN O
was NN NN O
further NN NN O
examined NN NN O
. NN NN O
   
A NN NN O
second NN NN O
translocation NN NN O
adjacent NN NN O
to NN NN O
rhombotin NN NN B-Protein
was NN NN O
found NN NN O
and NN NN O
at NN NN O
the NN NN O
same NN NN O
position NN NN O
as NN NN O
in NN NN O
the NN NN O
previous NN NN O
example NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
chromosome NN NN O
bands NN NN O
11p15 NN NN O
( NN NN O
rhombotin NN NN B-Protein
) NN NN O
and NN NN O
11p13 NN NN O
( NN NN O
Rhom NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
are NN NN O
consistent NN NN O
sites NN NN O
of NN NN O
chromosome NN NN O
translocation NN NN O
in NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
, NN NN O
with NN NN O
the NN NN O
11p15 NN NN O
target NN NN O
more NN NN O
rarely NN NN O
involved NN NN O
. NN NN O
   
The NN NN O
results NN NN O
define NN NN O
the NN NN O
rhombotin NN NN O
gene NN NN O
family NN NN O
as NN NN O
a NN NN O
class NN NN O
of NN NN O
T NN NN O
- NN NN O
cell NN NN O
oncogenes NN NN O
with NN NN O
duplicated NN NN O
cysteine NN NN O
- NN NN O
rich NN NN O
LIM NN NN O
domains NN NN O
. NN NN O
   
Two NN NN O
distinct NN NN O
forms NN NN O
of NN NN O
active NN NN O
transcription NN NN O
factor NN NN O
CREB NN NN B-Protein
( NN NN O
cAMP NN NN B-Protein
response NN NN I-Protein
element NN NN I-Protein
binding NN NN I-Protein
protein NN NN I-Protein
) NN NN O
. NN NN O
   
Mammalian NN NN O
cells NN NN O
express NN NN O
two NN NN O
distinct NN NN O
forms NN NN O
of NN NN O
transcription NN NN O
factor NN NN O
CREB NN NN B-Protein
( NN NN O
cAMP NN NN B-Protein
response NN NN I-Protein
element NN NN I-Protein
binding NN NN I-Protein
protein NN NN I-Protein
) NN NN O
that NN NN O
are NN NN O
apparently NN NN O
the NN NN O
products NN NN O
of NN NN O
alternative NN NN O
splicing NN NN O
of NN NN O
the NN NN O
CREB NN NN B-Protein
gene NN NN O
transcript NN NN O
. NN NN O
   
The NN NN O
two NN NN O
proteins NN NN O
differ NN NN O
by NN NN O
a NN NN O
14 NN NN O
- NN NN O
amino NN NN O
acid NN NN O
serine NN NN O
- NN NN O
rich NN NN O
insertion NN NN O
present NN NN O
in NN NN O
one NN NN O
of NN NN O
the NN NN O
CREB NN NN B-Protein
isoforms NN NN O
. NN NN O
   
We NN NN O
show NN NN O
that NN NN O
both NN NN O
CREB NN NN B-Protein
isoforms NN NN O
are NN NN O
expressed NN NN O
in NN NN O
many NN NN O
cell NN NN O
types NN NN O
and NN NN O
mammalian NN NN O
species NN NN O
. NN NN O
   
Both NN NN O
encode NN NN O
proteins NN NN O
that NN NN O
bind NN NN O
specifically NN NN O
to NN NN O
a NN NN O
cAMP NN NN O
response NN NN O
element NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
As NN NN O
expected NN NN O
for NN NN O
proteins NN NN O
of NN NN O
this NN NN O
class NN NN O
, NN NN O
the NN NN O
CREB NN NN B-Protein
proteins NN NN O
bind NN NN O
DNA NN NN O
as NN NN O
dimers NN NN O
. NN NN O
   
Both NN NN O
proteins NN NN O
impart NN NN O
cAMP NN NN O
- NN NN O
regulated NN NN O
transcriptional NN NN O
activity NN NN O
to NN NN O
a NN NN O
heterologous NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
domain NN NN O
, NN NN O
showing NN NN O
that NN NN O
cAMP NN NN O
directly NN NN O
modulates NN NN O
the NN NN O
transcriptional NN NN O
stimulatory NN NN O
activity NN NN O
of NN NN O
CREB NN NN B-Protein
. NN NN O
   
The NN NN O
presence NN NN O
of NN NN O
multiple NN NN O
CREB NN NN B-Protein
isoforms NN NN O
with NN NN O
identical NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
specificities NN NN O
but NN NN O
differences NN NN O
in NN NN O
the NN NN O
presumed NN NN O
regulatory NN NN O
domain NN NN O
raises NN NN O
the NN NN O
possibility NN NN O
that NN NN O
CREB NN NN B-Protein
proteins NN NN O
may NN NN O
be NN NN O
able NN NN O
to NN NN O
integrate NN NN O
distinct NN NN O
regulatory NN NN O
signals NN NN O
at NN NN O
the NN NN O
level NN NN O
of NN NN O
gene NN NN O
transcription NN NN O
. NN NN O
   
Constitutive NN NN O
expression NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
tat NN NN B-Protein
protein NN NN O
in NN NN O
human NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
using NN NN O
a NN NN O
BK NN NN O
virus NN NN O
vector NN NN O
. NN NN O
   
The NN NN O
production NN NN O
and NN NN O
characterization NN NN O
of NN NN O
Jurkat NN NN O
cell NN NN O
lines NN NN O
that NN NN O
constitutively NN NN O
express NN NN O
functional NN NN O
human NN NN O
immune NN NN O
deficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
tat NN NN B-Protein
protein NN NN O
, NN NN O
using NN NN O
a NN NN O
BK NN NN O
virus NN NN O
plasmid NN NN O
expression NN NN O
vector NN NN O
and NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
tat NN NN B-Protein
cDNA NN NN O
, NN NN O
is NN NN O
described NN NN O
. NN NN O
   
An NN NN O
increased NN NN O
growth NN NN O
rate NN NN O
of NN NN O
these NN NN O
Jurkat NN NN O
- NN NN O
tat NN NN B-Protein
cell NN NN O
lines NN NN O
as NN NN O
compared NN NN O
with NN NN O
control NN NN O
cell NN NN O
lines NN NN O
was NN NN O
observed NN NN O
. NN NN O
   
Effects NN NN O
of NN NN O
1 NN NN O
alpha NN NN O
, NN NN O
25 NN NN O
- NN NN O
dihydroxyvitamin NN NN O
D3 NN NN O
on NN NN O
the NN NN O
human NN NN O
chronic NN NN O
myelogenous NN NN O
leukemia NN NN O
cell NN NN O
line NN NN O
RWLeu NN NN O
- NN NN O
4 NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
1 NN NN O
alpha NN NN O
, NN NN O
25 NN NN O
- NN NN O
dihydroxyvitamin NN NN O
D3 NN NN O
( NN NN O
VD3 NN NN O
) NN NN O
on NN NN O
proliferation NN NN O
, NN NN O
differentiation NN NN O
, NN NN O
and NN NN O
macromolecular NN NN O
synthesis NN NN O
in NN NN O
the NN NN O
new NN NN O
Philadelphia NN NN O
chromosome NN NN O
- NN NN O
positive NN NN O
chronic NN NN O
myelogenous NN NN O
leukemia NN NN O
cell NN NN O
line NN NN O
, NN NN O
RWLeu NN NN O
- NN NN O
4 NN NN O
, NN NN O
were NN NN O
investigated NN NN O
. NN NN O
   
Binding NN NN O
of NN NN O
[ NN NN O
3H NN NN O
] NN NN O
VD3 NN NN O
was NN NN O
saturable NN NN O
, NN NN O
with NN NN O
approximately NN NN O
2000 NN NN O
- NN NN O
3000 NN NN O
sites NN NN O
/ NN NN O
cell NN NN O
, NN NN O
and NN NN O
half NN NN O
- NN NN O
maximal NN NN O
binding NN NN O
occurring NN NN O
at NN NN O
0 NN NN O
. NN NN O
21 NN NN O
- NN NN O
0 NN NN O
. NN NN O
33 NN NN O
nM NN NN O
. NN NN O
   
Treatment NN NN O
of NN NN O
RWLeu NN NN O
- NN NN O
4 NN NN O
cells NN NN O
with NN NN O
VD3 NN NN O
induced NN NN O
24R NN NN O
- NN NN O
hydroxylase NN NN O
activity NN NN O
, NN NN O
a NN NN O
marker NN NN O
of NN NN O
vitamin NN NN O
D3 NN NN O
responsiveness NN NN O
in NN NN O
many NN NN O
tissues NN NN O
. NN NN O
   
Exposure NN NN O
of NN NN O
RWLeu NN NN O
- NN NN O
4 NN NN O
cells NN NN O
to NN NN O
VD3 NN NN O
also NN NN O
inhibited NN NN O
proliferation NN NN O
and NN NN O
DNA NN NN O
synthesis NN NN O
with NN NN O
a NN NN O
50 NN NN O
% NN NN O
effective NN NN O
dose NN NN O
of NN NN O
3 NN NN O
. NN NN O
5 NN NN O
- NN NN O
10 NN NN O
nM NN NN O
within NN NN O
72 NN NN O
h NN NN O
; NN NN O
in NN NN O
addition NN NN O
, NN NN O
protein NN NN O
and NN NN O
RNA NN NN O
synthesis NN NN O
were NN NN O
inhibited NN NN O
by NN NN O
VD3 NN NN O
treatment NN NN O
. NN NN O
   
Exposure NN NN O
of NN NN O
RWLeu NN NN O
- NN NN O
4 NN NN O
cells NN NN O
to NN NN O
5 NN NN O
nM NN NN O
VD3 NN NN O
for NN NN O
72 NN NN O
h NN NN O
caused NN NN O
50 NN NN O
% NN NN O
of NN NN O
the NN NN O
cells NN NN O
to NN NN O
differentiate NN NN O
into NN NN O
macrophage NN NN O
/ NN NN O
monocyte NN NN O
type NN NN O
cells NN NN O
as NN NN O
judged NN NN O
by NN NN O
nitroblue NN NN O
tetrazolium NN NN O
staining NN NN O
and NN NN O
adherence NN NN O
to NN NN O
plastic NN NN O
. NN NN O
   
Progressive NN NN O
expression NN NN O
of NN NN O
cell NN NN O
surface NN NN O
maturation NN NN O
- NN NN O
specific NN NN O
antigens NN NN O
of NN NN O
the NN NN O
monocyte NN NN O
/ NN NN O
macrophage NN NN O
lineage NN NN O
was NN NN O
induced NN NN O
by NN NN O
treatment NN NN O
of NN NN O
RWLeu NN NN O
- NN NN O
4 NN NN O
cells NN NN O
with NN NN O
VD3 NN NN O
for NN NN O
24 NN NN O
to NN NN O
72 NN NN O
h NN NN O
at NN NN O
doses NN NN O
that NN NN O
inhibited NN NN O
cellular NN NN O
proliferation NN NN O
. NN NN O
   
c NN NN B-Protein
- NN NN I-Protein
myc NN NN I-Protein
RNA NN NN O
, NN NN O
which NN NN O
is NN NN O
constitutively NN NN O
expressed NN NN O
in NN NN O
RWLeu NN NN O
- NN NN O
4 NN NN O
cells NN NN O
, NN NN O
increased NN NN O
after NN NN O
0 NN NN O
. NN NN O
5 NN NN O
h NN NN O
of NN NN O
treatment NN NN O
with NN NN O
50 NN NN O
nM NN NN O
VD3 NN NN O
and NN NN O
then NN NN O
rapidly NN NN O
decreased NN NN O
to NN NN O
barely NN NN O
detectable NN NN O
levels NN NN O
after NN NN O
4 NN NN O
h NN NN O
of NN NN O
treatment NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
the NN NN O
in NN NN O
vitro NN NN O
tyrosine NN NN O
kinase NN NN O
activity NN NN O
associated NN NN O
with NN NN O
the NN NN O
p210bcr NN NN B-Protein
- NN NN I-Protein
abl NN NN I-Protein
oncogene NN NN I-Protein
product NN NN O
was NN NN O
decreased NN NN O
approximately NN NN O
50 NN NN O
% NN NN O
by NN NN O
VD3 NN NN O
treatment NN NN O
. NN NN O
   
Because NN NN O
of NN NN O
the NN NN O
presence NN NN O
of NN NN O
a NN NN O
functional NN NN O
receptor NN NN O
- NN NN O
effector NN NN O
system NN NN O
for NN NN O
VD3 NN NN O
and NN NN O
multiple NN NN O
biological NN NN O
responses NN NN O
to NN NN O
the NN NN O
hormone NN NN O
, NN NN O
these NN NN O
cells NN NN O
provide NN NN O
a NN NN O
unique NN NN O
model NN NN O
system NN NN O
with NN NN O
which NN NN O
to NN NN O
probe NN NN O
the NN NN O
specific NN NN O
effects NN NN O
of NN NN O
VD3 NN NN O
on NN NN O
cell NN NN O
growth NN NN O
and NN NN O
differentiation NN NN O
in NN NN O
chronic NN NN O
myelogenous NN NN O
leukemia NN NN O
. NN NN O
   
Lymphocyte NN NN O
cell NN NN O
lines NN NN O
from NN NN O
vitamin NN NN O
D NN NN O
- NN NN O
dependent NN NN O
rickets NN NN O
type NN NN O
II NN NN O
show NN NN O
functional NN NN O
defects NN NN O
in NN NN O
the NN NN O
1 NN NN B-Protein
alpha NN NN I-Protein
, NN NN I-Protein
25 NN NN I-Protein
- NN NN I-Protein
dihydroxyvitamin NN NN I-Protein
D3 NN NN I-Protein
receptor NN NN I-Protein
. NN NN O
   
Lymphocyte NN NN O
cell NN NN O
lines NN NN O
were NN NN O
established NN NN O
from NN NN O
five NN NN O
patients NN NN O
with NN NN O
vitamin NN NN O
D NN NN O
- NN NN O
dependent NN NN O
rickets NN NN O
, NN NN O
type NN NN O
II NN NN O
( NN NN O
VDDR NN NN O
- NN NN O
II NN NN O
) NN NN O
. NN NN O
   
These NN NN O
lines NN NN O
were NN NN O
established NN NN O
by NN NN O
infection NN NN O
with NN NN O
human NN NN O
T NN NN O
- NN NN O
lymphotrophic NN NN O
virus NN NN O
type NN NN O
I NN NN O
( NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
) NN NN O
. NN NN O
   
Binding NN NN O
of NN NN O
[ NN NN O
3H NN NN O
] NN NN O
1 NN NN O
alpha NN NN O
, NN NN O
25 NN NN O
- NN NN O
dihydroxyvitamin NN NN O
D3 NN NN O
( NN NN O
1 NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
) NN NN O
to NN NN O
its NN NN O
receptor NN NN O
in NN NN O
these NN NN O
cell NN NN O
lines NN NN O
was NN NN O
compared NN NN O
to NN NN O
binding NN NN O
studies NN NN O
using NN NN O
a NN NN O
T NN NN O
- NN NN O
lymphocyte NN NN O
cell NN NN O
line NN NN O
( NN NN O
S NN NN O
- NN NN O
LB1 NN NN O
) NN NN O
from NN NN O
a NN NN O
normal NN NN O
individual NN NN O
. NN NN O
   
The NN NN O
1 NN NN B-Protein
, NN NN I-Protein
25 NN NN I-Protein
( NN NN I-Protein
OH NN NN I-Protein
) NN NN I-Protein
2D3 NN NN I-Protein
receptor NN NN I-Protein
of NN NN O
S NN NN O
- NN NN O
LB1 NN NN O
was NN NN O
comparable NN NN O
to NN NN O
the NN NN O
well NN NN O
- NN NN O
characterized NN NN O
chick NN NN O
intestinal NN NN O
1 NN NN B-Protein
, NN NN I-Protein
25 NN NN I-Protein
( NN NN I-Protein
OH NN NN I-Protein
) NN NN I-Protein
2D3 NN NN I-Protein
receptor NN NN I-Protein
in NN NN O
terms NN NN O
of NN NN O
its NN NN O
ligand NN NN O
binding NN NN O
affinity NN NN O
and NN NN O
capacity NN NN O
, NN NN O
its NN NN O
mobility NN NN O
on NN NN O
5 NN NN O
- NN NN O
20 NN NN O
% NN NN O
sucrose NN NN O
gradients NN NN O
, NN NN O
and NN NN O
its NN NN O
adsorption NN NN O
to NN NN O
and NN NN O
elution NN NN O
properties NN NN O
from NN NN O
DNA NN NN O
- NN NN O
cellulose NN NN O
. NN NN O
   
Three NN NN O
cell NN NN O
lines NN NN O
established NN NN O
from NN NN O
patients NN NN O
with NN NN O
VDDR NN NN O
- NN NN O
II NN NN O
( NN NN O
Rh NN NN O
- NN NN O
VDR NN NN O
, NN NN O
Sh NN NN O
- NN NN O
VDR NN NN O
, NN NN O
and NN NN O
Ab NN NN O
- NN NN O
VDR NN NN O
) NN NN O
showed NN NN O
no NN NN O
specific NN NN O
binding NN NN O
of NN NN O
1 NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
to NN NN O
a NN NN O
receptor NN NN O
and NN NN O
treatment NN NN O
of NN NN O
the NN NN O
cultured NN NN O
cells NN NN O
with NN NN O
1 NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
did NN NN O
not NN NN O
stimulate NN NN O
production NN NN O
of NN NN O
24 NN NN O
, NN NN O
25 NN NN O
- NN NN O
dihydroxy NN NN O
- NN NN O
vitamin NN NN O
D3 NN NN O
( NN NN O
24 NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
) NN NN O
, NN NN O
a NN NN O
response NN NN O
which NN NN O
is NN NN O
diagnostic NN NN O
of NN NN O
the NN NN O
presence NN NN O
of NN NN O
a NN NN O
functional NN NN O
1 NN NN B-Protein
, NN NN I-Protein
25 NN NN I-Protein
( NN NN I-Protein
OH NN NN I-Protein
) NN NN I-Protein
2D3 NN NN I-Protein
receptor NN NN I-Protein
. NN NN O
   
In NN NN O
a NN NN O
fourth NN NN O
cell NN NN O
line NN NN O
, NN NN O
A1 NN NN O
- NN NN O
VDR NN NN O
, NN NN O
the NN NN O
receptor NN NN O
for NN NN O
1 NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
had NN NN O
a NN NN O
low NN NN O
binding NN NN O
capacity NN NN O
and NN NN O
25 NN NN B-Protein
( NN NN I-Protein
OH NN NN I-Protein
) NN NN I-Protein
D3 NN NN I-Protein
- NN NN I-Protein
24 NN NN I-Protein
- NN NN I-Protein
hydroxylase NN NN I-Protein
activity NN NN O
was NN NN O
not NN NN O
detectable NN NN O
. NN NN O
   
Induction NN NN O
of NN NN O
24 NN NN O
, NN NN O
25 NN NN O
- NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
synthesis NN NN O
by NN NN O
1 NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
was NN NN O
observed NN NN O
in NN NN O
the NN NN O
fifth NN NN O
cell NN NN O
line NN NN O
, NN NN O
designated NN NN O
Ro NN NN O
- NN NN O
VDR NN NN O
, NN NN O
although NN NN O
the NN NN O
sensitivity NN NN O
to NN NN O
hormone NN NN O
treatment NN NN O
was NN NN O
lower NN NN O
than NN NN O
in NN NN O
the NN NN O
control NN NN O
cell NN NN O
line NN NN O
from NN NN O
a NN NN O
normal NN NN O
donor NN NN O
. NN NN O
   
The NN NN O
capacity NN NN O
of NN NN O
the NN NN O
receptor NN NN O
for NN NN O
1 NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
was NN NN O
low NN NN O
in NN NN O
Ro NN NN O
- NN NN O
VDR NN NN O
. NN NN O
   
In NN NN O
all NN NN O
cell NN NN O
lines NN NN O
where NN NN O
1 NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
binding NN NN O
to NN NN O
a NN NN O
receptor NN NN O
was NN NN O
detectable NN NN O
, NN NN O
the NN NN O
receptor NN NN O
had NN NN O
the NN NN O
typical NN NN O
sedimentation NN NN O
coefficient NN NN O
of NN NN O
3 NN NN O
. NN NN O
7 NN NN O
S NN NN O
on NN NN O
sucrose NN NN O
density NN NN O
gradient NN NN O
analysis NN NN O
. NN NN O
   
Binding NN NN O
and NN NN O
elution NN NN O
properties NN NN O
to NN NN O
DNA NN NN O
- NN NN O
cellulose NN NN O
, NN NN O
however NN NN O
, NN NN O
differed NN NN O
from NN NN O
normal NN NN O
in NN NN O
both NN NN O
Ro NN NN O
- NN NN O
VDR NN NN O
and NN NN O
A1 NN NN O
- NN NN O
VDR NN NN O
cells NN NN O
where NN NN O
elution NN NN O
from NN NN O
DNA NN NN O
- NN NN O
cellulose NN NN O
occurred NN NN O
at NN NN O
a NN NN O
lower NN NN O
salt NN NN O
concentration NN NN O
than NN NN O
is NN NN O
typical NN NN O
of NN NN O
the NN NN O
1 NN NN B-Protein
, NN NN I-Protein
25 NN NN I-Protein
( NN NN I-Protein
OH NN NN I-Protein
) NN NN I-Protein
2D3 NN NN I-Protein
receptor NN NN I-Protein
. NN NN O
   
While NN NN O
Ro NN NN O
- NN NN O
VDR NN NN O
cells NN NN O
showed NN NN O
typical NN NN O
nuclear NN NN O
localization NN NN O
of NN NN O
the NN NN O
unoccupied NN NN O
1 NN NN B-Protein
, NN NN I-Protein
25 NN NN I-Protein
( NN NN I-Protein
OH NN NN I-Protein
) NN NN I-Protein
2D3 NN NN I-Protein
receptor NN NN I-Protein
, NN NN O
neither NN NN O
the NN NN O
unoccupied NN NN O
nor NN NN O
the NN NN O
occupied NN NN O
receptor NN NN O
from NN NN O
A1 NN NN O
- NN NN O
VDR NN NN O
cells NN NN O
was NN NN O
completely NN NN O
localized NN NN O
in NN NN O
the NN NN O
nucleus NN NN O
. NN NN O
   
In NN NN O
a NN NN O
series NN NN O
of NN NN O
functional NN NN O
studies NN NN O
we NN NN O
found NN NN O
that NN NN O
modulation NN NN O
of NN NN O
the NN NN O
level NN NN O
of NN NN O
the NN NN O
mRNAs NN NN O
coding NN NN O
for NN NN O
both NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
myc NN NN I-Protein
oncogene NN NN O
and NN NN O
the NN NN O
growth NN NN O
factor NN NN O
known NN NN O
as NN NN O
granulocyte NN NN O
- NN NN O
monocyte NN NN O
colony NN NN O
stimulating NN NN O
activity NN NN O
by NN NN O
1 NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
correlated NN NN O
with NN NN O
the NN NN O
1 NN NN B-Protein
, NN NN I-Protein
25 NN NN I-Protein
( NN NN I-Protein
OH NN NN I-Protein
) NN NN I-Protein
2D3 NN NN I-Protein
receptor NN NN I-Protein
status NN NN O
of NN NN O
these NN NN O
cells NN NN O
. NN NN O
   
Use NN NN O
of NN NN O
these NN NN O
cell NN NN O
lines NN NN O
will NN NN O
facilitate NN NN O
further NN NN O
study NN NN O
of NN NN O
the NN NN O
molecular NN NN O
defect NN NN O
( NN NN O
s NN NN O
) NN NN O
in NN NN O
the NN NN O
receptor NN NN O
for NN NN O
1 NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
in NN NN O
vitamin NN NN O
D NN NN O
- NN NN O
dependent NN NN O
rickets NN NN O
type NN NN O
II NN NN O
and NN NN O
will NN NN O
allow NN NN O
a NN NN O
correlation NN NN O
with NN NN O
impairment NN NN O
of NN NN O
cellular NN NN O
functions NN NN O
. NN NN O
   
Heterogeneity NN NN O
of NN NN O
antigen NN NN O
molecules NN NN O
recognized NN NN O
by NN NN O
anti NN NN O
- NN NN O
tax1 NN NN B-Protein
monoclonal NN NN O
antibody NN NN O
Lt NN NN O
- NN NN O
4 NN NN O
in NN NN O
cell NN NN O
lines NN NN O
bearing NN NN O
human NN NN O
T NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
I NN NN O
and NN NN O
related NN NN O
retroviruses NN NN O
. NN NN O
   
Using NN NN O
a NN NN O
monoclonal NN NN O
antibody NN NN O
, NN NN O
Lt NN NN O
- NN NN O
4 NN NN O
, NN NN O
directed NN NN O
against NN NN O
human NN NN O
T NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
I NN NN O
( NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
) NN NN O
trans NN NN O
- NN NN O
activator NN NN O
( NN NN O
tax1 NN NN B-Protein
) NN NN O
antigen NN NN O
, NN NN O
we NN NN O
examined NN NN O
the NN NN O
expression NN NN O
of NN NN O
tax1 NN NN B-Protein
and NN NN O
related NN NN O
antigens NN NN O
in NN NN O
a NN NN O
variety NN NN O
of NN NN O
T NN NN O
cell NN NN O
lines NN NN O
bearing NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
and NN NN O
related NN NN O
retroviruses NN NN O
, NN NN O
simian NN NN O
T NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
I NN NN O
( NN NN O
STLV NN NN O
- NN NN O
I NN NN O
) NN NN O
and NN NN O
HTLV NN NN O
- NN NN O
II NN NN O
, NN NN O
by NN NN O
immunofluorescence NN NN O
and NN NN O
immunoblot NN NN O
assays NN NN O
. NN NN O
   
Lt NN NN O
- NN NN O
4 NN NN O
reacted NN NN O
with NN NN O
all NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
- NN NN O
bearing NN NN O
cell NN NN O
lines NN NN O
tested NN NN O
and NN NN O
five NN NN O
out NN NN O
of NN NN O
eight NN NN O
simian NN NN O
cell NN NN O
lines NN NN O
bearing NN NN O
STLV NN NN O
- NN NN O
I NN NN O
, NN NN O
but NN NN O
not NN NN O
with NN NN O
an NN NN O
HTLV NN NN O
- NN NN O
II NN NN O
- NN NN O
bearing NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
Lt NN NN O
- NN NN O
4 NN NN O
detected NN NN O
40 NN NN O
kd NN NN O
tax1 NN NN B-Protein
antigen NN NN O
molecules NN NN O
in NN NN O
most NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
- NN NN O
bearing NN NN O
cell NN NN O
lines NN NN O
except NN NN O
one NN NN O
cell NN NN O
line NN NN O
that NN NN O
expressed NN NN O
39 NN NN O
kd NN NN O
tax1 NN NN B-Protein
antigen NN NN O
. NN NN O
   
In NN NN O
the NN NN O
STLV NN NN O
- NN NN O
I NN NN O
- NN NN O
bearing NN NN O
T NN NN O
cell NN NN O
lines NN NN O
, NN NN O
tax1 NN NN B-Protein
- NN NN O
related NN NN O
antigen NN NN O
molecules NN NN O
detected NN NN O
by NN NN O
Lt NN NN O
- NN NN O
4 NN NN O
were NN NN O
heterogeneous NN NN O
, NN NN O
having NN NN O
molecular NN NN O
weights NN NN O
in NN NN O
the NN NN O
range NN NN O
of NN NN O
36 NN NN O
- NN NN O
41 NN NN O
kd NN NN O
. NN NN O
   
The NN NN O
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
( NN NN O
EBV NN NN O
) NN NN O
BMRF1 NN NN B-Protein
promoter NN NN O
for NN NN O
early NN NN O
antigen NN NN O
( NN NN O
EA NN NN B-Protein
- NN NN I-Protein
D NN NN I-Protein
) NN NN O
is NN NN O
regulated NN NN O
by NN NN O
the NN NN O
EBV NN NN O
transactivators NN NN O
, NN NN O
BRLF1 NN NN B-Protein
and NN NN O
BZLF1 NN NN B-Protein
, NN NN O
in NN NN O
a NN NN O
cell NN NN O
- NN NN O
specific NN NN O
manner NN NN O
. NN NN O
   
The NN NN O
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
early NN NN O
antigen NN NN O
diffuse NN NN O
component NN NN O
( NN NN O
EA NN NN B-Protein
- NN NN I-Protein
D NN NN I-Protein
) NN NN O
is NN NN O
essential NN NN O
for NN NN O
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
DNA NN NN O
polymerase NN NN O
activity NN NN O
, NN NN O
and NN NN O
its NN NN O
activity NN NN O
is NN NN O
suppressed NN NN O
during NN NN O
latent NN NN O
infection NN NN O
. NN NN O
   
We NN NN O
investigated NN NN O
the NN NN O
regulation NN NN O
of NN NN O
the NN NN O
promoter NN NN O
( NN NN O
BMRF1 NN NN B-Protein
) NN NN O
for NN NN O
this NN NN O
early NN NN O
gene NN NN O
by NN NN O
studying NN NN O
its NN NN O
responsiveness NN NN O
in NN NN O
vitro NN NN O
to NN NN O
two NN NN O
immediate NN NN O
- NN NN O
early NN NN O
viral NN NN O
transactivators NN NN O
, NN NN O
BZLF1 NN NN B-Protein
( NN NN O
Z NN NN O
) NN NN O
and NN NN O
BRLF1 NN NN B-Protein
( NN NN O
R NN NN O
) NN NN O
, NN NN O
focusing NN NN O
on NN NN O
the NN NN O
differences NN NN O
in NN NN O
response NN NN O
in NN NN O
lymphoid NN NN O
cells NN NN O
and NN NN O
epithelial NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
lymphoid NN NN O
cells NN NN O
, NN NN O
Z NN NN O
or NN NN O
R NN NN O
alone NN NN O
produced NN NN O
only NN NN O
small NN NN O
increases NN NN O
in NN NN O
EA NN NN B-Protein
- NN NN I-Protein
D NN NN I-Protein
promoter NN NN O
activity NN NN O
, NN NN O
whereas NN NN O
both NN NN O
transactivators NN NN O
together NN NN O
produced NN NN O
a NN NN O
large NN NN O
stimulatory NN NN O
effect NN NN O
. NN NN O
   
In NN NN O
epithelial NN NN O
cells NN NN O
, NN NN O
the NN NN O
Z NN NN O
transactivator NN NN O
alone NN NN O
produced NN NN O
maximal NN NN O
stimulation NN NN O
of NN NN O
the NN NN O
EA NN NN B-Protein
- NN NN I-Protein
D NN NN I-Protein
promoter NN NN O
; NN NN O
the NN NN O
effect NN NN O
of NN NN O
R NN NN O
and NN NN O
Z NN NN O
together NN NN O
was NN NN O
no NN NN O
greater NN NN O
than NN NN O
that NN NN O
of NN NN O
Z NN NN O
alone NN NN O
. NN NN O
   
Deletional NN NN O
analysis NN NN O
and NN NN O
site NN NN O
- NN NN O
directed NN NN O
mutagenesis NN NN O
of NN NN O
the NN NN O
EA NN NN B-Protein
- NN NN I-Protein
D NN NN I-Protein
promoter NN NN O
demonstrated NN NN O
that NN NN O
in NN NN O
epithelial NN NN O
cells NN NN O
the NN NN O
potential NN NN O
AP NN NN O
- NN NN O
1 NN NN O
binding NN NN O
site NN NN O
plays NN NN O
an NN NN O
essential NN NN O
role NN NN O
in NN NN O
Z NN NN O
responsiveness NN NN O
, NN NN O
although NN NN O
sequences NN NN O
further NN NN O
upstream NN NN O
are NN NN O
also NN NN O
important NN NN O
. NN NN O
   
In NN NN O
lymphoid NN NN O
cells NN NN O
, NN NN O
only NN NN O
the NN NN O
upstream NN NN O
sequences NN NN O
are NN NN O
required NN NN O
for NN NN O
transactivation NN NN O
by NN NN O
the NN NN O
Z NN NN O
/ NN NN O
R NN NN O
combination NN NN O
, NN NN O
and NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
site NN NN O
is NN NN O
dispensable NN NN O
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
EA NN NN B-Protein
- NN NN I-Protein
D NN NN I-Protein
( NN NN O
BMRF1 NN NN B-Protein
) NN NN O
promoter NN NN O
regulation NN NN O
by NN NN O
Z NN NN O
and NN NN O
R NN NN O
is NN NN O
cell NN NN O
type NN NN O
specific NN NN O
and NN NN O
appears NN NN O
to NN NN O
involve NN NN O
different NN NN O
mechanisms NN NN O
in NN NN O
each NN NN O
cell NN NN O
type NN NN O
. NN NN O
   
Decreased NN NN O
concentration NN NN O
of NN NN O
1 NN NN B-Protein
, NN NN I-Protein
25 NN NN I-Protein
- NN NN I-Protein
dihydroxyvitamin NN NN I-Protein
D3 NN NN I-Protein
receptors NN NN I-Protein
in NN NN O
peripheral NN NN O
mononuclear NN NN O
cells NN NN O
of NN NN O
patients NN NN O
with NN NN O
X NN NN O
- NN NN O
linked NN NN O
hypophosphatemic NN NN O
rickets NN NN O
: NN NN O
effect NN NN O
of NN NN O
phosphate NN NN O
supplementation NN NN O
. NN NN O
   
Abnormal NN NN O
renal NN NN O
tubular NN NN O
phosphate NN NN O
transport NN NN O
is NN NN O
considered NN NN O
to NN NN O
be NN NN O
the NN NN O
primary NN NN O
defect NN NN O
in NN NN O
X NN NN O
- NN NN O
linked NN NN O
hypophosphatemic NN NN O
rickets NN NN O
( NN NN O
XLH NN NN O
) NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
resistance NN NN O
to NN NN O
vitamin NN NN O
D NN NN O
treatment NN NN O
in NN NN O
XLH NN NN O
cannot NN NN O
be NN NN O
explained NN NN O
by NN NN O
hypophosphatemia NN NN O
alone NN NN O
. NN NN O
   
Since NN NN O
most NN NN O
of NN NN O
the NN NN O
actions NN NN O
of NN NN O
vitamin NN NN O
D NN NN O
are NN NN O
mediated NN NN O
by NN NN O
its NN NN O
receptors NN NN O
( NN NN O
VDR NN NN B-Protein
) NN NN O
, NN NN O
abnormalities NN NN O
of NN NN O
VDR NN NN B-Protein
have NN NN O
been NN NN O
postulated NN NN O
in NN NN O
XLH NN NN O
. NN NN O
   
In NN NN O
order NN NN O
to NN NN O
investigate NN NN O
this NN NN O
possibility NN NN O
, NN NN O
we NN NN O
measured NN NN O
the NN NN O
concentration NN NN O
of NN NN O
VDR NN NN B-Protein
in NN NN O
PHA NN NN O
- NN NN O
activated NN NN O
peripheral NN NN O
mononuclear NN NN O
cells NN NN O
from NN NN O
10 NN NN O
XLH NN NN O
patients NN NN O
. NN NN O
   
Patients NN NN O
without NN NN O
phosphate NN NN O
supplementation NN NN O
showed NN NN O
significantly NN NN O
lower NN NN O
concentration NN NN O
( NN NN O
21 NN NN O
. NN NN O
7 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
5 NN NN O
. NN NN O
1 NN NN O
fmol NN NN O
/ NN NN O
mg NN NN O
protein NN NN O
, NN NN O
mean NN NN O
+ NN NN O
/ NN NN O
- NN NN O
SEM NN NN O
) NN NN O
compared NN NN O
to NN NN O
the NN NN O
normal NN NN O
controls NN NN O
( NN NN O
60 NN NN O
. NN NN O
7 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
4 NN NN O
. NN NN O
0 NN NN O
) NN NN O
. NN NN O
   
On NN NN O
the NN NN O
contrary NN NN O
, NN NN O
there NN NN O
was NN NN O
no NN NN O
significant NN NN O
difference NN NN O
between NN NN O
the NN NN O
phosphate NN NN O
- NN NN O
supplemented NN NN O
patients NN NN O
( NN NN O
58 NN NN O
. NN NN O
3 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
. NN NN O
7 NN NN O
) NN NN O
and NN NN O
controls NN NN O
. NN NN O
   
There NN NN O
was NN NN O
a NN NN O
significant NN NN O
positive NN NN O
correlation NN NN O
between NN NN O
VDR NN NN B-Protein
concentration NN NN O
and NN NN O
serum NN NN O
phosphate NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
In NN NN O
two NN NN O
patients NN NN O
, NN NN O
VDR NN NN B-Protein
was NN NN O
increased NN NN O
after NN NN O
daily NN NN O
phosphate NN NN O
supplementation NN NN O
was NN NN O
started NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
a NN NN O
decreased NN NN O
concentration NN NN O
of NN NN O
VDR NN NN B-Protein
secondary NN NN O
to NN NN O
persistent NN NN O
hypophosphatemia NN NN O
is NN NN O
one NN NN O
of NN NN O
the NN NN O
causes NN NN O
of NN NN O
vitamin NN NN O
D NN NN O
resistance NN NN O
in NN NN O
XLH NN NN O
. NN NN O
   
Two NN NN O
glucocorticoid NN NN O
binding NN NN O
sites NN NN O
on NN NN O
the NN NN O
human NN NN O
glucocorticoid NN NN O
receptor NN NN O
. NN NN O
   
Glucocorticoids NN NN O
are NN NN O
known NN NN O
to NN NN O
have NN NN O
a NN NN O
lytic NN NN O
effect NN NN O
in NN NN O
leukemic NN NN O
cells NN NN O
via NN NN O
interactions NN NN O
with NN NN O
the NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
( NN NN O
GR NN NN B-Protein
) NN NN O
. NN NN O
   
Cortisol NN NN O
and NN NN O
various NN NN O
synthetic NN NN O
glucocorticoids NN NN O
bind NN NN O
to NN NN O
the NN NN O
GR NN NN B-Protein
with NN NN O
one NN NN O
- NN NN O
site NN NN O
kinetics NN NN O
. NN NN O
   
Cortivazol NN NN O
( NN NN O
CVZ NN NN O
) NN NN O
is NN NN O
a NN NN O
unique NN NN O
, NN NN O
high NN NN O
potency NN NN O
synthetic NN NN O
glucocorticoid NN NN O
, NN NN O
which NN NN O
has NN NN O
a NN NN O
phenylpyrazol NN NN O
fused NN NN O
to NN NN O
the NN NN O
A NN NN O
- NN NN O
ring NN NN O
of NN NN O
the NN NN O
steroid NN NN O
nucleus NN NN O
and NN NN O
displays NN NN O
binding NN NN O
consistent NN NN O
with NN NN O
two NN NN O
or NN NN O
more NN NN O
sites NN NN O
in NN NN O
the NN NN O
cytosol NN NN O
from NN NN O
CEM NN NN O
C7 NN NN O
cells NN NN O
( NN NN O
a NN NN O
human NN NN O
acute NN NN O
lymphoblastic NN NN O
T NN NN O
- NN NN O
cell NN NN O
line NN NN O
) NN NN O
. NN NN O
   
It NN NN O
has NN NN O
previously NN NN O
been NN NN O
shown NN NN O
that NN NN O
the NN NN O
lower NN NN O
affinity NN NN O
class NN NN O
of NN NN O
sites NN NN O
are NN NN O
similar NN NN O
in NN NN O
affinity NN NN O
and NN NN O
site NN NN O
molarity NN NN O
to NN NN O
those NN NN O
recognized NN NN O
by NN NN O
dexamethasone NN NN O
. NN NN O
   
The NN NN O
higher NN NN O
affinity NN NN O
sites NN NN O
bind NN NN O
CVZ NN NN O
with NN NN O
20 NN NN O
- NN NN O
to NN NN O
50 NN NN O
- NN NN O
fold NN NN O
greater NN NN O
affinity NN NN O
, NN NN O
consistent NN NN O
with NN NN O
CVZ NN NN O
' NN NN O
s NN NN O
enhanced NN NN O
biological NN NN O
effects NN NN O
. NN NN O
   
In NN NN O
mutant NN NN O
leukemic NN NN O
cells NN NN O
resistant NN NN O
to NN NN O
the NN NN O
lytic NN NN O
effects NN NN O
of NN NN O
dexamethasone NN NN O
, NN NN O
CVZ NN NN O
both NN NN O
lyses NN NN O
the NN NN O
cells NN NN O
and NN NN O
recognizes NN NN O
a NN NN O
single NN NN O
class NN NN O
of NN NN O
sites NN NN O
similar NN NN O
to NN NN O
the NN NN O
high NN NN O
affinity NN NN O
site NN NN O
in NN NN O
CEM NN NN O
C7 NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
have NN NN O
carried NN NN O
out NN NN O
experiments NN NN O
to NN NN O
define NN NN O
the NN NN O
nature NN NN O
of NN NN O
the NN NN O
higher NN NN O
affinity NN NN O
CVZ NN NN O
binding NN NN O
site NN NN O
. NN NN O
   
We NN NN O
now NN NN O
show NN NN O
that NN NN O
: NN NN O
1 NN NN O
) NN NN O
CVZ NN NN O
has NN NN O
more NN NN O
than NN NN O
one NN NN O
binding NN NN O
site NN NN O
in NN NN O
a NN NN O
second NN NN O
, NN NN O
independent NN NN O
, NN NN O
B NN NN O
- NN NN O
cell NN NN O
line NN NN O
, NN NN O
IM NN NN O
- NN NN O
9 NN NN O
; NN NN O
2 NN NN O
) NN NN O
the NN NN O
antiglucocorticoid NN NN O
RU NN NN O
38486 NN NN O
is NN NN O
able NN NN O
to NN NN O
block NN NN O
both NN NN O
CVZ NN NN O
' NN NN O
s NN NN O
higher NN NN O
and NN NN O
lower NN NN O
affinity NN NN O
sites NN NN O
; NN NN O
3 NN NN O
) NN NN O
all NN NN O
of NN NN O
CVZ NN NN O
' NN NN O
s NN NN O
binding NN NN O
sites NN NN O
are NN NN O
on NN NN O
a NN NN O
protein NN NN O
immunologically NN NN O
indistinguishable NN NN O
from NN NN O
the NN NN O
human NN NN O
GR NN NN B-Protein
; NN NN O
and NN NN O
4 NN NN O
) NN NN O
freshly NN NN O
isolated NN NN O
clones NN NN O
of NN NN O
CVZ NN NN O
- NN NN O
resistant NN NN O
cells NN NN O
have NN NN O
lost NN NN O
all NN NN O
binding NN NN O
sites NN NN O
for NN NN O
CVZ NN NN O
. NN NN O
   
These NN NN O
data NN NN O
indicate NN NN O
that NN NN O
CVZ NN NN O
is NN NN O
recognizing NN NN O
two NN NN O
glucocorticoid NN NN O
binding NN NN O
sites NN NN O
on NN NN O
the NN NN O
human NN NN O
GR NN NN B-Protein
or NN NN O
a NN NN O
protein NN NN O
very NN NN O
similar NN NN O
to NN NN O
it NN NN O
. NN NN O
   
[ NN NN O
The NN NN O
role NN NN O
of NN NN O
glucocorticoid NN NN B-Protein
receptors NN NN I-Protein
and NN NN O
HLA NN NN O
antigens NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
Cushing NN NN O
' NN NN O
s NN NN O
syndrome NN NN O
] NN NN O
   
Lymphocytic NN NN O
levels NN NN O
of NN NN O
glucocorticoid NN NN B-Protein
receptors NN NN I-Protein
were NN NN O
evaluated NN NN O
in NN NN O
114 NN NN O
patients NN NN O
suffering NN NN O
from NN NN O
Icenko NN NN O
- NN NN O
Cushing NN NN O
' NN NN O
s NN NN O
syndrome NN NN O
. NN NN O
   
Incidence NN NN O
of NN NN O
HLA NN NN O
antigens NN NN O
was NN NN O
determined NN NN O
in NN NN O
94 NN NN O
of NN NN O
them NN NN O
. NN NN O
   
A NN NN O
significant NN NN O
rise NN NN O
of NN NN O
A10 NN NN B-Protein
and NN NN O
B27 NN NN B-Protein
antigen NN NN I-Protein
incidence NN NN O
compared NN NN O
to NN NN O
that NN NN O
in NN NN O
normal NN NN O
subjects NN NN O
allows NN NN O
these NN NN O
antigens NN NN O
to NN NN O
be NN NN O
considered NN NN O
genetic NN NN O
markers NN NN O
of NN NN O
Icenko NN NN O
- NN NN O
Cushing NN NN O
' NN NN O
s NN NN O
syndrome NN NN O
. NN NN O
   
The NN NN O
levels NN NN O
of NN NN O
glucocorticoid NN NN B-Protein
receptors NN NN I-Protein
in NN NN O
lymphocytes NN NN O
of NN NN O
the NN NN O
patients NN NN O
are NN NN O
lower NN NN O
than NN NN O
in NN NN O
normal NN NN O
subjects NN NN O
both NN NN O
in NN NN O
the NN NN O
active NN NN O
stage NN NN O
of NN NN O
the NN NN O
disease NN NN O
and NN NN O
following NN NN O
bilateral NN NN O
total NN NN O
adrenalectomy NN NN O
. NN NN O
   
The NN NN O
patients NN NN O
carrying NN NN O
B27 NN NN B-Protein
antigen NN NN I-Protein
had NN NN O
lymphocytic NN NN O
receptor NN NN O
concentrations NN NN O
under NN NN O
the NN NN O
levels NN NN O
of NN NN O
such NN NN O
in NN NN O
patients NN NN O
free NN NN O
of NN NN O
the NN NN O
antigen NN NN O
carriage NN NN O
. NN NN O
   
Antigen NN NN B-Protein
B27 NN NN I-Protein
seems NN NN O
to NN NN O
be NN NN O
a NN NN O
cause NN NN O
of NN NN O
lower NN NN O
levels NN NN O
of NN NN O
glucocorticoid NN NN B-Protein
receptors NN NN I-Protein
in NN NN O
blood NN NN O
lymphocytes NN NN O
. NN NN O
   
Circadian NN NN O
rhythm NN NN O
of NN NN O
glucocorticoid NN NN B-Protein
receptors NN NN I-Protein
in NN NN O
human NN NN O
peripheral NN NN O
leukocytes NN NN O
and NN NN O
their NN NN O
reactivity NN NN O
to NN NN O
glucocorticoids NN NN O
. NN NN O
   
1 NN NN O
) NN NN O
There NN NN O
exists NN NN O
a NN NN O
CR NN NN O
of NN NN O
GR NN NN B-Protein
in NN NN O
human NN NN O
leukocytes NN NN O
, NN NN O
PMN NN NN O
, NN NN O
and NN NN O
monocytes NN NN O
with NN NN O
the NN NN O
peak NN NN O
values NN NN O
from NN NN O
0400 NN NN O
to NN NN O
0800 NN NN O
hr NN NN O
and NN NN O
the NN NN O
trough NN NN O
values NN NN O
between NN NN O
2300 NN NN O
and NN NN O
0000 NN NN O
hr NN NN O
. NN NN O
   
The NN NN O
difference NN NN O
between NN NN O
them NN NN O
was NN NN O
significant NN NN O
statistically NN NN O
. NN NN O
   
2 NN NN O
) NN NN O
The NN NN O
FI NN NN O
of NN NN O
the NN NN O
chemotactic NN NN O
migration NN NN O
rate NN NN O
of NN NN O
PMN NN NN O
by NN NN O
cortisol NN NN O
also NN NN O
showed NN NN O
diurnal NN NN O
changes NN NN O
which NN NN O
were NN NN O
synchronous NN NN O
with NN NN O
that NN NN O
of NN NN O
GR NN NN B-Protein
. NN NN O
   
This NN NN O
indicates NN NN O
that NN NN O
the NN NN O
CR NN NN O
of NN NN O
GR NN NN B-Protein
may NN NN O
be NN NN O
of NN NN O
functional NN NN O
significance NN NN O
. NN NN O
   
3 NN NN O
) NN NN O
In NN NN O
Cushing NN NN O
' NN NN O
s NN NN O
syndrome NN NN O
, NN NN O
the NN NN O
CR NN NN O
of NN NN O
GR NN NN B-Protein
was NN NN O
normal NN NN O
in NN NN O
spite NN NN O
of NN NN O
the NN NN O
fact NN NN O
that NN NN O
the NN NN O
CR NN NN O
of NN NN O
plasma NN NN O
cortisol NN NN O
was NN NN O
disturbed NN NN O
. NN NN O
   
This NN NN O
indicates NN NN O
the NN NN O
independency NN NN O
of NN NN O
the NN NN O
CR NN NN O
of NN NN O
GR NN NN B-Protein
from NN NN O
that NN NN O
of NN NN O
cortisol NN NN O
. NN NN O
   
4 NN NN O
) NN NN O
In NN NN O
apoplexy NN NN O
caused NN NN O
by NN NN O
brain NN NN O
ischemia NN NN O
, NN NN O
the NN NN O
CR NN NN O
of NN NN O
GR NN NN B-Protein
was NN NN O
abolished NN NN O
in NN NN O
patients NN NN O
with NN NN O
basal NN NN O
lesions NN NN O
but NN NN O
preserved NN NN O
when NN NN O
the NN NN O
lesions NN NN O
were NN NN O
located NN NN O
in NN NN O
the NN NN O
cerebral NN NN O
cortex NN NN O
. NN NN O
   
These NN NN O
results NN NN O
strongly NN NN O
suggest NN NN O
that NN NN O
the NN NN O
main NN NN O
"""""""" NN NN O
circadian NN NN O
pacemaker NN NN O
"""""""" NN NN O
of NN NN O
GR NN NN B-Protein
is NN NN O
located NN NN O
in NN NN O
the NN NN O
basal NN NN O
brain NN NN O
, NN NN O
most NN NN O
probably NN NN O
in NN NN O
the NN NN O
suprachiasmatic NN NN O
nuclei NN NN O
as NN NN O
has NN NN O
been NN NN O
suggested NN NN O
for NN NN O
rodents NN NN O
. NN NN O
   
Progesterone NN NN O
suppression NN NN O
of NN NN O
pregnancy NN NN O
lymphocytes NN NN O
is NN NN O
not NN NN O
mediated NN NN O
by NN NN O
glucocorticoid NN NN O
effect NN NN O
. NN NN O
   
This NN NN O
study NN NN O
investigated NN NN O
whether NN NN O
the NN NN O
suppressive NN NN O
effect NN NN O
of NN NN O
progesterone NN NN O
on NN NN O
pregnancy NN NN O
lymphocytes NN NN O
is NN NN O
mediated NN NN O
by NN NN O
specific NN NN O
progesterone NN NN O
receptors NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
a NN NN O
competitive NN NN O
progesterone NN NN O
antagonist NN NN O
( NN NN O
RU486 NN NN O
) NN NN O
and NN NN O
a NN NN O
specific NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
blocker NN NN O
( NN NN O
RU43044 NN NN O
) NN NN O
were NN NN O
tested NN NN O
on NN NN O
the NN NN O
release NN NN O
of NN NN O
a NN NN O
blocking NN NN O
factor NN NN O
by NN NN O
progesterone NN NN O
- NN NN O
treated NN NN O
pregnancy NN NN O
lymphocytes NN NN O
. NN NN O
   
RU NN NN O
486 NN NN O
tested NN NN O
at NN NN O
an NN NN O
equal NN NN O
concentration NN NN O
as NN NN O
progesterone NN NN O
significantly NN NN O
inhibited NN NN O
the NN NN O
production NN NN O
of NN NN O
the NN NN O
blocking NN NN O
factor NN NN O
, NN NN O
while NN NN O
RU NN NN O
43044 NN NN O
was NN NN O
without NN NN O
effect NN NN O
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
in NN NN O
pregnancy NN NN O
, NN NN O
lymphocyte NN NN O
progesterone NN NN O
acts NN NN O
on NN NN O
specific NN NN O
progesterone NN NN O
receptors NN NN O
and NN NN O
glucocorticoid NN NN O
binding NN NN O
sites NN NN O
are NN NN O
not NN NN O
involved NN NN O
. NN NN O
   
[ NN NN O
The NN NN O
effect NN NN O
of NN NN O
24 NN NN O
, NN NN O
25 NN NN O
- NN NN O
dihydroxyvitamin NN NN O
D3 NN NN O
( NN NN O
dioxyvit NN NN O
) NN NN O
on NN NN O
Ca NN NN O
metabolism NN NN O
and NN NN O
immune NN NN O
status NN NN O
during NN NN O
chronic NN NN O
kidney NN NN O
failure NN NN O
] NN NN O
   
Active NN NN O
metabolite NN NN O
of NN NN O
vitamin NN NN O
D3 NN NN O
, NN NN O
24R NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
( NN NN O
dioxyvit NN NN O
) NN NN O
was NN NN O
used NN NN O
at NN NN O
a NN NN O
daily NN NN O
dose NN NN O
of NN NN O
100 NN NN O
micrograms NN NN O
in NN NN O
treatment NN NN O
of NN NN O
children NN NN O
affected NN NN O
with NN NN O
tubulointerstitial NN NN O
disease NN NN O
of NN NN O
kidney NN NN O
and NN NN O
with NN NN O
chronic NN NN O
glomerulonephritis NN NN O
under NN NN O
conditions NN NN O
of NN NN O
kidney NN NN O
insufficiency NN NN O
. NN NN O
   
The NN NN O
drug NN NN O
exhibited NN NN O
distinct NN NN O
normalizing NN NN O
effect NN NN O
on NN NN O
patterns NN NN O
of NN NN O
calcium NN NN O
metabolism NN NN O
: NN NN O
increase NN NN O
of NN NN O
total NN NN O
and NN NN O
ionized NN NN O
Ca2 NN NN O
+ NN NN O
and NN NN O
of NN NN O
25 NN NN O
- NN NN O
OHD NN NN O
, NN NN O
decrease NN NN O
in NN NN O
concentration NN NN O
of NN NN O
parath NN NN O
hormone NN NN O
and NN NN O
osteocalcine NN NN B-Protein
in NN NN O
blood NN NN O
serum NN NN O
as NN NN O
well NN NN O
as NN NN O
on NN NN O
immunological NN NN O
parameters NN NN O
: NN NN O
restoration NN NN O
of NN NN O
decreased NN NN O
content NN NN O
of NN NN O
T NN NN O
- NN NN O
and NN NN O
0 NN NN O
- NN NN O
lymphocytes NN NN O
. NN NN O
   
Concentration NN NN O
of NN NN O
receptors NN NN O
of NN NN O
hormonal NN NN O
form NN NN O
of NN NN O
1 NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
minimal NN NN O
in NN NN O
lymphocytes NN NN O
under NN NN O
conditions NN NN O
of NN NN O
chronic NN NN O
kidney NN NN O
insufficiency NN NN O
, NN NN O
while NN NN O
their NN NN O
expression NN NN O
, NN NN O
after NN NN O
the NN NN O
dioxyvit NN NN O
action NN NN O
, NN NN O
was NN NN O
detected NN NN O
only NN NN O
in NN NN O
patients NN NN O
with NN NN O
glomerulonephritis NN NN O
. NN NN O
   
Specific NN NN O
calcitropic NN NN O
effect NN NN O
of NN NN O
dioxyvit NN NN O
with NN NN O
simultaneous NN NN O
correction NN NN O
of NN NN O
vitamin NN NN O
D NN NN O
deficiency NN NN O
were NN NN O
apparently NN NN O
responsible NN NN O
for NN NN O
high NN NN O
efficacy NN NN O
of NN NN O
the NN NN O
drug NN NN O
in NN NN O
treatment NN NN O
of NN NN O
calcium NN NN O
metabolism NN NN O
and NN NN O
immunity NN NN O
impairments NN NN O
in NN NN O
children NN NN O
with NN NN O
renal NN NN O
deteriorations NN NN O
at NN NN O
the NN NN O
step NN NN O
of NN NN O
chronic NN NN O
kidney NN NN O
insufficiency NN NN O
. NN NN O
   
Disruption NN NN O
of NN NN O
the NN NN O
human NN NN O
SCL NN NN B-Protein
locus NN NN O
by NN NN O
"""""""" NN NN O
illegitimate NN NN O
"""""""" NN NN O
V NN NN O
- NN NN O
( NN NN O
D NN NN O
) NN NN O
- NN NN O
J NN NN O
recombinase NN NN O
activity NN NN O
. NN NN O
   
A NN NN O
fusion NN NN O
complementary NN NN O
DNA NN NN O
in NN NN O
the NN NN O
T NN NN O
cell NN NN O
line NN NN O
HSB NN NN O
- NN NN O
2 NN NN O
elucidates NN NN O
a NN NN O
provocative NN NN O
mechanism NN NN O
for NN NN O
the NN NN O
disruption NN NN O
of NN NN O
the NN NN O
putative NN NN O
hematopoietic NN NN O
transcription NN NN O
factor NN NN O
SCL NN NN B-Protein
. NN NN O
   
The NN NN O
fusion NN NN O
cDNA NN NN O
results NN NN O
from NN NN O
an NN NN O
interstitial NN NN O
deletion NN NN O
between NN NN O
a NN NN O
previously NN NN O
unknown NN NN O
locus NN NN O
, NN NN O
SIL NN NN O
( NN NN O
SCL NN NN B-Protein
interrupting NN NN O
locus NN NN O
) NN NN O
, NN NN O
and NN NN O
the NN NN O
5 NN NN O
' NN NN O
untranslated NN NN O
region NN NN O
of NN NN O
SCL NN NN B-Protein
. NN NN O
   
Similar NN NN O
to NN NN O
1 NN NN O
; NN NN O
14 NN NN O
translocations NN NN O
, NN NN O
this NN NN O
deletion NN NN O
disrupts NN NN O
the NN NN O
SCL NN NN B-Protein
5 NN NN O
' NN NN O
regulatory NN NN O
region NN NN O
. NN NN O
   
This NN NN O
event NN NN O
is NN NN O
probably NN NN O
mediated NN NN O
by NN NN O
V NN NN O
- NN NN O
( NN NN O
D NN NN O
) NN NN O
- NN NN O
J NN NN O
recombinase NN NN O
activity NN NN O
, NN NN O
although NN NN O
neither NN NN O
locus NN NN O
is NN NN O
an NN NN O
immunoglobulin NN NN O
or NN NN O
a NN NN O
T NN NN O
cell NN NN O
receptor NN NN O
. NN NN O
   
Two NN NN O
other NN NN O
T NN NN O
cell NN NN O
lines NN NN O
, NN NN O
CEM NN NN O
and NN NN O
RPMI NN NN O
8402 NN NN O
, NN NN O
have NN NN O
essentially NN NN O
identical NN NN O
deletions NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
in NN NN O
lymphocytes NN NN O
, NN NN O
growth NN NN O
- NN NN O
affecting NN NN O
genes NN NN O
other NN NN O
than NN NN O
immune NN NN O
receptors NN NN O
risk NN NN O
rearrangements NN NN O
. NN NN O
   
[ NN NN O
Effect NN NN O
of NN NN O
the NN NN O
regimen NN NN O
of NN NN O
kidney NN NN O
- NN NN O
tonifying NN NN O
and NN NN O
qi NN NN O
- NN NN O
invigorating NN NN O
on NN NN O
aging NN NN O
changes NN NN O
of NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
] NN NN O
   
The NN NN O
plasma NN NN O
cortisol NN NN O
concentration NN NN O
and NN NN O
the NN NN O
sites NN NN O
of NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
( NN NN O
GCR NN NN B-Protein
) NN NN O
in NN NN O
the NN NN O
peripheral NN NN O
lymphocytes NN NN O
were NN NN O
measured NN NN O
in NN NN O
32 NN NN O
healthy NN NN O
aged NN NN O
persons NN NN O
and NN NN O
13 NN NN O
young NN NN O
adults NN NN O
. NN NN O
   
In NN NN O
animal NN NN O
experiment NN NN O
, NN NN O
GCR NN NN B-Protein
of NN NN O
spleen NN NN O
lymphocytic NN NN O
cell NN NN O
was NN NN O
also NN NN O
measured NN NN O
in NN NN O
18 NN NN O
aged NN NN O
rats NN NN O
and NN NN O
9 NN NN O
young NN NN O
rats NN NN O
. NN NN O
   
The NN NN O
results NN NN O
showed NN NN O
that NN NN O
GCR NN NN B-Protein
was NN NN O
significantly NN NN O
lower NN NN O
in NN NN O
the NN NN O
aged NN NN O
persons NN NN O
or NN NN O
rats NN NN O
than NN NN O
that NN NN O
in NN NN O
the NN NN O
young NN NN O
while NN NN O
the NN NN O
plasma NN NN O
cortisol NN NN O
level NN NN O
didn NN NN O
' NN NN O
t NN NN O
change NN NN O
with NN NN O
aging NN NN O
. NN NN O
   
So NN NN O
we NN NN O
think NN NN O
that NN NN O
GCR NN NN B-Protein
is NN NN O
more NN NN O
sensitive NN NN O
than NN NN O
the NN NN O
plasma NN NN O
cortisol NN NN O
level NN NN O
to NN NN O
reflect NN NN O
the NN NN O
aging NN NN O
change NN NN O
of NN NN O
the NN NN O
adrenal NN NN O
cortex NN NN O
function NN NN O
. NN NN O
   
After NN NN O
the NN NN O
treatment NN NN O
with NN NN O
the NN NN O
regimen NN NN O
of NN NN O
Kidney NN NN O
- NN NN O
tonifying NN NN O
and NN NN O
Qi NN NN O
- NN NN O
invigorating NN NN O
, NN NN O
the NN NN O
GCR NN NN B-Protein
of NN NN O
the NN NN O
aged NN NN O
persons NN NN O
and NN NN O
rats NN NN O
was NN NN O
enhanced NN NN O
, NN NN O
and NN NN O
in NN NN O
this NN NN O
way NN NN O
, NN NN O
the NN NN O
function NN NN O
of NN NN O
the NN NN O
aged NN NN O
adrenal NN NN O
cortex NN NN O
was NN NN O
improved NN NN O
. NN NN O
   
Thyroid NN NN O
hormone NN NN O
receptors NN NN O
form NN NN O
distinct NN NN O
nuclear NN NN O
protein NN NN O
- NN NN O
dependent NN NN O
and NN NN O
independent NN NN O
complexes NN NN O
with NN NN O
a NN NN O
thyroid NN NN O
hormone NN NN O
response NN NN O
element NN NN O
. NN NN O
   
We NN NN O
have NN NN O
examined NN NN O
the NN NN O
binding NN NN O
of NN NN O
nuclear NN NN O
proteins NN NN O
and NN NN O
recombinant NN NN O
thyroid NN NN O
hormone NN NN O
receptors NN NN O
( NN NN O
TRs NN NN O
) NN NN O
to NN NN O
the NN NN O
palindromic NN NN O
thyroid NN NN O
hormone NN NN O
responsive NN NN O
element NN NN O
AGGTCATGACCT NN NN O
( NN NN O
TREp NN NN O
) NN NN O
using NN NN O
a NN NN O
gel NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assay NN NN O
. NN NN O
   
Four NN NN O
specific NN NN O
protein NN NN O
- NN NN O
DNA NN NN O
complexes NN NN O
were NN NN O
detected NN NN O
after NN NN O
incubation NN NN O
of NN NN O
nuclear NN NN O
extracts NN NN O
( NN NN O
NE NN NN O
) NN NN O
from NN NN O
T3 NN NN O
- NN NN O
responsive NN NN O
pituitary NN NN O
( NN NN O
GH3 NN NN O
) NN NN O
cells NN NN O
with NN NN O
a NN NN O
TREp NN NN O
- NN NN O
containing NN NN O
DNA NN NN O
fragment NN NN O
. NN NN O
   
This NN NN O
was NN NN O
compared NN NN O
with NN NN O
the NN NN O
TREp NN NN O
binding NN NN O
of NN NN O
reticulocyte NN NN O
lysate NN NN O
- NN NN O
synthesized NN NN O
TRs NN NN O
. NN NN O
   
TR NN NN B-Protein
alpha NN NN I-Protein
1 NN NN I-Protein
and NN NN O
TR NN NN B-Protein
beta NN NN I-Protein
2 NN NN I-Protein
each NN NN O
formed NN NN O
a NN NN O
single NN NN O
major NN NN O
TR NN NN O
: NN NN O
TREp NN NN O
complex NN NN O
which NN NN O
comigrated NN NN O
with NN NN O
the NN NN O
least NN NN O
retarded NN NN O
complex NN NN O
formed NN NN O
by NN NN O
GH3 NN NN O
NE NN NN O
, NN NN O
while NN NN O
TR NN NN B-Protein
beta NN NN I-Protein
1 NN NN I-Protein
formed NN NN O
multiple NN NN O
complexes NN NN O
suggesting NN NN O
that NN NN O
it NN NN O
can NN NN O
bind NN NN O
to NN NN O
TREp NN NN O
as NN NN O
an NN NN O
oligomer NN NN O
. NN NN O
   
Interestingly NN NN O
, NN NN O
coincubation NN NN O
of NN NN O
35S NN NN O
- NN NN O
TR NN NN B-Protein
alpha NN NN I-Protein
1 NN NN I-Protein
, NN NN O
GH3 NN NN O
NE NN NN O
, NN NN O
and NN NN O
unlabeled NN NN O
TREp NN NN O
resulted NN NN O
in NN NN O
not NN NN O
only NN NN O
the NN NN O
35S NN NN O
- NN NN O
TR NN NN O
: NN NN O
TREp NN NN O
complex NN NN O
, NN NN O
but NN NN O
in NN NN O
two NN NN O
additional NN NN O
more NN NN O
greatly NN NN O
retarded NN NN O
complexes NN NN O
containing NN NN O
35S NN NN O
- NN NN O
TR NN NN B-Protein
alpha NN NN I-Protein
1 NN NN I-Protein
and NN NN O
comigrating NN NN O
with NN NN O
those NN NN O
formed NN NN O
by NN NN O
GH3 NN NN O
extract NN NN O
alone NN NN O
. NN NN O
   
Incubation NN NN O
of NN NN O
each NN NN O
of NN NN O
the NN NN O
TRs NN NN O
with NN NN O
NE NN NN O
from NN NN O
COS NN NN O
- NN NN O
7 NN NN O
cells NN NN O
, NN NN O
which NN NN O
do NN NN O
not NN NN O
possess NN NN O
sufficient NN NN O
endogenous NN NN O
TRs NN NN O
to NN NN O
mediate NN NN O
T3 NN NN O
- NN NN O
responses NN NN O
, NN NN O
resulted NN NN O
in NN NN O
formation NN NN O
of NN NN O
a NN NN O
new NN NN O
, NN NN O
more NN NN O
greatly NN NN O
shifted NN NN O
complex NN NN O
. NN NN O
   
A NN NN O
similar NN NN O
, NN NN O
heat NN NN O
labile NN NN O
activity NN NN O
which NN NN O
altered NN NN O
mobility NN NN O
of NN NN O
the NN NN O
TR NN NN O
: NN NN O
TRE NN NN O
complex NN NN O
was NN NN O
also NN NN O
present NN NN O
in NN NN O
NE NN NN O
from NN NN O
T3 NN NN O
- NN NN O
unresponsive NN NN O
JEG NN NN O
- NN NN O
3 NN NN O
cells NN NN O
. NN NN O
   
At NN NN O
high NN NN O
concentration NN NN O
of NN NN O
NE NN NN O
, NN NN O
all NN NN O
of NN NN O
the NN NN O
TR NN NN O
bound NN NN O
to NN NN O
TREp NN NN O
was NN NN O
more NN NN O
greatly NN NN O
retarded NN NN O
than NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
NE NN NN O
. NN NN O
   
Truncation NN NN O
of NN NN O
TR NN NN B-Protein
alpha NN NN I-Protein
1 NN NN I-Protein
at NN NN O
amino NN NN O
acid NN NN O
210 NN NN O
prevented NN NN O
additional NN NN O
complex NN NN O
formation NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
NE NN NN O
without NN NN O
affecting NN NN O
DNA NN NN O
binding NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
the NN NN O
carboxyl NN NN O
- NN NN O
terminus NN NN O
of NN NN O
the NN NN O
TRs NN NN O
is NN NN O
essential NN NN O
for NN NN O
interaction NN NN O
with NN NN O
nuclear NN NN O
proteins NN NN O
. NN NN O
   
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
   
[ NN NN O
Glucocorticoid NN NN B-Protein
receptors NN NN I-Protein
in NN NN O
peripheral NN NN O
blood NN NN O
lymphocytes NN NN O
of NN NN O
patients NN NN O
with NN NN O
bronchial NN NN O
asthma NN NN O
] NN NN O
   
Quantitation NN NN O
of NN NN O
glucocorticoid NN NN B-Protein
receptors NN NN I-Protein
( NN NN O
GCR NN NN B-Protein
) NN NN O
and NN NN O
the NN NN O
study NN NN O
of NN NN O
their NN NN O
affinity NN NN O
for NN NN O
glucocorticosteroids NN NN O
( NN NN O
GCS NN NN O
) NN NN O
were NN NN O
made NN NN O
in NN NN O
peripheral NN NN O
blood NN NN O
lymphocytes NN NN O
of NN NN O
bronchial NN NN O
asthma NN NN O
( NN NN O
BA NN NN O
) NN NN O
patients NN NN O
in NN NN O
consideration NN NN O
of NN NN O
GCR NN NN B-Protein
treatment NN NN O
and NN NN O
serum NN NN O
levels NN NN O
of NN NN O
endogenous NN NN O
cortisol NN NN O
. NN NN O
   
It NN NN O
is NN NN O
stated NN NN O
that NN NN O
GCR NN NN B-Protein
of NN NN O
healthy NN NN O
controls NN NN O
and NN NN O
GCS NN NN O
- NN NN O
untreated NN NN O
patients NN NN O
outnumbered NN NN O
those NN NN O
of NN NN O
cortisol NN NN O
- NN NN O
dependent NN NN O
BA NN NN O
patients NN NN O
on NN NN O
hormone NN NN O
therapy NN NN O
. NN NN O
   
Following NN NN O
discontinuation NN NN O
of NN NN O
glucocorticoid NN NN O
drugs NN NN O
GCR NN NN B-Protein
count NN NN O
in NN NN O
cortisol NN NN O
- NN NN O
dependent NN NN O
BA NN NN O
tends NN NN O
to NN NN O
rise NN NN O
. NN NN O
   
Endogenous NN NN O
cortisol NN NN O
has NN NN O
no NN NN O
effect NN NN O
on NN NN O
GCR NN NN B-Protein
level NN NN O
estimated NN NN O
by NN NN O
3H NN NN O
- NN NN O
triamcinolone NN NN O
acetonide NN NN O
. NN NN O
   
Megakaryocytic NN NN O
and NN NN O
erythrocytic NN NN O
lineages NN NN O
share NN NN O
specific NN NN O
transcription NN NN O
factors NN NN O
. NN NN O
   
Erythroid NN NN O
- NN NN O
specific NN NN O
genes NN NN O
contain NN NN O
binding NN NN O
sites NN NN O
for NN NN O
NF NN NN B-Protein
- NN NN I-Protein
E1 NN NN I-Protein
( NN NN O
also NN NN O
called NN NN O
GF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
Eryf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
; NN NN O
refs NN NN O
1 NN NN O
- NN NN O
3 NN NN O
respectively NN NN O
) NN NN O
, NN NN O
the NN NN O
principal NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
protein NN NN O
of NN NN O
the NN NN O
erythrocytic NN NN O
lineage NN NN O
. NN NN O
   
NF NN NN B-Protein
- NN NN I-Protein
E1 NN NN I-Protein
expression NN NN O
seems NN NN O
to NN NN O
be NN NN O
restricted NN NN O
to NN NN O
the NN NN O
erythrocytic NN NN O
lineage NN NN O
. NN NN O
   
A NN NN O
closely NN NN O
related NN NN O
( NN NN O
if NN NN O
not NN NN O
identical NN NN O
) NN NN O
protein NN NN O
is NN NN O
found NN NN O
in NN NN O
both NN NN O
a NN NN O
human NN NN O
megakaryocytic NN NN O
cell NN NN O
line NN NN O
and NN NN O
purified NN NN O
human NN NN O
megakaryocytes NN NN O
; NN NN O
it NN NN O
binds NN NN O
to NN NN O
promoter NN NN O
regions NN NN O
of NN NN O
two NN NN O
megakaryocytic NN NN O
- NN NN O
specific NN NN O
genes NN NN O
. NN NN O
   
The NN NN O
binding NN NN O
sites NN NN O
and NN NN O
partial NN NN O
proteolysis NN NN O
profile NN NN O
of NN NN O
this NN NN O
protein NN NN O
are NN NN O
indistinguishable NN NN O
from NN NN O
those NN NN O
of NN NN O
the NN NN O
erythroid NN NN O
protein NN NN O
; NN NN O
also NN NN O
, NN NN O
NF NN NN B-Protein
- NN NN I-Protein
E1 NN NN I-Protein
messenger NN NN O
RNA NN NN O
is NN NN O
the NN NN O
same NN NN O
size NN NN O
in NN NN O
both NN NN O
the NN NN O
megakaryocytic NN NN O
and NN NN O
erythroid NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
point NN NN O
mutations NN NN O
that NN NN O
abolish NN NN O
binding NN NN O
of NN NN O
NF NN NN B-Protein
- NN NN I-Protein
E1 NN NN I-Protein
result NN NN O
in NN NN O
a NN NN O
70 NN NN O
% NN NN O
decrease NN NN O
in NN NN O
the NN NN O
transcriptional NN NN O
activity NN NN O
of NN NN O
a NN NN O
megakaryocytic NN NN O
- NN NN O
specific NN NN O
promoter NN NN O
. NN NN O
   
We NN NN O
also NN NN O
find NN NN O
that NN NN O
NF NN NN O
- NN NN O
E2 NN NN O
, NN NN O
another NN NN O
trans NN NN O
- NN NN O
acting NN NN O
factor NN NN O
of NN NN O
the NN NN O
erythrocytic NN NN O
lineage NN NN O
, NN NN O
is NN NN O
present NN NN O
in NN NN O
megakaryocytes NN NN O
. NN NN O
   
Transcriptional NN NN O
effects NN NN O
in NN NN O
both NN NN O
lineages NN NN O
might NN NN O
then NN NN O
be NN NN O
mediated NN NN O
in NN NN O
part NN NN O
by NN NN O
the NN NN O
same NN NN O
specific NN NN O
trans NN NN O
- NN NN O
acting NN NN O
factors NN NN O
. NN NN O
   
Our NN NN O
data NN NN O
strengthen NN NN O
the NN NN O
idea NN NN O
of NN NN O
a NN NN O
close NN NN O
association NN NN O
between NN NN O
the NN NN O
erythrocytic NN NN O
and NN NN O
the NN NN O
megakaryocytic NN NN O
lineages NN NN O
and NN NN O
could NN NN O
also NN NN O
explain NN NN O
the NN NN O
expression NN NN O
of NN NN O
markers NN NN O
specific NN NN O
to NN NN O
the NN NN O
erythrocytic NN NN O
and NN NN O
megakaryocytic NN NN O
lineages NN NN O
in NN NN O
most NN NN O
erythroblastic NN NN O
and NN NN O
megakaryoblastic NN NN O
permanent NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
A NN NN O
new NN NN O
member NN NN O
of NN NN O
the NN NN O
leucine NN NN O
zipper NN NN O
class NN NN O
of NN NN O
proteins NN NN O
that NN NN O
binds NN NN O
to NN NN O
the NN NN O
HLA NN NN B-Protein
DR NN NN I-Protein
alpha NN NN I-Protein
promoter NN NN O
. NN NN O
   
Several NN NN O
mutants NN NN O
derived NN NN O
from NN NN O
transformed NN NN O
human NN NN O
B NN NN O
cell NN NN O
lines NN NN O
are NN NN O
defective NN NN O
in NN NN O
expressing NN NN O
major NN NN O
histocompatibility NN NN O
complex NN NN O
( NN NN O
MHC NN NN O
) NN NN O
class NN NN O
II NN NN O
genes NN NN O
. NN NN O
   
The NN NN O
failure NN NN O
to NN NN O
express NN NN O
a NN NN O
class NN NN O
II NN NN O
gene NN NN O
in NN NN O
at NN NN O
least NN NN O
one NN NN O
such NN NN O
mutant NN NN O
line NN NN O
has NN NN O
been NN NN O
mapped NN NN O
to NN NN O
the NN NN O
MHC NN NN O
class NN NN O
II NN NN O
X NN NN O
box NN NN O
, NN NN O
a NN NN O
conserved NN NN O
transcriptional NN NN O
element NN NN O
in NN NN O
the NN NN O
promoter NN NN O
region NN NN O
. NN NN O
   
A NN NN O
complementary NN NN O
DNA NN NN O
encoding NN NN O
a NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
protein NN NN O
( NN NN O
human NN NN B-Protein
X NN NN I-Protein
box NN NN I-Protein
binding NN NN I-Protein
protein NN NN I-Protein
, NN NN O
hXBP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
whose NN NN O
target NN NN O
is NN NN O
the NN NN O
human NN NN O
DR NN NN B-Protein
alpha NN NN I-Protein
X NN NN O
box NN NN O
and NN NN O
the NN NN O
3 NN NN O
' NN NN O
flanking NN NN O
region NN NN O
has NN NN O
now NN NN O
been NN NN O
cloned NN NN O
. NN NN O
   
This NN NN O
complementary NN NN O
DNA NN NN O
encoded NN NN O
a NN NN O
protein NN NN O
with NN NN O
structural NN NN O
similarities NN NN O
to NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
proto NN NN O
- NN NN O
oncogene NN NN O
product NN NN O
, NN NN O
and NN NN O
its NN NN O
target NN NN O
sequence NN NN O
was NN NN O
closely NN NN O
related NN NN O
to NN NN O
the NN NN O
palindromic NN NN O
target NN NN O
sequence NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
. NN NN O
   
Mutation NN NN O
of NN NN O
the NN NN O
hXBP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
DNA NN NN O
target NN NN O
sequence NN NN O
decreased NN NN O
DR NN NN B-Protein
alpha NN NN I-Protein
promoter NN NN O
activity NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
These NN NN O
studies NN NN O
suggest NN NN O
that NN NN O
the NN NN O
hXBP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
protein NN NN O
acts NN NN O
as NN NN O
a NN NN O
transcription NN NN O
factor NN NN O
in NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
Epstein NN NN B-Protein
- NN NN I-Protein
Barr NN NN I-Protein
virus NN NN I-Protein
nuclear NN NN I-Protein
antigen NN NN I-Protein
2 NN NN I-Protein
transactivates NN NN O
latent NN NN O
membrane NN NN O
protein NN NN O
LMP1 NN NN B-Protein
. NN NN O
   
Several NN NN O
lines NN NN O
of NN NN O
evidence NN NN O
are NN NN O
compatible NN NN O
with NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
Epstein NN NN B-Protein
- NN NN I-Protein
Barr NN NN I-Protein
virus NN NN I-Protein
( NN NN I-Protein
EBV NN NN I-Protein
) NN NN I-Protein
nuclear NN NN I-Protein
antigen NN NN I-Protein
2 NN NN I-Protein
( NN NN O
EBNA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
or NN NN O
leader NN NN O
protein NN NN O
( NN NN O
EBNA NN NN B-Protein
- NN NN I-Protein
LP NN NN I-Protein
) NN NN O
affects NN NN O
expression NN NN O
of NN NN O
the NN NN O
EBV NN NN O
latent NN NN O
infection NN NN O
membrane NN NN O
protein NN NN O
LMP1 NN NN B-Protein
. NN NN O
   
We NN NN O
now NN NN O
demonstrate NN NN O
the NN NN O
following NN NN O
. NN NN O
   
( NN NN O
i NN NN O
) NN NN O
Acute NN NN O
transfection NN NN O
and NN NN O
expression NN NN O
of NN NN O
EBNA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
under NN NN O
control NN NN O
of NN NN O
simian NN NN O
virus NN NN O
40 NN NN O
or NN NN O
Moloney NN NN O
murine NN NN O
leukemia NN NN O
virus NN NN O
promoters NN NN O
resulted NN NN O
in NN NN O
increased NN NN O
LMP1 NN NN B-Protein
expression NN NN O
in NN NN O
P3HR NN NN O
- NN NN O
1 NN NN O
- NN NN O
infected NN NN O
Burkitt NN NN O
' NN NN O
s NN NN O
lymphoma NN NN O
cells NN NN O
and NN NN O
the NN NN O
P3HR NN NN O
- NN NN O
1 NN NN O
or NN NN O
Daudi NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
( NN NN O
ii NN NN O
) NN NN O
Transfection NN NN O
and NN NN O
expression NN NN O
of NN NN O
EBNA NN NN B-Protein
- NN NN I-Protein
LP NN NN I-Protein
alone NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
LMP1 NN NN B-Protein
expression NN NN O
and NN NN O
did NN NN O
not NN NN O
act NN NN O
synergistically NN NN O
with NN NN O
EBNA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
to NN NN O
affect NN NN O
LMP1 NN NN B-Protein
expression NN NN O
. NN NN O
   
( NN NN O
iii NN NN O
) NN NN O
LMP1 NN NN B-Protein
expression NN NN O
in NN NN O
Daudi NN NN O
and NN NN O
P3HR NN NN O
- NN NN O
1 NN NN O
- NN NN O
infected NN NN O
cells NN NN O
was NN NN O
controlled NN NN O
at NN NN O
the NN NN O
mRNA NN NN O
level NN NN O
, NN NN O
and NN NN O
EBNA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
in NN NN O
Daudi NN NN O
cells NN NN O
increased NN NN O
LMP1 NN NN B-Protein
mRNA NN NN O
. NN NN O
   
( NN NN O
iv NN NN O
) NN NN O
No NN NN O
other NN NN O
EBV NN NN O
genes NN NN O
were NN NN O
required NN NN O
for NN NN O
EBNA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
transactivation NN NN O
of NN NN O
LMP1 NN NN B-Protein
since NN NN O
cotransfection NN NN O
of NN NN O
recombinant NN NN O
EBNA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
vectors NN NN O
and NN NN O
genomic NN NN O
LMP1 NN NN B-Protein
DNA NN NN O
fragments NN NN O
enhanced NN NN O
LMP1 NN NN B-Protein
expression NN NN O
in NN NN O
the NN NN O
EBV NN NN O
- NN NN O
negative NN NN O
B NN NN O
- NN NN O
lymphoma NN NN O
cell NN NN O
lines NN NN O
BJAB NN NN O
, NN NN O
Louckes NN NN O
, NN NN O
and NN NN O
BL30 NN NN O
. NN NN O
   
( NN NN O
v NN NN O
) NN NN O
An NN NN O
EBNA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
responsive NN NN O
element NN NN O
was NN NN O
found NN NN O
within NN NN O
the NN NN O
- NN NN O
512 NN NN O
to NN NN O
+ NN NN O
40 NN NN O
LMP1 NN NN B-Protein
DNA NN NN O
since NN NN O
this NN NN O
DNA NN NN O
linked NN NN O
to NN NN O
a NN NN O
chloramphenicol NN NN B-Protein
acetyltransferase NN NN I-Protein
reporter NN NN O
gene NN NN O
was NN NN O
transactivated NN NN O
by NN NN O
cotransfection NN NN O
with NN NN O
an NN NN O
EBNA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
vector NN NN O
. NN NN O
   
( NN NN O
vi NN NN O
) NN NN O
The NN NN O
EBV NN NN O
type NN NN O
2 NN NN O
EBNA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
transactivated NN NN O
LMP1 NN NN B-Protein
as NN NN O
well NN NN O
as NN NN O
the NN NN O
EBV NN NN O
type NN NN O
1 NN NN O
EBNA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
( NN NN O
vii NN NN O
) NN NN O
Two NN NN O
deletions NN NN O
within NN NN O
the NN NN O
EBNA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
which NN NN O
rendered NN NN O
EBV NN NN O
transformation NN NN O
incompetent NN NN O
did NN NN O
not NN NN O
transactivate NN NN O
LMP1 NN NN B-Protein
, NN NN O
whereas NN NN O
a NN NN O
transformation NN NN O
- NN NN O
competent NN NN O
EBNA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
deletion NN NN O
mutant NN NN O
did NN NN O
transactivate NN NN O
LMP1 NN NN B-Protein
. NN NN O
   
LMP1 NN NN B-Protein
is NN NN O
a NN NN O
potent NN NN O
effector NN NN O
of NN NN O
B NN NN O
- NN NN O
lymphocyte NN NN O
activation NN NN O
and NN NN O
can NN NN O
act NN NN O
synergistically NN NN O
with NN NN O
EBNA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
to NN NN O
induce NN NN O
cellular NN NN O
CD23 NN NN B-Protein
gene NN NN O
expression NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
EBNA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
transactivation NN NN O
of NN NN O
LMP1 NN NN B-Protein
amplifies NN NN O
the NN NN O
biological NN NN O
impact NN NN O
of NN NN O
EBNA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
underscores NN NN O
its NN NN O
central NN NN O
role NN NN O
in NN NN O
EBV NN NN O
- NN NN O
induced NN NN O
growth NN NN O
transformation NN NN O
. NN NN O
   
Protein NN NN O
kinase NN NN O
inhibitor NN NN O
H NN NN O
- NN NN O
7 NN NN O
blocks NN NN O
accumulation NN NN O
of NN NN O
unspliced NN NN O
mRNA NN NN O
of NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
I NN NN O
( NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
) NN NN O
. NN NN O
   
Rex NN NN B-Protein
, NN NN O
the NN NN O
post NN NN O
- NN NN O
transcriptional NN NN O
regulator NN NN O
of NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
I NN NN O
( NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
) NN NN O
, NN NN O
is NN NN O
known NN NN O
to NN NN O
induce NN NN O
accumulation NN NN O
of NN NN O
the NN NN O
unspliced NN NN O
viral NN NN O
gag NN NN B-Protein
- NN NN O
pol NN NN B-Protein
mRNA NN NN O
. NN NN O
   
Rex NN NN B-Protein
is NN NN O
a NN NN O
phosphoprotein NN NN O
found NN NN O
in NN NN O
the NN NN O
cell NN NN O
nucleolus NN NN O
, NN NN O
whose NN NN O
function NN NN O
may NN NN O
be NN NN O
regulated NN NN O
by NN NN O
its NN NN O
localization NN NN O
and NN NN O
phosphorylation NN NN O
. NN NN O
   
We NN NN O
have NN NN O
examined NN NN O
the NN NN O
role NN NN O
of NN NN O
phosphorylation NN NN O
on NN NN O
Rex NN NN B-Protein
function NN NN O
by NN NN O
using NN NN O
a NN NN O
protein NN NN O
kinase NN NN O
inhibitor NN NN O
, NN NN O
H NN NN O
- NN NN O
7 NN NN O
[ NN NN O
1 NN NN O
- NN NN O
( NN NN O
5 NN NN O
- NN NN O
isoquinolinyl NN NN O
- NN NN O
sulfonyl NN NN O
) NN NN O
- NN NN O
2 NN NN O
- NN NN O
methylpiperazine NN NN O
] NN NN O
. NN NN O
   
Treatment NN NN O
of NN NN O
an NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
infected NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
line NN NN O
with NN NN O
H NN NN O
- NN NN O
7 NN NN O
blocked NN NN O
specifically NN NN O
accumulation NN NN O
of NN NN O
the NN NN O
unspliced NN NN O
gag NN NN B-Protein
- NN NN O
pol NN NN B-Protein
mRNA NN NN O
, NN NN O
resulting NN NN O
in NN NN O
the NN NN O
decreased NN NN O
Gag NN NN B-Protein
protein NN NN O
synthesis NN NN O
that NN NN O
corresponds NN NN O
with NN NN O
the NN NN O
decreased NN NN O
in NN NN O
vivo NN NN O
phosphorylation NN NN O
of NN NN O
Rex NN NN B-Protein
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
other NN NN O
viral NN NN O
and NN NN O
cellular NN NN O
products NN NN O
have NN NN O
not NN NN O
been NN NN O
influenced NN NN O
by NN NN O
the NN NN O
level NN NN O
of NN NN O
H NN NN O
- NN NN O
7 NN NN O
used NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
the NN NN O
phosphorylation NN NN O
of NN NN O
Rex NN NN B-Protein
is NN NN O
required NN NN O
for NN NN O
the NN NN O
viral NN NN O
RNA NN NN O
partition NN NN O
of NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
. NN NN O
   
Mononuclear NN NN O
leukocyte NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
binding NN NN O
characteristics NN NN O
and NN NN O
down NN NN O
- NN NN O
regulation NN NN O
in NN NN O
major NN NN O
depression NN NN O
. NN NN O
   
Some NN NN O
patients NN NN O
with NN NN O
major NN NN O
depressive NN NN O
disorder NN NN O
( NN NN O
MDD NN NN O
) NN NN O
have NN NN O
elevated NN NN O
plasma NN NN O
cortisol NN NN O
concentrations NN NN O
and NN NN O
show NN NN O
failure NN NN O
to NN NN O
suppress NN NN O
cortisol NN NN O
secretion NN NN O
upon NN NN O
administration NN NN O
of NN NN O
dexamethasone NN NN O
( NN NN O
DEX NN NN O
) NN NN O
, NN NN O
yet NN NN O
they NN NN O
do NN NN O
not NN NN O
have NN NN O
Cushingoid NN NN O
features NN NN O
. NN NN O
   
To NN NN O
study NN NN O
whether NN NN O
this NN NN O
represents NN NN O
glucocorticoid NN NN O
( NN NN O
GC NN NN O
) NN NN O
resistance NN NN O
, NN NN O
[ NN NN O
3H NN NN O
] NN NN O
- NN NN O
DEX NN NN O
- NN NN O
binding NN NN O
assays NN NN O
were NN NN O
used NN NN O
to NN NN O
measure NN NN O
, NN NN O
in NN NN O
vitro NN NN O
, NN NN O
the NN NN O
GC NN NN O
receptor NN NN O
affinity NN NN O
( NN NN O
1 NN NN O
/ NN NN O
Kd NN NN O
) NN NN O
and NN NN O
number NN NN O
( NN NN O
Bmax NN NN O
) NN NN O
in NN NN O
mononuclear NN NN O
leukocytes NN NN O
of NN NN O
11 NN NN O
MDD NN NN O
patients NN NN O
and NN NN O
15 NN NN O
control NN NN O
subjects NN NN O
. NN NN O
   
No NN NN O
receptor NN NN O
abnormalities NN NN O
were NN NN O
detected NN NN O
in NN NN O
the NN NN O
MDD NN NN O
group NN NN O
; NN NN O
thus NN NN O
any NN NN O
cellular NN NN O
defect NN NN O
leading NN NN O
to NN NN O
a NN NN O
lack NN NN O
of NN NN O
responsiveness NN NN O
to NN NN O
GC NN NN O
in NN NN O
the NN NN O
MDD NN NN O
patients NN NN O
, NN NN O
if NN NN O
present NN NN O
, NN NN O
probably NN NN O
lies NN NN O
beyond NN NN O
the NN NN O
initial NN NN O
receptor NN NN O
binding NN NN O
. NN NN O
   
DEX NN NN O
( NN NN O
1 NN NN O
. NN NN O
0 NN NN O
mg NN NN O
orally NN NN O
) NN NN O
was NN NN O
administered NN NN O
to NN NN O
study NN NN O
in NN NN O
vivo NN NN O
GC NN NN O
receptor NN NN O
down NN NN O
- NN NN O
regulation NN NN O
. NN NN O
   
Compared NN NN O
to NN NN O
the NN NN O
control NN NN O
group NN NN O
, NN NN O
fewer NN NN O
depressed NN NN O
subjects NN NN O
down NN NN O
- NN NN O
regulated NN NN O
Bmax NN NN O
after NN NN O
DEX NN NN O
. NN NN O
   
By NN NN O
paired NN NN O
t NN NN O
- NN NN O
test NN NN O
, NN NN O
Bmax NN NN O
decreased NN NN O
significantly NN NN O
in NN NN O
the NN NN O
control NN NN O
group NN NN O
but NN NN O
not NN NN O
in NN NN O
the NN NN O
depressed NN NN O
group NN NN O
. NN NN O
   
Receptor NN NN O
number NN NN O
on NN NN O
the NN NN O
control NN NN O
day NN NN O
did NN NN O
not NN NN O
correlate NN NN O
significantly NN NN O
with NN NN O
the NN NN O
degree NN NN O
of NN NN O
receptor NN NN O
down NN NN O
- NN NN O
regulation NN NN O
, NN NN O
severity NN NN O
of NN NN O
depression NN NN O
or NN NN O
cortisol NN NN O
concentrations NN NN O
across NN NN O
all NN NN O
the NN NN O
subjects NN NN O
. NN NN O
   
These NN NN O
results NN NN O
do NN NN O
not NN NN O
lend NN NN O
support NN NN O
to NN NN O
previous NN NN O
reports NN NN O
suggesting NN NN O
that NN NN O
GC NN NN O
resistance NN NN O
in NN NN O
MDD NN NN O
results NN NN O
from NN NN O
a NN NN O
GC NN NN O
receptor NN NN O
- NN NN O
binding NN NN O
abnormality NN NN O
, NN NN O
and NN NN O
they NN NN O
emphasize NN NN O
the NN NN O
importance NN NN O
of NN NN O
considering NN NN O
receptor NN NN O
studies NN NN O
in NN NN O
the NN NN O
context NN NN O
of NN NN O
GC NN NN O
- NN NN O
mediated NN NN O
cell NN NN O
processes NN NN O
in NN NN O
order NN NN O
to NN NN O
identify NN NN O
the NN NN O
exact NN NN O
cellular NN NN O
defect NN NN O
( NN NN O
s NN NN O
) NN NN O
leading NN NN O
to NN NN O
GC NN NN O
resistance NN NN O
. NN NN O
   
The NN NN O
56 NN NN O
- NN NN O
59 NN NN O
- NN NN O
kilodalton NN NN O
protein NN NN O
identified NN NN O
in NN NN O
untransformed NN NN O
steroid NN NN O
receptor NN NN O
complexes NN NN O
is NN NN O
a NN NN O
unique NN NN O
protein NN NN O
that NN NN O
exists NN NN O
in NN NN O
cytosol NN NN O
in NN NN O
a NN NN O
complex NN NN O
with NN NN O
both NN NN O
the NN NN O
70 NN NN B-Protein
- NN NN I-Protein
and NN NN O
90 NN NN B-Protein
- NN NN I-Protein
kilodalton NN NN I-Protein
heat NN NN I-Protein
shock NN NN I-Protein
proteins NN NN I-Protein
. NN NN O
   
It NN NN O
has NN NN O
previously NN NN O
been NN NN O
shown NN NN O
that NN NN O
9S NN NN O
, NN NN O
untransformed NN NN O
progestin NN NN O
, NN NN O
estrogen NN NN O
, NN NN O
androgen NN NN O
, NN NN O
and NN NN O
glucocorticoid NN NN O
receptor NN NN O
complexes NN NN O
in NN NN O
rabbit NN NN O
uterine NN NN O
and NN NN O
liver NN NN O
cytosols NN NN O
contain NN NN O
a NN NN O
59 NN NN O
- NN NN O
kDa NN NN O
protein NN NN O
[ NN NN O
Tai NN NN O
, NN NN O
P NN NN O
. NN NN O
K NN NN O
. NN NN O
, NN NN O
Maeda NN NN O
, NN NN O
Y NN NN O
. NN NN O
, NN NN O
Nakao NN NN O
, NN NN O
K NN NN O
. NN NN O
, NN NN O
Wakim NN NN O
, NN NN O
N NN NN O
. NN NN O
G NN NN O
. NN NN O
, NN NN O
Duhring NN NN O
, NN NN O
J NN NN O
. NN NN O
L NN NN O
. NN NN O
, NN NN O
& NN NN O
Faber NN NN O
, NN NN O
L NN NN O
. NN NN O
E NN NN O
. NN NN O
( NN NN O
1986 NN NN O
) NN NN O
Biochemistry NN NN O
25 NN NN O
, NN NN O
5269 NN NN O
- NN NN O
5275 NN NN O
] NN NN O
. NN NN O
   
In NN NN O
this NN NN O
work NN NN O
we NN NN O
show NN NN O
that NN NN O
the NN NN O
monoclonal NN NN O
antibody NN NN O
KN NN NN O
382 NN NN O
/ NN NN O
EC1 NN NN O
raised NN NN O
against NN NN O
the NN NN O
rabbit NN NN O
59 NN NN O
- NN NN O
kDa NN NN O
protein NN NN O
reacts NN NN O
with NN NN O
9S NN NN O
, NN NN O
untransformed NN NN O
glucocorticoid NN NN O
receptor NN NN O
complexes NN NN O
in NN NN O
cytosol NN NN O
prepared NN NN O
from NN NN O
human NN NN O
IM NN NN O
- NN NN O
9 NN NN O
lymphocytes NN NN O
but NN NN O
not NN NN O
with NN NN O
4S NN NN O
salt NN NN O
- NN NN O
transformed NN NN O
receptors NN NN O
. NN NN O
   
The NN NN O
human NN NN O
protein NN NN O
recognized NN NN O
by NN NN O
the NN NN O
EC1 NN NN O
antibody NN NN O
is NN NN O
a NN NN O
56 NN NN O
- NN NN O
kDa NN NN O
protein NN NN O
( NN NN O
p56 NN NN O
) NN NN O
of NN NN O
moderate NN NN O
abundance NN NN O
located NN NN O
predominantly NN NN O
in NN NN O
the NN NN O
cytoplasm NN NN O
by NN NN O
indirect NN NN O
immunofluorescence NN NN O
. NN NN O
   
There NN NN O
are NN NN O
at NN NN O
least NN NN O
six NN NN O
isomorphs NN NN O
of NN NN O
p56 NN NN O
by NN NN O
two NN NN O
- NN NN O
dimensional NN NN O
gel NN NN O
analysis NN NN O
. NN NN O
   
N NN NN O
- NN NN O
Terminal NN NN O
sequencing NN NN O
( NN NN O
20 NN NN O
amino NN NN O
acids NN NN O
) NN NN O
shows NN NN O
that NN NN O
p56 NN NN O
is NN NN O
a NN NN O
unique NN NN O
human NN NN O
protein NN NN O
. NN NN O
   
When NN NN O
p56 NN NN O
is NN NN O
immunoadsorbed NN NN O
from NN NN O
IM NN NN O
- NN NN O
9 NN NN O
cell NN NN O
cytosol NN NN O
, NN NN O
both NN NN O
the NN NN O
70 NN NN B-Protein
- NN NN I-Protein
and NN NN O
90 NN NN B-Protein
- NN NN I-Protein
kDa NN NN I-Protein
heat NN NN I-Protein
shock NN NN I-Protein
proteins NN NN I-Protein
are NN NN O
coadsorbed NN NN O
in NN NN O
an NN NN O
immune NN NN O
- NN NN O
specific NN NN O
manner NN NN O
. NN NN O
   
Neither NN NN O
heat NN NN O
shock NN NN O
protein NN NN O
reacts NN NN O
directly NN NN O
with NN NN O
the NN NN O
EC1 NN NN O
antibody NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
p56 NN NN O
exists NN NN O
in NN NN O
cytosol NN NN O
in NN NN O
a NN NN O
higher NN NN O
order NN NN O
complex NN NN O
containing NN NN O
hsp70 NN NN B-Protein
and NN NN O
hsp90 NN NN B-Protein
, NN NN O
both NN NN O
of NN NN O
which NN NN O
in NN NN O
turn NN NN O
have NN NN O
been NN NN O
found NN NN O
to NN NN O
be NN NN O
associated NN NN O
with NN NN O
untransformed NN NN O
steroid NN NN O
receptors NN NN O
. NN NN O
   
Detection NN NN O
in NN NN O
non NN NN O
- NN NN O
erythroid NN NN O
cells NN NN O
of NN NN O
a NN NN O
factor NN NN O
with NN NN O
the NN NN O
binding NN NN O
characteristics NN NN O
of NN NN O
the NN NN O
erythroid NN NN O
cell NN NN O
transcription NN NN O
factor NN NN O
EF1 NN NN B-Protein
. NN NN O
   
The NN NN O
erythroid NN NN O
transcription NN NN O
factor NN NN O
erythroid NN NN B-Protein
factor NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
EF1 NN NN B-Protein
) NN NN O
plays NN NN O
a NN NN O
critical NN NN O
role NN NN O
in NN NN O
the NN NN O
transcription NN NN O
of NN NN O
erythroid NN NN O
- NN NN O
specific NN NN O
genes NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
report NN NN O
the NN NN O
presence NN NN O
of NN NN O
a NN NN O
factor NN NN O
with NN NN O
the NN NN O
mobility NN NN O
and NN NN O
sequence NN NN O
- NN NN O
specific NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
characteristics NN NN O
of NN NN O
EF1 NN NN B-Protein
at NN NN O
low NN NN O
abundance NN NN O
in NN NN O
a NN NN O
wide NN NN O
variety NN NN O
of NN NN O
non NN NN O
- NN NN O
erythroid NN NN O
cell NN NN O
types NN NN O
. NN NN O
   
This NN NN O
is NN NN O
the NN NN O
first NN NN O
report NN NN O
of NN NN O
an NN NN O
EF1 NN NN B-Protein
- NN NN O
like NN NN O
activity NN NN O
in NN NN O
non NN NN O
- NN NN O
erythroid NN NN O
cells NN NN O
and NN NN O
indicates NN NN O
that NN NN O
this NN NN O
factor NN NN O
may NN NN O
play NN NN O
a NN NN O
role NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
genes NN NN O
expressed NN NN O
in NN NN O
such NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
internal NN NN O
methionine NN NN O
codons NN NN O
of NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
II NN NN O
rex NN NN B-Protein
gene NN NN O
are NN NN O
not NN NN O
required NN NN O
for NN NN O
p24rex NN NN B-Protein
production NN NN O
or NN NN O
virus NN NN O
replication NN NN O
and NN NN O
transformation NN NN O
. NN NN O
   
Human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
types NN NN O
I NN NN O
( NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
) NN NN O
and NN NN O
II NN NN O
( NN NN O
HTLV NN NN O
- NN NN O
II NN NN O
) NN NN O
have NN NN O
two NN NN O
nonstructural NN NN O
trans NN NN O
- NN NN O
acting NN NN O
regulatory NN NN O
genes NN NN O
, NN NN O
tax NN NN B-Protein
and NN NN O
rex NN NN B-Protein
, NN NN O
located NN NN O
in NN NN O
the NN NN O
3 NN NN O
' NN NN O
region NN NN O
of NN NN O
the NN NN O
viral NN NN O
genome NN NN O
. NN NN O
   
The NN NN O
tax NN NN B-Protein
gene NN NN O
product NN NN O
( NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
p40tax NN NN B-Protein
and NN NN O
HTLV NN NN O
- NN NN O
II NN NN O
p37tax NN NN B-Protein
) NN NN O
is NN NN O
the NN NN O
transcriptional NN NN O
activator NN NN O
of NN NN O
the NN NN O
viral NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
. NN NN O
   
The NN NN O
rex NN NN B-Protein
gene NN NN O
encodes NN NN O
two NN NN O
protein NN NN O
products NN NN O
, NN NN O
p27rex NN NN B-Protein
/ NN NN O
p21rex NN NN B-Protein
and NN NN O
p26rex NN NN B-Protein
/ NN NN O
p24rex NN NN B-Protein
in NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
and NN NN O
HTLV NN NN O
- NN NN O
II NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Rex NN NN B-Protein
acts NN NN O
posttranscriptionally NN NN O
to NN NN O
facilitate NN NN O
accumulation NN NN O
of NN NN O
full NN NN O
- NN NN O
length NN NN O
gag NN NN B-Protein
/ NN NN O
pol NN NN B-Protein
and NN NN O
singly NN NN O
spliced NN NN O
env NN NN B-Protein
mRNA NN NN O
in NN NN O
the NN NN O
cytoplasm NN NN O
of NN NN O
HTLV NN NN O
- NN NN O
infected NN NN O
cells NN NN O
. NN NN O
   
Previous NN NN O
studies NN NN O
showed NN NN O
that NN NN O
the NN NN O
first NN NN O
ATG NN NN O
of NN NN O
the NN NN O
rex NN NN B-Protein
gene NN NN O
is NN NN O
critical NN NN O
for NN NN O
Rex NN NN B-Protein
production NN NN O
and NN NN O
function NN NN O
. NN NN O
   
The NN NN O
importance NN NN O
of NN NN O
the NN NN O
internal NN NN O
ATGs NN NN O
to NN NN O
Rex NN NN B-Protein
function NN NN O
is NN NN O
not NN NN O
known NN NN O
. NN NN O
   
However NN NN O
, NN NN O
in NN NN O
vitro NN NN O
mutagenesis NN NN O
of NN NN O
the NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
rex NN NN B-Protein
gene NN NN O
has NN NN O
provided NN NN O
indirect NN NN O
evidence NN NN O
which NN NN O
suggests NN NN O
that NN NN O
p21rex NN NN B-Protein
, NN NN O
and NN NN O
by NN NN O
analogy NN NN O
HTLV NN NN O
- NN NN O
II NN NN O
p24rex NN NN B-Protein
, NN NN O
results NN NN O
from NN NN O
initiation NN NN O
at NN NN O
an NN NN O
internal NN NN O
AUG NN NN O
of NN NN O
the NN NN O
tax NN NN B-Protein
/ NN NN I-Protein
rex NN NN I-Protein
mRNA NN NN O
. NN NN O
   
By NN NN O
using NN NN O
an NN NN O
infectious NN NN O
molecular NN NN O
clone NN NN O
of NN NN O
HTLV NN NN O
- NN NN O
II NN NN O
, NN NN O
we NN NN O
investigated NN NN O
the NN NN O
importance NN NN O
of NN NN O
the NN NN O
internal NN NN O
ATGs NN NN O
of NN NN O
the NN NN O
rex NN NN B-Protein
gene NN NN O
on NN NN O
Rex NN NN B-Protein
protein NN NN O
production NN NN O
and NN NN O
function NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
indicate NN NN O
that NN NN O
p24rex NN NN B-Protein
of NN NN O
HTLV NN NN O
- NN NN O
II NN NN O
is NN NN O
not NN NN O
initiated NN NN O
at NN NN O
an NN NN O
internal NN NN O
AUG NN NN O
and NN NN O
that NN NN O
the NN NN O
internal NN NN O
methionine NN NN O
codons NN NN O
are NN NN O
not NN NN O
crucial NN NN O
to NN NN O
the NN NN O
function NN NN O
of NN NN O
the NN NN O
rex NN NN B-Protein
gene NN NN O
and NN NN O
, NN NN O
ultimately NN NN O
, NN NN O
the NN NN O
transforming NN NN O
properties NN NN O
of NN NN O
the NN NN O
virus NN NN O
. NN NN O
   
[ NN NN O
Glucocorticoid NN NN B-Protein
receptors NN NN I-Protein
on NN NN O
human NN NN O
peripheral NN NN O
mononuclear NN NN O
and NN NN O
polymorphonuclear NN NN O
leucocytes NN NN O
: NN NN O
changes NN NN O
in NN NN O
patients NN NN O
with NN NN O
yang NN NN O
- NN NN O
deficiency NN NN O
] NN NN O
   
It NN NN O
was NN NN O
found NN NN O
that NN NN O
, NN NN O
in NN NN O
former NN NN O
works NN NN O
, NN NN O
the NN NN O
glucocorticoid NN NN B-Protein
receptors NN NN I-Protein
( NN NN O
GCR NN NN B-Protein
) NN NN O
on NN NN O
peripheral NN NN O
mixed NN NN O
leucocytes NN NN O
in NN NN O
patients NN NN O
with NN NN O
Yang NN NN O
- NN NN O
deficiency NN NN O
were NN NN O
decreased NN NN O
. NN NN O
   
In NN NN O
this NN NN O
work NN NN O
, NN NN O
the NN NN O
mixed NN NN O
leucocytes NN NN O
were NN NN O
further NN NN O
separated NN NN O
into NN NN O
mononuclear NN NN O
( NN NN O
MNL NN NN O
) NN NN O
and NN NN O
polymorphonuclear NN NN O
( NN NN O
PML NN NN O
) NN NN O
leucocytes NN NN O
, NN NN O
and NN NN O
GCR NN NN B-Protein
were NN NN O
determined NN NN O
in NN NN O
each NN NN O
part NN NN O
of NN NN O
leucocytes NN NN O
. NN NN O
   
GCR NN NN B-Protein
on NN NN O
MNL NN NN O
and NN NN O
PML NN NN O
in NN NN O
6 NN NN O
Yang NN NN O
deficient NN NN O
patients NN NN O
were NN NN O
3473 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
413 NN NN O
and NN NN O
4433 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
651 NN NN O
sites NN NN O
/ NN NN O
cell NN NN O
respectively NN NN O
, NN NN O
statistically NN NN O
significant NN NN O
from NN NN O
the NN NN O
normal NN NN O
control NN NN O
group NN NN O
( NN NN O
4462 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
962 NN NN O
and NN NN O
5622 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
782 NN NN O
sites NN NN O
/ NN NN O
cell NN NN O
respectively NN NN O
, NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
GCR NN NN B-Protein
on NN NN O
MNL NN NN O
, NN NN O
PML NN NN O
and NN NN O
mixed NN NN O
leucocytes NN NN O
in NN NN O
5 NN NN O
patients NN NN O
were NN NN O
determined NN NN O
simultaneously NN NN O
, NN NN O
and NN NN O
all NN NN O
lowered NN NN O
from NN NN O
the NN NN O
control NN NN O
group NN NN O
. NN NN O
   
The NN NN O
results NN NN O
were NN NN O
3369 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
370 NN NN O
, NN NN O
4986 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
419 NN NN O
and NN NN O
4524 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
852 NN NN O
sites NN NN O
/ NN NN O
cell NN NN O
respectively NN NN O
, NN NN O
with NN NN O
the NN NN O
lowest NN NN O
GCR NN NN B-Protein
on NN NN O
MNL NN NN O
and NN NN O
highest NN NN O
on NN NN O
PML NN NN O
. NN NN O
   
The NN NN O
murine NN NN O
BCL6 NN NN B-Protein
gene NN NN O
is NN NN O
induced NN NN O
in NN NN O
activated NN NN O
lymphocytes NN NN O
as NN NN O
an NN NN O
immediate NN NN O
early NN NN O
gene NN NN O
. NN NN O
   
The NN NN O
chromosomal NN NN O
translocation NN NN O
involving NN NN O
3q27 NN NN O
is NN NN O
often NN NN O
detected NN NN O
in NN NN O
human NN NN O
B NN NN O
- NN NN O
cell NN NN O
lymphomas NN NN O
, NN NN O
especially NN NN O
diffuse NN NN O
lymphomas NN NN O
with NN NN O
a NN NN O
large NN NN O
- NN NN O
cell NN NN O
component NN NN O
. NN NN O
   
The NN NN O
BCL6 NN NN B-Protein
gene NN NN O
has NN NN O
been NN NN O
isolated NN NN O
from NN NN O
the NN NN O
chromosomal NN NN O
breakpoint NN NN O
in NN NN O
these NN NN O
lymphomas NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
cloned NN NN O
the NN NN O
murine NN NN O
BCL6 NN NN B-Protein
( NN NN O
mBCL6 NN NN B-Protein
) NN NN O
cDNA NN NN O
from NN NN O
the NN NN O
muscle NN NN O
cDNA NN NN O
library NN NN O
using NN NN O
the NN NN O
human NN NN O
BCL6 NN NN B-Protein
( NN NN O
hBCL6 NN NN B-Protein
) NN NN O
cDNA NN NN O
as NN NN O
a NN NN O
probe NN NN O
. NN NN O
   
The NN NN O
predicted NN NN O
amino NN NN O
acid NN NN O
sequence NN NN O
was NN NN O
95 NN NN O
% NN NN O
identical NN NN O
to NN NN O
that NN NN O
of NN NN O
hBCL6 NN NN B-Protein
. NN NN O
   
It NN NN O
contains NN NN O
six NN NN O
repeats NN NN O
of NN NN O
the NN NN O
Kruppel NN NN O
- NN NN O
like NN NN O
zinc NN NN O
- NN NN O
finger NN NN O
motif NN NN O
that NN NN O
are NN NN O
completely NN NN O
identical NN NN O
to NN NN O
those NN NN O
of NN NN O
hBCL6 NN NN B-Protein
, NN NN O
indicating NN NN O
that NN NN O
the NN NN O
BCL6 NN NN B-Protein
gene NN NN O
is NN NN O
well NN NN O
conserved NN NN O
between NN NN O
humans NN NN O
and NN NN O
mice NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
the NN NN O
mBCL6 NN NN B-Protein
gene NN NN O
was NN NN O
ubiquitously NN NN O
detected NN NN O
in NN NN O
adult NN NN O
mouse NN NN O
tissues NN NN O
including NN NN O
lymphatic NN NN O
organs NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
it NN NN O
was NN NN O
induced NN NN O
in NN NN O
lymphocytes NN NN O
activated NN NN O
with NN NN O
phorbol NN NN O
ester NN NN O
and NN NN O
Ca2 NN NN O
+ NN NN O
ionophore NN NN O
within NN NN O
30 NN NN O
min NN NN O
after NN NN O
stimulation NN NN O
. NN NN O
   
This NN NN O
induction NN NN O
was NN NN O
not NN NN O
inhibited NN NN O
by NN NN O
treatment NN NN O
of NN NN O
the NN NN O
cells NN NN O
with NN NN O
a NN NN O
protein NN NN O
synthesis NN NN O
inhibitor NN NN O
, NN NN O
cycloheximide NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
BCL6 NN NN B-Protein
plays NN NN O
a NN NN O
role NN NN O
in NN NN O
activated NN NN O
lymphocytes NN NN O
as NN NN O
an NN NN O
immediate NN NN O
early NN NN O
gene NN NN O
. NN NN O
   
Bik NN NN B-Protein
, NN NN O
a NN NN O
novel NN NN O
death NN NN O
- NN NN O
inducing NN NN O
protein NN NN O
shares NN NN O
a NN NN O
distinct NN NN O
sequence NN NN O
motif NN NN O
with NN NN O
Bcl NN NN O
- NN NN O
2 NN NN O
family NN NN O
proteins NN NN O
and NN NN O
interacts NN NN O
with NN NN O
viral NN NN O
and NN NN O
cellular NN NN O
survival NN NN O
- NN NN O
promoting NN NN O
proteins NN NN O
. NN NN O
   
The NN NN O
survival NN NN O
- NN NN O
promoting NN NN O
activity NN NN O
of NN NN O
the NN NN O
Bcl NN NN O
- NN NN O
2 NN NN O
family NN NN O
of NN NN O
proteins NN NN O
appears NN NN O
to NN NN O
be NN NN O
modulated NN NN O
by NN NN O
interactions NN NN O
between NN NN O
various NN NN O
cellular NN NN O
proteins NN NN O
. NN NN O
   
We NN NN O
have NN NN O
identified NN NN O
a NN NN O
novel NN NN O
cellular NN NN O
protein NN NN O
, NN NN O
Bik NN NN B-Protein
, NN NN O
that NN NN O
interacts NN NN O
with NN NN O
the NN NN O
cellular NN NN O
survival NN NN O
- NN NN O
promoting NN NN O
proteins NN NN O
, NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
xL NN NN I-Protein
, NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
viral NN NN O
survival NN NN O
- NN NN O
promoting NN NN O
proteins NN NN O
, NN NN O
Epstein NN NN O
Barr NN NN O
virus NN NN O
- NN NN O
BHRF1 NN NN B-Protein
and NN NN O
adenovirus NN NN O
E1B NN NN B-Protein
- NN NN I-Protein
19 NN NN I-Protein
kDa NN NN I-Protein
. NN NN O
   
In NN NN O
transient NN NN O
transfection NN NN O
assays NN NN O
, NN NN O
Bik NN NN B-Protein
promotes NN NN O
cell NN NN O
death NN NN O
in NN NN O
a NN NN O
manner NN NN O
similar NN NN O
to NN NN O
the NN NN O
death NN NN O
- NN NN O
promoting NN NN O
members NN NN O
of NN NN O
the NN NN O
Bcl NN NN O
- NN NN O
2 NN NN O
family NN NN O
, NN NN O
Bax NN NN B-Protein
and NN NN O
Bak NN NN B-Protein
. NN NN O
   
This NN NN O
death NN NN O
- NN NN O
promoting NN NN O
activity NN NN O
of NN NN O
Bik NN NN B-Protein
can NN NN O
be NN NN O
suppressed NN NN O
by NN NN O
coexpression NN NN O
of NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
XL NN NN I-Protein
, NN NN O
EBV NN NN B-Protein
- NN NN I-Protein
BHRF1 NN NN I-Protein
and NN NN O
E1B NN NN O
- NN NN O
19 NN NN O
kDa NN NN O
proteins NN NN O
suggesting NN NN O
that NN NN O
Bik NN NN B-Protein
may NN NN O
be NN NN O
a NN NN O
common NN NN O
target NN NN O
for NN NN O
both NN NN O
cellular NN NN O
and NN NN O
viral NN NN O
anti NN NN O
- NN NN O
apoptotic NN NN O
proteins NN NN O
. NN NN O
   
While NN NN O
Bik NN NN B-Protein
does NN NN O
not NN NN O
show NN NN O
overt NN NN O
homology NN NN O
to NN NN O
the NN NN O
BH1 NN NN B-Protein
and NN NN O
BH2 NN NN B-Protein
conserved NN NN O
domains NN NN O
characteristic NN NN O
of NN NN O
the NN NN O
Bcl NN NN O
- NN NN O
2 NN NN O
family NN NN O
, NN NN O
it NN NN O
does NN NN O
share NN NN O
a NN NN O
9 NN NN O
amino NN NN O
acid NN NN O
domain NN NN O
( NN NN O
BH3 NN NN B-Protein
) NN NN O
with NN NN O
Bax NN NN B-Protein
and NN NN O
Bak NN NN B-Protein
which NN NN O
may NN NN O
be NN NN O
a NN NN O
critical NN NN O
determinant NN NN O
for NN NN O
the NN NN O
death NN NN O
- NN NN O
promoting NN NN O
activity NN NN O
of NN NN O
these NN NN O
proteins NN NN O
. NN NN O
   
Staphylococcal NN NN O
enterotoxins NN NN O
modulate NN NN O
interleukin NN NN O
2 NN NN O
receptor NN NN O
expression NN NN O
and NN NN O
ligand NN NN O
- NN NN O
induced NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
the NN NN O
Janus NN NN B-Protein
protein NN NN I-Protein
- NN NN I-Protein
tyrosine NN NN I-Protein
kinase NN NN I-Protein
3 NN NN I-Protein
( NN NN O
Jak3 NN NN B-Protein
) NN NN O
and NN NN O
signal NN NN O
transducers NN NN O
and NN NN O
activators NN NN O
of NN NN O
transcription NN NN O
( NN NN O
Stat NN NN O
proteins NN NN O
) NN NN O
. NN NN O
   
Staphylococcal NN NN O
enterotoxins NN NN O
( NN NN O
SE NN NN O
) NN NN O
stimulate NN NN O
T NN NN O
cells NN NN O
expressing NN NN O
the NN NN O
appropriate NN NN O
variable NN NN O
region NN NN O
beta NN NN O
chain NN NN O
of NN NN O
( NN NN O
V NN NN O
beta NN NN O
) NN NN O
T NN NN O
- NN NN O
cell NN NN O
receptors NN NN O
and NN NN O
have NN NN O
been NN NN O
implicated NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
several NN NN O
autoimmune NN NN O
diseases NN NN O
. NN NN O
   
Depending NN NN O
on NN NN O
costimulatory NN NN O
signals NN NN O
, NN NN O
SE NN NN O
induce NN NN O
either NN NN O
proliferation NN NN O
or NN NN O
anergy NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
SE NN NN O
can NN NN O
induce NN NN O
an NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
nonresponsive NN NN O
state NN NN O
and NN NN O
apoptosis NN NN O
. NN NN O
   
Here NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
SE NN NN O
induce NN NN O
dynamic NN NN O
changes NN NN O
in NN NN O
the NN NN O
expression NN NN O
of NN NN O
and NN NN O
signal NN NN O
transduction NN NN O
through NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
receptor NN NN I-Protein
( NN NN I-Protein
IL NN NN I-Protein
- NN NN I-Protein
2R NN NN I-Protein
) NN NN I-Protein
beta NN NN I-Protein
and NN NN O
gamma NN NN B-Protein
chains NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
beta NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
gamma NN NN I-Protein
) NN NN O
in NN NN O
human NN NN O
antigen NN NN O
- NN NN O
specific NN NN O
CD4 NN NN B-Protein
+ NN NN O
T NN NN O
- NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
after NN NN O
4 NN NN O
hr NN NN O
of NN NN O
exposure NN NN O
to NN NN O
SEA NN NN B-Protein
and NN NN O
SEB NN NN B-Protein
, NN NN O
the NN NN O
expression NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
beta NN NN I-Protein
was NN NN O
down NN NN O
- NN NN O
regulated NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
gamma NN NN I-Protein
was NN NN O
slightly NN NN O
up NN NN O
- NN NN O
regulated NN NN O
, NN NN O
while NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
remained NN NN O
largely NN NN O
unaffected NN NN O
. NN NN O
   
The NN NN O
changes NN NN O
in NN NN O
the NN NN O
composition NN NN O
of NN NN O
IL NN NN O
- NN NN O
2Rs NN NN O
were NN NN O
accompanied NN NN O
by NN NN O
inhibition NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
induced NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
the NN NN O
Janus NN NN B-Protein
protein NN NN I-Protein
- NN NN I-Protein
tyrosine NN NN I-Protein
kinase NN NN I-Protein
3 NN NN I-Protein
( NN NN O
Jak3 NN NN B-Protein
) NN NN O
and NN NN O
signal NN NN O
transducers NN NN O
and NN NN O
activators NN NN O
of NN NN O
transcription NN NN O
called NN NN O
Stat3 NN NN B-Protein
and NN NN O
Stat5 NN NN B-Protein
. NN NN O
   
In NN NN O
parallel NN NN O
experiments NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
driven NN NN O
proliferation NN NN O
was NN NN O
inhibited NN NN O
significantly NN NN O
. NN NN O
   
After NN NN O
16 NN NN O
hr NN NN O
of NN NN O
exposure NN NN O
to NN NN O
SE NN NN O
, NN NN O
the NN NN O
expression NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
beta NN NN I-Protein
remained NN NN O
low NN NN O
, NN NN O
while NN NN O
that NN NN O
of NN NN O
IL2R NN NN B-Protein
alpha NN NN I-Protein
and NN NN O
IL2R NN NN B-Protein
gamma NN NN I-Protein
was NN NN O
further NN NN O
up NN NN O
- NN NN O
regulated NN NN O
, NN NN O
and NN NN O
ligand NN NN O
- NN NN O
induced NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
Jak3 NN NN B-Protein
and NN NN O
Stat NN NN O
proteins NN NN O
was NN NN O
partly NN NN O
normalized NN NN O
. NN NN O
   
Yet NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
driven NN NN O
proliferation NN NN O
remained NN NN O
profoundly NN NN O
inhibited NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
signaling NN NN O
events NN NN O
other NN NN O
than NN NN O
Jak3 NN NN B-Protein
/ NN NN O
Stat NN NN O
activation NN NN O
had NN NN O
also NN NN O
been NN NN O
changed NN NN O
following NN NN O
SE NN NN O
stimulation NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
our NN NN O
data NN NN O
suggest NN NN O
that NN NN O
SE NN NN O
can NN NN O
modulate NN NN O
IL NN NN O
- NN NN O
2R NN NN O
expression NN NN O
and NN NN O
signal NN NN O
transduction NN NN O
involving NN NN O
the NN NN O
Jak NN NN O
/ NN NN O
Stat NN NN O
pathway NN NN O
in NN NN O
CD4 NN NN B-Protein
+ NN NN O
T NN NN O
- NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Mutation NN NN O
of NN NN O
Jak3 NN NN B-Protein
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
SCID NN NN O
: NN NN O
essential NN NN O
role NN NN O
of NN NN O
Jak3 NN NN B-Protein
in NN NN O
lymphoid NN NN O
development NN NN O
. NN NN O
   
Males NN NN O
with NN NN O
X NN NN O
- NN NN O
linked NN NN O
severe NN NN O
combined NN NN O
immunodeficiency NN NN O
( NN NN O
XSCID NN NN O
) NN NN O
have NN NN O
defects NN NN O
in NN NN O
the NN NN O
common NN NN O
cytokine NN NN B-Protein
receptor NN NN I-Protein
gamma NN NN I-Protein
chain NN NN I-Protein
( NN NN O
gamma NN NN B-Protein
c NN NN I-Protein
) NN NN O
gene NN NN O
that NN NN O
encodes NN NN O
a NN NN O
shared NN NN O
, NN NN O
essential NN NN O
component NN NN O
of NN NN O
the NN NN O
receptors NN NN O
of NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
7 NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
9 NN NN I-Protein
, NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
15 NN NN I-Protein
. NN NN O
   
The NN NN O
Janus NN NN O
family NN NN O
tyrosine NN NN O
kinase NN NN O
Jak3 NN NN B-Protein
is NN NN O
the NN NN O
only NN NN O
signaling NN NN O
molecule NN NN O
known NN NN O
to NN NN O
be NN NN O
associated NN NN O
with NN NN O
gamma NN NN B-Protein
c NN NN I-Protein
, NN NN O
so NN NN O
it NN NN O
was NN NN O
hypothesized NN NN O
that NN NN O
defects NN NN O
in NN NN O
Jak3 NN NN B-Protein
might NN NN O
cause NN NN O
an NN NN O
XSCID NN NN O
- NN NN O
like NN NN O
phenotype NN NN O
. NN NN O
   
A NN NN O
girl NN NN O
with NN NN O
immunological NN NN O
features NN NN O
indistinguishable NN NN O
from NN NN O
those NN NN O
of NN NN O
XSCID NN NN O
was NN NN O
therefore NN NN O
selected NN NN O
for NN NN O
analysis NN NN O
. NN NN O
   
An NN NN O
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
( NN NN O
EBV NN NN O
) NN NN O
- NN NN O
transformed NN NN O
cell NN NN O
line NN NN O
derived NN NN O
from NN NN O
her NN NN O
lymphocytes NN NN O
had NN NN O
normal NN NN O
gamma NN NN B-Protein
c NN NN I-Protein
expression NN NN O
but NN NN O
lacked NN NN O
Jak3 NN NN B-Protein
protein NN NN O
and NN NN O
had NN NN O
greatly NN NN O
diminished NN NN O
Jak3 NN NN B-Protein
messenger NN NN O
RNA NN NN O
. NN NN O
   
Sequencing NN NN O
revealed NN NN O
a NN NN O
different NN NN O
mutation NN NN O
on NN NN O
each NN NN O
allele NN NN O
: NN NN O
a NN NN O
single NN NN O
nucleotide NN NN O
insertion NN NN O
resulting NN NN O
in NN NN O
a NN NN O
frame NN NN O
shift NN NN O
and NN NN O
premature NN NN O
termination NN NN O
in NN NN O
the NN NN O
Jak3 NN NN B-Protein
JH4 NN NN O
domain NN NN O
and NN NN O
a NN NN O
nonsense NN NN O
mutation NN NN O
in NN NN O
the NN NN O
Jak3 NN NN B-Protein
JH2 NN NN O
domain NN NN O
. NN NN O
   
The NN NN O
lack NN NN O
of NN NN O
Jak3 NN NN B-Protein
expression NN NN O
correlated NN NN O
with NN NN O
impaired NN NN O
B NN NN O
cell NN NN O
signaling NN NN O
, NN NN O
as NN NN O
demonstrated NN NN O
by NN NN O
the NN NN O
inability NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
to NN NN O
activate NN NN O
Stat6 NN NN B-Protein
in NN NN O
the NN NN O
EBV NN NN O
- NN NN O
transformed NN NN O
cell NN NN O
line NN NN O
from NN NN O
the NN NN O
patient NN NN O
. NN NN O
   
These NN NN O
observations NN NN O
indicate NN NN O
that NN NN O
the NN NN O
functions NN NN O
of NN NN O
gamma NN NN B-Protein
c NN NN I-Protein
are NN NN O
dependent NN NN O
on NN NN O
Jak3 NN NN B-Protein
and NN NN O
that NN NN O
Jak3 NN NN B-Protein
is NN NN O
essential NN NN O
for NN NN O
lymphoid NN NN O
development NN NN O
and NN NN O
signaling NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
dexamethasone NN NN O
binding NN NN O
to NN NN O
human NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
by NN NN O
New NN NN O
World NN NN O
primate NN NN O
cell NN NN O
extracts NN NN O
. NN NN O
   
To NN NN O
determine NN NN O
if NN NN O
New NN NN O
World NN NN O
primates NN NN O
express NN NN O
an NN NN O
inhibitor NN NN O
that NN NN O
influences NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
( NN NN O
GR NN NN B-Protein
) NN NN O
binding NN NN O
characteristics NN NN O
, NN NN O
we NN NN O
examined NN NN O
[ NN NN O
3H NN NN O
] NN NN O
dexamethasone NN NN O
binding NN NN O
in NN NN O
cytosol NN NN O
prepared NN NN O
from NN NN O
B95 NN NN O
- NN NN O
8 NN NN O
lymphoid NN NN O
cells NN NN O
, NN NN O
derived NN NN O
from NN NN O
the NN NN O
cotton NN NN O
top NN NN O
tamarin NN NN O
( NN NN O
Saguinus NN NN O
oedipus NN NN O
) NN NN O
, NN NN O
in NN NN O
combination NN NN O
with NN NN O
cytosol NN NN O
prepared NN NN O
from NN NN O
human NN NN O
or NN NN O
rat NN NN O
tissues NN NN O
. NN NN O
   
B95 NN NN O
- NN NN O
8 NN NN O
cytosol NN NN O
inhibited NN NN O
specific NN NN O
binding NN NN O
of NN NN O
[ NN NN O
3H NN NN O
] NN NN O
dexamethasone NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
when NN NN O
mixed NN NN O
with NN NN O
cytosol NN NN O
prepared NN NN O
from NN NN O
either NN NN O
a NN NN O
human NN NN O
lymphoid NN NN O
cell NN NN O
line NN NN O
( NN NN O
HL NN NN O
) NN NN O
or NN NN O
rat NN NN O
thymus NN NN O
. NN NN O
   
The NN NN O
inhibitory NN NN O
activity NN NN O
was NN NN O
heat NN NN O
labile NN NN O
and NN NN O
trypsin NN NN O
sensitive NN NN O
. NN NN O
   
Peak NN NN O
inhibitory NN NN O
activity NN NN O
was NN NN O
found NN NN O
in NN NN O
the NN NN O
150 NN NN O
- NN NN O
200 NN NN O
kd NN NN O
fractions NN NN O
after NN NN O
Sephacryl NN NN O
G NN NN O
- NN NN O
200 NN NN O
ultrafiltration NN NN O
. NN NN O
   
Scatchard NN NN O
analysis NN NN O
of NN NN O
[ NN NN O
3H NN NN O
] NN NN O
dexamethasone NN NN O
binding NN NN O
using NN NN O
mixed NN NN O
cytosol NN NN O
showed NN NN O
a NN NN O
diminished NN NN O
GR NN NN B-Protein
apparent NN NN O
binding NN NN O
affinity NN NN O
when NN NN O
compared NN NN O
to NN NN O
HL NN NN O
cytosol NN NN O
. NN NN O
   
Kinetic NN NN O
studies NN NN O
using NN NN O
mixed NN NN O
cytosol NN NN O
indicated NN NN O
that NN NN O
B95 NN NN O
- NN NN O
8 NN NN O
cytosol NN NN O
did NN NN O
not NN NN O
affect NN NN O
the NN NN O
apparent NN NN O
dissociation NN NN O
rate NN NN O
of NN NN O
[ NN NN O
3H NN NN O
] NN NN O
dexamethasone NN NN O
. NN NN O
   
These NN NN O
data NN NN O
demonstrate NN NN O
that NN NN O
B95 NN NN O
- NN NN O
8 NN NN O
cells NN NN O
contain NN NN O
a NN NN O
competitive NN NN O
inhibitor NN NN O
that NN NN O
prevents NN NN O
binding NN NN O
of NN NN O
dexamethasone NN NN O
to NN NN O
its NN NN O
cognate NN NN O
receptor NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
the NN NN O
chemokine NN NN O
receptor NN NN O
BLR2 NN NN B-Protein
/ NN NN O
EBI1 NN NN B-Protein
is NN NN O
specifically NN NN O
transactivated NN NN O
by NN NN O
Epstein NN NN B-Protein
- NN NN I-Protein
Barr NN NN I-Protein
virus NN NN I-Protein
nuclear NN NN I-Protein
antigen NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
In NN NN O
our NN NN O
attempt NN NN O
to NN NN O
identify NN NN O
chemokine NN NN O
receptors NN NN O
that NN NN O
are NN NN O
related NN NN O
to NN NN O
Burkitt NN NN B-Protein
' NN NN I-Protein
s NN NN I-Protein
lymphoma NN NN I-Protein
receptor NN NN I-Protein
1 NN NN I-Protein
( NN NN O
BLR1 NN NN B-Protein
) NN NN O
and NN NN O
are NN NN O
expressed NN NN O
in NN NN O
activated NN NN O
lymphocytes NN NN O
we NN NN O
used NN NN O
RT NN NN O
- NN NN O
PCR NN NN O
resulting NN NN O
in NN NN O
the NN NN O
isolation NN NN O
of NN NN O
a NN NN O
cDNA NN NN O
encoding NN NN O
a NN NN O
seven NN NN O
transmembrane NN NN O
receptor NN NN O
termed NN NN O
BLR2 NN NN B-Protein
. NN NN O
   
The NN NN O
protein NN NN O
shows NN NN O
significant NN NN O
sequence NN NN O
similarities NN NN O
to NN NN O
the NN NN O
family NN NN O
of NN NN O
G NN NN O
- NN NN O
protein NN NN O
coupled NN NN O
chemokine NN NN O
receptors NN NN O
and NN NN O
turned NN NN O
out NN NN O
to NN NN O
be NN NN O
identical NN NN O
to NN NN O
the NN NN O
recently NN NN O
described NN NN O
receptor NN NN O
EBI1 NN NN B-Protein
. NN NN O
   
Northern NN NN O
blot NN NN O
analysis NN NN O
revealed NN NN O
that NN NN O
BLR2 NN NN B-Protein
mRNA NN NN O
could NN NN O
be NN NN O
highly NN NN O
stimulated NN NN O
in NN NN O
mitogen NN NN O
- NN NN O
and NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
- NN NN O
treated NN NN O
peripheral NN NN O
blood NN NN O
lymphocytes NN NN O
. NN NN O
   
BLR2 NN NN B-Protein
- NN NN O
specific NN NN O
mRNA NN NN O
could NN NN O
be NN NN O
detected NN NN O
in NN NN O
all NN NN O
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
positive NN NN O
B NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
We NN NN O
show NN NN O
that NN NN O
transcription NN NN O
of NN NN O
the NN NN O
BLR2 NN NN B-Protein
gene NN NN O
could NN NN O
be NN NN O
specifically NN NN O
induced NN NN O
in NN NN O
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
negative NN NN O
BL NN NN O
41 NN NN O
cells NN NN O
via NN NN O
estrogen NN NN O
- NN NN O
mediated NN NN O
activation NN NN O
of NN NN O
Epstein NN NN B-Protein
- NN NN I-Protein
Barr NN NN I-Protein
virus NN NN I-Protein
nuclear NN NN I-Protein
antigen NN NN I-Protein
2 NN NN I-Protein
, NN NN O
a NN NN O
key NN NN O
regulator NN NN O
of NN NN O
viral NN NN O
and NN NN O
cellular NN NN O
genes NN NN O
in NN NN O
immortalized NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
Our NN NN O
data NN NN O
suggest NN NN O
an NN NN O
involvement NN NN O
of NN NN O
BLR2 NN NN B-Protein
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
migration NN NN O
in NN NN O
activated NN NN O
lymphocytes NN NN O
and NN NN O
in NN NN O
viral NN NN O
pathogenesis NN NN O
. NN NN O
   
Interleukin NN NN B-Protein
- NN NN I-Protein
7 NN NN I-Protein
can NN NN O
induce NN NN O
the NN NN O
activation NN NN O
of NN NN O
Jak NN NN B-Protein
1 NN NN I-Protein
, NN NN O
Jak NN NN B-Protein
3 NN NN I-Protein
and NN NN O
STAT NN NN B-Protein
5 NN NN I-Protein
proteins NN NN O
in NN NN O
murine NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
activation NN NN O
of NN NN O
Janus NN NN O
protein NN NN O
tyrosine NN NN O
kinases NN NN O
( NN NN O
Jak NN NN O
) NN NN O
and NN NN O
STAT NN NN O
( NN NN O
signal NN NN O
transducer NN NN O
and NN NN O
activator NN NN O
of NN NN O
transcription NN NN O
) NN NN O
proteins NN NN O
has NN NN O
recently NN NN O
been NN NN O
linked NN NN O
to NN NN O
the NN NN O
signal NN NN O
transduction NN NN O
mechanism NN NN O
of NN NN O
several NN NN O
cytokines NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
7 NN NN I-Protein
was NN NN O
observed NN NN O
to NN NN O
induce NN NN O
a NN NN O
rapid NN NN O
and NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
Jak NN NN B-Protein
1 NN NN I-Protein
and NN NN O
Jak NN NN B-Protein
3 NN NN I-Protein
and NN NN O
concomitantly NN NN O
, NN NN O
the NN NN O
tyrosine NN NN O
phosphorylation NN NN O
and NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
of NN NN O
multiple NN NN O
STAT NN NN O
proteins NN NN O
. NN NN O
   
The NN NN O
STAT NN NN O
proteins NN NN O
utilized NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
7 NN NN I-Protein
were NN NN O
identical NN NN O
to NN NN O
those NN NN O
induced NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
could NN NN O
be NN NN O
identified NN NN O
as NN NN O
various NN NN O
STAT NN NN O
5 NN NN O
isoforms NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
the NN NN O
induction NN NN O
of NN NN O
both NN NN O
Jak NN NN B-Protein
1 NN NN I-Protein
and NN NN O
3 NN NN B-Protein
, NN NN O
and NN NN O
STAT NN NN B-Protein
5 NN NN I-Protein
activity NN NN O
strongly NN NN O
correlated NN NN O
with NN NN O
the NN NN O
growth NN NN O
- NN NN O
promoting NN NN O
effects NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
7 NN NN I-Protein
, NN NN O
suggesting NN NN O
that NN NN O
this NN NN O
signal NN NN O
transduction NN NN O
mechanism NN NN O
may NN NN O
play NN NN O
a NN NN O
key NN NN O
role NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
7 NN NN I-Protein
- NN NN O
induced NN NN O
proliferation NN NN O
. NN NN O
   
Lymphocyte NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
: NN NN O
predictor NN NN O
of NN NN O
sertraline NN NN O
response NN NN O
in NN NN O
adolescent NN NN O
major NN NN O
depressive NN NN O
disorder NN NN O
( NN NN O
MDD NN NN O
) NN NN O
. NN NN O
   
Major NN NN O
depressive NN NN O
disorder NN NN O
( NN NN O
MDD NN NN O
) NN NN O
in NN NN O
adolescents NN NN O
demonstrates NN NN O
resistance NN NN O
to NN NN O
tricyclic NN NN O
antidepressants NN NN O
and NN NN O
absence NN NN O
of NN NN O
hypercortisolemia NN NN O
. NN NN O
   
The NN NN O
efficacy NN NN O
of NN NN O
serotonin NN NN O
reuptake NN NN O
inhibitors NN NN O
( NN NN O
SRIs NN NN O
) NN NN O
is NN NN O
uncertain NN NN O
, NN NN O
and NN NN O
response NN NN O
predictors NN NN O
are NN NN O
unavailable NN NN O
. NN NN O
   
Abnormal NN NN O
fast NN NN O
feedback NN NN O
and NN NN O
negative NN NN O
feedback NN NN O
of NN NN O
the NN NN O
hypothalamic NN NN O
- NN NN O
pituitary NN NN O
- NN NN O
adrenal NN NN O
axis NN NN O
implicates NN NN O
a NN NN O
dampened NN NN O
limbic NN NN O
- NN NN O
hippocampal NN NN O
glucocorticoid NN NN B-Protein
type NN NN I-Protein
II NN NN I-Protein
receptor NN NN I-Protein
( NN NN O
GCII NN NN B-Protein
) NN NN O
. NN NN O
   
We NN NN O
hypothesized NN NN O
that NN NN O
lymphocyte NN NN O
GCII NN NN B-Protein
is NN NN O
altered NN NN O
in NN NN O
adolescent NN NN O
MDD NN NN O
and NN NN O
could NN NN O
serve NN NN O
as NN NN O
a NN NN O
marker NN NN O
for NN NN O
response NN NN O
to NN NN O
SRIs NN NN O
. NN NN O
   
In NN NN O
an NN NN O
open NN NN O
- NN NN O
label NN NN O
study NN NN O
, NN NN O
adolescents NN NN O
( NN NN O
n NN NN O
= NN NN O
20 NN NN O
) NN NN O
meeting NN NN O
DSM NN NN O
- NN NN O
III NN NN O
- NN NN O
R NN NN O
criteria NN NN O
for NN NN O
MDD NN NN O
showed NN NN O
baseline NN NN O
lymphocyte NN NN O
GCII NN NN B-Protein
sites NN NN O
per NN NN O
cell NN NN O
( NN NN O
sites NN NN O
/ NN NN O
cell NN NN O
) NN NN O
values NN NN O
of NN NN O
793 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
106 NN NN O
versus NN NN O
2 NN NN O
, NN NN O
563 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
499 NN NN O
( NN NN O
+ NN NN O
/ NN NN O
- NN NN O
SEM NN NN O
) NN NN O
for NN NN O
matched NN NN O
controls NN NN O
( NN NN O
n NN NN O
= NN NN O
18 NN NN O
) NN NN O
( NN NN O
t NN NN O
= NN NN O
3 NN NN O
. NN NN O
5 NN NN O
; NN NN O
df NN NN O
= NN NN O
36 NN NN O
; NN NN O
p NN NN O
< NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
GCII NN NN B-Protein
was NN NN O
bimodally NN NN O
distributed NN NN O
, NN NN O
with NN NN O
SRI NN NN O
responders NN NN O
differing NN NN O
from NN NN O
nonresponders NN NN O
( NN NN O
t NN NN O
= NN NN O
3 NN NN O
. NN NN O
9 NN NN O
; NN NN O
df NN NN O
= NN NN O
14 NN NN O
; NN NN O
p NN NN O
< NN NN O
. NN NN O
001 NN NN O
) NN NN O
. NN NN O
   
GCII NN NN B-Protein
accurately NN NN O
classified NN NN O
90 NN NN O
percent NN NN O
of NN NN O
sertraline NN NN O
responders NN NN O
and NN NN O
80 NN NN O
percent NN NN O
of NN NN O
nonresponders NN NN O
. NN NN O
   
Only NN NN O
SRI NN NN O
responders NN NN O
showed NN NN O
GCII NN NN B-Protein
sites NN NN O
/ NN NN O
cell NN NN O
upregulated NN NN O
after NN NN O
6 NN NN O
weeks NN NN O
of NN NN O
treatment NN NN O
( NN NN O
t NN NN O
= NN NN O
2 NN NN O
. NN NN O
1 NN NN O
, NN NN O
df NN NN O
= NN NN O
10 NN NN O
; NN NN O
p NN NN O
< NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
Oncogenicity NN NN O
of NN NN O
human NN NN O
papillomavirus NN NN O
- NN NN O
or NN NN O
adenovirus NN NN O
- NN NN O
transformed NN NN O
cells NN NN O
correlates NN NN O
with NN NN O
resistance NN NN O
to NN NN O
lysis NN NN O
by NN NN O
natural NN NN O
killer NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
reasons NN NN O
for NN NN O
the NN NN O
dissimilar NN NN O
oncogenicities NN NN O
of NN NN O
human NN NN O
adenoviruses NN NN O
and NN NN O
human NN NN O
papillomaviruses NN NN O
( NN NN O
HPV NN NN O
) NN NN O
in NN NN O
humans NN NN O
are NN NN O
unknown NN NN O
but NN NN O
may NN NN O
relate NN NN O
to NN NN O
differences NN NN O
in NN NN O
the NN NN O
capacities NN NN O
of NN NN O
the NN NN O
E1A NN NN B-Protein
and NN NN O
E7 NN NN B-Protein
proteins NN NN O
to NN NN O
target NN NN O
cells NN NN O
for NN NN O
rejection NN NN O
by NN NN O
the NN NN O
host NN NN O
natural NN NN O
killer NN NN O
( NN NN O
NK NN NN O
) NN NN O
cell NN NN O
response NN NN O
. NN NN O
   
As NN NN O
one NN NN O
test NN NN O
of NN NN O
this NN NN O
hypothesis NN NN O
, NN NN O
we NN NN O
compared NN NN O
the NN NN O
abilities NN NN O
of NN NN O
E1A NN NN B-Protein
- NN NN O
and NN NN O
E7 NN NN B-Protein
- NN NN O
expressing NN NN O
human NN NN O
fibroblastic NN NN O
or NN NN O
keratinocyte NN NN O
- NN NN O
derived NN NN O
human NN NN O
cells NN NN O
to NN NN O
be NN NN O
selectively NN NN O
killed NN NN O
by NN NN O
either NN NN O
unstimulated NN NN O
or NN NN O
interferon NN NN O
( NN NN O
IFN NN NN O
) NN NN O
- NN NN O
activated NN NN O
NK NN NN O
cells NN NN O
. NN NN O
   
Cells NN NN O
expressing NN NN O
the NN NN O
E1A NN NN B-Protein
oncoprotein NN NN O
were NN NN O
selectively NN NN O
killed NN NN O
by NN NN O
unstimulated NN NN O
NK NN NN O
cells NN NN O
, NN NN O
while NN NN O
the NN NN O
same NN NN O
parental NN NN O
cells NN NN O
but NN NN O
expressing NN NN O
the NN NN O
HPV NN NN O
type NN NN O
16 NN NN O
( NN NN O
HPV NN NN O
- NN NN O
16 NN NN O
) NN NN O
or NN NN O
HPV NN NN O
- NN NN O
18 NN NN O
E7 NN NN B-Protein
oncoprotein NN NN O
were NN NN O
resistant NN NN O
to NN NN O
NK NN NN O
cell NN NN O
lysis NN NN O
. NN NN O
   
The NN NN O
ability NN NN O
of NN NN O
IFN NN NN O
- NN NN O
activated NN NN O
NK NN NN O
cells NN NN O
to NN NN O
selectively NN NN O
kill NN NN O
virally NN NN O
transformed NN NN O
cells NN NN O
depends NN NN O
on NN NN O
IFN NN NN O
' NN NN O
s NN NN O
ability NN NN O
to NN NN O
induce NN NN O
resistance NN NN O
to NN NN O
NK NN NN O
cell NN NN O
lysis NN NN O
in NN NN O
normal NN NN O
( NN NN O
i NN NN O
. NN NN O
e NN NN O
. NN NN O
, NN NN O
non NN NN O
- NN NN O
viral NN NN O
oncogene NN NN O
- NN NN O
expressing NN NN O
) NN NN O
but NN NN O
not NN NN O
virally NN NN O
transformed NN NN O
cells NN NN O
. NN NN O
   
E1A NN NN B-Protein
blocked NN NN O
IFN NN NN O
' NN NN O
s NN NN O
induction NN NN O
of NN NN O
cytolytic NN NN O
resistance NN NN O
, NN NN O
resulting NN NN O
in NN NN O
the NN NN O
selective NN NN O
lysis NN NN O
of NN NN O
adenovirus NN NN O
- NN NN O
transformed NN NN O
cells NN NN O
by NN NN O
IFN NN NN O
- NN NN O
activated NN NN O
NK NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
extent NN NN O
of NN NN O
IFN NN NN O
- NN NN O
induced NN NN O
NK NN NN O
cell NN NN O
killing NN NN O
of NN NN O
E1A NN NN B-Protein
- NN NN O
expressing NN NN O
cells NN NN O
was NN NN O
proportional NN NN O
to NN NN O
the NN NN O
level NN NN O
of NN NN O
E1A NN NN B-Protein
expression NN NN O
and NN NN O
correlated NN NN O
with NN NN O
the NN NN O
ability NN NN O
of NN NN O
E1A NN NN B-Protein
to NN NN O
block NN NN O
IFN NN NN O
- NN NN O
stimulated NN NN O
gene NN NN O
expression NN NN O
in NN NN O
target NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
E7 NN NN B-Protein
blocked NN NN O
neither NN NN O
IFN NN NN O
- NN NN O
stimulated NN NN O
gene NN NN O
expression NN NN O
nor NN NN O
IFN NN NN O
' NN NN O
s NN NN O
induction NN NN O
of NN NN O
cytolytic NN NN O
resistance NN NN O
, NN NN O
thereby NN NN O
precluding NN NN O
the NN NN O
selective NN NN O
lysis NN NN O
of NN NN O
HPV NN NN O
- NN NN O
transformed NN NN O
cells NN NN O
by NN NN O
IFN NN NN O
- NN NN O
activated NN NN O
NK NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
E1A NN NN B-Protein
expression NN NN O
marks NN NN O
cells NN NN O
for NN NN O
destruction NN NN O
by NN NN O
the NN NN O
host NN NN O
NK NN NN O
cell NN NN O
response NN NN O
, NN NN O
whereas NN NN O
the NN NN O
E7 NN NN B-Protein
oncoprotein NN NN O
lacks NN NN O
this NN NN O
activity NN NN O
. NN NN O
   
Regulation NN NN O
of NN NN O
the NN NN O
balance NN NN O
of NN NN O
cytokine NN NN O
production NN NN O
and NN NN O
the NN NN O
signal NN NN O
transducer NN NN O
and NN NN O
activator NN NN O
of NN NN O
transcription NN NN O
( NN NN O
STAT NN NN O
) NN NN O
transcription NN NN O
factor NN NN O
activity NN NN O
by NN NN O
cytokines NN NN O
and NN NN O
inflammatory NN NN O
synovial NN NN O
fluids NN NN O
. NN NN O
   
The NN NN O
balance NN NN O
between NN NN O
type NN NN O
1 NN NN O
and NN NN O
2 NN NN O
T NN NN O
helper NN NN O
cell NN NN O
cytokine NN NN O
production NN NN O
plays NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
several NN NN O
animal NN NN O
models NN NN O
of NN NN O
autoimmunity NN NN O
, NN NN O
and NN NN O
skewed NN NN O
patterns NN NN O
of NN NN O
cytokine NN NN O
expression NN NN O
have NN NN O
been NN NN O
described NN NN O
in NN NN O
human NN NN O
inflammatory NN NN O
diseases NN NN O
. NN NN O
   
Many NN NN O
cytokines NN NN O
activate NN NN O
signal NN NN O
transducer NN NN O
and NN NN O
activation NN NN O
of NN NN O
transcription NN NN O
( NN NN O
STAT NN NN O
) NN NN O
transcription NN NN O
factors NN NN O
, NN NN O
which NN NN O
, NN NN O
in NN NN O
turn NN NN O
, NN NN O
activate NN NN O
transcription NN NN O
of NN NN O
inflammatory NN NN O
effector NN NN O
genes NN NN O
. NN NN O
   
We NN NN O
used NN NN O
mononuclear NN NN O
cell NN NN O
priming NN NN O
cultures NN NN O
and NN NN O
inflammatory NN NN O
synovial NN NN O
fluids NN NN O
( NN NN O
SFs NN NN O
) NN NN O
derived NN NN O
from NN NN O
arthritis NN NN O
patients NN NN O
to NN NN O
examine NN NN O
the NN NN O
regulation NN NN O
of NN NN O
cytokine NN NN O
production NN NN O
and NN NN O
STAT NN NN O
activity NN NN O
by NN NN O
an NN NN O
inflammatory NN NN O
synovial NN NN O
microenvironment NN NN O
. NN NN O
   
Exposure NN NN O
to NN NN O
SFs NN NN O
during NN NN O
priming NN NN O
resulted NN NN O
in NN NN O
an NN NN O
81 NN NN O
% NN NN O
inhibition NN NN O
of NN NN O
interferon NN NN B-Protein
( NN NN I-Protein
IFN NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
gamma NN NN I-Protein
, NN NN O
but NN NN O
not NN NN O
interleukin NN NN B-Protein
( NN NN I-Protein
IL NN NN I-Protein
) NN NN I-Protein
4 NN NN I-Protein
, NN NN O
production NN NN O
by NN NN O
effector NN NN O
cells NN NN O
generated NN NN O
in NN NN O
priming NN NN O
cultures NN NN O
. NN NN O
   
SF NN NN O
suppression NN NN O
was NN NN O
mediated NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
and NN NN O
inhibition NN NN O
of NN NN O
IL NN NN O
- NN NN O
12 NN NN O
expression NN NN O
, NN NN O
and NN NN O
it NN NN O
was NN NN O
reversed NN NN O
in NN NN O
a NN NN O
dominant NN NN O
fashion NN NN O
by NN NN O
exogenous NN NN O
IL NN NN O
- NN NN O
12 NN NN O
. NN NN O
   
SFs NN NN O
blocked NN NN O
the NN NN O
sustained NN NN O
activity NN NN O
of NN NN O
transcription NN NN O
factor NN NN O
Stat1 NN NN B-Protein
, NN NN O
but NN NN O
not NN NN O
Stat3 NN NN B-Protein
, NN NN O
during NN NN O
the NN NN O
priming NN NN O
period NN NN O
, NN NN O
and NN NN O
Stat1 NN NN B-Protein
activity NN NN O
was NN NN O
differentially NN NN O
regulated NN NN O
by NN NN O
cytokines NN NN O
in NN NN O
parallel NN NN O
with NN NN O
their NN NN O
positive NN NN O
or NN NN O
negative NN NN O
regulation NN NN O
of NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
production NN NN O
. NN NN O
   
Active NN NN O
Stat3 NN NN B-Protein
, NN NN O
but NN NN O
not NN NN O
Stat1 NN NN B-Protein
, NN NN O
was NN NN O
detected NN NN O
in NN NN O
cells NN NN O
from NN NN O
inflamed NN NN O
joints NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
a NN NN O
role NN NN O
for NN NN O
altered NN NN O
balance NN NN O
of NN NN O
Stat1 NN NN B-Protein
and NN NN O
Stat3 NN NN B-Protein
transcriptional NN NN O
activity NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
T NN NN O
cell NN NN O
differentiation NN NN O
and NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
inflammatory NN NN O
synovitis NN NN O
. NN NN O
   
Anti NN NN O
- NN NN O
immunoglobulin NN NN O
M NN NN O
activates NN NN O
nuclear NN NN O
calcium NN NN B-Protein
/ NN NN I-Protein
calmodulin NN NN I-Protein
- NN NN I-Protein
dependent NN NN I-Protein
protein NN NN I-Protein
kinase NN NN I-Protein
II NN NN I-Protein
in NN NN O
human NN NN O
B NN NN O
lymphocytes NN NN O
. NN NN O
   
We NN NN O
and NN NN O
others NN NN O
have NN NN O
previously NN NN O
shown NN NN O
that NN NN O
the NN NN O
nuclear NN NN O
protein NN NN O
, NN NN O
Ets NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
is NN NN O
phosphorylated NN NN O
in NN NN O
a NN NN O
calcium NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
after NN NN O
ligation NN NN O
of NN NN O
immunoglobulin NN NN O
( NN NN O
Ig NN NN O
) NN NN O
M NN NN O
on NN NN O
B NN NN O
lymphocytes NN NN O
. NN NN O
   
As NN NN O
this NN NN O
phosphorylation NN NN O
was NN NN O
independent NN NN O
of NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
activity NN NN O
, NN NN O
we NN NN O
tested NN NN O
whether NN NN O
a NN NN O
calcium NN NN O
/ NN NN O
calmodulin NN NN O
- NN NN O
dependent NN NN O
protein NN NN O
kinase NN NN O
( NN NN O
CaM NN NN O
kinase NN NN O
) NN NN O
might NN NN O
phosphorylate NN NN O
the NN NN O
Ets NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
protein NN NN O
after NN NN O
elevation NN NN O
of NN NN O
intracellular NN NN O
free NN NN O
calcium NN NN O
concentrations NN NN O
. NN NN O
   
The NN NN O
dephosphorylated NN NN O
form NN NN O
of NN NN O
Ets NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
bind NN NN O
to NN NN O
chromatin NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
the NN NN O
operative NN NN O
kinase NN NN O
should NN NN O
be NN NN O
detectable NN NN O
in NN NN O
the NN NN O
nucleus NN NN O
. NN NN O
   
We NN NN O
prepared NN NN O
nuclear NN NN O
extracts NN NN O
from NN NN O
two NN NN O
human NN NN O
B NN NN O
cell NN NN O
lines NN NN O
in NN NN O
which NN NN O
increased NN NN O
intracellular NN NN O
free NN NN O
calcium NN NN O
levels NN NN O
correlated NN NN O
with NN NN O
increased NN NN O
phosphorylation NN NN O
of NN NN O
the NN NN O
Ets NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
protein NN NN O
. NN NN O
   
Activity NN NN O
of NN NN O
the NN NN O
CaM NN NN O
kinases NN NN O
was NN NN O
determined NN NN O
using NN NN O
a NN NN O
synthetic NN NN O
peptide NN NN O
substrate NN NN O
both NN NN O
in NN NN O
the NN NN O
absence NN NN O
and NN NN O
presence NN NN O
of NN NN O
an NN NN O
inhibitor NN NN O
specific NN NN O
for NN NN O
the NN NN O
CaM NN NN O
kinase NN NN O
family NN NN O
, NN NN O
KN NN NN O
- NN NN O
62 NN NN O
. NN NN O
   
Stimulation NN NN O
of NN NN O
cells NN NN O
with NN NN O
anti NN NN O
- NN NN O
IgM NN NN O
led NN NN O
to NN NN O
increased NN NN O
activity NN NN O
of NN NN O
a NN NN O
nuclear NN NN O
kinase NN NN O
that NN NN O
could NN NN O
phosphorylate NN NN O
the NN NN O
peptide NN NN O
, NN NN O
and NN NN O
this NN NN O
activity NN NN O
was NN NN O
reduced NN NN O
by NN NN O
10 NN NN O
microM NN NN O
KN NN NN O
- NN NN O
62 NN NN O
. NN NN O
   
Kinase NN NN O
activity NN NN O
was NN NN O
reduced NN NN O
in NN NN O
lysates NN NN O
preadsorbed NN NN O
using NN NN O
an NN NN O
antibody NN NN O
specific NN NN O
for NN NN O
CaM NN NN B-Protein
kinase NN NN I-Protein
II NN NN I-Protein
. NN NN O
   
Two NN NN O
- NN NN O
dimensional NN NN O
phosphopeptide NN NN O
maps NN NN O
of NN NN O
the NN NN O
Ets NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
protein NN NN O
from NN NN O
cells NN NN O
incubated NN NN O
with NN NN O
ionomycin NN NN O
or NN NN O
anti NN NN O
- NN NN O
IgM NN NN O
contained NN NN O
two NN NN O
unique NN NN O
phosphopeptides NN NN O
that NN NN O
were NN NN O
absent NN NN O
in NN NN O
untreated NN NN O
cells NN NN O
. NN NN O
   
Incubation NN NN O
of NN NN O
isolated NN NN O
Ets NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
protein NN NN O
with NN NN O
purified NN NN O
CaM NN NN B-Protein
kinase NN NN I-Protein
II NN NN I-Protein
produced NN NN O
phosphorylation NN NN O
of NN NN O
peptides NN NN O
that NN NN O
migrated NN NN O
identically NN NN O
to NN NN O
those NN NN O
found NN NN O
in NN NN O
cells NN NN O
incubated NN NN O
with NN NN O
either NN NN O
anti NN NN O
- NN NN O
IgM NN NN O
or NN NN O
ionomycin NN NN O
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
a NN NN O
model NN NN O
of NN NN O
signal NN NN O
transduction NN NN O
by NN NN O
the NN NN O
antigen NN NN O
receptor NN NN O
on NN NN O
B NN NN O
lymphocytes NN NN O
in NN NN O
which NN NN O
increased NN NN O
intracellular NN NN O
free NN NN O
calcium NN NN O
can NN NN O
rapidly NN NN O
activate NN NN O
nuclear NN NN O
CaM NN NN B-Protein
kinase NN NN I-Protein
II NN NN I-Protein
, NN NN O
potentially NN NN O
resulting NN NN O
in NN NN O
phosphorylation NN NN O
and NN NN O
regulation NN NN O
of NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
proteins NN NN O
. NN NN O
   
rel NN NN B-Protein
Is NN NN O
rapidly NN NN O
tyrosine NN NN O
- NN NN O
phosphorylated NN NN O
following NN NN O
granulocyte NN NN B-Protein
- NN NN I-Protein
colony NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
treatment NN NN O
of NN NN O
human NN NN O
neutrophils NN NN O
. NN NN O
   
Stimulation NN NN O
of NN NN O
neutrophils NN NN O
with NN NN O
granulocyte NN NN B-Protein
- NN NN I-Protein
colony NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
( NN NN O
G NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
) NN NN O
results NN NN O
in NN NN O
an NN NN O
enhanced NN NN O
respiratory NN NN O
burst NN NN O
, NN NN O
prolonged NN NN O
survival NN NN O
, NN NN O
and NN NN O
increased NN NN O
tumor NN NN O
cell NN NN O
killing NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
G NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
are NN NN O
mediated NN NN O
by NN NN O
binding NN NN O
to NN NN O
specific NN NN O
, NN NN O
high NN NN O
affinity NN NN O
receptors NN NN O
. NN NN O
   
G NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
receptors NN NN O
lack NN NN O
intrinsic NN NN O
tyrosine NN NN O
kinase NN NN O
activity NN NN O
, NN NN O
but NN NN O
activation NN NN O
of NN NN O
the NN NN O
receptor NN NN O
results NN NN O
in NN NN O
the NN NN O
rapid NN NN O
induction NN NN O
of NN NN O
tyrosine NN NN O
kinase NN NN O
activity NN NN O
. NN NN O
   
Antiphosphotyrosine NN NN O
immunoblots NN NN O
of NN NN O
whole NN NN O
cell NN NN O
lysates NN NN O
prepared NN NN O
from NN NN O
neutrophils NN NN O
show NN NN O
that NN NN O
the NN NN O
G NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
rapidly NN NN O
induces NN NN O
prominent NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
a NN NN O
protein NN NN O
of NN NN O
a NN NN O
relative NN NN O
molecular NN NN O
mass NN NN O
of NN NN O
80 NN NN O
kDa NN NN O
. NN NN O
   
Using NN NN O
monospecific NN NN O
antibodies NN NN O
, NN NN O
the NN NN O
80 NN NN O
- NN NN O
kDa NN NN O
tyrosine NN NN O
- NN NN O
phosphorylated NN NN O
protein NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
be NN NN O
p80c NN NN B-Protein
- NN NN I-Protein
rel NN NN I-Protein
, NN NN O
a NN NN O
proto NN NN O
- NN NN O
oncogene NN NN O
belonging NN NN O
to NN NN O
a NN NN O
family NN NN O
of NN NN O
transcriptional NN NN O
regulators NN NN O
which NN NN O
include NN NN O
NF NN NN O
- NN NN O
kB NN NN O
. NN NN O
   
The NN NN O
induction NN NN O
of NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
p80c NN NN B-Protein
- NN NN I-Protein
rel NN NN I-Protein
was NN NN O
unique NN NN O
to NN NN O
G NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
in NN NN O
that NN NN O
granulocyte NN NN B-Protein
- NN NN I-Protein
macrophage NN NN I-Protein
colony NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
which NN NN O
also NN NN O
stimulates NN NN O
neutrophils NN NN O
and NN NN O
induces NN NN O
tyrosine NN NN O
phosphorylation NN NN O
does NN NN O
not NN NN O
result NN NN O
in NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
p80c NN NN B-Protein
- NN NN I-Protein
rel NN NN I-Protein
. NN NN O
   
The NN NN O
consequences NN NN O
of NN NN O
p80c NN NN B-Protein
- NN NN I-Protein
rel NN NN I-Protein
tyrosine NN NN O
phosphorylation NN NN O
are NN NN O
not NN NN O
yet NN NN O
known NN NN O
; NN NN O
however NN NN O
, NN NN O
tyrosine NN NN O
- NN NN O
phosphorylated NN NN O
p80c NN NN B-Protein
- NN NN I-Protein
rel NN NN I-Protein
is NN NN O
capable NN NN O
of NN NN O
binding NN NN O
to NN NN O
DNA NN NN O
, NN NN O
and NN NN O
G NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
stimulation NN NN O
results NN NN O
in NN NN O
an NN NN O
increase NN NN O
in NN NN O
the NN NN O
amount NN NN O
of NN NN O
p80c NN NN B-Protein
- NN NN I-Protein
rel NN NN I-Protein
which NN NN O
binds NN NN O
to NN NN O
DNA NN NN O
. NN NN O
   
These NN NN O
results NN NN O
demonstrate NN NN O
that NN NN O
one NN NN O
of NN NN O
the NN NN O
first NN NN O
biochemical NN NN O
events NN NN O
which NN NN O
occurs NN NN O
in NN NN O
neutrophils NN NN O
following NN NN O
G NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
stimulation NN NN O
, NN NN O
activation NN NN O
of NN NN O
a NN NN O
tyrosine NN NN O
kinase NN NN O
, NN NN O
leads NN NN O
directly NN NN O
to NN NN O
the NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
p80c NN NN B-Protein
- NN NN I-Protein
rel NN NN I-Protein
. NN NN O
   
Thus NN NN O
, NN NN O
the NN NN O
tyrosine NN NN O
kinase NN NN O
activated NN NN O
by NN NN O
G NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
appears NN NN O
to NN NN O
directly NN NN O
transduce NN NN O
a NN NN O
signal NN NN O
to NN NN O
a NN NN O
protein NN NN O
which NN NN O
functions NN NN O
as NN NN O
a NN NN O
transcriptional NN NN O
regulator NN NN O
. NN NN O
   
Retinoic NN NN O
acid NN NN O
- NN NN O
induced NN NN O
expression NN NN O
of NN NN O
CD38 NN NN B-Protein
antigen NN NN O
in NN NN O
myeloid NN NN O
cells NN NN O
is NN NN O
mediated NN NN O
through NN NN O
retinoic NN NN B-Protein
acid NN NN I-Protein
receptor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
. NN NN O
   
CD38 NN NN B-Protein
is NN NN O
a NN NN O
leukocyte NN NN O
differentiation NN NN O
antigen NN NN O
that NN NN O
has NN NN O
been NN NN O
thought NN NN O
to NN NN O
be NN NN O
a NN NN O
phenotypic NN NN O
marker NN NN O
of NN NN O
different NN NN O
subpopulations NN NN O
of NN NN O
T NN NN O
- NN NN O
and NN NN O
B NN NN O
- NN NN O
lymphocytes NN NN O
. NN NN O
   
In NN NN O
myeloid NN NN O
cells NN NN O
, NN NN O
CD38 NN NN B-Protein
is NN NN O
expressed NN NN O
during NN NN O
early NN NN O
stages NN NN O
of NN NN O
differentiation NN NN O
. NN NN O
   
Virtually NN NN O
no NN NN O
information NN NN O
is NN NN O
available NN NN O
on NN NN O
regulation NN NN O
and NN NN O
functions NN NN O
of NN NN O
CD38 NN NN B-Protein
. NN NN O
   
Recently NN NN O
we NN NN O
reported NN NN O
that NN NN O
all NN NN O
- NN NN O
trans NN NN O
- NN NN O
retinoic NN NN O
acid NN NN O
( NN NN O
ATRA NN NN O
) NN NN O
is NN NN O
a NN NN O
potent NN NN O
and NN NN O
highly NN NN O
specific NN NN O
inducer NN NN O
of NN NN O
CD38 NN NN B-Protein
expression NN NN O
in NN NN O
human NN NN O
promyelocytic NN NN O
leukemia NN NN O
cells NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
report NN NN O
that NN NN O
ATRA NN NN O
- NN NN O
induced NN NN O
expression NN NN O
of NN NN O
CD38 NN NN B-Protein
antigen NN NN O
in NN NN O
myeloid NN NN O
cells NN NN O
is NN NN O
mediated NN NN O
through NN NN O
retinoic NN NN B-Protein
acid NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
receptor NN NN I-Protein
( NN NN O
RAR NN NN B-Protein
alpha NN NN I-Protein
) NN NN O
. NN NN O
   
ATRA NN NN O
failed NN NN O
to NN NN O
induce NN NN O
CD38 NN NN B-Protein
expression NN NN O
in NN NN O
a NN NN O
mutant NN NN O
subclone NN NN O
of NN NN O
the NN NN O
HL NN NN O
- NN NN O
60 NN NN O
myeloid NN NN O
leukemia NN NN O
cell NN NN O
line NN NN O
( NN NN O
designated NN NN O
HL NN NN O
- NN NN O
60R NN NN O
) NN NN O
that NN NN O
is NN NN O
relatively NN NN O
resistant NN NN O
to NN NN O
ATRA NN NN O
- NN NN O
induced NN NN O
granulocytic NN NN O
differentiation NN NN O
. NN NN O
   
Retroviral NN NN O
vector NN NN O
- NN NN O
mediated NN NN O
transduction NN NN O
of NN NN O
RA NN NN O
receptor NN NN O
( NN NN O
RAR NN NN B-Protein
alpha NN NN I-Protein
) NN NN O
into NN NN O
this NN NN O
HL NN NN O
- NN NN O
60R NN NN O
subclone NN NN O
completely NN NN O
restored NN NN O
the NN NN O
sensitivity NN NN O
of NN NN O
these NN NN O
cells NN NN O
to NN NN O
ATRA NN NN O
in NN NN O
terms NN NN O
of NN NN O
their NN NN O
ability NN NN O
to NN NN O
express NN NN O
CD38 NN NN B-Protein
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
CD38 NN NN B-Protein
expression NN NN O
was NN NN O
not NN NN O
inducible NN NN O
by NN NN O
ATRA NN NN O
in NN NN O
HL NN NN O
- NN NN O
60R NN NN O
cells NN NN O
, NN NN O
transfected NN NN O
with NN NN O
a NN NN O
functional NN NN O
RAR NN NN B-Protein
beta NN NN I-Protein
, NN NN O
RAR NN NN B-Protein
gamma NN NN I-Protein
, NN NN O
or NN NN O
RXR NN NN B-Protein
alpha NN NN I-Protein
receptor NN NN O
. NN NN O
   
Induction NN NN O
of NN NN O
CD38 NN NN B-Protein
in NN NN O
acute NN NN O
promyelocytic NN NN O
and NN NN O
acute NN NN O
myeloblastic NN NN O
leukemia NN NN O
cells NN NN O
was NN NN O
independent NN NN O
of NN NN O
ATRA NN NN O
- NN NN O
induced NN NN O
cytodifferentiation NN NN O
. NN NN O
   
Following NN NN O
culture NN NN O
with NN NN O
ATRA NN NN O
, NN NN O
increased NN NN O
CD38 NN NN B-Protein
protein NN NN O
levels NN NN O
were NN NN O
also NN NN O
observed NN NN O
in NN NN O
normal NN NN O
CD34 NN NN O
+ NN NN O
bone NN NN O
marrow NN NN O
cells NN NN O
, NN NN O
but NN NN O
not NN NN O
on NN NN O
normal NN NN O
circulating NN NN O
granulocytes NN NN O
. NN NN O
   
From NN NN O
these NN NN O
results NN NN O
, NN NN O
we NN NN O
conclude NN NN O
that NN NN O
CD38 NN NN B-Protein
is NN NN O
ATRA NN NN O
inducible NN NN O
in NN NN O
myeloid NN NN O
leukemia NN NN O
cells NN NN O
and NN NN O
normal NN NN O
CD34 NN NN O
+ NN NN O
bone NN NN O
marrow NN NN O
cells NN NN O
. NN NN O
   
This NN NN O
effect NN NN O
is NN NN O
independent NN NN O
of NN NN O
differentiation NN NN O
and NN NN O
is NN NN O
mediated NN NN O
by NN NN O
RAR NN NN B-Protein
alpha NN NN I-Protein
in NN NN O
HL NN NN O
- NN NN O
60 NN NN O
cells NN NN O
, NN NN O
suggesting NN NN O
a NN NN O
similar NN NN O
role NN NN O
for NN NN O
RAR NN NN B-Protein
alpha NN NN I-Protein
in NN NN O
CD38 NN NN B-Protein
expression NN NN O
in NN NN O
other NN NN O
hematopoietic NN NN O
cells NN NN O
. NN NN O
   
Comparison NN NN O
of NN NN O
retinoic NN NN O
acid NN NN O
and NN NN O
phorbol NN NN O
myristate NN NN O
acetate NN NN O
as NN NN O
inducers NN NN O
of NN NN O
monocytic NN NN O
differentiation NN NN O
. NN NN O
   
Several NN NN O
human NN NN O
myeloid NN NN O
leukemia NN NN O
cell NN NN O
lines NN NN O
growing NN NN O
in NN NN O
vitro NN NN O
can NN NN O
be NN NN O
induced NN NN O
to NN NN O
differentiate NN NN O
to NN NN O
more NN NN O
mature NN NN O
monocyte NN NN O
/ NN NN O
macrophage NN NN O
- NN NN O
like NN NN O
cells NN NN O
by NN NN O
treatment NN NN O
with NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
- NN NN O
activating NN NN O
phorbol NN NN O
esters NN NN O
, NN NN O
such NN NN O
as NN NN O
PMA NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
to NN NN O
PMA NN NN O
, NN NN O
cells NN NN O
of NN NN O
the NN NN O
THP NN NN O
- NN NN O
1 NN NN O
myeloid NN NN O
leukemia NN NN O
cell NN NN O
line NN NN O
acquire NN NN O
macrophage NN NN O
- NN NN O
like NN NN O
characteristics NN NN O
after NN NN O
treatment NN NN O
with NN NN O
all NN NN O
- NN NN O
trans NN NN O
retinoic NN NN O
acid NN NN O
( NN NN O
RA NN NN O
) NN NN O
. NN NN O
   
To NN NN O
analyze NN NN O
the NN NN O
signal NN NN O
transduction NN NN O
mechanisms NN NN O
induced NN NN O
by NN NN O
RA NN NN O
, NN NN O
we NN NN O
first NN NN O
compared NN NN O
the NN NN O
effects NN NN O
of NN NN O
PMA NN NN O
and NN NN O
RA NN NN O
on NN NN O
the NN NN O
expression NN NN O
of NN NN O
genes NN NN O
which NN NN O
are NN NN O
known NN NN O
to NN NN O
be NN NN O
regulated NN NN O
during NN NN O
monocytic NN NN O
differentiation NN NN O
. NN NN O
   
Both NN NN O
RA NN NN O
and NN NN O
PMA NN NN O
effectively NN NN O
down NN NN O
- NN NN O
regulated NN NN O
c NN NN B-Protein
- NN NN I-Protein
myc NN NN I-Protein
expression NN NN O
, NN NN O
while NN NN O
c NN NN B-Protein
- NN NN I-Protein
myb NN NN I-Protein
expression NN NN O
decreased NN NN O
only NN NN O
after NN NN O
PMA NN NN O
treatment NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
the NN NN O
beta NN NN O
2 NN NN O
- NN NN O
integrin NN NN O
genes NN NN O
, NN NN O
CD11a NN NN B-Protein
and NN NN O
CD11b NN NN B-Protein
, NN NN O
was NN NN O
clearly NN NN O
increased NN NN O
after NN NN O
both NN NN O
of NN NN O
these NN NN O
treatments NN NN O
. NN NN O
   
Their NN NN O
effects NN NN O
on NN NN O
the NN NN O
src NN NN O
- NN NN O
family NN NN O
tyrosine NN NN O
kinase NN NN O
genes NN NN O
were NN NN O
different NN NN O
: NN NN O
hck NN NN B-Protein
expression NN NN O
was NN NN O
similarly NN NN O
induced NN NN O
by NN NN O
these NN NN O
agents NN NN O
but NN NN O
lyn NN NN B-Protein
expression NN NN O
was NN NN O
stronger NN NN O
and NN NN O
more NN NN O
rapid NN NN O
after NN NN O
RA NN NN O
treatment NN NN O
. NN NN O
   
RA NN NN O
also NN NN O
enhanced NN NN O
lyn NN NN B-Protein
mRNA NN NN O
production NN NN O
rapidly NN NN O
in NN NN O
HL NN NN O
- NN NN O
60 NN NN O
, NN NN O
indicating NN NN O
that NN NN O
the NN NN O
activation NN NN O
of NN NN O
lyn NN NN B-Protein
gene NN NN O
expression NN NN O
is NN NN O
common NN NN O
in NN NN O
monocytic NN NN O
and NN NN O
granulocytic NN NN O
maturation NN NN O
of NN NN O
myeloid NN NN O
leukemia NN NN O
cells NN NN O
. NN NN O
   
To NN NN O
examine NN NN O
whether NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
enhancer NN NN O
activity NN NN O
is NN NN O
involved NN NN O
in NN NN O
RA NN NN O
- NN NN O
induced NN NN O
monocytic NN NN O
differentiation NN NN O
, NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cells NN NN O
were NN NN O
transiently NN NN O
transfected NN NN O
with NN NN O
a NN NN O
chloramphenicol NN NN B-Protein
acetyl NN NN I-Protein
transferase NN NN I-Protein
( NN NN O
CAT NN NN B-Protein
) NN NN O
- NN NN O
reporter NN NN O
gene NN NN O
containing NN NN O
5 NN NN O
copies NN NN O
of NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
binding NN NN O
sites NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
to NN NN O
PMA NN NN O
, NN NN O
RA NN NN O
did NN NN O
not NN NN O
induce NN NN O
any NN NN O
CAT NN NN B-Protein
activity NN NN O
in NN NN O
these NN NN O
cells NN NN O
, NN NN O
thus NN NN O
suggesting NN NN O
that NN NN O
the NN NN O
RA NN NN O
- NN NN O
induced NN NN O
changes NN NN O
in NN NN O
the NN NN O
expression NN NN O
of NN NN O
those NN NN O
genes NN NN O
described NN NN O
above NN NN O
were NN NN O
not NN NN O
dependent NN NN O
on NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
enhancer NN NN O
activity NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
T NN NN O
cell NN NN O
activation NN NN O
by NN NN O
the NN NN O
extracellular NN NN O
matrix NN NN O
protein NN NN O
tenascin NN NN O
. NN NN O
   
Tenascin NN NN O
( NN NN O
TN NN NN O
) NN NN O
is NN NN O
an NN NN O
extracellular NN NN O
matrix NN NN O
protein NN NN O
that NN NN O
is NN NN O
expressed NN NN O
widely NN NN O
in NN NN O
the NN NN O
fetus NN NN O
and NN NN O
sparingly NN NN O
in NN NN O
the NN NN O
adult NN NN O
, NN NN O
but NN NN O
reappears NN NN O
at NN NN O
high NN NN O
levels NN NN O
in NN NN O
certain NN NN O
areas NN NN O
of NN NN O
tissue NN NN O
insult NN NN O
such NN NN O
as NN NN O
tumor NN NN O
matrices NN NN O
and NN NN O
sites NN NN O
of NN NN O
wound NN NN O
healing NN NN O
. NN NN O
   
We NN NN O
show NN NN O
here NN NN O
that NN NN O
soluble NN NN O
TN NN NN O
inhibits NN NN O
proliferation NN NN O
of NN NN O
human NN NN O
T NN NN O
cells NN NN O
in NN NN O
response NN NN O
to NN NN O
alpha NN NN O
CD3 NN NN O
Ab NN NN O
co NN NN O
- NN NN O
immobilized NN NN O
with NN NN O
the NN NN O
extracellular NN NN O
matrix NN NN O
protein NN NN O
fibronectin NN NN B-Protein
( NN NN O
FN NN NN B-Protein
) NN NN O
. NN NN O
   
TN NN NN O
also NN NN O
inhibits NN NN O
proliferation NN NN O
driven NN NN O
by NN NN O
alpha NN NN O
CD3 NN NN O
/ NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
or NN NN O
by NN NN O
phorbol NN NN O
ester NN NN O
/ NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
and NN NN O
it NN NN O
prevents NN NN O
high NN NN O
level NN NN O
induction NN NN O
of NN NN O
IL NN NN O
- NN NN O
2R NN NN O
. NN NN O
   
The NN NN O
presence NN NN O
of NN NN O
TN NN NN O
in NN NN O
culture NN NN O
medium NN NN O
does NN NN O
not NN NN O
detectably NN NN O
alter NN NN O
the NN NN O
pattern NN NN O
of NN NN O
tyrosine NN NN O
phosphorylation NN NN O
resulting NN NN O
from NN NN O
T NN NN O
cell NN NN O
triggering NN NN O
with NN NN O
alpha NN NN O
CD3 NN NN O
, NN NN O
but NN NN O
at NN NN O
later NN NN O
time NN NN O
points NN NN O
prevents NN NN O
the NN NN O
appearance NN NN O
of NN NN O
functional NN NN O
NF NN NN O
- NN NN O
AT1 NN NN O
transcription NN NN O
factor NN NN O
complexes NN NN O
in NN NN O
T NN NN O
cell NN NN O
nuclear NN NN O
extracts NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
are NN NN O
consistent NN NN O
with NN NN O
the NN NN O
postulated NN NN O
role NN NN O
for NN NN O
TN NN NN O
as NN NN O
a NN NN O
natural NN NN O
antagonist NN NN O
to NN NN O
FN NN NN B-Protein
action NN NN O
, NN NN O
and NN NN O
suggest NN NN O
that NN NN O
T NN NN O
cell NN NN O
responses NN NN O
occurring NN NN O
at NN NN O
tissue NN NN O
sites NN NN O
in NN NN O
which NN NN O
TN NN NN O
is NN NN O
expressed NN NN O
could NN NN O
be NN NN O
influenced NN NN O
by NN NN O
its NN NN O
presence NN NN O
. NN NN O
   
HLA NN NN O
- NN NN O
DR NN NN O
- NN NN O
, NN NN O
CD33 NN NN B-Protein
+ NN NN O
, NN NN O
CD56 NN NN B-Protein
+ NN NN O
, NN NN O
CD16 NN NN B-Protein
- NN NN O
myeloid NN NN O
/ NN NN O
natural NN NN O
killer NN NN O
cell NN NN O
acute NN NN O
leukemia NN NN O
: NN NN O
a NN NN O
previously NN NN O
unrecognized NN NN O
form NN NN O
of NN NN O
acute NN NN O
leukemia NN NN O
potentially NN NN O
misdiagnosed NN NN O
as NN NN O
French NN NN O
- NN NN O
American NN NN O
- NN NN O
British NN NN O
acute NN NN O
myeloid NN NN O
leukemia NN NN O
- NN NN O
M3 NN NN O
[ NN NN O
see NN NN O
comments NN NN O
] NN NN O
   
We NN NN O
have NN NN O
identified NN NN O
and NN NN O
characterized NN NN O
a NN NN O
previously NN NN O
unrecognized NN NN O
form NN NN O
of NN NN O
acute NN NN O
leukemia NN NN O
that NN NN O
shares NN NN O
features NN NN O
of NN NN O
both NN NN O
myeloid NN NN O
and NN NN O
natural NN NN O
killer NN NN O
( NN NN O
NK NN NN O
) NN NN O
cells NN NN O
. NN NN O
   
From NN NN O
a NN NN O
consecutive NN NN O
series NN NN O
of NN NN O
350 NN NN O
cases NN NN O
of NN NN O
adult NN NN O
de NN NN O
novo NN NN O
acute NN NN O
myeloid NN NN O
leukemia NN NN O
( NN NN O
AML NN NN O
) NN NN O
, NN NN O
we NN NN O
identified NN NN O
20 NN NN O
cases NN NN O
( NN NN O
6 NN NN O
% NN NN O
) NN NN O
with NN NN O
a NN NN O
unique NN NN O
immunophenotype NN NN O
: NN NN O
CD33 NN NN B-Protein
+ NN NN O
, NN NN O
CD56 NN NN B-Protein
+ NN NN O
, NN NN O
CD11a NN NN B-Protein
+ NN NN O
, NN NN O
CD13lo NN NN B-Protein
, NN NN O
CD15lo NN NN B-Protein
, NN NN O
CD34 NN NN B-Protein
+ NN NN O
/ NN NN O
- NN NN O
, NN NN O
HLA NN NN O
- NN NN O
DR NN NN O
- NN NN O
, NN NN O
CD16 NN NN B-Protein
- NN NN O
. NN NN O
   
Multicolor NN NN O
flow NN NN O
cytometric NN NN O
assays NN NN O
confirmed NN NN O
the NN NN O
coexpression NN NN O
of NN NN O
myeloid NN NN O
( NN NN O
CD33 NN NN B-Protein
, NN NN O
CD13 NN NN B-Protein
, NN NN O
CD15 NN NN B-Protein
) NN NN O
and NN NN O
NK NN NN O
cell NN NN O
- NN NN O
associated NN NN O
( NN NN O
CD56 NN NN B-Protein
) NN NN O
antigens NN NN O
in NN NN O
each NN NN O
case NN NN O
, NN NN O
whereas NN NN O
reverse NN NN O
transcription NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
( NN NN O
RT NN NN O
- NN NN O
PCR NN NN O
) NN NN O
assays NN NN O
confirmed NN NN O
the NN NN O
identity NN NN O
of NN NN O
CD56 NN NN B-Protein
( NN NN O
neural NN NN O
cell NN NN O
adhesion NN NN O
molecule NN NN O
) NN NN O
in NN NN O
leukemic NN NN O
blasts NN NN O
. NN NN O
   
Although NN NN O
two NN NN O
cases NN NN O
expressed NN NN O
CD4 NN NN B-Protein
, NN NN O
no NN NN O
case NN NN O
expressed NN NN O
CD2 NN NN B-Protein
, NN NN O
CD3 NN NN O
, NN NN O
or NN NN O
CD8 NN NN B-Protein
and NN NN O
no NN NN O
case NN NN O
showed NN NN O
clonal NN NN O
rearrangement NN NN O
of NN NN O
genes NN NN O
encoding NN NN O
the NN NN O
T NN NN O
- NN NN O
cell NN NN O
receptor NN NN O
( NN NN O
TCR NN NN B-Protein
beta NN NN I-Protein
, NN NN O
gamma NN NN B-Protein
, NN NN O
delta NN NN B-Protein
) NN NN O
. NN NN O
   
Leukemic NN NN O
blasts NN NN O
in NN NN O
the NN NN O
majority NN NN O
of NN NN O
cases NN NN O
shared NN NN O
unique NN NN O
morphologic NN NN O
features NN NN O
( NN NN O
deeply NN NN O
invaginated NN NN O
nuclear NN NN O
membranes NN NN O
, NN NN O
scant NN NN O
cytoplasm NN NN O
with NN NN O
fine NN NN O
azurophilic NN NN O
granularity NN NN O
, NN NN O
and NN NN O
finely NN NN O
granular NN NN O
Sudan NN NN O
black NN NN O
B NN NN O
and NN NN O
myeloperoxidase NN NN B-Protein
cytochemical NN NN O
reactivity NN NN O
) NN NN O
that NN NN O
were NN NN O
remarkably NN NN O
similar NN NN O
to NN NN O
those NN NN O
of NN NN O
acute NN NN O
promyelocytic NN NN O
leukemia NN NN O
( NN NN O
APL NN NN O
) NN NN O
; NN NN O
particularly NN NN O
the NN NN O
microgranular NN NN O
variant NN NN O
( NN NN O
FAB NN NN O
AML NN NN O
- NN NN O
M3v NN NN O
) NN NN O
. NN NN O
   
However NN NN O
, NN NN O
all NN NN O
20 NN NN O
cases NN NN O
lacked NN NN O
the NN NN O
t NN NN O
( NN NN O
15 NN NN O
; NN NN O
17 NN NN O
) NN NN O
and NN NN O
17 NN NN O
cases NN NN O
tested NN NN O
lacked NN NN O
the NN NN O
promyelocytic NN NN B-Protein
/ NN NN I-Protein
retinoic NN NN I-Protein
acid NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
RAR NN NN B-Protein
alpha NN NN I-Protein
) NN NN O
fusion NN NN O
transcript NN NN O
in NN NN O
RT NN NN O
- NN NN O
PCR NN NN O
assays NN NN O
; NN NN O
12 NN NN O
cases NN NN O
had NN NN O
46 NN NN O
, NN NN O
XX NN NN O
or NN NN O
46 NN NN O
, NN NN O
XY NN NN O
karyotypes NN NN O
, NN NN O
whereas NN NN O
2 NN NN O
cases NN NN O
had NN NN O
abnormalities NN NN O
of NN NN O
chromosome NN NN O
17q NN NN O
: NN NN O
1 NN NN O
with NN NN O
del NN NN O
( NN NN O
17 NN NN O
) NN NN O
( NN NN O
q25 NN NN O
) NN NN O
and NN NN O
the NN NN O
other NN NN O
with NN NN O
t NN NN O
( NN NN O
11 NN NN O
; NN NN O
17 NN NN O
) NN NN O
( NN NN O
q23 NN NN O
; NN NN O
q21 NN NN O
) NN NN O
and NN NN O
the NN NN O
promyelocytic NN NN B-Protein
leukemia NN NN I-Protein
zinc NN NN I-Protein
finger NN NN I-Protein
/ NN NN O
RAR NN NN B-Protein
alpha NN NN I-Protein
fusion NN NN O
transcript NN NN O
. NN NN O
   
All NN NN O
cases NN NN O
tested NN NN O
( NN NN O
6 NN NN O
/ NN NN O
20 NN NN O
) NN NN O
, NN NN O
including NN NN O
the NN NN O
case NN NN O
with NN NN O
t NN NN O
( NN NN O
11 NN NN O
; NN NN O
17 NN NN O
) NN NN O
, NN NN O
failed NN NN O
to NN NN O
differentiate NN NN O
in NN NN O
vitro NN NN O
in NN NN O
response NN NN O
to NN NN O
all NN NN O
- NN NN O
trans NN NN O
retinoic NN NN O
acid NN NN O
( NN NN O
ATRA NN NN O
) NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
these NN NN O
cases NN NN O
may NN NN O
account NN NN O
for NN NN O
some NN NN O
APLs NN NN O
that NN NN O
have NN NN O
not NN NN O
shown NN NN O
a NN NN O
clinical NN NN O
response NN NN O
to NN NN O
ATRA NN NN O
. NN NN O
   
Four NN NN O
of NN NN O
6 NN NN O
cases NN NN O
tested NN NN O
showed NN NN O
functional NN NN O
NK NN NN O
cell NN NN O
- NN NN O
mediated NN NN O
cytotoxicity NN NN O
, NN NN O
suggesting NN NN O
a NN NN O
relationship NN NN O
between NN NN O
these NN NN O
unique NN NN O
CD33 NN NN B-Protein
+ NN NN O
, NN NN O
CD56 NN NN B-Protein
+ NN NN O
, NN NN O
CD16 NN NN B-Protein
- NN NN O
acute NN NN O
leukemias NN NN O
and NN NN O
normal NN NN O
CD56 NN NN B-Protein
+ NN NN O
, NN NN O
CD16 NN NN B-Protein
- NN NN O
NK NN NN O
precursor NN NN O
cells NN NN O
. NN NN O
   
Using NN NN O
a NN NN O
combination NN NN O
of NN NN O
panning NN NN O
and NN NN O
multiparameter NN NN O
flow NN NN O
cytometric NN NN O
sorting NN NN O
, NN NN O
we NN NN O
identified NN NN O
a NN NN O
normal NN NN O
CD56 NN NN B-Protein
+ NN NN O
, NN NN O
CD33 NN NN B-Protein
+ NN NN O
, NN NN O
CD16 NN NN B-Protein
- NN NN O
counterpart NN NN O
cell NN NN O
at NN NN O
a NN NN O
frequency NN NN O
of NN NN O
1 NN NN O
% NN NN O
to NN NN O
2 NN NN O
% NN NN O
in NN NN O
the NN NN O
peripheral NN NN O
blood NN NN O
of NN NN O
healthy NN NN O
individuals NN NN O
. NN NN O
   
Our NN NN O
studies NN NN O
suggest NN NN O
that NN NN O
this NN NN O
form NN NN O
of NN NN O
acute NN NN O
leukemia NN NN O
may NN NN O
arise NN NN O
from NN NN O
transformation NN NN O
of NN NN O
a NN NN O
precursor NN NN O
cell NN NN O
common NN NN O
to NN NN O
both NN NN O
the NN NN O
myeloid NN NN O
and NN NN O
NK NN NN O
cell NN NN O
lineages NN NN O
; NN NN O
thus NN NN O
we NN NN O
propose NN NN O
the NN NN O
designation NN NN O
myeloid NN NN O
/ NN NN O
NK NN NN O
acute NN NN O
leukemia NN NN O
. NN NN O
   
Recognition NN NN O
of NN NN O
this NN NN O
new NN NN O
leukemic NN NN O
entity NN NN O
will NN NN O
be NN NN O
important NN NN O
in NN NN O
distinguishing NN NN O
these NN NN O
ATRA NN NN O
- NN NN O
nonresponsive NN NN O
cases NN NN O
from NN NN O
ATRA NN NN O
- NN NN O
responsive NN NN O
true NN NN O
APL NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
the NN NN O
differentiation NN NN O
of NN NN O
human NN NN O
myeloid NN NN O
cell NN NN O
lines NN NN O
by NN NN O
redox NN NN O
changes NN NN O
induced NN NN O
through NN NN O
glutathione NN NN O
depletion NN NN O
. NN NN O
   
We NN NN O
have NN NN O
investigated NN NN O
the NN NN O
effect NN NN O
of NN NN O
redox NN NN O
changes NN NN O
in NN NN O
vivo NN NN O
on NN NN O
the NN NN O
differentiation NN NN O
of NN NN O
two NN NN O
human NN NN O
myeloid NN NN O
cell NN NN O
lines NN NN O
, NN NN O
HL NN NN O
- NN NN O
60 NN NN O
and NN NN O
KG NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
The NN NN O
glutathione NN NN O
- NN NN O
depleting NN NN O
agent NN NN O
diethyl NN NN O
maleate NN NN O
( NN NN O
DEM NN NN O
) NN NN O
prevented NN NN O
the NN NN O
development NN NN O
of NN NN O
differentiated NN NN O
features NN NN O
in NN NN O
response NN NN O
to NN NN O
phorbol NN NN O
esters NN NN O
, NN NN O
including NN NN O
adherence NN NN O
of NN NN O
the NN NN O
cells NN NN O
to NN NN O
plastic NN NN O
surfaces NN NN O
and NN NN O
repression NN NN O
of NN NN O
the NN NN O
myeloperoxidase NN NN B-Protein
and NN NN O
CD34 NN NN B-Protein
genes NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
DEM NN NN O
abolished NN NN O
phorbol NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
- NN NN O
induced NN NN O
activation NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factors NN NN O
AP NN NN O
- NN NN O
1 NN NN O
and NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
suggesting NN NN O
that NN NN O
inhibition NN NN O
of NN NN O
differentiation NN NN O
may NN NN O
be NN NN O
due NN NN O
, NN NN O
at NN NN O
least NN NN O
in NN NN O
part NN NN O
, NN NN O
to NN NN O
redox NN NN O
modifications NN NN O
of NN NN O
these NN NN O
proteins NN NN O
. NN NN O
   
Interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
induces NN NN O
tyrosine NN NN O
phosphorylation NN NN O
and NN NN O
nuclear NN NN O
translocation NN NN O
of NN NN O
stat3 NN NN B-Protein
in NN NN O
human NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
An NN NN O
early NN NN O
biochemical NN NN O
event NN NN O
associated NN NN O
with NN NN O
T NN NN O
cell NN NN O
activation NN NN O
through NN NN O
the NN NN O
interleukin NN NN O
- NN NN O
2 NN NN O
receptor NN NN O
( NN NN O
IL NN NN O
- NN NN O
2R NN NN O
) NN NN O
is NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
several NN NN O
intracellular NN NN O
substrates NN NN O
. NN NN O
   
The NN NN O
exact NN NN O
mechanism NN NN O
by NN NN O
which NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
regulates NN NN O
transcription NN NN O
of NN NN O
different NN NN O
genes NN NN O
is NN NN O
presently NN NN O
unknown NN NN O
. NN NN O
   
Here NN NN O
, NN NN O
we NN NN O
report NN NN O
that NN NN O
stimulation NN NN O
through NN NN O
the NN NN O
IL NN NN O
- NN NN O
2R NN NN O
induced NN NN O
tyrosine NN NN O
phosphorylation NN NN O
and NN NN O
subsequent NN NN O
nuclear NN NN O
translocation NN NN O
of NN NN O
stat3 NN NN B-Protein
, NN NN O
a NN NN O
newly NN NN O
identified NN NN O
member NN NN O
of NN NN O
the NN NN O
signal NN NN O
transducers NN NN O
and NN NN O
activators NN NN O
of NN NN O
transcription NN NN O
( NN NN O
STAT NN NN O
) NN NN O
family NN NN O
of NN NN O
proteins NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
stat1 NN NN O
proteins NN NN O
were NN NN O
not NN NN O
tyrosine NN NN O
phosphorylated NN NN O
after NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
ligation NN NN O
, NN NN O
whereas NN NN O
tyrosine NN NN O
- NN NN O
phosphorylated NN NN O
stat1 NN NN O
proteins NN NN O
( NN NN O
91 NN NN O
and NN NN O
84 NN NN O
kDa NN NN O
proteins NN NN O
) NN NN O
were NN NN O
translocated NN NN O
to NN NN O
the NN NN O
nucleus NN NN O
following NN NN O
interferon NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
treatment NN NN O
of NN NN O
HeLa NN NN O
cells NN NN O
. NN NN O
   
Apart NN NN O
from NN NN O
stat3 NN NN B-Protein
, NN NN O
another NN NN O
cytoplasmic NN NN O
protein NN NN O
was NN NN O
tyrosine NN NN O
phosphorylated NN NN O
and NN NN O
subsequently NN NN O
translocated NN NN O
to NN NN O
the NN NN O
nucleus NN NN O
in NN NN O
response NN NN O
to NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
This NN NN O
protein NN NN O
had NN NN O
an NN NN O
apparent NN NN O
molecular NN NN O
mass NN NN O
of NN NN O
84 NN NN O
kDa NN NN O
and NN NN O
was NN NN O
not NN NN O
recognized NN NN O
by NN NN O
stat3 NN NN B-Protein
or NN NN O
stat1 NN NN O
mAb NN NN O
or NN NN O
antisera NN NN O
. NN NN O
   
Since NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
induced NN NN O
nuclear NN NN O
translocation NN NN O
of NN NN O
the NN NN O
84 NN NN O
kDa NN NN O
protein NN NN O
and NN NN O
stat3 NN NN B-Protein
followed NN NN O
identical NN NN O
kinetics NN NN O
, NN NN O
p84 NN NN O
is NN NN O
a NN NN O
candidate NN NN O
for NN NN O
a NN NN O
new NN NN O
, NN NN O
yet NN NN O
undefined NN NN O
, NN NN O
member NN NN O
of NN NN O
the NN NN O
STAT NN NN O
family NN NN O
. NN NN O
   
Taken NN NN O
together NN NN O
, NN NN O
we NN NN O
report NN NN O
that NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
induces NN NN O
tyrosine NN NN O
phosphorylation NN NN O
and NN NN O
subsequent NN NN O
nuclear NN NN O
translocation NN NN O
of NN NN O
stat3 NN NN B-Protein
and NN NN O
an NN NN O
as NN NN O
yet NN NN O
undefined NN NN O
84 NN NN O
- NN NN O
kDa NN NN O
protein NN NN O
in NN NN O
antigen NN NN O
- NN NN O
specific NN NN O
human NN NN O
T NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Induction NN NN O
of NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
LFA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
by NN NN O
Tax1 NN NN B-Protein
of NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
1 NN NN O
and NN NN O
mechanism NN NN O
of NN NN O
down NN NN O
- NN NN O
regulation NN NN O
of NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
or NN NN O
LFA NN NN O
- NN NN O
1 NN NN O
in NN NN O
adult NN NN O
- NN NN O
T NN NN O
- NN NN O
cell NN NN O
- NN NN O
leukemia NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
was NN NN O
undertaken NN NN O
to NN NN O
determine NN NN O
the NN NN O
role NN NN O
of NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
TaxI NN NN B-Protein
in NN NN O
the NN NN O
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
I NN NN I-Protein
and NN NN O
LFA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
in NN NN O
human NN NN O
T NN NN O
cells NN NN O
transformed NN NN O
with NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
and NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
down NN NN O
- NN NN O
regulation NN NN O
of NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
I NN NN I-Protein
and NN NN O
LFA NN NN O
- NN NN O
I NN NN O
in NN NN O
ATL NN NN O
- NN NN O
derived NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Induction NN NN O
of NN NN O
TaxI NN NN B-Protein
in NN NN O
a NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
line NN NN O
Jurkat NN NN O
carrying NN NN O
the NN NN O
TaxI NN NN B-Protein
gene NN NN O
under NN NN O
the NN NN O
metallothionein NN NN O
promoter NN NN O
led NN NN O
to NN NN O
increases NN NN O
in NN NN O
mRNA NN NN O
and NN NN O
surface NN NN O
expression NN NN O
of NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
I NN NN I-Protein
. NN NN O
   
The NN NN O
response NN NN O
of NN NN O
LFA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
to NN NN O
TaxI NN NN B-Protein
induction NN NN O
was NN NN O
, NN NN O
on NN NN O
the NN NN O
other NN NN O
hand NN NN O
, NN NN O
relatively NN NN O
slow NN NN O
and NN NN O
weak NN NN O
, NN NN O
and NN NN O
might NN NN O
be NN NN O
indirect NN NN O
. NN NN O
   
Transactivation NN NN O
of NN NN O
the NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
I NN NN I-Protein
promoter NN NN O
by NN NN O
TaxI NN NN B-Protein
was NN NN O
further NN NN O
shown NN NN O
by NN NN O
co NN NN O
- NN NN O
transfection NN NN O
of NN NN O
a NN NN O
CAT NN NN B-Protein
reporter NN NN O
construct NN NN O
with NN NN O
the NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
I NN NN I-Protein
promoter NN NN O
and NN NN O
a NN NN O
plasmid NN NN O
expressing NN NN O
TaxI NN NN B-Protein
. NN NN O
   
The NN NN O
mechanism NN NN O
of NN NN O
down NN NN O
- NN NN O
regulation NN NN O
of NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
I NN NN I-Protein
or NN NN O
LFA NN NN O
- NN NN O
I NN NN O
in NN NN O
4 NN NN O
ATL NN NN O
cell NN NN O
lines NN NN O
was NN NN O
next NN NN O
examined NN NN O
. NN NN O
   
ICAM NN NN B-Protein
- NN NN I-Protein
I NN NN I-Protein
mRNA NN NN O
was NN NN O
quite NN NN O
low NN NN O
in NN NN O
MT NN NN O
- NN NN O
I NN NN O
, NN NN O
but NN NN O
no NN NN O
genomic NN NN O
changes NN NN O
were NN NN O
found NN NN O
. NN NN O
   
The NN NN O
CAT NN NN B-Protein
reporter NN NN O
with NN NN O
the NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
I NN NN I-Protein
promoter NN NN O
was NN NN O
inactive NN NN O
in NN NN O
MT NN NN O
- NN NN O
I NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
combined NN NN O
treatment NN NN O
of NN NN O
MT NN NN O
- NN NN O
I NN NN O
with NN NN O
5 NN NN O
- NN NN O
azacytidine NN NN O
and NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
induced NN NN O
re NN NN O
- NN NN O
expression NN NN O
of NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
I NN NN I-Protein
. NN NN O
   
Collectively NN NN O
, NN NN O
( NN NN O
a NN NN O
) NN NN O
transcriptional NN NN O
factor NN NN O
( NN NN O
s NN NN O
) NN NN O
necessary NN NN O
for NN NN O
expression NN NN O
of NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
I NN NN I-Protein
gene NN NN O
may NN NN O
be NN NN O
repressed NN NN O
in NN NN O
MT NN NN O
- NN NN O
I NN NN O
through NN NN O
DNA NN NN O
methylation NN NN O
. NN NN O
   
Three NN NN O
other NN NN O
ATL NN NN O
cell NN NN O
lines NN NN O
( NN NN O
TL NN NN O
- NN NN O
OmI NN NN O
, NN NN O
H582 NN NN O
, NN NN O
HuT102 NN NN O
) NN NN O
were NN NN O
found NN NN O
to NN NN O
have NN NN O
little NN NN O
mRNA NN NN O
for NN NN O
the NN NN O
LFA NN NN B-Protein
- NN NN I-Protein
I NN NN I-Protein
beta NN NN I-Protein
chain NN NN I-Protein
( NN NN O
CD18 NN NN B-Protein
) NN NN O
. NN NN O
   
H582 NN NN O
and NN NN O
HuT102 NN NN O
were NN NN O
also NN NN O
negative NN NN O
for NN NN O
the NN NN O
LFA NN NN B-Protein
- NN NN I-Protein
I NN NN I-Protein
alpha NN NN I-Protein
chain NN NN I-Protein
( NN NN O
CDIIa NN NN B-Protein
) NN NN O
mRNA NN NN O
. NN NN O
   
No NN NN O
genomic NN NN O
changes NN NN O
were NN NN O
found NN NN O
, NN NN O
and NN NN O
a NN NN O
CAT NN NN B-Protein
reporter NN NN O
gene NN NN O
with NN NN O
the NN NN O
CD18 NN NN B-Protein
promoter NN NN O
was NN NN O
inactive NN NN O
in NN NN O
the NN NN O
3 NN NN O
of NN NN O
them NN NN O
, NN NN O
again NN NN O
suggesting NN NN O
lack NN NN O
of NN NN O
( NN NN O
a NN NN O
) NN NN O
transcriptional NN NN O
factor NN NN O
( NN NN O
s NN NN O
) NN NN O
necessary NN NN O
for NN NN O
CD18 NN NN B-Protein
expression NN NN O
. NN NN O
   
Growth NN NN O
regulation NN NN O
and NN NN O
cellular NN NN O
changes NN NN O
during NN NN O
differentiation NN NN O
of NN NN O
human NN NN O
prostatic NN NN O
cancer NN NN O
LNCaP NN NN O
cells NN NN O
as NN NN O
induced NN NN O
by NN NN O
T NN NN O
lymphocyte NN NN O
- NN NN O
conditioned NN NN O
medium NN NN O
. NN NN O
   
Human NN NN O
prostatic NN NN O
epithelial NN NN O
cells NN NN O
from NN NN O
an NN NN O
androgen NN NN O
- NN NN O
dependent NN NN O
LNCaP NN NN O
cell NN NN O
line NN NN O
were NN NN O
examined NN NN O
in NN NN O
response NN NN O
to NN NN O
conditioned NN NN O
medium NN NN O
( NN NN O
CM NN NN O
) NN NN O
derived NN NN O
from NN NN O
phytohemagglutinin NN NN B-Protein
( NN NN O
PHA NN NN B-Protein
) NN NN O
- NN NN O
stimulated NN NN O
lymphocytes NN NN O
. NN NN O
   
Addition NN NN O
of NN NN O
CM NN NN O
caused NN NN O
a NN NN O
greater NN NN O
than NN NN O
70 NN NN O
% NN NN O
reduction NN NN O
of NN NN O
cell NN NN O
proliferation NN NN O
by NN NN O
cell NN NN O
counting NN NN O
and NN NN O
cell NN NN O
cycle NN NN O
. NN NN O
   
These NN NN O
cells NN NN O
showed NN NN O
G1 NN NN O
phase NN NN O
arrest NN NN O
and NN NN O
the NN NN O
clonogenicity NN NN O
was NN NN O
reduced NN NN O
. NN NN O
   
The NN NN O
growth NN NN O
- NN NN O
modulating NN NN O
effect NN NN O
was NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
and NN NN O
not NN NN O
due NN NN O
to NN NN O
cell NN NN O
lysis NN NN O
or NN NN O
apoptosis NN NN O
. NN NN O
   
The NN NN O
binding NN NN O
of NN NN O
androgen NN NN O
to NN NN O
androgen NN NN O
receptor NN NN O
on NN NN O
these NN NN O
cells NN NN O
showed NN NN O
approximately NN NN O
50 NN NN O
% NN NN O
reduction NN NN O
, NN NN O
underlining NN NN O
a NN NN O
proliferation NN NN O
reduction NN NN O
mechanism NN NN O
. NN NN O
   
The NN NN O
prostate NN NN B-Protein
- NN NN I-Protein
specific NN NN I-Protein
antigen NN NN I-Protein
( NN NN O
PSA NN NN B-Protein
) NN NN O
was NN NN O
downregulated NN NN O
to NN NN O
approximately NN NN O
75 NN NN O
% NN NN O
during NN NN O
the NN NN O
process NN NN O
. NN NN O
   
Cell NN NN O
morphology NN NN O
showed NN NN O
dendritic NN NN O
processes NN NN O
extending NN NN O
from NN NN O
cytoplasm NN NN O
and NN NN O
other NN NN O
neuroendocrine NN NN O
cell NN NN O
characteristics NN NN O
. NN NN O
   
The NN NN O
expression NN NN O
of NN NN O
several NN NN O
cytoskeleton NN NN O
and NN NN O
intracellular NN NN O
proteins NN NN O
increased NN NN O
as NN NN O
determined NN NN O
by NN NN O
immunostaining NN NN O
on NN NN O
slides NN NN O
and NN NN O
by NN NN O
ELISA NN NN O
procedures NN NN O
. NN NN O
   
These NN NN O
included NN NN O
vimentin NN NN B-Protein
, NN NN O
correlating NN NN O
to NN NN O
cell NN NN O
shape NN NN O
changes NN NN O
, NN NN O
cytokeratins NN NN O
8 NN NN O
and NN NN O
18 NN NN O
, NN NN O
associated NN NN O
with NN NN O
differentiated NN NN O
cell NN NN O
types NN NN O
of NN NN O
prostate NN NN O
epithelia NN NN O
, NN NN O
and NN NN O
neuron NN NN B-Protein
- NN NN I-Protein
specific NN NN I-Protein
enolase NN NN I-Protein
and NN NN O
serotonin NN NN O
, NN NN O
associated NN NN O
with NN NN O
neuroendocrine NN NN O
cells NN NN O
. NN NN O
   
From NN NN O
these NN NN O
cellular NN NN O
changes NN NN O
, NN NN O
we NN NN O
can NN NN O
infer NN NN O
that NN NN O
the NN NN O
cell NN NN O
growth NN NN O
was NN NN O
modulated NN NN O
along NN NN O
with NN NN O
induction NN NN O
of NN NN O
terminal NN NN O
differentiation NN NN O
. NN NN O
   
Activated NN NN O
T NN NN O
cells NN NN O
were NN NN O
demonstrated NN NN O
to NN NN O
be NN NN O
important NN NN O
in NN NN O
providing NN NN O
the NN NN O
modulating NN NN O
activity NN NN O
. NN NN O
   
This NN NN O
growth NN NN O
modulator NN NN O
was NN NN O
semipurified NN NN O
and NN NN O
had NN NN O
an NN NN O
estimated NN NN O
molecular NN NN O
weight NN NN O
13 NN NN O
, NN NN O
000 NN NN O
to NN NN O
24 NN NN O
, NN NN O
000 NN NN O
Da NN NN O
. NN NN O
   
The NN NN O
activity NN NN O
was NN NN O
determined NN NN O
to NN NN O
be NN NN O
distinct NN NN O
from NN NN O
TGF NN NN O
, NN NN O
TNF NN NN O
, NN NN O
and NN NN O
some NN NN O
commonly NN NN O
known NN NN O
lymphokines NN NN O
. NN NN O
   
The NN NN O
interaction NN NN O
between NN NN O
lymphoid NN NN O
and NN NN O
prostatic NN NN O
cells NN NN O
in NN NN O
growth NN NN O
and NN NN O
development NN NN O
is NN NN O
described NN NN O
. NN NN O
   
The NN NN O
Ah NN NN B-Protein
receptor NN NN I-Protein
recognizes NN NN O
DNA NN NN O
binding NN NN O
sites NN NN O
for NN NN O
the NN NN O
B NN NN B-Protein
cell NN NN I-Protein
transcription NN NN I-Protein
factor NN NN I-Protein
, NN NN O
BSAP NN NN B-Protein
: NN NN O
a NN NN O
possible NN NN O
mechanism NN NN O
for NN NN O
dioxin NN NN O
- NN NN O
mediated NN NN O
alteration NN NN O
of NN NN O
CD19 NN NN B-Protein
gene NN NN O
expression NN NN O
in NN NN O
human NN NN O
B NN NN O
lymphocytes NN NN O
. NN NN O
   
2 NN NN O
, NN NN O
3 NN NN O
, NN NN O
7 NN NN O
, NN NN O
8 NN NN O
- NN NN O
tetrachlorodibenzo NN NN O
- NN NN O
p NN NN O
- NN NN O
dioxin NN NN O
( NN NN O
TCDD NN NN O
) NN NN O
inhibits NN NN O
murine NN NN O
and NN NN O
human NN NN O
B NN NN O
lymphocyte NN NN O
immunoglobulin NN NN O
production NN NN O
through NN NN O
an NN NN O
unknown NN NN O
mechanism NN NN O
. NN NN O
   
This NN NN O
study NN NN O
investigated NN NN O
the NN NN O
effect NN NN O
of NN NN O
TCDD NN NN O
on NN NN O
expression NN NN O
of NN NN O
the NN NN O
CD19 NN NN B-Protein
gene NN NN O
in NN NN O
a NN NN O
human NN NN O
B NN NN O
lymphocyte NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
Northern NN NN O
blot NN NN O
analysis NN NN O
showed NN NN O
that NN NN O
TCDD NN NN O
treatment NN NN O
decreased NN NN O
steady NN NN O
state NN NN O
levels NN NN O
of NN NN O
CD19 NN NN B-Protein
mRNA NN NN O
by NN NN O
67 NN NN O
% NN NN O
in NN NN O
the NN NN O
IM NN NN O
- NN NN O
9 NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
Using NN NN O
a NN NN O
gel NN NN O
mobility NN NN O
shift NN NN O
assay NN NN O
, NN NN O
we NN NN O
identified NN NN O
a NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
complex NN NN O
in NN NN O
IM NN NN O
- NN NN O
9 NN NN O
nuclear NN NN O
extracts NN NN O
that NN NN O
by NN NN O
several NN NN O
criteria NN NN O
appears NN NN O
to NN NN O
be NN NN O
the NN NN O
Ah NN NN B-Protein
receptor NN NN I-Protein
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
the NN NN O
Ah NN NN B-Protein
receptor NN NN I-Protein
complex NN NN O
recognized NN NN O
a NN NN O
DNA NN NN O
binding NN NN O
site NN NN O
for NN NN O
B NN NN B-Protein
cell NN NN I-Protein
lineage NN NN I-Protein
- NN NN I-Protein
specific NN NN I-Protein
activator NN NN I-Protein
protein NN NN I-Protein
( NN NN O
BSAP NN NN B-Protein
) NN NN O
in NN NN O
the NN NN O
promoter NN NN O
region NN NN O
of NN NN O
the NN NN O
human NN NN O
CD19 NN NN B-Protein
gene NN NN O
which NN NN O
is NN NN O
similar NN NN O
to NN NN O
the NN NN O
consensus NN NN O
Ah NN NN B-Protein
receptor NN NN I-Protein
DNA NN NN O
binding NN NN O
site NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
the NN NN O
AhR NN NN B-Protein
could NN NN O
interfere NN NN O
with NN NN O
BSAP NN NN B-Protein
- NN NN O
stimulated NN NN O
CD19 NN NN B-Protein
gene NN NN O
transcription NN NN O
by NN NN O
competition NN NN O
for NN NN O
a NN NN O
common NN NN O
DNA NN NN O
binding NN NN O
site NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
induces NN NN O
the NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
tyk2 NN NN B-Protein
and NN NN O
Jak1 NN NN B-Protein
and NN NN O
the NN NN O
differential NN NN O
assembly NN NN O
of NN NN O
STAT1 NN NN B-Protein
alpha NN NN I-Protein
and NN NN O
STAT3 NN NN B-Protein
complexes NN NN O
in NN NN O
human NN NN O
T NN NN O
cells NN NN O
and NN NN O
monocytes NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
affects NN NN O
monocytes NN NN O
and NN NN O
T NN NN O
cells NN NN O
by NN NN O
driving NN NN O
the NN NN O
progression NN NN O
of NN NN O
immune NN NN O
responsiveness NN NN O
such NN NN O
that NN NN O
Th2 NN NN O
lymphocyte NN NN O
- NN NN O
mediated NN NN O
effects NN NN O
predominate NN NN O
. NN NN O
   
In NN NN O
this NN NN O
report NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
in NN NN O
monocytes NN NN O
and NN NN O
T NN NN O
cells NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
stimulates NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
the NN NN O
signal NN NN O
transducers NN NN O
and NN NN O
activators NN NN O
of NN NN O
transcription NN NN O
, NN NN O
STAT1 NN NN B-Protein
alpha NN NN I-Protein
and NN NN O
STAT3 NN NN B-Protein
, NN NN O
in NN NN O
a NN NN O
differential NN NN O
manner NN NN O
such NN NN O
that NN NN O
the NN NN O
relative NN NN O
formation NN NN O
of NN NN O
homo NN NN O
- NN NN O
and NN NN O
heterodimers NN NN O
varies NN NN O
between NN NN O
the NN NN O
two NN NN O
cell NN NN O
types NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
monocytes NN NN O
express NN NN O
a NN NN O
novel NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
- NN NN O
stimulated NN NN O
STAT NN NN O
protein NN NN O
with NN NN O
an NN NN O
M NN NN O
( NN NN O
r NN NN O
) NN NN O
of NN NN O
70 NN NN O
kDa NN NN O
that NN NN O
is NN NN O
recognized NN NN O
by NN NN O
the NN NN O
anti NN NN O
- NN NN O
STAT3 NN NN B-Protein
Ab NN NN O
but NN NN O
is NN NN O
not NN NN O
observed NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
treatment NN NN O
of NN NN O
both NN NN O
T NN NN O
cells NN NN O
and NN NN O
monocytes NN NN O
results NN NN O
in NN NN O
the NN NN O
ligand NN NN O
- NN NN O
induced NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
tyk2 NN NN B-Protein
and NN NN O
Jak1 NN NN B-Protein
, NN NN O
but NN NN O
not NN NN O
Jak2 NN NN B-Protein
or NN NN O
Jak3 NN NN B-Protein
. NN NN O
   
Selective NN NN O
modulation NN NN O
of NN NN O
immune NN NN O
responsiveness NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
in NN NN O
cells NN NN O
such NN NN O
as NN NN O
monocytes NN NN O
and NN NN O
T NN NN O
cells NN NN O
may NN NN O
result NN NN O
in NN NN O
part NN NN O
from NN NN O
the NN NN O
differential NN NN O
activation NN NN O
of NN NN O
STAT NN NN O
protein NN NN O
pairs NN NN O
. NN NN O
   
Interleukin NN NN B-Protein
2 NN NN I-Protein
signaling NN NN O
involves NN NN O
the NN NN O
phosphorylation NN NN O
of NN NN O
Stat NN NN O
proteins NN NN O
. NN NN O
   
One NN NN O
of NN NN O
the NN NN O
most NN NN O
important NN NN O
cytokines NN NN O
involved NN NN O
in NN NN O
immune NN NN O
response NN NN O
regulation NN NN O
is NN NN O
interleukin NN NN B-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
, NN NN O
a NN NN O
potent NN NN O
activator NN NN O
of NN NN O
the NN NN O
proliferation NN NN O
and NN NN O
function NN NN O
of NN NN O
T NN NN O
lymphocytes NN NN O
and NN NN O
natural NN NN O
killer NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
mechanisms NN NN O
by NN NN O
which NN NN O
the NN NN O
effects NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
are NN NN O
propagated NN NN O
within NN NN O
cells NN NN O
are NN NN O
not NN NN O
understood NN NN O
. NN NN O
   
While NN NN O
the NN NN O
binding NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
to NN NN O
its NN NN O
receptor NN NN O
was NN NN O
recently NN NN O
shown NN NN O
to NN NN O
lead NN NN O
to NN NN O
the NN NN O
activation NN NN O
of NN NN O
two NN NN O
kinases NN NN O
, NN NN O
Jak NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
Jak NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
, NN NN O
subsequent NN NN O
steps NN NN O
in NN NN O
the NN NN O
signaling NN NN O
pathway NN NN O
to NN NN O
the NN NN O
nucleus NN NN O
that NN NN O
lead NN NN O
to NN NN O
the NN NN O
activation NN NN O
of NN NN O
specific NN NN O
genes NN NN O
had NN NN O
not NN NN O
been NN NN O
characterized NN NN O
. NN NN O
   
Since NN NN O
many NN NN O
cytokines NN NN O
that NN NN O
activate NN NN O
Jak NN NN O
kinases NN NN O
also NN NN O
lead NN NN O
to NN NN O
the NN NN O
tyrosine NN NN O
phosphorylation NN NN O
and NN NN O
activation NN NN O
of NN NN O
members NN NN O
of NN NN O
the NN NN O
Stat NN NN O
family NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
, NN NN O
the NN NN O
ability NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
to NN NN O
trigger NN NN O
Stat NN NN O
phosphorylation NN NN O
was NN NN O
examined NN NN O
. NN NN O
   
Exposure NN NN O
of NN NN O
activated NN NN O
human NN NN O
T NN NN O
lymphocytes NN NN O
or NN NN O
of NN NN O
a NN NN O
natural NN NN O
killer NN NN O
cell NN NN O
line NN NN O
( NN NN O
NKL NN NN O
) NN NN O
to NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
leads NN NN O
to NN NN O
the NN NN O
phosphorylation NN NN O
of NN NN O
Stat1 NN NN B-Protein
alpha NN NN I-Protein
, NN NN O
Stat1 NN NN B-Protein
beta NN NN I-Protein
, NN NN O
and NN NN O
Stat3 NN NN B-Protein
, NN NN O
as NN NN O
well NN NN O
as NN NN O
of NN NN O
two NN NN O
Stat NN NN O
- NN NN O
related NN NN O
proteins NN NN O
, NN NN O
p94 NN NN B-Protein
and NN NN O
p95 NN NN B-Protein
. NN NN O
   
p94 NN NN B-Protein
and NN NN O
p95 NN NN B-Protein
share NN NN O
homology NN NN O
with NN NN O
Stat1 NN NN B-Protein
at NN NN O
the NN NN O
phosphorylation NN NN O
site NN NN O
and NN NN O
in NN NN O
the NN NN O
Src NN NN O
homology NN NN O
2 NN NN O
( NN NN O
SH2 NN NN O
) NN NN O
domain NN NN O
, NN NN O
but NN NN O
otherwise NN NN O
are NN NN O
immunologically NN NN O
distinct NN NN O
from NN NN O
Stat1 NN NN B-Protein
. NN NN O
   
These NN NN O
Stat NN NN O
proteins NN NN O
were NN NN O
found NN NN O
to NN NN O
translocate NN NN O
to NN NN O
the NN NN O
nucleus NN NN O
and NN NN O
to NN NN O
bind NN NN O
to NN NN O
a NN NN O
specific NN NN O
DNA NN NN O
sequence NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
suggest NN NN O
a NN NN O
mechanism NN NN O
by NN NN O
which NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
binding NN NN O
to NN NN O
its NN NN O
receptor NN NN O
may NN NN O
activate NN NN O
specific NN NN O
genes NN NN O
involved NN NN O
in NN NN O
immune NN NN O
cell NN NN O
function NN NN O
. NN NN O
   
Direct NN NN O
demonstration NN NN O
of NN NN O
NFATp NN NN B-Protein
dephosphorylation NN NN O
and NN NN O
nuclear NN NN O
localization NN NN O
in NN NN O
activated NN NN O
HT NN NN O
- NN NN O
2 NN NN O
cells NN NN O
using NN NN O
a NN NN O
specific NN NN O
NFATp NN NN B-Protein
polyclonal NN NN O
antibody NN NN O
. NN NN O
   
Nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
( NN NN O
NFAT NN NN O
) NN NN O
regulates NN NN O
transcription NN NN O
of NN NN O
a NN NN O
number NN NN O
of NN NN O
cytokine NN NN O
genes NN NN O
, NN NN O
and NN NN O
NFAT NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
is NN NN O
stimulated NN NN O
following NN NN O
T NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
Several NN NN O
lines NN NN O
of NN NN O
evidence NN NN O
have NN NN O
suggested NN NN O
that NN NN O
NFAT NN NN O
is NN NN O
a NN NN O
substrate NN NN O
for NN NN O
calcineurin NN NN O
, NN NN O
a NN NN O
serine NN NN O
/ NN NN O
threonine NN NN O
phosphatase NN NN O
. NN NN O
   
Using NN NN O
a NN NN O
polyclonal NN NN O
antibody NN NN O
to NN NN O
murine NN NN O
NFATp NN NN B-Protein
, NN NN O
Western NN NN O
blot NN NN O
analysis NN NN O
of NN NN O
various NN NN O
mouse NN NN O
tissues NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
110 NN NN O
- NN NN O
130 NN NN O
- NN NN O
kDa NN NN O
NFATp NN NN B-Protein
protein NN NN O
was NN NN O
highly NN NN O
expressed NN NN O
in NN NN O
thymus NN NN O
and NN NN O
spleen NN NN O
. NN NN O
   
Treatment NN NN O
of NN NN O
immunoprecipitated NN NN O
NFATp NN NN B-Protein
from NN NN O
untreated NN NN O
HT NN NN O
- NN NN O
2 NN NN O
cells NN NN O
with NN NN O
calcineurin NN NN O
resulted NN NN O
in NN NN O
the NN NN O
dephosphorylation NN NN O
of NN NN O
NFATp NN NN B-Protein
, NN NN O
demonstrating NN NN O
that NN NN O
NFATp NN NN B-Protein
is NN NN O
an NN NN O
in NN NN O
vitro NN NN O
substrate NN NN O
for NN NN O
calcineurin NN NN O
. NN NN O
   
NFATp NN NN B-Protein
immunoprecipitated NN NN O
from NN NN O
32P NN NN O
- NN NN O
labeled NN NN O
HT NN NN O
- NN NN O
2 NN NN O
cells NN NN O
migrated NN NN O
as NN NN O
an NN NN O
approximately NN NN O
120 NN NN O
- NN NN O
kDa NN NN O
protein NN NN O
that NN NN O
was NN NN O
localized NN NN O
to NN NN O
the NN NN O
cytosol NN NN O
of NN NN O
the NN NN O
cells NN NN O
. NN NN O
   
Treatment NN NN O
of NN NN O
the NN NN O
cells NN NN O
with NN NN O
ionomycin NN NN O
resulted NN NN O
in NN NN O
a NN NN O
decrease NN NN O
in NN NN O
the NN NN O
molecular NN NN O
weight NN NN O
of NN NN O
NFATp NN NN B-Protein
and NN NN O
a NN NN O
loss NN NN O
of NN NN O
32P NN NN O
, NN NN O
consistent NN NN O
with NN NN O
NFATp NN NN B-Protein
dephosphorylation NN NN O
. NN NN O
   
The NN NN O
dephosphorylation NN NN O
of NN NN O
NFATp NN NN B-Protein
was NN NN O
accompanied NN NN O
by NN NN O
localization NN NN O
of NN NN O
the NN NN O
protein NN NN O
to NN NN O
the NN NN O
nuclear NN NN O
fraction NN NN O
. NN NN O
   
Both NN NN O
of NN NN O
these NN NN O
events NN NN O
were NN NN O
blocked NN NN O
by NN NN O
preincubation NN NN O
of NN NN O
the NN NN O
cells NN NN O
with NN NN O
FK506 NN NN O
, NN NN O
a NN NN O
calcineurin NN NN O
inhibitor NN NN O
, NN NN O
consistent NN NN O
with NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
NFATp NN NN B-Protein
is NN NN O
a NN NN O
calcineurin NN NN O
substrate NN NN O
in NN NN O
cells NN NN O
. NN NN O
   
Temperature NN NN O
- NN NN O
induced NN NN O
down NN NN O
- NN NN O
regulation NN NN O
of NN NN O
the NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
in NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
leucocyte NN NN O
in NN NN O
patients NN NN O
with NN NN O
sepsis NN NN O
or NN NN O
septic NN NN O
shock NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
Activation NN NN O
of NN NN O
the NN NN O
hypothalamic NN NN O
- NN NN O
pituitary NN NN O
- NN NN O
adrenal NN NN O
axis NN NN O
is NN NN O
of NN NN O
vital NN NN O
importance NN NN O
during NN NN O
critical NN NN O
illness NN NN O
. NN NN O
   
We NN NN O
have NN NN O
studied NN NN O
the NN NN O
adaptive NN NN O
mechanisms NN NN O
which NN NN O
occur NN NN O
at NN NN O
the NN NN O
level NN NN O
of NN NN O
the NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
in NN NN O
glucocorticoid NN NN O
target NN NN O
tissues NN NN O
in NN NN O
patients NN NN O
with NN NN O
sepsis NN NN O
or NN NN O
septic NN NN O
shock NN NN O
. NN NN O
   
DESIGN NN NN O
: NN NN O
The NN NN O
effects NN NN O
of NN NN O
hypercortisolaemia NN NN O
, NN NN O
hyperthermia NN NN O
and NN NN O
cellular NN NN O
composition NN NN O
on NN NN O
number NN NN O
of NN NN O
glucocorticoid NN NN B-Protein
receptors NN NN I-Protein
per NN NN O
cell NN NN O
and NN NN O
their NN NN O
affinity NN NN O
were NN NN O
evaluated NN NN O
, NN NN O
both NN NN O
in NN NN O
vitro NN NN O
and NN NN O
in NN NN O
vivo NN NN O
, NN NN O
in NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
leucocytes NN NN O
of NN NN O
control NN NN O
subjects NN NN O
and NN NN O
in NN NN O
patients NN NN O
with NN NN O
sepsis NN NN O
or NN NN O
septic NN NN O
shock NN NN O
. NN NN O
   
SUBJECTS NN NN O
: NN NN O
Fifteen NN NN O
patients NN NN O
( NN NN O
age NN NN O
25 NN NN O
- NN NN O
79 NN NN O
) NN NN O
with NN NN O
sepsis NN NN O
or NN NN O
septic NN NN O
shock NN NN O
who NN NN O
were NN NN O
admitted NN NN O
to NN NN O
an NN NN O
intensive NN NN O
care NN NN O
unit NN NN O
were NN NN O
studied NN NN O
. NN NN O
   
The NN NN O
control NN NN O
group NN NN O
consisted NN NN O
of NN NN O
24 NN NN O
healthy NN NN O
laboratory NN NN O
employees NN NN O
. NN NN O
   
MEASUREMENTS NN NN O
: NN NN O
The NN NN O
binding NN NN O
capacity NN NN O
and NN NN O
affinity NN NN O
of NN NN O
the NN NN O
glucocorticoid NN NN B-Protein
receptors NN NN I-Protein
were NN NN O
measured NN NN O
and NN NN O
compared NN NN O
to NN NN O
clinical NN NN O
data NN NN O
and NN NN O
the NN NN O
plasma NN NN O
cortisol NN NN O
concentrations NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Hypercortisolaemia NN NN O
, NN NN O
in NN NN O
vitro NN NN O
, NN NN O
resulted NN NN O
in NN NN O
a NN NN O
decreased NN NN O
affinity NN NN O
and NN NN O
a NN NN O
decreased NN NN O
binding NN NN O
capacity NN NN O
of NN NN O
the NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
. NN NN O
   
In NN NN O
vitro NN NN O
, NN NN O
hyperthermia NN NN O
as NN NN O
well NN NN O
as NN NN O
variations NN NN O
in NN NN O
the NN NN O
cellular NN NN O
composition NN NN O
did NN NN O
not NN NN O
influence NN NN O
the NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
. NN NN O
   
In NN NN O
vivo NN NN O
, NN NN O
there NN NN O
was NN NN O
no NN NN O
change NN NN O
in NN NN O
the NN NN O
number NN NN O
of NN NN O
receptors NN NN O
per NN NN O
cell NN NN O
in NN NN O
patients NN NN O
with NN NN O
sepsis NN NN O
or NN NN O
septic NN NN O
shock NN NN O
as NN NN O
compared NN NN O
to NN NN O
healthy NN NN O
controls NN NN O
. NN NN O
   
However NN NN O
, NN NN O
a NN NN O
decreased NN NN O
affinity NN NN O
of NN NN O
the NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
was NN NN O
observed NN NN O
. NN NN O
   
There NN NN O
was NN NN O
a NN NN O
weak NN NN O
but NN NN O
significant NN NN O
negative NN NN O
correlation NN NN O
between NN NN O
body NN NN O
temperature NN NN O
and NN NN O
the NN NN O
number NN NN O
of NN NN O
glucocorticoid NN NN B-Protein
receptors NN NN I-Protein
in NN NN O
the NN NN O
patient NN NN O
group NN NN O
. NN NN O
   
There NN NN O
was NN NN O
no NN NN O
relation NN NN O
between NN NN O
circulating NN NN O
cortisol NN NN O
concentrations NN NN O
and NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
affinity NN NN O
and NN NN O
number NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
There NN NN O
is NN NN O
no NN NN O
obvious NN NN O
regulation NN NN O
of NN NN O
the NN NN O
number NN NN O
of NN NN O
glucocorticoid NN NN B-Protein
receptors NN NN I-Protein
by NN NN O
plasma NN NN O
cortisol NN NN O
concentrations NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
The NN NN O
decreased NN NN O
affinity NN NN O
of NN NN O
the NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
together NN NN O
with NN NN O
the NN NN O
negative NN NN O
correlation NN NN O
between NN NN O
hyperthermia NN NN O
and NN NN O
the NN NN O
number NN NN O
of NN NN O
glucocorticoid NN NN B-Protein
receptors NN NN I-Protein
in NN NN O
patients NN NN O
with NN NN O
sepsis NN NN O
or NN NN O
septic NN NN O
shock NN NN O
suggest NN NN O
that NN NN O
hypothalamic NN NN O
- NN NN O
pituitary NN NN O
- NN NN O
adrenal NN NN O
axis NN NN O
activation NN NN O
during NN NN O
critical NN NN O
illness NN NN O
is NN NN O
accompanied NN NN O
by NN NN O
peripheral NN NN O
adaptation NN NN O
in NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
number NN NN O
and NN NN O
affinity NN NN O
. NN NN O
   
Evidence NN NN O
for NN NN O
normal NN NN O
vitamin NN NN B-Protein
D NN NN I-Protein
receptor NN NN I-Protein
messenger NN NN O
ribonucleic NN NN O
acid NN NN O
and NN NN O
genotype NN NN O
in NN NN O
absorptive NN NN O
hypercalciuria NN NN O
. NN NN O
   
Absorptive NN NN O
hypercalciuria NN NN O
( NN NN O
a NN NN O
stone NN NN O
- NN NN O
forming NN NN O
condition NN NN O
) NN NN O
is NN NN O
characterized NN NN O
by NN NN O
gut NN NN O
hyperabsorption NN NN O
of NN NN O
calcium NN NN O
, NN NN O
hypercalciuria NN NN O
, NN NN O
and NN NN O
reduced NN NN O
bone NN NN O
density NN NN O
. NN NN O
   
Inasmuch NN NN O
as NN NN O
these NN NN O
features NN NN O
implicate NN NN O
enhanced NN NN O
calcitriol NN NN O
action NN NN O
in NN NN O
gut NN NN O
and NN NN O
bone NN NN O
, NN NN O
we NN NN O
analyzed NN NN O
the NN NN O
vitamin NN NN B-Protein
D NN NN I-Protein
receptor NN NN I-Protein
( NN NN O
VDR NN NN B-Protein
) NN NN O
gene NN NN O
to NN NN O
ascertain NN NN O
whether NN NN O
an NN NN O
abnormality NN NN O
of NN NN O
this NN NN O
gene NN NN O
marks NN NN O
patients NN NN O
with NN NN O
intestinal NN NN O
hyperabsorption NN NN O
of NN NN O
calcium NN NN O
. NN NN O
   
We NN NN O
have NN NN O
compared NN NN O
the NN NN O
frequency NN NN O
of NN NN O
a NN NN O
restriction NN NN O
fragment NN NN O
length NN NN O
polymorphism NN NN O
( NN NN O
Bsm NN NN O
I NN NN O
) NN NN O
associated NN NN O
with NN NN O
different NN NN O
alleles NN NN O
of NN NN O
the NN NN O
VDR NN NN B-Protein
gene NN NN O
in NN NN O
a NN NN O
group NN NN O
of NN NN O
33 NN NN O
well NN NN O
characterized NN NN O
absorptive NN NN O
hypercalciuric NN NN O
patients NN NN O
and NN NN O
a NN NN O
group NN NN O
of NN NN O
36 NN NN O
normal NN NN O
race NN NN O
- NN NN O
and NN NN O
age NN NN O
- NN NN O
matched NN NN O
control NN NN O
subjects NN NN O
. NN NN O
   
There NN NN O
was NN NN O
no NN NN O
difference NN NN O
between NN NN O
the NN NN O
distribution NN NN O
of NN NN O
the NN NN O
VDR NN NN B-Protein
alleles NN NN O
in NN NN O
the NN NN O
patient NN NN O
population NN NN O
when NN NN O
compared NN NN O
with NN NN O
the NN NN O
normal NN NN O
population NN NN O
. NN NN O
   
The NN NN O
coding NN NN O
region NN NN O
of NN NN O
VDR NN NN B-Protein
messenger NN NN O
RNA NN NN O
was NN NN O
also NN NN O
normal NN NN O
, NN NN O
as NN NN O
determined NN NN O
by NN NN O
both NN NN O
DNA NN NN O
sequence NN NN O
analysis NN NN O
and NN NN O
chemical NN NN O
mismatch NN NN O
cleavage NN NN O
analysis NN NN O
of NN NN O
copy NN NN O
DNA NN NN O
from NN NN O
11 NN NN O
index NN NN O
absorptive NN NN O
hypercalciuric NN NN O
patients NN NN O
. NN NN O
   
On NN NN O
the NN NN O
basis NN NN O
of NN NN O
these NN NN O
results NN NN O
, NN NN O
we NN NN O
propose NN NN O
that NN NN O
the NN NN O
enhanced NN NN O
intestinal NN NN O
calcium NN NN O
absorption NN NN O
invariably NN NN O
seen NN NN O
in NN NN O
absorptive NN NN O
hypercalciuria NN NN O
and NN NN O
attendant NN NN O
symptoms NN NN O
of NN NN O
this NN NN O
disorder NN NN O
are NN NN O
not NN NN O
attributable NN NN O
to NN NN O
mutations NN NN O
of NN NN O
the NN NN O
VDR NN NN B-Protein
and NN NN O
are NN NN O
not NN NN O
linked NN NN O
to NN NN O
a NN NN O
common NN NN O
VDR NN NN B-Protein
genotype NN NN O
. NN NN O
   
The NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
properties NN NN O
of NN NN O
two NN NN O
heat NN NN O
shock NN NN O
factors NN NN O
, NN NN O
HSF1 NN NN B-Protein
and NN NN O
HSF3 NN NN B-Protein
, NN NN O
are NN NN O
induced NN NN O
in NN NN O
the NN NN O
avian NN NN O
erythroblast NN NN O
cell NN NN O
line NN NN O
HD6 NN NN O
. NN NN O
   
Avian NN NN O
cells NN NN O
express NN NN O
three NN NN O
heat NN NN O
shock NN NN O
transcription NN NN O
factor NN NN O
( NN NN O
HSF NN NN O
) NN NN O
genes NN NN O
corresponding NN NN O
to NN NN O
a NN NN O
novel NN NN O
factor NN NN O
, NN NN O
HSF3 NN NN B-Protein
, NN NN O
and NN NN O
homologs NN NN O
of NN NN O
mouse NN NN O
and NN NN O
human NN NN O
HSF1 NN NN B-Protein
and NN NN O
HSF2 NN NN B-Protein
. NN NN O
   
Analysis NN NN O
of NN NN O
the NN NN O
biochemical NN NN O
and NN NN O
cell NN NN O
biological NN NN O
properties NN NN O
of NN NN O
these NN NN O
HSFs NN NN O
reveals NN NN O
that NN NN O
HSF3 NN NN B-Protein
has NN NN O
properties NN NN O
in NN NN O
common NN NN O
with NN NN O
both NN NN O
HSF1 NN NN B-Protein
and NN NN O
HSF2 NN NN B-Protein
and NN NN O
yet NN NN O
has NN NN O
features NN NN O
which NN NN O
are NN NN O
distinct NN NN O
from NN NN O
both NN NN O
. NN NN O
   
HSF3 NN NN B-Protein
is NN NN O
constitutively NN NN O
expressed NN NN O
in NN NN O
the NN NN O
erythroblast NN NN O
cell NN NN O
line NN NN O
HD6 NN NN O
, NN NN O
the NN NN O
lymphoblast NN NN O
cell NN NN O
line NN NN O
MSB NN NN O
, NN NN O
and NN NN O
embryo NN NN O
fibroblasts NN NN O
, NN NN O
and NN NN O
yet NN NN O
its NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
is NN NN O
induced NN NN O
only NN NN O
upon NN NN O
exposure NN NN O
of NN NN O
HD6 NN NN O
cells NN NN O
to NN NN O
heat NN NN O
shock NN NN O
. NN NN O
   
Acquisition NN NN O
of NN NN O
HSF3 NN NN B-Protein
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
in NN NN O
HD6 NN NN O
cells NN NN O
is NN NN O
accompanied NN NN O
by NN NN O
oligomerization NN NN O
from NN NN O
a NN NN O
non NN NN O
- NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
dimer NN NN O
to NN NN O
a NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
trimer NN NN O
, NN NN O
whereas NN NN O
the NN NN O
effect NN NN O
of NN NN O
heat NN NN O
shock NN NN O
on NN NN O
HSF1 NN NN B-Protein
is NN NN O
oligomerization NN NN O
of NN NN O
an NN NN O
inert NN NN O
monomer NN NN O
to NN NN O
a NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
trimer NN NN O
. NN NN O
   
Induction NN NN O
of NN NN O
HSF3 NN NN B-Protein
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
is NN NN O
delayed NN NN O
compared NN NN O
with NN NN O
that NN NN O
of NN NN O
HSF1 NN NN B-Protein
. NN NN O
   
As NN NN O
occurs NN NN O
for NN NN O
HSF1 NN NN B-Protein
, NN NN O
heat NN NN O
shock NN NN O
leads NN NN O
to NN NN O
the NN NN O
translocation NN NN O
of NN NN O
HSF3 NN NN B-Protein
to NN NN O
the NN NN O
nucleus NN NN O
. NN NN O
   
HSF NN NN O
exhibits NN NN O
the NN NN O
properties NN NN O
of NN NN O
a NN NN O
transcriptional NN NN O
activator NN NN O
, NN NN O
as NN NN O
judged NN NN O
from NN NN O
the NN NN O
stimulatory NN NN O
activity NN NN O
of NN NN O
transiently NN NN O
overexpressed NN NN O
HSF3 NN NN B-Protein
measured NN NN O
by NN NN O
using NN NN O
a NN NN O
heat NN NN O
shock NN NN O
element NN NN O
- NN NN O
containing NN NN O
reporter NN NN O
construct NN NN O
and NN NN O
as NN NN O
independently NN NN O
assayed NN NN O
by NN NN O
the NN NN O
activity NN NN O
of NN NN O
a NN NN O
chimeric NN NN O
GAL4 NN NN B-Protein
- NN NN O
HSF3 NN NN B-Protein
protein NN NN O
on NN NN O
a NN NN O
GAL4 NN NN B-Protein
reporter NN NN O
construct NN NN O
. NN NN O
   
These NN NN O
results NN NN O
reveal NN NN O
that NN NN O
HSF3 NN NN B-Protein
is NN NN O
negatively NN NN O
regulated NN NN O
in NN NN O
avian NN NN O
cells NN NN O
and NN NN O
acquires NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
in NN NN O
certain NN NN O
cells NN NN O
upon NN NN O
heat NN NN O
shock NN NN O
. NN NN O
   
A NN NN O
central NN NN O
role NN NN O
for NN NN O
a NN NN O
single NN NN O
c NN NN B-Protein
- NN NN I-Protein
Myb NN NN I-Protein
binding NN NN O
site NN NN O
in NN NN O
a NN NN O
thymic NN NN O
locus NN NN O
control NN NN O
region NN NN O
. NN NN O
   
Locus NN NN O
control NN NN O
regions NN NN O
( NN NN O
LCRs NN NN O
) NN NN O
are NN NN O
powerful NN NN O
assemblies NN NN O
of NN NN O
cis NN NN O
elements NN NN O
that NN NN O
organize NN NN O
the NN NN O
actions NN NN O
of NN NN O
cell NN NN O
- NN NN O
type NN NN O
- NN NN O
specific NN NN O
trans NN NN O
- NN NN O
acting NN NN O
factors NN NN O
. NN NN O
   
A NN NN O
2 NN NN O
. NN NN O
3 NN NN O
- NN NN O
kb NN NN O
LCR NN NN O
in NN NN O
the NN NN O
human NN NN O
adenosine NN NN B-Protein
deaminase NN NN I-Protein
( NN NN O
ADA NN NN B-Protein
) NN NN O
gene NN NN O
first NN NN O
intron NN NN O
, NN NN O
which NN NN O
controls NN NN O
expression NN NN O
in NN NN O
thymocytes NN NN O
, NN NN O
is NN NN O
composed NN NN O
of NN NN O
a NN NN O
200 NN NN O
- NN NN O
bp NN NN O
enhancer NN NN O
domain NN NN O
and NN NN O
extended NN NN O
flanking NN NN O
sequences NN NN O
that NN NN O
facilitate NN NN O
activation NN NN O
from NN NN O
within NN NN O
chromatin NN NN O
. NN NN O
   
Prior NN NN O
analyses NN NN O
have NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
enhancer NN NN O
contains NN NN O
a NN NN O
28 NN NN O
- NN NN O
bp NN NN O
core NN NN O
region NN NN O
and NN NN O
local NN NN O
adjacent NN NN O
augmentative NN NN O
cis NN NN O
elements NN NN O
. NN NN O
   
We NN NN O
now NN NN O
show NN NN O
that NN NN O
the NN NN O
core NN NN O
contains NN NN O
a NN NN O
single NN NN O
critical NN NN O
c NN NN B-Protein
- NN NN I-Protein
Myb NN NN I-Protein
binding NN NN O
site NN NN O
. NN NN O
   
In NN NN O
both NN NN O
transiently NN NN O
cotransfected NN NN O
human NN NN O
cells NN NN O
and NN NN O
stable NN NN O
chromatin NN NN O
- NN NN O
integrated NN NN O
yeast NN NN O
cells NN NN O
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
Myb NN NN I-Protein
strongly NN NN O
transactivated NN NN O
reporter NN NN O
constructs NN NN O
that NN NN O
contained NN NN O
polymerized NN NN O
core NN NN O
sequences NN NN O
. NN NN O
   
c NN NN B-Protein
- NN NN I-Protein
Myb NN NN I-Protein
protein NN NN O
was NN NN O
strongly NN NN O
evident NN NN O
in NN NN O
T NN NN O
lymphoblasts NN NN O
in NN NN O
which NN NN O
the NN NN O
enhancer NN NN O
was NN NN O
active NN NN O
and NN NN O
was NN NN O
localized NN NN O
within NN NN O
discrete NN NN O
nuclear NN NN O
structures NN NN O
. NN NN O
   
Fetal NN NN O
murine NN NN O
thymus NN NN O
exhibited NN NN O
a NN NN O
striking NN NN O
concordance NN NN O
of NN NN O
endogenous NN NN O
c NN NN B-Protein
- NN NN I-Protein
myb NN NN I-Protein
expression NN NN O
with NN NN O
that NN NN O
of NN NN O
mouse NN NN O
ADA NN NN B-Protein
and NN NN O
human NN NN O
ADA NN NN B-Protein
LCR NN NN O
- NN NN O
directed NN NN O
transgene NN NN O
expression NN NN O
. NN NN O
   
Point NN NN O
mutation NN NN O
of NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
Myb NN NN I-Protein
site NN NN O
within NN NN O
the NN NN O
intact NN NN O
2 NN NN O
. NN NN O
3 NN NN O
- NN NN O
kb NN NN O
LCR NN NN O
severely NN NN O
attenuated NN NN O
enhancer NN NN O
activity NN NN O
in NN NN O
transfections NN NN O
and NN NN O
LCR NN NN O
activity NN NN O
in NN NN O
transgenic NN NN O
thymocytes NN NN O
. NN NN O
   
Within NN NN O
the NN NN O
context NN NN O
of NN NN O
a NN NN O
complex NN NN O
enhancer NN NN O
and NN NN O
LCR NN NN O
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
Myb NN NN I-Protein
can NN NN O
act NN NN O
as NN NN O
an NN NN O
organizer NN NN O
of NN NN O
thymocyte NN NN O
- NN NN O
specific NN NN O
gene NN NN O
expression NN NN O
via NN NN O
a NN NN O
single NN NN O
binding NN NN O
site NN NN O
. NN NN O
   
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
( NN NN O
Spi NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
and NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
alpha NN NN I-Protein
regulate NN NN O
expression NN NN O
of NN NN O
the NN NN O
granulocyte NN NN B-Protein
- NN NN I-Protein
macrophage NN NN I-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
gene NN NN O
. NN NN O
   
Growth NN NN O
factor NN NN O
receptors NN NN O
play NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
hematopoiesis NN NN O
. NN NN O
   
In NN NN O
order NN NN O
to NN NN O
further NN NN O
understand NN NN O
the NN NN O
mechanisms NN NN O
directing NN NN O
the NN NN O
expression NN NN O
of NN NN O
these NN NN O
key NN NN O
regulators NN NN O
of NN NN O
hematopoiesis NN NN O
, NN NN O
we NN NN O
initiated NN NN O
a NN NN O
study NN NN O
investigating NN NN O
the NN NN O
transcription NN NN O
factors NN NN O
activating NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
granulocyte NN NN B-Protein
- NN NN I-Protein
macrophage NN NN I-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
( NN NN I-Protein
GM NN NN I-Protein
- NN NN I-Protein
CSF NN NN I-Protein
) NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
gene NN NN O
. NN NN O
   
Here NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
human NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
promoter NN NN O
directs NN NN O
reporter NN NN O
gene NN NN O
activity NN NN O
in NN NN O
a NN NN O
tissue NN NN O
- NN NN O
specific NN NN O
fashion NN NN O
in NN NN O
myelomonocytic NN NN O
cells NN NN O
, NN NN O
which NN NN O
correlates NN NN O
with NN NN O
its NN NN O
expression NN NN O
pattern NN NN O
as NN NN O
analyzed NN NN O
by NN NN O
reverse NN NN O
transcription NN NN O
PCR NN NN O
. NN NN O
   
The NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
promoter NN NN O
contains NN NN O
an NN NN O
important NN NN O
functional NN NN O
site NN NN O
between NN NN O
positions NN NN O
- NN NN O
53 NN NN O
and NN NN O
- NN NN O
41 NN NN O
as NN NN O
identified NN NN O
by NN NN O
deletion NN NN O
analysis NN NN O
of NN NN O
reporter NN NN O
constructs NN NN O
. NN NN O
   
We NN NN O
show NN NN O
that NN NN O
the NN NN O
myeloid NN NN O
and NN NN O
B NN NN O
cell NN NN O
transcription NN NN O
factor NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
binds NN NN O
specifically NN NN O
to NN NN O
this NN NN O
site NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
a NN NN O
CCAAT NN NN O
site NN NN O
located NN NN O
upstream NN NN O
of NN NN O
the NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
site NN NN O
between NN NN O
positions NN NN O
- NN NN O
70 NN NN O
and NN NN O
- NN NN O
54 NN NN O
is NN NN O
involved NN NN O
in NN NN O
positive NN NN O
- NN NN O
negative NN NN O
regulation NN NN O
of NN NN O
the NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
promoter NN NN O
activity NN NN O
. NN NN O
   
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
alpha NN NN I-Protein
is NN NN O
the NN NN O
major NN NN O
CCAAT NN NN O
/ NN NN O
enhancer NN NN O
- NN NN O
binding NN NN O
protein NN NN O
( NN NN O
C NN NN O
/ NN NN O
EBP NN NN O
) NN NN O
form NN NN O
binding NN NN O
to NN NN O
this NN NN O
site NN NN O
in NN NN O
nuclear NN NN O
extracts NN NN O
of NN NN O
U937 NN NN O
cells NN NN O
. NN NN O
   
Point NN NN O
mutations NN NN O
of NN NN O
either NN NN O
the NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
site NN NN O
or NN NN O
the NN NN O
C NN NN O
/ NN NN O
EBP NN NN O
site NN NN O
that NN NN O
abolish NN NN O
the NN NN O
binding NN NN O
of NN NN O
the NN NN O
respective NN NN O
factors NN NN O
result NN NN O
in NN NN O
a NN NN O
significant NN NN O
decrease NN NN O
of NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
promoter NN NN O
activity NN NN O
in NN NN O
myelomonocytic NN NN O
cells NN NN O
only NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
in NN NN O
myeloid NN NN O
and NN NN O
B NN NN O
cell NN NN O
extracts NN NN O
, NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
forms NN NN O
a NN NN O
novel NN NN O
, NN NN O
specific NN NN O
, NN NN O
more NN NN O
slowly NN NN O
migrating NN NN O
complex NN NN O
( NN NN O
PU NN NN O
- NN NN O
SF NN NN O
) NN NN O
when NN NN O
binding NN NN O
the NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
promoter NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
site NN NN O
. NN NN O
   
This NN NN O
is NN NN O
the NN NN O
first NN NN O
demonstration NN NN O
of NN NN O
a NN NN O
specific NN NN O
interaction NN NN O
with NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
on NN NN O
a NN NN O
myeloid NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
binding NN NN O
site NN NN O
. NN NN O
   
The NN NN O
novel NN NN O
complex NN NN O
is NN NN O
distinct NN NN O
from NN NN O
that NN NN O
described NN NN O
previously NN NN O
as NN NN O
binding NN NN O
to NN NN O
B NN NN O
cell NN NN O
enhancer NN NN O
sites NN NN O
and NN NN O
can NN NN O
be NN NN O
formed NN NN O
by NN NN O
addition NN NN O
of NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
to NN NN O
extracts NN NN O
from NN NN O
certain NN NN O
nonmyeloid NN NN O
cell NN NN O
types NN NN O
which NN NN O
do NN NN O
not NN NN O
express NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
, NN NN O
including NN NN O
T NN NN O
cells NN NN O
and NN NN O
epithelial NN NN O
cells NN NN O
, NN NN O
but NN NN O
not NN NN O
from NN NN O
erythroid NN NN O
cells NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
PU NN NN O
- NN NN O
SF NN NN O
complex NN NN O
binds NN NN O
to NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
sites NN NN O
found NN NN O
on NN NN O
a NN NN O
number NN NN O
of NN NN O
myeloid NN NN O
promoters NN NN O
, NN NN O
and NN NN O
its NN NN O
formation NN NN O
requires NN NN O
an NN NN O
intact NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
site NN NN O
adjacent NN NN O
to NN NN O
a NN NN O
single NN NN O
- NN NN O
stranded NN NN O
region NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
in NN NN O
nonmyeloid NN NN O
cells NN NN O
can NN NN O
activate NN NN O
the NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
promoter NN NN O
. NN NN O
   
Deletion NN NN O
of NN NN O
the NN NN O
amino NN NN O
- NN NN O
terminal NN NN O
region NN NN O
of NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
results NN NN O
in NN NN O
a NN NN O
failure NN NN O
to NN NN O
form NN NN O
the NN NN O
PU NN NN O
- NN NN O
SF NN NN O
complex NN NN O
and NN NN O
in NN NN O
a NN NN O
concomitant NN NN O
loss NN NN O
of NN NN O
transactivation NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
formation NN NN O
of NN NN O
the NN NN O
PU NN NN O
- NN NN O
SF NN NN O
complex NN NN O
is NN NN O
of NN NN O
functional NN NN O
importance NN NN O
for NN NN O
the NN NN O
activity NN NN O
of NN NN O
the NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
promoter NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
alpha NN NN I-Protein
can NN NN O
also NN NN O
active NN NN O
the NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
promoter NN NN O
in NN NN O
nonmyeloid NN NN O
cells NN NN O
. NN NN O
   
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
400 NN NN O
WORDS NN NN O
) NN NN O
   
Expression NN NN O
of NN NN O
the NN NN O
nucleoside NN NN B-Protein
diphosphate NN NN I-Protein
kinase NN NN I-Protein
in NN NN O
human NN NN O
skin NN NN O
cancers NN NN O
: NN NN O
an NN NN O
immunohistochemical NN NN O
study NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
nucleoside NN NN B-Protein
diphosphate NN NN I-Protein
( NN NN I-Protein
NDP NN NN I-Protein
) NN NN I-Protein
kinase NN NN I-Protein
, NN NN O
which NN NN O
is NN NN O
homologous NN NN O
to NN NN O
the NN NN O
nm23 NN NN B-Protein
gene NN NN O
product NN NN O
in NN NN O
a NN NN O
variety NN NN O
of NN NN O
species NN NN O
, NN NN O
has NN NN O
been NN NN O
found NN NN O
to NN NN O
be NN NN O
inversely NN NN O
associated NN NN O
with NN NN O
metastatic NN NN O
potential NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
relationship NN NN O
remains NN NN O
controversial NN NN O
according NN NN O
to NN NN O
the NN NN O
tumor NN NN O
cell NN NN O
types NN NN O
and NN NN O
experimental NN NN O
system NN NN O
, NN NN O
with NN NN O
conflicting NN NN O
results NN NN O
from NN NN O
different NN NN O
research NN NN O
groups NN NN O
. NN NN O
   
In NN NN O
order NN NN O
to NN NN O
determine NN NN O
whether NN NN O
NDP NN NN B-Protein
kinase NN NN I-Protein
expression NN NN O
serves NN NN O
as NN NN O
a NN NN O
marker NN NN O
for NN NN O
metastatic NN NN O
potential NN NN O
in NN NN O
human NN NN O
skin NN NN O
cancer NN NN O
, NN NN O
we NN NN O
assessed NN NN O
the NN NN O
levels NN NN O
of NN NN O
NDP NN NN B-Protein
kinase NN NN I-Protein
expression NN NN O
in NN NN O
9 NN NN O
keratoacanthomas NN NN O
( NN NN O
KAs NN NN O
) NN NN O
, NN NN O
26 NN NN O
squamous NN NN O
cell NN NN O
carcinomas NN NN O
( NN NN O
SCCs NN NN O
) NN NN O
, NN NN O
and NN NN O
25 NN NN O
basal NN NN O
cell NN NN O
carcinomas NN NN O
( NN NN O
BCCs NN NN O
) NN NN O
using NN NN O
immunohistochemistry NN NN O
. NN NN O
   
The NN NN O
expression NN NN O
of NN NN O
NDP NN NN B-Protein
kinase NN NN I-Protein
was NN NN O
intense NN NN O
in NN NN O
KA NN NN O
and NN NN O
SCC NN NN O
compared NN NN O
with NN NN O
BCC NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
difference NN NN O
of NN NN O
NDP NN NN B-Protein
kinase NN NN I-Protein
expression NN NN O
between NN NN O
KA NN NN O
and NN NN O
SCC NN NN O
was NN NN O
not NN NN O
statistically NN NN O
significant NN NN O
. NN NN O
   
And NN NN O
there NN NN O
was NN NN O
no NN NN O
statistically NN NN O
significant NN NN O
difference NN NN O
in NN NN O
NDP NN NN B-Protein
kinase NN NN I-Protein
expression NN NN O
between NN NN O
SCC NN NN O
with NN NN O
metastasis NN NN O
and NN NN O
SCC NN NN O
without NN NN O
metastasis NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
contradict NN NN O
the NN NN O
hypothesis NN NN O
concerning NN NN O
the NN NN O
possible NN NN O
role NN NN O
of NN NN O
nm23 NN NN B-Protein
gene NN NN O
as NN NN O
a NN NN O
metastatic NN NN O
suppressor NN NN O
gene NN NN O
in NN NN O
human NN NN O
skin NN NN O
cancer NN NN O
. NN NN O
   
The NN NN O
mechanism NN NN O
of NN NN O
overexpression NN NN O
in NN NN O
various NN NN O
tumor NN NN O
cell NN NN O
types NN NN O
and NN NN O
its NN NN O
biological NN NN O
significance NN NN O
in NN NN O
cutaneous NN NN O
carcinogenesis NN NN O
remain NN NN O
to NN NN O
be NN NN O
determined NN NN O
. NN NN O
   
Cloning NN NN O
a NN NN O
cDNA NN NN O
from NN NN O
human NN NN O
NK NN NN O
/ NN NN O
T NN NN O
cells NN NN O
which NN NN O
codes NN NN O
for NN NN O
a NN NN O
protein NN NN O
with NN NN O
high NN NN O
proline NN NN O
content NN NN O
. NN NN O
   
A NN NN O
cDNA NN NN O
clone NN NN O
, NN NN O
B4 NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
was NN NN O
isolated NN NN O
from NN NN O
a NN NN O
natural NN NN O
killer NN NN O
( NN NN O
NK NN NN O
) NN NN O
minus NN NN O
T NN NN O
cell NN NN O
subtractive NN NN O
library NN NN O
. NN NN O
   
The NN NN O
B4 NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
clone NN NN O
coded NN NN O
for NN NN O
an NN NN O
mRNA NN NN O
of NN NN O
2061 NN NN O
bp NN NN O
in NN NN O
length NN NN O
. NN NN O
   
It NN NN O
encodes NN NN O
a NN NN O
deduced NN NN O
327 NN NN O
aa NN NN O
protein NN NN O
with NN NN O
a NN NN O
calculated NN NN O
molecular NN NN O
mass NN NN O
of NN NN O
35 NN NN O
. NN NN O
2 NN NN O
kDa NN NN O
. NN NN O
   
Searching NN NN O
of NN NN O
B4 NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
DNA NN NN O
and NN NN O
protein NN NN O
sequences NN NN O
against NN NN O
various NN NN O
databases NN NN O
revealed NN NN O
no NN NN O
high NN NN O
homology NN NN O
to NN NN O
other NN NN O
sequences NN NN O
. NN NN O
   
However NN NN O
, NN NN O
B4 NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
has NN NN O
an NN NN O
unusually NN NN O
high NN NN O
proline NN NN O
content NN NN O
( NN NN O
13 NN NN O
% NN NN O
) NN NN O
, NN NN O
contains NN NN O
a NN NN O
putative NN NN O
nuclear NN NN O
targeting NN NN O
sequence NN NN O
, NN NN O
and NN NN O
has NN NN O
several NN NN O
SPXX NN NN O
motifs NN NN O
which NN NN O
are NN NN O
frequently NN NN O
found NN NN O
in NN NN O
gene NN NN O
regulatory NN NN O
proteins NN NN O
. NN NN O
   
One NN NN O
of NN NN O
the NN NN O
stretches NN NN O
of NN NN O
prolines NN NN O
in NN NN O
B4 NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
closely NN NN O
resembles NN NN O
the NN NN O
ligand NN NN O
for NN NN O
proteins NN NN O
with NN NN O
SH3 NN NN O
domains NN NN O
. NN NN O
   
Northern NN NN O
hybridization NN NN O
data NN NN O
showed NN NN O
that NN NN O
B4 NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
is NN NN O
not NN NN O
a NN NN O
lymphoid NN NN O
specific NN NN O
gene NN NN O
and NN NN O
is NN NN O
expressed NN NN O
in NN NN O
a NN NN O
hepatoma NN NN O
cell NN NN O
line NN NN O
and NN NN O
also NN NN O
weakly NN NN O
transcribed NN NN O
or NN NN O
absent NN NN O
in NN NN O
a NN NN O
variety NN NN O
of NN NN O
other NN NN O
cells NN NN O
. NN NN O
   
A NN NN O
polyclonal NN NN O
antiserum NN NN O
raised NN NN O
against NN NN O
recombinant NN NN O
B4 NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
recognizes NN NN O
a NN NN O
32 NN NN O
- NN NN O
34 NN NN O
kDa NN NN O
protein NN NN O
in NN NN O
lymphocytes NN NN O
. NN NN O
   
The NN NN O
human NN NN O
TCF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
encodes NN NN O
a NN NN O
nuclear NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
protein NN NN O
uniquely NN NN O
expressed NN NN O
in NN NN O
normal NN NN O
and NN NN O
neoplastic NN NN O
T NN NN O
- NN NN O
lineage NN NN O
lymphocytes NN NN O
. NN NN O
   
The NN NN O
TCF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
encodes NN NN O
a NN NN O
putative NN NN O
transcription NN NN O
factor NN NN O
with NN NN O
affinity NN NN O
for NN NN O
a NN NN O
sequence NN NN O
motif NN NN O
occurring NN NN O
in NN NN O
a NN NN O
number NN NN O
of NN NN O
T NN NN O
- NN NN O
cell NN NN O
enhancers NN NN O
. NN NN O
   
TCF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
mRNA NN NN O
was NN NN O
originally NN NN O
found NN NN O
to NN NN O
be NN NN O
expressed NN NN O
in NN NN O
a NN NN O
T NN NN O
cell NN NN O
- NN NN O
specific NN NN O
fashion NN NN O
within NN NN O
a NN NN O
set NN NN O
of NN NN O
human NN NN O
and NN NN O
mouse NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
expression NN NN O
reportedly NN NN O
occurs NN NN O
in NN NN O
multiple NN NN O
nonlymphoid NN NN O
tissues NN NN O
during NN NN O
murine NN NN O
embryogenesis NN NN O
. NN NN O
   
We NN NN O
have NN NN O
now NN NN O
raised NN NN O
a NN NN O
monoclonal NN NN O
antibody NN NN O
to NN NN O
document NN NN O
expression NN NN O
and NN NN O
biochemistry NN NN O
of NN NN O
the NN NN O
human NN NN O
TCF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
protein NN NN O
. NN NN O
   
As NN NN O
expected NN NN O
, NN NN O
the NN NN O
TCF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
protein NN NN O
was NN NN O
detectable NN NN O
only NN NN O
in NN NN O
cell NN NN O
lines NN NN O
of NN NN O
T NN NN O
lineage NN NN O
. NN NN O
   
Its NN NN O
expression NN NN O
was NN NN O
always NN NN O
restricted NN NN O
to NN NN O
the NN NN O
nucleus NN NN O
. NN NN O
   
Immunohistochemistry NN NN O
on NN NN O
a NN NN O
panel NN NN O
of NN NN O
human NN NN O
tissues NN NN O
revealed NN NN O
that NN NN O
the NN NN O
TCF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
protein NN NN O
was NN NN O
found NN NN O
exclusively NN NN O
in NN NN O
thymocytes NN NN O
and NN NN O
in NN NN O
CD3 NN NN O
+ NN NN O
T NN NN O
cells NN NN O
in NN NN O
peripheral NN NN O
lymphoid NN NN O
tissues NN NN O
. NN NN O
   
Western NN NN O
blotting NN NN O
yielded NN NN O
a NN NN O
set NN NN O
of NN NN O
bands NN NN O
ranging NN NN O
from NN NN O
25 NN NN O
kD NN NN O
to NN NN O
55 NN NN O
kD NN NN O
, NN NN O
resulting NN NN O
from NN NN O
extensive NN NN O
alternative NN NN O
splicing NN NN O
. NN NN O
   
The NN NN O
TCF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
protein NN NN O
was NN NN O
detectable NN NN O
in NN NN O
all NN NN O
samples NN NN O
of NN NN O
a NN NN O
set NN NN O
of NN NN O
22 NN NN O
T NN NN O
- NN NN O
cell NN NN O
malignancies NN NN O
of NN NN O
various NN NN O
stages NN NN O
of NN NN O
maturation NN NN O
, NN NN O
but NN NN O
was NN NN O
absent NN NN O
from NN NN O
a NN NN O
large NN NN O
number NN NN O
of NN NN O
other NN NN O
hematologic NN NN O
neoplasms NN NN O
. NN NN O
   
These NN NN O
observations NN NN O
imply NN NN O
a NN NN O
T NN NN O
cell NN NN O
- NN NN O
specific NN NN O
function NN NN O
for NN NN O
TCF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
a NN NN O
notion NN NN O
corroborated NN NN O
by NN NN O
recent NN NN O
observations NN NN O
on NN NN O
Tcf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
knock NN NN O
- NN NN O
out NN NN O
mice NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
these NN NN O
results NN NN O
indicate NN NN O
that NN NN O
nuclear NN NN O
TCF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
can NN NN O
serve NN NN O
as NN NN O
a NN NN O
pan NN NN O
- NN NN O
T NN NN O
- NN NN O
lineage NN NN O
marker NN NN O
in NN NN O
the NN NN O
diagnosis NN NN O
of NN NN O
lymphoid NN NN O
malignancies NN NN O
. NN NN O
   
Constitutive NN NN O
overexpression NN NN O
of NN NN O
the NN NN O
L NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
gene NN NN O
in NN NN O
fresh NN NN O
leukemic NN NN O
cells NN NN O
of NN NN O
adult NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
that NN NN O
can NN NN O
be NN NN O
transactivated NN NN O
by NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
lymphotropic NN NN O
virus NN NN O
type NN NN O
1 NN NN O
Tax NN NN B-Protein
. NN NN O
   
L NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
is NN NN O
an NN NN O
adhesion NN NN O
molecule NN NN O
of NN NN O
the NN NN O
selectin NN NN O
family NN NN O
that NN NN O
mediates NN NN O
the NN NN O
initial NN NN O
step NN NN O
of NN NN O
leukocyte NN NN O
adhesion NN NN O
to NN NN O
vascular NN NN O
endothelium NN NN O
. NN NN O
   
Upon NN NN O
cellular NN NN O
activation NN NN O
, NN NN O
expression NN NN O
of NN NN O
the NN NN O
L NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
gene NN NN O
is NN NN O
downregulated NN NN O
at NN NN O
both NN NN O
the NN NN O
protein NN NN O
and NN NN O
mRNA NN NN O
levels NN NN O
. NN NN O
   
To NN NN O
understand NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
leukemic NN NN O
cell NN NN O
infiltration NN NN O
into NN NN O
organs NN NN O
, NN NN O
we NN NN O
studied NN NN O
the NN NN O
expression NN NN O
and NN NN O
regulation NN NN O
of NN NN O
L NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
mRNA NN NN O
in NN NN O
fresh NN NN O
leukemic NN NN O
cells NN NN O
of NN NN O
adult NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
( NN NN O
ATL NN NN O
) NN NN O
patients NN NN O
and NN NN O
investigated NN NN O
the NN NN O
response NN NN O
of NN NN O
the NN NN O
L NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
promoter NN NN O
to NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
lymphotropic NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
) NN NN O
Tax NN NN B-Protein
, NN NN O
which NN NN O
is NN NN O
a NN NN O
viral NN NN O
transcriptional NN NN O
transactivator NN NN O
. NN NN O
   
Flow NN NN O
cytometry NN NN O
showed NN NN O
that NN NN O
L NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
was NN NN O
expressed NN NN O
on NN NN O
fresh NN NN O
ATL NN NN O
cells NN NN O
along NN NN O
with NN NN O
other NN NN O
activation NN NN O
antigens NN NN O
. NN NN O
   
Northern NN NN O
blot NN NN O
analysis NN NN O
showed NN NN O
that NN NN O
ATL NN NN O
cells NN NN O
overexpressed NN NN O
that NN NN O
L NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
mRNA NN NN O
and NN NN O
that NN NN O
the NN NN O
level NN NN O
was NN NN O
aberrantly NN NN O
upregulated NN NN O
after NN NN O
PMA NN NN O
stimulation NN NN O
. NN NN O
   
Studies NN NN O
using NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
showed NN NN O
expression NN NN O
of NN NN O
the NN NN O
L NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
mRNA NN NN O
in NN NN O
the NN NN O
infiltrating NN NN O
leukemic NN NN O
cells NN NN O
in NN NN O
the NN NN O
liver NN NN O
of NN NN O
two NN NN O
ATL NN NN O
patients NN NN O
. NN NN O
   
Intravenous NN NN O
injection NN NN O
of NN NN O
a NN NN O
rat NN NN O
T NN NN O
- NN NN O
cell NN NN O
line NN NN O
that NN NN O
overexpresses NN NN O
L NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
showed NN NN O
increased NN NN O
organ NN NN O
infiltration NN NN O
. NN NN O
   
The NN NN O
induction NN NN O
of NN NN O
Tax NN NN B-Protein
expression NN NN O
in NN NN O
JPX9 NN NN O
cells NN NN O
resulted NN NN O
in NN NN O
about NN NN O
a NN NN O
twofold NN NN O
increase NN NN O
in NN NN O
the NN NN O
mRNA NN NN O
expression NN NN O
levels NN NN O
compared NN NN O
with NN NN O
the NN NN O
basal NN NN O
level NN NN O
. NN NN O
   
Chloramphenicol NN NN B-Protein
acetyltransferase NN NN I-Protein
( NN NN O
CAT NN NN B-Protein
) NN NN O
assay NN NN O
after NN NN O
transient NN NN O
cotransfection NN NN O
showed NN NN O
about NN NN O
a NN NN O
fivefold NN NN O
transactivation NN NN O
of NN NN O
the NN NN O
L NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
promoter NN NN O
by NN NN O
Tax NN NN B-Protein
. NN NN O
   
The NN NN O
serum NN NN O
level NN NN O
of NN NN O
the NN NN O
shed NN NN O
form NN NN O
of NN NN O
L NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
was NN NN O
significantly NN NN O
increased NN NN O
in NN NN O
ATL NN NN O
patients NN NN O
( NN NN O
mean NN NN O
+ NN NN O
/ NN NN O
- NN NN O
SD NN NN O
, NN NN O
4 NN NN O
, NN NN O
215 NN NN O
. NN NN O
4 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
4 NN NN O
, NN NN O
111 NN NN O
ng NN NN O
/ NN NN O
mL NN NN O
) NN NN O
compared NN NN O
with NN NN O
those NN NN O
of NN NN O
asymptomatic NN NN O
carriers NN NN O
and NN NN O
healthy NN NN O
blood NN NN O
donors NN NN O
( NN NN O
mean NN NN O
+ NN NN O
/ NN NN O
- NN NN O
SD NN NN O
, NN NN O
1 NN NN O
, NN NN O
148 NN NN O
. NN NN O
0 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
269 NN NN O
. NN NN O
0 NN NN O
ng NN NN O
/ NN NN O
mL NN NN O
and NN NN O
991 NN NN O
. NN NN O
9 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
224 NN NN O
ng NN NN O
/ NN NN O
mL NN NN O
, NN NN O
respectively NN NN O
) NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicated NN NN O
that NN NN O
ATL NN NN O
cells NN NN O
constitutively NN NN O
overexpress NN NN O
the NN NN O
L NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
gene NN NN O
that NN NN O
can NN NN O
be NN NN O
transactivated NN NN O
by NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
Tax NN NN B-Protein
. NN NN O
   
The NN NN O
overexpression NN NN O
of NN NN O
L NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
, NN NN O
as NN NN O
well NN NN O
as NN NN O
of NN NN O
inflammatory NN NN O
cytokines NN NN O
, NN NN O
by NN NN O
ATL NN NN O
cells NN NN O
may NN NN O
provide NN NN O
a NN NN O
basis NN NN O
for NN NN O
ATL NN NN O
cells NN NN O
to NN NN O
attach NN NN O
the NN NN O
vascular NN NN O
endothelium NN NN O
, NN NN O
leading NN NN O
to NN NN O
transmigration NN NN O
and NN NN O
organ NN NN O
infitration NN NN O
. NN NN O
   
The NN NN O
DNA NN NN O
and NN NN O
steroid NN NN O
binding NN NN O
domains NN NN O
of NN NN O
the NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
are NN NN O
not NN NN O
altered NN NN O
in NN NN O
mononuclear NN NN O
cells NN NN O
of NN NN O
treated NN NN O
CLL NN NN O
patients NN NN O
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
investigate NN NN O
whether NN NN O
mutations NN NN O
in NN NN O
the NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
could NN NN O
account NN NN O
for NN NN O
the NN NN O
increasing NN NN O
unresponsiveness NN NN O
of NN NN O
patients NN NN O
with NN NN O
chronic NN NN O
lymphatic NN NN O
leukemia NN NN O
( NN NN O
CLL NN NN O
) NN NN O
to NN NN O
combination NN NN O
chemotherapy NN NN O
. NN NN O
   
The NN NN O
receptor NN NN O
was NN NN O
tested NN NN O
immunocytochemically NN NN O
, NN NN O
in NN NN O
steroid NN NN O
binding NN NN O
assays NN NN O
, NN NN O
and NN NN O
by NN NN O
a NN NN O
mutation NN NN O
screening NN NN O
( NN NN O
denaturing NN NN O
gradient NN NN O
gel NN NN O
electrophoresis NN NN O
) NN NN O
of NN NN O
the NN NN O
receptor NN NN O
- NN NN O
cDNA NN NN O
. NN NN O
   
The NN NN O
receptor NN NN O
concentration NN NN O
, NN NN O
as NN NN O
measured NN NN O
by NN NN O
staining NN NN O
and NN NN O
steroid NN NN O
binding NN NN O
test NN NN O
, NN NN O
varied NN NN O
considerably NN NN O
but NN NN O
showed NN NN O
no NN NN O
clear NN NN O
correlation NN NN O
to NN NN O
clinical NN NN O
response NN NN O
. NN NN O
   
Using NN NN O
a NN NN O
highly NN NN O
sensitive NN NN O
mutation NN NN O
screening NN NN O
assay NN NN O
of NN NN O
the NN NN O
DNA NN NN O
- NN NN O
and NN NN O
the NN NN O
steroid NN NN O
- NN NN O
binding NN NN O
region NN NN O
, NN NN O
none NN NN O
of NN NN O
the NN NN O
treated NN NN O
patients NN NN O
revealed NN NN O
any NN NN O
mutation NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
the NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
in NN NN O
the NN NN O
CLL NN NN O
patients NN NN O
tested NN NN O
is NN NN O
not NN NN O
altered NN NN O
in NN NN O
these NN NN O
domains NN NN O
. NN NN O
   
In NN NN O
one NN NN O
individual NN NN O
who NN NN O
had NN NN O
not NN NN O
been NN NN O
treated NN NN O
before NN NN O
analysis NN NN O
a NN NN O
silent NN NN O
mutation NN NN O
was NN NN O
found NN NN O
in NN NN O
one NN NN O
receptor NN NN O
allele NN NN O
. NN NN O
   
The NN NN O
results NN NN O
suggest NN NN O
that NN NN O
mechanisms NN NN O
other NN NN O
than NN NN O
altered NN NN O
ligand NN NN O
or NN NN O
DNA NN NN O
binding NN NN O
of NN NN O
the NN NN O
receptor NN NN O
may NN NN O
be NN NN O
responsible NN NN O
for NN NN O
the NN NN O
lack NN NN O
of NN NN O
response NN NN O
to NN NN O
chemotherapy NN NN O
. NN NN O
   
This NN NN O
conclusion NN NN O
is NN NN O
discussed NN NN O
in NN NN O
relation NN NN O
to NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
corticoid NN NN O
resistance NN NN O
in NN NN O
mouse NN NN O
and NN NN O
human NN NN O
lymphoma NN NN O
cells NN NN O
in NN NN O
culture NN NN O
. NN NN O
   
BCL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
and NN NN O
the NN NN O
molecular NN NN O
pathogenesis NN NN O
of NN NN O
B NN NN O
- NN NN O
cell NN NN O
lymphoma NN NN O
. NN NN O
   
The NN NN O
results NN NN O
presented NN NN O
identify NN NN O
the NN NN O
first NN NN O
genetic NN NN O
lesion NN NN O
associated NN NN O
with NN NN O
DLCL NN NN O
, NN NN O
the NN NN O
most NN NN O
clinically NN NN O
relevant NN NN O
form NN NN O
of NN NN O
NHL NN NN O
. NN NN O
   
Although NN NN O
no NN NN O
proof NN NN O
yet NN NN O
exists NN NN O
of NN NN O
a NN NN O
role NN NN O
for NN NN O
these NN NN O
lesions NN NN O
in NN NN O
DLCL NN NN O
pathogenesis NN NN O
, NN NN O
the NN NN O
feature NN NN O
of NN NN O
the NN NN O
BCL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
gene NN NN O
product NN NN O
, NN NN O
its NN NN O
specific NN NN O
pattern NN NN O
of NN NN O
expression NN NN O
in NN NN O
B NN NN O
cells NN NN O
, NN NN O
and NN NN O
the NN NN O
clustering NN NN O
of NN NN O
lesions NN NN O
disrupting NN NN O
its NN NN O
regulatory NN NN O
domain NN NN O
strongly NN NN O
suggest NN NN O
that NN NN O
deregulation NN NN O
of NN NN O
BCL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
expression NN NN O
may NN NN O
contribute NN NN O
to NN NN O
DLCL NN NN O
development NN NN O
. NN NN O
   
A NN NN O
more NN NN O
precise NN NN O
definition NN NN O
of NN NN O
the NN NN O
role NN NN O
of NN NN O
BCL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
in NN NN O
normal NN NN O
and NN NN O
neoplastic NN NN O
B NN NN O
- NN NN O
cell NN NN O
development NN NN O
is NN NN O
the NN NN O
goal NN NN O
of NN NN O
ongoing NN NN O
study NN NN O
of NN NN O
transgenic NN NN O
mice NN NN O
engineered NN NN O
either NN NN O
to NN NN O
express NN NN O
BCL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
under NN NN O
heterologous NN NN O
promoters NN NN O
or NN NN O
lacking NN NN O
BCL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
function NN NN O
due NN NN O
to NN NN O
targeted NN NN O
deletions NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
to NN NN O
contributing NN NN O
to NN NN O
the NN NN O
understanding NN NN O
of NN NN O
DLCL NN NN O
pathogenesis NN NN O
, NN NN O
the NN NN O
identification NN NN O
of NN NN O
BCL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
lesions NN NN O
may NN NN O
have NN NN O
relevant NN NN O
clinical NN NN O
implications NN NN O
. NN NN O
   
DLCL NN NN O
represent NN NN O
a NN NN O
heterogeneous NN NN O
group NN NN O
of NN NN O
neoplasms NN NN O
which NN NN O
are NN NN O
treated NN NN O
homogeneously NN NN O
despite NN NN O
the NN NN O
fact NN NN O
that NN NN O
only NN NN O
50 NN NN O
% NN NN O
of NN NN O
patients NN NN O
experience NN NN O
long NN NN O
- NN NN O
term NN NN O
disease NN NN O
- NN NN O
free NN NN O
survival NN NN O
( NN NN O
Schneider NN NN O
et NN NN O
al NN NN O
. NN NN O
1990 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
fact NN NN O
that NN NN O
BCL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
rearrangements NN NN O
identify NN NN O
biologically NN NN O
and NN NN O
clinically NN NN O
distinct NN NN O
subsets NN NN O
of NN NN O
DLCL NN NN O
suggests NN NN O
that NN NN O
these NN NN O
lesions NN NN O
may NN NN O
be NN NN O
useful NN NN O
as NN NN O
markers NN NN O
in NN NN O
selection NN NN O
of NN NN O
differential NN NN O
therapeutic NN NN O
strategies NN NN O
based NN NN O
on NN NN O
different NN NN O
risk NN NN O
groups NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
the NN NN O
BCL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
rearrangements NN NN O
can NN NN O
be NN NN O
used NN NN O
to NN NN O
identify NN NN O
and NN NN O
monitor NN NN O
the NN NN O
malignant NN NN O
clone NN NN O
with NN NN O
sensitive NN NN O
PCR NN NN O
- NN NN O
based NN NN O
techniques NN NN O
. NN NN O
   
Since NN NN O
clinical NN NN O
remission NN NN O
has NN NN O
been NN NN O
observed NN NN O
in NN NN O
a NN NN O
significant NN NN O
fraction NN NN O
of NN NN O
DLCL NN NN O
cases NN NN O
, NN NN O
these NN NN O
markers NN NN O
may NN NN O
serve NN NN O
as NN NN O
critical NN NN O
tools NN NN O
for NN NN O
sensitive NN NN O
monitoring NN NN O
of NN NN O
minimal NN NN O
residual NN NN O
disease NN NN O
and NN NN O
early NN NN O
diagnosis NN NN O
of NN NN O
relapse NN NN O
( NN NN O
Gribben NN NN O
et NN NN O
al NN NN O
. NN NN O
1993 NN NN O
) NN NN O
. NN NN O
   
Prolactin NN NN B-Protein
and NN NN O
interleukin NN NN O
- NN NN O
2 NN NN O
receptors NN NN O
in NN NN O
T NN NN O
lymphocytes NN NN O
signal NN NN O
through NN NN O
a NN NN O
MGF NN NN O
- NN NN O
STAT5 NN NN O
- NN NN O
like NN NN O
transcription NN NN O
factor NN NN O
. NN NN O
   
The NN NN O
cell NN NN O
surface NN NN O
receptors NN NN O
for NN NN O
PRL NN NN B-Protein
and NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
are NN NN O
structurally NN NN O
distinct NN NN O
, NN NN O
but NN NN O
share NN NN O
regulatory NN NN O
tasks NN NN O
in NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
They NN NN O
can NN NN O
stimulate NN NN O
proliferation NN NN O
and NN NN O
activate NN NN O
transcription NN NN O
of NN NN O
over NN NN O
- NN NN O
lapping NN NN O
sets NN NN O
of NN NN O
genes NN NN O
of NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
PRL NN NN O
and NN NN O
IL NN NN O
- NN NN O
2 NN NN O
receptor NN NN O
activation NN NN O
are NN NN O
both NN NN O
linked NN NN O
to NN NN O
the NN NN O
Jak NN NN O
/ NN NN O
Stat NN NN O
( NN NN O
signal NN NN O
transducer NN NN O
and NN NN O
activator NN NN O
of NN NN O
transcription NN NN O
) NN NN O
pathway NN NN O
. NN NN O
   
We NN NN O
investigated NN NN O
the NN NN O
ability NN NN O
of NN NN O
PRL NN NN B-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
to NN NN O
activate NN NN O
Stat NN NN O
proteins NN NN O
in NN NN O
different NN NN O
T NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
The NN NN O
DNA NN NN O
binding NN NN O
specificities NN NN O
, NN NN O
the NN NN O
reactivities NN NN O
toward NN NN O
Stat NN NN O
- NN NN O
specific NN NN O
antisera NN NN O
, NN NN O
and NN NN O
the NN NN O
mol NN NN O
wt NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
and NN NN O
PRL NN NN B-Protein
- NN NN O
induced NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
proteins NN NN O
in NN NN O
Nb2 NN NN O
and NN NN O
C196 NN NN O
T NN NN O
cell NN NN O
lines NN NN O
were NN NN O
investigated NN NN O
. NN NN O
   
A NN NN O
comparison NN NN O
with NN NN O
the NN NN O
Stat NN NN O
proteins NN NN O
induced NN NN O
by NN NN O
interferon NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
, NN NN O
PRL NN NN B-Protein
, NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
in NN NN O
T47D NN NN O
mammary NN NN O
tumor NN NN O
cells NN NN O
was NN NN O
made NN NN O
. NN NN O
   
We NN NN O
found NN NN O
that NN NN O
these NN NN O
parameters NN NN O
were NN NN O
indistinguishable NN NN O
for NN NN O
one NN NN O
of NN NN O
the NN NN O
PRL NN NN B-Protein
- NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
induced NN NN O
factors NN NN O
. NN NN O
   
A NN NN O
transcription NN NN O
factor NN NN O
closely NN NN O
related NN NN O
to NN NN O
mammary NN NN O
gland NN NN O
factor NN NN O
- NN NN O
Stat5 NN NN O
is NN NN O
rapidly NN NN O
activated NN NN O
upon NN NN O
interaction NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
PRL NN NN B-Protein
with NN NN O
their NN NN O
respective NN NN O
receptors NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
a NN NN O
second NN NN O
protein NN NN O
related NN NN O
to NN NN O
Stat1 NN NN O
was NN NN O
also NN NN O
observed NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
emphasize NN NN O
the NN NN O
role NN NN O
of NN NN O
PRL NN NN B-Protein
as NN NN O
a NN NN O
regulator NN NN O
of NN NN O
the NN NN O
immune NN NN O
response NN NN O
and NN NN O
indicate NN NN O
that NN NN O
the NN NN O
Stat NN NN O
factors NN NN O
mammary NN NN O
gland NN NN O
factor NN NN O
- NN NN O
Stat5 NN NN O
and NN NN O
Stat1 NN NN O
play NN NN O
a NN NN O
role NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
gene NN NN O
expression NN NN O
during NN NN O
T NN NN O
cell NN NN O
development NN NN O
. NN NN O
   
Attenuation NN NN O
of NN NN O
gamma NN NN B-Protein
interferon NN NN I-Protein
- NN NN O
induced NN NN O
tyrosine NN NN O
phosphorylation NN NN O
in NN NN O
mononuclear NN NN O
phagocytes NN NN O
infected NN NN O
with NN NN O
Leishmania NN NN O
donovani NN NN O
: NN NN O
selective NN NN O
inhibition NN NN O
of NN NN O
signaling NN NN O
through NN NN O
Janus NN NN O
kinases NN NN O
and NN NN O
Stat1 NN NN O
. NN NN O
   
The NN NN O
induction NN NN O
of NN NN O
gene NN NN O
transcription NN NN O
in NN NN O
response NN NN O
to NN NN O
gamma NN NN B-Protein
interferon NN NN I-Protein
is NN NN O
impaired NN NN O
in NN NN O
mononuclear NN NN O
phagocytes NN NN O
infected NN NN O
with NN NN O
Leishmania NN NN O
donovani NN NN O
, NN NN O
and NN NN O
the NN NN O
mechanisms NN NN O
involved NN NN O
are NN NN O
not NN NN O
fully NN NN O
understood NN NN O
. NN NN O
   
The NN NN O
changes NN NN O
in NN NN O
gene NN NN O
expression NN NN O
brought NN NN O
about NN NN O
by NN NN O
gamma NN NN B-Protein
interferon NN NN I-Protein
are NN NN O
thought NN NN O
to NN NN O
involve NN NN O
transient NN NN O
increases NN NN O
in NN NN O
the NN NN O
activities NN NN O
of NN NN O
cellular NN NN O
protein NN NN O
tyrosine NN NN O
kinases NN NN O
, NN NN O
including NN NN O
the NN NN O
Janus NN NN O
kinases NN NN O
Jak1 NN NN B-Protein
and NN NN O
Jak2 NN NN B-Protein
, NN NN O
leading NN NN O
to NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
Stat1 NN NN O
. NN NN O
   
To NN NN O
investigate NN NN O
the NN NN O
mechanisms NN NN O
accounting NN NN O
for NN NN O
the NN NN O
impaired NN NN O
responses NN NN O
to NN NN O
gamma NN NN B-Protein
interferon NN NN I-Protein
, NN NN O
a NN NN O
model NN NN O
system NN NN O
for NN NN O
examining NN NN O
overall NN NN O
changes NN NN O
in NN NN O
protein NN NN O
tyrosine NN NN O
phosphorylation NN NN O
, NN NN O
activation NN NN O
of NN NN O
Jak1 NN NN B-Protein
and NN NN O
Jak2 NN NN B-Protein
and NN NN O
phosphorylation NN NN O
of NN NN O
Stat1 NN NN O
was NN NN O
developed NN NN O
in NN NN O
phorbol NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
- NN NN O
differentiated NN NN O
U NN NN O
- NN NN O
937 NN NN O
cells NN NN O
. NN NN O
   
Analysis NN NN O
of NN NN O
whole NN NN O
- NN NN O
cell NN NN O
lysates NN NN O
by NN NN O
antiphosphotyrosine NN NN O
immunoblotting NN NN O
showed NN NN O
that NN NN O
incubation NN NN O
with NN NN O
gamma NN NN B-Protein
interferon NN NN I-Protein
brought NN NN O
about NN NN O
specific NN NN O
increases NN NN O
in NN NN O
phosphotyrosine NN NN O
labeling NN NN O
of NN NN O
several NN NN O
proteins NN NN O
. NN NN O
   
Increased NN NN O
labeling NN NN O
of NN NN O
these NN NN O
proteins NN NN O
occurred NN NN O
to NN NN O
similar NN NN O
extents NN NN O
in NN NN O
control NN NN O
cells NN NN O
and NN NN O
in NN NN O
cells NN NN O
that NN NN O
had NN NN O
been NN NN O
infected NN NN O
with NN NN O
L NN NN O
. NN NN O
donovani NN NN O
for NN NN O
16 NN NN O
h NN NN O
. NN NN O
   
Jak1 NN NN B-Protein
, NN NN O
Jak2 NN NN B-Protein
, NN NN O
and NN NN O
Stat1 NN NN O
were NN NN O
immunoprecipitated NN NN O
from NN NN O
control NN NN O
and NN NN O
interferon NN NN O
- NN NN O
treated NN NN O
cells NN NN O
, NN NN O
and NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
these NN NN O
proteins NN NN O
, NN NN O
detected NN NN O
by NN NN O
antiphosphotyrosine NN NN O
immunoblotting NN NN O
was NN NN O
used NN NN O
to NN NN O
measured NN NN O
their NN NN O
activation NN NN O
. NN NN O
   
Tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
Jak1 NN NN B-Protein
, NN NN O
Jak2 NN NN B-Protein
, NN NN O
and NN NN O
Stat1 NN NN O
increased NN NN O
markedly NN NN O
, NN NN O
in NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
, NN NN O
in NN NN O
U NN NN O
- NN NN O
937 NN NN O
cells NN NN O
incubated NN NN O
with NN NN O
gamma NN NN B-Protein
interferon NN NN I-Protein
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
in NN NN O
cells NN NN O
infected NN NN O
with NN NN O
L NN NN O
. NN NN O
donovani NN NN O
, NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
Jak1 NN NN B-Protein
, NN NN O
Jak2 NN NN B-Protein
, NN NN O
and NN NN O
Stat1 NN NN O
was NN NN O
markedly NN NN O
impaired NN NN O
. NN NN O
   
This NN NN O
effect NN NN O
was NN NN O
dependent NN NN O
upon NN NN O
the NN NN O
duration NN NN O
of NN NN O
exposure NN NN O
to NN NN O
L NN NN O
. NN NN O
donovani NN NN O
and NN NN O
was NN NN O
maximal NN NN O
and NN NN O
complete NN NN O
at NN NN O
16 NN NN O
h NN NN O
. NN NN O
   
Results NN NN O
similar NN NN O
to NN NN O
those NN NN O
observed NN NN O
with NN NN O
U NN NN O
- NN NN O
937 NN NN O
cells NN NN O
were NN NN O
also NN NN O
obtained NN NN O
with NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
monocytes NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
indicate NN NN O
that NN NN O
infection NN NN O
of NN NN O
human NN NN O
mononuclear NN NN O
phagocytes NN NN O
with NN NN O
L NN NN O
. NN NN O
donovani NN NN O
leads NN NN O
to NN NN O
impaired NN NN O
gamma NN NN B-Protein
interferon NN NN I-Protein
- NN NN O
mediated NN NN O
tyrosine NN NN O
phosphorylation NN NN O
and NN NN O
selective NN NN O
effects NN NN O
on NN NN O
the NN NN O
Jak NN NN O
- NN NN O
Stat1 NN NN O
pathway NN NN O
. NN NN O
   
Unresponsiveness NN NN O
to NN NN O
gamma NN NN B-Protein
interferon NN NN I-Protein
for NN NN O
activation NN NN O
of NN NN O
this NN NN O
pathway NN NN O
may NN NN O
explain NN NN O
impaired NN NN O
transcriptional NN NN O
responses NN NN O
in NN NN O
leishmania NN NN O
- NN NN O
infected NN NN O
cells NN NN O
. NN NN O
   
Nonopsonic NN NN O
phagocytosis NN NN O
of NN NN O
Pseudomonas NN NN O
aeruginosa NN NN O
by NN NN O
macrophages NN NN O
and NN NN O
polymorphonuclear NN NN O
leukocytes NN NN O
requires NN NN O
the NN NN O
presence NN NN O
of NN NN O
the NN NN O
bacterial NN NN O
flagellum NN NN O
. NN NN O
   
Whereas NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
nonopsonic NN NN O
phagocytosis NN NN O
of NN NN O
Pseudomonas NN NN O
aeruginosa NN NN O
has NN NN O
been NN NN O
described NN NN O
, NN NN O
the NN NN O
bacterial NN NN O
ligands NN NN O
required NN NN O
are NN NN O
poorly NN NN O
understood NN NN O
. NN NN O
   
To NN NN O
identify NN NN O
the NN NN O
requisite NN NN O
bacterial NN NN O
ligands NN NN O
, NN NN O
studies NN NN O
with NN NN O
isogenic NN NN O
mutants NN NN O
of NN NN O
P NN NN O
. NN NN O
aeruginosa NN NN O
PAK NN NN O
lacking NN NN O
pili NN NN O
, NN NN O
flagella NN NN O
, NN NN O
and NN NN O
the NN NN O
RpoN NN NN B-Protein
sigma NN NN I-Protein
factor NN NN I-Protein
were NN NN O
undertaken NN NN O
. NN NN O
   
The NN NN O
RpoN NN NN O
mutant NN NN O
, NN NN O
lacking NN NN O
pili NN NN O
, NN NN O
flagella NN NN O
, NN NN O
and NN NN O
nonpilus NN NN O
adhesins NN NN O
, NN NN O
bound NN NN O
poorly NN NN O
and NN NN O
was NN NN O
resistant NN NN O
to NN NN O
ingestion NN NN O
by NN NN O
both NN NN O
macrophages NN NN O
and NN NN O
neutrophils NN NN O
. NN NN O
   
Pili NN NN O
were NN NN O
not NN NN O
absolutely NN NN O
required NN NN O
for NN NN O
binding NN NN O
or NN NN O
phagocytosis NN NN O
of NN NN O
P NN NN O
. NN NN O
aeruginosa NN NN O
. NN NN O
   
The NN NN O
presence NN NN O
of NN NN O
a NN NN O
flagellum NN NN O
was NN NN O
not NN NN O
required NN NN O
for NN NN O
binding NN NN O
of NN NN O
P NN NN O
. NN NN O
aeruginosa NN NN O
to NN NN O
macrophages NN NN O
but NN NN O
was NN NN O
critical NN NN O
for NN NN O
the NN NN O
subsequent NN NN O
internalization NN NN O
of NN NN O
the NN NN O
bacterium NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
this NN NN O
factor NN NN O
or NN NN O
a NN NN O
surface NN NN O
ligand NN NN O
associated NN NN O
with NN NN O
its NN NN O
assembly NN NN O
was NN NN O
responsible NN NN O
for NN NN O
stimulation NN NN O
of NN NN O
nonopsonic NN NN O
phagocytosis NN NN O
. NN NN O
   
Identification NN NN O
of NN NN O
essential NN NN O
GATA NN NN O
and NN NN O
Ets NN NN O
binding NN NN O
motifs NN NN O
within NN NN O
the NN NN O
promoter NN NN O
of NN NN O
the NN NN O
platelet NN NN B-Protein
glycoprotein NN NN I-Protein
Ib NN NN I-Protein
alpha NN NN I-Protein
gene NN NN O
. NN NN O
   
Platelet NN NN O
glycoprotein NN NN O
( NN NN O
GP NN NN O
) NN NN O
Ib NN NN O
- NN NN O
IX NN NN O
- NN NN O
V NN NN O
is NN NN O
a NN NN O
multisubunit NN NN O
adhesion NN NN O
receptor NN NN O
that NN NN O
supports NN NN O
platelet NN NN O
attachment NN NN O
to NN NN O
thrombogenic NN NN O
surfaces NN NN O
at NN NN O
sites NN NN O
of NN NN O
vascular NN NN O
injury NN NN O
. NN NN O
   
The NN NN O
congenital NN NN O
absence NN NN O
of NN NN O
the NN NN O
receptor NN NN O
results NN NN O
in NN NN O
a NN NN O
bleeding NN NN O
disorder NN NN O
associated NN NN O
with NN NN O
"""""""" NN NN O
giant NN NN O
"""""""" NN NN O
platelets NN NN O
, NN NN O
a NN NN O
condition NN NN O
linking NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
complex NN NN O
to NN NN O
platelet NN NN O
morphogenesis NN NN O
. NN NN O
   
To NN NN O
understand NN NN O
better NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
GP NN NN O
Ib NN NN O
- NN NN O
IX NN NN O
- NN NN O
V NN NN O
complex NN NN O
, NN NN O
studies NN NN O
were NN NN O
undertaken NN NN O
to NN NN O
define NN NN O
the NN NN O
essential NN NN O
genetic NN NN O
elements NN NN O
supporting NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
alpha NN NN O
- NN NN O
subunit NN NN O
of NN NN O
the NN NN O
complex NN NN O
( NN NN O
GP NN NN B-Protein
Ib NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
. NN NN O
   
GP NN NN B-Protein
Ib NN NN I-Protein
alpha NN NN I-Protein
promoter NN NN O
activity NN NN O
was NN NN O
evaluated NN NN O
by NN NN O
transfection NN NN O
of NN NN O
human NN NN O
erythroleukemia NN NN O
cells NN NN O
with NN NN O
reporter NN NN O
plasmids NN NN O
coding NN NN O
for NN NN O
the NN NN O
enzyme NN NN O
, NN NN O
luciferase NN NN O
. NN NN O
   
Studies NN NN O
were NN NN O
initiated NN NN O
with NN NN O
a NN NN O
fragment NN NN O
extending NN NN O
2 NN NN O
, NN NN O
738 NN NN O
nucleotides NN NN O
5 NN NN O
' NN NN O
to NN NN O
the NN NN O
transcription NN NN O
start NN NN O
site NN NN O
and NN NN O
lead NN NN O
to NN NN O
the NN NN O
identification NN NN O
of NN NN O
253 NN NN O
nucleotides NN NN O
retaining NN NN O
full NN NN O
promoter NN NN O
activity NN NN O
in NN NN O
human NN NN O
erythroleukemia NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
cells NN NN O
of NN NN O
nonhematopoietic NN NN O
lineage NN NN O
, NN NN O
human NN NN O
endothelial NN NN O
and NN NN O
HeLa NN NN O
cells NN NN O
, NN NN O
the NN NN O
GP NN NN B-Protein
Ib NN NN I-Protein
alpha NN NN I-Protein
promoter NN NN O
activity NN NN O
was NN NN O
no NN NN O
greater NN NN O
than NN NN O
background NN NN O
levels NN NN O
obtained NN NN O
with NN NN O
promoterless NN NN O
constructs NN NN O
. NN NN O
   
Gel NN NN O
shift NN NN O
assays NN NN O
and NN NN O
site NN NN O
- NN NN O
directed NN NN O
mutagenesis NN NN O
studies NN NN O
defined NN NN O
essential NN NN O
GATA NN NN O
and NN NN O
Ets NN NN O
binding NN NN O
motifs NN NN O
93 NN NN O
and NN NN O
150 NN NN O
nucleotides NN NN O
upstream NN NN O
of NN NN O
the NN NN O
transcription NN NN O
start NN NN O
site NN NN O
, NN NN O
a NN NN O
finding NN NN O
which NN NN O
further NN NN O
substantiates NN NN O
these NN NN O
elements NN NN O
as NN NN O
important NN NN O
determinants NN NN O
of NN NN O
megakaryocytic NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
The NN NN O
results NN NN O
define NN NN O
essential NN NN O
cis NN NN O
- NN NN O
acting NN NN O
elements NN NN O
responsible NN NN O
for NN NN O
the NN NN O
expression NN NN O
of NN NN O
GP NN NN B-Protein
Ib NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
provide NN NN O
insights NN NN O
into NN NN O
molecular NN NN O
events NN NN O
coinciding NN NN O
with NN NN O
the NN NN O
release NN NN O
of NN NN O
normal NN NN O
platelets NN NN O
into NN NN O
the NN NN O
bloodstream NN NN O
. NN NN O
   
Multiple NN NN O
proteins NN NN O
interact NN NN O
with NN NN O
the NN NN O
nuclear NN NN O
inhibitory NN NN O
protein NN NN O
repressor NN NN O
element NN NN O
in NN NN O
the NN NN O
human NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
promoter NN NN O
. NN NN O
   
T NN NN O
cell NN NN O
expression NN NN O
of NN NN O
interleukin NN NN B-Protein
3 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
) NN NN O
is NN NN O
directed NN NN O
by NN NN O
positive NN NN O
and NN NN O
negative NN NN O
cis NN NN O
- NN NN O
acting NN NN O
DNA NN NN O
elements NN NN O
clustered NN NN O
within NN NN O
300 NN NN O
base NN NN O
pairs NN NN O
of NN NN O
the NN NN O
transcriptional NN NN O
start NN NN O
site NN NN O
. NN NN O
   
A NN NN O
strong NN NN O
repressor NN NN O
element NN NN O
, NN NN O
termed NN NN O
nuclear NN NN O
inhibitory NN NN O
protein NN NN O
( NN NN O
NIP NN NN O
) NN NN O
, NN NN O
was NN NN O
previously NN NN O
mapped NN NN O
to NN NN O
a NN NN O
segment NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
promoter NN NN O
between NN NN O
nucleotides NN NN O
- NN NN O
271 NN NN O
and NN NN O
- NN NN O
250 NN NN O
. NN NN O
   
Functional NN NN O
characterization NN NN O
of NN NN O
this NN NN O
element NN NN O
demonstrates NN NN O
that NN NN O
it NN NN O
can NN NN O
mediate NN NN O
repression NN NN O
when NN NN O
linked NN NN O
in NN NN O
cis NN NN O
to NN NN O
a NN NN O
heterologous NN NN O
promoter NN NN O
. NN NN O
   
DNA NN NN O
binding NN NN O
experiments NN NN O
were NN NN O
carried NN NN O
out NN NN O
to NN NN O
characterize NN NN O
the NN NN O
repressor NN NN O
activity NN NN O
. NN NN O
   
Using NN NN O
varying NN NN O
conditions NN NN O
, NN NN O
three NN NN O
distinct NN NN O
complexes NN NN O
were NN NN O
shown NN NN O
to NN NN O
interact NN NN O
specifically NN NN O
with NN NN O
the NN NN O
NIP NN NN O
region NN NN O
, NN NN O
although NN NN O
only NN NN O
one NN NN O
correlates NN NN O
with NN NN O
repressor NN NN O
activity NN NN O
. NN NN O
   
Complex NN NN O
1 NN NN O
results NN NN O
from NN NN O
binding NN NN O
of NN NN O
a NN NN O
ubiquitous NN NN O
polypeptide NN NN O
that NN NN O
recognizes NN NN O
the NN NN O
3 NN NN O
' NN NN O
portion NN NN O
of NN NN O
this NN NN O
sequence NN NN O
and NN NN O
is NN NN O
not NN NN O
required NN NN O
for NN NN O
repression NN NN O
. NN NN O
   
Complex NN NN O
2 NN NN O
corresponds NN NN O
to NN NN O
binding NN NN O
of NN NN O
transcription NN NN O
factor NN NN O
( NN NN O
upstream NN NN O
stimulatory NN NN O
factor NN NN O
) NN NN O
to NN NN O
an NN NN O
E NN NN O
- NN NN O
box NN NN O
motif NN NN O
in NN NN O
the NN NN O
5 NN NN O
' NN NN O
portion NN NN O
of NN NN O
the NN NN O
NIP NN NN O
region NN NN O
. NN NN O
   
DNA NN NN O
binding NN NN O
specificity NN NN O
of NN NN O
complex NN NN O
3 NN NN O
overlaps NN NN O
with NN NN O
that NN NN O
of NN NN O
upstream NN NN O
stimulatory NN NN O
factor NN NN O
but NN NN O
is NN NN O
clearly NN NN O
distinct NN NN O
. NN NN O
   
To NN NN O
determine NN NN O
which NN NN O
of NN NN O
the NN NN O
latter NN NN O
two NN NN O
complexes NN NN O
represents NN NN O
NIP NN NN O
activity NN NN O
, NN NN O
we NN NN O
incorporated NN NN O
small NN NN O
alterations NN NN O
into NN NN O
the NN NN O
NIP NN NN O
site NN NN O
of NN NN O
an NN NN O
IL NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
promoter NN NN O
- NN NN O
linked NN NN O
reporter NN NN O
construct NN NN O
and NN NN O
examined NN NN O
their NN NN O
effects NN NN O
on NN NN O
NIP NN NN O
- NN NN O
mediated NN NN O
repression NN NN O
. NN NN O
   
Functional NN NN O
specificity NN NN O
for NN NN O
repression NN NN O
matches NN NN O
the NN NN O
DNA NN NN O
binding NN NN O
specificity NN NN O
of NN NN O
complex NN NN O
3 NN NN O
; NN NN O
both NN NN O
repressor NN NN O
activity NN NN O
and NN NN O
complex NN NN O
3 NN NN O
binding NN NN O
require NN NN O
the NN NN O
consensus NN NN O
sequence NN NN O
CTCACNTNC NN NN O
. NN NN O
   
The NN NN O
activation NN NN O
of NN NN O
the NN NN O
Jak NN NN O
- NN NN O
STAT NN NN B-Protein
1 NN NN I-Protein
signaling NN NN O
pathway NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
in NN NN O
eosinophils NN NN O
. NN NN O
   
The NN NN O
intracellular NN NN O
signal NN NN O
transduction NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
in NN NN O
eosinophils NN NN O
is NN NN O
unknown NN NN O
. NN NN O
   
The NN NN O
objective NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
investigate NN NN O
the NN NN O
involvement NN NN O
of NN NN O
the NN NN O
newly NN NN O
discovered NN NN O
Jak NN NN O
- NN NN O
STAT NN NN O
pathway NN NN O
in NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
signal NN NN O
transduction NN NN O
mechanism NN NN O
. NN NN O
   
Eosinophils NN NN O
were NN NN O
purified NN NN O
from NN NN O
peripheral NN NN O
blood NN NN O
by NN NN O
discontinuous NN NN O
Percoll NN NN O
gradients NN NN O
and NN NN O
stimulated NN NN O
with NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
. NN NN O
   
The NN NN O
involvement NN NN O
of NN NN O
Jak NN NN B-Protein
2 NN NN I-Protein
was NN NN O
investigated NN NN O
by NN NN O
immunoprecipitation NN NN O
followed NN NN O
by NN NN O
immunoblotting NN NN O
for NN NN O
tyrosine NN NN O
phosphorylation NN NN O
. NN NN O
   
The NN NN O
activation NN NN O
of NN NN O
Jak NN NN B-Protein
2 NN NN I-Protein
was NN NN O
studied NN NN O
by NN NN O
autophosphorylation NN NN O
of NN NN O
the NN NN O
immunoprecipitated NN NN O
kinase NN NN O
. NN NN O
   
Jak NN NN B-Protein
2 NN NN I-Protein
was NN NN O
tyrosine NN NN O
phosphorylated NN NN O
within NN NN O
1 NN NN O
to NN NN O
3 NN NN O
min NN NN O
after NN NN O
stimulation NN NN O
of NN NN O
eosinophils NN NN O
with NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
. NN NN O
   
Further NN NN O
, NN NN O
the NN NN O
immunoprecipitated NN NN O
Jak NN NN B-Protein
2 NN NN I-Protein
obtained NN NN O
from NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
- NN NN O
stimulated NN NN O
cells NN NN O
underwent NN NN O
autophosphorylation NN NN O
. NN NN O
   
Jak NN NN B-Protein
2 NN NN I-Protein
coprecipitated NN NN O
with NN NN O
the NN NN O
beta NN NN O
- NN NN O
subunit NN NN O
of NN NN O
the NN NN O
IL NN NN O
- NN NN O
5 NN NN O
receptor NN NN O
, NN NN O
suggesting NN NN O
a NN NN O
physical NN NN O
association NN NN O
of NN NN O
the NN NN O
kinase NN NN O
with NN NN O
the NN NN O
receptor NN NN O
. NN NN O
   
The NN NN O
nuclear NN NN O
factor NN NN O
STAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
p91 NN NN B-Protein
) NN NN O
was NN NN O
investigated NN NN O
by NN NN O
immunoprecipitation NN NN O
followed NN NN O
by NN NN O
immunoblotting NN NN O
for NN NN O
tyrosine NN NN O
phosphorylation NN NN O
. NN NN O
   
STAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
was NN NN O
tyrosine NN NN O
phosphorylated NN NN O
within NN NN O
15 NN NN O
min NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
stimulation NN NN O
. NN NN O
   
The NN NN O
presence NN NN O
of NN NN O
STAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
in NN NN O
the NN NN O
nuclear NN NN O
extract NN NN O
was NN NN O
studied NN NN O
by NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assay NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
induced NN NN O
two NN NN O
proteins NN NN O
that NN NN O
bound NN NN O
to NN NN O
the NN NN O
gamma NN NN O
- NN NN O
activating NN NN O
sequence NN NN O
. NN NN O
   
In NN NN O
the NN NN O
presence NN NN O
of NN NN O
an NN NN O
anti NN NN O
- NN NN O
STAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
Ab NN NN O
, NN NN O
the NN NN O
band NN NN O
was NN NN O
supershifted NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
we NN NN O
demonstrated NN NN O
that NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
activated NN NN O
the NN NN O
Jak NN NN B-Protein
2 NN NN I-Protein
- NN NN O
STAT NN NN B-Protein
1 NN NN I-Protein
signaling NN NN O
pathway NN NN O
in NN NN O
eosinophils NN NN O
. NN NN O
   
We NN NN O
speculate NN NN O
that NN NN O
the NN NN O
Jak NN NN B-Protein
2 NN NN I-Protein
- NN NN O
STAT NN NN B-Protein
1 NN NN I-Protein
pathway NN NN O
may NN NN O
be NN NN O
involved NN NN O
in NN NN O
the NN NN O
activation NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
- NN NN O
inducible NN NN O
genes NN NN O
in NN NN O
eosinophils NN NN O
. NN NN O
   
Constitutively NN NN O
activated NN NN O
Jak NN NN O
- NN NN O
STAT NN NN O
pathway NN NN O
in NN NN O
T NN NN O
cells NN NN O
transformed NN NN O
with NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
. NN NN O
   
Human NN NN O
T NN NN O
cell NN NN O
lymphotropic NN NN O
virus NN NN O
I NN NN O
( NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
) NN NN O
is NN NN O
the NN NN O
etiological NN NN O
agent NN NN O
for NN NN O
adult NN NN O
T NN NN O
cell NN NN O
leukemia NN NN O
and NN NN O
tropical NN NN O
spastic NN NN O
paraparesis NN NN O
( NN NN O
also NN NN O
termed NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
- NN NN O
associated NN NN O
myelopathy NN NN O
) NN NN O
. NN NN O
   
HTLV NN NN O
- NN NN O
I NN NN O
- NN NN O
infected NN NN O
peripheral NN NN O
blood NN NN O
T NN NN O
cells NN NN O
exhibit NN NN O
an NN NN O
initial NN NN O
phase NN NN O
of NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
- NN NN O
dependent NN NN O
growth NN NN O
; NN NN O
over NN NN O
time NN NN O
, NN NN O
by NN NN O
an NN NN O
unknown NN NN O
mechanism NN NN O
, NN NN O
the NN NN O
cells NN NN O
become NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
independent NN NN O
. NN NN O
   
Whereas NN NN O
the NN NN O
Jak NN NN O
kinases NN NN O
Jak1 NN NN B-Protein
and NN NN O
Jak3 NN NN B-Protein
and NN NN O
the NN NN O
signal NN NN O
transducer NN NN O
and NN NN O
activator NN NN O
of NN NN O
transcription NN NN O
proteins NN NN O
Stat3 NN NN B-Protein
and NN NN O
Stat5 NN NN B-Protein
are NN NN O
activated NN NN O
in NN NN O
normal NN NN O
T NN NN O
cells NN NN O
in NN NN O
response NN NN O
to NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
this NN NN O
signaling NN NN O
pathway NN NN O
was NN NN O
constitutively NN NN O
activated NN NN O
in NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
- NN NN O
transformed NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
- NN NN O
infected NN NN O
cord NN NN O
blood NN NN O
lymphocytes NN NN O
, NN NN O
the NN NN O
transition NN NN O
from NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
dependent NN NN O
to NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
independent NN NN O
growth NN NN O
correlated NN NN O
with NN NN O
the NN NN O
acquisition NN NN O
of NN NN O
a NN NN O
constitutively NN NN O
activated NN NN O
Jak NN NN O
- NN NN O
STAT NN NN O
pathway NN NN O
, NN NN O
which NN NN O
suggests NN NN O
that NN NN O
this NN NN O
pathway NN NN O
participates NN NN O
in NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
- NN NN O
mediated NN NN O
T NN NN O
cell NN NN O
transformation NN NN O
. NN NN O
   
Heterogeneous NN NN O
expression NN NN O
of NN NN O
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
latent NN NN O
proteins NN NN O
in NN NN O
endemic NN NN O
Burkitt NN NN O
' NN NN O
s NN NN O
lymphoma NN NN O
. NN NN O
   
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
( NN NN O
EBV NN NN O
) NN NN O
- NN NN O
infected NN NN O
cells NN NN O
may NN NN O
sustain NN NN O
three NN NN O
distinct NN NN O
forms NN NN O
of NN NN O
virus NN NN O
latency NN NN O
. NN NN O
   
In NN NN O
lymphoblastoid NN NN O
cell NN NN O
lines NN NN O
, NN NN O
six NN NN O
EBV NN NN O
- NN NN O
encoded NN NN O
nuclear NN NN O
antigens NN NN O
( NN NN O
EBNA1 NN NN B-Protein
, NN NN O
2 NN NN B-Protein
, NN NN O
3A NN NN B-Protein
, NN NN O
3B NN NN B-Protein
, NN NN O
3C NN NN B-Protein
, NN NN O
- NN NN B-Protein
LP NN NN I-Protein
) NN NN O
, NN NN O
three NN NN O
latent NN NN O
membrane NN NN O
proteins NN NN O
( NN NN O
LMP1 NN NN B-Protein
, NN NN O
2A NN NN B-Protein
, NN NN O
2B NN NN B-Protein
) NN NN O
, NN NN O
and NN NN O
two NN NN O
nuclear NN NN O
RNAs NN NN O
( NN NN O
EBERs NN NN O
) NN NN O
are NN NN O
expressed NN NN O
. NN NN O
   
This NN NN O
form NN NN O
of NN NN O
latency NN NN O
, NN NN O
termed NN NN O
latency NN NN O
III NN NN O
, NN NN O
is NN NN O
also NN NN O
encountered NN NN O
in NN NN O
some NN NN O
posttransplant NN NN O
lymphoproliferative NN NN O
disorders NN NN O
. NN NN O
   
In NN NN O
EBV NN NN O
- NN NN O
positive NN NN O
cases NN NN O
of NN NN O
Hodgkin NN NN O
' NN NN O
s NN NN O
disease NN NN O
, NN NN O
the NN NN O
EBERs NN NN O
, NN NN O
EBNA1 NN NN B-Protein
, NN NN O
and NN NN O
the NN NN O
LMPs NN NN O
are NN NN O
expressed NN NN O
( NN NN O
latency NN NN O
II NN NN O
) NN NN O
, NN NN O
whereas NN NN O
in NN NN O
Burkitt NN NN O
' NN NN O
s NN NN O
lymphoma NN NN O
( NN NN O
BL NN NN O
) NN NN O
only NN NN O
the NN NN O
EBERs NN NN O
and NN NN O
EBNA1 NN NN B-Protein
have NN NN O
been NN NN O
detected NN NN O
( NN NN O
latency NN NN O
I NN NN O
) NN NN O
. NN NN O
   
We NN NN O
have NN NN O
studied NN NN O
the NN NN O
expression NN NN O
of NN NN O
EBV NN NN O
proteins NN NN O
in NN NN O
17 NN NN O
cases NN NN O
of NN NN O
EBV NN NN O
- NN NN O
positive NN NN O
endemic NN NN O
BL NN NN O
by NN NN O
immunohistology NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
LMP1 NN NN B-Protein
was NN NN O
seen NN NN O
in NN NN O
variable NN NN O
proportions NN NN O
of NN NN O
tumor NN NN O
cells NN NN O
in NN NN O
two NN NN O
cases NN NN O
and NN NN O
EBNA2 NN NN B-Protein
was NN NN O
detected NN NN O
in NN NN O
some NN NN O
tumor NN NN O
cells NN NN O
in NN NN O
three NN NN O
other NN NN O
cases NN NN O
. NN NN O
   
Also NN NN O
, NN NN O
the NN NN O
BZLF1 NN NN B-Protein
trans NN NN I-Protein
- NN NN I-Protein
activator NN NN I-Protein
protein NN NN I-Protein
was NN NN O
expressed NN NN O
in NN NN O
a NN NN O
few NN NN O
tumor NN NN O
cells NN NN O
in NN NN O
6 NN NN O
cases NN NN O
, NN NN O
indicating NN NN O
entry NN NN O
into NN NN O
the NN NN O
lytic NN NN O
cycle NN NN O
. NN NN O
   
A NN NN O
phenotypic NN NN O
drift NN NN O
from NN NN O
latency NN NN O
I NN NN O
to NN NN O
latency NN NN O
III NN NN O
has NN NN O
been NN NN O
observed NN NN O
previously NN NN O
in NN NN O
some NN NN O
BL NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
suggest NN NN O
that NN NN O
a NN NN O
similar NN NN O
phenomenon NN NN O
may NN NN O
occur NN NN O
in NN NN O
BL NN NN O
in NN NN O
vivo NN NN O
and NN NN O
indicate NN NN O
that NN NN O
the NN NN O
operational NN NN O
definition NN NN O
of NN NN O
EBV NN NN O
latencies NN NN O
is NN NN O
not NN NN O
easily NN NN O
applied NN NN O
to NN NN O
human NN NN O
tumors NN NN O
. NN NN O
   
Does NN NN O
activation NN NN O
of NN NN O
the NN NN O
TAL1 NN NN B-Protein
gene NN NN O
occur NN NN O
in NN NN O
a NN NN O
majority NN NN O
of NN NN O
patients NN NN O
with NN NN O
T NN NN O
- NN NN O
cell NN NN O
acute NN NN O
lymphoblastic NN NN O
leukemia NN NN O
? NN NN O
   
A NN NN O
pediatric NN NN O
oncology NN NN O
group NN NN O
study NN NN O
. NN NN O
   
Almost NN NN O
25 NN NN O
% NN NN O
of NN NN O
patients NN NN O
with NN NN O
T NN NN O
- NN NN O
cell NN NN O
acute NN NN O
lymphoblastic NN NN O
leukemia NN NN O
( NN NN O
T NN NN O
- NN NN O
ALL NN NN O
) NN NN O
have NN NN O
tumor NN NN O
- NN NN O
specific NN NN O
rearrangements NN NN O
of NN NN O
the NN NN O
TAL1 NN NN B-Protein
gene NN NN O
. NN NN O
   
Although NN NN O
TAL1 NN NN B-Protein
expression NN NN O
has NN NN O
not NN NN O
been NN NN O
observed NN NN O
in NN NN O
normal NN NN O
lymphocytes NN NN O
, NN NN O
TAL1 NN NN B-Protein
gene NN NN O
products NN NN O
are NN NN O
readily NN NN O
detected NN NN O
in NN NN O
leukemic NN NN O
cells NN NN O
that NN NN O
harbor NN NN O
a NN NN O
rearranged NN NN O
TAL1 NN NN B-Protein
allele NN NN O
. NN NN O
   
Hence NN NN O
, NN NN O
it NN NN O
has NN NN O
been NN NN O
proposed NN NN O
that NN NN O
ectopic NN NN O
expression NN NN O
of NN NN O
TAL1 NN NN B-Protein
promotes NN NN O
the NN NN O
development NN NN O
of NN NN O
T NN NN O
- NN NN O
ALL NN NN O
. NN NN O
   
In NN NN O
this NN NN O
report NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
TAL1 NN NN B-Protein
is NN NN O
expressed NN NN O
in NN NN O
the NN NN O
leukemic NN NN O
cells NN NN O
of NN NN O
most NN NN O
patients NN NN O
with NN NN O
T NN NN O
- NN NN O
ALL NN NN O
, NN NN O
including NN NN O
many NN NN O
that NN NN O
do NN NN O
not NN NN O
display NN NN O
an NN NN O
apparent NN NN O
TAL1 NN NN B-Protein
gene NN NN O
alteration NN NN O
. NN NN O
   
A NN NN O
polymorphic NN NN O
dinucleotide NN NN O
repeat NN NN O
in NN NN O
the NN NN O
transcribed NN NN O
sequences NN NN O
of NN NN O
TAL1 NN NN B-Protein
was NN NN O
used NN NN O
to NN NN O
determine NN NN O
the NN NN O
allele NN NN O
specificity NN NN O
of NN NN O
TAL1 NN NN B-Protein
transcription NN NN O
in NN NN O
primary NN NN O
T NN NN O
- NN NN O
ALL NN NN O
cells NN NN O
. NN NN O
   
Monoallelic NN NN O
expression NN NN O
of NN NN O
TAL1 NN NN B-Protein
was NN NN O
observed NN NN O
in NN NN O
the NN NN O
leukemic NN NN O
cells NN NN O
of NN NN O
all NN NN O
patients NN NN O
( NN NN O
8 NN NN O
of NN NN O
8 NN NN O
) NN NN O
bearing NN NN O
a NN NN O
TAL1 NN NN B-Protein
gene NN NN O
rearrangement NN NN O
. NN NN O
   
In NN NN O
the NN NN O
leukemic NN NN O
cells NN NN O
of NN NN O
patients NN NN O
without NN NN O
detectable NN NN O
TAL1 NN NN B-Protein
rearrangements NN NN O
, NN NN O
TAL1 NN NN B-Protein
transcription NN NN O
occurred NN NN O
in NN NN O
either NN NN O
a NN NN O
monoallelic NN NN O
( NN NN O
3 NN NN O
of NN NN O
7 NN NN O
patients NN NN O
) NN NN O
or NN NN O
a NN NN O
biallelic NN NN O
( NN NN O
4 NN NN O
of NN NN O
7 NN NN O
patients NN NN O
) NN NN O
fashion NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
TAL1 NN NN B-Protein
activation NN NN O
in NN NN O
these NN NN O
patients NN NN O
may NN NN O
result NN NN O
from NN NN O
subtle NN NN O
alterations NN NN O
in NN NN O
cis NN NN O
- NN NN O
acting NN NN O
regulatory NN NN O
sequences NN NN O
( NN NN O
affecting NN NN O
expression NN NN O
of NN NN O
a NN NN O
single NN NN O
TAL1 NN NN B-Protein
allele NN NN O
) NN NN O
or NN NN O
changes NN NN O
in NN NN O
trans NN NN O
- NN NN O
acting NN NN O
factors NN NN O
that NN NN O
control NN NN O
TAL1 NN NN B-Protein
transcription NN NN O
( NN NN O
affecting NN NN O
expression NN NN O
of NN NN O
both NN NN O
TAL1 NN NN B-Protein
alleles NN NN O
) NN NN O
. NN NN O
   
A NN NN O
conserved NN NN O
motif NN NN O
in NN NN O
the NN NN O
promoters NN NN O
of NN NN O
several NN NN O
cytokines NN NN O
expressed NN NN O
by NN NN O
human NN NN O
Th2 NN NN O
- NN NN O
type NN NN O
lymphocytes NN NN O
. NN NN O
   
We NN NN O
have NN NN O
recently NN NN O
found NN NN O
a NN NN O
novel NN NN O
conserved NN NN O
motif NN NN O
in NN NN O
the NN NN O
promoters NN NN O
of NN NN O
several NN NN O
T NN NN O
- NN NN O
cell NN NN O
- NN NN O
expressed NN NN O
cytokines NN NN O
[ NN NN O
human NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
- NN NN B-Protein
4 NN NN I-Protein
, NN NN O
- NN NN B-Protein
5 NN NN I-Protein
and NN NN O
- NN NN B-Protein
13 NN NN I-Protein
and NN NN O
human NN NN O
and NN NN O
mouse NN NN O
granulocyte NN NN B-Protein
/ NN NN I-Protein
macrophage NN NN I-Protein
- NN NN I-Protein
colony NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
( NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
) NN NN O
] NN NN O
. NN NN O
   
It NN NN O
contains NN NN O
a NN NN O
core NN NN O
sequence NN NN O
CTTGG NN NN O
. NN NN O
. NN NN O
. NN NN O
   
CCAAG NN NN O
which NN NN O
is NN NN O
present NN NN O
as NN NN O
part NN NN O
of NN NN O
larger NN NN O
palindromic NN NN O
sequences NN NN O
in NN NN O
each NN NN O
gene NN NN O
. NN NN O
   
This NN NN O
suggest NN NN O
that NN NN O
they NN NN O
may NN NN O
interact NN NN O
with NN NN O
a NN NN O
new NN NN O
family NN NN O
of NN NN O
trans NN NN O
- NN NN O
acting NN NN O
factors NN NN O
. NN NN O
   
In NN NN O
transfection NN NN O
assays NN NN O
, NN NN O
the NN NN O
human NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
element NN NN O
has NN NN O
a NN NN O
strong NN NN O
positive NN NN O
effect NN NN O
on NN NN O
the NN NN O
expression NN NN O
of NN NN O
a NN NN O
reporter NN NN O
gene NN NN O
by NN NN O
the NN NN O
human NN NN O
T NN NN O
cell NN NN O
line NN NN O
Jurkat NN NN O
J6 NN NN O
upon NN NN O
stimulation NN NN O
. NN NN O
   
In NN NN O
DNA NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
, NN NN O
this NN NN O
sequence NN NN O
can NN NN O
give NN NN O
either NN NN O
six NN NN O
different NN NN O
specific NN NN O
bands NN NN O
which NN NN O
are NN NN O
competed NN NN O
out NN NN O
by NN NN O
different NN NN O
parts NN NN O
of NN NN O
the NN NN O
sequence NN NN O
or NN NN O
one NN NN O
specific NN NN O
band NN NN O
which NN NN O
is NN NN O
competed NN NN O
out NN NN O
by NN NN O
each NN NN O
of NN NN O
the NN NN O
inverted NN NN O
repeats NN NN O
, NN NN O
depending NN NN O
on NN NN O
the NN NN O
reconstitution NN NN O
conditions NN NN O
. NN NN O
   
In NN NN O
different NN NN O
genes NN NN O
, NN NN O
the NN NN O
core NN NN O
sequences NN NN O
are NN NN O
separated NN NN O
by NN NN O
integer NN NN O
numbers NN NN O
of NN NN O
helical NN NN O
turns NN NN O
. NN NN O
   
Considering NN NN O
the NN NN O
strong NN NN O
positive NN NN O
regulatory NN NN O
effect NN NN O
of NN NN O
this NN NN O
element NN NN O
and NN NN O
its NN NN O
presence NN NN O
in NN NN O
several NN NN O
T NN NN O
- NN NN O
cell NN NN O
- NN NN O
expressed NN NN O
cytokine NN NN O
genes NN NN O
, NN NN O
it NN NN O
may NN NN O
be NN NN O
crucial NN NN O
to NN NN O
the NN NN O
coordinated NN NN O
expression NN NN O
of NN NN O
these NN NN O
cytokines NN NN O
in NN NN O
T NN NN O
helper NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
/ NN NN O
receptor NN NN O
interaction NN NN O
activates NN NN O
Lyn NN NN B-Protein
and NN NN O
Jak2 NN NN B-Protein
tyrosine NN NN I-Protein
kinases NN NN I-Protein
and NN NN O
propagates NN NN O
signals NN NN O
via NN NN O
the NN NN O
Ras NN NN O
- NN NN O
Raf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
- NN NN O
MAP NN NN O
kinase NN NN O
and NN NN O
the NN NN O
Jak NN NN O
- NN NN O
STAT NN NN O
pathways NN NN O
in NN NN O
eosinophils NN NN O
. NN NN O
   
We NN NN O
have NN NN O
shown NN NN O
that NN NN O
the NN NN O
interaction NN NN O
of NN NN O
interleukin NN NN B-Protein
( NN NN I-Protein
IL NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
5 NN NN I-Protein
with NN NN O
the NN NN O
receptor NN NN O
activates NN NN O
Lyn NN NN B-Protein
tyrosine NN NN I-Protein
kinase NN NN I-Protein
within NN NN O
1 NN NN O
min NN NN O
and NN NN O
Jak2 NN NN B-Protein
tyrosine NN NN I-Protein
kinase NN NN I-Protein
within NN NN O
1 NN NN O
- NN NN O
3 NN NN O
min NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
also NN NN O
stimulates NN NN O
GTP NN NN O
binding NN NN O
to NN NN O
p21ras NN NN B-Protein
. NN NN O
   
The NN NN O
signal NN NN O
is NN NN O
subsequently NN NN O
propagated NN NN O
through NN NN O
the NN NN O
activation NN NN O
of NN NN O
Raf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
MEK NN NN O
, NN NN O
and NN NN O
MAP NN NN O
kinases NN NN O
as NN NN O
shown NN NN O
by NN NN O
their NN NN O
increased NN NN O
autophosphorylation NN NN O
in NN NN O
vitro NN NN O
and NN NN O
phosphorylation NN NN O
in NN NN O
situ NN NN O
. NN NN O
   
Jak2 NN NN B-Protein
kinase NN NN I-Protein
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
phosphorylate NN NN O
STAT NN NN O
nuclear NN NN O
proteins NN NN O
. NN NN O
   
The NN NN O
activation NN NN O
of NN NN O
STAT NN NN O
nuclear NN NN O
factors NN NN O
was NN NN O
studied NN NN O
by NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assay NN NN O
using NN NN O
a NN NN O
gamma NN NN O
activation NN NN O
site NN NN O
( NN NN O
GAS NN NN O
) NN NN O
probe NN NN O
. NN NN O
   
We NN NN O
found NN NN O
that NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
induces NN NN O
two NN NN O
GAS NN NN O
- NN NN O
binding NN NN O
proteins NN NN O
in NN NN O
eosinophils NN NN O
, NN NN O
one NN NN O
of NN NN O
which NN NN O
is NN NN O
STAT1 NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
induced NN NN O
signals NN NN O
are NN NN O
propagated NN NN O
through NN NN O
two NN NN O
distinct NN NN O
pathways NN NN O
: NN NN O
( NN NN O
1 NN NN O
) NN NN O
Lyn NN NN B-Protein
- NN NN O
- NN NN O
> NN NN O
Ras NN NN O
- NN NN O
- NN NN O
> NN NN O
Raf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
- NN NN O
- NN NN O
> NN NN O
MEK NN NN O
- NN NN O
- NN NN O
> NN NN O
MAP NN NN O
kinase NN NN O
and NN NN O
( NN NN O
2 NN NN O
) NN NN O
Jak2 NN NN B-Protein
- NN NN O
- NN NN O
> NN NN O
STAT1 NN NN O
. NN NN O
   
E1A NN NN B-Protein
gene NN NN O
expression NN NN O
induces NN NN O
susceptibility NN NN O
to NN NN O
killing NN NN O
by NN NN O
NK NN NN O
cells NN NN O
following NN NN O
immortalization NN NN O
but NN NN O
not NN NN O
adenovirus NN NN O
infection NN NN O
of NN NN O
human NN NN O
cells NN NN O
. NN NN O
   
Adenovirus NN NN O
( NN NN O
Ad NN NN O
) NN NN O
infection NN NN O
and NN NN O
E1A NN NN B-Protein
transfection NN NN O
were NN NN O
used NN NN O
to NN NN O
model NN NN O
changes NN NN O
in NN NN O
susceptibility NN NN O
to NN NN O
NK NN NN O
cell NN NN O
killing NN NN O
caused NN NN O
by NN NN O
transient NN NN O
vs NN NN O
stable NN NN O
E1A NN NN B-Protein
expression NN NN O
in NN NN O
human NN NN O
cells NN NN O
. NN NN O
   
Only NN NN O
stably NN NN O
transfected NN NN O
target NN NN O
cells NN NN O
exhibited NN NN O
cytolytic NN NN O
susceptibility NN NN O
, NN NN O
despite NN NN O
expression NN NN O
of NN NN O
equivalent NN NN O
levels NN NN O
of NN NN O
E1A NN NN B-Protein
proteins NN NN O
in NN NN O
Ad NN NN O
- NN NN O
infected NN NN O
targets NN NN O
. NN NN O
   
The NN NN O
inability NN NN O
of NN NN O
E1A NN NN B-Protein
gene NN NN O
products NN NN O
to NN NN O
induce NN NN O
cytolytic NN NN O
susceptibility NN NN O
during NN NN O
infection NN NN O
was NN NN O
not NN NN O
explained NN NN O
by NN NN O
an NN NN O
inhibitory NN NN O
effect NN NN O
of NN NN O
viral NN NN O
infection NN NN O
on NN NN O
otherwise NN NN O
susceptible NN NN O
target NN NN O
cells NN NN O
or NN NN O
by NN NN O
viral NN NN O
gene NN NN O
effects NN NN O
on NN NN O
class NN NN O
I NN NN O
MHC NN NN O
antigen NN NN O
expression NN NN O
on NN NN O
target NN NN O
cells NN NN O
. NN NN O
   
This NN NN O
differential NN NN O
effect NN NN O
of NN NN O
E1A NN NN B-Protein
expression NN NN O
on NN NN O
the NN NN O
cytolytic NN NN O
phenotypes NN NN O
of NN NN O
infected NN NN O
and NN NN O
stably NN NN O
transfected NN NN O
human NN NN O
cells NN NN O
suggests NN NN O
that NN NN O
human NN NN O
NK NN NN O
cells NN NN O
provide NN NN O
an NN NN O
effective NN NN O
immunologic NN NN O
barrier NN NN O
against NN NN O
the NN NN O
in NN NN O
vivo NN NN O
survival NN NN O
and NN NN O
neoplastic NN NN O
progression NN NN O
of NN NN O
E1A NN NN B-Protein
- NN NN O
immortalized NN NN O
cells NN NN O
that NN NN O
may NN NN O
emerge NN NN O
from NN NN O
the NN NN O
reservoir NN NN O
of NN NN O
persistently NN NN O
infected NN NN O
cells NN NN O
in NN NN O
the NN NN O
human NN NN O
host NN NN O
. NN NN O
   
RB NN NN B-Protein
and NN NN O
a NN NN O
novel NN NN O
E2F NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
binding NN NN O
protein NN NN O
in NN NN O
MHC NN NN O
class NN NN O
II NN NN O
deficient NN NN O
B NN NN O
- NN NN O
cell NN NN O
lines NN NN O
and NN NN O
normal NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
induction NN NN O
of NN NN O
the NN NN O
class NN NN O
IL NN NN O
transactivator NN NN O
CIITA NN NN B-Protein
in NN NN O
class NN NN O
II NN NN O
non NN NN O
- NN NN O
inducible NN NN O
RB NN NN B-Protein
- NN NN O
defective NN NN O
tumor NN NN O
lines NN NN O
. NN NN O
   
The NN NN O
major NN NN O
histocompatibility NN NN O
( NN NN O
MHC NN NN O
) NN NN O
class NN NN O
II NN NN O
genes NN NN O
encode NN NN O
cell NN NN O
surface NN NN O
proteins NN NN O
that NN NN O
bind NN NN O
antigenic NN NN O
peptide NN NN O
for NN NN O
presentation NN NN O
to NN NN O
T NN NN O
- NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
class NN NN O
II NN NN O
proteins NN NN O
are NN NN O
expressed NN NN O
constitutively NN NN O
on NN NN O
B NN NN O
- NN NN O
cells NN NN O
and NN NN O
EBV NN NN O
- NN NN O
transformed NN NN O
B NN NN O
- NN NN O
cells NN NN O
, NN NN O
and NN NN O
are NN NN O
inducible NN NN O
by NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
on NN NN O
a NN NN O
wide NN NN O
variety NN NN O
of NN NN O
cell NN NN O
types NN NN O
. NN NN O
   
Retinoblastoma NN NN B-Protein
protein NN NN I-Protein
( NN NN O
RB NN NN B-Protein
) NN NN O
is NN NN O
a NN NN O
tumor NN NN O
suppressor NN NN O
and NN NN O
functions NN NN O
as NN NN O
a NN NN O
transcriptional NN NN O
repressor NN NN O
by NN NN O
binding NN NN O
and NN NN O
inactivating NN NN O
the NN NN O
transactivator NN NN O
E2F NN NN B-Protein
- NN NN I-Protein
I NN NN I-Protein
. NN NN O
   
RB NN NN B-Protein
- NN NN O
defective NN NN O
tumor NN NN O
lines NN NN O
are NN NN O
non NN NN O
- NN NN O
inducible NN NN O
for NN NN O
MHC NN NN O
class NN NN O
II NN NN O
by NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
, NN NN O
or NN NN O
very NN NN O
weakly NN NN O
inducible NN NN O
, NN NN O
but NN NN O
transfection NN NN O
of NN NN O
2 NN NN O
different NN NN O
lines NN NN O
with NN NN O
RB NN NN B-Protein
expression NN NN O
vectors NN NN O
re NN NN O
- NN NN O
establishes NN NN O
or NN NN O
substantially NN NN O
enhances NN NN O
class NN NN O
II NN NN O
inducibility NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
we NN NN O
examined NN NN O
the NN NN O
RB NN NN B-Protein
status NN NN O
of NN NN O
a NN NN O
series NN NN O
of NN NN O
B NN NN O
- NN NN O
cell NN NN O
mutants NN NN O
that NN NN O
are NN NN O
defective NN NN O
in NN NN O
class NN NN O
II NN NN O
expression NN NN O
, NN NN O
generated NN NN O
either NN NN O
in NN NN O
vitro NN NN O
or NN NN O
derived NN NN O
from NN NN O
Bare NN NN O
Lymphocyte NN NN O
Syndrome NN NN O
( NN NN O
BLS NN NN O
) NN NN O
patients NN NN O
. NN NN O
   
Nuclear NN NN O
matrix NN NN O
- NN NN O
bound NN NN O
RB NN NN B-Protein
was NN NN O
detectable NN NN O
in NN NN O
all NN NN O
cases NN NN O
, NN NN O
indicating NN NN O
that NN NN O
loss NN NN O
of NN NN O
RB NN NN B-Protein
is NN NN O
not NN NN O
responsible NN NN O
for NN NN O
decreased NN NN O
class NN NN O
II NN NN O
expression NN NN O
in NN NN O
these NN NN O
lines NN NN O
. NN NN O
   
A NN NN O
second NN NN O
E2F NN NN B-Protein
- NN NN I-Protein
I NN NN I-Protein
binding NN NN O
protein NN NN O
, NN NN O
most NN NN O
likely NN NN O
DP NN NN B-Protein
- NN NN I-Protein
I NN NN I-Protein
, NN NN O
was NN NN O
also NN NN O
apparently NN NN O
normal NN NN O
in NN NN O
both NN NN O
class NN NN O
II NN NN O
- NN NN O
positive NN NN O
and NN NN O
- NN NN O
negative NN NN O
B NN NN O
- NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
We NN NN O
also NN NN O
examined NN NN O
the NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
induction NN NN O
of NN NN O
CIITA NN NN B-Protein
in NN NN O
RB NN NN B-Protein
- NN NN O
defective NN NN O
lines NN NN O
. NN NN O
   
CIITA NN NN B-Protein
is NN NN O
a NN NN O
class NN NN O
II NN NN O
gene NN NN O
transactivator NN NN O
known NN NN O
to NN NN O
be NN NN O
defective NN NN O
in NN NN O
one NN NN O
form NN NN O
of NN NN O
BLS NN NN O
and NN NN O
to NN NN O
be NN NN O
required NN NN O
for NN NN O
the NN NN O
induction NN NN O
of NN NN O
MHC NN NN O
class NN NN O
II NN NN O
by NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
. NN NN O
   
CIITA NN NN B-Protein
mRNA NN NN O
is NN NN O
normally NN NN O
inducible NN NN O
by NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
in NN NN O
class NN NN O
II NN NN O
non NN NN O
- NN NN O
inducible NN NN O
, NN NN O
RB NN NN B-Protein
- NN NN O
defective NN NN O
lines NN NN O
, NN NN O
and NN NN O
in NN NN O
one NN NN O
line NN NN O
, NN NN O
re NN NN O
- NN NN O
expression NN NN O
of NN NN O
RB NN NN B-Protein
has NN NN O
no NN NN O
effect NN NN O
on NN NN O
CIITA NN NN B-Protein
mRNA NN NN O
induction NN NN O
levels NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
the NN NN O
block NN NN O
in NN NN O
MHC NN NN O
class NN NN O
II NN NN O
inducibility NN NN O
in NN NN O
RB NN NN B-Protein
- NN NN O
defective NN NN O
cells NN NN O
is NN NN O
not NN NN O
due NN NN O
to NN NN O
a NN NN O
block NN NN O
in NN NN O
CIITA NN NN B-Protein
inducibility NN NN O
. NN NN O
   
Latent NN NN B-Protein
membrane NN NN I-Protein
protein NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
induces NN NN O
cyclin NN NN B-Protein
D2 NN NN I-Protein
expression NN NN O
, NN NN O
pRb NN NN B-Protein
hyperphosphorylation NN NN O
, NN NN O
and NN NN O
loss NN NN O
of NN NN O
TGF NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
1 NN NN I-Protein
- NN NN O
mediated NN NN O
growth NN NN O
inhibition NN NN O
in NN NN O
EBV NN NN O
- NN NN O
positive NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
normal NN NN O
cell NN NN O
cycle NN NN O
is NN NN O
regulated NN NN O
by NN NN O
several NN NN O
molecules NN NN O
, NN NN O
such NN NN O
as NN NN O
the NN NN O
tumor NN NN O
- NN NN O
suppressor NN NN O
protein NN NN O
pRb NN NN B-Protein
, NN NN O
the NN NN O
G1 NN NN O
cyclins NN NN O
, NN NN O
the NN NN O
cyclin NN NN O
- NN NN O
dependent NN NN O
kinases NN NN O
, NN NN O
and NN NN O
their NN NN O
inhibitors NN NN O
. NN NN O
   
These NN NN O
regulators NN NN O
are NN NN O
targeted NN NN O
by NN NN O
negative NN NN O
growth NN NN O
regulatory NN NN O
signals NN NN O
, NN NN O
such NN NN O
as NN NN O
that NN NN O
provided NN NN O
by NN NN O
TGF NN NN O
- NN NN O
beta NN NN O
. NN NN O
   
Here NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
the NN NN O
presence NN NN O
of NN NN O
either NN NN O
wild NN NN O
- NN NN O
type NN NN O
EBV NN NN O
or NN NN O
its NN NN O
transforming NN NN O
latent NN NN B-Protein
membrane NN NN I-Protein
protein NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
LMP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
results NN NN O
in NN NN O
the NN NN O
loss NN NN O
of NN NN O
TGF NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
1 NN NN I-Protein
- NN NN O
mediated NN NN O
growth NN NN O
inhibition NN NN O
in NN NN O
human NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
Chemical NN NN O
cross NN NN O
- NN NN O
linking NN NN O
with NN NN O
125I NN NN O
- NN NN O
labeled NN NN O
TGF NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
1 NN NN I-Protein
showed NN NN O
an NN NN O
essentially NN NN O
normal NN NN O
TGF NN NN O
- NN NN O
beta NN NN O
receptor NN NN O
profile NN NN O
in NN NN O
EBV NN NN O
- NN NN O
positive NN NN O
and NN NN O
EBV NN NN O
- NN NN O
negative NN NN O
Burkitt NN NN O
' NN NN O
s NN NN O
lymphoma NN NN O
cell NN NN O
lines NN NN O
, NN NN O
and NN NN O
these NN NN O
receptors NN NN O
were NN NN O
shown NN NN O
to NN NN O
be NN NN O
functional NN NN O
in NN NN O
transducing NN NN O
signals NN NN O
, NN NN O
as NN NN O
evidenced NN NN O
by NN NN O
the NN NN O
TGF NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
1 NN NN I-Protein
- NN NN O
mediated NN NN O
modulation NN NN O
of NN NN O
junB NN NN B-Protein
gene NN NN O
expression NN NN O
. NN NN O
   
However NN NN O
, NN NN O
TGF NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
1 NN NN I-Protein
did NN NN O
not NN NN O
induce NN NN O
dephosphorylation NN NN O
of NN NN O
pRb NN NN B-Protein
in NN NN O
EBV NN NN O
( NN NN O
or NN NN O
LMP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
- NN NN O
positive NN NN O
cells NN NN O
as NN NN O
opposed NN NN O
to NN NN O
EBV NN NN O
- NN NN O
negative NN NN O
cells NN NN O
, NN NN O
suggesting NN NN O
a NN NN O
dichotomy NN NN O
in NN NN O
the NN NN O
TGF NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
1 NN NN I-Protein
signaling NN NN O
pathway NN NN O
leading NN NN O
to NN NN O
separable NN NN O
gene NN NN O
regulatory NN NN O
and NN NN O
growth NN NN O
inhibitory NN NN O
responses NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
LMP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
was NN NN O
found NN NN O
to NN NN O
induce NN NN O
the NN NN O
expression NN NN O
of NN NN O
cyclin NN NN B-Protein
D2 NN NN I-Protein
; NN NN O
normal NN NN O
B NN NN O
cells NN NN O
or NN NN O
EBV NN NN O
- NN NN O
negative NN NN O
Burkitt NN NN O
' NN NN O
s NN NN O
lymphoma NN NN O
cells NN NN O
do NN NN O
not NN NN O
express NN NN O
D NN NN O
- NN NN O
type NN NN O
cyclins NN NN O
. NN NN O
   
Taken NN NN O
together NN NN O
, NN NN O
these NN NN O
data NN NN O
point NN NN O
to NN NN O
a NN NN O
potential NN NN O
mechanism NN NN O
underlying NN NN O
EBV NN NN O
- NN NN O
mediated NN NN O
B NN NN O
cell NN NN O
transformation NN NN O
whereby NN NN O
constitutive NN NN O
induction NN NN O
of NN NN O
key NN NN O
cell NN NN O
cycle NN NN O
regulators NN NN O
by NN NN O
LMP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
can NN NN O
lead NN NN O
to NN NN O
pRb NN NN B-Protein
hyperphosphorylation NN NN O
and NN NN O
uncontrolled NN NN O
cell NN NN O
proliferation NN NN O
. NN NN O
   
C NN NN O
/ NN NN O
EBP NN NN O
proteins NN NN O
activate NN NN O
transcription NN NN O
from NN NN O
the NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
in NN NN O
macrophages NN NN O
/ NN NN O
monocytes NN NN O
. NN NN O
   
Three NN NN O
binding NN NN O
sites NN NN O
for NN NN O
C NN NN O
/ NN NN O
EBP NN NN O
proteins NN NN O
are NN NN O
found NN NN O
in NN NN O
the NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
( NN NN O
LTR NN NN O
) NN NN O
( NN NN O
V NN NN O
. NN NN O
M NN NN O
. NN NN O
Tesmer NN NN O
, NN NN O
A NN NN O
. NN NN O
Rajadhyaksha NN NN O
, NN NN O
J NN NN O
. NN NN O
Babin NN NN O
, NN NN O
and NN NN O
M NN NN O
. NN NN O
Bina NN NN O
, NN NN O
Proc NN NN O
. NN NN O
Natl NN NN O
. NN NN O
Acad NN NN O
. NN NN O
Sci NN NN O
. NN NN O
USA NN NN O
90 NN NN O
: NN NN O
7298 NN NN O
- NN NN O
7302 NN NN O
, NN NN O
1993 NN NN O
) NN NN O
. NN NN O
   
We NN NN O
have NN NN O
determined NN NN O
the NN NN O
functional NN NN O
role NN NN O
of NN NN O
C NN NN O
/ NN NN O
EBP NN NN O
proteins NN NN O
and NN NN O
C NN NN O
/ NN NN O
EBP NN NN O
sites NN NN O
in NN NN O
regulating NN NN O
transcription NN NN O
from NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
in NN NN O
monocytes NN NN O
/ NN NN O
macrophages NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
endogenous NN NN O
C NN NN O
/ NN NN O
EBP NN NN O
proteins NN NN O
, NN NN O
using NN NN O
either NN NN O
an NN NN O
excess NN NN O
of NN NN O
C NN NN O
/ NN NN O
EBP NN NN O
binding NN NN O
sites NN NN O
or NN NN O
a NN NN O
trans NN NN O
- NN NN O
dominant NN NN O
negative NN NN O
inhibitor NN NN O
, NN NN O
demonstrated NN NN O
that NN NN O
C NN NN O
/ NN NN O
EBP NN NN O
proteins NN NN O
are NN NN O
required NN NN O
for NN NN O
basal NN NN O
and NN NN O
activated NN NN O
levels NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
transcription NN NN O
in NN NN O
the NN NN O
promonocytic NN NN O
cell NN NN O
line NN NN O
U937 NN NN O
. NN NN O
   
Northern NN NN O
( NN NN O
RNA NN NN O
) NN NN O
blots NN NN O
and NN NN O
binding NN NN O
assays NN NN O
showed NN NN O
that NN NN O
NF NN NN B-Protein
- NN NN I-Protein
IL6 NN NN I-Protein
is NN NN O
the NN NN O
only NN NN O
known NN NN O
C NN NN O
/ NN NN O
EBP NN NN O
family NN NN O
member NN NN O
which NN NN O
is NN NN O
increased NN NN O
when NN NN O
U937 NN NN O
cells NN NN O
are NN NN O
activated NN NN O
. NN NN O
   
Mutational NN NN O
analyses NN NN O
of NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
showed NN NN O
that NN NN O
one NN NN O
C NN NN O
/ NN NN O
EBP NN NN O
site NN NN O
is NN NN O
required NN NN O
for NN NN O
normal NN NN O
LTR NN NN O
transcription NN NN O
both NN NN O
before NN NN O
and NN NN O
after NN NN O
cellular NN NN O
activation NN NN O
and NN NN O
that NN NN O
the NN NN O
two NN NN O
3 NN NN O
' NN NN O
C NN NN O
/ NN NN O
EBP NN NN O
sites NN NN O
are NN NN O
functionally NN NN O
equivalent NN NN O
. NN NN O
   
However NN NN O
, NN NN O
transcription NN NN O
from NN NN O
crippled NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTRs NN NN O
lacking NN NN O
C NN NN O
/ NN NN O
EBP NN NN O
sites NN NN O
can NN NN O
still NN NN O
be NN NN O
induced NN NN O
following NN NN O
activation NN NN O
of NN NN O
U937 NN NN O
cells NN NN O
. NN NN O
   
Several NN NN O
models NN NN O
are NN NN O
suggested NN NN O
for NN NN O
how NN NN O
elevated NN NN O
NF NN NN B-Protein
- NN NN I-Protein
IL6 NN NN I-Protein
may NN NN O
participate NN NN O
in NN NN O
an NN NN O
autostimulatory NN NN O
loop NN NN O
involving NN NN O
HIV NN NN O
infection NN NN O
, NN NN O
macrophage NN NN O
activation NN NN O
, NN NN O
cytokine NN NN O
expression NN NN O
, NN NN O
and NN NN O
HIV NN NN O
replication NN NN O
. NN NN O
   
Sp1 NN NN B-Protein
functions NN NN O
in NN NN O
a NN NN O
chromatin NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
to NN NN O
augment NN NN O
human NN NN O
alpha NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
promoter NN NN O
activity NN NN O
. NN NN O
   
The NN NN O
5 NN NN O
' NN NN O
flanking NN NN O
region NN NN O
of NN NN O
the NN NN O
human NN NN O
alpha NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
gene NN NN O
is NN NN O
highly NN NN O
G NN NN O
+ NN NN O
C NN NN O
rich NN NN O
and NN NN O
contains NN NN O
multiple NN NN O
copies NN NN O
of NN NN O
the NN NN O
consensus NN NN O
sequence NN NN O
for NN NN O
the NN NN O
Sp1 NN NN B-Protein
binding NN NN O
site NN NN O
. NN NN O
   
We NN NN O
investigated NN NN O
the NN NN O
role NN NN O
of NN NN O
this NN NN O
G NN NN O
+ NN NN O
C NN NN O
- NN NN O
rich NN NN O
region NN NN O
in NN NN O
augmenting NN NN O
alpha NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
promoter NN NN O
activity NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
the NN NN O
far NN NN O
- NN NN O
upstream NN NN O
alpha NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
enhancer NN NN O
, NN NN O
HS NN NN B-Protein
- NN NN I-Protein
40 NN NN I-Protein
. NN NN O
   
We NN NN O
show NN NN O
that NN NN O
in NN NN O
transiently NN NN O
transfected NN NN O
erythroid NN NN O
cells NN NN O
, NN NN O
deletion NN NN O
of NN NN O
the NN NN O
alpha NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
G NN NN O
+ NN NN O
C NN NN O
- NN NN O
rich NN NN O
5 NN NN O
' NN NN O
flanking NN NN O
region NN NN O
has NN NN O
no NN NN O
effect NN NN O
on NN NN O
alpha NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
promoter NN NN O
activity NN NN O
. NN NN O
   
However NN NN O
, NN NN O
upon NN NN O
stable NN NN O
integration NN NN O
into NN NN O
chromatin NN NN O
, NN NN O
deletion NN NN O
of NN NN O
this NN NN O
region NN NN O
causes NN NN O
a NN NN O
nearly NN NN O
90 NN NN O
% NN NN O
decrease NN NN O
in NN NN O
promoter NN NN O
activity NN NN O
compared NN NN O
with NN NN O
expression NN NN O
from NN NN O
an NN NN O
alpha NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
promoter NN NN O
retaining NN NN O
this NN NN O
region NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
the NN NN O
alpha NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
G NN NN O
+ NN NN O
C NN NN O
- NN NN O
rich NN NN O
5 NN NN O
' NN NN O
flanking NN NN O
region NN NN O
augments NN NN O
alpha NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
promoter NN NN O
activity NN NN O
in NN NN O
a NN NN O
chromatin NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
. NN NN O
   
We NN NN O
further NN NN O
show NN NN O
that NN NN O
this NN NN O
G NN NN O
+ NN NN O
C NN NN O
- NN NN O
rich NN NN O
region NN NN O
is NN NN O
required NN NN O
for NN NN O
the NN NN O
activation NN NN O
of NN NN O
alpha NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
gene NN NN O
expression NN NN O
during NN NN O
erythroid NN NN O
differentiation NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
we NN NN O
show NN NN O
by NN NN O
both NN NN O
footprint NN NN O
analysis NN NN O
and NN NN O
functional NN NN O
assays NN NN O
that NN NN O
the NN NN O
ability NN NN O
of NN NN O
the NN NN O
G NN NN O
+ NN NN O
C NN NN O
- NN NN O
rich NN NN O
region NN NN O
to NN NN O
increase NN NN O
alpha NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
promoter NN NN O
activity NN NN O
from NN NN O
a NN NN O
stably NN NN O
integrated NN NN O
alpha NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
gene NN NN O
is NN NN O
mediated NN NN O
by NN NN O
its NN NN O
multiple NN NN O
binding NN NN O
sites NN NN O
for NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
Sp1 NN NN B-Protein
. NN NN O
   
Interleukin NN NN O
12 NN NN O
induces NN NN O
tyrosine NN NN O
phosphorylation NN NN O
and NN NN O
activation NN NN O
of NN NN O
STAT4 NN NN B-Protein
in NN NN O
human NN NN O
lymphocytes NN NN O
. NN NN O
   
Interleukin NN NN O
12 NN NN O
( NN NN O
IL NN NN O
- NN NN O
12 NN NN O
) NN NN O
is NN NN O
an NN NN O
important NN NN O
immunoregulatory NN NN O
cytokine NN NN O
whose NN NN O
receptor NN NN O
is NN NN O
a NN NN O
member NN NN O
of NN NN O
the NN NN O
hematopoietin NN NN O
receptor NN NN O
superfamily NN NN O
. NN NN O
   
We NN NN O
have NN NN O
recently NN NN O
demonstrated NN NN O
that NN NN O
stimulation NN NN O
of NN NN O
human NN NN O
T NN NN O
and NN NN O
natural NN NN O
killer NN NN O
cells NN NN O
with NN NN O
IL NN NN O
- NN NN O
12 NN NN O
induces NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
the NN NN O
Janus NN NN O
family NN NN O
tyrosine NN NN O
kinase NN NN O
JAK2 NN NN B-Protein
and NN NN O
Tyk2 NN NN B-Protein
, NN NN O
implicating NN NN O
these NN NN O
kinases NN NN O
in NN NN O
the NN NN O
immediate NN NN O
biochemical NN NN O
response NN NN O
to NN NN O
IL NN NN O
- NN NN O
12 NN NN O
. NN NN O
   
Recently NN NN O
, NN NN O
transcription NN NN O
factors NN NN O
known NN NN O
as NN NN O
STATs NN NN O
( NN NN O
signal NN NN O
transducers NN NN O
and NN NN O
activators NN NN O
of NN NN O
transcription NN NN O
) NN NN O
have NN NN O
been NN NN O
shown NN NN O
to NN NN O
be NN NN O
tyrosine NN NN O
phosphorylated NN NN O
and NN NN O
activated NN NN O
in NN NN O
response NN NN O
to NN NN O
a NN NN O
number NN NN O
of NN NN O
cytokines NN NN O
that NN NN O
bind NN NN O
hematopoietin NN NN O
receptors NN NN O
and NN NN O
activate NN NN O
JAK NN NN O
kinases NN NN O
. NN NN O
   
In NN NN O
this NN NN O
report NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
IL NN NN O
- NN NN O
12 NN NN O
induces NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
a NN NN O
recently NN NN O
identified NN NN O
STAT NN NN O
family NN NN O
member NN NN O
, NN NN O
STAT4 NN NN B-Protein
, NN NN O
and NN NN O
show NN NN O
that NN NN O
STAT4 NN NN B-Protein
expression NN NN O
is NN NN O
regulated NN NN O
by NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
IL NN NN O
- NN NN O
12 NN NN O
stimulates NN NN O
formation NN NN O
of NN NN O
a NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
complex NN NN O
that NN NN O
recognizes NN NN O
a NN NN O
DNA NN NN O
sequence NN NN O
previously NN NN O
shown NN NN O
to NN NN O
bind NN NN O
STAT NN NN O
proteins NN NN O
and NN NN O
that NN NN O
this NN NN O
complex NN NN O
contains NN NN O
STAT4 NN NN B-Protein
. NN NN O
   
These NN NN O
data NN NN O
, NN NN O
and NN NN O
the NN NN O
recent NN NN O
demonstration NN NN O
of NN NN O
JAK NN NN O
phosphorylation NN NN O
by NN NN O
IL NN NN O
- NN NN O
12 NN NN O
, NN NN O
identify NN NN O
a NN NN O
rapid NN NN O
signal NN NN O
- NN NN O
transduction NN NN O
pathway NN NN O
likely NN NN O
to NN NN O
mediate NN NN O
IL NN NN O
- NN NN O
12 NN NN O
- NN NN O
induced NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
Overexpression NN NN O
of NN NN O
DR NN NN B-Protein
- NN NN I-Protein
nm23 NN NN I-Protein
, NN NN O
a NN NN O
protein NN NN O
encoded NN NN O
by NN NN O
a NN NN O
member NN NN O
of NN NN O
the NN NN O
nm23 NN NN O
gene NN NN O
family NN NN O
, NN NN O
inhibits NN NN O
granulocyte NN NN O
differentiation NN NN O
and NN NN O
induces NN NN O
apoptosis NN NN O
in NN NN O
32Dc13 NN NN O
myeloid NN NN O
cells NN NN O
. NN NN O
   
Chronic NN NN O
myelogenous NN NN O
leukemia NN NN O
evolves NN NN O
in NN NN O
two NN NN O
clinically NN NN O
distinct NN NN O
stages NN NN O
: NN NN O
a NN NN O
chronic NN NN O
and NN NN O
a NN NN O
blast NN NN O
crisis NN NN O
phase NN NN O
. NN NN O
   
The NN NN O
molecular NN NN O
changes NN NN O
associated NN NN O
with NN NN O
chronic NN NN O
phase NN NN O
to NN NN O
blast NN NN O
crisis NN NN O
transition NN NN O
are NN NN O
largely NN NN O
unknown NN NN O
. NN NN O
   
We NN NN O
have NN NN O
identified NN NN O
a NN NN O
cDNA NN NN O
clone NN NN O
, NN NN O
DR NN NN B-Protein
- NN NN I-Protein
nm23 NN NN I-Protein
, NN NN O
differentially NN NN O
expressed NN NN O
in NN NN O
a NN NN O
blast NN NN O
- NN NN O
crisis NN NN O
cDNA NN NN O
library NN NN O
, NN NN O
which NN NN O
has NN NN O
approximately NN NN O
70 NN NN O
% NN NN O
sequence NN NN O
similarity NN NN O
to NN NN O
the NN NN O
putative NN NN O
metastatic NN NN O
suppressor NN NN O
genes NN NN O
, NN NN O
nm23 NN NN B-Protein
- NN NN I-Protein
H1 NN NN I-Protein
and NN NN O
nm23 NN NN B-Protein
- NN NN I-Protein
H2 NN NN I-Protein
. NN NN O
   
The NN NN O
deduced NN NN O
amino NN NN O
acid NN NN O
sequence NN NN O
similarity NN NN O
to NN NN O
the NN NN O
proteins NN NN O
encoded NN NN O
by NN NN O
these NN NN O
two NN NN O
latter NN NN O
genes NN NN O
is NN NN O
approximately NN NN O
65 NN NN O
% NN NN O
and NN NN O
includes NN NN O
domains NN NN O
and NN NN O
amino NN NN O
acid NN NN O
residues NN NN O
( NN NN O
the NN NN O
leucine NN NN O
zipper NN NN O
- NN NN O
like NN NN O
and NN NN O
the NN NN O
RGD NN NN O
domain NN NN O
, NN NN O
a NN NN O
serine NN NN O
and NN NN O
a NN NN O
histidine NN NN O
residue NN NN O
in NN NN O
the NN NN O
NH2 NN NN O
- NN NN O
and NN NN O
in NN NN O
the NN NN O
COOH NN NN O
- NN NN O
terminal NN NN O
portion NN NN O
of NN NN O
the NN NN O
protein NN NN O
, NN NN O
respectively NN NN O
) NN NN O
postulated NN NN O
to NN NN O
be NN NN O
important NN NN O
for NN NN O
nm23 NN NN O
function NN NN O
. NN NN O
   
DR NN NN B-Protein
- NN NN I-Protein
nm23 NN NN I-Protein
mRNA NN NN O
is NN NN O
preferentially NN NN O
expressed NN NN O
at NN NN O
early NN NN O
stages NN NN O
of NN NN O
myeloid NN NN O
differentiation NN NN O
of NN NN O
highly NN NN O
purified NN NN O
CD34 NN NN B-Protein
+ NN NN O
cells NN NN O
. NN NN O
   
Its NN NN O
constitutive NN NN O
expression NN NN O
in NN NN O
the NN NN O
myeloid NN NN O
precursor NN NN O
32Dc13 NN NN O
cell NN NN O
line NN NN O
, NN NN O
which NN NN O
is NN NN O
growth NN NN O
- NN NN O
factor NN NN O
dependent NN NN O
for NN NN O
both NN NN O
proliferation NN NN O
and NN NN O
differentiation NN NN O
, NN NN O
results NN NN O
in NN NN O
inhibition NN NN O
of NN NN O
granulocytic NN NN O
differentiation NN NN O
induced NN NN O
by NN NN O
granulocyte NN NN B-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
and NN NN O
causes NN NN O
apoptotic NN NN O
cell NN NN O
death NN NN O
. NN NN O
   
These NN NN O
results NN NN O
are NN NN O
consistent NN NN O
with NN NN O
a NN NN O
role NN NN O
for NN NN O
DR NN NN B-Protein
- NN NN I-Protein
nm23 NN NN I-Protein
in NN NN O
normal NN NN O
hematopoiesis NN NN O
and NN NN O
raise NN NN O
the NN NN O
possibility NN NN O
that NN NN O
its NN NN O
overexpression NN NN O
contributes NN NN O
to NN NN O
differentiation NN NN O
arrest NN NN O
, NN NN O
a NN NN O
feature NN NN O
of NN NN O
blastic NN NN O
transformation NN NN O
in NN NN O
chronic NN NN O
myelogenous NN NN O
leukemia NN NN O
. NN NN O
   
Transcription NN NN O
factors NN NN O
as NN NN O
targets NN NN O
for NN NN O
oxidative NN NN O
signalling NN NN O
during NN NN O
lymphocyte NN NN O
activation NN NN O
. NN NN O
   
We NN NN O
previously NN NN O
have NN NN O
demonstrated NN NN O
a NN NN O
requirement NN NN O
for NN NN O
oxidative NN NN O
events NN NN O
during NN NN O
cell NN NN O
cycle NN NN O
entry NN NN O
in NN NN O
T NN NN O
lymphocytes NN NN O
and NN NN O
have NN NN O
hypothesised NN NN O
that NN NN O
reactive NN NN O
oxygen NN NN O
species NN NN O
may NN NN O
act NN NN O
as NN NN O
intracellular NN NN O
signalling NN NN O
agents NN NN O
during NN NN O
lymphocyte NN NN O
activation NN NN O
. NN NN O
   
In NN NN O
the NN NN O
current NN NN O
study NN NN O
, NN NN O
cysteamine NN NN O
, NN NN O
an NN NN O
aminothiol NN NN O
compound NN NN O
with NN NN O
antioxidant NN NN O
activity NN NN O
, NN NN O
has NN NN O
been NN NN O
used NN NN O
to NN NN O
further NN NN O
investigate NN NN O
the NN NN O
role NN NN O
of NN NN O
oxidative NN NN O
signalling NN NN O
during NN NN O
lymphocyte NN NN O
activation NN NN O
. NN NN O
   
Treatment NN NN O
of NN NN O
normal NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
lymphocytes NN NN O
with NN NN O
cysteamine NN NN O
in NN NN O
vitro NN NN O
was NN NN O
found NN NN O
to NN NN O
inhibit NN NN O
proliferation NN NN O
in NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
, NN NN O
with NN NN O
essentially NN NN O
complete NN NN O
inhibition NN NN O
occurring NN NN O
at NN NN O
a NN NN O
dose NN NN O
of NN NN O
400 NN NN O
microM NN NN O
. NN NN O
   
This NN NN O
inhibitory NN NN O
effect NN NN O
was NN NN O
limited NN NN O
to NN NN O
the NN NN O
first NN NN O
2 NN NN O
h NN NN O
after NN NN O
mitogenic NN NN O
activation NN NN O
, NN NN O
localizing NN NN O
the NN NN O
time NN NN O
- NN NN O
frame NN NN O
of NN NN O
action NN NN O
of NN NN O
cysteamine NN NN O
to NN NN O
within NN NN O
the NN NN O
commitment NN NN O
period NN NN O
. NN NN O
   
It NN NN O
therefore NN NN O
was NN NN O
of NN NN O
interest NN NN O
to NN NN O
establish NN NN O
which NN NN O
, NN NN O
if NN NN O
any NN NN O
, NN NN O
commitment NN NN O
events NN NN O
were NN NN O
affected NN NN O
by NN NN O
oxidative NN NN O
signalling NN NN O
during NN NN O
cell NN NN O
cycle NN NN O
entry NN NN O
. NN NN O
   
Taking NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
as NN NN O
a NN NN O
candidate NN NN O
, NN NN O
we NN NN O
examined NN NN O
the NN NN O
effect NN NN O
of NN NN O
cysteamine NN NN O
treatment NN NN O
on NN NN O
early NN NN O
gene NN NN O
expression NN NN O
during NN NN O
lymphocyte NN NN O
activation NN NN O
, NN NN O
and NN NN O
on NN NN O
the NN NN O
activity NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
AP NN NN O
- NN NN O
1 NN NN O
, NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
NF NN NN O
- NN NN O
AT NN NN O
and NN NN O
Oct1 NN NN B-Protein
, NN NN O
whose NN NN O
functions NN NN O
are NN NN O
required NN NN O
for NN NN O
expression NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
mRNA NN NN O
. NN NN O
   
Cysteamine NN NN O
treatment NN NN O
inhibited NN NN O
both NN NN O
expression NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
mRNA NN NN O
and NN NN O
secretion NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
into NN NN O
the NN NN O
culture NN NN O
medium NN NN O
. NN NN O
   
The NN NN O
inhibitory NN NN O
effect NN NN O
of NN NN O
cysteamine NN NN O
may NN NN O
be NN NN O
mediated NN NN O
at NN NN O
least NN NN O
in NN NN O
part NN NN O
by NN NN O
an NN NN O
effect NN NN O
on NN NN O
transcription NN NN O
factor NN NN O
function NN NN O
, NN NN O
as NN NN O
the NN NN O
DNA NN NN O
binding NN NN O
activities NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
extracted NN NN O
from NN NN O
mitogen NN NN O
- NN NN O
stimulated NN NN O
cells NN NN O
were NN NN O
significantly NN NN O
inhibited NN NN O
by NN NN O
cysteamine NN NN O
treatment NN NN O
. NN NN O
   
Interestingly NN NN O
, NN NN O
Oct1 NN NN B-Protein
and NN NN O
NF NN NN O
- NN NN O
AT NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
were NN NN O
not NN NN O
affected NN NN O
by NN NN O
cysteamine NN NN O
treatment NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
oxidative NN NN O
signalling NN NN O
processes NN NN O
operate NN NN O
in NN NN O
a NN NN O
selective NN NN O
manner NN NN O
. NN NN O
   
The NN NN O
identification NN NN O
of NN NN O
regulatory NN NN O
proteins NN NN O
, NN NN O
such NN NN O
as NN NN O
transcription NN NN O
factors NN NN O
, NN NN O
as NN NN O
molecular NN NN O
targets NN NN O
for NN NN O
oxidative NN NN O
signalling NN NN O
provides NN NN O
further NN NN O
evidence NN NN O
to NN NN O
implicate NN NN O
oxidative NN NN O
signalling NN NN O
as NN NN O
being NN NN O
intimately NN NN O
involved NN NN O
in NN NN O
the NN NN O
G0 NN NN O
to NN NN O
G1 NN NN O
phase NN NN O
transition NN NN O
in NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
Flutamide NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
hirsutism NN NN O
: NN NN O
long NN NN O
- NN NN O
term NN NN O
clinical NN NN O
effects NN NN O
, NN NN O
endocrine NN NN O
changes NN NN O
, NN NN O
and NN NN O
androgen NN NN B-Protein
receptor NN NN I-Protein
behavior NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
investigate NN NN O
the NN NN O
long NN NN O
- NN NN O
term NN NN O
effects NN NN O
of NN NN O
treatment NN NN O
with NN NN O
low NN NN O
doses NN NN O
of NN NN O
flutamide NN NN O
on NN NN O
clinical NN NN O
and NN NN O
hormonal NN NN O
parameters NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
on NN NN O
the NN NN O
androgen NN NN B-Protein
receptor NN NN I-Protein
status NN NN O
, NN NN O
in NN NN O
hirsute NN NN O
women NN NN O
. NN NN O
   
DESIGN NN NN O
: NN NN O
Eighteen NN NN O
hirsute NN NN O
patients NN NN O
with NN NN O
regular NN NN O
menses NN NN O
were NN NN O
studied NN NN O
basally NN NN O
and NN NN O
during NN NN O
treatment NN NN O
with NN NN O
125 NN NN O
mg NN NN O
flutamide NN NN O
, NN NN O
three NN NN O
times NN NN O
per NN NN O
day NN NN O
for NN NN O
12 NN NN O
months NN NN O
. NN NN O
   
Barrier NN NN O
or NN NN O
intrauterine NN NN O
contraception NN NN O
was NN NN O
used NN NN O
during NN NN O
the NN NN O
study NN NN O
in NN NN O
sexually NN NN O
active NN NN O
women NN NN O
. NN NN O
   
Safety NN NN O
parameters NN NN O
were NN NN O
assessed NN NN O
throughout NN NN O
the NN NN O
study NN NN O
. NN NN O
   
Hirsutism NN NN O
, NN NN O
graded NN NN O
by NN NN O
the NN NN O
modified NN NN O
Ferriman NN NN O
- NN NN O
Gallwey NN NN O
score NN NN O
, NN NN O
and NN NN O
hormonal NN NN O
parameters NN NN O
were NN NN O
evaluated NN NN O
basally NN NN O
and NN NN O
at NN NN O
4 NN NN O
- NN NN O
month NN NN O
intervals NN NN O
during NN NN O
treatment NN NN O
. NN NN O
   
Gonadotropin NN NN O
- NN NN O
releasing NN NN O
hormone NN NN O
and NN NN O
ACTH NN NN O
stimulation NN NN O
tests NN NN O
were NN NN O
performed NN NN O
before NN NN O
and NN NN O
after NN NN O
3 NN NN O
to NN NN O
4 NN NN O
months NN NN O
of NN NN O
therapy NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
the NN NN O
concentration NN NN O
of NN NN O
androgen NN NN B-Protein
receptors NN NN I-Protein
in NN NN O
mononuclear NN NN O
leukocytes NN NN O
was NN NN O
measured NN NN O
, NN NN O
in NN NN O
both NN NN O
the NN NN O
follicular NN NN O
and NN NN O
luteal NN NN O
phases NN NN O
of NN NN O
the NN NN O
menstrual NN NN O
cycle NN NN O
, NN NN O
basally NN NN O
and NN NN O
after NN NN O
4 NN NN O
months NN NN O
of NN NN O
flutamide NN NN O
treatment NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Flutamide NN NN O
was NN NN O
well NN NN O
tolerated NN NN O
in NN NN O
all NN NN O
women NN NN O
, NN NN O
with NN NN O
the NN NN O
noticeable NN NN O
exception NN NN O
of NN NN O
one NN NN O
patient NN NN O
who NN NN O
presented NN NN O
increased NN NN O
serum NN NN O
transaminase NN NN O
after NN NN O
8 NN NN O
months NN NN O
of NN NN O
therapy NN NN O
. NN NN O
   
Hirsutism NN NN O
markedly NN NN O
improved NN NN O
in NN NN O
all NN NN O
women NN NN O
during NN NN O
the NN NN O
treatment NN NN O
( NN NN O
Ferriman NN NN O
- NN NN O
Gallwey NN NN O
score NN NN O
after NN NN O
1 NN NN O
year NN NN O
: NN NN O
4 NN NN O
. NN NN O
1 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
5 NN NN O
versus NN NN O
14 NN NN O
. NN NN O
1 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
9 NN NN O
) NN NN O
. NN NN O
   
A NN NN O
reduction NN NN O
of NN NN O
serum NN NN O
androgens NN NN O
was NN NN O
found NN NN O
, NN NN O
whereas NN NN O
no NN NN O
change NN NN O
was NN NN O
observed NN NN O
in NN NN O
either NN NN O
basal NN NN O
or NN NN O
GnRH NN NN O
- NN NN O
stimulated NN NN O
gonadotropins NN NN O
or NN NN O
in NN NN O
the NN NN O
cortisol NN NN O
and NN NN O
17 NN NN O
alpha NN NN O
- NN NN O
hydroxyprogesterone NN NN O
response NN NN O
to NN NN O
ACTH NN NN O
. NN NN O
   
Cycles NN NN O
remained NN NN O
ovulatory NN NN O
. NN NN O
   
Before NN NN O
treatment NN NN O
, NN NN O
the NN NN O
number NN NN O
of NN NN O
androgen NN NN B-Protein
receptors NN NN I-Protein
was NN NN O
higher NN NN O
in NN NN O
the NN NN O
luteal NN NN O
than NN NN O
in NN NN O
the NN NN O
follicular NN NN O
phase NN NN O
. NN NN O
   
This NN NN O
rhythmic NN NN O
differentiation NN NN O
disappeared NN NN O
after NN NN O
the NN NN O
patients NN NN O
had NN NN O
been NN NN O
given NN NN O
the NN NN O
antiandrogen NN NN O
drug NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Flutamide NN NN O
is NN NN O
effective NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
hirsutism NN NN O
but NN NN O
requires NN NN O
constant NN NN O
surveillance NN NN O
of NN NN O
liver NN NN O
function NN NN O
. NN NN O
   
Androgen NN NN B-Protein
receptor NN NN I-Protein
blockade NN NN O
might NN NN O
be NN NN O
potentiated NN NN O
by NN NN O
a NN NN O
reduction NN NN O
of NN NN O
serum NN NN O
androgens NN NN O
. NN NN O
   
Flutamide NN NN O
affects NN NN O
androgen NN NN B-Protein
receptor NN NN I-Protein
behavior NN NN O
during NN NN O
the NN NN O
menstrual NN NN O
cycle NN NN O
. NN NN O
   
The NN NN O
meaning NN NN O
of NN NN O
this NN NN O
finding NN NN O
remains NN NN O
to NN NN O
be NN NN O
elucidated NN NN O
. NN NN O
   
HIV NN NN O
- NN NN O
1 NN NN O
envelope NN NN O
glycoproteins NN NN O
induce NN NN O
activation NN NN O
of NN NN O
activated NN NN O
protein NN NN O
- NN NN O
1 NN NN O
in NN NN O
CD4 NN NN B-Protein
+ NN NN O
T NN NN O
cells NN NN O
[ NN NN O
published NN NN O
erratum NN NN O
appears NN NN O
in NN NN O
J NN NN O
Biol NN NN O
Chem NN NN O
1995 NN NN O
Dec NN NN O
1 NN NN O
; NN NN O
270 NN NN O
( NN NN O
48 NN NN O
) NN NN O
: NN NN O
29038 NN NN O
] NN NN O
   
Activation NN NN O
of NN NN O
CD4 NN NN B-Protein
positive NN NN O
T NN NN O
cells NN NN O
is NN NN O
a NN NN O
primary NN NN O
requirement NN NN O
for NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
( NN NN O
HIV NN NN O
) NN NN O
entry NN NN O
, NN NN O
efficient NN NN O
HIV NN NN O
replication NN NN O
, NN NN O
and NN NN O
progression NN NN O
to NN NN O
AIDS NN NN O
, NN NN O
Utilizing NN NN O
CD4 NN NN B-Protein
positive NN NN O
T NN NN O
cell NN NN O
lines NN NN O
and NN NN O
purified NN NN O
T NN NN O
cells NN NN O
from NN NN O
normal NN NN O
individuals NN NN O
, NN NN O
we NN NN O
have NN NN O
demonstrated NN NN O
that NN NN O
native NN NN O
envelope NN NN O
glycoproteins NN NN O
of NN NN O
HIV NN NN O
, NN NN O
gp NN NN B-Protein
160 NN NN I-Protein
, NN NN O
can NN NN O
induce NN NN O
activation NN NN O
of NN NN O
transcription NN NN O
factor NN NN O
, NN NN O
activated NN NN O
protein NN NN O
- NN NN O
1 NN NN O
( NN NN O
AP NN NN O
- NN NN O
1 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
stimulatory NN NN O
effects NN NN O
of NN NN O
gp160 NN NN B-Protein
are NN NN O
mediated NN NN O
through NN NN O
the NN NN O
CD4 NN NN B-Protein
molecule NN NN O
, NN NN O
since NN NN O
treatment NN NN O
of NN NN O
gp160 NN NN B-Protein
with NN NN O
soluble NN NN O
CD4 NN NN B-Protein
- NN NN O
IgG NN NN O
abrogates NN NN O
its NN NN O
activity NN NN O
, NN NN O
and NN NN O
CD4 NN NN B-Protein
negative NN NN O
T NN NN O
cell NN NN O
lines NN NN O
fail NN NN O
to NN NN O
be NN NN O
stimulated NN NN O
with NN NN O
gp160 NN NN B-Protein
. NN NN O
   
Immunoprecipitation NN NN O
of NN NN O
the NN NN O
gp NN NN B-Protein
160 NN NN I-Protein
- NN NN O
induced NN NN O
nuclear NN NN O
extracts NN NN O
with NN NN O
polyclonal NN NN O
antibodies NN NN O
to NN NN O
Fos NN NN O
and NN NN O
Jun NN NN O
proteins NN NN O
indicates NN NN O
that NN NN O
AP NN NN O
- NN NN O
1 NN NN O
complex NN NN O
is NN NN O
comprised NN NN O
of NN NN O
members NN NN O
of NN NN O
these NN NN O
family NN NN O
of NN NN O
proteins NN NN O
. NN NN O
   
The NN NN O
gp160 NN NN B-Protein
- NN NN O
induced NN NN O
AP NN NN O
- NN NN O
1 NN NN O
complex NN NN O
is NN NN O
dependent NN NN O
upon NN NN O
protein NN NN O
tyrosine NN NN O
phosphorylation NN NN O
and NN NN O
is NN NN O
protein NN NN O
synthesis NN NN O
- NN NN O
independent NN NN O
. NN NN O
   
This NN NN O
stimulation NN NN O
can NN NN O
also NN NN O
be NN NN O
abolished NN NN O
by NN NN O
inhibitors NN NN O
of NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
, NN NN O
but NN NN O
it NN NN O
is NN NN O
unaffected NN NN O
by NN NN O
calcium NN NN O
channel NN NN O
blocker NN NN O
or NN NN O
cyclosporine NN NN O
A NN NN O
. NN NN O
   
This NN NN O
gp160 NN NN B-Protein
treatment NN NN O
adversely NN NN O
affects NN NN O
the NN NN O
functional NN NN O
capabilities NN NN O
of NN NN O
T NN NN O
cells NN NN O
: NN NN O
pre NN NN O
- NN NN O
treatment NN NN O
of NN NN O
CD4 NN NN B-Protein
+ NN NN O
T NN NN O
cells NN NN O
with NN NN O
gp160 NN NN B-Protein
for NN NN O
4 NN NN O
h NN NN O
at NN NN O
37 NN NN O
degrees NN NN O
C NN NN O
inhibited NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
- NN NN O
induced NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
secretion NN NN O
. NN NN O
   
Effects NN NN O
similar NN NN O
to NN NN O
gp160 NN NN B-Protein
were NN NN O
seen NN NN O
with NN NN O
anti NN NN O
- NN NN O
CD4 NN NN B-Protein
mAb NN NN O
. NN NN O
   
The NN NN O
aberrant NN NN O
activation NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
by NN NN O
gp160 NN NN B-Protein
in NN NN O
CD4 NN NN B-Protein
positive NN NN O
T NN NN O
cells NN NN O
could NN NN O
result NN NN O
in NN NN O
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
cytokines NN NN O
containing NN NN O
AP NN NN O
- NN NN O
1 NN NN O
sites NN NN O
, NN NN O
e NN NN O
. NN NN O
g NN NN O
. NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
and NN NN O
granulocyte NN NN B-Protein
macrophage NN NN I-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
, NN NN O
and NN NN O
concurrently NN NN O
lead NN NN O
to NN NN O
T NN NN O
cell NN NN O
unresponsiveness NN NN O
by NN NN O
inhibiting NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
secretion NN NN O
. NN NN O
   
Cellular NN NN O
and NN NN O
molecular NN NN O
mechanisms NN NN O
of NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
production NN NN O
induced NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
IL NN NN O
- NN NN O
12 NN NN O
in NN NN O
a NN NN O
human NN NN O
NK NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
Interferon NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
( NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
) NN NN O
is NN NN O
an NN NN O
important NN NN O
immunoregulatory NN NN O
protein NN NN O
produced NN NN O
predominantly NN NN O
by NN NN O
T NN NN O
cells NN NN O
and NN NN O
large NN NN O
granular NN NN O
lymphocytes NN NN O
( NN NN O
LGL NN NN O
) NN NN O
in NN NN O
response NN NN O
to NN NN O
different NN NN O
extracellular NN NN O
signals NN NN O
. NN NN O
   
In NN NN O
particular NN NN O
, NN NN O
two NN NN O
interleukins NN NN O
( NN NN O
ILs NN NN O
) NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
IL NN NN O
- NN NN O
12 NN NN O
, NN NN O
have NN NN O
been NN NN O
shown NN NN O
to NN NN O
be NN NN O
potent NN NN O
inducers NN NN O
of NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
gene NN NN O
expression NN NN O
in NN NN O
both NN NN O
T NN NN O
cells NN NN O
and NN NN O
LGL NN NN O
. NN NN O
   
Although NN NN O
it NN NN O
has NN NN O
been NN NN O
reported NN NN O
that NN NN O
there NN NN O
are NN NN O
some NN NN O
T NN NN O
cell NN NN O
lines NN NN O
that NN NN O
produce NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
in NN NN O
response NN NN O
to NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
IL NN NN O
- NN NN O
12 NN NN O
stimulation NN NN O
, NN NN O
there NN NN O
has NN NN O
as NN NN O
yet NN NN O
been NN NN O
no NN NN O
report NN NN O
of NN NN O
a NN NN O
natural NN NN O
killer NN NN O
( NN NN O
NK NN NN O
) NN NN O
cell NN NN O
line NN NN O
that NN NN O
responds NN NN O
in NN NN O
a NN NN O
similar NN NN O
manner NN NN O
. NN NN O
   
In NN NN O
this NN NN O
report NN NN O
we NN NN O
present NN NN O
evidence NN NN O
that NN NN O
the NN NN O
cell NN NN O
line NN NN O
NK3 NN NN O
. NN NN O
3 NN NN O
derived NN NN O
from NN NN O
human NN NN O
NK NN NN O
cells NN NN O
, NN NN O
responds NN NN O
to NN NN O
both NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
IL NN NN O
- NN NN O
12 NN NN O
, NN NN O
as NN NN O
measured NN NN O
by NN NN O
increases NN NN O
in NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
and NN NN O
granulocyte NN NN B-Protein
- NN NN I-Protein
macrophage NN NN I-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
( NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
) NN NN O
cytoplasmic NN NN O
mRNA NN NN O
and NN NN O
protein NN NN O
expression NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
when NN NN O
used NN NN O
together NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
IL NN NN O
- NN NN O
12 NN NN O
synergized NN NN O
in NN NN O
the NN NN O
induction NN NN O
of NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
and NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
and NN NN O
this NN NN O
synergy NN NN O
was NN NN O
attributed NN NN O
to NN NN O
an NN NN O
increased NN NN O
accumulation NN NN O
and NN NN O
stability NN NN O
of NN NN O
the NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
and NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
mRNAs NN NN O
. NN NN O
   
To NN NN O
investigate NN NN O
the NN NN O
signaling NN NN O
pathways NN NN O
involved NN NN O
in NN NN O
the NN NN O
gene NN NN O
induction NN NN O
, NN NN O
five NN NN O
inhibitors NN NN O
, NN NN O
cyclosporin NN NN O
A NN NN O
( NN NN O
CsA NN NN O
) NN NN O
, NN NN O
transforming NN NN B-Protein
growth NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
beta NN NN I-Protein
, NN NN O
cycloheximide NN NN O
, NN NN O
genistein NN NN O
, NN NN O
and NN NN O
staurosporine NN NN O
A NN NN O
, NN NN O
were NN NN O
used NN NN O
in NN NN O
analyzing NN NN O
the NN NN O
effects NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
IL NN NN O
- NN NN O
12 NN NN O
on NN NN O
NK3 NN NN O
. NN NN O
3 NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
results NN NN O
suggest NN NN O
that NN NN O
activation NN NN O
of NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
, NN NN O
but NN NN O
not NN NN O
new NN NN O
protein NN NN O
synthesis NN NN O
, NN NN O
is NN NN O
required NN NN O
for NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
induction NN NN O
of NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
and NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
cytoplasmic NN NN O
mRNA NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
IL NN NN O
- NN NN O
12 NN NN O
induction NN NN O
of NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
cytoplasmic NN NN O
mRNA NN NN O
appears NN NN O
to NN NN O
only NN NN O
partially NN NN O
depend NN NN O
on NN NN O
activation NN NN O
of NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
both NN NN O
transforming NN NN O
growth NN NN O
factor NN NN O
- NN NN O
beta NN NN O
and NN NN O
genistein NN NN O
, NN NN O
a NN NN O
tyrosine NN NN O
kinase NN NN O
inhibitor NN NN O
, NN NN O
could NN NN O
suppress NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
IL NN NN O
- NN NN O
12 NN NN O
signaling NN NN O
but NN NN O
CsA NN NN O
was NN NN O
generally NN NN O
inactive NN NN O
. NN NN O
   
It NN NN O
also NN NN O
was NN NN O
observed NN NN O
that NN NN O
suppression NN NN O
of NN NN O
cytokine NN NN O
gene NN NN O
expression NN NN O
by NN NN O
these NN NN O
agents NN NN O
was NN NN O
independent NN NN O
of NN NN O
the NN NN O
inhibition NN NN O
of NN NN O
proliferation NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
but NN NN O
not NN NN O
IL NN NN O
- NN NN O
12 NN NN O
induced NN NN O
nuclear NN NN O
factors NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
AP1 NN NN O
, NN NN O
and NN NN O
regulation NN NN O
of NN NN O
the NN NN O
nuclear NN NN O
levels NN NN O
of NN NN O
these NN NN O
two NN NN O
DNA NN NN O
binding NN NN O
protein NN NN O
complexes NN NN O
is NN NN O
correlated NN NN O
with NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
and NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
gene NN NN O
expression NN NN O
. NN NN O
   
These NN NN O
data NN NN O
indicate NN NN O
that NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
IL NN NN O
- NN NN O
12 NN NN O
may NN NN O
have NN NN O
distinct NN NN O
signaling NN NN O
pathways NN NN O
leading NN NN O
to NN NN O
the NN NN O
induction NN NN O
of NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
and NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
gene NN NN O
expression NN NN O
, NN NN O
and NN NN O
that NN NN O
the NN NN O
NK3 NN NN O
. NN NN O
3 NN NN O
cell NN NN O
line NN NN O
may NN NN O
serve NN NN O
as NN NN O
a NN NN O
novel NN NN O
model NN NN O
for NN NN O
dissecting NN NN O
the NN NN O
biochemical NN NN O
and NN NN O
molecular NN NN O
events NN NN O
involved NN NN O
in NN NN O
these NN NN O
pathways NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
erythroid NN NN O
- NN NN O
specific NN NN O
genes NN NN O
in NN NN O
acute NN NN O
megakaryoblastic NN NN O
leukaemia NN NN O
and NN NN O
transient NN NN O
myeloproliferative NN NN O
disorder NN NN O
in NN NN O
Down NN NN O
' NN NN O
s NN NN O
syndrome NN NN O
. NN NN O
   
Acute NN NN O
megakaryoblastic NN NN O
leukaemia NN NN O
( NN NN O
M7 NN NN O
) NN NN O
and NN NN O
transient NN NN O
myeloproliferative NN NN O
disorder NN NN O
in NN NN O
Down NN NN O
' NN NN O
s NN NN O
syndrome NN NN O
( NN NN O
TMD NN NN O
) NN NN O
are NN NN O
characterized NN NN O
by NN NN O
rapid NN NN O
growth NN NN O
of NN NN O
abnormal NN NN O
blast NN NN O
cells NN NN O
which NN NN O
express NN NN O
megakaryocytic NN NN O
markers NN NN O
. NN NN O
   
To NN NN O
clarify NN NN O
properties NN NN O
of NN NN O
the NN NN O
blast NN NN O
cells NN NN O
in NN NN O
M7 NN NN O
and NN NN O
TMD NN NN O
cases NN NN O
, NN NN O
we NN NN O
examined NN NN O
erythroid NN NN O
markers NN NN O
expression NN NN O
in NN NN O
blasts NN NN O
from NN NN O
six NN NN O
cases NN NN O
with NN NN O
M7 NN NN O
and NN NN O
seven NN NN O
cases NN NN O
with NN NN O
TMD NN NN O
in NN NN O
this NN NN O
study NN NN O
. NN NN O
   
Erythroid NN NN O
- NN NN O
specific NN NN O
mRNAs NN NN O
encoding NN NN O
gamma NN NN O
- NN NN O
globin NN NN O
and NN NN O
erythroid NN NN O
delta NN NN B-Protein
- NN NN I-Protein
aminolevulinate NN NN I-Protein
synthase NN NN I-Protein
were NN NN O
found NN NN O
to NN NN O
be NN NN O
expressed NN NN O
in NN NN O
blasts NN NN O
from NN NN O
most NN NN O
of NN NN O
these NN NN O
cases NN NN O
, NN NN O
indicating NN NN O
that NN NN O
majorities NN NN O
of NN NN O
the NN NN O
blasts NN NN O
in NN NN O
M7 NN NN O
and NN NN O
TMD NN NN O
cases NN NN O
have NN NN O
erythroid NN NN O
and NN NN O
megakaryocytic NN NN O
phenotypes NN NN O
. NN NN O
   
We NN NN O
also NN NN O
found NN NN O
that NN NN O
mRNAs NN NN O
encoding NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
are NN NN O
expressed NN NN O
in NN NN O
all NN NN O
these NN NN O
cases NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
M7 NN NN O
blasts NN NN O
and NN NN O
TMD NN NN O
blasts NN NN O
correspond NN NN O
to NN NN O
the NN NN O
erythroid NN NN O
/ NN NN O
megakaryocytic NN NN O
bipotential NN NN O
progenitor NN NN O
cells NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
enhancer NN NN O
by NN NN O
the NN NN O
LEF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
HMG NN NN O
protein NN NN O
on NN NN O
nucleosome NN NN O
- NN NN O
assembled NN NN O
DNA NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
Lymphoid NN NN B-Protein
enhancer NN NN I-Protein
- NN NN I-Protein
binding NN NN I-Protein
factor NN NN I-Protein
1 NN NN I-Protein
( NN NN O
LEF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
is NN NN O
a NN NN O
regulatory NN NN O
high NN NN O
mobility NN NN O
group NN NN O
( NN NN O
HMG NN NN O
) NN NN O
protein NN NN O
that NN NN O
activates NN NN O
the NN NN O
T NN NN B-Protein
cell NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TCR NN NN B-Protein
alpha NN NN I-Protein
) NN NN O
enhancer NN NN O
in NN NN O
a NN NN O
context NN NN O
- NN NN O
restricted NN NN O
manner NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
this NN NN O
paper NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
distal NN NN O
region NN NN O
of NN NN O
the NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
- NN NN O
1 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
enhancer NN NN O
, NN NN O
which NN NN O
contains NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
sites NN NN O
for NN NN O
LEF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
Ets NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
also NN NN O
provides NN NN O
a NN NN O
functional NN NN O
context NN NN O
for NN NN O
activation NN NN O
by NN NN O
LEF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
First NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
mutations NN NN O
in NN NN O
the NN NN O
LEF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
- NN NN O
binding NN NN O
site NN NN O
inhibit NN NN O
the NN NN O
activity NN NN O
of NN NN O
multimerized NN NN O
copies NN NN O
of NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
enhancer NN NN O
in NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
, NN NN O
and NN NN O
that NN NN O
LEF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
/ NN NN O
GAL4 NN NN B-Protein
can NN NN O
activate NN NN O
a NN NN O
GAL4 NN NN B-Protein
- NN NN O
substituted NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
enhancer NN NN O
80 NN NN O
- NN NN O
to NN NN O
100 NN NN O
- NN NN O
fold NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
Second NN NN O
, NN NN O
recombinant NN NN O
LEF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
is NN NN O
shown NN NN O
to NN NN O
activate NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
transcription NN NN O
on NN NN O
chromatin NN NN O
- NN NN O
assembled NN NN O
DNA NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
By NN NN O
using NN NN O
a NN NN O
nucleosome NN NN O
- NN NN O
assembly NN NN O
system NN NN O
derived NN NN O
from NN NN O
Drosophila NN NN O
embryos NN NN O
, NN NN O
we NN NN O
find NN NN O
that NN NN O
the NN NN O
packaging NN NN O
of NN NN O
DNA NN NN O
into NN NN O
chromatin NN NN O
in NN NN O
vitro NN NN O
strongly NN NN O
represses NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
transcription NN NN O
and NN NN O
that NN NN O
repression NN NN O
can NN NN O
be NN NN O
counteracted NN NN O
efficiently NN NN O
by NN NN O
preincubation NN NN O
of NN NN O
the NN NN O
DNA NN NN O
with NN NN O
LEF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
or NN NN O
LEF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
Ets NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
supplemented NN NN O
with NN NN O
fractions NN NN O
containing NN NN O
the NN NN O
promoter NN NN O
- NN NN O
binding NN NN O
protein NN NN O
, NN NN O
Sp1 NN NN B-Protein
. NN NN O
   
Addition NN NN O
of NN NN O
TFE NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
, NN NN O
which NN NN O
binds NN NN O
to NN NN O
an NN NN O
E NN NN O
- NN NN O
box NN NN O
motif NN NN O
upstream NN NN O
of NN NN O
the NN NN O
LEF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
Ets NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
sites NN NN O
, NN NN O
further NN NN O
augments NN NN O
transcription NN NN O
in NN NN O
this NN NN O
system NN NN O
. NN NN O
   
Individually NN NN O
or NN NN O
collectively NN NN O
, NN NN O
none NN NN O
of NN NN O
the NN NN O
three NN NN O
enhancer NN NN O
- NN NN O
binding NN NN O
proteins NN NN O
( NN NN O
LEF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
Ets NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
and NN NN O
TFE NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
) NN NN O
could NN NN O
activate NN NN O
transcription NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
Sp1 NN NN B-Protein
. NN NN O
   
A NN NN O
truncation NN NN O
mutant NN NN O
of NN NN O
LEF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
HMG NN NN O
- NN NN O
88 NN NN O
) NN NN O
, NN NN O
which NN NN O
contains NN NN O
the NN NN O
HMG NN NN O
box NN NN O
but NN NN O
lacks NN NN O
the NN NN O
trans NN NN O
- NN NN O
activation NN NN O
domain NN NN O
, NN NN O
did NN NN O
not NN NN O
activate NN NN O
transcription NN NN O
from NN NN O
nucleosomal NN NN O
DNA NN NN O
, NN NN O
indicating NN NN O
that NN NN O
bending NN NN O
of NN NN O
DNA NN NN O
by NN NN O
the NN NN O
HMG NN NN O
domain NN NN O
is NN NN O
not NN NN O
sufficient NN NN O
to NN NN O
activate NN NN O
transcription NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
transcription NN NN O
activation NN NN O
by NN NN O
LEF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
in NN NN O
vitro NN NN O
is NN NN O
a NN NN O
chromatin NN NN O
- NN NN O
dependent NN NN O
process NN NN O
that NN NN O
requires NN NN O
a NN NN O
functional NN NN O
trans NN NN O
- NN NN O
activation NN NN O
domain NN NN O
in NN NN O
addition NN NN O
to NN NN O
the NN NN O
HMG NN NN O
domain NN NN O
. NN NN O
   
Phosphorylation NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
NFATp NN NN B-Protein
inhibits NN NN O
its NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
in NN NN O
cyclosporin NN NN O
A NN NN O
- NN NN O
treated NN NN O
human NN NN O
B NN NN O
and NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Cyclosporin NN NN O
A NN NN O
( NN NN O
CsA NN NN O
) NN NN O
exerts NN NN O
its NN NN O
immunosuppressive NN NN O
effect NN NN O
by NN NN O
inhibiting NN NN O
the NN NN O
activity NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
( NN NN O
NFAT NN NN O
) NN NN O
, NN NN O
thus NN NN O
preventing NN NN O
transcriptional NN NN O
induction NN NN O
of NN NN O
several NN NN O
cytokine NN NN O
genes NN NN O
. NN NN O
   
This NN NN O
effect NN NN O
is NN NN O
thought NN NN O
to NN NN O
be NN NN O
largely NN NN O
mediated NN NN O
through NN NN O
inactivation NN NN O
of NN NN O
the NN NN O
phosphatase NN NN O
calcineurin NN NN O
, NN NN O
which NN NN O
in NN NN O
turn NN NN O
inhibits NN NN O
translocation NN NN O
of NN NN O
an NN NN O
NFAT NN NN O
component NN NN O
to NN NN O
the NN NN O
nucleus NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
report NN NN O
that NN NN O
CsA NN NN O
treatment NN NN O
of NN NN O
Raji NN NN O
B NN NN O
and NN NN O
Jurkat NN NN O
T NN NN O
cell NN NN O
lines NN NN O
yields NN NN O
a NN NN O
phosphorylated NN NN O
form NN NN O
of NN NN O
NFATp NN NN B-Protein
that NN NN O
is NN NN O
inhibited NN NN O
in NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
and NN NN O
in NN NN O
its NN NN O
ability NN NN O
to NN NN O
form NN NN O
an NN NN O
NFAT NN NN O
complex NN NN O
with NN NN O
Fos NN NN O
and NN NN O
Jun NN NN O
. NN NN O
   
Immunoblot NN NN O
analyses NN NN O
and NN NN O
metabolic NN NN O
labeling NN NN O
with NN NN O
[ NN NN O
32P NN NN O
] NN NN O
orthophosphate NN NN O
show NN NN O
that NN NN O
CsA NN NN O
alters NN NN O
NFATp NN NN B-Protein
migration NN NN O
on NN NN O
SDS NN NN O
- NN NN O
polyacrylamide NN NN O
gel NN NN O
electrophoresis NN NN O
by NN NN O
increasing NN NN O
its NN NN O
phosphorylation NN NN O
level NN NN O
without NN NN O
affecting NN NN O
subcellular NN NN O
distribution NN NN O
. NN NN O
   
Dephosphorylation NN NN O
by NN NN O
in NN NN O
vitro NN NN O
treatment NN NN O
with NN NN O
calcineurin NN NN O
or NN NN O
alkaline NN NN B-Protein
phosphatase NN NN I-Protein
restores NN NN O
NFATp NN NN B-Protein
DNA NN NN O
binding NN NN O
activity NN NN O
and NN NN O
its NN NN O
ability NN NN O
to NN NN O
reconstitute NN NN O
an NN NN O
NFAT NN NN O
complex NN NN O
with NN NN O
Fos NN NN O
and NN NN O
Jun NN NN O
proteins NN NN O
. NN NN O
   
These NN NN O
data NN NN O
point NN NN O
to NN NN O
a NN NN O
new NN NN O
mechanism NN NN O
for NN NN O
CsA NN NN O
- NN NN O
sensitive NN NN O
regulation NN NN O
of NN NN O
NFATp NN NN B-Protein
in NN NN O
which NN NN O
dephosphorylation NN NN O
is NN NN O
critical NN NN O
for NN NN O
DNA NN NN O
binding NN NN O
. NN NN O
   
Disruption NN NN O
of NN NN O
a NN NN O
GATA NN NN O
motif NN NN O
in NN NN O
the NN NN O
Duffy NN NN B-Protein
gene NN NN O
promoter NN NN O
abolishes NN NN O
erythroid NN NN O
gene NN NN O
expression NN NN O
in NN NN O
Duffy NN NN B-Protein
- NN NN O
negative NN NN O
individuals NN NN O
. NN NN O
   
The NN NN O
mRNA NN NN O
for NN NN O
the NN NN O
Duffy NN NN B-Protein
blood NN NN O
group NN NN O
antigen NN NN O
, NN NN O
the NN NN O
erythrocyte NN NN O
receptor NN NN O
for NN NN O
the NN NN O
Plasmodium NN NN O
vivax NN NN O
malaria NN NN O
parasite NN NN O
, NN NN O
has NN NN O
recently NN NN O
been NN NN O
cloned NN NN O
and NN NN O
shown NN NN O
to NN NN O
encode NN NN O
a NN NN O
widely NN NN O
expressed NN NN O
chemokine NN NN O
receptor NN NN O
. NN NN O
   
Here NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
the NN NN O
Duffy NN NN B-Protein
antigen NN NN I-Protein
/ NN NN I-Protein
chemokine NN NN I-Protein
receptor NN NN I-Protein
gene NN NN O
( NN NN O
DARC NN NN B-Protein
) NN NN O
is NN NN O
composed NN NN O
of NN NN O
a NN NN O
single NN NN O
exon NN NN O
and NN NN O
that NN NN O
most NN NN O
Duffy NN NN B-Protein
- NN NN O
negative NN NN O
blacks NN NN O
carry NN NN O
a NN NN O
silent NN NN O
FY NN NN B-Protein
* NN NN I-Protein
B NN NN I-Protein
allele NN NN O
with NN NN O
a NN NN O
single NN NN O
T NN NN O
to NN NN O
C NN NN O
substitution NN NN O
at NN NN O
nucleotide NN NN O
- NN NN O
46 NN NN O
. NN NN O
   
This NN NN O
mutation NN NN O
impairs NN NN O
the NN NN O
promoter NN NN O
activity NN NN O
in NN NN O
erythroid NN NN O
cells NN NN O
by NN NN O
disrupting NN NN O
a NN NN O
binding NN NN O
site NN NN O
for NN NN O
the NN NN O
GATA1 NN NN B-Protein
erythroid NN NN O
transcription NN NN O
factor NN NN O
. NN NN O
   
With NN NN O
the NN NN O
recent NN NN O
characterization NN NN O
of NN NN O
the NN NN O
FY NN NN B-Protein
* NN NN I-Protein
A NN NN I-Protein
and NN NN O
FY NN NN B-Protein
* NN NN I-Protein
B NN NN I-Protein
alleles NN NN O
, NN NN O
these NN NN O
findings NN NN O
provide NN NN O
the NN NN O
molecular NN NN O
basis NN NN O
of NN NN O
the NN NN O
Duffy NN NN B-Protein
blood NN NN O
group NN NN O
system NN NN O
and NN NN O
an NN NN O
explanation NN NN O
for NN NN O
the NN NN O
erythroid NN NN O
- NN NN O
specific NN NN O
repression NN NN O
of NN NN O
the NN NN O
DARC NN NN B-Protein
gene NN NN O
in NN NN O
Duffy NN NN B-Protein
- NN NN O
negative NN NN O
individuals NN NN O
. NN NN O
   
Nonradioactive NN NN O
quantification NN NN O
of NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
expression NN NN O
during NN NN O
differentiation NN NN O
of NN NN O
human NN NN O
monocytic NN NN O
cells NN NN O
( NN NN O
U937 NN NN O
) NN NN O
. NN NN O
   
We NN NN O
describe NN NN O
a NN NN O
method NN NN O
for NN NN O
relative NN NN O
quantification NN NN O
of NN NN O
specific NN NN O
mRNA NN NN O
using NN NN O
a NN NN O
nonradioactive NN NN O
assay NN NN O
based NN NN O
on NN NN O
DNA NN NN O
strand NN NN O
competition NN NN O
between NN NN O
identical NN NN O
sequences NN NN O
of NN NN O
biotin NN NN O
- NN NN O
and NN NN O
fluorescein NN NN O
- NN NN O
labeled NN NN O
amplicon NN NN O
( NN NN O
probe NN NN O
) NN NN O
and NN NN O
unlabeled NN NN O
amplicon NN NN O
( NN NN O
target NN NN O
) NN NN O
during NN NN O
hybridization NN NN O
. NN NN O
   
As NN NN O
the NN NN O
target NN NN O
quantity NN NN O
increased NN NN O
, NN NN O
that NN NN O
of NN NN O
the NN NN O
double NN NN O
- NN NN O
labeled NN NN O
probe NN NN O
decreased NN NN O
in NN NN O
accordance NN NN O
with NN NN O
the NN NN O
mass NN NN O
action NN NN O
law NN NN O
. NN NN O
   
This NN NN O
technique NN NN O
was NN NN O
successfully NN NN O
applied NN NN O
to NN NN O
evaluate NN NN O
differences NN NN O
in NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
expression NN NN O
in NN NN O
U937 NN NN O
cells NN NN O
before NN NN O
and NN NN O
after NN NN O
the NN NN O
addition NN NN O
of NN NN O
potent NN NN O
differentiation NN NN O
inducers NN NN O
: NN NN O
12 NN NN O
- NN NN O
O NN NN O
- NN NN O
tetradecanoylphorbol NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
( NN NN O
TPA NN NN O
) NN NN O
and NN NN O
a NN NN O
combination NN NN O
of NN NN O
all NN NN O
- NN NN O
trans NN NN O
retinoic NN NN O
acid NN NN O
( NN NN O
RA NN NN O
) NN NN O
and NN NN O
1 NN NN O
, NN NN O
25 NN NN O
- NN NN O
dihydroxyvitamin NN NN O
D2 NN NN O
( NN NN O
VD NN NN O
) NN NN O
. NN NN O
   
We NN NN O
observed NN NN O
that NN NN O
TPA NN NN O
treatment NN NN O
was NN NN O
associated NN NN O
with NN NN O
an NN NN O
increase NN NN O
in NN NN O
specific NN NN O
binding NN NN O
of NN NN O
[ NN NN O
3H NN NN O
] NN NN O
dexamethasone NN NN O
and NN NN O
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
GR NN NN B-Protein
mRNA NN NN O
while NN NN O
no NN NN O
enhanced NN NN O
GR NN NN B-Protein
expression NN NN O
was NN NN O
perceived NN NN O
with NN NN O
RA NN NN O
/ NN NN O
VD NN NN O
treatment NN NN O
. NN NN O
   
Microtubules NN NN O
mediate NN NN O
cellular NN NN O
25 NN NN O
- NN NN O
hydroxyvitamin NN NN O
D3 NN NN O
trafficking NN NN O
and NN NN O
the NN NN O
genomic NN NN O
response NN NN O
to NN NN O
1 NN NN O
, NN NN O
25 NN NN O
- NN NN O
dihydroxyvitamin NN NN O
D3 NN NN O
in NN NN O
normal NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
The NN NN O
genomic NN NN O
actions NN NN O
of NN NN O
1 NN NN O
, NN NN O
25 NN NN O
- NN NN O
dihydroxyvitamin NN NN O
D3 NN NN O
( NN NN O
1 NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
) NN NN O
are NN NN O
mediated NN NN O
by NN NN O
the NN NN O
intracellular NN NN O
vitamin NN NN B-Protein
D NN NN I-Protein
receptor NN NN I-Protein
( NN NN O
VDR NN NN B-Protein
) NN NN O
. NN NN O
   
Although NN NN O
immunocytochemistry NN NN O
has NN NN O
shown NN NN O
that NN NN O
disruption NN NN O
of NN NN O
microtubular NN NN O
assembly NN NN O
prevents NN NN O
nuclear NN NN O
access NN NN O
of NN NN O
the NN NN O
sterol NN NN O
- NN NN O
VDR NN NN B-Protein
complex NN NN O
, NN NN O
the NN NN O
role NN NN O
of NN NN O
microtubules NN NN O
in NN NN O
the NN NN O
response NN NN O
to NN NN O
1 NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
has NN NN O
not NN NN O
been NN NN O
studied NN NN O
in NN NN O
viable NN NN O
cells NN NN O
. NN NN O
   
Our NN NN O
studies NN NN O
examined NN NN O
this NN NN O
interaction NN NN O
in NN NN O
normal NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
Monocytes NN NN O
convert NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
D3 NN NN O
to NN NN O
1 NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
and NN NN O
to NN NN O
24 NN NN O
- NN NN O
hydroxylated NN NN O
metabolites NN NN O
more NN NN O
polar NN NN O
than NN NN O
1 NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
. NN NN O
   
Microtubule NN NN O
disruption NN NN O
totally NN NN O
abolished NN NN O
the NN NN O
ability NN NN O
of NN NN O
exogenous NN NN O
1 NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
to NN NN O
suppress NN NN O
its NN NN O
own NN NN O
synthesis NN NN O
and NN NN O
to NN NN O
induce NN NN O
24 NN NN O
- NN NN O
hydroxylase NN NN O
mRNA NN NN O
and NN NN O
activity NN NN O
, NN NN O
without NN NN O
affecting NN NN O
either NN NN O
total NN NN O
1 NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
uptake NN NN O
or NN NN O
maximal NN NN O
1 NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
- NN NN O
VDR NN NN B-Protein
binding NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
intact NN NN O
microtubules NN NN O
are NN NN O
essential NN NN O
for NN NN O
1 NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
- NN NN O
dependent NN NN O
modulation NN NN O
of NN NN O
gene NN NN O
transcription NN NN O
. NN NN O
   
Interestingly NN NN O
, NN NN O
microtubule NN NN O
disruption NN NN O
also NN NN O
decreased NN NN O
monocyte NN NN O
1 NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
synthesis NN NN O
, NN NN O
not NN NN O
by NN NN O
decreasing NN NN O
the NN NN O
Vmax NN NN O
of NN NN O
monocyte NN NN O
mitochondrial NN NN O
1 NN NN O
alpha NN NN O
- NN NN O
hydroxylase NN NN O
but NN NN O
through NN NN O
an NN NN O
increase NN NN O
in NN NN O
the NN NN O
Km NN NN O
for NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
. NN NN O
   
We NN NN O
examined NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
D3 NN NN O
transport NN NN O
. NN NN O
   
Microtubule NN NN O
disruption NN NN O
did NN NN O
not NN NN O
affect NN NN O
total NN NN O
cellular NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
D3 NN NN O
uptake NN NN O
but NN NN O
reduced NN NN O
its NN NN O
intracellular NN NN O
trafficking NN NN O
to NN NN O
the NN NN O
mitochondria NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
microtubules NN NN O
participate NN NN O
in NN NN O
intracellular NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
D3 NN NN O
transport NN NN O
, NN NN O
and NN NN O
their NN NN O
integrity NN NN O
determines NN NN O
normal NN NN O
1 NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
synthesis NN NN O
. NN NN O
   
The NN NN O
zinc NN NN O
finger NN NN O
transcription NN NN O
factor NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
is NN NN O
essential NN NN O
for NN NN O
and NN NN O
restricts NN NN O
differentiation NN NN O
along NN NN O
the NN NN O
macrophage NN NN O
lineage NN NN O
. NN NN O
   
We NN NN O
have NN NN O
isolated NN NN O
cDNA NN NN O
clones NN NN O
of NN NN O
myeloid NN NN O
differentiation NN NN O
primary NN NN O
response NN NN O
( NN NN O
MyD NN NN O
) NN NN O
genes NN NN O
, NN NN O
activated NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
de NN NN O
novo NN NN O
protein NN NN O
synthesis NN NN O
following NN NN O
induction NN NN O
for NN NN O
differentiation NN NN O
along NN NN O
either NN NN O
the NN NN O
macrophage NN NN O
or NN NN O
granulocyte NN NN O
lineage NN NN O
in NN NN O
human NN NN O
myeloblastic NN NN O
leukemia NN NN O
HL NN NN O
- NN NN O
60 NN NN O
cells NN NN O
. NN NN O
   
One NN NN O
cDNA NN NN O
clone NN NN O
of NN NN O
a NN NN O
primary NN NN O
response NN NN O
gene NN NN O
, NN NN O
expressed NN NN O
upon NN NN O
macrophage NN NN O
differentiation NN NN O
, NN NN O
encoded NN NN O
for NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
a NN NN O
zinc NN NN O
finger NN NN O
transcription NN NN O
factor NN NN O
. NN NN O
   
The NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
was NN NN O
observed NN NN O
to NN NN O
be NN NN O
transcriptionally NN NN O
silent NN NN O
in NN NN O
HL NN NN O
- NN NN O
60 NN NN O
cells NN NN O
, NN NN O
but NN NN O
active NN NN O
in NN NN O
U NN NN O
- NN NN O
937 NN NN O
and NN NN O
M1 NN NN O
cells NN NN O
, NN NN O
the NN NN O
latter NN NN O
two NN NN O
being NN NN O
predetermined NN NN O
for NN NN O
macrophage NN NN O
differentiation NN NN O
. NN NN O
   
Egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
antisense NN NN O
oligomers NN NN O
in NN NN O
the NN NN O
culture NN NN O
media NN NN O
blocked NN NN O
macrophage NN NN O
differentiation NN NN O
in NN NN O
both NN NN O
myeloid NN NN O
leukemia NN NN O
cell NN NN O
lines NN NN O
and NN NN O
normal NN NN O
myeloblasts NN NN O
. NN NN O
   
HL NN NN O
- NN NN O
60 NN NN O
cells NN NN O
constitutively NN NN O
expressing NN NN O
an NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
transgene NN NN O
( NN NN O
HL NN NN O
- NN NN O
60Egr NN NN O
- NN NN O
1 NN NN O
) NN NN O
could NN NN O
be NN NN O
induced NN NN O
for NN NN O
macrophage NN NN O
, NN NN O
but NN NN O
not NN NN O
granulocyte NN NN O
, NN NN O
differentiation NN NN O
. NN NN O
   
These NN NN O
observations NN NN O
indicate NN NN O
that NN NN O
expression NN NN O
of NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
is NN NN O
essential NN NN O
for NN NN O
and NN NN O
restricts NN NN O
differentiation NN NN O
of NN NN O
myeloblasts NN NN O
along NN NN O
the NN NN O
macrophage NN NN O
lineage NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
tal NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
GATA NN NN O
- NN NN O
binding NN NN O
proteins NN NN O
during NN NN O
human NN NN O
hematopoiesis NN NN O
. NN NN O
   
Tal NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
rearrangements NN NN O
are NN NN O
associated NN NN O
with NN NN O
nearly NN NN O
30 NN NN O
% NN NN O
of NN NN O
human NN NN O
T NN NN O
acute NN NN O
lymphoblastic NN NN O
leukemia NN NN O
. NN NN O
   
Tal NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
encodes NN NN O
a NN NN O
putative NN NN O
transcription NN NN O
factor NN NN O
with NN NN O
a NN NN O
basic NN NN O
helix NN NN O
- NN NN O
loop NN NN O
- NN NN O
helix NN NN O
domain NN NN O
and NN NN O
is NN NN O
known NN NN O
to NN NN O
be NN NN O
predominantly NN NN O
expressed NN NN O
in NN NN O
hematopoietic NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
investigated NN NN O
the NN NN O
pattern NN NN O
of NN NN O
tal NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
in NN NN O
purified NN NN O
human NN NN O
hematopoietic NN NN O
cells NN NN O
by NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
and NN NN O
reverse NN NN O
transcriptase NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
analysis NN NN O
. NN NN O
   
Both NN NN O
methods NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
tal NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
is NN NN O
expressed NN NN O
in NN NN O
megakaryocytes NN NN O
and NN NN O
erythroblasts NN NN O
as NN NN O
well NN NN O
as NN NN O
in NN NN O
basophilic NN NN O
granulocytes NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
our NN NN O
results NN NN O
indicate NN NN O
that NN NN O
the NN NN O
tal NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
1A NN NN O
promoter NN NN O
, NN NN O
which NN NN O
contains NN NN O
two NN NN O
consensus NN NN O
GATA NN NN O
- NN NN O
binding NN NN O
sites NN NN O
, NN NN O
is NN NN O
active NN NN O
mainly NN NN O
in NN NN O
these NN NN O
lineages NN NN O
. NN NN O
   
Because NN NN O
the NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
is NN NN O
known NN NN O
to NN NN O
transactivate NN NN O
several NN NN O
genes NN NN O
specific NN NN O
for NN NN O
the NN NN O
erythroid NN NN O
, NN NN O
megakaryocytic NN NN O
, NN NN O
and NN NN O
mastocytic NN NN O
/ NN NN O
basophilic NN NN O
lineages NN NN O
, NN NN O
we NN NN O
studied NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
in NN NN O
these NN NN O
purified NN NN O
hematopoietic NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
found NN NN O
that NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
tal NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
genes NN NN O
are NN NN O
coexpressed NN NN O
in NN NN O
these NN NN O
three NN NN O
lineages NN NN O
. NN NN O
   
Remarkably NN NN O
, NN NN O
the NN NN O
expression NN NN O
of NN NN O
both NN NN O
genes NN NN O
is NN NN O
downmodulated NN NN O
during NN NN O
erythroid NN NN O
and NN NN O
megakaryocytic NN NN O
terminal NN NN O
maturation NN NN O
. NN NN O
   
In NN NN O
immature NN NN O
hematopoietic NN NN O
cells NN NN O
, NN NN O
tal NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
genes NN NN O
are NN NN O
coexpressed NN NN O
in NN NN O
committed NN NN O
progenitors NN NN O
cells NN NN O
( NN NN O
CD34 NN NN B-Protein
+ NN NN O
/ NN NN O
CD38 NN NN B-Protein
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
) NN NN O
, NN NN O
whereas NN NN O
they NN NN O
are NN NN O
not NN NN O
detectable NN NN O
in NN NN O
the NN NN O
most NN NN O
primitive NN NN O
cells NN NN O
( NN NN O
CD34 NN NN B-Protein
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
/ NN NN O
CD38 NN NN B-Protein
- NN NN O
) NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
is NN NN O
strongly NN NN O
expressed NN NN O
in NN NN O
both NN NN O
most NN NN O
primitive NN NN O
and NN NN O
committed NN NN O
progenitors NN NN O
cells NN NN O
, NN NN O
whereas NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
is NN NN O
mostly NN NN O
detected NN NN O
in NN NN O
most NN NN O
primitive NN NN O
ones NN NN O
. NN NN O
   
Altogether NN NN O
our NN NN O
results NN NN O
strongly NN NN O
suggest NN NN O
that NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
modulates NN NN O
the NN NN O
transcription NN NN O
of NN NN O
tal NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
during NN NN O
the NN NN O
differentiation NN NN O
of NN NN O
the NN NN O
erythroid NN NN O
, NN NN O
megakaryocytic NN NN O
, NN NN O
and NN NN O
basosophilic NN NN O
lineages NN NN O
. NN NN O
   
Cell NN NN O
type NN NN O
- NN NN O
and NN NN O
stage NN NN O
- NN NN O
specific NN NN O
expression NN NN O
of NN NN O
the NN NN O
CD20 NN NN B-Protein
/ NN NN O
B1 NN NN B-Protein
antigen NN NN O
correlates NN NN O
with NN NN O
the NN NN O
activity NN NN O
of NN NN O
a NN NN O
diverged NN NN O
octamer NN NN O
DNA NN NN O
motif NN NN O
present NN NN O
in NN NN O
its NN NN O
promoter NN NN O
. NN NN O
   
The NN NN O
CD20 NN NN B-Protein
( NN NN O
B1 NN NN B-Protein
) NN NN O
gene NN NN O
encodes NN NN O
a NN NN O
B NN NN O
cell NN NN O
- NN NN O
specific NN NN O
protein NN NN O
involved NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
human NN NN O
B NN NN O
cell NN NN O
proliferation NN NN O
and NN NN O
differentiation NN NN O
. NN NN O
   
Studies NN NN O
with NN NN O
5 NN NN O
' NN NN O
deletion NN NN O
CD20 NN NN B-Protein
promoter NN NN O
- NN NN O
CAT NN NN B-Protein
constructs NN NN O
have NN NN O
previously NN NN O
revealed NN NN O
two NN NN O
regions NN NN O
of NN NN O
the NN NN O
promoter NN NN O
between NN NN O
bases NN NN O
- NN NN O
186 NN NN O
and NN NN O
- NN NN O
280 NN NN O
and NN NN O
between NN NN O
bases NN NN O
- NN NN O
280 NN NN O
and NN NN O
- NN NN O
454 NN NN O
which NN NN O
contained NN NN O
positive NN NN O
regulatory NN NN O
elements NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
we NN NN O
identified NN NN O
a NN NN O
sequence NN NN O
element NN NN O
present NN NN O
in NN NN O
the NN NN O
most NN NN O
proximal NN NN O
region NN NN O
located NN NN O
between NN NN O
bases NN NN O
- NN NN O
214 NN NN O
and NN NN O
- NN NN O
201 NN NN O
, NN NN O
TTCTTCTAATTAA NN NN O
, NN NN O
which NN NN O
is NN NN O
important NN NN O
in NN NN O
the NN NN O
high NN NN O
constitutive NN NN O
expression NN NN O
of NN NN O
CD20 NN NN B-Protein
in NN NN O
mature NN NN O
B NN NN O
cells NN NN O
and NN NN O
the NN NN O
induction NN NN O
of NN NN O
CD20 NN NN B-Protein
in NN NN O
pre NN NN O
- NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
This NN NN O
sequence NN NN O
element NN NN O
was NN NN O
referred NN NN O
to NN NN O
as NN NN O
the NN NN O
BAT NN NN O
box NN NN O
and NN NN O
its NN NN O
deletion NN NN O
significantly NN NN O
reduced NN NN O
the NN NN O
activity NN NN O
of NN NN O
a NN NN O
CD20 NN NN B-Protein
promoter NN NN O
- NN NN O
CAT NN NN B-Protein
construct NN NN O
in NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
Mobility NN NN O
shift NN NN O
assays NN NN O
with NN NN O
various NN NN O
mutant NN NN O
probes NN NN O
and NN NN O
B NN NN O
cell NN NN O
nuclear NN NN O
extracts NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
core NN NN O
sequence NN NN O
TAAT NN NN O
was NN NN O
essential NN NN O
for NN NN O
binding NN NN O
to NN NN O
this NN NN O
site NN NN O
. NN NN O
   
Cross NN NN O
competition NN NN O
experiments NN NN O
with NN NN O
an NN NN O
octamer NN NN O
sequence NN NN O
from NN NN O
the NN NN O
Ig NN NN O
heavy NN NN O
chain NN NN O
promoter NN NN O
, NN NN O
the NN NN O
BAT NN NN O
box NN NN O
, NN NN O
and NN NN O
a NN NN O
TA NN NN O
- NN NN O
rich NN NN O
sequence NN NN O
present NN NN O
in NN NN O
the NN NN O
CD21 NN NN B-Protein
promoter NN NN O
revealed NN NN O
that NN NN O
all NN NN O
three NN NN O
sequences NN NN O
bound NN NN O
the NN NN O
same NN NN O
nuclear NN NN O
proteins NN NN O
suggesting NN NN O
that NN NN O
the NN NN O
BAT NN NN O
box NN NN O
binding NN NN O
proteins NN NN O
were NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
Southwestern NN NN O
blotting NN NN O
and NN NN O
UV NN NN O
cross NN NN O
- NN NN O
linking NN NN O
studies NN NN O
confirmed NN NN O
that NN NN O
the NN NN O
BAT NN NN O
box NN NN O
binding NN NN O
proteins NN NN O
were NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
The NN NN O
affinity NN NN O
of NN NN O
the NN NN O
BAT NN NN O
box NN NN O
binding NN NN O
proteins NN NN O
for NN NN O
the NN NN O
BAT NN NN O
box NN NN O
was NN NN O
approximately NN NN O
25 NN NN O
- NN NN O
fold NN NN O
less NN NN O
than NN NN O
for NN NN O
the NN NN O
octamer NN NN O
sequence NN NN O
and NN NN O
the NN NN O
BAT NN NN O
box NN NN O
binding NN NN O
proteins NN NN O
dissociated NN NN O
from NN NN O
the NN NN O
BAT NN NN O
box NN NN O
10 NN NN O
- NN NN O
fold NN NN O
more NN NN O
rapidly NN NN O
than NN NN O
from NN NN O
the NN NN O
octamer NN NN O
sequence NN NN O
. NN NN O
   
Despite NN NN O
this NN NN O
lower NN NN O
affinity NN NN O
, NN NN O
a NN NN O
trimer NN NN O
of NN NN O
the NN NN O
BAT NN NN O
box NN NN O
sequence NN NN O
was NN NN O
as NN NN O
efficiently NN NN O
transactivated NN NN O
by NN NN O
an NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
vector NN NN O
as NN NN O
was NN NN O
a NN NN O
trimer NN NN O
of NN NN O
the NN NN O
octamer NN NN O
sequence NN NN O
in NN NN O
HeLa NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
BAT NN NN O
box NN NN O
and NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
were NN NN O
also NN NN O
implicated NN NN O
in NN NN O
the NN NN O
induction NN NN O
of NN NN O
CD20 NN NN B-Protein
in NN NN O
the NN NN O
pre NN NN O
- NN NN O
B NN NN O
cell NN NN O
line NN NN O
, NN NN O
PB NN NN O
- NN NN O
697 NN NN O
, NN NN O
via NN NN O
phorbol NN NN O
esters NN NN O
. NN NN O
   
The NN NN O
induction NN NN O
of NN NN O
CD20 NN NN B-Protein
mRNA NN NN O
was NN NN O
temporally NN NN O
associated NN NN O
with NN NN O
induction NN NN O
of NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
mRNA NN NN O
and NN NN O
a NN NN O
BAT NN NN O
box NN NN O
- NN NN O
deleted NN NN O
CD20 NN NN B-Protein
- NN NN O
CAT NN NN O
construct NN NN O
, NN NN O
in NN NN O
contrast NN NN O
to NN NN O
the NN NN O
wild NN NN O
type NN NN O
, NN NN O
was NN NN O
poorly NN NN O
induced NN NN O
by NN NN O
phorbol NN NN O
esters NN NN O
. NN NN O
   
Together NN NN O
these NN NN O
results NN NN O
suggest NN NN O
that NN NN O
the NN NN O
BAT NN NN O
box NN NN O
binding NN NN O
proteins NN NN O
are NN NN O
important NN NN O
in NN NN O
the NN NN O
B NN NN O
cell NN NN O
specific NN NN O
expression NN NN O
of NN NN O
CD20 NN NN B-Protein
and NN NN O
perhaps NN NN O
CD21 NN NN B-Protein
. NN NN O
   
A NN NN O
mutation NN NN O
of NN NN O
the NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
in NN NN O
primary NN NN O
cortisol NN NN O
resistance NN NN O
. NN NN O
   
The NN NN O
precise NN NN O
molecular NN NN O
abnormalities NN NN O
that NN NN O
cause NN NN O
primary NN NN O
cortisol NN NN O
resistance NN NN O
have NN NN O
not NN NN O
been NN NN O
completely NN NN O
described NN NN O
. NN NN O
   
In NN NN O
a NN NN O
subject NN NN O
with NN NN O
primary NN NN O
cortisol NN NN O
resistance NN NN O
we NN NN O
have NN NN O
observed NN NN O
glucocorticoid NN NN B-Protein
receptors NN NN I-Protein
( NN NN O
hGR NN NN B-Protein
) NN NN O
with NN NN O
a NN NN O
decreased NN NN O
affinity NN NN O
for NN NN O
dexamethasone NN NN O
. NN NN O
   
We NN NN O
hypothesize NN NN O
that NN NN O
a NN NN O
mutation NN NN O
of NN NN O
the NN NN O
hGR NN NN B-Protein
glucocorticoid NN NN O
- NN NN O
binding NN NN O
domain NN NN O
is NN NN O
the NN NN O
cause NN NN O
of NN NN O
cortisol NN NN O
resistance NN NN O
. NN NN O
   
Total NN NN O
RNA NN NN O
isolated NN NN O
from NN NN O
the NN NN O
index NN NN O
subject NN NN O
' NN NN O
s NN NN O
mononuclear NN NN O
leukocytes NN NN O
was NN NN O
used NN NN O
to NN NN O
produce NN NN O
first NN NN O
strand NN NN O
hGR NN NN B-Protein
cDNAs NN NN O
, NN NN O
and NN NN O
the NN NN O
entire NN NN O
hGR NN NN B-Protein
cDNA NN NN O
was NN NN O
amplified NN NN O
in NN NN O
segments NN NN O
and NN NN O
sequenced NN NN O
. NN NN O
   
At NN NN O
nucleotide NN NN O
2 NN NN O
, NN NN O
317 NN NN O
we NN NN O
identified NN NN O
a NN NN O
homozygous NN NN O
A NN NN O
for NN NN O
G NN NN O
point NN NN O
mutation NN NN O
that NN NN O
predicts NN NN O
an NN NN O
isoleucine NN NN O
( NN NN O
ATT NN NN O
) NN NN O
for NN NN O
valine NN NN O
( NN NN O
GTT NN NN O
) NN NN O
substitution NN NN O
at NN NN O
amino NN NN O
acid NN NN O
729 NN NN O
. NN NN O
   
When NN NN O
the NN NN O
wild NN NN O
- NN NN O
type NN NN O
hGR NN NN B-Protein
and NN NN O
hGR NN NN B-Protein
- NN NN O
Ile NN NN O
729 NN NN O
were NN NN O
expressed NN NN O
in NN NN O
COS NN NN O
- NN NN O
1 NN NN O
cells NN NN O
and NN NN O
assayed NN NN O
for NN NN O
[ NN NN O
3H NN NN O
] NN NN O
- NN NN O
Dexamethasone NN NN O
binding NN NN O
, NN NN O
the NN NN O
dissociation NN NN O
constants NN NN O
were NN NN O
0 NN NN O
. NN NN O
799 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
068 NN NN O
and NN NN O
1 NN NN O
. NN NN O
54 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
06 NN NN O
nM NN NN O
( NN NN O
mean NN NN O
+ NN NN O
/ NN NN O
- NN NN O
SEM NN NN O
) NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
When NN NN O
the NN NN O
wild NN NN O
- NN NN O
type NN NN O
hGR NN NN B-Protein
and NN NN O
hGR NN NN B-Protein
- NN NN O
Ile NN NN O
729 NN NN O
were NN NN O
expressed NN NN O
in NN NN O
CV NN NN O
- NN NN O
1 NN NN O
cells NN NN O
that NN NN O
were NN NN O
cotransfected NN NN O
with NN NN O
the NN NN O
mouse NN NN O
mammary NN NN O
tumor NN NN O
virus NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
fused NN NN O
to NN NN O
the NN NN O
chloramphenicol NN NN B-Protein
acetyl NN NN I-Protein
transferase NN NN I-Protein
( NN NN O
CAT NN NN B-Protein
) NN NN O
gene NN NN O
, NN NN O
the NN NN O
hGR NN NN B-Protein
- NN NN O
Ile NN NN O
729 NN NN O
conferred NN NN O
a NN NN O
fourfold NN NN O
decrease NN NN O
in NN NN O
apparent NN NN O
potency NN NN O
on NN NN O
dexamethasone NN NN O
stimulation NN NN O
of NN NN O
CAT NN NN B-Protein
activity NN NN O
. NN NN O
   
The NN NN O
isoleucine NN NN O
for NN NN O
valine NN NN O
substitution NN NN O
at NN NN O
amino NN NN O
acid NN NN O
729 NN NN O
impairs NN NN O
the NN NN O
function NN NN O
of NN NN O
the NN NN O
hGR NN NN B-Protein
and NN NN O
is NN NN O
the NN NN O
likely NN NN O
cause NN NN O
of NN NN O
primary NN NN O
cortisol NN NN O
resistance NN NN O
in NN NN O
this NN NN O
subject NN NN O
. NN NN O
   
FK506 NN NN O
and NN NN O
ciclosporin NN NN O
: NN NN O
molecular NN NN O
probes NN NN O
for NN NN O
studying NN NN O
intracellular NN NN O
signal NN NN O
transduction NN NN O
. NN NN O
   
The NN NN O
immunosuppressants NN NN O
ciclosporin NN NN O
and NN NN O
FK506 NN NN O
block NN NN O
the NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
- NN NN O
dependent NN NN O
signal NN NN O
- NN NN O
transduction NN NN O
pathway NN NN O
emanating NN NN O
from NN NN O
the NN NN O
T NN NN O
- NN NN O
cell NN NN O
receptor NN NN O
, NN NN O
thereby NN NN O
inhibiting NN NN O
the NN NN O
activation NN NN O
of NN NN O
helper NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Using NN NN O
these NN NN O
drugs NN NN O
as NN NN O
probes NN NN O
, NN NN O
chemists NN NN O
and NN NN O
biologists NN NN O
have NN NN O
uncovered NN NN O
several NN NN O
intracellular NN NN O
signalling NN NN O
molecules NN NN O
bridging NN NN O
the NN NN O
generation NN NN O
of NN NN O
second NN NN O
- NN NN O
messenger NN NN O
Ca2 NN NN O
+ NN NN O
ions NN NN O
and NN NN O
the NN NN O
transcriptional NN NN O
activation NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
among NN NN O
which NN NN O
are NN NN O
calmodulin NN NN B-Protein
, NN NN O
calcineurin NN NN O
and NN NN O
the NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
( NN NN O
NF NN NN O
- NN NN O
AT NN NN O
) NN NN O
. NN NN O
   
Hence NN NN O
, NN NN O
Ca2 NN NN O
+ NN NN O
binds NN NN O
to NN NN O
calmodulin NN NN B-Protein
, NN NN O
leading NN NN O
to NN NN O
the NN NN O
binding NN NN O
of NN NN O
calmodulin NN NN B-Protein
to NN NN O
calcineurin NN NN O
; NN NN O
the NN NN O
activated NN NN O
calcineurin NN NN O
, NN NN O
in NN NN O
turn NN NN O
, NN NN O
may NN NN O
dephosphorylate NN NN O
the NN NN O
cytoplasmic NN NN O
subunit NN NN O
of NN NN O
NF NN NN O
- NN NN O
AT NN NN O
, NN NN O
resulting NN NN O
in NN NN O
its NN NN O
translocation NN NN O
from NN NN O
the NN NN O
cytoplasm NN NN O
into NN NN O
the NN NN O
nucleus NN NN O
to NN NN O
form NN NN O
a NN NN O
competent NN NN O
transcriptional NN NN O
activator NN NN O
. NN NN O
   
As NN NN O
described NN NN O
by NN NN O
Jun NN NN O
Liu NN NN O
, NN NN O
these NN NN O
drugs NN NN O
manifest NN NN O
their NN NN O
effects NN NN O
in NN NN O
an NN NN O
unprecedented NN NN O
fashion NN NN O
. NN NN O
   
They NN NN O
do NN NN O
not NN NN O
directly NN NN O
intercept NN NN O
intracellular NN NN O
signalling NN NN O
molecules NN NN O
. NN NN O
   
Instead NN NN O
, NN NN O
they NN NN O
form NN NN O
tight NN NN O
complexes NN NN O
with NN NN O
two NN NN O
different NN NN O
classes NN NN O
of NN NN O
abundant NN NN O
cytosolic NN NN O
receptors NN NN O
called NN NN O
immunophilins NN NN O
upon NN NN O
entering NN NN O
the NN NN O
cell NN NN O
, NN NN O
and NN NN O
consequently NN NN O
inhibit NN NN O
their NN NN O
peptidyl NN NN O
prolyl NN NN O
cis NN NN O
- NN NN O
trans NN NN O
isomerase NN NN O
activities NN NN O
. NN NN O
   
The NN NN O
two NN NN O
structurally NN NN O
distinct NN NN O
immunophilin NN NN O
- NN NN O
drug NN NN O
complexes NN NN O
bind NN NN O
to NN NN O
, NN NN O
and NN NN O
inhibit NN NN O
, NN NN O
the NN NN O
phosphatase NN NN O
activity NN NN O
of NN NN O
calcineurin NN NN O
. NN NN O
   
Effects NN NN O
of NN NN O
intranasal NN NN O
glucocorticoids NN NN O
on NN NN O
endogenous NN NN O
glucocorticoid NN NN O
peripheral NN NN O
and NN NN O
central NN NN O
function NN NN O
. NN NN O
   
Glucocorticoids NN NN O
are NN NN O
among NN NN O
the NN NN O
most NN NN O
potent NN NN O
antiinflammatory NN NN O
agents NN NN O
that NN NN O
can NN NN O
be NN NN O
used NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
rhinitis NN NN O
. NN NN O
   
Their NN NN O
mechanisms NN NN O
of NN NN O
action NN NN O
are NN NN O
multiple NN NN O
and NN NN O
complex NN NN O
and NN NN O
a NN NN O
number NN NN O
of NN NN O
reports NN NN O
describe NN NN O
significant NN NN O
systemic NN NN O
effects NN NN O
of NN NN O
locally NN NN O
administered NN NN O
glucocorticoids NN NN O
. NN NN O
   
In NN NN O
order NN NN O
to NN NN O
evaluate NN NN O
the NN NN O
short NN NN O
- NN NN O
term NN NN O
systemic NN NN O
effects NN NN O
of NN NN O
intranasally NN NN O
administered NN NN O
glucocorticoids NN NN O
, NN NN O
14 NN NN O
normal NN NN O
healthy NN NN O
subjects NN NN O
were NN NN O
treated NN NN O
with NN NN O
two NN NN O
doses NN NN O
of NN NN O
either NN NN O
budesonide NN NN O
( NN NN O
BUD NN NN O
) NN NN O
or NN NN O
fluticasone NN NN O
propionate NN NN O
( NN NN O
FP NN NN O
) NN NN O
for NN NN O
2 NN NN O
weeks NN NN O
. NN NN O
   
Before NN NN O
treatment NN NN O
, NN NN O
at NN NN O
regular NN NN O
intervals NN NN O
during NN NN O
the NN NN O
treatment NN NN O
, NN NN O
1 NN NN O
week NN NN O
and NN NN O
finally NN NN O
6 NN NN O
weeks NN NN O
after NN NN O
termination NN NN O
of NN NN O
treatment NN NN O
, NN NN O
the NN NN O
effects NN NN O
on NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
( NN NN O
GR NN NN B-Protein
) NN NN O
and NN NN O
methallothionein NN NN B-Protein
( NN NN O
MTIIa NN NN B-Protein
) NN NN O
mRNA NN NN O
expression NN NN O
levels NN NN O
were NN NN O
examined NN NN O
in NN NN O
peripheral NN NN O
lymphocytes NN NN O
using NN NN O
a NN NN O
solution NN NN O
hybridization NN NN O
assay NN NN O
. NN NN O
   
Serum NN NN O
cortisol NN NN O
, NN NN O
osteocalcin NN NN B-Protein
and NN NN O
urinary NN NN O
cortisol NN NN O
levels NN NN O
were NN NN O
also NN NN O
determined NN NN O
. NN NN O
   
An NN NN O
insulin NN NN O
tolerance NN NN O
test NN NN O
( NN NN O
ITT NN NN O
) NN NN O
was NN NN O
performed NN NN O
at NN NN O
the NN NN O
end NN NN O
of NN NN O
the NN NN O
second NN NN O
week NN NN O
of NN NN O
treatment NN NN O
and NN NN O
at NN NN O
the NN NN O
end NN NN O
of NN NN O
the NN NN O
6 NN NN O
- NN NN O
week NN NN O
washout NN NN O
period NN NN O
with NN NN O
no NN NN O
statistically NN NN O
significant NN NN O
change NN NN O
in NN NN O
cortisol NN NN O
response NN NN O
. NN NN O
   
In NN NN O
peripheral NN NN O
lymphocytes NN NN O
, NN NN O
GR NN NN B-Protein
mRNA NN NN O
levels NN NN O
were NN NN O
significantly NN NN O
down NN NN O
- NN NN O
regulated NN NN O
. NN NN O
   
MTIIa NN NN B-Protein
mRNA NN NN O
levels NN NN O
increased NN NN O
significantly NN NN O
. NN NN O
   
Serum NN NN O
osteocalcin NN NN B-Protein
decreased NN NN O
significantly NN NN O
during NN NN O
treatment NN NN O
with NN NN O
both NN NN O
BUD NN NN O
and NN NN O
FP NN NN O
. NN NN O
   
Serum NN NN O
cortisol NN NN O
decreased NN NN O
after NN NN O
1 NN NN O
week NN NN O
of NN NN O
treatment NN NN O
whereas NN NN O
urinary NN NN O
cortisol NN NN O
was NN NN O
not NN NN O
affected NN NN O
until NN NN O
the NN NN O
second NN NN O
week NN NN O
of NN NN O
treatment NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
intranasal NN NN O
glucocorticoids NN NN O
at NN NN O
clinically NN NN O
recommended NN NN O
doses NN NN O
have NN NN O
not NN NN O
only NN NN O
significant NN NN O
systemic NN NN O
effects NN NN O
on NN NN O
adrenal NN NN O
function NN NN O
, NN NN O
but NN NN O
also NN NN O
have NN NN O
an NN NN O
effect NN NN O
on NN NN O
specific NN NN O
gene NN NN O
expression NN NN O
in NN NN O
peripheral NN NN O
lymphocytes NN NN O
. NN NN O
   
These NN NN O
effects NN NN O
are NN NN O
receptor NN NN O
- NN NN O
dependent NN NN O
, NN NN O
reversible NN NN O
, NN NN O
and NN NN O
according NN NN O
to NN NN O
serum NN NN O
and NN NN O
urinary NN NN O
cortisol NN NN O
levels NN NN O
and NN NN O
ITT NN NN O
, NN NN O
leave NN NN O
the NN NN O
hypothalamic NN NN O
- NN NN O
pituitary NN NN O
- NN NN O
adrenal NN NN O
function NN NN O
intact NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
these NN NN O
short NN NN O
- NN NN O
term NN NN O
systemic NN NN O
effects NN NN O
were NN NN O
not NN NN O
associated NN NN O
with NN NN O
any NN NN O
of NN NN O
the NN NN O
noticeable NN NN O
side NN NN O
- NN NN O
effects NN NN O
usually NN NN O
observed NN NN O
during NN NN O
long NN NN O
- NN NN O
term NN NN O
treatment NN NN O
with NN NN O
glucocorticoids NN NN O
. NN NN O
   
Transcriptional NN NN O
activity NN NN O
of NN NN O
core NN NN O
binding NN NN O
factor NN NN O
- NN NN O
alpha NN NN O
( NN NN O
AML1 NN NN B-Protein
) NN NN O
and NN NN O
beta NN NN O
subunits NN NN O
on NN NN O
murine NN NN O
leukemia NN NN O
virus NN NN O
enhancer NN NN O
cores NN NN O
. NN NN O
   
Core NN NN O
binding NN NN O
factor NN NN O
( NN NN O
CBF NN NN O
) NN NN O
, NN NN O
also NN NN O
known NN NN O
as NN NN O
polyomavirus NN NN O
enhancer NN NN O
- NN NN O
binding NN NN O
protein NN NN O
2 NN NN O
and NN NN O
SL3 NN NN O
enhancer NN NN O
factor NN NN O
1 NN NN O
, NN NN O
is NN NN O
a NN NN O
mammalian NN NN O
transcription NN NN O
factor NN NN O
that NN NN O
binds NN NN O
to NN NN O
an NN NN O
element NN NN O
termed NN NN O
the NN NN O
core NN NN O
within NN NN O
the NN NN O
enhancers NN NN O
of NN NN O
the NN NN O
murine NN NN O
leukemia NN NN O
virus NN NN O
family NN NN O
of NN NN O
retroviruses NN NN O
. NN NN O
   
The NN NN O
core NN NN O
elements NN NN O
of NN NN O
the NN NN O
SL3 NN NN O
virus NN NN O
are NN NN O
important NN NN O
genetic NN NN O
determinants NN NN O
of NN NN O
the NN NN O
ability NN NN O
of NN NN O
this NN NN O
virus NN NN O
to NN NN O
induce NN NN O
T NN NN O
- NN NN O
cell NN NN O
lymphomas NN NN O
and NN NN O
the NN NN O
transcriptional NN NN O
activity NN NN O
of NN NN O
the NN NN O
viral NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
in NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
CBF NN NN O
consists NN NN O
of NN NN O
two NN NN O
subunits NN NN O
, NN NN O
a NN NN O
DNA NN NN O
binding NN NN O
subunit NN NN O
, NN NN O
CBF NN NN B-Protein
alpha NN NN I-Protein
, NN NN O
and NN NN O
a NN NN O
second NN NN O
subunit NN NN O
, NN NN O
CBF NN NN B-Protein
beta NN NN I-Protein
, NN NN O
that NN NN O
stimulates NN NN O
the NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
of NN NN O
CBF NN NN B-Protein
alpha NN NN I-Protein
. NN NN O
   
One NN NN O
of NN NN O
the NN NN O
genes NN NN O
that NN NN O
encodes NN NN O
a NN NN O
CBF NN NN B-Protein
alpha NN NN I-Protein
subunit NN NN O
is NN NN O
AML1 NN NN B-Protein
, NN NN O
also NN NN O
called NN NN O
Cbf NN NN B-Protein
alpha NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
This NN NN O
locus NN NN O
is NN NN O
rearranged NN NN O
by NN NN O
chromosomal NN NN O
translocations NN NN O
in NN NN O
human NN NN O
myeloproliferative NN NN O
disorders NN NN O
and NN NN O
leukemias NN NN O
. NN NN O
   
An NN NN O
exogenously NN NN O
expressed NN NN O
Cbf NN NN B-Protein
alpha NN NN I-Protein
2 NN NN I-Protein
- NN NN O
encoded NN NN O
subunit NN NN O
( NN NN O
CBF NN NN B-Protein
alpha NN NN I-Protein
2 NN NN O
- NN NN O
451 NN NN O
) NN NN O
stimulated NN NN O
transcription NN NN O
from NN NN O
the NN NN O
SL3 NN NN O
enhancer NN NN O
in NN NN O
P19 NN NN O
and NN NN O
HeLa NN NN O
cells NN NN O
. NN NN O
   
Activity NN NN O
was NN NN O
mediated NN NN O
through NN NN O
the NN NN O
core NN NN O
elements NN NN O
. NN NN O
   
Three NN NN O
different NN NN O
isoforms NN NN O
of NN NN O
CBF NN NN B-Protein
beta NN NN I-Protein
were NN NN O
also NN NN O
tested NN NN O
for NN NN O
transcriptional NN NN O
activity NN NN O
on NN NN O
the NN NN O
SL3 NN NN O
enhancer NN NN O
. NN NN O
   
The NN NN O
longest NN NN O
form NN NN O
, NN NN O
CBF NN NN B-Protein
beta NN NN I-Protein
- NN NN O
187 NN NN O
, NN NN O
increased NN NN O
the NN NN O
transcriptional NN NN O
stimulation NN NN O
by NN NN O
CBF NN NN B-Protein
alpha NN NN I-Protein
2 NN NN O
- NN NN O
451 NN NN O
twofold NN NN O
in NN NN O
HeLa NN NN O
cells NN NN O
, NN NN O
although NN NN O
it NN NN O
had NN NN O
no NN NN O
effect NN NN O
in NN NN O
P19 NN NN O
cells NN NN O
. NN NN O
   
Transcriptional NN NN O
activation NN NN O
by NN NN O
CBF NN NN B-Protein
beta NN NN I-Protein
required NN NN O
binding NN NN O
to NN NN O
the NN NN O
CBF NN NN B-Protein
alpha NN NN I-Protein
subunit NN NN O
, NN NN O
as NN NN O
a NN NN O
form NN NN O
of NN NN O
CBF NN NN B-Protein
beta NN NN I-Protein
that NN NN O
lacked NN NN O
binding NN NN O
ability NN NN O
, NN NN O
CBF NN NN B-Protein
beta NN NN I-Protein
- NN NN O
148 NN NN O
, NN NN O
failed NN NN O
to NN NN O
increase NN NN O
activity NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicated NN NN O
that NN NN O
at NN NN O
least NN NN O
in NN NN O
certain NN NN O
cell NN NN O
types NN NN O
, NN NN O
the NN NN O
maximum NN NN O
activity NN NN O
of NN NN O
CBF NN NN O
required NN NN O
both NN NN O
subunits NN NN O
. NN NN O
   
They NN NN O
also NN NN O
provided NN NN O
support NN NN O
for NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
CBF NN NN O
is NN NN O
a NN NN O
factor NN NN O
in NN NN O
T NN NN O
lymphocytes NN NN O
that NN NN O
is NN NN O
responsible NN NN O
for NN NN O
recognition NN NN O
of NN NN O
the NN NN O
SL3 NN NN O
cores NN NN O
. NN NN O
   
We NN NN O
also NN NN O
examined NN NN O
whether NN NN O
CBF NN NN O
could NN NN O
distinguish NN NN O
a NN NN O
1 NN NN O
- NN NN O
bp NN NN O
difference NN NN O
between NN NN O
the NN NN O
enhancer NN NN O
core NN NN O
of NN NN O
SL3 NN NN O
and NN NN O
the NN NN O
core NN NN O
of NN NN O
the NN NN O
nonleukemogenic NN NN O
virus NN NN O
, NN NN O
Akv NN NN O
. NN NN O
   
This NN NN O
difference NN NN O
strongly NN NN O
affects NN NN O
transcription NN NN O
in NN NN O
T NN NN O
cells NN NN O
and NN NN O
leukemogenicity NN NN O
of NN NN O
SL3 NN NN O
. NN NN O
   
However NN NN O
, NN NN O
no NN NN O
combination NN NN O
of NN NN O
CBF NN NN B-Protein
alpha NN NN I-Protein
and NN NN O
CBF NN NN B-Protein
beta NN NN I-Protein
subunits NN NN O
that NN NN O
we NN NN O
tested NN NN O
was NN NN O
able NN NN O
to NN NN O
distinguish NN NN O
the NN NN O
1 NN NN O
- NN NN O
bp NN NN O
difference NN NN O
in NN NN O
transcription NN NN O
assays NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
a NN NN O
complete NN NN O
understanding NN NN O
of NN NN O
how NN NN O
T NN NN O
cells NN NN O
recognize NN NN O
the NN NN O
SL3 NN NN O
core NN NN O
remains NN NN O
to NN NN O
be NN NN O
elucidated NN NN O
. NN NN O
   
A NN NN O
newly NN NN O
established NN NN O
megakaryoblastic NN NN O
/ NN NN O
erythroid NN NN O
cell NN NN O
line NN NN O
that NN NN O
differentiates NN NN O
to NN NN O
red NN NN O
cells NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
erythropoietin NN NN B-Protein
and NN NN O
produces NN NN O
platelet NN NN O
- NN NN O
like NN NN O
particles NN NN O
. NN NN O
   
In NN NN O
August NN NN O
, NN NN O
1992 NN NN O
, NN NN O
we NN NN O
established NN NN O
a NN NN O
leukemic NN NN O
cell NN NN O
line NN NN O
( NN NN O
NS NN NN O
- NN NN O
Meg NN NN O
) NN NN O
from NN NN O
a NN NN O
patient NN NN O
in NN NN O
megakaryoblastic NN NN O
transformation NN NN O
of NN NN O
Philadelphia NN NN O
chromosome NN NN O
- NN NN O
positive NN NN O
chronic NN NN O
myeloid NN NN O
leukemia NN NN O
. NN NN O
   
The NN NN O
NS NN NN O
- NN NN O
Meg NN NN O
cells NN NN O
were NN NN O
positive NN NN O
for NN NN O
alpha NN NN O
- NN NN O
naphthyl NN NN O
acetate NN NN O
esterase NN NN O
and NN NN O
periodic NN NN O
acid NN NN O
- NN NN O
Schiff NN NN O
( NN NN O
PAS NN NN O
) NN NN O
staining NN NN O
and NN NN O
for NN NN O
surface NN NN O
CD4 NN NN B-Protein
, NN NN O
CD7 NN NN B-Protein
, NN NN O
CD13 NN NN B-Protein
, NN NN O
CD34 NN NN B-Protein
, NN NN O
CD41a NN NN B-Protein
, NN NN O
and NN NN O
glycophorin NN NN B-Protein
A NN NN I-Protein
antigens NN NN O
. NN NN O
   
Ultrastructurally NN NN O
, NN NN O
the NN NN O
cells NN NN O
had NN NN O
alpha NN NN O
- NN NN O
granules NN NN O
, NN NN O
demarcation NN NN O
membranes NN NN O
, NN NN O
and NN NN O
platelet NN NN O
peroxidase NN NN O
activity NN NN O
. NN NN O
   
The NN NN O
NS NN NN O
- NN NN O
Meg NN NN O
cells NN NN O
spontaneously NN NN O
produced NN NN O
platelet NN NN O
- NN NN O
like NN NN O
particles NN NN O
which NN NN O
contained NN NN O
alpha NN NN O
- NN NN O
granules NN NN O
, NN NN O
mitochondria NN NN O
and NN NN O
dense NN NN O
bodies NN NN O
, NN NN O
strongly NN NN O
suggesting NN NN O
platelet NN NN O
production NN NN O
. NN NN O
   
Erythropoietin NN NN B-Protein
( NN NN O
Epo NN NN B-Protein
) NN NN O
, NN NN O
granulocyte NN NN B-Protein
/ NN NN I-Protein
macrophage NN NN I-Protein
colony NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
( NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
) NN NN O
, NN NN O
and NN NN O
interleukin NN NN B-Protein
3 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
) NN NN O
promoted NN NN O
the NN NN O
growth NN NN O
of NN NN O
NS NN NN O
- NN NN O
Meg NN NN O
cells NN NN O
. NN NN O
   
Phorbol NN NN O
- NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
- NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
increased NN NN O
the NN NN O
expression NN NN O
of NN NN O
both NN NN O
CD41a NN NN B-Protein
and NN NN O
CD61 NN NN B-Protein
antigens NN NN O
. NN NN O
   
Ten NN NN O
- NN NN O
day NN NN O
exposure NN NN O
to NN NN O
Epo NN NN B-Protein
induced NN NN O
mature NN NN O
erythroblasts NN NN O
and NN NN O
red NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
benzidine NN NN O
- NN NN O
positive NN NN O
cells NN NN O
were NN NN O
positive NN NN O
for NN NN O
hemoglobin NN NN O
F NN NN O
staining NN NN O
. NN NN O
   
Untreated NN NN O
NS NN NN O
- NN NN O
Meg NN NN O
cells NN NN O
expressed NN NN O
mRNA NN NN O
for NN NN O
the NN NN O
Epo NN NN B-Protein
receptor NN NN I-Protein
( NN NN O
EpoR NN NN B-Protein
) NN NN O
, NN NN O
for NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
and NN NN O
for NN NN O
alpha NN NN O
1 NN NN O
, NN NN O
alpha NN NN O
2 NN NN O
and NN NN O
gamma NN NN O
globin NN NN O
genes NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
NS NN NN O
- NN NN O
Meg NN NN O
cells NN NN O
undergo NN NN O
terminal NN NN O
differentiation NN NN O
of NN NN O
both NN NN O
megakaryocytic NN NN O
and NN NN O
erythroid NN NN O
lineages NN NN O
. NN NN O
   
This NN NN O
cell NN NN O
line NN NN O
should NN NN O
be NN NN O
a NN NN O
very NN NN O
useful NN NN O
tool NN NN O
for NN NN O
the NN NN O
investigation NN NN O
of NN NN O
both NN NN O
megakaryocytic NN NN O
and NN NN O
erythroid NN NN O
maturation NN NN O
. NN NN O
   
Identification NN NN O
and NN NN O
purification NN NN O
of NN NN O
human NN NN O
Stat NN NN O
proteins NN NN O
activated NN NN O
in NN NN O
response NN NN O
to NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
A NN NN O
key NN NN O
cytokine NN NN O
induced NN NN O
during NN NN O
the NN NN O
immune NN NN O
response NN NN O
is NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
Following NN NN O
T NN NN O
cell NN NN O
activation NN NN O
, NN NN O
the NN NN O
genes NN NN O
encoding NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
the NN NN O
various NN NN O
chains NN NN O
of NN NN O
its NN NN O
receptor NN NN O
are NN NN O
transcriptionally NN NN O
induced NN NN O
. NN NN O
   
In NN NN O
turn NN NN O
, NN NN O
secreted NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
serves NN NN O
to NN NN O
stimulate NN NN O
the NN NN O
proliferation NN NN O
and NN NN O
differentiation NN NN O
of NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
Several NN NN O
recent NN NN O
studies NN NN O
have NN NN O
implicated NN NN O
Jak NN NN O
kinases NN NN O
in NN NN O
the NN NN O
signaling NN NN O
pathway NN NN O
induced NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
Following NN NN O
this NN NN O
lead NN NN O
, NN NN O
we NN NN O
set NN NN O
out NN NN O
to NN NN O
identify NN NN O
transcription NN NN O
factors NN NN O
induced NN NN O
in NN NN O
response NN NN O
to NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
Human NN NN O
peripheral NN NN O
blood NN NN O
lymphocytes NN NN O
were NN NN O
observed NN NN O
to NN NN O
contain NN NN O
several NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
inducible NN NN O
DNA NN NN O
binding NN NN O
activities NN NN O
. NN NN O
   
Similar NN NN O
activities NN NN O
were NN NN O
also NN NN O
observed NN NN O
in NN NN O
a NN NN O
transformed NN NN O
human NN NN O
lymphocyte NN NN O
line NN NN O
, NN NN O
termed NN NN O
YT NN NN O
. NN NN O
   
We NN NN O
have NN NN O
purified NN NN O
these NN NN O
activities NN NN O
and NN NN O
found NN NN O
that NN NN O
the NN NN O
principal NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
inducible NN NN O
component NN NN O
bears NN NN O
significant NN NN O
relatedness NN NN O
to NN NN O
a NN NN O
prolactin NN NN B-Protein
- NN NN O
induced NN NN O
transcription NN NN O
factor NN NN O
first NN NN O
identified NN NN O
in NN NN O
sheep NN NN O
mammary NN NN O
gland NN NN O
tissue NN NN O
. NN NN O
   
We NN NN O
hypothesize NN NN O
that NN NN O
activation NN NN O
of NN NN O
this NN NN O
protein NN NN O
, NN NN O
designated NN NN O
hStat5 NN NN B-Protein
, NN NN O
helps NN NN O
govern NN NN O
the NN NN O
biological NN NN O
effects NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
during NN NN O
the NN NN O
immune NN NN O
response NN NN O
. NN NN O
   
The NN NN O
role NN NN O
of NN NN O
shared NN NN O
receptor NN NN O
motifs NN NN O
and NN NN O
common NN NN O
Stat NN NN O
proteins NN NN O
in NN NN O
the NN NN O
generation NN NN O
of NN NN O
cytokine NN NN O
pleiotropy NN NN O
and NN NN O
redundancy NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
7 NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13 NN NN I-Protein
, NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
15 NN NN I-Protein
. NN NN O
   
To NN NN O
understand NN NN O
the NN NN O
molecular NN NN O
bases NN NN O
for NN NN O
cytokine NN NN O
redundancy NN NN O
and NN NN O
pleiotropy NN NN O
, NN NN O
we NN NN O
have NN NN O
compared NN NN O
the NN NN O
Stat NN NN O
proteins NN NN O
activated NN NN O
in NN NN O
peripheral NN NN O
blood NN NN O
lymphocytes NN NN O
( NN NN O
PBLs NN NN O
) NN NN O
by NN NN O
cytokines NN NN O
with NN NN O
shared NN NN O
and NN NN O
distinct NN NN O
actions NN NN O
. NN NN O
   
Interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
rapidly NN NN O
activated NN NN O
Stat5 NN NN B-Protein
in NN NN O
fresh NN NN O
PBL NN NN O
, NN NN O
and NN NN O
Stat3 NN NN B-Protein
and NN NN O
Stat5 NN NN B-Protein
in NN NN O
preactivated NN NN O
PBL NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
7 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
15 NN NN I-Protein
induced NN NN O
the NN NN O
same NN NN O
complexes NN NN O
as NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
a NN NN O
feature NN NN O
explained NN NN O
by NN NN O
the NN NN O
existence NN NN O
of NN NN O
similar NN NN O
tyrosine NN NN O
- NN NN O
phosphorylated NN NN O
motifs NN NN O
in NN NN O
the NN NN O
cytoplasmic NN NN O
domains NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
beta NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
7R NN NN I-Protein
that NN NN O
can NN NN O
serve NN NN O
as NN NN O
docking NN NN O
sites NN NN O
for NN NN O
Stat NN NN O
proteins NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
13 NN NN I-Protein
Induced NN NN O
the NN NN O
same NN NN O
complexes NN NN O
as NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
, NN NN O
a NN NN O
finding NN NN O
explained NN NN O
by NN NN O
our NN NN O
studies NN NN O
implicating NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4R NN NN I-Protein
as NN NN O
a NN NN O
shared NN NN O
component NN NN O
of NN NN O
the NN NN O
receptors NN NN O
. NN NN O
   
These NN NN O
studies NN NN O
demonstrate NN NN O
that NN NN O
a NN NN O
single NN NN O
cytokine NN NN O
can NN NN O
activate NN NN O
different NN NN O
combinations NN NN O
of NN NN O
Stat NN NN O
proteins NN NN O
under NN NN O
different NN NN O
physiological NN NN O
conditions NN NN O
, NN NN O
and NN NN O
also NN NN O
indicate NN NN O
two NN NN O
mechanisms NN NN O
by NN NN O
which NN NN O
distinct NN NN O
cytokines NN NN O
can NN NN O
activate NN NN O
the NN NN O
same NN NN O
Stat NN NN O
protein NN NN O
. NN NN O
   
Functional NN NN O
roles NN NN O
of NN NN O
in NN NN O
vivo NN NN O
footprinted NN NN O
DNA NN NN O
motifs NN NN O
within NN NN O
an NN NN O
alpha NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
enhancer NN NN O
. NN NN O
   
Erythroid NN NN O
lineage NN NN O
and NN NN O
developmental NN NN O
stage NN NN O
specificities NN NN O
. NN NN O
   
Transcriptional NN NN O
regulation NN NN O
of NN NN O
the NN NN O
human NN NN O
alpha NN NN O
- NN NN O
like NN NN O
globin NN NN O
genes NN NN O
, NN NN O
embryonic NN NN O
zeta NN NN O
2 NN NN O
and NN NN O
adult NN NN O
alpha NN NN O
, NN NN O
during NN NN O
erythroid NN NN O
development NN NN O
is NN NN O
mediated NN NN O
by NN NN O
a NN NN O
distal NN NN O
enhancer NN NN O
, NN NN O
HS NN NN B-Protein
- NN NN I-Protein
40 NN NN I-Protein
. NN NN O
   
Previous NN NN O
protein NN NN O
- NN NN O
DNA NN NN O
binding NN NN O
studies NN NN O
have NN NN O
shown NN NN O
that NN NN O
HS NN NN B-Protein
- NN NN I-Protein
40 NN NN I-Protein
consists NN NN O
of NN NN O
multiple NN NN O
nuclear NN NN O
factor NN NN O
binding NN NN O
motifs NN NN O
that NN NN O
are NN NN O
occupied NN NN O
in NN NN O
vivo NN NN O
in NN NN O
an NN NN O
erythroid NN NN O
lineage NN NN O
- NN NN O
and NN NN O
developmental NN NN O
stage NN NN O
- NN NN O
specific NN NN O
manner NN NN O
. NN NN O
   
We NN NN O
have NN NN O
systematically NN NN O
analyzed NN NN O
the NN NN O
functional NN NN O
roles NN NN O
of NN NN O
these NN NN O
factor NN NN O
binding NN NN O
motifs NN NN O
of NN NN O
HS NN NN B-Protein
- NN NN I-Protein
40 NN NN I-Protein
by NN NN O
site NN NN O
- NN NN O
directed NN NN O
mutagenesis NN NN O
and NN NN O
transient NN NN O
expression NN NN O
assay NN NN O
in NN NN O
erythroid NN NN O
cell NN NN O
cultures NN NN O
. NN NN O
   
Three NN NN O
of NN NN O
these NN NN O
HS NN NN B-Protein
- NN NN I-Protein
40 NN NN I-Protein
enhancer NN NN O
motifs NN NN O
, NN NN O
5 NN NN O
' NN NN O
NF NN NN O
- NN NN O
E2 NN NN O
/ NN NN O
AP1 NN NN O
, NN NN O
GT NN NN O
II NN NN O
, NN NN O
and NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
c NN NN O
) NN NN O
, NN NN O
positively NN NN O
regulate NN NN O
the NN NN O
zeta NN NN B-Protein
2 NN NN I-Protein
- NN NN I-Protein
globin NN NN I-Protein
promoter NN NN O
activity NN NN O
in NN NN O
embryonic NN NN O
/ NN NN O
fetal NN NN O
erythroid NN NN O
K562 NN NN O
cells NN NN O
and NN NN O
the NN NN O
adult NN NN B-Protein
alpha NN NN I-Protein
- NN NN I-Protein
globin NN NN I-Protein
promoter NN NN O
activity NN NN O
in NN NN O
adult NN NN O
erythroid NN NN O
MEL NN NN O
cells NN NN O
. NN NN O
   
On NN NN O
the NN NN O
other NN NN O
hand NN NN O
, NN NN O
the NN NN O
3 NN NN O
' NN NN O
NF NN NN O
- NN NN O
E2 NN NN O
/ NN NN O
AP1 NN NN O
motif NN NN O
is NN NN O
able NN NN O
to NN NN O
exert NN NN O
both NN NN O
positive NN NN O
and NN NN O
negative NN NN O
regulatory NN NN O
effects NN NN O
on NN NN O
the NN NN O
zeta NN NN B-Protein
2 NN NN I-Protein
- NN NN I-Protein
globin NN NN I-Protein
promoter NN NN O
activity NN NN O
in NN NN O
K562 NN NN O
cells NN NN O
, NN NN O
and NN NN O
this NN NN O
dual NN NN O
function NN NN O
appears NN NN O
to NN NN O
be NN NN O
modulated NN NN O
through NN NN O
differential NN NN O
binding NN NN O
of NN NN O
the NN NN O
ubiquitous NN NN O
AP1 NN NN O
factors NN NN O
and NN NN O
the NN NN O
erythroid NN NN O
- NN NN O
enriched NN NN O
NF NN NN O
- NN NN O
E2 NN NN O
factor NN NN O
. NN NN O
   
Mutation NN NN O
in NN NN O
the NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
d NN NN O
) NN NN O
motif NN NN O
, NN NN O
which NN NN O
exhibits NN NN O
an NN NN O
adult NN NN O
erythroid NN NN O
- NN NN O
specific NN NN O
genomic NN NN O
footprint NN NN O
, NN NN O
decreases NN NN O
the NN NN O
HS NN NN B-Protein
- NN NN I-Protein
40 NN NN I-Protein
enhancer NN NN O
function NN NN O
in NN NN O
dimethyl NN NN O
sulfoxide NN NN O
- NN NN O
induced NN NN O
MEL NN NN O
cells NN NN O
but NN NN O
not NN NN O
in NN NN O
K562 NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
studies NN NN O
have NN NN O
defined NN NN O
the NN NN O
regulatory NN NN O
roles NN NN O
of NN NN O
the NN NN O
different NN NN O
HS NN NN B-Protein
- NN NN I-Protein
40 NN NN I-Protein
motifs NN NN O
. NN NN O
   
The NN NN O
remarkable NN NN O
correlation NN NN O
between NN NN O
genomic NN NN O
footprinting NN NN O
data NN NN O
and NN NN O
the NN NN O
mutagenesis NN NN O
results NN NN O
also NN NN O
suggests NN NN O
that NN NN O
the NN NN O
erythroid NN NN O
lineage NN NN O
- NN NN O
and NN NN O
developmental NN NN O
stage NN NN O
- NN NN O
specific NN NN O
regulation NN NN O
of NN NN O
human NN NN O
alpha NN NN O
- NN NN O
like NN NN O
globin NN NN O
promoters NN NN O
is NN NN O
indeed NN NN O
modulated NN NN O
by NN NN O
stable NN NN O
binding NN NN O
of NN NN O
specific NN NN O
nuclear NN NN O
factors NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
Erythropoietin NN NN B-Protein
stimulates NN NN O
transcription NN NN O
of NN NN O
the NN NN O
TAL1 NN NN B-Protein
/ NN NN O
SCL NN NN B-Protein
gene NN NN O
and NN NN O
phosphorylation NN NN O
of NN NN O
its NN NN O
protein NN NN O
products NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
the NN NN O
TAL1 NN NN B-Protein
( NN NN O
or NN NN O
SCL NN NN B-Protein
) NN NN O
gene NN NN O
, NN NN O
originally NN NN O
identified NN NN O
through NN NN O
its NN NN O
involvement NN NN O
by NN NN O
a NN NN O
recurrent NN NN O
chromosomal NN NN O
translocation NN NN O
, NN NN O
is NN NN O
the NN NN O
most NN NN O
frequent NN NN O
molecular NN NN O
lesion NN NN O
recognized NN NN O
in NN NN O
T NN NN O
- NN NN O
cell NN NN O
acute NN NN O
lymphoblastic NN NN O
leukemia NN NN O
. NN NN O
   
The NN NN O
protein NN NN O
products NN NN O
of NN NN O
this NN NN O
gene NN NN O
contain NN NN O
the NN NN O
basic NN NN O
- NN NN O
helix NN NN O
- NN NN O
loop NN NN O
- NN NN O
helix NN NN O
motif NN NN O
characteristic NN NN O
of NN NN O
a NN NN O
large NN NN O
family NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
that NN NN O
bind NN NN O
to NN NN O
the NN NN O
canonical NN NN O
DNA NN NN O
sequence NN NN O
CANNTG NN NN O
as NN NN O
protein NN NN O
heterodimers NN NN O
. NN NN O
   
TAL1 NN NN B-Protein
expression NN NN O
by NN NN O
erythroid NN NN O
cells NN NN O
in NN NN O
vivo NN NN O
and NN NN O
in NN NN O
chemical NN NN O
- NN NN O
induced NN NN O
erythroleukemia NN NN O
cell NN NN O
lines NN NN O
in NN NN O
vivo NN NN O
suggested NN NN O
the NN NN O
gene NN NN O
might NN NN O
regulate NN NN O
aspects NN NN O
of NN NN O
erythroid NN NN O
differentiation NN NN O
. NN NN O
   
Since NN NN O
the NN NN O
terminal NN NN O
events NN NN O
of NN NN O
erythropoiesis NN NN O
are NN NN O
controlled NN NN O
by NN NN O
the NN NN O
glycoprotein NN NN O
hormone NN NN O
erythropoietin NN NN B-Protein
( NN NN O
Epo NN NN B-Protein
) NN NN O
, NN NN O
we NN NN O
investigated NN NN O
whether NN NN O
the NN NN O
expression NN NN O
or NN NN O
activity NN NN O
of NN NN O
the NN NN O
TAL1 NN NN B-Protein
gene NN NN O
and NN NN O
its NN NN O
protein NN NN O
products NN NN O
were NN NN O
affected NN NN O
by NN NN O
Epo NN NN B-Protein
in NN NN O
splenic NN NN O
erythroblasts NN NN O
from NN NN O
mice NN NN O
infected NN NN O
with NN NN O
an NN NN O
anemia NN NN O
- NN NN O
inducing NN NN O
strain NN NN O
of NN NN O
Friend NN NN O
virus NN NN O
( NN NN O
FVA NN NN O
cells NN NN O
) NN NN O
. NN NN O
   
Epo NN NN B-Protein
elicited NN NN O
a NN NN O
rapid NN NN O
, NN NN O
dose NN NN O
- NN NN O
related NN NN O
increase NN NN O
in NN NN O
TAL1 NN NN B-Protein
mRNA NN NN O
by NN NN O
increasing NN NN O
transcription NN NN O
of NN NN O
the NN NN O
gene NN NN O
and NN NN O
stabilizing NN NN O
one NN NN O
of NN NN O
its NN NN O
mRNAs NN NN O
. NN NN O
   
An NN NN O
Epo NN NN B-Protein
- NN NN O
inducible NN NN O
TAL1 NN NN B-Protein
DNA NN NN O
binding NN NN O
activity NN NN O
was NN NN O
identified NN NN O
in NN NN O
FVA NN NN O
cell NN NN O
nuclear NN NN O
extracts NN NN O
that NN NN O
subsequently NN NN O
decayed NN NN O
despite NN NN O
accumulating NN NN O
mRNA NN NN O
and NN NN O
protein NN NN O
. NN NN O
   
Induction NN NN O
of NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
was NN NN O
associated NN NN O
temporally NN NN O
with NN NN O
Epo NN NN B-Protein
- NN NN O
induced NN NN O
phosphorylation NN NN O
of NN NN O
nuclear NN NN O
TAL1 NN NN B-Protein
protein NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
Epo NN NN B-Protein
acts NN NN O
at NN NN O
both NN NN O
transcriptional NN NN O
and NN NN O
posttranscriptional NN NN O
levels NN NN O
on NN NN O
the NN NN O
TAL1 NN NN B-Protein
locus NN NN O
in NN NN O
Friend NN NN O
virus NN NN O
- NN NN O
induced NN NN O
erythroblasts NN NN O
and NN NN O
establish NN NN O
a NN NN O
link NN NN O
between NN NN O
Epo NN NN B-Protein
signaling NN NN O
mechanisms NN NN O
and NN NN O
a NN NN O
member NN NN O
of NN NN O
a NN NN O
family NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
involved NN NN O
in NN NN O
the NN NN O
differentiation NN NN O
of NN NN O
diverse NN NN O
cell NN NN O
lineages NN NN O
. NN NN O
   
Infection NN NN O
with NN NN O
Theileria NN NN O
annulata NN NN O
induces NN NN O
expression NN NN O
of NN NN O
matrix NN NN B-Protein
metalloproteinase NN NN I-Protein
9 NN NN I-Protein
and NN NN O
transcription NN NN O
factor NN NN O
AP NN NN O
- NN NN O
1 NN NN O
in NN NN O
bovine NN NN O
leucocytes NN NN O
. NN NN O
   
Theileria NN NN O
annulata NN NN O
infects NN NN O
bovine NN NN O
leucocytes NN NN O
and NN NN O
results NN NN O
in NN NN O
their NN NN O
reversible NN NN O
transformation NN NN O
such NN NN O
that NN NN O
they NN NN O
become NN NN O
immortalised NN NN O
and NN NN O
metastatic NN NN O
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
describes NN NN O
parasite NN NN O
- NN NN O
induced NN NN O
changes NN NN O
in NN NN O
host NN NN O
cell NN NN O
gene NN NN O
expression NN NN O
which NN NN O
have NN NN O
a NN NN O
direct NN NN O
bearing NN NN O
on NN NN O
this NN NN O
transformation NN NN O
process NN NN O
. NN NN O
   
T NN NN O
. NN NN O
annulata NN NN O
- NN NN O
infected NN NN O
leucocytes NN NN O
produce NN NN O
a NN NN O
number NN NN O
of NN NN O
novel NN NN O
metalloproteinase NN NN O
activities NN NN O
. NN NN O
   
One NN NN O
of NN NN O
these NN NN O
, NN NN O
previously NN NN O
called NN NN O
B1 NN NN O
, NN NN O
is NN NN O
a NN NN O
97 NN NN O
- NN NN O
kDa NN NN O
protein NN NN O
which NN NN O
is NN NN O
secreted NN NN O
in NN NN O
large NN NN O
amounts NN NN O
and NN NN O
has NN NN O
been NN NN O
purified NN NN O
from NN NN O
protein NN NN O
- NN NN O
free NN NN O
, NN NN O
conditioned NN NN O
medium NN NN O
. NN NN O
   
An NN NN O
antiserum NN NN O
to NN NN O
this NN NN O
enzyme NN NN O
was NN NN O
used NN NN O
to NN NN O
isolate NN NN O
a NN NN O
cDNA NN NN O
clone NN NN O
. NN NN O
   
The NN NN O
predicted NN NN O
protein NN NN O
sequence NN NN O
of NN NN O
B1 NN NN O
is NN NN O
81 NN NN O
% NN NN O
identical NN NN O
to NN NN O
human NN NN O
matrix NN NN B-Protein
metalloproteinase NN NN I-Protein
9 NN NN I-Protein
( NN NN O
MMP9 NN NN B-Protein
) NN NN O
, NN NN O
demonstrating NN NN O
that NN NN O
it NN NN O
is NN NN O
the NN NN O
bovine NN NN O
homologue NN NN O
of NN NN O
this NN NN O
enzyme NN NN O
. NN NN O
   
RNAase NN NN O
protection NN NN O
assays NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
MMP9 NN NN B-Protein
activity NN NN O
, NN NN O
unique NN NN O
to NN NN O
infected NN NN O
cells NN NN O
, NN NN O
is NN NN O
due NN NN O
to NN NN O
increased NN NN O
MMP9 NN NN B-Protein
mRNA NN NN O
levels NN NN O
. NN NN O
   
We NN NN O
also NN NN O
assayed NN NN O
the NN NN O
levels NN NN O
of NN NN O
transcription NN NN O
factor NN NN O
AP NN NN O
- NN NN O
1 NN NN O
and NN NN O
demonstrated NN NN O
that NN NN O
it NN NN O
was NN NN O
constitutively NN NN O
present NN NN O
in NN NN O
increased NN NN O
amounts NN NN O
in NN NN O
Theileria NN NN O
- NN NN O
infected NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
we NN NN O
assayed NN NN O
the NN NN O
level NN NN O
of NN NN O
mRNA NN NN O
encoding NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
, NN NN O
a NN NN O
common NN NN O
component NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
and NN NN O
observed NN NN O
that NN NN O
it NN NN O
was NN NN O
indeed NN NN O
up NN NN O
- NN NN O
regulated NN NN O
in NN NN O
infected NN NN O
cells NN NN O
. NN NN O
   
Since NN NN O
AP NN NN O
- NN NN O
1 NN NN O
is NN NN O
implicated NN NN O
in NN NN O
the NN NN O
control NN NN O
of NN NN O
the NN NN O
cell NN NN O
cycle NN NN O
, NN NN O
and NN NN O
MMP9 NN NN B-Protein
can NN NN O
confer NN NN O
metastatic NN NN O
properties NN NN O
, NN NN O
these NN NN O
results NN NN O
are NN NN O
of NN NN O
considerable NN NN O
significance NN NN O
with NN NN O
respect NN NN O
to NN NN O
the NN NN O
transformed NN NN O
phenotype NN NN O
induced NN NN O
by NN NN O
Theileria NN NN O
infection NN NN O
. NN NN O
   
The NN NN O
role NN NN O
of NN NN O
NFATp NN NN B-Protein
in NN NN O
cyclosporin NN NN O
A NN NN O
- NN NN O
sensitive NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
gene NN NN O
transcription NN NN O
. NN NN O
   
The NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
alpha NN NN I-Protein
) NN NN O
gene NN NN O
is NN NN O
an NN NN O
immediate NN NN O
early NN NN O
gene NN NN O
in NN NN O
activated NN NN O
T NN NN O
cells NN NN O
, NN NN O
in NN NN O
that NN NN O
it NN NN O
is NN NN O
rapidly NN NN O
induced NN NN O
without NN NN O
a NN NN O
requirement NN NN O
for NN NN O
protein NN NN O
synthesis NN NN O
. NN NN O
   
Maximal NN NN O
induction NN NN O
of NN NN O
TNF NN NN B-Protein
alpha NN NN I-Protein
mRNA NN NN O
can NN NN O
be NN NN O
induced NN NN O
by NN NN O
treatment NN NN O
of NN NN O
T NN NN O
cells NN NN O
with NN NN O
calcium NN NN O
ionophores NN NN O
alone NN NN O
, NN NN O
via NN NN O
a NN NN O
calcineurin NN NN O
- NN NN O
dependent NN NN O
process NN NN O
that NN NN O
is NN NN O
blocked NN NN O
by NN NN O
cyclosporin NN NN O
A NN NN O
. NN NN O
   
We NN NN O
have NN NN O
previously NN NN O
identified NN NN O
a NN NN O
promoter NN NN O
element NN NN O
, NN NN O
kappa NN NN O
3 NN NN O
, NN NN O
that NN NN O
is NN NN O
required NN NN O
for NN NN O
calcium NN NN O
- NN NN O
stimulated NN NN O
, NN NN O
cyclosporin NN NN O
A NN NN O
- NN NN O
sensitive NN NN O
induction NN NN O
of NN NN O
the NN NN O
TNF NN NN B-Protein
alpha NN NN I-Protein
gene NN NN O
in NN NN O
activated NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Here NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
kappa NN NN O
3 NN NN O
binding NN NN O
factor NN NN O
contains NN NN O
NFATp NN NN B-Protein
, NN NN O
a NN NN O
cyclosporin NN NN O
- NN NN O
sensitive NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
protein NN NN O
required NN NN O
for NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
transcription NN NN O
. NN NN O
   
NFATp NN NN B-Protein
binds NN NN O
to NN NN O
two NN NN O
sites NN NN O
within NN NN O
the NN NN O
kappa NN NN O
3 NN NN O
element NN NN O
, NN NN O
and NN NN O
occupancy NN NN O
of NN NN O
both NN NN O
sites NN NN O
is NN NN O
required NN NN O
for NN NN O
TNF NN NN B-Protein
alpha NN NN I-Protein
gene NN NN O
induction NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
although NN NN O
the NN NN O
kappa NN NN O
3 NN NN O
element NN NN O
has NN NN O
little NN NN O
sequence NN NN O
similarity NN NN O
to NN NN O
other NN NN O
NFATp NN NN B-Protein
- NN NN O
binding NN NN O
sites NN NN O
, NN NN O
it NN NN O
appears NN NN O
to NN NN O
function NN NN O
as NN NN O
a NN NN O
cyclosporin NN NN O
- NN NN O
sensitive NN NN O
promoter NN NN O
element NN NN O
in NN NN O
T NN NN O
cells NN NN O
by NN NN O
virtue NN NN O
of NN NN O
its NN NN O
ability NN NN O
to NN NN O
bind NN NN O
NFATp NN NN B-Protein
. NN NN O
   
The NN NN O
involvement NN NN O
of NN NN O
NFATp NN NN B-Protein
in NN NN O
transcriptional NN NN O
activation NN NN O
of NN NN O
both NN NN O
the NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
TNF NN NN B-Protein
alpha NN NN I-Protein
genes NN NN O
suggests NN NN O
that NN NN O
this NN NN O
factor NN NN O
plays NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
the NN NN O
coordinate NN NN O
induction NN NN O
of NN NN O
multiple NN NN O
cytokine NN NN O
genes NN NN O
, NN NN O
starting NN NN O
at NN NN O
the NN NN O
earliest NN NN O
stages NN NN O
of NN NN O
T NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
Glucocorticoid NN NN O
- NN NN O
mediated NN NN O
inhibition NN NN O
of NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
- NN NN B-Protein
beta NN NN I-Protein
subunit NN NN O
expression NN NN O
by NN NN O
human NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
To NN NN O
determine NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
glucocorticoid NN NN O
( NN NN O
GC NN NN O
) NN NN O
- NN NN O
mediated NN NN O
inhibition NN NN O
of NN NN O
T NN NN O
cell NN NN O
functions NN NN O
, NN NN O
the NN NN O
effect NN NN O
of NN NN O
dexamethasone NN NN O
( NN NN O
DM NN NN O
) NN NN O
on NN NN O
T NN NN O
cell NN NN O
proliferation NN NN O
and NN NN O
interleukin NN NN O
- NN NN O
2 NN NN O
receptor NN NN O
( NN NN O
IL NN NN O
- NN NN O
2R NN NN O
) NN NN O
generation NN NN O
were NN NN O
studied NN NN O
. NN NN O
   
Dexamethasone NN NN O
inhibited NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
induced NN NN O
T NN NN O
cell NN NN O
proliferation NN NN O
by NN NN O
30 NN NN O
% NN NN O
- NN NN O
88 NN NN O
% NN NN O
, NN NN O
relative NN NN O
to NN NN O
its NN NN O
concentration NN NN O
within NN NN O
the NN NN O
cultures NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
DM NN NN O
on NN NN O
expression NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
Tac NN NN B-Protein
, NN NN O
p55 NN NN B-Protein
, NN NN O
CD25 NN NN B-Protein
) NN NN O
and NN NN O
beta NN NN B-Protein
( NN NN O
p75 NN NN B-Protein
) NN NN O
genes NN NN O
in NN NN O
activated NN NN O
T NN NN O
cells NN NN O
was NN NN O
examined NN NN O
next NN NN O
. NN NN O
   
In NN NN O
T NN NN O
cells NN NN O
stimulated NN NN O
with NN NN O
purified NN NN O
phytohemagglutinin NN NN B-Protein
( NN NN O
PHA NN NN B-Protein
- NN NN I-Protein
p NN NN I-Protein
) NN NN O
and NN NN O
4 NN NN O
beta NN NN O
- NN NN O
phorbol NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
( NN NN O
PMA NN NN O
) NN NN O
addition NN NN O
of NN NN O
DM NN NN O
to NN NN O
the NN NN O
cultures NN NN O
resulted NN NN O
in NN NN O
a NN NN O
60 NN NN O
% NN NN O
reduction NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
a NN NN O
30 NN NN O
% NN NN O
reduction NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
beta NN NN I-Protein
membrane NN NN O
expression NN NN O
compared NN NN O
to NN NN O
T NN NN O
cells NN NN O
cultured NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
DM NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
membrane NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
beta NN NN I-Protein
expression NN NN O
by NN NN O
10 NN NN O
( NN NN O
- NN NN O
6 NN NN O
) NN NN O
M NN NN O
DM NN NN O
was NN NN O
partially NN NN O
reversible NN NN O
by NN NN O
recombinant NN NN O
human NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
( NN NN O
rhIL NN NN O
- NN NN O
2 NN NN O
) NN NN O
. NN NN O
   
By NN NN O
Northern NN NN O
blot NN NN O
analysis NN NN O
, NN NN O
DM NN NN O
caused NN NN O
a NN NN O
comparable NN NN O
decrease NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
beta NN NN I-Protein
mRNA NN NN O
levels NN NN O
to NN NN O
membrane NN NN O
receptor NN NN O
expression NN NN O
in NN NN O
mitogen NN NN O
- NN NN O
stimulated NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
By NN NN O
in NN NN O
vitro NN NN O
transcription NN NN O
assays NN NN O
, NN NN O
DM NN NN O
regulated NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
gene NN NN O
expression NN NN O
at NN NN O
a NN NN O
transcriptional NN NN O
level NN NN O
while NN NN O
transcription NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
beta NN NN I-Protein
gene NN NN O
was NN NN O
unaffected NN NN O
by NN NN O
DM NN NN O
. NN NN O
   
The NN NN O
mechanism NN NN O
of NN NN O
action NN NN O
of NN NN O
DM NN NN O
on NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
transcription NN NN O
was NN NN O
examined NN NN O
by NN NN O
determining NN NN O
the NN NN O
mRNA NN NN O
levels NN NN O
of NN NN O
the NN NN O
p50 NN NN B-Protein
subunit NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
, NN NN O
a NN NN O
transcription NN NN O
factor NN NN O
that NN NN O
stimulates NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
gene NN NN O
expression NN NN O
. NN NN O
   
The NN NN O
data NN NN O
indicate NN NN O
that NN NN O
10 NN NN O
( NN NN O
- NN NN O
6 NN NN O
) NN NN O
M NN NN O
DM NN NN O
increased NN NN O
T NN NN O
cell NN NN O
p50 NN NN B-Protein
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
mRNA NN NN O
levels NN NN O
by NN NN O
four NN NN O
- NN NN O
fold NN NN O
compared NN NN O
to NN NN O
the NN NN O
levels NN NN O
obtained NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
DM NN NN O
. NN NN O
   
Further NN NN O
, NN NN O
the NN NN O
level NN NN O
of NN NN O
nuclear NN NN O
proteins NN NN O
capable NN NN O
of NN NN O
binding NN NN O
to NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
sites NN NN O
in NN NN O
activated NN NN O
T NN NN O
cells NN NN O
increased NN NN O
in NN NN O
response NN NN O
to NN NN O
DM NN NN O
. NN NN O
   
In NN NN O
sum NN NN O
, NN NN O
DM NN NN O
regulates NN NN O
T NN NN O
cell NN NN O
membrane NN NN O
expression NN NN O
of NN NN O
IL NN NN O
- NN NN O
2R NN NN O
by NN NN O
more NN NN O
than NN NN O
one NN NN O
molecular NN NN O
mechanism NN NN O
. NN NN O
   
Visualization NN NN O
of NN NN O
the NN NN O
endogenous NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
p50 NN NN B-Protein
subunit NN NN O
in NN NN O
the NN NN O
nucleus NN NN O
of NN NN O
follicular NN NN O
dendritic NN NN O
cells NN NN O
in NN NN O
germinal NN NN O
centers NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
a NN NN O
50 NN NN O
kDa NN NN O
/ NN NN O
65 NN NN O
kDa NN NN O
( NN NN O
p50 NN NN B-Protein
/ NN NN O
p65 NN NN B-Protein
) NN NN O
heterodimer NN NN O
, NN NN O
is NN NN O
a NN NN O
ubiquitous NN NN O
transcription NN NN O
factor NN NN O
involved NN NN O
in NN NN O
the NN NN O
positive NN NN O
regulation NN NN O
of NN NN O
various NN NN O
immune NN NN O
genes NN NN O
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
determine NN NN O
whether NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
is NN NN O
related NN NN O
to NN NN O
a NN NN O
particular NN NN O
cell NN NN O
type NN NN O
and NN NN O
/ NN NN O
or NN NN O
differentiation NN NN O
step NN NN O
during NN NN O
immunopoiesis NN NN O
. NN NN O
   
Using NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
on NN NN O
sections NN NN O
from NN NN O
non NN NN O
HIV NN NN O
hyperplastic NN NN O
lymph NN NN O
nodes NN NN O
, NN NN O
we NN NN O
found NN NN O
that NN NN O
the NN NN O
gene NN NN O
of NN NN O
the NN NN O
105 NN NN O
kDa NN NN O
precursor NN NN O
of NN NN O
p50 NN NN B-Protein
was NN NN O
overexpressed NN NN O
in NN NN O
the NN NN O
light NN NN O
zone NN NN O
of NN NN O
germinal NN NN O
centers NN NN O
, NN NN O
with NN NN O
a NN NN O
network NN NN O
aspect NN NN O
, NN NN O
which NN NN O
suggested NN NN O
the NN NN O
involvement NN NN O
of NN NN O
follicular NN NN O
dendritic NN NN O
cells NN NN O
( NN NN O
FDC NN NN O
) NN NN O
. NN NN O
   
By NN NN O
immunohistochemistry NN NN O
, NN NN O
p50 NN NN B-Protein
protein NN NN O
was NN NN O
detected NN NN O
in NN NN O
the NN NN O
cytoplasm NN NN O
and NN NN O
nucleus NN NN O
of NN NN O
FDC NN NN O
, NN NN O
confirming NN NN O
the NN NN O
involvement NN NN O
of NN NN O
FDC NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
p50 NN NN B-Protein
protein NN NN O
was NN NN O
detected NN NN O
in NN NN O
the NN NN O
cytoplasm NN NN O
of NN NN O
all NN NN O
lymphocytes NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
we NN NN O
focused NN NN O
our NN NN O
study NN NN O
on NN NN O
isolated NN NN O
FDC NN NN O
clusters NN NN O
from NN NN O
normal NN NN O
tonsils NN NN O
. NN NN O
   
As NN NN O
showed NN NN O
on NN NN O
tissue NN NN O
sections NN NN O
, NN NN O
we NN NN O
detected NN NN O
the NN NN O
p50 NN NN B-Protein
in NN NN O
both NN NN O
cytoplasm NN NN O
and NN NN O
nucleus NN NN O
of NN NN O
FDC NN NN O
. NN NN O
   
Nuclei NN NN O
of NN NN O
lymphocytes NN NN O
from NN NN O
FDC NN NN O
clusters NN NN O
were NN NN O
negative NN NN O
. NN NN O
   
We NN NN O
next NN NN O
studied NN NN O
p65 NN NN B-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
protein NN NN O
expression NN NN O
in NN NN O
FDC NN NN O
clusters NN NN O
. NN NN O
   
p65 NN NN B-Protein
was NN NN O
detected NN NN O
in NN NN O
the NN NN O
cytoplasm NN NN O
of NN NN O
FDC NN NN O
, NN NN O
whereas NN NN O
nuclei NN NN O
were NN NN O
negative NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
p65 NN NN B-Protein
was NN NN O
detected NN NN O
in NN NN O
the NN NN O
nuclei NN NN O
of NN NN O
some NN NN O
lymphocytes NN NN O
. NN NN O
   
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
protein NN NN O
was NN NN O
detected NN NN O
only NN NN O
in NN NN O
the NN NN O
cytoplasm NN NN O
of NN NN O
lymphocytes NN NN O
and NN NN O
not NN NN O
in NN NN O
the NN NN O
nucleus NN NN O
and NN NN O
cytoplasm NN NN O
of NN NN O
FDC NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
indicated NN NN O
that NN NN O
, NN NN O
in NN NN O
the NN NN O
context NN NN O
of NN NN O
T NN NN O
cell NN NN O
- NN NN O
dependent NN NN O
B NN NN O
cell NN NN O
immunopoiesis NN NN O
occurring NN NN O
in NN NN O
FDC NN NN O
clusters NN NN O
, NN NN O
p50 NN NN B-Protein
is NN NN O
mainly NN NN O
related NN NN O
to NN NN O
FDC NN NN O
with NN NN O
a NN NN O
massive NN NN O
overexpression NN NN O
in NN NN O
the NN NN O
nuclei NN NN O
, NN NN O
whereas NN NN O
p65 NN NN B-Protein
is NN NN O
expressed NN NN O
in NN NN O
a NN NN O
scattered NN NN O
manner NN NN O
in NN NN O
the NN NN O
nuclei NN NN O
of NN NN O
lymphocytes NN NN O
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
protein NN NN O
exclusively NN NN O
in NN NN O
the NN NN O
cytoplasm NN NN O
of NN NN O
lymphocytes NN NN O
from NN NN O
FDC NN NN O
clusters NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggested NN NN O
that NN NN O
the NN NN O
two NN NN O
subunits NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
protein NN NN O
have NN NN O
different NN NN O
roles NN NN O
in NN NN O
different NN NN O
cell NN NN O
types NN NN O
during NN NN O
B NN NN O
cell NN NN O
immunopoiesis NN NN O
. NN NN O
   
Increased NN NN O
proliferation NN NN O
, NN NN O
cytotoxicity NN NN O
, NN NN O
and NN NN O
gene NN NN O
expression NN NN O
after NN NN O
stimulation NN NN O
of NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
T NN NN O
lymphocytes NN NN O
through NN NN O
a NN NN O
surface NN NN O
ganglioside NN NN O
( NN NN O
GD3 NN NN O
) NN NN O
[ NN NN O
published NN NN O
erratum NN NN O
appears NN NN O
in NN NN O
J NN NN O
Immunol NN NN O
1994 NN NN O
Jul NN NN O
15 NN NN O
; NN NN O
153 NN NN O
( NN NN O
2 NN NN O
) NN NN O
: NN NN O
910 NN NN O
] NN NN O
   
Previous NN NN O
studies NN NN O
have NN NN O
suggested NN NN O
that NN NN O
gangliosides NN NN O
have NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
cell NN NN O
signaling NN NN O
and NN NN O
recognition NN NN O
. NN NN O
   
However NN NN O
, NN NN O
their NN NN O
specific NN NN O
function NN NN O
in NN NN O
these NN NN O
processes NN NN O
has NN NN O
not NN NN O
been NN NN O
clearly NN NN O
defined NN NN O
. NN NN O
   
A NN NN O
mAb NN NN O
, NN NN O
R24 NN NN O
, NN NN O
that NN NN O
reacts NN NN O
specifically NN NN O
with NN NN O
a NN NN O
cell NN NN O
surface NN NN O
ganglioside NN NN O
( NN NN O
GD3 NN NN O
) NN NN O
has NN NN O
been NN NN O
demonstrated NN NN O
to NN NN O
stimulate NN NN O
proliferation NN NN O
of NN NN O
T NN NN O
cells NN NN O
derived NN NN O
from NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
have NN NN O
investigated NN NN O
the NN NN O
mechanisms NN NN O
by NN NN O
which NN NN O
the NN NN O
R24 NN NN O
mAb NN NN O
affects NN NN O
T NN NN O
cell NN NN O
functions NN NN O
. NN NN O
   
We NN NN O
have NN NN O
observed NN NN O
that NN NN O
the NN NN O
R24 NN NN O
mAb NN NN O
stimulates NN NN O
GD3 NN NN O
+ NN NN O
T NN NN O
cell NN NN O
proliferation NN NN O
, NN NN O
cytotoxicity NN NN O
, NN NN O
and NN NN O
surface NN NN O
marker NN NN O
expression NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
chain NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
beta NN NN I-Protein
- NN NN O
chain NN NN O
, NN NN O
HLA NN NN O
- NN NN O
DR NN NN O
, NN NN O
CD11a NN NN B-Protein
, NN NN O
and NN NN O
CD11c NN NN B-Protein
. NN NN O
   
Additionally NN NN O
, NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
activity NN NN O
but NN NN O
not NN NN O
IL NN NN O
- NN NN O
1 NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
or NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
activity NN NN O
was NN NN O
present NN NN O
in NN NN O
culture NN NN O
supernatants NN NN O
72 NN NN O
h NN NN O
after NN NN O
R24 NN NN O
stimulation NN NN O
. NN NN O
   
In NN NN O
some NN NN O
donors NN NN O
, NN NN O
increased NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
and NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
activity NN NN O
also NN NN O
was NN NN O
detected NN NN O
after NN NN O
R24 NN NN O
treatment NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
R24 NN NN O
treatment NN NN O
resulted NN NN O
in NN NN O
translocation NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
rel NN NN I-Protein
, NN NN O
but NN NN O
little NN NN O
or NN NN O
no NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
p50 NN NN B-Protein
or NN NN O
p65 NN NN B-Protein
, NN NN O
from NN NN O
the NN NN O
cytoplasm NN NN O
to NN NN O
the NN NN O
nucleus NN NN O
and NN NN O
an NN NN O
increase NN NN O
of NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
complexes NN NN O
containing NN NN O
c NN NN B-Protein
- NN NN I-Protein
rel NN NN I-Protein
and NN NN O
p50 NN NN B-Protein
. NN NN O
   
This NN NN O
treatment NN NN O
also NN NN O
caused NN NN O
increased NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
specific NN NN O
protein NN NN O
substrates NN NN O
. NN NN O
   
R24 NN NN O
- NN NN O
stimulated NN NN O
increases NN NN O
in NN NN O
proliferation NN NN O
, NN NN O
cytotoxicity NN NN O
, NN NN O
and NN NN O
cell NN NN O
surface NN NN O
protein NN NN O
expression NN NN O
could NN NN O
be NN NN O
blocked NN NN O
by NN NN O
cyclosporin NN NN O
and NN NN O
staurosporin NN NN O
, NN NN O
indicating NN NN O
that NN NN O
cyclophilin NN NN O
/ NN NN O
calcineurin NN NN O
and NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
may NN NN O
be NN NN O
involved NN NN O
in NN NN O
the NN NN O
R24 NN NN O
signaling NN NN O
pathway NN NN O
. NN NN O
   
Additionally NN NN O
, NN NN O
herbimycin NN NN O
A NN NN O
, NN NN O
a NN NN O
tyrosine NN NN O
kinase NN NN O
inhibitor NN NN O
, NN NN O
blocked NN NN O
the NN NN O
R24 NN NN O
- NN NN O
stimulated NN NN O
increase NN NN O
in NN NN O
proliferation NN NN O
but NN NN O
not NN NN O
cytotoxicity NN NN O
at NN NN O
concentrations NN NN O
consistent NN NN O
with NN NN O
specificity NN NN O
for NN NN O
tyrosine NN NN O
kinases NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
multiple NN NN O
biochemical NN NN O
pathways NN NN O
are NN NN O
involved NN NN O
in NN NN O
the NN NN O
activation NN NN O
of NN NN O
human NN NN O
T NN NN O
cells NN NN O
by NN NN O
R24 NN NN O
. NN NN O
   
Human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
I NN NN O
Tax NN NN B-Protein
associates NN NN O
with NN NN O
and NN NN O
is NN NN O
negatively NN NN O
regulated NN NN O
by NN NN O
the NN NN O
NF NN NN B-Protein
- NN NN I-Protein
kappa NN NN I-Protein
B2 NN NN I-Protein
p100 NN NN B-Protein
gene NN NN O
product NN NN O
: NN NN O
implications NN NN O
for NN NN O
viral NN NN O
latency NN NN O
. NN NN O
   
Human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
I NN NN O
( NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
) NN NN O
is NN NN O
the NN NN O
etiologic NN NN O
agent NN NN O
of NN NN O
the NN NN O
adult NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
, NN NN O
an NN NN O
aggressive NN NN O
and NN NN O
often NN NN O
fatal NN NN O
malignancy NN NN O
of NN NN O
activated NN NN O
human NN NN O
CD4 NN NN B-Protein
T NN NN O
cells NN NN O
. NN NN O
   
HTLV NN NN O
- NN NN O
I NN NN O
encodes NN NN O
an NN NN O
essential NN NN O
40 NN NN O
- NN NN O
kDa NN NN O
protein NN NN O
termed NN NN O
Tax NN NN B-Protein
that NN NN O
not NN NN O
only NN NN O
transactivates NN NN O
the NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
of NN NN O
this NN NN O
retrovirus NN NN O
but NN NN O
also NN NN O
induces NN NN O
an NN NN O
array NN NN O
of NN NN O
cellular NN NN O
genes NN NN O
. NN NN O
   
Tax NN NN B-Protein
- NN NN O
mediated NN NN O
transformation NN NN O
of NN NN O
T NN NN O
cells NN NN O
likely NN NN O
involves NN NN O
the NN NN O
deregulated NN NN O
expression NN NN O
of NN NN O
various NN NN O
cellular NN NN O
genes NN NN O
that NN NN O
normally NN NN O
regulate NN NN O
lymphocyte NN NN O
growth NN NN O
produced NN NN O
by NN NN O
altered NN NN O
activity NN NN O
of NN NN O
various NN NN O
endogenous NN NN O
host NN NN O
transcription NN NN O
factors NN NN O
. NN NN O
   
In NN NN O
particular NN NN O
, NN NN O
Tax NN NN B-Protein
is NN NN O
capable NN NN O
of NN NN O
modulating NN NN O
the NN NN O
expression NN NN O
or NN NN O
activity NN NN O
of NN NN O
various NN NN O
host NN NN O
transcription NN NN O
factors NN NN O
, NN NN O
including NN NN O
members NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
Rel NN NN O
and NN NN O
CREB NN NN O
/ NN NN O
ATF NN NN O
families NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
cellular NN NN O
factors NN NN O
HEB NN NN O
- NN NN O
1 NN NN O
and NN NN O
p67SRF NN NN B-Protein
. NN NN O
   
An NN NN O
additional NN NN O
distinguishing NN NN O
characteristic NN NN O
of NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
infection NN NN O
is NN NN O
the NN NN O
profound NN NN O
state NN NN O
of NN NN O
viral NN NN O
latency NN NN O
that NN NN O
is NN NN O
present NN NN O
in NN NN O
circulating NN NN O
primary NN NN O
leukemic NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
Tax NN NN B-Protein
can NN NN O
physically NN NN O
associate NN NN O
with NN NN O
p100 NN NN B-Protein
, NN NN O
the NN NN O
product NN NN O
of NN NN O
the NN NN O
Rel NN NN O
- NN NN O
related NN NN O
NF NN NN B-Protein
- NN NN I-Protein
kappa NN NN I-Protein
B2 NN NN I-Protein
gene NN NN O
, NN NN O
both NN NN O
in NN NN O
transfected NN NN O
cells NN NN O
and NN NN O
in NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
- NN NN O
infected NN NN O
leukemic NN NN O
T NN NN O
- NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
the NN NN O
physical NN NN O
interaction NN NN O
of NN NN O
Tax NN NN B-Protein
with NN NN O
p100 NN NN B-Protein
leads NN NN O
to NN NN O
the NN NN O
inhibition NN NN O
of NN NN O
Tax NN NN B-Protein
- NN NN O
induced NN NN O
activation NN NN O
of NN NN O
the NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
and NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
long NN NN O
terminal NN NN O
repeats NN NN O
, NN NN O
reflecting NN NN O
p100 NN NN B-Protein
- NN NN O
mediated NN NN O
cytoplasmic NN NN O
sequestration NN NN O
of NN NN O
the NN NN O
normally NN NN O
nuclearly NN NN O
expressed NN NN O
Tax NN NN B-Protein
protein NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
a NN NN O
mutant NN NN O
of NN NN O
Tax NN NN B-Protein
that NN NN O
selectively NN NN O
fails NN NN O
to NN NN O
activate NN NN O
nuclear NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
expression NN NN O
does NN NN O
not NN NN O
associate NN NN O
with NN NN O
p100 NN NN B-Protein
. NN NN O
   
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
   
G NN NN O
( NN NN O
Anh NN NN O
) NN NN O
MTetra NN NN O
, NN NN O
a NN NN O
natural NN NN O
bacterial NN NN O
cell NN NN O
wall NN NN O
breakdown NN NN O
product NN NN O
, NN NN O
induces NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
and NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
expression NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
A NN NN O
study NN NN O
of NN NN O
the NN NN O
molecular NN NN O
mechanisms NN NN O
involved NN NN O
in NN NN O
inflammatory NN NN O
cytokine NN NN O
expression NN NN O
[ NN NN O
published NN NN O
erratum NN NN O
appears NN NN O
in NN NN O
J NN NN O
Biol NN NN O
Chem NN NN O
1994 NN NN O
Jun NN NN O
17 NN NN O
; NN NN O
269 NN NN O
( NN NN O
24 NN NN O
) NN NN O
: NN NN O
16983 NN NN O
] NN NN O
   
It NN NN O
is NN NN O
believed NN NN O
that NN NN O
induction NN NN O
of NN NN O
cytokine NN NN O
expression NN NN O
by NN NN O
bacterial NN NN O
cell NN NN O
wall NN NN O
components NN NN O
plays NN NN O
a NN NN O
role NN NN O
in NN NN O
the NN NN O
development NN NN O
and NN NN O
course NN NN O
of NN NN O
sepsis NN NN O
. NN NN O
   
However NN NN O
, NN NN O
most NN NN O
attention NN NN O
has NN NN O
been NN NN O
focused NN NN O
on NN NN O
lipopolysaccharide NN NN O
( NN NN O
LPS NN NN O
) NN NN O
. NN NN O
   
We NN NN O
studied NN NN O
the NN NN O
ability NN NN O
of NN NN O
N NN NN O
- NN NN O
acetylglucosaminyl NN NN O
- NN NN O
1 NN NN O
, NN NN O
6 NN NN O
- NN NN O
anhydro NN NN O
- NN NN O
N NN NN O
- NN NN O
acetylmuramyl NN NN O
- NN NN O
L NN NN O
- NN NN O
alanyl NN NN O
- NN NN O
D NN NN O
- NN NN O
isoglutamyl NN NN O
- NN NN O
m NN NN O
- NN NN O
diaminopimelyl NN NN O
- NN NN O
D NN NN O
- NN NN O
alanine NN NN O
( NN NN O
G NN NN O
( NN NN O
Anh NN NN O
) NN NN O
MTetra NN NN O
) NN NN O
, NN NN O
a NN NN O
naturally NN NN O
occurring NN NN O
breakdown NN NN O
product NN NN O
of NN NN O
peptidoglycan NN NN O
that NN NN O
is NN NN O
produced NN NN O
by NN NN O
soluble NN NN O
lytic NN NN O
transglycosylase NN NN O
of NN NN O
Escherichia NN NN O
coli NN NN O
, NN NN O
to NN NN O
induce NN NN O
cytokine NN NN O
expression NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
G NN NN O
( NN NN O
Anh NN NN O
) NN NN O
MTetra NN NN O
was NN NN O
found NN NN O
to NN NN O
strongly NN NN O
induce NN NN O
interleukin NN NN B-Protein
( NN NN I-Protein
IL NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
mRNA NN NN O
expression NN NN O
after NN NN O
2 NN NN O
h NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
protein NN NN O
secretion NN NN O
after NN NN O
48 NN NN O
h NN NN O
of NN NN O
activation NN NN O
. NN NN O
   
The NN NN O
increase NN NN O
in NN NN O
mRNA NN NN O
accumulation NN NN O
was NN NN O
at NN NN O
least NN NN O
partly NN NN O
due NN NN O
to NN NN O
an NN NN O
increase NN NN O
in NN NN O
the NN NN O
transcription NN NN O
rates NN NN O
of NN NN O
the NN NN O
respective NN NN O
genes NN NN O
and NN NN O
was NN NN O
accompanied NN NN O
by NN NN O
a NN NN O
strong NN NN O
induction NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
activator NN NN O
protein NN NN O
- NN NN O
1 NN NN O
transcription NN NN O
factor NN NN O
expression NN NN O
. NN NN O
   
Experiments NN NN O
using NN NN O
inhibitors NN NN O
of NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
, NN NN O
protein NN NN O
kinase NN NN O
A NN NN O
, NN NN O
and NN NN O
tyrosine NN NN O
kinase NN NN O
- NN NN O
dependent NN NN O
pathways NN NN O
revealed NN NN O
that NN NN O
G NN NN O
( NN NN O
Anh NN NN O
) NN NN O
MTetra NN NN O
- NN NN O
induced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
mRNA NN NN O
expression NN NN O
involves NN NN O
activation NN NN O
of NN NN O
an NN NN O
H7 NN NN O
- NN NN O
inhibitable NN NN O
pathway NN NN O
. NN NN O
   
By NN NN O
using NN NN O
the NN NN O
protein NN NN O
synthesis NN NN O
inhibitor NN NN O
cycloheximide NN NN O
, NN NN O
it NN NN O
was NN NN O
shown NN NN O
that NN NN O
G NN NN O
( NN NN O
Anh NN NN O
) NN NN O
MTetra NN NN O
- NN NN O
induced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
mRNA NN NN O
expression NN NN O
depends NN NN O
on NN NN O
the NN NN O
synthesis NN NN O
of NN NN O
new NN NN O
protein NN NN O
, NN NN O
whereas NN NN O
G NN NN O
( NN NN O
Anh NN NN O
) NN NN O
MTetra NN NN O
- NN NN O
induced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
mRNA NN NN O
accumulation NN NN O
does NN NN O
not NN NN O
. NN NN O
   
When NN NN O
responses NN NN O
to NN NN O
G NN NN O
( NN NN O
Anh NN NN O
) NN NN O
MTetra NN NN O
were NN NN O
compared NN NN O
with NN NN O
those NN NN O
to NN NN O
LPS NN NN O
and NN NN O
muramyldipeptide NN NN O
( NN NN O
MDP NN NN O
) NN NN O
, NN NN O
it NN NN O
was NN NN O
found NN NN O
that NN NN O
the NN NN O
optimal NN NN O
response NN NN O
to NN NN O
G NN NN O
( NN NN O
Anh NN NN O
) NN NN O
MTetra NN NN O
induction NN NN O
was NN NN O
similar NN NN O
to NN NN O
that NN NN O
of NN NN O
LPS NN NN O
but NN NN O
significantly NN NN O
higher NN NN O
than NN NN O
the NN NN O
response NN NN O
to NN NN O
MDP NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
maximal NN NN O
G NN NN O
( NN NN O
Anh NN NN O
) NN NN O
MTetra NN NN O
- NN NN O
induced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
mRNA NN NN O
expression NN NN O
could NN NN O
be NN NN O
enhanced NN NN O
by NN NN O
co NN NN O
- NN NN O
stimulation NN NN O
with NN NN O
LPS NN NN O
or NN NN O
MDP NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
different NN NN O
receptors NN NN O
and NN NN O
/ NN NN O
or NN NN O
transduction NN NN O
pathways NN NN O
were NN NN O
involved NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
G NN NN O
( NN NN O
Anh NN NN O
) NN NN O
MTetra NN NN O
induces NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
expression NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
suggesting NN NN O
a NN NN O
possible NN NN O
role NN NN O
for NN NN O
G NN NN O
( NN NN O
Anh NN NN O
) NN NN O
MTetra NN NN O
in NN NN O
the NN NN O
release NN NN O
of NN NN O
cytokines NN NN O
during NN NN O
sepsis NN NN O
. NN NN O
   
The NN NN O
p65 NN NN B-Protein
subunit NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
regulates NN NN O
I NN NN O
kappa NN NN O
B NN NN O
by NN NN O
two NN NN O
distinct NN NN O
mechanisms NN NN O
. NN NN O
   
Transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
( NN NN O
p50 NN NN B-Protein
/ NN NN O
p65 NN NN B-Protein
) NN NN O
is NN NN O
generally NN NN O
localized NN NN O
to NN NN O
the NN NN O
cytoplasm NN NN O
by NN NN O
its NN NN O
inhibitor NN NN O
I NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
Overproduced NN NN O
I NN NN O
kappa NN NN O
B NN NN O
, NN NN O
free NN NN O
from NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
is NN NN O
rapidly NN NN O
degraded NN NN O
. NN NN O
   
Overexpression NN NN O
of NN NN O
p65 NN NN B-Protein
increases NN NN O
endogenous NN NN O
I NN NN O
kappa NN NN O
B NN NN O
protein NN NN O
in NN NN O
both NN NN O
carcinoma NN NN O
and NN NN O
lymphoid NN NN O
cells NN NN O
by NN NN O
two NN NN O
mechanisms NN NN O
: NN NN O
protein NN NN O
stabilization NN NN O
and NN NN O
increased NN NN O
transcription NN NN O
of NN NN O
I NN NN O
kappa NN NN O
B NN NN O
mRNA NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
p65 NN NN B-Protein
delta NN NN I-Protein
, NN NN O
a NN NN O
naturally NN NN O
occurring NN NN O
splice NN NN O
variant NN NN O
, NN NN O
fails NN NN O
to NN NN O
markedly NN NN O
augment NN NN O
I NN NN O
kappa NN NN O
B NN NN O
protein NN NN O
levels NN NN O
. NN NN O
   
Both NN NN O
overexpressed NN NN O
p65 NN NN B-Protein
and NN NN O
coexpressed NN NN O
p50 NN NN B-Protein
are NN NN O
cytoplasmic NN NN O
, NN NN O
whereas NN NN O
p65 NN NN B-Protein
delta NN NN I-Protein
is NN NN O
partly NN NN O
nuclear NN NN O
, NN NN O
indicating NN NN O
that NN NN O
the NN NN O
I NN NN O
kappa NN NN O
B NN NN O
induced NN NN O
by NN NN O
p65 NN NN B-Protein
can NN NN O
maintain NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
the NN NN O
cytoplasm NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
p65 NN NN B-Protein
and NN NN O
I NN NN O
kappa NN NN O
B NN NN O
are NN NN O
linked NN NN O
in NN NN O
an NN NN O
autoregulatory NN NN O
loop NN NN O
, NN NN O
ensuring NN NN O
that NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
is NN NN O
held NN NN O
in NN NN O
the NN NN O
cytoplasm NN NN O
until NN NN O
cells NN NN O
are NN NN O
specifically NN NN O
induced NN NN O
to NN NN O
translocate NN NN O
it NN NN O
to NN NN O
the NN NN O
nucleus NN NN O
. NN NN O
   
A NN NN O
chimeric NN NN O
type NN NN O
II NN NN O
/ NN NN O
type NN NN O
I NN NN O
interleukin NN NN O
- NN NN O
1 NN NN O
receptor NN NN O
can NN NN O
mediate NN NN O
interleukin NN NN O
- NN NN O
1 NN NN O
induction NN NN O
of NN NN O
gene NN NN O
expression NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
type NN NN B-Protein
I NN NN I-Protein
interleukin NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
receptor NN NN I-Protein
( NN NN O
IL NN NN O
- NN NN O
1R NN NN O
) NN NN O
is NN NN O
capable NN NN O
of NN NN O
transducing NN NN O
a NN NN O
signal NN NN O
resulting NN NN O
in NN NN O
promoter NN NN O
activation NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
This NN NN O
signal NN NN O
transduction NN NN O
is NN NN O
dependent NN NN O
on NN NN O
the NN NN O
cytoplasmic NN NN O
domain NN NN O
, NN NN O
which NN NN O
consists NN NN O
of NN NN O
213 NN NN O
amino NN NN O
acids NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
to NN NN O
the NN NN O
type NN NN O
I NN NN O
receptor NN NN O
, NN NN O
the NN NN O
type NN NN B-Protein
II NN NN I-Protein
IL NN NN I-Protein
- NN NN I-Protein
1R NN NN I-Protein
has NN NN O
a NN NN O
small NN NN O
cytoplasmic NN NN O
tail NN NN O
, NN NN O
and NN NN O
it NN NN O
is NN NN O
not NN NN O
clear NN NN O
whether NN NN O
this NN NN O
receptor NN NN O
is NN NN O
a NN NN O
signal NN NN O
- NN NN O
transducing NN NN O
or NN NN O
a NN NN O
regulatory NN NN O
molecule NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
report NN NN O
that NN NN O
the NN NN O
type NN NN B-Protein
II NN NN I-Protein
IL NN NN I-Protein
- NN NN I-Protein
1R NN NN I-Protein
does NN NN O
not NN NN O
mediate NN NN O
gene NN NN O
activation NN NN O
in NN NN O
Jurkat NN NN O
cells NN NN O
. NN NN O
   
However NN NN O
, NN NN O
a NN NN O
hybrid NN NN O
receptor NN NN O
composed NN NN O
of NN NN O
the NN NN O
extracellular NN NN O
and NN NN O
transmembrane NN NN O
regions NN NN O
of NN NN O
the NN NN O
human NN NN O
type NN NN B-Protein
II NN NN I-Protein
interleukin NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
fused NN NN O
to NN NN O
the NN NN O
cytoplasmic NN NN O
domain NN NN O
of NN NN O
the NN NN O
human NN NN O
type NN NN B-Protein
I NN NN I-Protein
IL NN NN I-Protein
- NN NN I-Protein
1R NN NN I-Protein
was NN NN O
capable NN NN O
of NN NN O
transducing NN NN O
a NN NN O
signal NN NN O
across NN NN O
the NN NN O
membrane NN NN O
resulting NN NN O
in NN NN O
a NN NN O
pattern NN NN O
of NN NN O
gene NN NN O
activation NN NN O
identical NN NN O
to NN NN O
that NN NN O
mediated NN NN O
by NN NN O
the NN NN O
type NN NN O
I NN NN O
IL NN NN O
- NN NN O
1R NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
indicated NN NN O
that NN NN O
the NN NN O
extracellular NN NN O
domain NN NN O
of NN NN O
the NN NN O
type NN NN B-Protein
II NN NN I-Protein
IL NN NN I-Protein
- NN NN I-Protein
1R NN NN I-Protein
was NN NN O
capable NN NN O
of NN NN O
functionally NN NN O
interacting NN NN O
with NN NN O
interleukin NN NN O
- NN NN O
1 NN NN O
and NN NN O
transmitting NN NN O
the NN NN O
resulting NN NN O
signal NN NN O
to NN NN O
a NN NN O
heterologous NN NN O
cytoplasmic NN NN O
domain NN NN O
. NN NN O
   
Mice NN NN O
deficient NN NN O
for NN NN O
the NN NN O
55 NN NN B-Protein
kd NN NN I-Protein
tumor NN NN I-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
receptor NN NN I-Protein
are NN NN O
resistant NN NN O
to NN NN O
endotoxic NN NN O
shock NN NN O
, NN NN O
yet NN NN O
succumb NN NN O
to NN NN O
L NN NN O
. NN NN O
monocytogenes NN NN O
infection NN NN O
. NN NN O
   
The NN NN O
multiple NN NN O
biological NN NN O
activities NN NN O
of NN NN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
( NN NN O
TNF NN NN O
) NN NN O
are NN NN O
mediated NN NN O
by NN NN O
two NN NN O
distinct NN NN O
cell NN NN O
surface NN NN O
receptors NN NN O
of NN NN O
55 NN NN O
kd NN NN O
( NN NN O
TNFRp55 NN NN B-Protein
) NN NN O
and NN NN O
75 NN NN O
kd NN NN O
( NN NN O
TNFRp75 NN NN B-Protein
) NN NN O
. NN NN O
   
Using NN NN O
gene NN NN O
targeting NN NN O
, NN NN O
we NN NN O
generated NN NN O
a NN NN O
TNFRp55 NN NN B-Protein
- NN NN O
deficient NN NN O
mouse NN NN O
strain NN NN O
. NN NN O
   
Cells NN NN O
from NN NN O
TNFRp55 NN NN B-Protein
- NN NN O
/ NN NN O
- NN NN O
mutant NN NN O
mice NN NN O
lack NN NN O
expression NN NN O
of NN NN O
TNFRp55 NN NN B-Protein
but NN NN O
display NN NN O
normal NN NN O
numbers NN NN O
of NN NN O
high NN NN O
affinity NN NN O
TNFRp75 NN NN B-Protein
molecules NN NN O
. NN NN O
   
Thymocyte NN NN O
development NN NN O
and NN NN O
lymphocyte NN NN O
populations NN NN O
are NN NN O
unaltered NN NN O
, NN NN O
and NN NN O
clonal NN NN O
deletion NN NN O
of NN NN O
potentially NN NN O
self NN NN O
- NN NN O
reactive NN NN O
T NN NN O
cells NN NN O
is NN NN O
not NN NN O
impaired NN NN O
. NN NN O
   
However NN NN O
, NN NN O
TNF NN NN O
signaling NN NN O
is NN NN O
largely NN NN O
abolished NN NN O
, NN NN O
as NN NN O
judged NN NN O
by NN NN O
the NN NN O
failure NN NN O
of NN NN O
TNF NN NN O
to NN NN O
induce NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
T NN NN O
lymphocytes NN NN O
from NN NN O
TNFRp55 NN NN B-Protein
- NN NN O
deficient NN NN O
mice NN NN O
. NN NN O
   
The NN NN O
loss NN NN O
of NN NN O
TNFRp55 NN NN B-Protein
function NN NN O
renders NN NN O
mice NN NN O
resistant NN NN O
to NN NN O
lethal NN NN O
dosages NN NN O
of NN NN O
either NN NN O
lipopolysaccharides NN NN O
or NN NN O
S NN NN O
. NN NN O
aureus NN NN O
enterotoxin NN NN B-Protein
B NN NN I-Protein
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
TNFRp55 NN NN B-Protein
- NN NN O
deficient NN NN O
mice NN NN O
are NN NN O
severely NN NN O
impaired NN NN O
to NN NN O
clear NN NN O
L NN NN O
. NN NN O
monocytogenes NN NN O
and NN NN O
readily NN NN O
succumb NN NN O
to NN NN O
infection NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
the NN NN O
55 NN NN B-Protein
kd NN NN I-Protein
TNFR NN NN I-Protein
plays NN NN O
a NN NN O
decisive NN NN O
role NN NN O
in NN NN O
the NN NN O
host NN NN O
' NN NN O
s NN NN O
defense NN NN O
against NN NN O
microorganisms NN NN O
and NN NN O
their NN NN O
pathogenic NN NN O
factors NN NN O
. NN NN O
   
Minimally NN NN O
modified NN NN O
low NN NN O
density NN NN O
lipoprotein NN NN O
- NN NN O
induced NN NN O
inflammatory NN NN O
responses NN NN O
in NN NN O
endothelial NN NN O
cells NN NN O
are NN NN O
mediated NN NN O
by NN NN O
cyclic NN NN O
adenosine NN NN O
monophosphate NN NN O
. NN NN O
   
We NN NN O
have NN NN O
previously NN NN O
shown NN NN O
that NN NN O
minimally NN NN O
oxidized NN NN O
LDL NN NN O
( NN NN O
MM NN NN O
- NN NN O
LDL NN NN O
) NN NN O
activated NN NN O
endothelial NN NN O
cells NN NN O
to NN NN O
increase NN NN O
their NN NN O
interaction NN NN O
with NN NN O
monocytes NN NN O
but NN NN O
not NN NN O
neutrophils NN NN O
, NN NN O
inducing NN NN O
monocyte NN NN O
but NN NN O
not NN NN O
neutrophil NN NN O
binding NN NN O
and NN NN O
synthesis NN NN O
of NN NN O
monocyte NN NN B-Protein
chemotactic NN NN I-Protein
protein NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
monocyte NN NN B-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
( NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
) NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
studies NN NN O
we NN NN O
have NN NN O
examined NN NN O
the NN NN O
signaling NN NN O
pathways NN NN O
by NN NN O
which NN NN O
this NN NN O
monocyte NN NN O
- NN NN O
specific NN NN O
response NN NN O
is NN NN O
induced NN NN O
. NN NN O
   
Both NN NN O
induction NN NN O
of NN NN O
monocyte NN NN O
binding NN NN O
and NN NN O
mRNA NN NN O
levels NN NN O
for NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
by NN NN O
MM NN NN O
- NN NN O
LDL NN NN O
were NN NN O
not NN NN O
inhibited NN NN O
in NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
- NN NN O
depleted NN NN O
endothelial NN NN O
cells NN NN O
. NN NN O
   
A NN NN O
number NN NN O
of NN NN O
our NN NN O
studies NN NN O
indicate NN NN O
that NN NN O
cAMP NN NN O
is NN NN O
the NN NN O
second NN NN O
messenger NN NN O
for NN NN O
the NN NN O
effects NN NN O
of NN NN O
MM NN NN O
- NN NN O
LDL NN NN O
cited NN NN O
above NN NN O
. NN NN O
   
Incubation NN NN O
of NN NN O
endothelial NN NN O
cells NN NN O
with NN NN O
MM NN NN O
- NN NN O
LDL NN NN O
caused NN NN O
a NN NN O
173 NN NN O
% NN NN O
increase NN NN O
in NN NN O
intracellular NN NN O
cAMP NN NN O
levels NN NN O
. NN NN O
   
Agents NN NN O
which NN NN O
increased NN NN O
cAMP NN NN O
levels NN NN O
, NN NN O
including NN NN O
cholera NN NN O
toxin NN NN O
, NN NN O
pertussis NN NN O
toxin NN NN O
, NN NN O
dibutyryl NN NN O
cAMP NN NN O
, NN NN O
and NN NN O
isoproterenol NN NN O
mimicked NN NN O
the NN NN O
actions NN NN O
of NN NN O
MM NN NN O
- NN NN O
LDL NN NN O
. NN NN O
   
Agents NN NN O
which NN NN O
elevated NN NN O
cAMP NN NN O
were NN NN O
also NN NN O
shown NN NN O
to NN NN O
activate NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
, NN NN O
suggesting NN NN O
a NN NN O
role NN NN O
for NN NN O
this NN NN O
transcription NN NN O
factor NN NN O
in NN NN O
activation NN NN O
of NN NN O
monocyte NN NN O
- NN NN O
endothelial NN NN O
interactions NN NN O
. NN NN O
   
Although NN NN O
endothelial NN NN B-Protein
leukocyte NN NN I-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
( NN NN O
ELAM NN NN B-Protein
) NN NN O
mRNA NN NN O
synthesis NN NN O
can NN NN O
be NN NN O
regulated NN NN O
by NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
, NN NN O
ELAM NN NN B-Protein
was NN NN O
not NN NN O
expressed NN NN O
and NN NN O
ELAM NN NN B-Protein
mRNA NN NN O
was NN NN O
only NN NN O
slightly NN NN O
elevated NN NN O
in NN NN O
response NN NN O
to NN NN O
MM NN NN O
- NN NN O
LDL NN NN O
. NN NN O
   
We NN NN O
present NN NN O
evidence NN NN O
that NN NN O
induction NN NN O
of NN NN O
neutrophil NN NN O
binding NN NN O
by NN NN O
LPS NN NN O
is NN NN O
actually NN NN O
suppressed NN NN O
by NN NN O
agents NN NN O
that NN NN O
elevated NN NN O
cAMP NN NN O
levels NN NN O
. NN NN O
   
Tumor NN NN O
necrosis NN NN O
factor NN NN O
receptor NN NN O
expression NN NN O
and NN NN O
signal NN NN O
transduction NN NN O
in NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
- NN NN O
infected NN NN O
cells NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
To NN NN O
examine NN NN O
the NN NN O
inter NN NN O
- NN NN O
relationship NN NN O
between NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
infection NN NN O
and NN NN O
the NN NN O
cell NN NN O
surface NN NN O
receptors NN NN O
for NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
( NN NN I-Protein
TNF NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
an NN NN O
immunoregulatory NN NN O
cytokine NN NN O
that NN NN O
can NN NN O
enhance NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
. NN NN O
   
DESIGN NN NN O
: NN NN O
Infected NN NN O
promyelocytic NN NN O
and NN NN O
promonocytic NN NN O
cells NN NN O
were NN NN O
examined NN NN O
because NN NN O
they NN NN O
normally NN NN O
express NN NN O
both NN NN O
types NN NN O
of NN NN O
TNF NN NN O
receptors NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
TNF NN NN O
receptor NN NN O
surface NN NN O
expression NN NN O
was NN NN O
determined NN NN O
by NN NN O
specific NN NN O
monoclonal NN NN O
antibody NN NN O
recognition NN NN O
and NN NN O
flow NN NN O
cytometry NN NN O
, NN NN O
and NN NN O
signal NN NN O
transduction NN NN O
was NN NN O
detected NN NN O
by NN NN O
gel NN NN O
shift NN NN O
analysis NN NN O
. NN NN O
   
HIV NN NN O
- NN NN O
1 NN NN O
activation NN NN O
and NN NN O
expression NN NN O
was NN NN O
quantitated NN NN O
by NN NN O
reverse NN NN B-Protein
transcriptase NN NN I-Protein
assay NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
In NN NN O
the NN NN O
OM NN NN O
- NN NN O
10 NN NN O
. NN NN O
1 NN NN O
promyelocytic NN NN O
model NN NN O
of NN NN O
chronic NN NN O
infection NN NN O
, NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
induced NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
expression NN NN O
also NN NN O
resulted NN NN O
in NN NN O
a NN NN O
substantial NN NN O
increase NN NN O
in NN NN O
75 NN NN B-Protein
kd NN NN I-Protein
TNF NN NN I-Protein
receptor NN NN I-Protein
( NN NN O
TR75 NN NN B-Protein
) NN NN O
expression NN NN O
although NN NN O
55 NN NN B-Protein
kD NN NN I-Protein
TNF NN NN I-Protein
receptor NN NN I-Protein
( NN NN O
TR55 NN NN B-Protein
) NN NN O
levels NN NN O
were NN NN O
not NN NN O
dramatically NN NN O
altered NN NN O
. NN NN O
   
A NN NN O
series NN NN O
of NN NN O
uninfected NN NN O
parental NN NN O
HL NN NN O
- NN NN O
60 NN NN O
subclones NN NN O
all NN NN O
reduced NN NN O
TR75 NN NN B-Protein
surface NN NN O
expression NN NN O
in NN NN O
response NN NN O
to NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
treatment NN NN O
. NN NN O
   
Enhanced NN NN O
TR75 NN NN B-Protein
expression NN NN O
on NN NN O
OM NN NN O
- NN NN O
10 NN NN O
. NN NN O
1 NN NN O
cells NN NN O
followed NN NN O
the NN NN O
same NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
dose NN NN O
dependency NN NN O
as NN NN O
that NN NN O
observed NN NN O
for NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
production NN NN O
. NN NN O
   
An NN NN O
increase NN NN O
in NN NN O
TR75 NN NN B-Protein
expression NN NN O
was NN NN O
also NN NN O
evident NN NN O
during NN NN O
the NN NN O
peak NN NN O
of NN NN O
an NN NN O
acute NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
infection NN NN O
of NN NN O
HL NN NN O
- NN NN O
60 NN NN O
promyelocytes NN NN O
. NN NN O
   
Although NN NN O
TR55 NN NN B-Protein
expression NN NN O
was NN NN O
unaltered NN NN O
during NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
induced NN NN O
HIV NN NN O
activation NN NN O
, NN NN O
this NN NN O
receptor NN NN O
was NN NN O
still NN NN O
involved NN NN O
in NN NN O
the NN NN O
viral NN NN O
activation NN NN O
process NN NN O
. NN NN O
   
Antibody NN NN O
cross NN NN O
- NN NN O
linking NN NN O
of NN NN O
TR55 NN NN B-Protein
, NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
exogenous NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
induced NN NN O
maximal NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
expression NN NN O
, NN NN O
an NN NN O
up NN NN O
- NN NN O
modulation NN NN O
of NN NN O
surface NN NN O
TR75 NN NN B-Protein
, NN NN O
and NN NN O
nuclear NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activity NN NN O
in NN NN O
OM NN NN O
- NN NN O
10 NN NN O
. NN NN O
1 NN NN O
cultures NN NN O
. NN NN O
   
Surprisingly NN NN O
, NN NN O
this NN NN O
was NN NN O
the NN NN O
case NN NN O
even NN NN O
when NN NN O
an NN NN O
antagonistic NN NN O
anti NN NN O
- NN NN O
TR55 NN NN B-Protein
antibody NN NN O
was NN NN O
used NN NN O
. NN NN O
   
Anti NN NN O
- NN NN O
TR55 NN NN B-Protein
antibody NN NN O
cross NN NN O
- NN NN O
linking NN NN O
in NN NN O
chronically NN NN O
infected NN NN O
U1 NN NN O
promonocytic NN NN O
cultures NN NN O
could NN NN O
only NN NN O
partially NN NN O
substitute NN NN O
for NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
induced NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
expression NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Our NN NN O
results NN NN O
demonstrated NN NN O
that NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
infection NN NN O
can NN NN O
selectively NN NN O
influence NN NN O
the NN NN O
surface NN NN O
expression NN NN O
of NN NN O
TNF NN NN O
receptors NN NN O
, NN NN O
potentially NN NN O
influencing NN NN O
its NN NN O
own NN NN O
expression NN NN O
and NN NN O
altering NN NN O
normal NN NN O
immunoregulatory NN NN O
signal NN NN O
transduction NN NN O
. NN NN O
   
Human NN NN O
immunodeficiency NN NN O
viruses NN NN O
containing NN NN O
heterologous NN NN O
enhancer NN NN O
/ NN NN O
promoters NN NN O
are NN NN O
replication NN NN O
competent NN NN O
and NN NN O
exhibit NN NN O
different NN NN O
lymphocyte NN NN O
tropisms NN NN O
. NN NN O
   
The NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
( NN NN O
HIV NN NN O
) NN NN O
type NN NN O
1 NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
( NN NN O
LTR NN NN O
) NN NN O
contains NN NN O
binding NN NN O
sites NN NN O
for NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
and NN NN O
the NN NN O
constitutively NN NN O
expressed NN NN O
transcription NN NN O
factor NN NN O
Sp1 NN NN B-Protein
, NN NN O
both NN NN O
of NN NN O
which NN NN O
are NN NN O
highly NN NN O
conserved NN NN O
in NN NN O
HIV NN NN O
and NN NN O
simian NN NN O
immunodeficiency NN NN O
virus NN NN O
isolates NN NN O
. NN NN O
   
To NN NN O
delineate NN NN O
the NN NN O
effects NN NN O
of NN NN O
these NN NN O
motifs NN NN O
on NN NN O
the NN NN O
replicative NN NN O
capacity NN NN O
of NN NN O
HIV NN NN O
and NN NN O
to NN NN O
explore NN NN O
the NN NN O
possibility NN NN O
of NN NN O
extending NN NN O
the NN NN O
virus NN NN O
host NN NN O
range NN NN O
, NN NN O
known NN NN O
heterologous NN NN O
enhancer NN NN O
/ NN NN O
promoters NN NN O
were NN NN O
inserted NN NN O
into NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
in NN NN O
place NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
Sp1 NN NN B-Protein
binding NN NN O
sites NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
these NN NN O
substitutions NN NN O
on NN NN O
viral NN NN O
replication NN NN O
in NN NN O
transfected NN NN O
HeLa NN NN O
cells NN NN O
and NN NN O
on NN NN O
HIV NN NN O
infection NN NN O
of NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
lymphocytes NN NN O
or NN NN O
continuous NN NN O
T NN NN O
- NN NN O
leukemia NN NN O
cell NN NN O
lines NN NN O
were NN NN O
evaluated NN NN O
. NN NN O
   
HIVs NN NN O
in NN NN O
which NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
Sp1 NN NN B-Protein
enhancer NN NN O
plus NN NN O
the NN NN O
downstream NN NN O
TATA NN NN O
element NN NN O
were NN NN O
replaced NN NN O
with NN NN O
heterologous NN NN O
enhancer NN NN O
/ NN NN O
promoters NN NN O
were NN NN O
also NN NN O
constructed NN NN O
. NN NN O
   
Viruses NN NN O
containing NN NN O
the NN NN O
human NN NN O
cytomegalovirus NN NN O
immediate NN NN O
- NN NN O
early NN NN O
enhancer NN NN O
exhibited NN NN O
infectious NN NN O
kinetics NN NN O
similar NN NN O
to NN NN O
that NN NN O
of NN NN O
wild NN NN O
- NN NN O
type NN NN O
HIV NN NN O
in NN NN O
activated NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
lymphocytes NN NN O
and NN NN O
AA2 NN NN O
cells NN NN O
but NN NN O
replicated NN NN O
less NN NN O
efficiently NN NN O
in NN NN O
H9 NN NN O
and NN NN O
CEM NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
studies NN NN O
indicate NN NN O
that NN NN O
heterologous NN NN O
enhancer NN NN O
elements NN NN O
are NN NN O
capable NN NN O
of NN NN O
restoring NN NN O
Tat NN NN B-Protein
responsiveness NN NN O
to NN NN O
the NN NN O
HIV NN NN O
LTR NN NN O
in NN NN O
the NN NN O
context NN NN O
of NN NN O
directing NN NN O
reporter NN NN O
gene NN NN O
expression NN NN O
as NN NN O
well NN NN O
as NN NN O
in NN NN O
the NN NN O
production NN NN O
of NN NN O
infectious NN NN O
progeny NN NN O
virions NN NN O
. NN NN O
   
Ras NN NN O
oncogene NN NN O
transformation NN NN O
of NN NN O
human NN NN O
B NN NN O
lymphoblasts NN NN O
is NN NN O
associated NN NN O
with NN NN O
lymphocyte NN NN O
activation NN NN O
and NN NN O
with NN NN O
a NN NN O
block NN NN O
of NN NN O
differentiation NN NN O
. NN NN O
   
The NN NN O
p21ras NN NN B-Protein
small NN NN O
GTP NN NN O
binding NN NN O
proteins NN NN O
participate NN NN O
in NN NN O
signal NN NN O
transduction NN NN O
from NN NN O
cell NN NN O
surface NN NN O
receptors NN NN O
and NN NN O
affect NN NN O
neoplastic NN NN O
transformation NN NN O
and NN NN O
development NN NN O
in NN NN O
many NN NN O
different NN NN O
cell NN NN O
types NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
study NN NN O
, NN NN O
we NN NN O
examined NN NN O
the NN NN O
relationship NN NN O
between NN NN O
ras NN NN O
transformation NN NN O
and NN NN O
differentiation NN NN O
of NN NN O
human NN NN O
B NN NN O
lymphocytes NN NN O
. NN NN O
   
We NN NN O
show NN NN O
that NN NN O
the NN NN O
constitutive NN NN O
expression NN NN O
of NN NN O
the NN NN O
T24 NN NN O
Ha NN NN O
- NN NN O
ras NN NN O
oncogene NN NN O
in NN NN O
EBV NN NN O
- NN NN O
immortalized NN NN O
B NN NN O
lymphoblasts NN NN O
was NN NN O
associated NN NN O
with NN NN O
the NN NN O
induction NN NN O
of NN NN O
the NN NN O
interleukin NN NN B-Protein
2 NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
subunit NN NN O
, NN NN O
with NN NN O
an NN NN O
impaired NN NN O
immunoglobulin NN NN O
gene NN NN O
expression NN NN O
, NN NN O
altered NN NN O
adhesion NN NN O
properties NN NN O
and NN NN O
increased NN NN O
survival NN NN O
in NN NN O
serum NN NN O
- NN NN O
free NN NN O
medium NN NN O
. NN NN O
   
Since NN NN O
induction NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
subunit NN NN O
is NN NN O
a NN NN O
hallmark NN NN O
of NN NN O
lymphocyte NN NN O
activation NN NN O
, NN NN O
we NN NN O
suggest NN NN O
that NN NN O
p21ras NN NN B-Protein
naturally NN NN O
triggers NN NN O
B NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
The NN NN O
ras NN NN O
- NN NN O
transformed NN NN O
lymphocytes NN NN O
displayed NN NN O
a NN NN O
fully NN NN O
functional NN NN O
IL NN NN O
- NN NN O
2r NN NN O
, NN NN O
as NN NN O
assessed NN NN O
by NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
induction NN NN O
following NN NN O
treatment NN NN O
with NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
; NN NN O
nevertheless NN NN O
, NN NN O
they NN NN O
were NN NN O
not NN NN O
growth NN NN O
stimulated NN NN O
by NN NN O
this NN NN O
lymphokine NN NN O
. NN NN O
   
The NN NN O
decreased NN NN O
expression NN NN O
of NN NN O
immunoglobulin NN NN O
genes NN NN O
indicates NN NN O
that NN NN O
the NN NN O
ras NN NN O
oncogene NN NN O
blocks NN NN O
terminal NN NN O
differentiation NN NN O
to NN NN O
plasma NN NN O
cells NN NN O
, NN NN O
possibly NN NN O
by NN NN O
inhibiting NN NN O
the NN NN O
activity NN NN O
of NN NN O
lymphocyte NN NN O
- NN NN O
specific NN NN O
transcription NN NN O
factors NN NN O
. NN NN O
   
Somewhat NN NN O
unexpectedly NN NN O
, NN NN O
the NN NN O
constitutive NN NN O
p21ras NN NN B-Protein
activity NN NN O
did NN NN O
not NN NN O
cause NN NN O
an NN NN O
increased NN NN O
DNA NN NN O
binding NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
PEA1 NN NN O
( NN NN O
AP1 NN NN O
) NN NN O
, NN NN O
PEA3 NN NN B-Protein
, NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
or NN NN O
NF NN NN O
- NN NN O
kB NN NN O
. NN NN O
   
The NN NN O
c NN NN B-Protein
- NN NN I-Protein
rel NN NN I-Protein
protooncogene NN NN O
product NN NN O
represses NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
p65 NN NN B-Protein
- NN NN O
mediated NN NN O
transcriptional NN NN O
activation NN NN O
of NN NN O
the NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
of NN NN O
type NN NN O
1 NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
. NN NN O
   
The NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
( NN NN O
LTR NN NN O
) NN NN O
of NN NN O
the NN NN O
type NN NN O
1 NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
and NN NN O
the NN NN O
5 NN NN O
' NN NN O
regulatory NN NN O
region NN NN O
of NN NN O
the NN NN O
gene NN NN O
encoding NN NN O
the NN NN O
interleukin NN NN B-Protein
2 NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
subunit NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
share NN NN O
functional NN NN O
kappa NN NN O
B NN NN O
enhancer NN NN O
elements NN NN O
involved NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
these NN NN O
inducible NN NN O
transcription NN NN O
units NN NN O
during NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
These NN NN O
kappa NN NN O
B NN NN O
enhancer NN NN O
elements NN NN O
are NN NN O
recognized NN NN O
by NN NN O
a NN NN O
structurally NN NN O
related NN NN O
family NN NN O
of NN NN O
interactive NN NN O
proteins NN NN O
that NN NN O
includes NN NN O
p50 NN NN B-Protein
, NN NN O
p65 NN NN B-Protein
, NN NN O
and NN NN O
the NN NN O
product NN NN O
of NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
rel NN NN I-Protein
protooncogene NN NN O
( NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
) NN NN O
. NN NN O
   
Recent NN NN O
biochemical NN NN O
studies NN NN O
have NN NN O
shown NN NN O
that NN NN O
p65 NN NN B-Protein
and NN NN O
p50 NN NN B-Protein
form NN NN O
the NN NN O
prototypical NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
complex NN NN O
, NN NN O
which NN NN O
is NN NN O
rapidly NN NN O
translocated NN NN O
from NN NN O
the NN NN O
cytoplasm NN NN O
to NN NN O
the NN NN O
nucleus NN NN O
during NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
This NN NN O
intracellular NN NN O
signaling NN NN O
complex NN NN O
potently NN NN O
stimulates NN NN O
kappa NN NN O
B NN NN O
- NN NN O
directed NN NN O
transcription NN NN O
from NN NN O
either NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
or NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
promoter NN NN O
via NN NN O
the NN NN O
strong NN NN O
transactivation NN NN O
domain NN NN O
present NN NN O
in NN NN O
p65 NN NN B-Protein
. NN NN O
   
We NN NN O
now NN NN O
demonstrate NN NN O
that NN NN O
nuclear NN NN O
expression NN NN O
of NN NN O
human NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
, NN NN O
which NN NN O
is NN NN O
induced NN NN O
by NN NN O
either NN NN O
phorbol NN NN O
ester NN NN O
or NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
with NN NN O
delayed NN NN O
kinetics NN NN O
relative NN NN O
to NN NN O
p65 NN NN B-Protein
, NN NN O
markedly NN NN O
represses NN NN O
p65 NN NN B-Protein
- NN NN O
mediated NN NN O
activation NN NN O
of NN NN O
these NN NN O
transcription NN NN O
units NN NN O
. NN NN O
   
These NN NN O
inhibitory NN NN O
effects NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
correlate NN NN O
with NN NN O
its NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
but NN NN O
not NN NN O
with NN NN O
its NN NN O
ability NN NN O
to NN NN O
heterodimerize NN NN O
with NN NN O
p50 NN NN B-Protein
, NN NN O
suggesting NN NN O
that NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
inhibition NN NN O
involves NN NN O
competition NN NN O
with NN NN O
p50 NN NN B-Protein
/ NN NN O
p65 NN NN B-Protein
for NN NN O
occupancy NN NN O
of NN NN O
the NN NN O
kappa NN NN O
B NN NN O
enhancer NN NN O
element NN NN O
. NN NN O
   
Together NN NN O
, NN NN O
these NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
one NN NN O
function NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
is NN NN O
as NN NN O
a NN NN O
physiologic NN NN O
repressor NN NN O
of NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
promoters NN NN O
, NN NN O
serving NN NN O
to NN NN O
efficiently NN NN O
counter NN NN O
the NN NN O
strong NN NN O
transcriptional NN NN O
activating NN NN O
effects NN NN O
of NN NN O
p65 NN NN B-Protein
. NN NN O
   
Dimerization NN NN O
of NN NN O
NF NN NN B-Protein
- NN NN I-Protein
KB2 NN NN I-Protein
with NN NN O
RelA NN NN B-Protein
( NN NN O
p65 NN NN B-Protein
) NN NN O
regulates NN NN O
DNA NN NN O
binding NN NN O
, NN NN O
transcriptional NN NN O
activation NN NN O
, NN NN O
and NN NN O
inhibition NN NN O
by NN NN O
an NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
MAD NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
) NN NN O
. NN NN O
   
Inducible NN NN O
expression NN NN O
of NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
( NN NN O
HIV NN NN O
) NN NN O
is NN NN O
regulated NN NN O
by NN NN O
a NN NN O
cellular NN NN O
transcription NN NN O
factor NN NN O
, NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
is NN NN O
composed NN NN O
of NN NN O
distinct NN NN O
subunits NN NN O
; NN NN O
five NN NN O
independent NN NN O
genes NN NN O
, NN NN O
NFKB1 NN NN B-Protein
( NN NN O
p105 NN NN B-Protein
) NN NN O
, NN NN O
NFKB2 NN NN B-Protein
( NN NN O
p100 NN NN B-Protein
) NN NN O
, NN NN O
RelA NN NN B-Protein
( NN NN O
p65 NN NN B-Protein
) NN NN O
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
rel NN NN I-Protein
and NN NN O
relB NN NN B-Protein
, NN NN O
that NN NN O
encode NN NN O
related NN NN O
proteins NN NN O
that NN NN O
bind NN NN O
to NN NN O
kappa NN NN O
B NN NN O
DNA NN NN O
elements NN NN O
have NN NN O
been NN NN O
isolated NN NN O
. NN NN O
   
We NN NN O
have NN NN O
previously NN NN O
found NN NN O
that NN NN O
NFKB2 NN NN B-Protein
( NN NN O
p49 NN NN B-Protein
/ NN NN O
p52 NN NN B-Protein
) NN NN O
acts NN NN O
in NN NN O
concert NN NN O
with NN NN O
RelA NN NN B-Protein
( NN NN O
p65 NN NN B-Protein
) NN NN O
to NN NN O
stimulate NN NN O
the NN NN O
HIV NN NN O
enhancer NN NN O
in NN NN O
Jurkat NN NN O
T NN NN O
- NN NN O
leukemia NN NN O
cells NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
examine NN NN O
the NN NN O
biochemical NN NN O
basis NN NN O
for NN NN O
the NN NN O
transcriptional NN NN O
regulation NN NN O
of NN NN O
HIV NN NN O
by NN NN O
NFKB2 NN NN B-Protein
. NN NN O
   
Using NN NN O
Scatchard NN NN O
analysis NN NN O
, NN NN O
we NN NN O
have NN NN O
determined NN NN O
the NN NN O
dissociation NN NN O
constants NN NN O
of NN NN O
homodimeric NN NN O
p49 NN NN B-Protein
and NN NN O
heterodimeric NN NN O
p49 NN NN B-Protein
/ NN NN O
p65 NN NN B-Protein
for NN NN O
binding NN NN O
to NN NN O
the NN NN O
HIV NN NN O
kappa NN NN O
B NN NN O
site NN NN O
. NN NN O
   
p49 NN NN B-Protein
has NN NN O
a NN NN O
approximately NN NN O
18 NN NN O
- NN NN O
fold NN NN O
- NN NN O
lower NN NN O
affinity NN NN O
for NN NN O
the NN NN O
HIV NN NN O
kappa NN NN O
B NN NN O
site NN NN O
( NN NN O
KD NN NN O
= NN NN O
69 NN NN O
. NN NN O
1 NN NN O
pM NN NN O
) NN NN O
than NN NN O
does NN NN O
the NN NN O
approximately NN NN O
50 NN NN O
- NN NN O
kDa NN NN O
protein NN NN O
NFKB1 NN NN B-Protein
( NN NN O
p50 NN NN B-Protein
) NN NN O
derived NN NN O
from NN NN O
p105 NN NN B-Protein
( NN NN O
KD NN NN O
= NN NN O
3 NN NN O
. NN NN O
9 NN NN O
pM NN NN O
) NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
the NN NN O
affinity NN NN O
of NN NN O
heterodimeric NN NN O
NFKB2 NN NN B-Protein
( NN NN O
p49 NN NN B-Protein
) NN NN O
/ NN NN O
RelA NN NN B-Protein
( NN NN O
p65 NN NN B-Protein
) NN NN O
for NN NN O
this NN NN O
site NN NN O
is NN NN O
approximately NN NN O
6 NN NN O
- NN NN O
fold NN NN O
higher NN NN O
( NN NN O
KD NN NN O
= NN NN O
11 NN NN O
. NN NN O
8 NN NN O
pM NN NN O
) NN NN O
than NN NN O
that NN NN O
of NN NN O
p49 NN NN B-Protein
alone NN NN O
. NN NN O
   
Consistent NN NN O
with NN NN O
these NN NN O
findings NN NN O
, NN NN O
in NN NN O
vitro NN NN O
transcription NN NN O
was NN NN O
stimulated NN NN O
18 NN NN O
- NN NN O
fold NN NN O
by NN NN O
the NN NN O
addition NN NN O
of NN NN O
preformed NN NN O
, NN NN O
heterodimeric NN NN O
NFKB2 NN NN B-Protein
( NN NN O
p49 NN NN B-Protein
) NN NN O
/ NN NN O
RelA NN NN B-Protein
( NN NN O
p65 NN NN B-Protein
) NN NN O
protein NN NN O
. NN NN O
   
Transcriptional NN NN O
activation NN NN O
of NN NN O
the NN NN O
HIV NN NN O
enhancer NN NN O
was NN NN O
also NN NN O
subject NN NN O
to NN NN O
regulation NN NN O
by NN NN O
recently NN NN O
cloned NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
MAD NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
) NN NN O
. NN NN O
   
Recombinant NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
MAD NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
) NN NN O
inhibited NN NN O
the NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
of NN NN O
p65 NN NN B-Protein
, NN NN O
p49 NN NN B-Protein
/ NN NN O
p65 NN NN B-Protein
, NN NN O
and NN NN O
p50 NN NN B-Protein
/ NN NN O
p65 NN NN B-Protein
but NN NN O
stimulated NN NN O
the NN NN O
binding NN NN O
of NN NN O
NFKB2 NN NN B-Protein
( NN NN O
p49 NN NN B-Protein
) NN NN O
or NN NN O
NFKB1 NN NN B-Protein
( NN NN O
p50 NN NN B-Protein
) NN NN O
. NN NN O
   
Functional NN NN O
activation NN NN O
of NN NN O
an NN NN O
HIV NN NN O
reporter NN NN O
plasmid NN NN O
by NN NN O
p49 NN NN B-Protein
/ NN NN O
p65 NN NN B-Protein
in NN NN O
transiently NN NN O
transfected NN NN O
Jurkat NN NN O
T NN NN O
- NN NN O
leukemia NN NN O
cells NN NN O
was NN NN O
also NN NN O
inhibited NN NN O
by NN NN O
coexpression NN NN O
of NN NN O
MAD NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
. NN NN O
   
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
   
The NN NN O
transcriptionally NN NN O
active NN NN O
factors NN NN O
mediating NN NN O
the NN NN O
effect NN NN O
of NN NN O
the NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
Tax NN NN B-Protein
transactivator NN NN O
on NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
kappa NN NN O
B NN NN O
enhancer NN NN O
include NN NN O
the NN NN O
product NN NN O
of NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
rel NN NN I-Protein
proto NN NN O
- NN NN O
oncogene NN NN O
. NN NN O
   
The NN NN O
transactivator NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
Tax NN NN B-Protein
activates NN NN O
the NN NN O
promoter NN NN O
of NN NN O
the NN NN O
gene NN NN O
coding NN NN O
for NN NN O
the NN NN O
interleukin NN NN B-Protein
2 NN NN I-Protein
alpha NN NN I-Protein
- NN NN I-Protein
chain NN NN I-Protein
receptor NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
via NN NN O
a NN NN O
kappa NN NN O
B NN NN O
site NN NN O
that NN NN O
can NN NN O
bind NN NN O
several NN NN O
protein NN NN O
species NN NN O
of NN NN O
the NN NN O
rel NN NN O
family NN NN O
. NN NN O
   
Tax1 NN NN B-Protein
strongly NN NN O
activates NN NN O
the NN NN O
enhancer NN NN O
activity NN NN O
of NN NN O
this NN NN O
motif NN NN O
, NN NN O
in NN NN O
both NN NN O
epithelial NN NN O
HeLa NN NN O
and NN NN O
lymphoid NN NN O
Jurkat NN NN O
cells NN NN O
. NN NN O
   
This NN NN O
activation NN NN O
was NN NN O
not NN NN O
observed NN NN O
in NN NN O
undifferentiated NN NN O
embryocarcinoma NN NN O
F9 NN NN O
cells NN NN O
. NN NN O
   
Overexpression NN NN O
of NN NN O
the NN NN O
p50 NN NN B-Protein
, NN NN O
p65 NN NN B-Protein
and NN NN O
Rel NN NN O
proteins NN NN O
in NN NN O
these NN NN O
cells NN NN O
showed NN NN O
that NN NN O
significant NN NN O
activation NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
kappa NN NN O
B NN NN O
site NN NN O
was NN NN O
observed NN NN O
only NN NN O
with NN NN O
Rel NN NN O
and NN NN O
Rel NN NN O
plus NN NN O
p65 NN NN B-Protein
. NN NN O
   
Moreover NN NN O
, NN NN O
whereas NN NN O
both NN NN O
Tax NN NN B-Protein
and NN NN O
phorbol NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
( NN NN O
PMA NN NN O
) NN NN O
are NN NN O
able NN NN O
to NN NN O
efficiently NN NN O
induce NN NN O
the NN NN O
binding NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
to NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
kappa NN NN O
B NN NN O
site NN NN O
, NN NN O
PMA NN NN O
is NN NN O
functionally NN NN O
inactive NN NN O
. NN NN O
   
Using NN NN O
the NN NN O
DNA NN NN O
affinity NN NN O
precipitation NN NN O
assay NN NN O
, NN NN O
we NN NN O
observed NN NN O
that NN NN O
Tax1 NN NN B-Protein
is NN NN O
able NN NN O
to NN NN O
efficiently NN NN O
induce NN NN O
the NN NN O
binding NN NN O
of NN NN O
Rel NN NN O
, NN NN O
whereas NN NN O
PMA NN NN O
is NN NN O
not NN NN O
. NN NN O
   
This NN NN O
established NN NN O
a NN NN O
clear NN NN O
difference NN NN O
between NN NN O
both NN NN O
stimuli NN NN O
, NN NN O
indicating NN NN O
that NN NN O
Rel NN NN O
is NN NN O
the NN NN O
functionally NN NN O
active NN NN O
factor NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
from NN NN O
these NN NN O
results NN NN O
that NN NN O
the NN NN O
functional NN NN O
activity NN NN O
of NN NN O
members NN NN O
of NN NN O
the NN NN O
rel NN NN O
family NN NN O
is NN NN O
regulated NN NN O
by NN NN O
their NN NN O
interaction NN NN O
with NN NN O
DNA NN NN O
and NN NN O
that NN NN O
Rel NN NN O
can NN NN O
be NN NN O
a NN NN O
potent NN NN O
transcriptional NN NN O
activator NN NN O
on NN NN O
specific NN NN O
kappa NN NN O
B NN NN O
sites NN NN O
. NN NN O
   
p105 NN NN B-Protein
and NN NN O
p98 NN NN B-Protein
precursor NN NN O
proteins NN NN O
play NN NN O
an NN NN O
active NN NN O
role NN NN O
in NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
mediated NN NN O
signal NN NN O
transduction NN NN O
. NN NN O
   
The NN NN O
Rel NN NN O
/ NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
family NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
is NN NN O
composed NN NN O
of NN NN O
two NN NN O
distinct NN NN O
subgroups NN NN O
, NN NN O
proteins NN NN O
that NN NN O
undergo NN NN O
proteolytic NN NN O
processing NN NN O
and NN NN O
contain NN NN O
SWI6 NN NN O
/ NN NN O
ankyrin NN NN O
repeats NN NN O
in NN NN O
their NN NN O
carboxyl NN NN O
termini NN NN O
( NN NN O
p105 NN NN B-Protein
, NN NN O
p98 NN NN B-Protein
) NN NN O
, NN NN O
and NN NN O
those NN NN O
without NN NN O
such NN NN O
repeats NN NN O
that NN NN O
do NN NN O
not NN NN O
require NN NN O
processing NN NN O
( NN NN O
p65 NN NN B-Protein
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
, NN NN O
RelB NN NN B-Protein
, NN NN O
and NN NN O
Dorsal NN NN B-Protein
) NN NN O
. NN NN O
   
We NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
p105 NN NN B-Protein
and NN NN O
p98 NN NN B-Protein
precursors NN NN O
share NN NN O
functional NN NN O
properties NN NN O
with NN NN O
the NN NN O
I NN NN O
kappa NN NN O
B NN NN O
proteins NN NN O
, NN NN O
which NN NN O
also NN NN O
contain NN NN O
SWI6 NN NN O
/ NN NN O
ankyrin NN NN O
repeats NN NN O
. NN NN O
   
Both NN NN O
p105 NN NN B-Protein
and NN NN O
p98 NN NN B-Protein
were NN NN O
found NN NN O
to NN NN O
form NN NN O
stable NN NN O
complexes NN NN O
with NN NN O
other NN NN O
Rel NN NN O
/ NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
family NN NN O
members NN NN O
, NN NN O
including NN NN O
p65 NN NN B-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
. NN NN O
   
Association NN NN O
with NN NN O
the NN NN O
precursors NN NN O
is NN NN O
sufficient NN NN O
for NN NN O
cytoplasmic NN NN O
retention NN NN O
of NN NN O
either NN NN O
p65 NN NN B-Protein
or NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
, NN NN O
both NN NN O
of NN NN O
which NN NN O
are NN NN O
otherwise NN NN O
nuclear NN NN O
. NN NN O
   
These NN NN O
complexes NN NN O
undergo NN NN O
stimulus NN NN O
- NN NN O
responsive NN NN O
processing NN NN O
to NN NN O
produce NN NN O
active NN NN O
p50 NN NN B-Protein
/ NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
and NN NN O
p55 NN NN B-Protein
/ NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
complexes NN NN O
. NN NN O
   
These NN NN O
observations NN NN O
suggest NN NN O
a NN NN O
second NN NN O
pathway NN NN O
leading NN NN O
to NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
induction NN NN O
, NN NN O
in NN NN O
which NN NN O
processing NN NN O
of NN NN O
the NN NN O
precursors NN NN O
rather NN NN O
than NN NN O
phosphorylation NN NN O
of NN NN O
I NN NN O
kappa NN NN O
B NN NN O
plays NN NN O
a NN NN O
major NN NN O
role NN NN O
. NN NN O
   
Mutual NN NN O
regulation NN NN O
of NN NN O
the NN NN O
transcriptional NN NN O
activator NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
its NN NN O
inhibitor NN NN O
, NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
. NN NN O
   
The NN NN O
NK NN NN O
- NN NN O
kappa NN NN O
B NN NN O
transcription NN NN O
factor NN NN O
complex NN NN O
is NN NN O
sequestered NN NN O
in NN NN O
the NN NN O
cytoplasm NN NN O
by NN NN O
the NN NN O
inhibitory NN NN O
protein NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
MAD NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
) NN NN O
. NN NN O
   
Various NN NN O
cellular NN NN O
stimuli NN NN O
relieve NN NN O
this NN NN O
inhibition NN NN O
by NN NN O
mechanisms NN NN O
largely NN NN O
unknown NN NN O
, NN NN O
leading NN NN O
to NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
nuclear NN NN O
localization NN NN O
and NN NN O
transactivation NN NN O
of NN NN O
its NN NN O
target NN NN O
genes NN NN O
. NN NN O
   
It NN NN O
is NN NN O
demonstrated NN NN O
here NN NN O
with NN NN O
human NN NN O
T NN NN O
lymphocytes NN NN O
and NN NN O
monocytes NN NN O
that NN NN O
different NN NN O
stimuli NN NN O
, NN NN O
including NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
phorbol NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
, NN NN O
cause NN NN O
rapid NN NN O
degradation NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
with NN NN O
concomitant NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
followed NN NN O
by NN NN O
a NN NN O
dramatic NN NN O
increase NN NN O
in NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
mRNA NN NN O
and NN NN O
protein NN NN O
synthesis NN NN O
. NN NN O
   
Transfection NN NN O
studies NN NN O
reveal NN NN O
that NN NN O
the NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
mRNA NN NN O
and NN NN O
the NN NN O
encoded NN NN O
protein NN NN O
are NN NN O
potently NN NN O
induced NN NN O
by NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
by NN NN O
homodimers NN NN O
of NN NN O
p65 NN NN B-Protein
and NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
. NN NN O
   
We NN NN O
propose NN NN O
a NN NN O
model NN NN O
in NN NN O
which NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
mutually NN NN O
regulate NN NN O
each NN NN O
other NN NN O
in NN NN O
a NN NN O
cycle NN NN O
: NN NN O
saturating NN NN O
amounts NN NN O
of NN NN O
the NN NN O
inhibitory NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
protein NN NN O
are NN NN O
destroyed NN NN O
upon NN NN O
stimulation NN NN O
, NN NN O
allowing NN NN O
rapid NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
Subsequently NN NN O
, NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
mRNA NN NN O
and NN NN O
protein NN NN O
levels NN NN O
are NN NN O
quickly NN NN O
induced NN NN O
by NN NN O
the NN NN O
activated NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
This NN NN O
resurgence NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
protein NN NN O
acts NN NN O
to NN NN O
restore NN NN O
an NN NN O
equilibrium NN NN O
in NN NN O
which NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
is NN NN O
again NN NN O
inhibited NN NN O
. NN NN O
   
Lipopolysaccharide NN NN O
induces NN NN O
phosphorylation NN NN O
of NN NN O
MAD3 NN NN B-Protein
and NN NN O
activation NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
and NN NN O
related NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
proteins NN NN O
in NN NN O
human NN NN O
monocytic NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cells NN NN O
. NN NN O
   
Many NN NN O
effects NN NN O
of NN NN O
lipopolysaccharide NN NN O
( NN NN O
LPS NN NN O
) NN NN O
on NN NN O
gene NN NN O
expression NN NN O
, NN NN O
including NN NN O
that NN NN O
of NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
( NN NN O
HIV NN NN O
) NN NN O
, NN NN O
in NN NN O
monocytic NN NN O
cells NN NN O
are NN NN O
mediated NN NN O
by NN NN O
activation NN NN O
of NN NN O
kappa NN NN O
B NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
proteins NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
specific NN NN O
members NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
Rel NN NN O
transcription NN NN O
factor NN NN O
family NN NN O
involved NN NN O
in NN NN O
the NN NN O
LPS NN NN O
response NN NN O
, NN NN O
and NN NN O
the NN NN O
mechanisms NN NN O
through NN NN O
which NN NN O
LPS NN NN O
- NN NN O
generated NN NN O
signals NN NN O
are NN NN O
transduced NN NN O
remain NN NN O
unclear NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
show NN NN O
that NN NN O
LPS NN NN O
induces NN NN O
nuclear NN NN O
expression NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
/ NN NN O
p50 NN NN B-Protein
heterodimers NN NN O
as NN NN O
well NN NN O
as NN NN O
p50 NN NN B-Protein
/ NN NN O
p65 NN NN B-Protein
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
kappa NN NN O
B NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
complexes NN NN O
in NN NN O
human NN NN O
monocytic NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cells NN NN O
. NN NN O
   
Nuclear NN NN O
localization NN NN O
of NN NN O
these NN NN O
proteins NN NN O
occurred NN NN O
concomitantly NN NN O
with NN NN O
a NN NN O
rapid NN NN O
decrease NN NN O
in NN NN O
their NN NN O
cytosolic NN NN O
levels NN NN O
and NN NN O
was NN NN O
independent NN NN O
of NN NN O
phorbol NN NN O
ester NN NN O
- NN NN O
sensitive NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
. NN NN O
   
Within NN NN O
24 NN NN O
h NN NN O
following NN NN O
LPS NN NN O
stimulation NN NN O
there NN NN O
was NN NN O
a NN NN O
striking NN NN O
increase NN NN O
in NN NN O
the NN NN O
levels NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
, NN NN O
p105 NN NN B-Protein
, NN NN O
and NN NN O
p50 NN NN B-Protein
in NN NN O
the NN NN O
cytosol NN NN O
. NN NN O
   
The NN NN O
increased NN NN O
levels NN NN O
of NN NN O
these NN NN O
proteins NN NN O
correlated NN NN O
with NN NN O
increases NN NN O
in NN NN O
the NN NN O
amounts NN NN O
of NN NN O
their NN NN O
mRNAs NN NN O
during NN NN O
LPS NN NN O
activation NN NN O
of NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cells NN NN O
. NN NN O
   
LPS NN NN O
activation NN NN O
of NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cells NN NN O
resulted NN NN O
in NN NN O
phosphorylation NN NN O
of NN NN O
MAD3 NN NN B-Protein
( NN NN O
an NN NN O
I NN NN O
kappa NN NN O
B NN NN O
- NN NN O
like NN NN O
protein NN NN O
) NN NN O
, NN NN O
a NN NN O
rapid NN NN O
increase NN NN O
in NN NN O
MAD3 NN NN B-Protein
mRNA NN NN O
, NN NN O
and NN NN O
an NN NN O
increase NN NN O
in NN NN O
MAD3 NN NN B-Protein
protein NN NN O
by NN NN O
2 NN NN O
h NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
LPS NN NN O
activation NN NN O
of NN NN O
human NN NN O
monocytic NN NN O
cells NN NN O
results NN NN O
in NN NN O
nuclear NN NN O
expression NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
/ NN NN O
p50 NN NN B-Protein
and NN NN O
p50 NN NN B-Protein
/ NN NN O
p65 NN NN B-Protein
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
and NN NN O
induces NN NN O
phosphorylation NN NN O
of NN NN O
MAD3 NN NN B-Protein
. NN NN O
   
Transcriptional NN NN O
activation NN NN O
of NN NN O
the NN NN O
macrophage NN NN O
colony NN NN O
- NN NN O
stimulating NN NN O
factor NN NN O
gene NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
is NN NN O
associated NN NN O
with NN NN O
secretion NN NN O
of NN NN O
bioactive NN NN O
macrophage NN NN B-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
protein NN NN O
by NN NN O
monocytes NN NN O
and NN NN O
involves NN NN O
activation NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
Human NN NN O
peripheral NN NN O
blood NN NN O
monocytes NN NN O
( NN NN O
Mo NN NN O
) NN NN O
constitutively NN NN O
display NN NN O
the NN NN O
beta NN NN O
- NN NN O
chain NN NN O
of NN NN O
the NN NN O
receptor NN NN O
for NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
whereas NN NN O
expression NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
chain NN NN O
is NN NN O
not NN NN O
constitutive NN NN O
but NN NN O
inducible NN NN O
with NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
Here NN NN O
we NN NN O
report NN NN O
that NN NN O
binding NN NN O
of NN NN O
human NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
to NN NN O
its NN NN O
binding NN NN O
site NN NN O
leads NN NN O
to NN NN O
transcriptional NN NN O
activation NN NN O
of NN NN O
the NN NN O
macrophage NN NN B-Protein
CSF NN NN I-Protein
( NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
) NN NN O
gene NN NN O
in NN NN O
Mo NN NN O
resulting NN NN O
in NN NN O
accumulation NN NN O
of NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
mRNA NN NN O
and NN NN O
subsequent NN NN O
release NN NN O
of NN NN O
bioactive NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
protein NN NN O
as NN NN O
demonstrated NN NN O
by NN NN O
ELISA NN NN O
and NN NN O
inhibition NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
induced NN NN O
release NN NN O
of NN NN O
an NN NN O
activity NN NN O
- NN NN O
stimulating NN NN O
growth NN NN O
of NN NN O
monocyte NN NN O
- NN NN O
type NN NN O
colonies NN NN O
by NN NN O
a NN NN O
neutralizing NN NN O
anti NN NN O
- NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
antibody NN NN O
. NN NN O
   
Transcriptional NN NN O
activation NN NN O
of NN NN O
the NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
gene NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
is NN NN O
preceded NN NN O
by NN NN O
enhanced NN NN O
binding NN NN O
activity NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
to NN NN O
its NN NN O
recognition NN NN O
sequence NN NN O
in NN NN O
the NN NN O
5 NN NN O
' NN NN O
regulatory NN NN O
enhancer NN NN O
region NN NN O
of NN NN O
the NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
gene NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
using NN NN O
a NN NN O
heterologous NN NN O
promoter NN NN O
( NN NN O
herpes NN NN O
thymidine NN NN O
kinase NN NN O
) NN NN O
construct NN NN O
containing NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
consensus NN NN O
sequence NN NN O
, NN NN O
it NN NN O
is NN NN O
shown NN NN O
that NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
by NN NN O
an NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
induced NN NN O
monocyte NN NN O
- NN NN O
derived NN NN O
nuclear NN NN O
protein NN NN O
confers NN NN O
reporter NN NN O
gene NN NN O
( NN NN O
human NN NN O
growth NN NN O
hormone NN NN O
) NN NN O
activity NN NN O
. NN NN O
   
Taken NN NN O
together NN NN O
, NN NN O
our NN NN O
findings NN NN O
indicate NN NN O
that NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
induces NN NN O
gene NN NN O
expression NN NN O
of NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
in NN NN O
human NN NN O
blood NN NN O
- NN NN O
derived NN NN O
Mo NN NN O
and NN NN O
provide NN NN O
evidence NN NN O
for NN NN O
involvement NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
transcriptional NN NN O
regulation NN NN O
of NN NN O
this NN NN O
gene NN NN O
. NN NN O
   
Age NN NN O
- NN NN O
related NN NN O
decreases NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
production NN NN O
by NN NN O
human NN NN O
T NN NN O
cells NN NN O
are NN NN O
associated NN NN O
with NN NN O
impaired NN NN O
activation NN NN O
of NN NN O
nuclear NN NN O
transcriptional NN NN O
factors NN NN O
AP NN NN O
- NN NN O
1 NN NN O
and NN NN O
NF NN NN O
- NN NN O
AT NN NN O
. NN NN O
   
Although NN NN O
transcriptional NN NN O
factors NN NN O
AP NN NN O
- NN NN O
1 NN NN O
and NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
( NN NN O
NF NN NN O
- NN NN O
AT NN NN O
) NN NN O
are NN NN O
important NN NN O
for NN NN O
the NN NN O
normal NN NN O
induction NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
it NN NN O
is NN NN O
unknown NN NN O
if NN NN O
the NN NN O
age NN NN O
- NN NN O
related NN NN O
decline NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
production NN NN O
by NN NN O
activated NN NN O
human NN NN O
T NN NN O
cells NN NN O
may NN NN O
be NN NN O
associated NN NN O
with NN NN O
aberrancies NN NN O
in NN NN O
transcriptional NN NN O
regulatory NN NN O
proteins NN NN O
. NN NN O
   
In NN NN O
the NN NN O
current NN NN O
studies NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
production NN NN O
by NN NN O
T NN NN O
cells NN NN O
from NN NN O
elderly NN NN O
( NN NN O
mean NN NN O
78 NN NN O
years NN NN O
) NN NN O
and NN NN O
young NN NN O
( NN NN O
mean NN NN O
37 NN NN O
years NN NN O
) NN NN O
humans NN NN O
was NN NN O
measured NN NN O
in NN NN O
cultures NN NN O
stimulated NN NN O
with NN NN O
PHA NN NN B-Protein
, NN NN O
PHA NN NN B-Protein
plus NN NN O
PMA NN NN O
, NN NN O
crosslinked NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
mAB NN NN O
OKT3 NN NN O
plus NN NN O
PMA NN NN O
, NN NN O
or NN NN O
PMA NN NN O
plus NN NN O
ionomycin NN NN O
. NN NN O
   
Substantial NN NN O
decreases NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
production NN NN O
were NN NN O
observed NN NN O
for NN NN O
cell NN NN O
cultures NN NN O
from NN NN O
7 NN NN O
of NN NN O
12 NN NN O
elderly NN NN O
individuals NN NN O
in NN NN O
response NN NN O
to NN NN O
the NN NN O
different NN NN O
stimuli NN NN O
, NN NN O
whereas NN NN O
the NN NN O
levels NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
produced NN NN O
by NN NN O
stimulated NN NN O
T NN NN O
cells NN NN O
from NN NN O
other NN NN O
elderly NN NN O
individuals NN NN O
were NN NN O
equivalent NN NN O
to NN NN O
those NN NN O
observed NN NN O
for NN NN O
stimulated NN NN O
T NN NN O
cells NN NN O
of NN NN O
young NN NN O
subjects NN NN O
. NN NN O
   
Analyses NN NN O
of NN NN O
nuclear NN NN O
extracts NN NN O
by NN NN O
electrophoretic NN NN O
DNA NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
showed NN NN O
that NN NN O
decreased NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
production NN NN O
by NN NN O
stimulated NN NN O
T NN NN O
cells NN NN O
of NN NN O
elderly NN NN O
individuals NN NN O
was NN NN O
closely NN NN O
associated NN NN O
with NN NN O
impairments NN NN O
in NN NN O
the NN NN O
activation NN NN O
of NN NN O
both NN NN O
AP NN NN O
- NN NN O
1 NN NN O
and NN NN O
NF NN NN O
- NN NN O
AT NN NN O
. NN NN O
   
By NN NN O
contrast NN NN O
, NN NN O
T NN NN O
cells NN NN O
from NN NN O
elderly NN NN O
subjects NN NN O
with NN NN O
normal NN NN O
levels NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
production NN NN O
exhibited NN NN O
normal NN NN O
activation NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
and NN NN O
NF NN NN O
- NN NN O
AT NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
the NN NN O
results NN NN O
of NN NN O
competition NN NN O
experiments NN NN O
analyzing NN NN O
the NN NN O
normal NN NN O
components NN NN O
of NN NN O
NF NN NN O
- NN NN O
AT NN NN O
showed NN NN O
that NN NN O
the NN NN O
age NN NN O
- NN NN O
related NN NN O
reductions NN NN O
in NN NN O
stimulus NN NN O
- NN NN O
dependent NN NN O
NF NN NN O
- NN NN O
AT NN NN O
complexes NN NN O
corresponded NN NN O
to NN NN O
the NN NN O
slow NN NN O
migrating NN NN O
complexes NN NN O
that NN NN O
were NN NN O
composed NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
/ NN NN O
c NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
AP NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
The NN NN O
resting NN NN O
and NN NN O
stimulated NN NN O
levels NN NN O
of NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
were NN NN O
reduced NN NN O
in NN NN O
T NN NN O
cells NN NN O
from NN NN O
certain NN NN O
elderly NN NN O
individuals NN NN O
; NN NN O
however NN NN O
, NN NN O
alterations NN NN O
of NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
did NN NN O
not NN NN O
correlate NN NN O
with NN NN O
changes NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
these NN NN O
results NN NN O
show NN NN O
that NN NN O
age NN NN O
- NN NN O
related NN NN O
impairments NN NN O
in NN NN O
the NN NN O
activation NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
and NN NN O
NF NN NN O
- NN NN O
AT NN NN O
are NN NN O
closely NN NN O
associated NN NN O
with NN NN O
decreased NN NN O
expression NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
further NN NN O
suggest NN NN O
that NN NN O
aberrancies NN NN O
in NN NN O
the NN NN O
signaling NN NN O
pathways NN NN O
important NN NN O
for NN NN O
the NN NN O
induction NN NN O
of NN NN O
transcriptionally NN NN O
active NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
/ NN NN O
c NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
AP NN NN O
- NN NN O
1 NN NN O
may NN NN O
contribute NN NN O
to NN NN O
the NN NN O
impaired NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
AT NN NN O
. NN NN O
   
Effects NN NN O
of NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
on NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cell NN NN O
responses NN NN O
to NN NN O
Cryptococcus NN NN O
neoformans NN NN O
, NN NN O
Candida NN NN O
albicans NN NN O
, NN NN O
and NN NN O
lipopolysaccharide NN NN O
. NN NN O
   
Deactivation NN NN O
of NN NN O
mononuclear NN NN O
phagocytes NN NN O
is NN NN O
critical NN NN O
to NN NN O
limit NN NN O
the NN NN O
inflammatory NN NN O
response NN NN O
but NN NN O
can NN NN O
be NN NN O
detrimental NN NN O
in NN NN O
the NN NN O
face NN NN O
of NN NN O
progressive NN NN O
infection NN NN O
. NN NN O
   
We NN NN O
compared NN NN O
the NN NN O
effects NN NN O
of NN NN O
the NN NN O
deactivating NN NN O
cytokine NN NN O
interleukin NN NN B-Protein
10 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
) NN NN O
on NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cell NN NN O
( NN NN O
PBMC NN NN O
) NN NN O
responses NN NN O
to NN NN O
lipopolysaccharide NN NN O
( NN NN O
LPS NN NN O
) NN NN O
, NN NN O
Cryptococcus NN NN O
neoformans NN NN O
, NN NN O
and NN NN O
Candida NN NN O
albicans NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
effected NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
inhibition NN NN O
of NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
release NN NN O
in NN NN O
PBMC NN NN O
stimulated NN NN O
by NN NN O
LPS NN NN O
and NN NN O
C NN NN O
. NN NN O
neoformans NN NN O
, NN NN O
with NN NN O
significant NN NN O
inhibition NN NN O
seen NN NN O
with NN NN O
0 NN NN O
. NN NN O
1 NN NN O
U NN NN O
/ NN NN O
ml NN NN O
and NN NN O
greater NN NN O
than NN NN O
90 NN NN O
% NN NN O
inhibition NN NN O
noted NN NN O
with NN NN O
10 NN NN O
U NN NN O
/ NN NN O
ml NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
even NN NN O
at NN NN O
doses NN NN O
as NN NN O
high NN NN O
as NN NN O
100 NN NN O
U NN NN O
/ NN NN O
ml NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
inhibited NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
release NN NN O
in NN NN O
response NN NN O
to NN NN O
C NN NN O
. NN NN O
albicans NN NN O
by NN NN O
only NN NN O
50 NN NN O
% NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
profoundly NN NN O
inhibited NN NN O
release NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
from NN NN O
PBMC NN NN O
stimulated NN NN O
by NN NN O
all NN NN O
three NN NN O
stimuli NN NN O
. NN NN O
   
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
mRNA NN NN O
and NN NN O
release NN NN O
was NN NN O
inhibited NN NN O
even NN NN O
if NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
was NN NN O
added NN NN O
up NN NN O
to NN NN O
8 NN NN O
h NN NN O
after NN NN O
cryptococcal NN NN O
stimulation NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
inhibition NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
mRNA NN NN O
was NN NN O
of NN NN O
lesser NN NN O
magnitude NN NN O
and NN NN O
occurred NN NN O
only NN NN O
when NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
was NN NN O
added NN NN O
within NN NN O
2 NN NN O
h NN NN O
of NN NN O
cryptococcal NN NN O
stimulation NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
inhibited NN NN O
translocation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
in NN NN O
response NN NN O
to NN NN O
LPS NN NN O
but NN NN O
not NN NN O
the NN NN O
fungal NN NN O
stimuli NN NN O
. NN NN O
   
All NN NN O
three NN NN O
stimuli NN NN O
induced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
production NN NN O
in NN NN O
PBMC NN NN O
, NN NN O
although NN NN O
over NN NN O
10 NN NN O
- NN NN O
fold NN NN O
less NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
was NN NN O
released NN NN O
in NN NN O
response NN NN O
to NN NN O
C NN NN O
. NN NN O
neoformans NN NN O
compared NN NN O
with NN NN O
LPS NN NN O
and NN NN O
C NN NN O
. NN NN O
albicans NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
while NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
has NN NN O
deactivating NN NN O
effects NN NN O
on NN NN O
PBMC NN NN O
responses NN NN O
to NN NN O
all NN NN O
three NN NN O
stimuli NN NN O
, NN NN O
disparate NN NN O
stimulus NN NN O
- NN NN O
and NN NN O
response NN NN O
- NN NN O
specific NN NN O
patterns NN NN O
of NN NN O
deactivation NN NN O
are NN NN O
seen NN NN O
. NN NN O
   
Inhibition NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
of NN NN O
proinflammatory NN NN O
cytokine NN NN O
release NN NN O
appears NN NN O
to NN NN O
occur NN NN O
at NN NN O
the NN NN O
level NN NN O
of NN NN O
gene NN NN O
transcription NN NN O
for NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
both NN NN O
transcriptionally NN NN O
and NN NN O
posttranscriptionally NN NN O
for NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
. NN NN O
   
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
nuclear NN NN B-Protein
antigen NN NN I-Protein
2 NN NN I-Protein
and NN NN O
latent NN NN O
membrane NN NN O
protein NN NN O
independently NN NN O
transactivate NN NN O
p53 NN NN B-Protein
through NN NN O
induction NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activity NN NN O
. NN NN O
   
B NN NN O
- NN NN O
cell NN NN O
immortalization NN NN O
by NN NN O
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
( NN NN O
EBV NN NN O
) NN NN O
is NN NN O
dependent NN NN O
on NN NN O
permanent NN NN O
control NN NN O
of NN NN O
the NN NN O
cellular NN NN O
processes NN NN O
which NN NN O
normally NN NN O
regulate NN NN O
cell NN NN O
division NN NN O
and NN NN O
apoptosis NN NN O
, NN NN O
functions NN NN O
possessed NN NN O
by NN NN O
p53 NN NN B-Protein
in NN NN O
a NN NN O
number NN NN O
of NN NN O
normal NN NN O
cell NN NN O
types NN NN O
. NN NN O
   
In NN NN O
studies NN NN O
initiated NN NN O
to NN NN O
evaluate NN NN O
relationships NN NN O
between NN NN O
EBV NN NN O
latent NN NN O
genes NN NN O
and NN NN O
p53 NN NN B-Protein
, NN NN O
p53 NN NN B-Protein
levels NN NN O
were NN NN O
found NN NN O
to NN NN O
increase NN NN O
approximately NN NN O
10 NN NN O
- NN NN O
fold NN NN O
4 NN NN O
to NN NN O
5 NN NN O
days NN NN O
after NN NN O
EBV NN NN O
infection NN NN O
of NN NN O
purified NN NN O
resting NN NN O
human NN NN O
B NN NN O
cells NN NN O
; NN NN O
the NN NN O
induced NN NN O
p53 NN NN B-Protein
was NN NN O
transcriptionally NN NN O
active NN NN O
. NN NN O
   
Latent NN NN B-Protein
membrane NN NN I-Protein
protein NN NN I-Protein
1 NN NN I-Protein
and NN NN O
, NN NN O
to NN NN O
a NN NN O
lesser NN NN O
extent NN NN O
, NN NN O
EBV NN NN O
nuclear NN NN B-Protein
antigen NN NN I-Protein
2 NN NN I-Protein
mediated NN NN O
the NN NN O
increase NN NN O
in NN NN O
p53 NN NN B-Protein
levels NN NN O
via NN NN O
activation NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
transcription NN NN O
factor NN NN O
. NN NN O
   
Protein NN NN O
- NN NN O
tyrosine NN NN O
kinase NN NN O
activation NN NN O
is NN NN O
required NN NN O
for NN NN O
lipopolysaccharide NN NN O
induction NN NN O
of NN NN O
interleukin NN NN B-Protein
1beta NN NN I-Protein
and NN NN O
NFkappaB NN NN O
activation NN NN O
, NN NN O
but NN NN O
not NN NN O
NFkappaB NN NN O
nuclear NN NN O
translocation NN NN O
. NN NN O
   
In NN NN O
human NN NN O
monocytes NN NN O
, NN NN O
interleukin NN NN B-Protein
1beta NN NN I-Protein
protein NN NN O
production NN NN O
and NN NN O
steady NN NN O
state NN NN O
mRNA NN NN O
levels NN NN O
are NN NN O
increased NN NN O
in NN NN O
response NN NN O
to NN NN O
lipopolysaccharide NN NN O
, NN NN O
predominantly NN NN O
as NN NN O
a NN NN O
result NN NN O
of NN NN O
increased NN NN O
transcription NN NN O
of NN NN O
the NN NN O
interleukin NN NN B-Protein
1beta NN NN I-Protein
gene NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
interleukin NN NN B-Protein
1beta NN NN I-Protein
and NN NN O
other NN NN O
cytokines NN NN O
, NN NN O
such NN NN O
as NN NN O
interleukin NN NN B-Protein
6 NN NN I-Protein
and NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
be NN NN O
dependent NN NN O
on NN NN O
the NN NN O
activation NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
, NN NN O
NFkappaB NN NN O
. NN NN O
   
Since NN NN O
recent NN NN O
studies NN NN O
have NN NN O
shown NN NN O
that NN NN O
lipopolysaccharide NN NN O
- NN NN O
induced NN NN O
tyrosine NN NN O
kinase NN NN O
activation NN NN O
is NN NN O
not NN NN O
required NN NN O
for NN NN O
NFkappaB NN NN O
nuclear NN NN O
translocation NN NN O
, NN NN O
we NN NN O
sought NN NN O
to NN NN O
determine NN NN O
whether NN NN O
NFkappaB NN NN O
translocated NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
tyrosine NN NN O
kinase NN NN O
activity NN NN O
was NN NN O
active NN NN O
in NN NN O
stimulating NN NN O
transcription NN NN O
. NN NN O
   
We NN NN O
have NN NN O
found NN NN O
that NN NN O
, NN NN O
in NN NN O
the NN NN O
human NN NN O
pro NN NN O
- NN NN O
monocytic NN NN O
cell NN NN O
line NN NN O
, NN NN O
THP NN NN O
- NN NN O
1 NN NN O
, NN NN O
the NN NN O
lipopolysaccharide NN NN O
- NN NN O
induced NN NN O
expression NN NN O
of NN NN O
interleukin NN NN B-Protein
1beta NN NN I-Protein
is NN NN O
dependent NN NN O
on NN NN O
tyrosine NN NN O
kinase NN NN O
activation NN NN O
. NN NN O
   
Tyrosine NN NN O
kinases NN NN O
are NN NN O
not NN NN O
required NN NN O
for NN NN O
lipopolysaccharide NN NN O
- NN NN O
mediated NN NN O
nuclear NN NN O
translocation NN NN O
of NN NN O
NFkappaB NN NN O
. NN NN O
   
However NN NN O
, NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
tyrosine NN NN O
kinase NN NN O
activity NN NN O
, NN NN O
the NN NN O
ability NN NN O
of NN NN O
NFkappaB NN NN O
to NN NN O
stimulate NN NN O
transcription NN NN O
is NN NN O
impaired NN NN O
. NN NN O
   
This NN NN O
inhibition NN NN O
of NN NN O
transcription NN NN O
is NN NN O
specific NN NN O
for NN NN O
NFkappaB NN NN O
; NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
tyrosine NN NN O
kinase NN NN O
activity NN NN O
, NN NN O
AP NN NN O
- NN NN O
1 NN NN O
- NN NN O
dependent NN NN O
transcription NN NN O
is NN NN O
enhanced NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
, NN NN O
while NN NN O
lipopolysaccharide NN NN O
- NN NN O
induced NN NN O
expression NN NN O
of NN NN O
inflammatory NN NN O
mediators NN NN O
requires NN NN O
tyrosine NN NN O
kinase NN NN O
activity NN NN O
, NN NN O
tyrosine NN NN O
kinase NN NN O
activity NN NN O
is NN NN O
not NN NN O
obligatory NN NN O
for NN NN O
lipopolysaccharide NN NN O
signal NN NN O
transduction NN NN O
. NN NN O
   
Elevated NN NN O
cyclic NN NN O
AMP NN NN O
inhibits NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
mediated NN NN O
transcription NN NN O
in NN NN O
human NN NN O
monocytic NN NN O
cells NN NN O
and NN NN O
endothelial NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
/ NN NN O
Rel NN NN O
family NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
regulates NN NN O
the NN NN O
inducible NN NN O
expression NN NN O
of NN NN O
many NN NN O
genes NN NN O
in NN NN O
activated NN NN O
human NN NN O
monocytes NN NN O
and NN NN O
endothelial NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
examined NN NN O
the NN NN O
molecular NN NN O
mechanism NN NN O
by NN NN O
which NN NN O
agents NN NN O
that NN NN O
elevate NN NN O
intracellular NN NN O
cAMP NN NN O
inhibit NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNFalpha NN NN B-Protein
) NN NN O
, NN NN O
tissue NN NN B-Protein
factor NN NN I-Protein
, NN NN O
endothelial NN NN B-Protein
leukocyte NN NN I-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
and NN NN O
vascular NN NN B-Protein
cell NN NN I-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
genes NN NN O
. NN NN O
   
Both NN NN O
forskolin NN NN O
and NN NN O
dibutyryl NN NN O
cAMP NN NN O
, NN NN O
which NN NN O
elevate NN NN O
intracellular NN NN O
cAMP NN NN O
by NN NN O
independent NN NN O
mechanisms NN NN O
, NN NN O
inhibited NN NN O
TNFalpha NN NN B-Protein
and NN NN O
tissue NN NN B-Protein
factor NN NN I-Protein
expression NN NN O
at NN NN O
the NN NN O
level NN NN O
of NN NN O
transcription NN NN O
. NN NN O
   
Induction NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
dependent NN NN O
gene NN NN O
expression NN NN O
in NN NN O
transiently NN NN O
transfected NN NN O
human NN NN O
monocytic NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cells NN NN O
and NN NN O
human NN NN O
umbilical NN NN O
vein NN NN O
endothelial NN NN O
cells NN NN O
was NN NN O
inhibited NN NN O
by NN NN O
elevated NN NN O
cAMP NN NN O
and NN NN O
by NN NN O
overexpression NN NN O
of NN NN O
the NN NN O
catalytic NN NN O
subunit NN NN O
of NN NN O
protein NN NN O
kinase NN NN O
A NN NN O
( NN NN O
PKA NN NN O
) NN NN O
. NN NN O
   
Elevated NN NN O
cAMP NN NN O
did NN NN O
not NN NN O
prevent NN NN O
nuclear NN NN O
translocation NN NN O
of NN NN O
p50 NN NN B-Protein
/ NN NN O
p65 NN NN B-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
/ NN NN O
p65 NN NN B-Protein
heterodimers NN NN O
, NN NN O
decrease NN NN O
nuclear NN NN O
translocation NN NN O
of NN NN O
p65 NN NN B-Protein
, NN NN O
or NN NN O
significantly NN NN O
modify NN NN O
TNFalpha NN NN B-Protein
- NN NN O
induced NN NN O
phosphorylation NN NN O
of NN NN O
p65 NN NN B-Protein
. NN NN O
   
Functional NN NN O
studies NN NN O
demonstrated NN NN O
that NN NN O
transcriptional NN NN O
activation NN NN O
of NN NN O
a NN NN O
plasmid NN NN O
containing NN NN O
multimerized NN NN O
kappaB NN NN O
sites NN NN O
by NN NN O
p65 NN NN B-Protein
was NN NN O
inhibited NN NN O
by NN NN O
agents NN NN O
that NN NN O
elevate NN NN O
cAMP NN NN O
and NN NN O
by NN NN O
overexpression NN NN O
of NN NN O
the NN NN O
catalytic NN NN O
subunit NN NN O
of NN NN O
PKA NN NN O
. NN NN O
   
This NN NN O
study NN NN O
indicates NN NN O
that NN NN O
activation NN NN O
of NN NN O
PKA NN NN O
reduces NN NN O
the NN NN O
induction NN NN O
of NN NN O
a NN NN O
distinct NN NN O
set NN NN O
of NN NN O
genes NN NN O
in NN NN O
monocytes NN NN O
and NN NN O
endothelial NN NN O
cells NN NN O
by NN NN O
inhibiting NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
mediated NN NN O
transcription NN NN O
. NN NN O
   
Retinoic NN NN O
acid NN NN O
activates NN NN O
interferon NN NN B-Protein
regulatory NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
expression NN NN O
in NN NN O
myeloid NN NN O
cells NN NN O
. NN NN O
   
All NN NN O
- NN NN O
trans NN NN O
- NN NN O
retinoic NN NN O
acid NN NN O
( NN NN O
ATRA NN NN O
) NN NN O
is NN NN O
the NN NN O
drug NN NN O
of NN NN O
choice NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
acute NN NN O
promyelocytic NN NN O
leukemia NN NN O
( NN NN O
APL NN NN O
) NN NN O
. NN NN O
   
ATRA NN NN O
induces NN NN O
both NN NN O
in NN NN O
vitro NN NN O
and NN NN O
in NN NN O
vivo NN NN O
differentiation NN NN O
of NN NN O
APL NN NN O
cells NN NN O
into NN NN O
mature NN NN O
granulocytes NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
molecular NN NN O
mechanisms NN NN O
involved NN NN O
in NN NN O
ATRA NN NN O
- NN NN O
dependent NN NN O
growth NN NN O
inhibition NN NN O
and NN NN O
cellular NN NN O
differentiation NN NN O
are NN NN O
not NN NN O
presently NN NN O
understood NN NN O
. NN NN O
   
The NN NN O
NB4 NN NN O
cell NN NN O
line NN NN O
, NN NN O
which NN NN O
is NN NN O
derived NN NN O
from NN NN O
the NN NN O
bone NN NN O
marrow NN NN O
of NN NN O
a NN NN O
patient NN NN O
with NN NN O
APL NN NN O
during NN NN O
relapse NN NN O
, NN NN O
can NN NN O
be NN NN O
used NN NN O
as NN NN O
a NN NN O
model NN NN O
system NN NN O
to NN NN O
study NN NN O
the NN NN O
growth NN NN O
and NN NN O
differentiation NN NN O
of NN NN O
APL NN NN O
cells NN NN O
. NN NN O
   
Because NN NN O
interferon NN NN O
( NN NN O
IFN NN NN O
) NN NN O
regulatory NN NN O
factors NN NN O
( NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
and NN NN O
other NN NN O
IFN NN NN O
- NN NN O
inducible NN NN O
gene NN NN O
products NN NN O
regulate NN NN O
cell NN NN O
growth NN NN O
, NN NN O
we NN NN O
analyzed NN NN O
the NN NN O
effects NN NN O
of NN NN O
ATRA NN NN O
on NN NN O
the NN NN O
expression NN NN O
of NN NN O
these NN NN O
genes NN NN O
. NN NN O
   
We NN NN O
show NN NN O
that NN NN O
ATRA NN NN O
directly NN NN O
activates NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
expression NN NN O
, NN NN O
followed NN NN O
by NN NN O
activation NN NN O
of NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
2 NN NN O
' NN NN O
- NN NN O
5 NN NN O
' NN NN O
oligoadenylate NN NN O
synthetase NN NN O
( NN NN O
OAS NN NN O
) NN NN O
gene NN NN O
expression NN NN O
with NN NN O
slower NN NN O
kinetics NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
to NN NN O
NB4 NN NN O
cells NN NN O
, NN NN O
ATRA NN NN O
also NN NN O
activated NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
expression NN NN O
in NN NN O
HL NN NN O
- NN NN O
60 NN NN O
, NN NN O
U937 NN NN O
, NN NN O
and NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cells NN NN O
, NN NN O
which NN NN O
all NN NN O
respond NN NN O
to NN NN O
ATRA NN NN O
by NN NN O
growth NN NN O
inhibition NN NN O
. NN NN O
   
A NN NN O
more NN NN O
than NN NN O
additive NN NN O
increase NN NN O
in NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
expression NN NN O
was NN NN O
seen NN NN O
with NN NN O
ATRA NN NN O
and NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
in NN NN O
NB4 NN NN O
cells NN NN O
. NN NN O
   
ATRA NN NN O
did NN NN O
not NN NN O
activate NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
or NN NN O
signal NN NN O
transducer NN NN O
and NN NN O
activator NN NN O
of NN NN O
transcription NN NN O
( NN NN O
STAT NN NN O
) NN NN O
activation NN NN O
pathways NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
an NN NN O
alternate NN NN O
mechanism NN NN O
is NN NN O
involved NN NN O
in NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
activation NN NN O
. NN NN O
   
The NN NN O
ATRA NN NN O
- NN NN O
induced NN NN O
expression NN NN O
of NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
an NN NN O
activator NN NN O
of NN NN O
transcription NN NN O
and NN NN O
repressor NN NN O
of NN NN O
transformation NN NN O
, NN NN O
may NN NN O
be NN NN O
one NN NN O
of NN NN O
the NN NN O
molecular NN NN O
mechanisms NN NN O
of NN NN O
ATRA NN NN O
- NN NN O
induced NN NN O
growth NN NN O
inhibition NN NN O
, NN NN O
and NN NN O
the NN NN O
basis NN NN O
for NN NN O
the NN NN O
synergistic NN NN O
actions NN NN O
of NN NN O
ATRA NN NN O
and NN NN O
IFNs NN NN O
in NN NN O
myeloid NN NN O
leukemia NN NN O
cells NN NN O
. NN NN O
   
Effects NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
on NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
transcription NN NN O
factors NN NN O
( NN NN O
AP NN NN O
- NN NN O
1 NN NN O
, NN NN O
NF NN NN B-Protein
- NN NN I-Protein
IL6 NN NN I-Protein
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
which NN NN O
are NN NN O
involved NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
regulation NN NN O
. NN NN O
   
Interleukin NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
) NN NN O
, NN NN O
like NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
, NN NN O
is NN NN O
known NN NN O
to NN NN O
inhibit NN NN O
cytokine NN NN O
expression NN NN O
in NN NN O
activated NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
We NN NN O
showed NN NN O
that NN NN O
both NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
inhibit NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
mRNA NN NN O
and NN NN O
protein NN NN O
expression NN NN O
by NN NN O
inhibiting NN NN O
the NN NN O
transcription NN NN O
rate NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
gene NN NN O
. NN NN O
   
The NN NN O
strong NN NN O
inhibition NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
transcription NN NN O
rate NN NN O
prompted NN NN O
us NN NN O
to NN NN O
study NN NN O
the NN NN O
effect NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
on NN NN O
the NN NN O
expression NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
. NN NN O
   
We NN NN O
questioned NN NN O
whether NN NN O
or NN NN O
not NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
affected NN NN O
the NN NN O
expression NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
that NN NN O
are NN NN O
known NN NN O
to NN NN O
be NN NN O
involved NN NN O
in NN NN O
the NN NN O
control NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
transcription NN NN O
rate NN NN O
, NN NN O
namely NN NN O
activator NN NN O
protein NN NN O
- NN NN O
1 NN NN O
( NN NN O
AP NN NN O
- NN NN O
1 NN NN O
) NN NN O
, NN NN O
nuclear NN NN B-Protein
factor NN NN I-Protein
IL NN NN I-Protein
- NN NN I-Protein
6 NN NN I-Protein
( NN NN O
NF NN NN B-Protein
- NN NN I-Protein
IL6 NN NN I-Protein
) NN NN O
, NN NN O
and NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
) NN NN O
. NN NN O
   
In NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
( NN NN O
EMSAs NN NN O
) NN NN O
we NN NN O
showed NN NN O
that NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
inhibited NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
AP NN NN O
- NN NN O
1 NN NN O
binding NN NN O
activity NN NN O
. NN NN O
   
The NN NN O
inhibiting NN NN O
effect NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
was NN NN O
slightly NN NN O
more NN NN O
pronounced NN NN O
than NN NN O
that NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
. NN NN O
   
Downregulation NN NN O
of NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
AP NN NN O
- NN NN O
1 NN NN O
was NN NN O
accompanied NN NN O
, NN NN O
and NN NN O
thus NN NN O
possibly NN NN O
explained NN NN O
, NN NN O
by NN NN O
a NN NN O
reduced NN NN O
expression NN NN O
at NN NN O
mRNA NN NN O
level NN NN O
of NN NN O
the NN NN O
two NN NN O
major NN NN O
components NN NN O
of NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
complex NN NN O
, NN NN O
namely NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
as NN NN O
determined NN NN O
by NN NN O
Northern NN NN O
experiments NN NN O
. NN NN O
   
Binding NN NN O
activity NN NN O
of NN NN O
NF NN NN B-Protein
- NN NN I-Protein
IL6 NN NN I-Protein
was NN NN O
also NN NN O
strongly NN NN O
inhibited NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
whereas NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
showed NN NN O
no NN NN O
effect NN NN O
. NN NN O
   
NF NN NN B-Protein
- NN NN I-Protein
IL6 NN NN I-Protein
mRNA NN NN O
levels NN NN O
were NN NN O
not NN NN O
affected NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
or NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
, NN NN O
suggesting NN NN O
that NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
affects NN NN O
binding NN NN O
activity NN NN O
of NN NN O
preexisting NN NN O
NF NN NN B-Protein
- NN NN I-Protein
IL6 NN NN I-Protein
. NN NN O
   
Neither NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
nor NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
inhibited NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
activity NN NN O
. NN NN O
   
In NN NN O
agreement NN NN O
with NN NN O
this NN NN O
finding NN NN O
, NN NN O
Northern NN NN O
experiments NN NN O
where NN NN O
p65 NN NN B-Protein
and NN NN O
p105 NN NN B-Protein
mRNA NN NN O
levels NN NN O
were NN NN O
determined NN NN O
, NN NN O
demonstrated NN NN O
that NN NN O
expression NN NN O
of NN NN O
these NN NN O
components NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
transcription NN NN O
factor NN NN O
were NN NN O
not NN NN O
affected NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
or NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
. NN NN O
   
Furthermore NN NN O
, NN NN O
neither NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
nor NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
showed NN NN O
any NN NN O
effect NN NN O
on NN NN O
I NN NN O
- NN NN O
kappa NN NN O
B NN NN O
mRNA NN NN O
expression NN NN O
as NN NN O
determined NN NN O
by NN NN O
Northern NN NN O
experiments NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
similarly NN NN O
affect NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
expression NN NN O
. NN NN O
   
However NN NN O
, NN NN O
for NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
this NN NN O
was NN NN O
accompanied NN NN O
with NN NN O
a NN NN O
reduction NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
and NN NN O
NF NN NN B-Protein
- NN NN I-Protein
IL6 NN NN I-Protein
binding NN NN O
activity NN NN O
whereas NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
only NN NN O
inhibited NN NN O
AP NN NN O
- NN NN O
1 NN NN O
binding NN NN O
activity NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
human NN NN O
monocytic NN NN O
cells NN NN O
by NN NN O
Treponema NN NN O
pallidum NN NN O
and NN NN O
Borrelia NN NN O
burgdorferi NN NN O
lipoproteins NN NN O
and NN NN O
synthetic NN NN O
lipopeptides NN NN O
proceeds NN NN O
via NN NN O
a NN NN O
pathway NN NN O
distinct NN NN O
from NN NN O
that NN NN O
of NN NN O
lipopolysaccharide NN NN O
but NN NN O
involves NN NN O
the NN NN O
transcriptional NN NN O
activator NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
There NN NN O
is NN NN O
increasing NN NN O
evidence NN NN O
that NN NN O
lipoproteins NN NN O
of NN NN O
Treponema NN NN O
pallidum NN NN O
and NN NN O
Borrelia NN NN O
burgdorferi NN NN O
are NN NN O
key NN NN O
inflammatory NN NN O
mediators NN NN O
during NN NN O
syphilis NN NN O
and NN NN O
Lyme NN NN O
disease NN NN O
. NN NN O
   
A NN NN O
principal NN NN O
objective NN NN O
of NN NN O
the NN NN O
present NN NN O
study NN NN O
was NN NN O
to NN NN O
identify NN NN O
more NN NN O
precisely NN NN O
similarities NN NN O
and NN NN O
divergences NN NN O
among NN NN O
lipopolysaccharide NN NN O
( NN NN O
LPS NN NN O
) NN NN O
- NN NN O
and NN NN O
lipoprotein NN NN O
- NN NN O
lipopeptide NN NN O
- NN NN O
induced NN NN O
immune NN NN O
cell NN NN O
signaling NN NN O
events NN NN O
. NN NN O
   
Like NN NN O
LPS NN NN O
, NN NN O
purified NN NN O
native NN NN O
B NN NN O
. NN NN O
burgdorferi NN NN O
OspA NN NN B-Protein
and NN NN O
synthetic NN NN O
analogs NN NN O
of NN NN O
OspA NN NN B-Protein
, NN NN O
OspB NN NN O
, NN NN O
and NN NN O
two NN NN O
T NN NN O
. NN NN O
pallidum NN NN O
lipoproteins NN NN O
( NN NN O
Tpp47 NN NN B-Protein
and NN NN O
Tpp17 NN NN B-Protein
) NN NN O
all NN NN O
induced NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
translocation NN NN O
in NN NN O
THP NN NN O
- NN NN O
1 NN NN O
human NN NN O
monocytoid NN NN O
cells NN NN O
. NN NN O
   
Acylation NN NN O
of NN NN O
OspA NN NN B-Protein
and NN NN O
the NN NN O
synthetic NN NN O
peptides NN NN O
was NN NN O
requisite NN NN O
for NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
Polymyxin NN NN O
B NN NN O
abrogated NN NN O
only NN NN O
the NN NN O
response NN NN O
to NN NN O
LPS NN NN O
. NN NN O
   
By NN NN O
using NN NN O
70Z NN NN O
/ NN NN O
3 NN NN O
- NN NN O
derived NN NN O
pre NN NN O
- NN NN O
B NN NN O
- NN NN O
cell NN NN O
lines NN NN O
either NN NN O
lacking NN NN O
or NN NN O
expressing NN NN O
human NN NN O
CD14 NN NN B-Protein
( NN NN O
the NN NN O
LPS NN NN O
receptor NN NN O
) NN NN O
, NN NN O
it NN NN O
was NN NN O
observed NN NN O
that NN NN O
expression NN NN O
of NN NN O
human NN NN O
CD14 NN NN B-Protein
imparted NN NN O
responsiveness NN NN O
to NN NN O
LPS NN NN O
but NN NN O
not NN NN O
to NN NN O
OspA NN NN B-Protein
or NN NN O
spirochetal NN NN O
lipopeptides NN NN O
( NN NN O
assessed NN NN O
by NN NN O
induction NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
expression NN NN O
of NN NN O
surface NN NN O
immunoglobulin NN NN O
M NN NN O
) NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
the NN NN O
biological NN NN O
relevance NN NN O
of NN NN O
the NN NN O
observation NN NN O
that NN NN O
T NN NN O
. NN NN O
pallidum NN NN O
lipoproteins NN NN O
- NN NN O
lipopeptides NN NN O
induce NN NN O
both NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
cytokine NN NN O
production NN NN O
in NN NN O
monocytes NN NN O
was NN NN O
supported NN NN O
by NN NN O
the NN NN O
ability NN NN O
of NN NN O
the NN NN O
synthetic NN NN O
analogs NN NN O
to NN NN O
promote NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
replication NN NN O
in NN NN O
chronically NN NN O
infected NN NN O
U1 NN NN O
monocytoid NN NN O
cells NN NN O
; NN NN O
these NN NN O
observations NN NN O
also NN NN O
suggest NN NN O
a NN NN O
potential NN NN O
mechanism NN NN O
whereby NN NN O
a NN NN O
syphilitic NN NN O
chancre NN NN O
can NN NN O
serve NN NN O
as NN NN O
a NN NN O
cofactor NN NN O
for NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
transmission NN NN O
. NN NN O
   
The NN NN O
combined NN NN O
data NN NN O
lend NN NN O
additional NN NN O
support NN NN O
to NN NN O
the NN NN O
proposal NN NN O
that NN NN O
spirochetal NN NN O
lipoproteins NN NN O
and NN NN O
LPS NN NN O
initiate NN NN O
monocyte NN NN O
activation NN NN O
via NN NN O
different NN NN O
cell NN NN O
surface NN NN O
events NN NN O
but NN NN O
that NN NN O
the NN NN O
signaling NN NN O
pathways NN NN O
ultimately NN NN O
converge NN NN O
to NN NN O
produce NN NN O
qualitatively NN NN O
similar NN NN O
cellular NN NN O
responses NN NN O
. NN NN O
   
Chronic NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
infection NN NN O
of NN NN O
myeloid NN NN O
cells NN NN O
disrupts NN NN O
the NN NN O
autoregulatory NN NN O
control NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
/ NN NN O
Rel NN NN O
pathway NN NN O
via NN NN O
enhanced NN NN O
IkappaBalpha NN NN B-Protein
degradation NN NN O
. NN NN O
   
Productive NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
infection NN NN O
causes NN NN O
sustained NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
in NN NN O
chronically NN NN O
infected NN NN O
monocytic NN NN O
cells NN NN O
. NN NN O
   
A NN NN O
direct NN NN O
temporal NN NN O
correlation NN NN O
exists NN NN O
between NN NN O
HIV NN NN O
infection NN NN O
and NN NN O
the NN NN O
appearance NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
in NN NN O
myelomonoblastic NN NN O
PLB NN NN O
- NN NN O
985 NN NN O
cells NN NN O
. NN NN O
   
To NN NN O
examine NN NN O
the NN NN O
molecular NN NN O
basis NN NN O
of NN NN O
constitutive NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
in NN NN O
HIV1 NN NN O
- NN NN O
infected NN NN O
cells NN NN O
, NN NN O
we NN NN O
analyzed NN NN O
the NN NN O
phosphorylation NN NN O
and NN NN O
turnover NN NN O
of NN NN O
IkappaBalpha NN NN B-Protein
protein NN NN O
, NN NN O
the NN NN O
activity NN NN O
of NN NN O
the NN NN O
double NN NN B-Protein
- NN NN I-Protein
stranded NN NN I-Protein
RNA NN NN I-Protein
- NN NN I-Protein
dependent NN NN I-Protein
protein NN NN I-Protein
kinase NN NN I-Protein
( NN NN O
PKR NN NN B-Protein
) NN NN O
and NN NN O
the NN NN O
intracellular NN NN O
levels NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
subunits NN NN O
in NN NN O
the NN NN O
PLB NN NN O
- NN NN O
985 NN NN O
and NN NN O
U937 NN NN O
myeloid NN NN O
cell NN NN O
models NN NN O
. NN NN O
   
HIV NN NN O
- NN NN O
1 NN NN O
infection NN NN O
resulted NN NN O
in NN NN O
constitutive NN NN O
, NN NN O
low NN NN O
- NN NN O
level NN NN O
expression NN NN O
of NN NN O
type NN NN O
1 NN NN O
interferon NN NN O
( NN NN O
IFN NN NN O
) NN NN O
at NN NN O
the NN NN O
mRNA NN NN O
level NN NN O
. NN NN O
   
Constitutive NN NN O
PKR NN NN B-Protein
activity NN NN O
was NN NN O
also NN NN O
detected NN NN O
in NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
- NN NN O
infected NN NN O
cells NN NN O
as NN NN O
a NN NN O
result NN NN O
of NN NN O
low NN NN O
- NN NN O
level NN NN O
IFN NN NN O
production NN NN O
, NN NN O
since NN NN O
the NN NN O
addition NN NN O
of NN NN O
anti NN NN O
- NN NN O
IFN NN NN O
- NN NN O
alpha NN NN O
/ NN NN O
beta NN NN O
antibody NN NN O
to NN NN O
the NN NN O
cells NN NN O
decreased NN NN O
PKR NN NN B-Protein
expression NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
the NN NN O
analysis NN NN O
of NN NN O
IkappaBalpha NN NN B-Protein
turnover NN NN O
demonstrated NN NN O
an NN NN O
increased NN NN O
degradation NN NN O
of NN NN O
IkappaBalpha NN NN B-Protein
in NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
- NN NN O
infected NN NN O
cells NN NN O
that NN NN O
may NN NN O
account NN NN O
for NN NN O
the NN NN O
constitutive NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
. NN NN O
   
A NN NN O
dramatic NN NN O
increase NN NN O
in NN NN O
the NN NN O
intracellular NN NN O
levels NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
subunits NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
and NN NN O
NF NN NN B-Protein
- NN NN I-Protein
kappaB2 NN NN I-Protein
p100 NN NN I-Protein
and NN NN O
a NN NN O
moderate NN NN O
increase NN NN O
in NN NN O
NF NN NN B-Protein
- NN NN I-Protein
kappaB2 NN NN I-Protein
p52 NN NN I-Protein
and NN NN O
RelA NN NN B-Protein
( NN NN O
p65 NN NN B-Protein
) NN NN O
were NN NN O
detected NN NN O
in NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
- NN NN O
infected NN NN O
cells NN NN O
, NN NN O
whereas NN NN O
NF NN NN B-Protein
- NN NN I-Protein
kappaB1 NN NN I-Protein
p105 NN NN I-Protein
/ NN NN O
p50 NN NN B-Protein
levels NN NN O
were NN NN O
not NN NN O
altered NN NN O
relative NN NN O
to NN NN O
the NN NN O
levels NN NN O
in NN NN O
uninfected NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
suggest NN NN O
that NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
infection NN NN O
of NN NN O
myeloid NN NN O
cells NN NN O
induces NN NN O
IFN NN NN O
production NN NN O
and NN NN O
PKR NN NN B-Protein
activity NN NN O
, NN NN O
which NN NN O
in NN NN O
turn NN NN O
contribute NN NN O
to NN NN O
enhanced NN NN O
IkappaBalpha NN NN B-Protein
phosphorylation NN NN O
and NN NN O
subsequent NN NN O
degradation NN NN O
. NN NN O
   
Nuclear NN NN O
translocation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
subunits NN NN O
may NN NN O
ultimately NN NN O
increase NN NN O
the NN NN O
intracellular NN NN O
pool NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
/ NN NN O
IkappaBalpha NN NN B-Protein
by NN NN O
an NN NN O
autoregulatory NN NN O
mechanism NN NN O
. NN NN O
   
Enhanced NN NN O
turnover NN NN O
of NN NN O
IkappaBalpha NN NN B-Protein
and NN NN O
the NN NN O
accumulation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
/ NN NN O
Rel NN NN O
proteins NN NN O
may NN NN O
contribute NN NN O
to NN NN O
the NN NN O
chronically NN NN O
activated NN NN O
state NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
- NN NN O
infected NN NN O
cells NN NN O
. NN NN O
   
Differential NN NN O
regulation NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
gene NN NN O
transcription NN NN O
and NN NN O
expression NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
in NN NN O
human NN NN O
monocytic NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
inhibit NN NN O
the NN NN O
cytokine NN NN O
production NN NN O
and NN NN O
mRNA NN NN O
expression NN NN O
by NN NN O
monocytes NN NN O
/ NN NN O
macrophages NN NN O
. NN NN O
   
To NN NN O
investigate NN NN O
the NN NN O
molecular NN NN O
mechanism NN NN O
of NN NN O
the NN NN O
inhibitory NN NN O
effect NN NN O
on NN NN O
transcriptional NN NN O
or NN NN O
post NN NN O
- NN NN O
transcriptional NN NN O
regulation NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
gene NN NN O
expression NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
, NN NN O
we NN NN O
studied NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
production NN NN O
, NN NN O
expression NN NN O
level NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
mRNA NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
promoter NN NN O
activity NN NN O
, NN NN O
transcriptional NN NN O
activity NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
and NN NN O
NF NN NN B-Protein
- NN NN I-Protein
IL NN NN I-Protein
- NN NN I-Protein
6 NN NN I-Protein
, NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
mRNA NN NN O
stability NN NN O
in NN NN O
human NN NN O
monocytic NN NN O
cell NN NN O
lines NN NN O
, NN NN O
THP NN NN O
- NN NN O
1 NN NN O
and NN NN O
U937 NN NN O
, NN NN O
stimulated NN NN O
by NN NN O
PMA NN NN O
and NN NN O
LPS NN NN O
in NN NN O
the NN NN O
absence NN NN O
or NN NN O
the NN NN O
presence NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
or NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
. NN NN O
   
Both NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
were NN NN O
seen NN NN O
to NN NN O
inhibit NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
production NN NN O
and NN NN O
the NN NN O
expression NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
mRNA NN NN O
in NN NN O
both NN NN O
monocytic NN NN O
cell NN NN O
lines NN NN O
studied NN NN O
. NN NN O
   
In NN NN O
chloramphenicol NN NN B-Protein
acetyltransferase NN NN I-Protein
assays NN NN O
, NN NN O
utilizing NN NN O
the NN NN O
transient NN NN O
transfection NN NN O
of NN NN O
a NN NN O
chloramphenicol NN NN B-Protein
acetyltransferase NN NN I-Protein
reporter NN NN O
plasmid NN NN O
containing NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
gene NN NN O
promoter NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
, NN NN O
but NN NN O
not NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
, NN NN O
suppressed NN NN O
the NN NN O
transcriptional NN NN O
activity NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
gene NN NN O
promoter NN NN O
stimulated NN NN O
by NN NN O
PMA NN NN O
and NN NN O
LPS NN NN O
. NN NN O
   
Electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
showed NN NN O
that NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
, NN NN O
but NN NN O
not NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
, NN NN O
inhibited NN NN O
nuclear NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activity NN NN O
, NN NN O
and NN NN O
that NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
did NN NN O
not NN NN O
affect NN NN O
NF NN NN B-Protein
- NN NN I-Protein
IL NN NN I-Protein
- NN NN I-Protein
6 NN NN I-Protein
activity NN NN O
. NN NN O
   
On NN NN O
the NN NN O
other NN NN O
hand NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
enhanced NN NN O
the NN NN O
degradation NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
mRNA NN NN O
in NN NN O
a NN NN O
mRNA NN NN O
stability NN NN O
assay NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
may NN NN O
inhibit NN NN O
the NN NN O
transcription NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
gene NN NN O
by NN NN O
affecting NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
binding NN NN O
activity NN NN O
, NN NN O
while NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
may NN NN O
inhibit NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
mRNA NN NN O
levels NN NN O
post NN NN O
- NN NN O
transcriptionally NN NN O
, NN NN O
without NN NN O
suppressing NN NN O
promoter NN NN O
activity NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
we NN NN O
conclude NN NN O
that NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
inhibit NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
production NN NN O
by NN NN O
different NN NN O
mechanisms NN NN O
in NN NN O
human NN NN O
monocytic NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Tyloxapol NN NN O
inhibits NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
cytokine NN NN O
release NN NN O
, NN NN O
scavenges NN NN O
HOCI NN NN O
, NN NN O
and NN NN O
reduces NN NN O
viscosity NN NN O
of NN NN O
cystic NN NN O
fibrosis NN NN O
sputum NN NN O
. NN NN O
   
Cystic NN NN O
fibrosis NN NN O
( NN NN O
CF NN NN O
) NN NN O
patients NN NN O
develop NN NN O
progressive NN NN O
cytokine NN NN O
- NN NN O
mediated NN NN O
inflammatory NN NN O
lung NN NN O
disease NN NN O
, NN NN O
with NN NN O
abundant NN NN O
production NN NN O
of NN NN O
thick NN NN O
, NN NN O
tenacious NN NN O
, NN NN O
protease NN NN O
- NN NN O
and NN NN O
oxidant NN NN O
- NN NN O
rich NN NN O
purulent NN NN O
airway NN NN O
secretions NN NN O
that NN NN O
are NN NN O
difficult NN NN O
to NN NN O
clear NN NN O
even NN NN O
with NN NN O
physiotherapy NN NN O
. NN NN O
   
In NN NN O
the NN NN O
search NN NN O
for NN NN O
a NN NN O
potential NN NN O
treatment NN NN O
, NN NN O
we NN NN O
have NN NN O
tested NN NN O
tyloxapol NN NN O
, NN NN O
an NN NN O
alkylaryl NN NN O
polyether NN NN O
alcohol NN NN O
polymer NN NN O
detergent NN NN O
previously NN NN O
used NN NN O
as NN NN O
a NN NN O
mucolytic NN NN O
agent NN NN O
in NN NN O
adult NN NN O
chronic NN NN O
bronchitis NN NN O
. NN NN O
   
Tyloxapol NN NN O
inhibits NN NN O
activation NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NK NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
, NN NN O
reduces NN NN O
resting NN NN O
secretion NN NN O
of NN NN O
the NN NN O
cytokine NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
) NN NN O
in NN NN O
cultured NN NN O
human NN NN O
monocytes NN NN O
, NN NN O
and NN NN O
inhibits NN NN O
lipopolysaccharide NN NN O
( NN NN O
LPS NN NN O
) NN NN O
- NN NN O
stimulated NN NN O
release NN NN O
of NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
, NN NN O
granulocyte NN NN B-Protein
- NN NN I-Protein
macrophage NN NN I-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
( NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
) NN NN O
, NN NN O
and NN NN O
the NN NN O
eiconsanoids NN NN O
thromboxane NN NN O
A2 NN NN O
and NN NN O
leukotriene NN NN O
B4 NN NN O
( NN NN O
LTB4 NN NN O
) NN NN O
. NN NN O
   
We NN NN O
have NN NN O
previously NN NN O
shown NN NN O
that NN NN O
tyloxapol NN NN O
is NN NN O
a NN NN O
potent NN NN O
antioxidant NN NN O
for NN NN O
hydroxyl NN NN O
radicals NN NN O
( NN NN O
OH NN NN O
) NN NN O
. NN NN O
   
Tyloxapol NN NN O
( NN NN O
0 NN NN O
. NN NN O
05 NN NN O
to NN NN O
0 NN NN O
. NN NN O
1 NN NN O
% NN NN O
wt NN NN O
/ NN NN O
vol NN NN O
) NN NN O
effectively NN NN O
scavenges NN NN O
the NN NN O
oxidant NN NN O
hypochlorous NN NN O
acid NN NN O
( NN NN O
HOCl NN NN O
; NN NN O
1 NN NN O
to NN NN O
7 NN NN O
. NN NN O
5 NN NN O
mM NN NN O
) NN NN O
in NN NN O
vitro NN NN O
, NN NN O
and NN NN O
protects NN NN O
from NN NN O
HOCl NN NN O
- NN NN O
mediated NN NN O
lung NN NN O
injury NN NN O
in NN NN O
rats NN NN O
. NN NN O
   
Tyloxapol NN NN O
also NN NN O
reduces NN NN O
the NN NN O
viscosity NN NN O
of NN NN O
CF NN NN O
sputum NN NN O
( NN NN O
from NN NN O
463 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
133 NN NN O
to NN NN O
128 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
52 NN NN O
centipoise NN NN O
) NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
tyloxapol NN NN O
is NN NN O
potentially NN NN O
useful NN NN O
as NN NN O
a NN NN O
new NN NN O
antiinflammatory NN NN O
therapy NN NN O
for NN NN O
CF NN NN O
lung NN NN O
disease NN NN O
, NN NN O
and NN NN O
could NN NN O
possibly NN NN O
promote NN NN O
clearance NN NN O
of NN NN O
secretions NN NN O
in NN NN O
the NN NN O
CF NN NN O
airway NN NN O
. NN NN O
   
Cytomegalovirus NN NN O
modulates NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
gene NN NN O
expression NN NN O
. NN NN O
   
Complications NN NN O
after NN NN O
lung NN NN O
transplantation NN NN O
include NN NN O
the NN NN O
development NN NN O
of NN NN O
rejection NN NN O
and NN NN O
an NN NN O
increased NN NN O
incidence NN NN O
of NN NN O
infection NN NN O
, NN NN O
particularly NN NN O
with NN NN O
cytomegalovirus NN NN O
( NN NN O
CMV NN NN O
) NN NN O
. NN NN O
   
Several NN NN O
recent NN NN O
studies NN NN O
have NN NN O
suggested NN NN O
that NN NN O
interleukin NN NN B-Protein
( NN NN I-Protein
IL NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
6 NN NN I-Protein
may NN NN O
be NN NN O
used NN NN O
to NN NN O
detect NN NN O
both NN NN O
infection NN NN O
and NN NN O
rejection NN NN O
after NN NN O
lung NN NN O
transplantation NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
may NN NN O
play NN NN O
a NN NN O
role NN NN O
in NN NN O
the NN NN O
development NN NN O
of NN NN O
bronchiolitis NN NN O
obliterans NN NN O
after NN NN O
transplantation NN NN O
. NN NN O
   
Because NN NN O
CMV NN NN O
is NN NN O
also NN NN O
associated NN NN O
with NN NN O
the NN NN O
development NN NN O
of NN NN O
bronchiolitis NN NN O
obliterans NN NN O
after NN NN O
transplantation NN NN O
, NN NN O
we NN NN O
determined NN NN O
whether NN NN O
CMV NN NN O
induces NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
gene NN NN O
expression NN NN O
. NN NN O
   
We NN NN O
demonstrated NN NN O
that NN NN O
CMV NN NN O
infection NN NN O
increased NN NN O
both NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
protein NN NN O
and NN NN O
mRNA NN NN O
in NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
also NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
CMV NN NN O
immediate NN NN B-Protein
early NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
product NN NN O
increased NN NN O
expression NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
promoter NN NN O
. NN NN O
   
This NN NN O
effect NN NN O
of NN NN O
the NN NN O
CMV NN NN O
immediate NN NN B-Protein
early NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
product NN NN O
was NN NN O
dependent NN NN O
upon NN NN O
the NN NN O
presence NN NN O
of NN NN O
specific NN NN O
transcription NN NN O
factor NN NN O
binding NN NN O
sites NN NN O
in NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
promoter NN NN O
. NN NN O
   
These NN NN O
studies NN NN O
demonstrate NN NN O
that NN NN O
CMV NN NN O
may NN NN O
be NN NN O
an NN NN O
important NN NN O
cofactor NN NN O
in NN NN O
the NN NN O
development NN NN O
of NN NN O
rejection NN NN O
and NN NN O
infection NN NN O
after NN NN O
transplantation NN NN O
through NN NN O
its NN NN O
effects NN NN O
on NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
. NN NN O
   
Molecular NN NN O
mechanisms NN NN O
of NN NN O
steroid NN NN O
action NN NN O
: NN NN O
a NN NN O
novel NN NN O
type NN NN O
of NN NN O
cross NN NN O
- NN NN O
talk NN NN O
between NN NN O
glucocorticoids NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
transcription NN NN O
factors NN NN O
. NN NN O
   
Despite NN NN O
the NN NN O
widespread NN NN O
use NN NN O
of NN NN O
glucocorticoids NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
diseases NN NN O
characterized NN NN O
by NN NN O
inflammation NN NN O
, NN NN O
the NN NN O
molecular NN NN O
mechanism NN NN O
( NN NN O
s NN NN O
) NN NN O
by NN NN O
which NN NN O
these NN NN O
hormones NN NN O
exert NN NN O
this NN NN O
beneficial NN NN O
effect NN NN O
in NN NN O
patients NN NN O
with NN NN O
asthma NN NN O
remains NN NN O
to NN NN O
be NN NN O
elucidated NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
we NN NN O
have NN NN O
studied NN NN O
the NN NN O
transcriptional NN NN O
regulation NN NN O
of NN NN O
intercellular NN NN B-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
as NN NN O
adhesion NN NN O
molecules NN NN O
are NN NN O
likely NN NN O
to NN NN O
play NN NN O
a NN NN O
causal NN NN O
role NN NN O
in NN NN O
inflammation NN NN O
in NN NN O
promoting NN NN O
cell NN NN O
- NN NN O
cell NN NN O
and NN NN O
cell NN NN O
- NN NN O
matrix NN NN O
interactions NN NN O
. NN NN O
   
We NN NN O
observed NN NN O
that NN NN O
in NN NN O
a NN NN O
monocytic NN NN O
( NN NN O
U937 NN NN O
) NN NN O
and NN NN O
a NN NN O
bronchial NN NN O
epithelial NN NN O
( NN NN O
H292 NN NN O
) NN NN O
cell NN NN O
- NN NN O
line NN NN O
dexamethasone NN NN O
strongly NN NN O
suppressed NN NN O
basal NN NN O
and NN NN O
induced NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
. NN NN O
   
Subsequent NN NN O
analysis NN NN O
of NN NN O
the NN NN O
human NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
promoter NN NN O
has NN NN O
revealed NN NN O
that NN NN O
both NN NN O
12 NN NN O
- NN NN O
O NN NN O
- NN NN O
tetradecanoylphorbol NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
( NN NN O
TPA NN NN O
) NN NN O
and NN NN O
tumour NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
upregulate NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
through NN NN O
the NN NN O
presence NN NN O
of NN NN O
a NN NN O
nuclear NN NN O
factor NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
target NN NN O
sequence NN NN O
( NN NN O
TGGAAATTCC NN NN O
) NN NN O
. NN NN O
   
No NN NN O
glucocorticoid NN NN O
recognition NN NN O
sequences NN NN O
are NN NN O
present NN NN O
in NN NN O
this NN NN O
promoter NN NN O
region NN NN O
and NN NN O
dexamethasone NN NN O
is NN NN O
still NN NN O
able NN NN O
to NN NN O
repress NN NN O
transcription NN NN O
when NN NN O
the NN NN O
multimerized NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
sequence NN NN O
is NN NN O
transactivated NN NN O
by NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
upon NN NN O
transfection NN NN O
in NN NN O
293 NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
propose NN NN O
that NN NN O
direct NN NN O
interaction NN NN O
between NN NN O
the NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
and NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
factors NN NN O
is NN NN O
at NN NN O
least NN NN O
a NN NN O
partial NN NN O
explanation NN NN O
for NN NN O
the NN NN O
effects NN NN O
of NN NN O
this NN NN O
hormone NN NN O
in NN NN O
inflammatory NN NN O
diseases NN NN O
. NN NN O
   
The NN NN O
suppression NN NN O
of NN NN O
T NN NN O
cell NN NN O
function NN NN O
and NN NN O
NF NN NN O
( NN NN O
kappa NN NN O
) NN NN O
B NN NN O
expression NN NN O
by NN NN O
serine NN NN O
protease NN NN O
inhibitors NN NN O
is NN NN O
blocked NN NN O
by NN NN O
N NN NN O
- NN NN O
acetylcysteine NN NN O
. NN NN O
   
Direct NN NN O
evidence NN NN O
that NN NN O
N NN NN O
- NN NN O
acetylcysteine NN NN O
( NN NN O
NAC NN NN O
) NN NN O
enhances NN NN O
the NN NN O
immune NN NN O
response NN NN O
of NN NN O
peripheral NN NN O
blood NN NN O
T NN NN O
cells NN NN O
at NN NN O
the NN NN O
level NN NN O
of NN NN O
NF NN NN O
( NN NN O
kappa NN NN O
) NN NN O
B NN NN O
is NN NN O
presented NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
NAC NN NN O
blocks NN NN O
the NN NN O
suppression NN NN O
of NN NN O
T NN NN O
cell NN NN O
mitogenesis NN NN O
and NN NN O
cytokine NN NN O
production NN NN O
by NN NN O
protease NN NN O
inhibitors NN NN O
such NN NN O
as NN NN O
N NN NN O
- NN NN O
tosylphenylalanine NN NN O
chloromethyl NN NN O
ketone NN NN O
( NN NN O
TPCK NN NN O
) NN NN O
. NN NN O
   
The NN NN O
proliferative NN NN O
responses NN NN O
of NN NN O
purified NN NN O
CD4 NN NN B-Protein
+ NN NN O
or NN NN O
CD8 NN NN O
+ NN NN O
T NN NN O
cells NN NN O
are NN NN O
suppressed NN NN O
more NN NN O
strongly NN NN O
by NN NN O
TPCK NN NN O
when NN NN O
anti NN NN O
- NN NN O
CD28 NN NN O
rather NN NN O
than NN NN O
the NN NN O
phorbol NN NN O
ester NN NN O
PMA NN NN O
is NN NN O
used NN NN O
as NN NN O
the NN NN O
mitogenic NN NN O
coactivator NN NN O
. NN NN O
   
Cytokine NN NN O
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
, NN NN O
INF NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
) NN NN O
production NN NN O
is NN NN O
inhibited NN NN O
95 NN NN O
- NN NN O
100 NN NN O
% NN NN O
by NN NN O
concentrations NN NN O
of NN NN O
TPCK NN NN O
that NN NN O
totally NN NN O
suppress NN NN O
the NN NN O
mitogenesis NN NN O
of NN NN O
CD4 NN NN B-Protein
+ NN NN O
or NN NN O
CD8 NN NN O
+ NN NN O
cells NN NN O
. NN NN O
   
Using NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
, NN NN O
we NN NN O
find NN NN O
that NN NN O
TPCK NN NN O
virtually NN NN O
abolishes NN NN O
( NN NN O
to NN NN O
less NN NN O
than NN NN O
1 NN NN O
% NN NN O
) NN NN O
the NN NN O
levels NN NN O
of NN NN O
NF NN NN O
( NN NN O
kappa NN NN O
) NN NN O
B NN NN O
( NN NN O
but NN NN O
not NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
found NN NN O
in NN NN O
nuclear NN NN O
and NN NN O
whole NN NN O
cell NN NN O
extracts NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Strikingly NN NN O
, NN NN O
the NN NN O
immunosuppressive NN NN O
effects NN NN O
of NN NN O
TPCK NN NN O
are NN NN O
blocked NN NN O
when NN NN O
T NN NN O
cells NN NN O
are NN NN O
pretreated NN NN O
for NN NN O
15 NN NN O
min NN NN O
with NN NN O
5 NN NN O
mM NN NN O
NAC NN NN O
. NN NN O
   
NAC NN NN O
not NN NN O
only NN NN O
blocks NN NN O
the NN NN O
effect NN NN O
of NN NN O
TPCK NN NN O
but NN NN O
enhances NN NN O
mitogenesis NN NN O
and NN NN O
cytokine NN NN O
production NN NN O
( NN NN O
> NN NN O
2 NN NN O
. NN NN O
5 NN NN O
- NN NN O
fold NN NN O
in NN NN O
some NN NN O
cases NN NN O
) NN NN O
upon NN NN O
activation NN NN O
of NN NN O
unsuppressed NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Our NN NN O
data NN NN O
support NN NN O
the NN NN O
notion NN NN O
that NN NN O
NF NN NN O
( NN NN O
kappa NN NN O
) NN NN O
B NN NN O
and NN NN O
I NN NN O
( NN NN O
kappa NN NN O
) NN NN O
B NN NN O
proteases NN NN O
play NN NN O
obligate NN NN O
roles NN NN O
in NN NN O
T NN NN O
cell NN NN O
activation NN NN O
and NN NN O
mitogenesis NN NN O
, NN NN O
roles NN NN O
that NN NN O
are NN NN O
enhanced NN NN O
significantly NN NN O
by NN NN O
NAC NN NN O
. NN NN O
   
Signal NN NN O
transduction NN NN O
by NN NN O
DR3 NN NN B-Protein
, NN NN O
a NN NN O
death NN NN O
domain NN NN O
- NN NN O
containing NN NN O
receptor NN NN O
related NN NN O
to NN NN O
TNFR NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
CD95 NN NN B-Protein
. NN NN O
   
Tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
receptor NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
TNFR NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
and NN NN O
CD95 NN NN B-Protein
( NN NN O
also NN NN O
called NN NN O
Fas NN NN B-Protein
or NN NN O
APO NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
are NN NN O
cytokine NN NN O
receptors NN NN O
that NN NN O
engage NN NN O
the NN NN O
apoptosis NN NN O
pathway NN NN O
through NN NN O
a NN NN O
region NN NN O
of NN NN O
intracellular NN NN O
homology NN NN O
, NN NN O
designated NN NN O
the NN NN O
"""""""" NN NN O
death NN NN O
domain NN NN O
. NN NN O
"""""""" NN NN O
Another NN NN O
death NN NN O
domain NN NN O
- NN NN O
containing NN NN O
member NN NN O
of NN NN O
the NN NN O
TNFR NN NN O
family NN NN O
, NN NN O
death NN NN B-Protein
receptor NN NN I-Protein
3 NN NN I-Protein
( NN NN O
DR3 NN NN B-Protein
) NN NN O
, NN NN O
was NN NN O
identified NN NN O
and NN NN O
was NN NN O
shown NN NN O
to NN NN O
induce NN NN O
both NN NN O
apoptosis NN NN O
and NN NN O
activation NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
kappaB NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
DR3 NN NN B-Protein
appears NN NN O
to NN NN O
be NN NN O
restricted NN NN O
to NN NN O
tissues NN NN O
enriched NN NN O
in NN NN O
lymphocytes NN NN O
. NN NN O
   
DR3 NN NN B-Protein
signal NN NN O
transduction NN NN O
is NN NN O
mediated NN NN O
by NN NN O
a NN NN O
complex NN NN O
of NN NN O
intracellular NN NN O
signaling NN NN O
molecules NN NN O
including NN NN O
TRADD NN NN B-Protein
, NN NN O
TRAF2 NN NN B-Protein
, NN NN O
FADD NN NN B-Protein
, NN NN O
and NN NN O
FLICE NN NN B-Protein
. NN NN O
   
Thus NN NN O
, NN NN O
DR3 NN NN B-Protein
likely NN NN O
plays NN NN O
a NN NN O
role NN NN O
in NN NN O
regulating NN NN O
lymphocyte NN NN O
homeostasis NN NN O
. NN NN O
   
Regulation NN NN O
of NN NN O
interferon NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
gene NN NN O
expression NN NN O
. NN NN O
   
Interferon NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
( NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
) NN NN O
, NN NN O
also NN NN O
known NN NN O
as NN NN O
type NN NN B-Protein
II NN NN I-Protein
interferon NN NN I-Protein
, NN NN O
is NN NN O
an NN NN O
important NN NN O
immunoregulatory NN NN O
gene NN NN O
that NN NN O
has NN NN O
multiple NN NN O
effects NN NN O
on NN NN O
the NN NN O
development NN NN O
, NN NN O
maturation NN NN O
, NN NN O
and NN NN O
function NN NN O
of NN NN O
the NN NN O
immune NN NN O
system NN NN O
. NN NN O
   
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
mRNA NN NN O
and NN NN O
protein NN NN O
are NN NN O
expressed NN NN O
predominantly NN NN O
by NN NN O
T NN NN O
cells NN NN O
and NN NN O
large NN NN O
granular NN NN O
lymphocytes NN NN O
. NN NN O
   
The NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
mRNA NN NN O
is NN NN O
induced NN NN O
/ NN NN O
inhibited NN NN O
in NN NN O
these NN NN O
cell NN NN O
types NN NN O
by NN NN O
a NN NN O
wide NN NN O
variety NN NN O
of NN NN O
extracellular NN NN O
signals NN NN O
, NN NN O
thus NN NN O
implicating NN NN O
a NN NN O
number NN NN O
of NN NN O
diverse NN NN O
, NN NN O
yet NN NN O
convergent NN NN O
signal NN NN O
transduction NN NN O
pathways NN NN O
in NN NN O
its NN NN O
transcriptional NN NN O
control NN NN O
. NN NN O
   
In NN NN O
this NN NN O
review NN NN O
, NN NN O
I NN NN O
describe NN NN O
how NN NN O
DNA NN NN O
methylation NN NN O
and NN NN O
specific NN NN O
DNA NN NN O
binding NN NN O
proteins NN NN O
may NN NN O
regulate NN NN O
transcription NN NN O
of NN NN O
the NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
gene NN NN O
in NN NN O
response NN NN O
to NN NN O
extracellular NN NN O
signals NN NN O
. NN NN O
   
CD14 NN NN B-Protein
- NN NN O
mediated NN NN O
signal NN NN O
pathway NN NN O
of NN NN O
Porphyromonas NN NN O
gingivalis NN NN O
lipopolysaccharide NN NN O
in NN NN O
human NN NN O
gingival NN NN O
fibroblasts NN NN O
. NN NN O
   
Lipopolysaccharide NN NN O
( NN NN O
LPS NN NN O
) NN NN O
induces NN NN O
expression NN NN O
of NN NN O
inflammatory NN NN O
cytokines NN NN O
in NN NN O
monocytes NN NN O
/ NN NN O
macrophages NN NN O
via NN NN O
CD14 NN NN B-Protein
, NN NN O
one NN NN O
of NN NN O
the NN NN O
LPS NN NN O
receptors NN NN O
, NN NN O
which NN NN O
is NN NN O
expressed NN NN O
predominantly NN NN O
in NN NN O
these NN NN O
cells NN NN O
. NN NN O
   
It NN NN O
has NN NN O
been NN NN O
demonstrated NN NN O
that NN NN O
Porphyromonas NN NN O
gingivalis NN NN O
LPS NN NN O
( NN NN O
P NN NN O
- NN NN O
LPS NN NN O
) NN NN O
also NN NN O
is NN NN O
able NN NN O
to NN NN O
induce NN NN O
inflammatory NN NN O
cytokines NN NN O
in NN NN O
human NN NN O
gingival NN NN O
fibroblasts NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
it NN NN O
is NN NN O
important NN NN O
to NN NN O
determine NN NN O
whether NN NN O
CD14 NN NN B-Protein
is NN NN O
expressed NN NN O
in NN NN O
gingival NN NN O
fibroblasts NN NN O
and NN NN O
to NN NN O
define NN NN O
the NN NN O
P NN NN O
- NN NN O
LPS NN NN O
- NN NN O
mediated NN NN O
signal NN NN O
- NN NN O
transducing NN NN O
mechanism NN NN O
in NN NN O
the NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
observed NN NN O
unexpectedly NN NN O
by NN NN O
immunohistochemical NN NN O
, NN NN O
Western NN NN O
blotting NN NN O
( NN NN O
immunoblotting NN NN O
) NN NN O
, NN NN O
and NN NN O
Northern NN NN O
( NN NN O
RNA NN NN O
) NN NN O
blotting NN NN O
assays NN NN O
that NN NN O
CD14 NN NN B-Protein
is NN NN O
expressed NN NN O
at NN NN O
high NN NN O
density NN NN O
in NN NN O
human NN NN O
gingival NN NN O
fibroblasts NN NN O
. NN NN O
   
P NN NN O
- NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
expression NN NN O
of NN NN O
the NN NN O
monocyte NN NN B-Protein
chemoattractant NN NN I-Protein
protein NN NN I-Protein
1 NN NN I-Protein
( NN NN O
MCP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
gene NN NN O
in NN NN O
the NN NN O
cells NN NN O
was NN NN O
inhibited NN NN O
markedly NN NN O
by NN NN O
treatment NN NN O
with NN NN O
anti NN NN O
- NN NN O
human NN NN O
CD14 NN NN B-Protein
antibody NN NN O
and NN NN O
was NN NN O
completely NN NN O
inhibited NN NN O
by NN NN O
herbimycin NN NN O
A NN NN O
, NN NN O
a NN NN O
potent NN NN O
inhibitor NN NN O
of NN NN O
tyrosine NN NN O
kinase NN NN O
. NN NN O
   
The NN NN O
inhibitor NN NN O
also NN NN O
dramatically NN NN O
inhibited NN NN O
monocyte NN NN O
chemotactic NN NN O
activity NN NN O
of NN NN O
and NN NN O
MCP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
production NN NN O
by NN NN O
the NN NN O
cells NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
P NN NN O
- NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
expression NN NN O
of NN NN O
the NN NN O
MCP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
in NN NN O
the NN NN O
cells NN NN O
also NN NN O
was NN NN O
blocked NN NN O
by NN NN O
inhibitors NN NN O
of NN NN O
two NN NN O
transcription NN NN O
factors NN NN O
, NN NN O
i NN NN O
. NN NN O
e NN NN O
. NN NN O
, NN NN O
curcumin NN NN O
, NN NN O
an NN NN O
inhibitor NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
, NN NN O
and NN NN O
pyrolidine NN NN O
dithiocarbamate NN NN O
, NN NN O
an NN NN O
inhibitor NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
. NN NN O
   
Both NN NN O
inhibitors NN NN O
inhibited NN NN O
monocyte NN NN O
chemotactic NN NN O
activity NN NN O
in NN NN O
the NN NN O
culture NN NN O
supernatant NN NN O
of NN NN O
P NN NN O
- NN NN O
LPS NN NN O
- NN NN O
treated NN NN O
cells NN NN O
. NN NN O
   
Gel NN NN O
shift NN NN O
mobility NN NN O
assay NN NN O
showed NN NN O
stimulation NN NN O
of NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
contents NN NN O
in NN NN O
P NN NN O
- NN NN O
LPS NN NN O
- NN NN O
treated NN NN O
cells NN NN O
. NN NN O
   
This NN NN O
study NN NN O
is NN NN O
the NN NN O
first NN NN O
to NN NN O
demonstrate NN NN O
the NN NN O
expression NN NN O
of NN NN O
CD14 NN NN B-Protein
in NN NN O
human NN NN O
gingival NN NN O
fibroblasts NN NN O
and NN NN O
to NN NN O
show NN NN O
that NN NN O
the NN NN O
signal NN NN O
- NN NN O
transducing NN NN O
pathway NN NN O
of NN NN O
P NN NN O
- NN NN O
LPS NN NN O
in NN NN O
the NN NN O
cells NN NN O
is NN NN O
mediated NN NN O
by NN NN O
CD14 NN NN B-Protein
. NN NN O
   
Comparative NN NN O
analysis NN NN O
identifies NN NN O
conserved NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
receptor NN NN I-Protein
- NN NN I-Protein
associated NN NN I-Protein
factor NN NN I-Protein
3 NN NN I-Protein
binding NN NN O
sites NN NN O
in NN NN O
the NN NN O
human NN NN O
and NN NN O
simian NN NN O
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
oncogene NN NN O
LMP1 NN NN B-Protein
. NN NN O
   
Nonhuman NN NN O
primates NN NN O
are NN NN O
naturally NN NN O
infected NN NN O
with NN NN O
a NN NN O
B NN NN O
- NN NN O
lymphotropic NN NN O
herpesvirus NN NN O
closely NN NN O
related NN NN O
to NN NN O
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
( NN NN O
EBV NN NN O
) NN NN O
. NN NN O
   
These NN NN O
simian NN NN O
EBV NN NN O
share NN NN O
considerable NN NN O
genetic NN NN O
, NN NN O
biologic NN NN O
, NN NN O
and NN NN O
epidemiologic NN NN O
features NN NN O
with NN NN O
human NN NN O
EBV NN NN O
, NN NN O
including NN NN O
virus NN NN O
- NN NN O
induced NN NN O
tumorigenesis NN NN O
. NN NN O
   
However NN NN O
, NN NN O
latent NN NN O
, NN NN O
transformation NN NN O
- NN NN O
associated NN NN O
viral NN NN O
genes NN NN O
demonstrate NN NN O
marked NN NN O
sequence NN NN O
divergence NN NN O
among NN NN O
species NN NN O
despite NN NN O
the NN NN O
conserved NN NN O
functions NN NN O
. NN NN O
   
We NN NN O
have NN NN O
cloned NN NN O
the NN NN O
latent NN NN B-Protein
membrane NN NN I-Protein
protein NN NN I-Protein
1 NN NN I-Protein
( NN NN O
LMP1 NN NN B-Protein
) NN NN O
homologs NN NN O
from NN NN O
the NN NN O
simian NN NN O
EBV NN NN O
naturally NN NN O
infecting NN NN O
baboons NN NN O
( NN NN O
cercopithicine NN NN O
herpesvirus NN NN O
12 NN NN O
, NN NN O
herpesvirus NN NN O
papio NN NN O
) NN NN O
and NN NN O
rhesus NN NN O
monkeys NN NN O
( NN NN O
cercopithicine NN NN O
herpesvirus NN NN O
15 NN NN O
) NN NN O
for NN NN O
a NN NN O
comparative NN NN O
study NN NN O
with NN NN O
the NN NN O
human NN NN O
EBV NN NN O
oncogene NN NN O
. NN NN O
   
The NN NN O
transmembrane NN NN O
domains NN NN O
are NN NN O
well NN NN O
conserved NN NN O
, NN NN O
but NN NN O
there NN NN O
is NN NN O
striking NN NN O
sequence NN NN O
divergence NN NN O
of NN NN O
the NN NN O
carboxy NN NN O
- NN NN O
terminal NN NN O
cytoplasmic NN NN O
domain NN NN O
essential NN NN O
for NN NN O
B NN NN O
- NN NN O
cell NN NN O
immortalization NN NN O
and NN NN O
interaction NN NN O
with NN NN O
the NN NN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
receptor NN NN O
signaling NN NN O
pathway NN NN O
. NN NN O
   
Nevertheless NN NN O
, NN NN O
the NN NN O
simian NN NN O
EBV NN NN O
LMP1s NN NN B-Protein
retain NN NN O
most NN NN O
functions NN NN O
in NN NN O
common NN NN O
with NN NN O
EBV NN NN O
LMP1 NN NN B-Protein
, NN NN O
including NN NN O
the NN NN O
ability NN NN O
to NN NN O
induce NN NN O
NF NN NN O
- NN NN O
( NN NN O
kappa NN NN O
) NN NN O
B NN NN O
activity NN NN O
in NN NN O
human NN NN O
cells NN NN O
, NN NN O
to NN NN O
bind NN NN O
the NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
associated NN NN I-Protein
factor NN NN I-Protein
3 NN NN I-Protein
( NN NN O
TRAF3 NN NN B-Protein
) NN NN O
in NN NN O
vitro NN NN O
, NN NN O
and NN NN O
to NN NN O
induce NN NN O
expression NN NN O
of NN NN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
- NN NN O
responsive NN NN O
genes NN NN O
, NN NN O
such NN NN O
as NN NN O
ICAM1 NN NN B-Protein
, NN NN O
in NN NN O
human NN NN O
B NN NN O
lymphocytes NN NN O
. NN NN O
   
Multiple NN NN O
TRAF3 NN NN B-Protein
binding NN NN O
sites NN NN O
containing NN NN O
a NN NN O
PXQXT NN NN O
/ NN NN O
S NN NN O
core NN NN O
sequence NN NN O
can NN NN O
be NN NN O
identified NN NN O
in NN NN O
the NN NN O
simian NN NN O
EBV NN NN O
LMP1s NN NN B-Protein
by NN NN O
an NN NN O
in NN NN O
vitro NN NN O
binding NN NN O
assay NN NN O
. NN NN O
   
A NN NN O
PXQXT NN NN O
/ NN NN O
S NN NN O
- NN NN O
containing NN NN O
sequence NN NN O
is NN NN O
also NN NN O
present NN NN O
in NN NN O
the NN NN O
cytoplasmic NN NN O
domain NN NN O
of NN NN O
the NN NN O
Hodgkin NN NN O
' NN NN O
s NN NN O
disease NN NN O
marker NN NN O
, NN NN O
CD30 NN NN B-Protein
, NN NN O
and NN NN O
binds NN NN O
TRAF3 NN NN B-Protein
in NN NN O
vitro NN NN O
. NN NN O
   
The NN NN O
last NN NN O
13 NN NN O
amino NN NN O
acids NN NN O
containing NN NN O
a NN NN O
PXQXT NN NN O
/ NN NN O
S NN NN O
sequence NN NN O
are NN NN O
highly NN NN O
conserved NN NN O
in NN NN O
human NN NN O
and NN NN O
simian NN NN O
EBV NN NN O
LMP1 NN NN B-Protein
but NN NN O
do NN NN O
not NN NN O
bind NN NN O
TRAF3 NN NN B-Protein
, NN NN O
suggesting NN NN O
a NN NN O
distinct NN NN O
role NN NN O
for NN NN O
this NN NN O
conserved NN NN O
region NN NN O
of NN NN O
LMP1 NN NN B-Protein
. NN NN O
   
The NN NN O
conserved NN NN O
TRAF3 NN NN B-Protein
binding NN NN O
sites NN NN O
in NN NN O
LMP1 NN NN B-Protein
and NN NN O
the NN NN O
CD30 NN NN B-Protein
Hodgkin NN NN O
' NN NN O
s NN NN O
disease NN NN O
marker NN NN O
provides NN NN O
further NN NN O
evidence NN NN O
that NN NN O
a NN NN O
TRAF3 NN NN B-Protein
- NN NN O
mediated NN NN O
signal NN NN O
transduction NN NN O
pathway NN NN O
may NN NN O
be NN NN O
important NN NN O
in NN NN O
malignant NN NN O
transformation NN NN O
. NN NN O
   
Tyrosine NN NN O
kinase NN NN O
and NN NN O
cAMP NN NN O
- NN NN O
dependent NN NN O
protein NN NN O
kinase NN NN O
activities NN NN O
in NN NN O
CD40 NN NN B-Protein
- NN NN O
activated NN NN O
human NN NN O
B NN NN O
lymphocytes NN NN O
. NN NN O
   
In NN NN O
vitro NN NN O
, NN NN O
human NN NN O
B NN NN O
lymphocytes NN NN O
undergo NN NN O
long NN NN O
- NN NN O
term NN NN O
proliferation NN NN O
when NN NN O
activated NN NN O
through NN NN O
CD40 NN NN B-Protein
, NN NN O
a NN NN O
protein NN NN O
expressed NN NN O
on NN NN O
their NN NN O
cell NN NN O
surface NN NN O
. NN NN O
   
The NN NN O
nature NN NN O
of NN NN O
CD40 NN NN B-Protein
- NN NN O
dependent NN NN O
signals NN NN O
in NN NN O
proliferating NN NN O
fresh NN NN O
human NN NN O
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
- NN NN O
negative NN NN O
B NN NN O
lymphocytes NN NN O
is NN NN O
currently NN NN O
unknown NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
a NN NN O
CD40 NN NN B-Protein
- NN NN O
dependent NN NN O
B NN NN O
cell NN NN O
culture NN NN O
system NN NN O
was NN NN O
used NN NN O
to NN NN O
examine NN NN O
the NN NN O
role NN NN O
of NN NN O
different NN NN O
signal NN NN O
transduction NN NN O
elements NN NN O
. NN NN O
   
Protein NN NN O
kinase NN NN O
C NN NN O
( NN NN O
PKC NN NN O
) NN NN O
depletion NN NN O
generated NN NN O
by NN NN O
a NN NN O
long NN NN O
- NN NN O
term NN NN O
phorbol NN NN O
12 NN NN O
myristate NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
treatment NN NN O
had NN NN O
weak NN NN O
effects NN NN O
on NN NN O
proliferation NN NN O
. NN NN O
   
Rather NN NN O
, NN NN O
tyrosine NN NN O
phosphorylation NN NN O
was NN NN O
shown NN NN O
to NN NN O
be NN NN O
directly NN NN O
involved NN NN O
in NN NN O
mediating NN NN O
CD40 NN NN B-Protein
- NN NN O
dependent NN NN O
signals NN NN O
. NN NN O
   
The NN NN O
use NN NN O
of NN NN O
the NN NN O
protein NN NN O
tyrosine NN NN O
kinase NN NN O
( NN NN O
PTK NN NN O
) NN NN O
- NN NN O
specific NN NN O
inhibitor NN NN O
herbimycin NN NN O
A NN NN O
dramatically NN NN O
decreased NN NN O
cellular NN NN O
proliferation NN NN O
without NN NN O
altering NN NN O
the NN NN O
activity NN NN O
of NN NN O
the NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
- NN NN O
1 NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
) NN NN O
, NN NN O
a NN NN O
promoter NN NN O
largely NN NN O
dependent NN NN O
on NN NN O
the NN NN O
binding NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
the NN NN O
cAMP NN NN O
- NN NN O
dependent NN NN O
protein NN NN O
kinase NN NN O
specific NN NN O
inhibitor NN NN O
H NN NN O
- NN NN O
89 NN NN O
totally NN NN O
inhibited NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
activity NN NN O
at NN NN O
a NN NN O
concentration NN NN O
as NN NN O
low NN NN O
as NN NN O
100 NN NN O
nM NN NN O
without NN NN O
affecting NN NN O
cellular NN NN O
proliferation NN NN O
. NN NN O
   
Electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assay NN NN O
( NN NN O
EMSA NN NN O
) NN NN O
and NN NN O
supershift NN NN O
assay NN NN O
using NN NN O
an NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
sequence NN NN O
from NN NN O
the NN NN O
kappa NN NN O
light NN NN O
chain NN NN O
as NN NN O
a NN NN O
probe NN NN O
, NN NN O
revealed NN NN O
that NN NN O
both NN NN O
p65 NN NN B-Protein
( NN NN O
RelA NN NN B-Protein
) NN NN O
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
were NN NN O
present NN NN O
in NN NN O
CD40 NN NN B-Protein
- NN NN O
stimulated NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
While NN NN O
PKC NN NN O
depletion NN NN O
did NN NN O
not NN NN O
alter NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
level NN NN O
, NN NN O
treatment NN NN O
of NN NN O
B NN NN O
lymphocytes NN NN O
with NN NN O
H NN NN O
- NN NN O
89 NN NN O
or NN NN O
herbimycin NN NN O
A NN NN O
provoked NN NN O
a NN NN O
decrease NN NN O
in NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
level NN NN O
. NN NN O
   
These NN NN O
observations NN NN O
establish NN NN O
the NN NN O
importance NN NN O
of NN NN O
different NN NN O
signal NN NN O
transducing NN NN O
pathways NN NN O
leading NN NN O
to NN NN O
CD40 NN NN B-Protein
activation NN NN O
of NN NN O
B NN NN O
lymphocytes NN NN O
. NN NN O
   
Characterization NN NN O
of NN NN O
a NN NN O
CD43 NN NN B-Protein
/ NN NN O
leukosialin NN NN B-Protein
- NN NN O
mediated NN NN O
pathway NN NN O
for NN NN O
inducing NN NN O
apoptosis NN NN O
in NN NN O
human NN NN O
T NN NN O
- NN NN O
lymphoblastoid NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
monoclonal NN NN O
antibody NN NN O
( NN NN O
mAb NN NN O
) NN NN O
J393 NN NN O
induces NN NN O
apoptosis NN NN O
in NN NN O
Jurkat NN NN O
T NN NN O
- NN NN O
cells NN NN O
. NN NN O
   
NH2 NN NN O
- NN NN O
terminal NN NN O
amino NN NN O
acid NN NN O
sequence NN NN O
analysis NN NN O
identified NN NN O
the NN NN O
140 NN NN O
- NN NN O
kDa NN NN O
surface NN NN O
antigen NN NN O
for NN NN O
mAb NN NN O
J393 NN NN O
as NN NN O
CD43 NN NN B-Protein
/ NN NN O
leukosialin NN NN B-Protein
, NN NN O
the NN NN O
major NN NN O
sialoglycoprotein NN NN O
of NN NN O
leukocytes NN NN O
. NN NN O
   
While NN NN O
Jurkat NN NN O
cells NN NN O
co NN NN O
- NN NN O
expressed NN NN O
two NN NN O
discrete NN NN O
cell NN NN O
- NN NN O
surface NN NN O
isoforms NN NN O
of NN NN O
CD43 NN NN B-Protein
, NN NN O
recognized NN NN O
by NN NN O
mAb NN NN O
J393 NN NN O
and NN NN O
mAb NN NN O
G10 NN NN O
- NN NN O
2 NN NN O
, NN NN O
respectively NN NN O
, NN NN O
only NN NN O
J393 NN NN O
/ NN NN O
CD43 NN NN B-Protein
signaled NN NN O
apoptosis NN NN O
. NN NN O
   
J393 NN NN O
/ NN NN O
CD43 NN NN B-Protein
was NN NN O
found NN NN O
to NN NN O
be NN NN O
hyposialylated NN NN O
, NN NN O
bearing NN NN O
predominantly NN NN O
O NN NN O
- NN NN O
linked NN NN O
monosaccharide NN NN O
glycans NN NN O
, NN NN O
whereas NN NN O
G10 NN NN O
- NN NN O
2 NN NN O
/ NN NN O
CD43 NN NN B-Protein
bore NN NN O
complex NN NN O
sialylated NN NN O
tetra NN NN O
- NN NN O
and NN NN O
hexasaccharide NN NN O
chains NN NN O
. NN NN O
   
Treatment NN NN O
with NN NN O
soluble NN NN O
, NN NN O
bivalent NN NN O
mAb NN NN O
J393 NN NN O
killed NN NN O
25 NN NN O
- NN NN O
50 NN NN O
% NN NN O
of NN NN O
the NN NN O
cell NN NN O
population NN NN O
, NN NN O
while NN NN O
concomitant NN NN O
engagement NN NN O
of NN NN O
either NN NN O
the NN NN O
CD3 NN NN O
. NN NN O
TcR NN NN O
complex NN NN O
or NN NN O
the NN NN O
integrins NN NN O
CD18 NN NN B-Protein
and NN NN O
CD29 NN NN B-Protein
significantly NN NN O
potentiated NN NN O
this NN NN O
effect NN NN O
. NN NN O
   
Treatment NN NN O
of NN NN O
Jurkat NN NN O
cells NN NN O
with NN NN O
mAb NN NN O
J393 NN NN O
induced NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
specific NN NN O
protein NN NN O
substrates NN NN O
that NN NN O
underwent NN NN O
hyperphosphorylation NN NN O
upon NN NN O
antigen NN NN O
receptor NN NN O
costimulation NN NN O
. NN NN O
   
Tyrosine NN NN O
kinase NN NN O
inhibition NN NN O
by NN NN O
herbimycin NN NN O
A NN NN O
diminished NN NN O
J393 NN NN O
/ NN NN O
CD43 NN NN B-Protein
- NN NN O
mediated NN NN O
apoptosis NN NN O
, NN NN O
whereas NN NN O
inhibition NN NN O
of NN NN O
phosphotyrosine NN NN O
phosphatase NN NN O
activity NN NN O
by NN NN O
bis NN NN O
( NN NN O
maltolato NN NN O
) NN NN O
oxovanadium NN NN O
- NN NN O
IV NN NN O
enhanced NN NN O
cell NN NN O
death NN NN O
. NN NN O
   
Signal NN NN O
transduction NN NN O
through NN NN O
tyrosine NN NN O
kinase NN NN O
activation NN NN O
may NN NN O
lead NN NN O
to NN NN O
altered NN NN O
gene NN NN O
expression NN NN O
, NN NN O
as NN NN O
J393 NN NN O
/ NN NN O
CD43 NN NN B-Protein
ligation NN NN O
prompted NN NN O
decreases NN NN O
in NN NN O
the NN NN O
nuclear NN NN O
localization NN NN O
of NN NN O
the NN NN O
transcriptional NN NN O
regulatory NN NN O
protein NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
and NN NN O
proteins NN NN O
binding NN NN O
the NN NN O
interferon NN NN O
- NN NN O
inducible NN NN O
regulatory NN NN O
element NN NN O
. NN NN O
   
Since NN NN O
peripheral NN NN O
blood NN NN O
T NN NN O
- NN NN O
lymphocytes NN NN O
express NN NN O
cryptic NN NN O
epitopes NN NN O
for NN NN O
mAb NN NN O
J393 NN NN O
, NN NN O
these NN NN O
findings NN NN O
demonstrate NN NN O
the NN NN O
existence NN NN O
of NN NN O
a NN NN O
tightly NN NN O
regulated NN NN O
CD43 NN NN B-Protein
- NN NN O
mediated NN NN O
pathway NN NN O
for NN NN O
inducing NN NN O
apoptosis NN NN O
in NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
lineages NN NN O
. NN NN O
   
Naive NN NN O
( NN NN O
CD45RA NN NN B-Protein
+ NN NN O
) NN NN O
T NN NN O
lymphocytes NN NN O
are NN NN O
more NN NN O
sensitive NN NN O
to NN NN O
oxidative NN NN O
stress NN NN O
- NN NN O
induced NN NN O
signals NN NN O
than NN NN O
memory NN NN O
( NN NN O
CD45RO NN NN B-Protein
+ NN NN O
) NN NN O
cells NN NN O
. NN NN O
   
Formation NN NN O
of NN NN O
reactive NN NN O
oxygen NN NN O
intermediates NN NN O
( NN NN O
ROI NN NN O
) NN NN O
after NN NN O
oxidative NN NN O
stress NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
be NN NN O
an NN NN O
activation NN NN O
signal NN NN O
for NN NN O
T NN NN O
lymphocytes NN NN O
, NN NN O
e NN NN O
. NN NN O
g NN NN O
. NN NN O
, NN NN O
expression NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
its NN NN O
receptor NN NN O
are NN NN O
induced NN NN O
. NN NN O
   
These NN NN O
ROI NN NN O
- NN NN O
induced NN NN O
effects NN NN O
can NN NN O
, NN NN O
to NN NN O
a NN NN O
large NN NN O
extent NN NN O
, NN NN O
be NN NN O
attributed NN NN O
to NN NN O
the NN NN O
activation NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
. NN NN O
   
Now NN NN O
we NN NN O
have NN NN O
examined NN NN O
whether NN NN O
naive NN NN O
and NN NN O
memory NN NN O
T NN NN O
lymphocytes NN NN O
differ NN NN O
in NN NN O
their NN NN O
sensitivity NN NN O
to NN NN O
ROI NN NN O
- NN NN O
mediated NN NN O
signals NN NN O
. NN NN O
   
When NN NN O
CD45RA NN NN B-Protein
+ NN NN O
( NN NN O
naive NN NN O
) NN NN O
and NN NN O
CD45RO NN NN B-Protein
+ NN NN O
( NN NN O
memory NN NN O
) NN NN O
T NN NN O
lymphocytes NN NN O
were NN NN O
directly NN NN O
stimulated NN NN O
with NN NN O
H2O2 NN NN O
, NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
nuclear NN NN O
translocation NN NN O
was NN NN O
stronger NN NN O
in NN NN O
naive NN NN O
cells NN NN O
than NN NN O
in NN NN O
memory NN NN O
cells NN NN O
and NN NN O
it NN NN O
could NN NN O
be NN NN O
induced NN NN O
with NN NN O
lower NN NN O
doses NN NN O
. NN NN O
   
The NN NN O
composition NN NN O
of NN NN O
the NN NN O
induced NN NN O
nuclear NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
( NN NN O
levels NN NN O
of NN NN O
p50 NN NN B-Protein
and NN NN O
RelA NN NN B-Protein
proteins NN NN O
) NN NN O
was NN NN O
similar NN NN O
in NN NN O
these NN NN O
cell NN NN O
types NN NN O
. NN NN O
   
The NN NN O
magnitude NN NN O
and NN NN O
kinetics NN NN O
of NN NN O
intracellular NN NN O
ROI NN NN O
were NN NN O
similar NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
there NN NN O
were NN NN O
no NN NN O
differences NN NN O
in NN NN O
ROI NN NN O
- NN NN O
forming NN NN O
mechanisms NN NN O
or NN NN O
antioxidative NN NN O
capacities NN NN O
. NN NN O
   
The NN NN O
probable NN NN O
regulatory NN NN O
point NN NN O
was NN NN O
the NN NN O
cytoplasmic NN NN O
IkappaB NN NN O
inhibitor NN NN O
: NN NN O
in NN NN O
CD45RA NN NN B-Protein
+ NN NN O
cells NN NN O
, NN NN O
H2O2 NN NN O
caused NN NN O
a NN NN O
more NN NN O
profound NN NN O
depression NN NN O
in NN NN O
the NN NN O
levels NN NN O
of NN NN O
IkappaB NN NN B-Protein
alpha NN NN I-Protein
. NN NN O
   
These NN NN O
findings NN NN O
indicate NN NN O
that NN NN O
T NN NN O
cells NN NN O
representing NN NN O
different NN NN O
activation NN NN O
and NN NN O
/ NN NN O
or NN NN O
differentiation NN NN O
stages NN NN O
can NN NN O
be NN NN O
differentially NN NN O
responsive NN NN O
to NN NN O
ROI NN NN O
- NN NN O
mediated NN NN O
signals NN NN O
. NN NN O
   
Differential NN NN O
nuclear NN NN O
localization NN NN O
of NN NN O
p50 NN NN B-Protein
, NN NN O
p52 NN NN B-Protein
, NN NN O
and NN NN O
RelB NN NN B-Protein
proteins NN NN O
in NN NN O
human NN NN O
accessory NN NN O
cells NN NN O
of NN NN O
the NN NN O
immune NN NN O
response NN NN O
in NN NN O
situ NN NN O
. NN NN O
   
The NN NN O
Rel NN NN O
/ NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
proteins NN NN O
, NN NN O
p50 NN NN B-Protein
, NN NN O
p52 NN NN B-Protein
, NN NN O
p65 NN NN B-Protein
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
, NN NN O
and NN NN O
RelB NN NN B-Protein
, NN NN O
constitute NN NN O
a NN NN O
family NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
involved NN NN O
in NN NN O
the NN NN O
positive NN NN O
regulation NN NN O
of NN NN O
a NN NN O
variety NN NN O
of NN NN O
genes NN NN O
during NN NN O
the NN NN O
immune NN NN O
response NN NN O
. NN NN O
   
Recently NN NN O
, NN NN O
it NN NN O
has NN NN O
been NN NN O
shown NN NN O
that NN NN O
RelB NN NN B-Protein
knockout NN NN O
mice NN NN O
have NN NN O
no NN NN O
dendritic NN NN O
cells NN NN O
( NN NN O
DC NN NN O
) NN NN O
. NN NN O
   
An NN NN O
overexpression NN NN O
of NN NN O
p50 NN NN B-Protein
has NN NN O
been NN NN O
described NN NN O
in NN NN O
follicular NN NN O
dendritic NN NN O
cells NN NN O
( NN NN O
FDC NN NN O
) NN NN O
. NN NN O
   
A NN NN O
constitutive NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activity NN NN O
has NN NN O
been NN NN O
reported NN NN O
in NN NN O
mature NN NN O
macrophages NN NN O
. NN NN O
   
This NN NN O
led NN NN O
to NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
some NN NN O
of NN NN O
the NN NN O
Rel NN NN O
/ NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
proteins NN NN O
were NN NN O
key NN NN O
nuclear NN NN O
factors NN NN O
in NN NN O
functions NN NN O
of NN NN O
accessory NN NN O
cells NN NN O
of NN NN O
the NN NN O
immune NN NN O
response NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
we NN NN O
investigated NN NN O
in NN NN O
situ NN NN O
the NN NN O
nuclear NN NN O
localization NN NN O
of NN NN O
Rel NN NN O
/ NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
proteins NN NN O
in NN NN O
accessory NN NN O
cells NN NN O
of NN NN O
the NN NN O
immune NN NN O
system NN NN O
by NN NN O
immunohistochemistry NN NN O
and NN NN O
double NN NN O
labeling NN NN O
by NN NN O
immunofluorescence NN NN O
from NN NN O
five NN NN O
normal NN NN O
human NN NN O
tonsils NN NN O
and NN NN O
five NN NN O
lymph NN NN O
nodes NN NN O
with NN NN O
follicular NN NN O
hyperplasia NN NN O
. NN NN O
   
Nuclear NN NN O
p65 NN NN B-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
proteins NN NN O
were NN NN O
found NN NN O
in NN NN O
all NN NN O
cell NN NN O
types NN NN O
including NN NN O
lymphocytes NN NN O
. NN NN O
   
In NN NN O
germinal NN NN O
centers NN NN O
GC NN NN O
, NN NN O
p50 NN NN B-Protein
, NN NN O
p52 NN NN B-Protein
, NN NN O
and NN NN O
RelB NN NN B-Protein
were NN NN O
found NN NN O
in NN NN O
the NN NN O
nuclei NN NN O
of NN NN O
FDC NN NN O
only NN NN O
and NN NN O
were NN NN O
not NN NN O
detected NN NN O
in NN NN O
the NN NN O
nuclei NN NN O
of NN NN O
CD68 NN NN B-Protein
+ NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
T NN NN O
cell NN NN O
areas NN NN O
, NN NN O
p50 NN NN B-Protein
, NN NN O
p52 NN NN B-Protein
, NN NN O
and NN NN O
RelB NN NN B-Protein
were NN NN O
found NN NN O
in NN NN O
the NN NN O
nuclei NN NN O
of NN NN O
HLA NN NN B-Protein
- NN NN I-Protein
DR NN NN I-Protein
+ NN NN O
cells NN NN O
with NN NN O
an NN NN O
antigen NN NN O
- NN NN O
presenting NN NN O
cell NN NN O
( NN NN O
APC NN NN O
) NN NN O
morphology NN NN O
. NN NN O
   
p52 NN NN B-Protein
and NN NN O
RelB NN NN B-Protein
were NN NN O
detected NN NN O
in NN NN O
the NN NN O
nuclei NN NN O
in NN NN O
both NN NN O
CD1a NN NN B-Protein
+ NN NN O
and NN NN O
CD68 NN NN B-Protein
+ NN NN O
cells NN NN O
from NN NN O
the NN NN O
T NN NN O
cell NN NN O
area NN NN O
, NN NN O
whereas NN NN O
p50 NN NN B-Protein
was NN NN O
found NN NN O
only NN NN O
in NN NN O
CD68 NN NN B-Protein
- NN NN O
and NN NN O
CD1a NN NN B-Protein
- NN NN O
cells NN NN O
. NN NN O
   
Cells NN NN O
with NN NN O
nuclear NN NN O
p50 NN NN B-Protein
were NN NN O
negative NN NN O
for NN NN O
the NN NN O
CD38 NN NN B-Protein
, NN NN O
CD20 NN NN B-Protein
and NN NN O
CD2 NN NN B-Protein
markers NN NN O
. NN NN O
   
These NN NN O
results NN NN O
show NN NN O
that NN NN O
, NN NN O
physiologically NN NN O
, NN NN O
high NN NN O
levels NN NN O
of NN NN O
nuclear NN NN O
of NN NN O
p50 NN NN B-Protein
, NN NN O
p52 NN NN B-Protein
and NN NN O
RelB NN NN B-Protein
are NN NN O
restricted NN NN O
to NN NN O
accessory NN NN O
cells NN NN O
of NN NN O
the NN NN O
immune NN NN O
system NN NN O
, NN NN O
which NN NN O
include NN NN O
FDC NN NN O
in NN NN O
GC NN NN O
, NN NN O
and NN NN O
DC NN NN O
and NN NN O
macrophages NN NN O
in NN NN O
the NN NN O
T NN NN O
cell NN NN O
zone NN NN O
, NN NN O
that NN NN O
specialized NN NN O
scavenger NN NN O
macrophages NN NN O
from NN NN O
GC NN NN O
do NN NN O
not NN NN O
have NN NN O
detectable NN NN O
levels NN NN O
of NN NN O
p52 NN NN B-Protein
and NN NN O
RelB NN NN B-Protein
, NN NN O
whereas NN NN O
macrophages NN NN O
from NN NN O
the NN NN O
T NN NN O
cell NN NN O
area NN NN O
, NN NN O
known NN NN O
to NN NN O
present NN NN O
the NN NN O
antigen NN NN O
to NN NN O
T NN NN O
cells NN NN O
, NN NN O
do NN NN O
have NN NN O
both NN NN O
nuclear NN NN O
p52 NN NN B-Protein
and NN NN O
RelB NN NN B-Protein
, NN NN O
and NN NN O
that NN NN O
in NN NN O
the NN NN O
T NN NN O
cell NN NN O
zone NN NN O
, NN NN O
p52 NN NN B-Protein
and NN NN O
RelB NN NN B-Protein
are NN NN O
located NN NN O
in NN NN O
nuclei NN NN O
of NN NN O
both NN NN O
CD1a NN NN B-Protein
+ NN NN O
, NN NN O
CD68 NN NN B-Protein
+ NN NN O
or NN NN O
both NN NN O
, NN NN O
cells NN NN O
APC NN NN O
, NN NN O
whereas NN NN O
p50 NN NN B-Protein
is NN NN O
restricted NN NN O
to NN NN O
CD1a NN NN B-Protein
- NN NN O
and NN NN O
CD68 NN NN B-Protein
- NN NN O
APC NN NN O
. NN NN O
   
The NN NN O
different NN NN O
patterns NN NN O
of NN NN O
p50 NN NN B-Protein
, NN NN O
p52 NN NN B-Protein
and NN NN O
RelB NN NN B-Protein
protein NN NN O
nuclear NN NN O
localization NN NN O
may NN NN O
provide NN NN O
insight NN NN O
into NN NN O
their NN NN O
different NN NN O
roles NN NN O
during NN NN O
the NN NN O
immune NN NN O
response NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
CD40 NN NN B-Protein
, NN NN O
but NN NN O
not NN NN O
lipopolysaccharide NN NN O
and NN NN O
anti NN NN O
- NN NN O
IgM NN NN B-Protein
stimulation NN NN O
of NN NN O
primary NN NN O
B NN NN O
lymphocytes NN NN O
, NN NN O
leads NN NN O
to NN NN O
a NN NN O
persistent NN NN O
nuclear NN NN O
accumulation NN NN O
of NN NN O
RelB NN NN B-Protein
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
we NN NN O
analyzed NN NN O
the NN NN O
effect NN NN O
of NN NN O
CD40 NN NN B-Protein
stimulation NN NN O
on NN NN O
the NN NN O
activity NN NN O
and NN NN O
nuclear NN NN O
appearance NN NN O
of NN NN O
Rel NN NN O
/ NN NN O
nuclear NN NN O
factor NN NN O
kappaB NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
) NN NN O
factors NN NN O
in NN NN O
primary NN NN O
murine NN NN O
B NN NN O
lymphocytes NN NN O
. NN NN O
   
We NN NN O
show NN NN O
that NN NN O
triggering NN NN O
of NN NN O
CD40 NN NN B-Protein
signaling NN NN O
pathway NN NN O
( NN NN O
s NN NN O
) NN NN O
by NN NN O
CD40 NN NN B-Protein
ligands NN NN O
expressed NN NN O
on NN NN O
L NN NN O
cells NN NN O
led NN NN O
to NN NN O
strong NN NN O
activation NN NN O
of NN NN O
an NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
controlled NN NN O
beta NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
reporter NN NN O
gene NN NN O
in NN NN O
primary NN NN O
B NN NN O
lymphocytes NN NN O
from NN NN O
transgenic NN NN O
mice NN NN O
. NN NN O
   
Analyses NN NN O
of NN NN O
nuclear NN NN O
translocation NN NN O
of NN NN O
individual NN NN O
members NN NN O
of NN NN O
Rel NN NN O
proteins NN NN O
after NN NN O
CD40 NN NN B-Protein
induction NN NN O
of NN NN O
primary NN NN O
B NN NN O
cells NN NN O
showed NN NN O
a NN NN O
strong NN NN O
and NN NN O
long NN NN O
- NN NN O
lasting NN NN O
accumulation NN NN O
of NN NN O
RelB NN NN B-Protein
and NN NN O
, NN NN O
less NN NN O
pronounced NN NN O
, NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
. NN NN O
   
LPS NN NN O
stimulation NN NN O
did NN NN O
not NN NN O
give NN NN O
rise NN NN O
to NN NN O
a NN NN O
persistent NN NN O
nuclear NN NN O
accumulation NN NN O
of NN NN O
RelB NN NN B-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
, NN NN O
whereas NN NN O
nuclear NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
, NN NN O
but NN NN O
not NN NN O
RelB NN NN B-Protein
, NN NN O
accumulated NN NN O
after NN NN O
B NN NN O
cell NN NN O
receptor NN NN O
stimulation NN NN O
. NN NN O
   
CD40 NN NN B-Protein
induced NN NN O
not NN NN O
only NN NN O
nuclear NN NN O
translocation NN NN O
but NN NN O
also NN NN O
de NN NN O
novo NN NN O
synthesis NN NN O
of NN NN O
RelB NN NN B-Protein
RNA NN NN O
and NN NN O
protein NN NN O
. NN NN O
   
S107 NN NN O
plasmacytoma NN NN O
cells NN NN O
, NN NN O
which NN NN O
express NN NN O
CD40 NN NN B-Protein
but NN NN O
are NN NN O
defective NN NN O
for NN NN O
the NN NN O
nuclear NN NN O
appearance NN NN O
of NN NN O
p50 NN NN B-Protein
/ NN NN O
p65 NN NN B-Protein
- NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
, NN NN O
do NN NN O
not NN NN O
express NN NN O
RelB NN NN B-Protein
after NN NN O
CD40 NN NN B-Protein
stimulation NN NN O
. NN NN O
   
In NN NN O
S107 NN NN O
cells NN NN O
stably NN NN O
transfected NN NN O
with NN NN O
relB NN NN B-Protein
genes NN NN O
, NN NN O
stimulation NN NN O
of NN NN O
nuclear NN NN O
RelB NN NN B-Protein
translocation NN NN O
by NN NN O
CD40 NN NN B-Protein
was NN NN O
observed NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
stimulation NN NN O
of NN NN O
CD40 NN NN B-Protein
signaling NN NN O
pathways NN NN O
exerts NN NN O
a NN NN O
long NN NN O
- NN NN O
lasting NN NN O
stimulatory NN NN O
effect NN NN O
on NN NN O
both NN NN O
the NN NN O
transcription NN NN O
and NN NN O
nuclear NN NN O
translocation NN NN O
of NN NN O
RelB NN NN B-Protein
. NN NN O
   
Since NN NN O
LPS NN NN O
and NN NN O
anti NN NN O
- NN NN O
IgM NN NN B-Protein
were NN NN O
unable NN NN O
to NN NN O
activate NN NN O
RelB NN NN B-Protein
, NN NN O
CD40 NN NN B-Protein
appears NN NN O
to NN NN O
trigger NN NN O
a NN NN O
special NN NN O
program NN NN O
of NN NN O
gene NN NN O
expression NN NN O
involved NN NN O
in NN NN O
the NN NN O
proliferation NN NN O
and NN NN O
/ NN NN O
or NN NN O
differentiation NN NN O
of NN NN O
B NN NN O
lymphocytes NN NN O
. NN NN O
   
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
activity NN NN O
in NN NN O
human NN NN O
CD40 NN NN B-Protein
- NN NN O
activated NN NN O
B NN NN O
lymphocytes NN NN O
is NN NN O
dependent NN NN O
on NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
. NN NN O
   
CD40 NN NN B-Protein
- NN NN O
stimulated NN NN O
human NN NN O
B NN NN O
lymphocytes NN NN O
are NN NN O
highly NN NN O
permissive NN NN O
to NN NN O
a NN NN O
productive NN NN O
infection NN NN O
by NN NN O
the NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
. NN NN O
   
In NN NN O
these NN NN O
cells NN NN O
, NN NN O
nuclear NN NN O
factors NN NN O
involved NN NN O
in NN NN O
activation NN NN O
of NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
, NN NN O
which NN NN O
contains NN NN O
the NN NN O
transcriptional NN NN O
control NN NN O
elements NN NN O
of NN NN O
the NN NN O
virus NN NN O
, NN NN O
are NN NN O
unknown NN NN O
. NN NN O
   
Transient NN NN O
expression NN NN O
assays NN NN O
with NN NN O
plasmids NN NN O
containing NN NN O
deleted NN NN O
parts NN NN O
of NN NN O
the NN NN O
LTR NN NN O
region NN NN O
linked NN NN O
to NN NN O
a NN NN O
reporter NN NN O
gene NN NN O
showed NN NN O
that NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
binding NN NN O
site NN NN O
was NN NN O
essential NN NN O
for NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
activity NN NN O
in NN NN O
CD40 NN NN B-Protein
- NN NN O
stimulated NN NN O
B NN NN O
lymphocytes NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
and NN NN O
supershift NN NN O
assays NN NN O
revealed NN NN O
that NN NN O
important NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
binding NN NN O
activity NN NN O
composed NN NN O
of NN NN O
at NN NN O
least NN NN O
p50 NN NN B-Protein
, NN NN O
p65 NN NN B-Protein
, NN NN O
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
NF NN NN O
- NN NN O
kappaB NN NN O
subunits NN NN O
was NN NN O
present NN NN O
in NN NN O
nuclei NN NN O
of NN NN O
CD40 NN NN B-Protein
- NN NN O
stimulated NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
results NN NN O
confirm NN NN O
at NN NN O
a NN NN O
molecular NN NN O
level NN NN O
the NN NN O
ability NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
to NN NN O
replicate NN NN O
in NN NN O
B NN NN O
cells NN NN O
and NN NN O
that NN NN O
this NN NN O
activity NN NN O
is NN NN O
strongly NN NN O
associated NN NN O
with NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
via NN NN O
T NN NN O
cell NN NN O
receptor NN NN O
requires NN NN O
a NN NN O
Raf NN NN O
kinase NN NN O
and NN NN O
Ca2 NN NN O
+ NN NN O
influx NN NN O
. NN NN O
   
Functional NN NN O
synergy NN NN O
between NN NN O
Raf NN NN O
and NN NN O
calcineurin NN NN O
. NN NN O
   
Signals NN NN O
transduced NN NN O
via NN NN O
the NN NN O
TCR NN NN O
activate NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
) NN NN O
, NN NN O
which NN NN O
, NN NN O
in NN NN O
turn NN NN O
, NN NN O
is NN NN O
critical NN NN O
to NN NN O
the NN NN O
transcriptional NN NN O
induction NN NN O
of NN NN O
many NN NN O
genes NN NN O
important NN NN O
for NN NN O
the NN NN O
proliferation NN NN O
and NN NN O
expression NN NN O
of NN NN O
a NN NN O
differentiated NN NN O
phenotype NN NN O
. NN NN O
   
Treatment NN NN O
of NN NN O
T NN NN O
cells NN NN O
with NN NN O
the NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
activator NN NN O
PMA NN NN O
in NN NN O
combination NN NN O
with NN NN O
Ca2 NN NN O
+ NN NN O
ionophores NN NN O
mimics NN NN O
this NN NN O
process NN NN O
, NN NN O
and NN NN O
the NN NN O
two NN NN O
agents NN NN O
are NN NN O
often NN NN O
substituted NN NN O
for NN NN O
TCR NN NN O
stimulation NN NN O
, NN NN O
bypassing NN NN O
the NN NN O
TCR NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
identify NN NN O
intracellular NN NN O
signaling NN NN O
components NN NN O
involved NN NN O
in NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
following NN NN O
TCR NN NN O
stimulation NN NN O
. NN NN O
   
TCR NN NN O
signaling NN NN O
was NN NN O
triggered NN NN O
by NN NN O
treating NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
with NN NN O
PHA NN NN B-Protein
or NN NN O
anti NN NN O
- NN NN O
CD3 NN NN B-Protein
Abs NN NN O
, NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
was NN NN O
monitored NN NN O
by NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
and NN NN O
/ NN NN O
or NN NN O
by NN NN O
kappaB NN NN O
- NN NN O
dependent NN NN O
reporter NN NN O
assays NN NN O
. NN NN O
   
Contrary NN NN O
to NN NN O
the NN NN O
idea NN NN O
that NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
is NN NN O
involved NN NN O
in NN NN O
TCR NN NN O
- NN NN O
mediated NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
, NN NN O
high NN NN O
doses NN NN O
of NN NN O
staurosporine NN NN O
did NN NN O
not NN NN O
interfere NN NN O
with NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
by NN NN O
PHA NN NN B-Protein
, NN NN O
while NN NN O
the NN NN O
same NN NN O
dose NN NN O
of NN NN O
staurosporine NN NN O
completely NN NN O
blocked NN NN O
activation NN NN O
by NN NN O
PMA NN NN O
. NN NN O
   
PHA NN NN B-Protein
- NN NN O
induced NN NN O
kappaB NN NN O
- NN NN O
dependent NN NN O
reporter NN NN O
activity NN NN O
was NN NN O
, NN NN O
however NN NN O
, NN NN O
effectively NN NN O
blocked NN NN O
by NN NN O
a NN NN O
dominant NN NN O
negative NN NN O
form NN NN O
of NN NN O
Raf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
suggesting NN NN O
a NN NN O
critical NN NN O
role NN NN O
for NN NN O
a NN NN O
Raf NN NN O
kinase NN NN O
. NN NN O
   
The NN NN O
TCR NN NN O
- NN NN O
mediated NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
was NN NN O
also NN NN O
dependent NN NN O
on NN NN O
a NN NN O
Ca2 NN NN O
+ NN NN O
influx NN NN O
, NN NN O
because NN NN O
the NN NN O
Ca2 NN NN O
+ NN NN O
channel NN NN O
blocker NN NN O
, NN NN O
SK NN NN O
& NN NN O
F NN NN O
96365 NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
other NN NN O
agents NN NN O
that NN NN O
prevented NN NN O
the NN NN O
Ca2 NN NN O
+ NN NN O
influx NN NN O
, NN NN O
inhibited NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
. NN NN O
   
Cotransfection NN NN O
of NN NN O
a NN NN O
constitutively NN NN O
active NN NN O
form NN NN O
of NN NN O
calcineurin NN NN O
largely NN NN O
substituted NN NN O
for NN NN O
the NN NN O
Ca2 NN NN O
+ NN NN O
requirement NN NN O
and NN NN O
reversed NN NN O
the NN NN O
blockade NN NN O
by NN NN O
SK NN NN O
& NN NN O
F NN NN O
96365 NN NN O
. NN NN O
   
Consistent NN NN O
with NN NN O
these NN NN O
observations NN NN O
, NN NN O
coexpression NN NN O
of NN NN O
constitutively NN NN O
active NN NN O
forms NN NN O
of NN NN O
Raf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
calcineurin NN NN O
synergistically NN NN O
induced NN NN O
kappaB NN NN O
- NN NN O
dependent NN NN O
reporter NN NN O
activity NN NN O
, NN NN O
suggesting NN NN O
a NN NN O
physiologically NN NN O
relevant NN NN O
functional NN NN O
interaction NN NN O
between NN NN O
the NN NN O
kinase NN NN O
and NN NN O
the NN NN O
phosphatase NN NN O
. NN NN O
   
Synergistic NN NN O
interactions NN NN O
between NN NN O
overlapping NN NN O
binding NN NN O
sites NN NN O
for NN NN O
the NN NN O
serum NN NN B-Protein
response NN NN I-Protein
factor NN NN I-Protein
and NN NN O
ELK NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
proteins NN NN O
mediate NN NN O
both NN NN O
basal NN NN O
enhancement NN NN O
and NN NN O
phorbol NN NN O
ester NN NN O
responsiveness NN NN O
of NN NN O
primate NN NN O
cytomegalovirus NN NN O
major NN NN O
immediate NN NN O
- NN NN O
early NN NN O
promoters NN NN O
in NN NN O
monocyte NN NN O
and NN NN O
T NN NN O
- NN NN O
lymphocyte NN NN O
cell NN NN O
types NN NN O
. NN NN O
   
Cytomegalovirus NN NN O
( NN NN O
CMV NN NN O
) NN NN O
infection NN NN O
is NN NN O
nonpermissive NN NN O
or NN NN O
persistent NN NN O
in NN NN O
many NN NN O
lymphoid NN NN O
and NN NN O
myeloid NN NN O
cell NN NN O
types NN NN O
but NN NN O
can NN NN O
be NN NN O
activated NN NN O
in NN NN O
differentiated NN NN O
macrophages NN NN O
. NN NN O
   
We NN NN O
have NN NN O
shown NN NN O
elsewhere NN NN O
that NN NN O
both NN NN O
the NN NN O
major NN NN O
immediate NN NN O
- NN NN O
early NN NN O
gene NN NN O
( NN NN O
MIE NN NN O
) NN NN O
and NN NN O
lytic NN NN O
cycle NN NN O
infectious NN NN O
progeny NN NN O
virus NN NN O
expression NN NN O
can NN NN O
be NN NN O
induced NN NN O
in NN NN O
otherwise NN NN O
nonpermissive NN NN O
monocyte NN NN O
- NN NN O
like NN NN O
U NN NN O
- NN NN O
937 NN NN O
cell NN NN O
cultures NN NN O
infected NN NN O
with NN NN O
either NN NN O
human NN NN O
CMV NN NN O
( NN NN O
HCMV NN NN O
) NN NN O
or NN NN O
simian NN NN O
CMV NN NN O
( NN NN O
SCMV NN NN O
) NN NN O
by NN NN O
treatment NN NN O
with NN NN O
the NN NN O
phorbol NN NN O
ester NN NN O
12 NN NN O
- NN NN O
O NN NN O
- NN NN O
tetradecanoylphorbol NN NN O
- NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
( NN NN O
TPA NN NN O
) NN NN O
. NN NN O
   
Two NN NN O
multicopy NN NN O
basal NN NN O
enhancer NN NN O
motifs NN NN O
within NN NN O
the NN NN O
SCMV NN NN O
MIE NN NN O
enhancer NN NN O
, NN NN O
namely NN NN O
, NN NN O
11 NN NN O
copies NN NN O
of NN NN O
the NN NN O
16 NN NN O
- NN NN O
bp NN NN O
cyclic NN NN O
AMP NN NN O
response NN NN O
element NN NN O
( NN NN O
CRE NN NN O
) NN NN O
and NN NN O
3 NN NN O
copies NN NN O
of NN NN O
novel NN NN O
17 NN NN O
- NN NN O
bp NN NN O
serum NN NN B-Protein
response NN NN I-Protein
factor NN NN I-Protein
( NN NN O
SRF NN NN B-Protein
) NN NN O
binding NN NN O
sites NN NN O
referred NN NN O
to NN NN O
as NN NN O
the NN NN O
SNE NN NN O
( NN NN O
SRF NN NN B-Protein
/ NN NN O
NFkappaB NN NN O
- NN NN O
like NN NN O
element NN NN O
) NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
four NN NN O
classical NN NN O
NFkappaB NN NN O
sites NN NN O
within NN NN O
the NN NN O
HCMV NN NN O
version NN NN O
, NN NN O
contribute NN NN O
to NN NN O
TPA NN NN O
responsiveness NN NN O
in NN NN O
transient NN NN O
assays NN NN O
in NN NN O
monocyte NN NN O
and NN NN O
T NN NN O
- NN NN O
cell NN NN O
types NN NN O
. NN NN O
   
The NN NN O
SCMV NN NN O
SNE NN NN O
sites NN NN O
contain NN NN O
potential NN NN O
overlapping NN NN O
core NN NN O
recognition NN NN O
binding NN NN O
motifs NN NN O
for NN NN O
SRF NN NN B-Protein
, NN NN O
Rel NN NN O
/ NN NN O
NFkappaB NN NN O
, NN NN O
ETS NN NN O
, NN NN O
and NN NN O
YY1 NN NN O
class NN NN O
transcription NN NN O
factors NN NN O
but NN NN O
fail NN NN O
to NN NN O
respond NN NN O
to NN NN O
either NN NN O
serum NN NN O
or NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
. NN NN O
   
Therefore NN NN O
, NN NN O
to NN NN O
evaluate NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
TPA NN NN O
responsiveness NN NN O
of NN NN O
the NN NN O
SNE NN NN O
motifs NN NN O
and NN NN O
of NN NN O
a NN NN O
related NN NN O
16 NN NN O
- NN NN O
bp NN NN O
SEE NN NN O
( NN NN O
SRF NN NN B-Protein
/ NN NN O
ETS NN NN O
element NN NN O
) NN NN O
motif NN NN O
found NN NN O
in NN NN O
the NN NN O
HCMV NN NN O
and NN NN O
chimpanzee NN NN O
CMV NN NN O
MIE NN NN O
enhancers NN NN O
, NN NN O
we NN NN O
have NN NN O
examined NN NN O
the NN NN O
functional NN NN O
responses NN NN O
and NN NN O
protein NN NN O
binding NN NN O
properties NN NN O
of NN NN O
multimerized NN NN O
wild NN NN O
- NN NN O
type NN NN O
and NN NN O
mutant NN NN O
elements NN NN O
added NN NN O
upstream NN NN O
to NN NN O
the NN NN O
SCMV NN NN O
MIE NN NN O
or NN NN O
simian NN NN O
virus NN NN O
40 NN NN O
minimal NN NN O
promoter NN NN O
regions NN NN O
in NN NN O
the NN NN O
U NN NN O
- NN NN O
937 NN NN O
, NN NN O
K NN NN O
- NN NN O
562 NN NN O
, NN NN O
HL NN NN O
- NN NN O
60 NN NN O
, NN NN O
THP NN NN O
- NN NN O
1 NN NN O
, NN NN O
and NN NN O
Jurkat NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Unlike NN NN O
classical NN NN O
NFkappaB NN NN O
sites NN NN O
, NN NN O
neither NN NN O
the NN NN O
SNE NN NN O
nor NN NN O
the NN NN O
SEE NN NN O
motif NN NN O
responded NN NN O
to NN NN O
phosphatase NN NN O
inhibition NN NN O
by NN NN O
okadaic NN NN O
acid NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
TPA NN NN O
responsiveness NN NN O
of NN NN O
both NN NN O
CMV NN NN O
elements NN NN O
proved NN NN O
to NN NN O
involve NN NN O
synergistic NN NN O
interactions NN NN O
between NN NN O
the NN NN O
core NN NN O
SRF NN NN B-Protein
binding NN NN O
site NN NN O
( NN NN O
CCATATATGG NN NN O
) NN NN O
and NN NN O
the NN NN O
adjacent NN NN O
inverted NN NN O
ETS NN NN O
binding NN NN O
motifs NN NN O
( NN NN O
TTCC NN NN O
) NN NN O
, NN NN O
which NN NN O
correlated NN NN O
directly NN NN O
with NN NN O
formation NN NN O
of NN NN O
a NN NN O
bound NN NN O
tripartite NN NN O
complex NN NN O
containing NN NN O
both NN NN O
the NN NN O
cellular NN NN O
SRF NN NN B-Protein
and NN NN O
ELK NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
proteins NN NN O
. NN NN O
   
This NN NN O
protein NN NN O
complex NN NN O
was NN NN O
more NN NN O
abundant NN NN O
in NN NN O
U NN NN O
- NN NN O
937 NN NN O
, NN NN O
K NN NN O
- NN NN O
562 NN NN O
, NN NN O
and NN NN O
HeLa NN NN O
cell NN NN O
extracts NN NN O
than NN NN O
in NN NN O
Raji NN NN O
, NN NN O
HF NN NN O
, NN NN O
BALB NN NN O
/ NN NN O
c NN NN O
3T3 NN NN O
, NN NN O
or NN NN O
HL NN NN O
- NN NN O
60 NN NN O
cells NN NN O
, NN NN O
but NN NN O
the NN NN O
binding NN NN O
activity NN NN O
was NN NN O
altered NN NN O
only NN NN O
twofold NN NN O
after NN NN O
TPA NN NN O
treatment NN NN O
. NN NN O
   
A NN NN O
40 NN NN O
- NN NN O
fold NN NN O
stimulation NN NN O
of NN NN O
chloramphenicol NN NN B-Protein
acetyltransferase NN NN I-Protein
activity NN NN O
mediated NN NN O
by NN NN O
four NN NN O
tandem NN NN O
repeats NN NN O
of NN NN O
the NN NN O
SNE NN NN O
could NN NN O
be NN NN O
induced NN NN O
within NN NN O
2 NN NN O
h NN NN O
( NN NN O
and NN NN O
up NN NN O
to NN NN O
250 NN NN O
- NN NN O
fold NN NN O
within NN NN O
6 NN NN O
h NN NN O
) NN NN O
after NN NN O
addition NN NN O
of NN NN O
TPA NN NN O
in NN NN O
DNA NN NN O
- NN NN O
transfected NN NN O
U NN NN O
- NN NN O
937 NN NN O
cells NN NN O
, NN NN O
indicating NN NN O
that NN NN O
the NN NN O
stimulation NN NN O
appeared NN NN O
likely NN NN O
to NN NN O
be NN NN O
a NN NN O
true NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
- NN NN O
mediated NN NN O
signal NN NN O
transduction NN NN O
event NN NN O
rather NN NN O
than NN NN O
a NN NN O
differentiation NN NN O
response NN NN O
. NN NN O
   
Slight NN NN O
differences NN NN O
in NN NN O
the NN NN O
sequence NN NN O
of NN NN O
the NN NN O
core NN NN O
SRF NN NN B-Protein
binding NN NN O
site NN NN O
compared NN NN O
with NN NN O
that NN NN O
of NN NN O
the NN NN O
classical NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
promoter NN NN O
serum NN NN O
response NN NN O
element NN NN O
, NN NN O
together NN NN O
with NN NN O
differences NN NN O
in NN NN O
the NN NN O
spacing NN NN O
between NN NN O
the NN NN O
SRF NN NN B-Protein
and NN NN O
ETS NN NN O
motifs NN NN O
, NN NN O
appear NN NN O
to NN NN O
account NN NN O
for NN NN O
the NN NN O
inability NN NN O
of NN NN O
the NN NN O
SCMV NN NN O
SNEs NN NN O
to NN NN O
respond NN NN O
to NN NN O
serum NN NN O
induction NN NN O
. NN NN O
   
Acetylsalicylic NN NN O
acid NN NN O
and NN NN O
sodium NN NN O
salicylate NN NN O
inhibit NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
nuclear NN NN O
translocation NN NN O
, NN NN O
and NN NN O
synthesis NN NN O
of NN NN O
tissue NN NN B-Protein
factor NN NN I-Protein
( NN NN O
TF NN NN B-Protein
) NN NN O
and NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alfa NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
We NN NN O
have NN NN O
investigated NN NN O
the NN NN O
effects NN NN O
of NN NN O
acetylsalicylic NN NN O
acid NN NN O
and NN NN O
sodium NN NN O
salicylate NN NN O
on NN NN O
the NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
synthesis NN NN O
of NN NN O
the NN NN O
pro NN NN O
- NN NN O
coagulant NN NN O
protein NN NN O
tissue NN NN O
factor NN NN O
( NN NN O
TF NN NN O
) NN NN O
and NN NN O
the NN NN O
pro NN NN O
- NN NN O
inflammatory NN NN O
protein NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
prostaglandin NN NN O
PGE2 NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
Both NN NN O
drugs NN NN O
dose NN NN O
- NN NN O
dependently NN NN O
inhibited NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
TF NN NN O
and NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
synthesis NN NN O
at NN NN O
the NN NN O
mRNA NN NN O
and NN NN O
the NN NN O
protein NN NN O
level NN NN O
, NN NN O
and NN NN O
reduced NN NN O
PGE2 NN NN O
production NN NN O
. NN NN O
   
As NN NN O
evidenced NN NN O
by NN NN O
electro NN NN O
mobility NN NN O
shift NN NN O
assay NN NN O
( NN NN O
EMSA NN NN O
) NN NN O
and NN NN O
the NN NN O
use NN NN O
of NN NN O
a NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
prototypic NN NN O
probe NN NN O
, NN NN O
these NN NN O
drugs NN NN O
probably NN NN O
exert NN NN O
their NN NN O
inhibitory NN NN O
effects NN NN O
by NN NN O
interference NN NN O
with NN NN O
the NN NN O
nuclear NN NN O
translocation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
proteins NN NN O
. NN NN O
   
These NN NN O
data NN NN O
may NN NN O
expand NN NN O
the NN NN O
understanding NN NN O
of NN NN O
the NN NN O
anti NN NN O
- NN NN O
thrombotic NN NN O
and NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
effects NN NN O
of NN NN O
these NN NN O
drugs NN NN O
when NN NN O
activation NN NN O
of NN NN O
monocytes NN NN O
occurs NN NN O
. NN NN O
   
The NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
inhibitor NN NN O
, NN NN O
tepoxalin NN NN O
, NN NN O
suppresses NN NN O
surface NN NN O
expression NN NN O
of NN NN O
the NN NN O
cell NN NN O
adhesion NN NN O
molecules NN NN O
CD62E NN NN B-Protein
, NN NN O
CD11b NN NN B-Protein
/ NN NN O
CD18 NN NN B-Protein
and NN NN O
CD106 NN NN B-Protein
. NN NN O
   
Tepoxalin NN NN O
, NN NN O
a NN NN O
dual NN NN O
enzyme NN NN O
inhibitor NN NN O
of NN NN O
cyclooxygenase NN NN O
and NN NN O
5 NN NN O
- NN NN O
lipoxygenase NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
inhibit NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
Its NN NN O
immunosuppressive NN NN O
property NN NN O
is NN NN O
distinct NN NN O
from NN NN O
cyclosporin NN NN O
because NN NN O
only NN NN O
tepoxalin NN NN O
, NN NN O
but NN NN O
not NN NN O
cyclosporin NN NN O
, NN NN O
suppresses NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
report NN NN O
that NN NN O
tepoxalin NN NN O
selectively NN NN O
inhibits NN NN O
intercellular NN NN B-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
CD54 NN NN B-Protein
) NN NN O
/ NN NN O
MAC NN NN O
- NN NN O
1 NN NN O
( NN NN O
CD11b NN NN B-Protein
/ NN NN O
CD18 NN NN B-Protein
) NN NN O
dependent NN NN O
adhesion NN NN O
of NN NN O
polymorphonuclear NN NN O
cells NN NN O
to NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
activated NN NN O
human NN NN O
umbilical NN NN O
vein NN NN O
endothelial NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
mechanism NN NN O
of NN NN O
inhibition NN NN O
is NN NN O
related NN NN O
to NN NN O
the NN NN O
surface NN NN O
expression NN NN O
of NN NN O
several NN NN O
cell NN NN O
adhesion NN NN O
molecules NN NN O
. NN NN O
   
Flow NN NN O
cytometry NN NN O
analyses NN NN O
on NN NN O
cultured NN NN O
cells NN NN O
that NN NN O
were NN NN O
treated NN NN O
with NN NN O
tepoxalin NN NN O
or NN NN O
antisense NN NN O
oligonucleotides NN NN O
to NN NN O
the NN NN O
P65 NN NN B-Protein
/ NN NN O
p50 NN NN B-Protein
subunit NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
and NN NN O
then NN NN O
stimulated NN NN O
with NN NN O
PMA NN NN O
, NN NN O
revealed NN NN O
a NN NN O
reduced NN NN O
expression NN NN O
of NN NN O
CD11b NN NN B-Protein
/ NN NN O
CD18 NN NN B-Protein
on NN NN O
monocytic NN NN O
HL60 NN NN O
cells NN NN O
, NN NN O
and NN NN O
endothelial NN NN B-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
CD62E NN NN B-Protein
) NN NN O
and NN NN O
vascular NN NN B-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
CD106 NN NN B-Protein
) NN NN O
on NN NN O
human NN NN O
umbilical NN NN O
vein NN NN O
endothelial NN NN O
cells NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
other NN NN O
adhesion NN NN O
molecules NN NN O
such NN NN O
as NN NN O
lymphocyte NN NN O
function NN NN O
associated NN NN O
- NN NN O
antigen NN NN O
- NN NN O
1 NN NN O
( NN NN O
CD11a NN NN B-Protein
/ NN NN O
CD18 NN NN B-Protein
) NN NN O
and NN NN O
CD54 NN NN B-Protein
were NN NN O
unaffected NN NN O
. NN NN O
   
Tepoxalin NN NN O
also NN NN O
inhibited NN NN O
the NN NN O
secretion NN NN O
of NN NN O
a NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
regulated NN NN O
chemokine NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
, NN NN O
a NN NN O
known NN NN O
inducer NN NN O
of NN NN O
CD11b NN NN B-Protein
/ NN NN O
CD18 NN NN B-Protein
expression NN NN O
. NN NN O
   
Thus NN NN O
the NN NN O
suppression NN NN O
of NN NN O
CD11b NN NN B-Protein
/ NN NN O
CD18 NN NN B-Protein
expression NN NN O
by NN NN O
tepoxalin NN NN O
may NN NN O
involve NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
. NN NN O
   
Our NN NN O
results NN NN O
suggest NN NN O
that NN NN O
by NN NN O
inhibiting NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
, NN NN O
surface NN NN O
expression NN NN O
of NN NN O
several NN NN O
adhesion NN NN O
molecules NN NN O
can NN NN O
be NN NN O
modulated NN NN O
and NN NN O
that NN NN O
tepoxalin NN NN O
may NN NN O
be NN NN O
useful NN NN O
in NN NN O
treating NN NN O
selected NN NN O
adhesion NN NN O
mediated NN NN O
events NN NN O
such NN NN O
as NN NN O
leukocyte NN NN O
migration NN NN O
or NN NN O
atherosclerotic NN NN O
plaque NN NN O
formation NN NN O
. NN NN O
   
Nuclear NN NN O
NF NN NN B-Protein
- NN NN I-Protein
ATp NN NN I-Protein
is NN NN O
a NN NN O
hallmark NN NN O
of NN NN O
unstimulated NN NN O
B NN NN O
cells NN NN O
from NN NN O
B NN NN O
- NN NN O
CLL NN NN O
patients NN NN O
. NN NN O
   
B NN NN O
lymphocytes NN NN O
from NN NN O
the NN NN O
peripheral NN NN O
blood NN NN O
of NN NN O
patients NN NN O
with NN NN O
chronic NN NN O
lymphocytic NN NN O
leukaemia NN NN O
( NN NN O
CLL NN NN O
) NN NN O
were NN NN O
analysed NN NN O
for NN NN O
the NN NN O
nuclear NN NN O
presence NN NN O
and NN NN O
DNA NN NN O
binding NN NN O
of NN NN O
a NN NN O
panel NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
which NN NN O
are NN NN O
involved NN NN O
in NN NN O
the NN NN O
gene NN NN O
control NN NN O
of NN NN O
lymphoid NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
following NN NN O
transcription NN NN O
factors NN NN O
were NN NN O
studied NN NN O
: NN NN O
the NN NN O
Octamer NN NN O
factors NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
members NN NN O
of NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
factor NN NN O
family NN NN O
, NN NN O
NF NN NN O
- NN NN O
AT NN NN O
factors NN NN O
, NN NN O
in NN NN O
particular NN NN O
NF NN NN B-Protein
- NN NN I-Protein
ATp NN NN I-Protein
, NN NN O
and NN NN O
members NN NN O
of NN NN O
the NN NN O
Rel NN NN O
/ NN NN O
NF NN NN O
- NN NN O
kB NN NN O
family NN NN O
. NN NN O
   
We NN NN O
show NN NN O
that NN NN O
the NN NN O
constitutive NN NN O
nuclear NN NN O
translocation NN NN O
of NN NN O
NF NN NN B-Protein
- NN NN I-Protein
ATp NN NN I-Protein
, NN NN O
a NN NN O
member NN NN O
of NN NN O
the NN NN O
growing NN NN O
family NN NN O
of NN NN O
NF NN NN O
- NN NN O
AT NN NN O
factors NN NN O
, NN NN O
is NN NN O
a NN NN O
hallmark NN NN O
of NN NN O
nonstimulated NN NN O
B NN NN O
cells NN NN O
from NN NN O
CLL NN NN O
patients NN NN O
that NN NN O
distinguishes NN NN O
B NN NN O
- NN NN O
CLL NN NN O
cells NN NN O
from NN NN O
' NN NN O
normal NN NN O
' NN NN O
B NN NN O
lymphocytes NN NN O
. NN NN O
   
Constitutive NN NN O
nuclear NN NN O
appearance NN NN O
was NN NN O
also NN NN O
observed NN NN O
for NN NN O
NF NN NN O
- NN NN O
kB2 NN NN O
/ NN NN O
p52 NN NN B-Protein
. NN NN O
   
Constitutive NN NN O
binding NN NN O
of NN NN O
further NN NN O
factor NN NN O
proteins NN NN O
to NN NN O
DNA NN NN O
, NN NN O
such NN NN O
as NN NN O
JunD NN NN B-Protein
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
and NN NN O
FosB NN NN B-Protein
, NN NN O
was NN NN O
detected NN NN O
in NN NN O
several NN NN O
patients NN NN O
whereas NN NN O
the NN NN O
localisation NN NN O
and NN NN O
DNA NN NN O
binding NN NN O
of NN NN O
other NN NN O
factors NN NN O
such NN NN O
as NN NN O
c NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
, NN NN O
RelA NN NN B-Protein
/ NN NN O
p65 NN NN B-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
was NN NN O
unaltered NN NN O
. NN NN O
   
It NN NN O
is NN NN O
remarkable NN NN O
that NN NN O
in NN NN O
B NN NN O
- NN NN O
CLL NN NN O
cells NN NN O
the NN NN O
nuclear NN NN O
appearance NN NN O
and NN NN O
DNA NN NN O
binding NN NN O
of NN NN O
specific NN NN O
transcription NN NN O
factors NN NN O
is NN NN O
dramatically NN NN O
affected NN NN O
whereas NN NN O
other NN NN O
members NN NN O
of NN NN O
the NN NN O
same NN NN O
factor NN NN O
family NN NN O
remained NN NN O
unaltered NN NN O
in NN NN O
these NN NN O
leukemic NN NN O
cells NN NN O
. NN NN O
   
It NN NN O
remains NN NN O
to NN NN O
be NN NN O
shown NN NN O
which NN NN O
molecular NN NN O
events NN NN O
lead NN NN O
to NN NN O
the NN NN O
specific NN NN O
' NN NN O
pre NN NN O
- NN NN O
activation NN NN O
' NN NN O
, NN NN O
i NN NN O
. NN NN O
e NN NN O
. NN NN O
constitutive NN NN O
nuclear NN NN O
translocation NN NN O
and NN NN O
DNA NN NN O
binding NN NN O
, NN NN O
of NN NN O
these NN NN O
members NN NN O
of NN NN O
NF NN NN O
- NN NN O
AT NN NN O
, NN NN O
NF NN NN O
- NN NN O
kB NN NN O
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
factor NN NN O
families NN NN O
. NN NN O
   
Induction NN NN O
of NN NN O
vascular NN NN B-Protein
cell NN NN I-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
by NN NN O
low NN NN O
- NN NN O
density NN NN O
lipoprotein NN NN O
. NN NN O
   
Low NN NN O
- NN NN O
density NN NN O
lipoprotein NN NN O
( NN NN O
LDL NN NN O
) NN NN O
is NN NN O
a NN NN O
well NN NN O
- NN NN O
established NN NN O
risk NN NN O
factor NN NN O
for NN NN O
atherosclerosis NN NN O
. NN NN O
   
When NN NN O
endothelial NN NN O
cells NN NN O
are NN NN O
incubated NN NN O
with NN NN O
this NN NN O
lipoprotein NN NN O
in NN NN O
pathophysiologic NN NN O
amounts NN NN O
, NN NN O
the NN NN O
cells NN NN O
are NN NN O
activated NN NN O
. NN NN O
   
Among NN NN O
the NN NN O
documented NN NN O
cellular NN NN O
responses NN NN O
to NN NN O
LDL NN NN O
is NN NN O
increased NN NN O
recruitment NN NN O
of NN NN O
monocytes NN NN O
, NN NN O
which NN NN O
are NN NN O
believed NN NN O
to NN NN O
play NN NN O
a NN NN O
major NN NN O
role NN NN O
in NN NN O
promoting NN NN O
intimal NN NN O
plaque NN NN O
formation NN NN O
. NN NN O
   
The NN NN O
findings NN NN O
presented NN NN O
here NN NN O
link NN NN O
an NN NN O
atheogenic NN NN O
lipoprotein NN NN O
, NN NN O
LDL NN NN O
, NN NN O
with NN NN O
the NN NN O
induction NN NN O
of NN NN O
an NN NN O
adhesion NN NN O
molecule NN NN O
important NN NN O
in NN NN O
atherogenesis NN NN O
Human NN NN O
LDL NN NN O
induces NN NN O
the NN NN O
vascular NN NN B-Protein
cell NN NN I-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
transcriptionally NN NN O
with NN NN O
an NN NN O
increase NN NN O
in NN NN O
mRNA NN NN O
levels NN NN O
through NN NN O
activation NN NN O
of NN NN O
the NN NN O
VCAM NN NN O
promoter NN NN O
. NN NN O
   
This NN NN O
effect NN NN O
is NN NN O
blocked NN NN O
by NN NN O
anti NN NN O
- NN NN O
VCAM NN NN O
antibodies NN NN O
. NN NN O
   
After NN NN O
a NN NN O
2 NN NN O
- NN NN O
day NN NN O
incubation NN NN O
in NN NN O
LDL NN NN O
, NN NN O
the NN NN O
binding NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
which NN NN O
is NN NN O
believed NN NN O
to NN NN O
be NN NN O
a NN NN O
key NN NN O
oxidative NN NN O
- NN NN O
stress NN NN O
sensor NN NN O
for NN NN O
VCAM NN NN O
regulation NN NN O
, NN NN O
remains NN NN O
at NN NN O
basal NN NN O
level NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
the NN NN O
binding NN NN O
activities NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
and NN NN O
GATA NN NN O
, NN NN O
on NN NN O
the NN NN O
other NN NN O
hand NN NN O
, NN NN O
are NN NN O
increased NN NN O
by NN NN O
LDL NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
a NN NN O
component NN NN O
of NN NN O
LDL NN NN O
- NN NN O
enhanced NN NN O
endothelial NN NN O
recruitment NN NN O
of NN NN O
monocytes NN NN O
is NN NN O
attributed NN NN O
to NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
, NN NN O
which NN NN O
appears NN NN O
to NN NN O
be NN NN O
mediated NN NN O
through NN NN O
AP NN NN O
- NN NN O
1 NN NN O
and NN NN O
GATA NN NN O
. NN NN O
   
These NN NN O
data NN NN O
identify NN NN O
LDL NN NN O
as NN NN O
a NN NN O
VCAM NN NN O
- NN NN O
inducer NN NN O
possibly NN NN O
distinct NN NN O
from NN NN O
cytokines NN NN O
and NN NN O
endotoxin NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
subunit NN NN O
p65 NN NN B-Protein
mRNA NN NN O
accumulation NN NN O
in NN NN O
lipopolysaccharide NN NN O
- NN NN O
stimulated NN NN O
human NN NN O
monocytic NN NN O
cells NN NN O
treated NN NN O
with NN NN O
sodium NN NN O
salicylate NN NN O
. NN NN O
   
Lipopolysaccharide NN NN O
is NN NN O
one NN NN O
of NN NN O
the NN NN O
most NN NN O
potent NN NN O
trigger NN NN O
substances NN NN O
for NN NN O
monocytes NN NN O
and NN NN O
macrophages NN NN O
causing NN NN O
secretion NN NN O
of NN NN O
inflammatory NN NN O
mediators NN NN O
such NN NN O
as NN NN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
and NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
The NN NN O
nature NN NN O
of NN NN O
the NN NN O
nuclear NN NN O
factors NN NN O
involved NN NN O
in NN NN O
regulation NN NN O
of NN NN O
these NN NN O
cytokine NN NN O
genes NN NN O
is NN NN O
still NN NN O
unknown NN NN O
. NN NN O
   
Nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
; NN NN O
heterodimer NN NN O
of NN NN O
p50 NN NN B-Protein
and NN NN O
p65 NN NN B-Protein
) NN NN O
proteins NN NN O
have NN NN O
been NN NN O
suggested NN NN O
to NN NN O
play NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
gene NN NN O
transcription NN NN O
of NN NN O
inflammatory NN NN O
mediators NN NN O
when NN NN O
monocytes NN NN O
are NN NN O
stimulated NN NN O
with NN NN O
lipopolysaccharide NN NN O
. NN NN O
   
Nonsteroidal NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
drugs NN NN O
such NN NN O
as NN NN O
salicylates NN NN O
have NN NN O
been NN NN O
used NN NN O
to NN NN O
treat NN NN O
symptoms NN NN O
of NN NN O
inflammation NN NN O
, NN NN O
and NN NN O
a NN NN O
new NN NN O
mechanism NN NN O
of NN NN O
drug NN NN O
action NN NN O
was NN NN O
suggested NN NN O
recently NN NN O
. NN NN O
   
Salicylates NN NN O
have NN NN O
been NN NN O
shown NN NN O
to NN NN O
inhibit NN NN O
lipopolysaccharide NN NN O
- NN NN O
induced NN NN O
gene NN NN O
transcription NN NN O
via NN NN O
inhibition NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
by NN NN O
preventing NN NN O
the NN NN O
degradation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
inhibitor NN NN O
"""""""" NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
"""""""" NN NN O
, NN NN O
blocking NN NN O
the NN NN O
translocation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
into NN NN O
the NN NN O
nuclear NN NN O
compartment NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
nature NN NN O
of NN NN O
the NN NN O
subunit NN NN O
involved NN NN O
in NN NN O
this NN NN O
mechanism NN NN O
has NN NN O
not NN NN O
been NN NN O
defined NN NN O
. NN NN O
   
To NN NN O
examine NN NN O
the NN NN O
mechanisms NN NN O
by NN NN O
which NN NN O
salicylates NN NN O
affect NN NN O
cytokine NN NN O
gene NN NN O
transcription NN NN O
, NN NN O
the NN NN O
amount NN NN O
of NN NN O
active NN NN O
and NN NN O
inactive NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
mRNA NN NN O
, NN NN O
in NN NN O
Porphyromonas NN NN O
gingivalis NN NN O
lipopolysaccharide NN NN O
- NN NN O
stimulated NN NN O
human NN NN O
monocytic NN NN O
cells NN NN O
was NN NN O
assessed NN NN O
. NN NN O
   
High NN NN O
doses NN NN O
of NN NN O
sodium NN NN O
salicylate NN NN O
suppressed NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
p65 NN NN B-Protein
mRNA NN NN O
accumulation NN NN O
, NN NN O
resulting NN NN O
in NN NN O
suppression NN NN O
of NN NN O
total NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
p50 NN NN B-Protein
on NN NN O
tissue NN NN O
oligonucleotide NN NN O
had NN NN O
no NN NN O
effects NN NN O
on NN NN O
lipopolysaccharide NN NN O
- NN NN O
induced NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
. NN NN O
   
The NN NN O
data NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
p65 NN NN B-Protein
subunit NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
is NN NN O
inhibited NN NN O
by NN NN O
salicylate NN NN O
treatment NN NN O
and NN NN O
highlight NN NN O
the NN NN O
role NN NN O
of NN NN O
salicylate NN NN O
in NN NN O
the NN NN O
control NN NN O
of NN NN O
gene NN NN O
expression NN NN O
of NN NN O
inflammatory NN NN O
mediators NN NN O
. NN NN O
   
Genes NN NN O
that NN NN O
regulate NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
expression NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Interleukin NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
is NN NN O
an NN NN O
immunomodulatory NN NN O
cytokine NN NN O
which NN NN O
plays NN NN O
a NN NN O
central NN NN O
role NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
allergic NN NN O
and NN NN O
atopic NN NN O
immune NN NN O
responses NN NN O
. NN NN O
   
Significant NN NN O
progress NN NN O
has NN NN O
been NN NN O
made NN NN O
in NN NN O
gaining NN NN O
a NN NN O
detailed NN NN O
understanding NN NN O
of NN NN O
the NN NN O
transcriptional NN NN O
regulation NN NN O
of NN NN O
the NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
gene NN NN O
. NN NN O
   
The NN NN O
recent NN NN O
identification NN NN O
and NN NN O
characterization NN NN O
of NN NN O
several NN NN O
key NN NN O
transcription NN NN O
factors NN NN O
has NN NN O
helped NN NN O
to NN NN O
elucidate NN NN O
the NN NN O
molecular NN NN O
mechanisms NN NN O
of NN NN O
T NN NN O
helper NN NN O
cell NN NN O
cytokine NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
Regulation NN NN O
of NN NN O
the NN NN O
human NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
by NN NN O
the NN NN O
alpha NN NN O
and NN NN O
beta NN NN O
isoforms NN NN O
of NN NN O
the NN NN O
glucocorticoid NN NN O
receptor NN NN O
. NN NN O
   
The NN NN O
immunosuppressive NN NN O
effects NN NN O
of NN NN O
glucocorticoids NN NN O
are NN NN O
largely NN NN O
due NN NN O
to NN NN O
transcriptional NN NN O
inhibition NN NN O
of NN NN O
immunologically NN NN O
relevant NN NN O
genes NN NN O
, NN NN O
such NN NN O
as NN NN O
the NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
gene NN NN O
. NN NN O
   
These NN NN O
effects NN NN O
are NN NN O
mediated NN NN O
by NN NN O
the NN NN O
intracellular NN NN O
glucocorticoid NN NN O
receptor NN NN O
( NN NN O
GR NN NN O
) NN NN O
. NN NN O
   
In NN NN O
humans NN NN O
, NN NN O
alternative NN NN O
splicing NN NN O
of NN NN O
the NN NN O
GR NN NN O
precursor NN NN O
mRNA NN NN O
gives NN NN O
rise NN NN O
to NN NN O
two NN NN O
receptor NN NN O
isoforms NN NN O
, NN NN O
termed NN NN O
GRalpha NN NN B-Protein
and NN NN O
GRbeta NN NN B-Protein
. NN NN O
   
We NN NN O
previously NN NN O
demonstrated NN NN O
that NN NN O
GRbeta NN NN B-Protein
could NN NN O
antagonize NN NN O
GRalpha NN NN B-Protein
- NN NN O
mediated NN NN O
transactivation NN NN O
of NN NN O
a NN NN O
glucocorticoid NN NN O
- NN NN O
responsive NN NN O
element NN NN O
( NN NN O
GRE NN NN O
) NN NN O
- NN NN O
driven NN NN O
reporter NN NN O
gene NN NN O
in NN NN O
COS NN NN O
- NN NN O
7 NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
was NN NN O
designed NN NN O
to NN NN O
analyze NN NN O
the NN NN O
roles NN NN O
of NN NN O
the NN NN O
two NN NN O
GR NN NN O
isoforms NN NN O
on NN NN O
glucocorticoid NN NN B-Protein
- NN NN O
mediated NN NN O
transrepression NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
. NN NN O
   
Using NN NN O
a NN NN O
recently NN NN O
developed NN NN O
transfection NN NN O
technique NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
in NN NN O
primary NN NN O
human NN NN O
lymphocytes NN NN O
, NN NN O
stimulation NN NN O
of NN NN O
a NN NN O
548 NN NN O
bp NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
- NN NN O
luciferase NN NN O
reporter NN NN O
construct NN NN O
by NN NN O
phorbol NN NN O
ester NN NN O
and NN NN O
calcium NN NN O
ionophore NN NN O
is NN NN O
reversed NN NN O
by NN NN O
dexamethasone NN NN O
to NN NN O
a NN NN O
similar NN NN O
extent NN NN O
as NN NN O
in NN NN O
Jurkat NN NN O
T NN NN O
lymphoma NN NN O
cells NN NN O
transfected NN NN O
with NN NN O
a NN NN O
GRalpha NN NN B-Protein
expression NN NN O
vector NN NN O
. NN NN O
   
Transfection NN NN O
of NN NN O
a NN NN O
GRbeta NN NN B-Protein
expression NN NN O
vector NN NN O
alone NN NN O
did NN NN O
not NN NN O
result NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
repression NN NN O
in NN NN O
response NN NN O
to NN NN O
glucocorticoids NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
GRbeta NN NN B-Protein
did NN NN O
not NN NN O
antagonize NN NN O
the NN NN O
repressive NN NN O
effects NN NN O
of NN NN O
GRalpha NN NN B-Protein
on NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
activity NN NN O
. NN NN O
   
Surprisingly NN NN O
, NN NN O
overexpression NN NN O
of NN NN O
GRbeta NN NN B-Protein
in NN NN O
Jurkat NN NN O
cells NN NN O
did NN NN O
not NN NN O
cause NN NN O
significant NN NN O
inhibition NN NN O
of NN NN O
GRalpha NN NN B-Protein
- NN NN O
induced NN NN O
transactivation NN NN O
of NN NN O
a NN NN O
GRE NN NN O
- NN NN O
dependent NN NN O
luciferase NN NN O
reporter NN NN O
gene NN NN O
either NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
the NN NN O
transrepressive NN NN O
effect NN NN O
of NN NN O
glucocorticoids NN NN O
on NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
transcription NN NN O
is NN NN O
exclusively NN NN O
mediated NN NN O
by NN NN O
GRalpha NN NN B-Protein
. NN NN O
   
GRbeta NN NN B-Protein
can NN NN O
neither NN NN O
antagonize NN NN O
GRalpha NN NN B-Protein
- NN NN O
mediated NN NN O
transactivation NN NN O
nor NN NN O
transrepression NN NN O
in NN NN O
Jurkat NN NN O
cells NN NN O
, NN NN O
indicating NN NN O
a NN NN O
cell NN NN O
type NN NN O
- NN NN O
specific NN NN O
pattern NN NN O
of NN NN O
GRbeta NN NN B-Protein
- NN NN O
mediated NN NN O
antiglucocorticoid NN NN O
activity NN NN O
. NN NN O
   
Interleukin NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
production NN NN O
in NN NN O
hemorrhagic NN NN O
shock NN NN O
is NN NN O
accompanied NN NN O
by NN NN O
neutrophil NN NN O
recruitment NN NN O
and NN NN O
lung NN NN O
injury NN NN O
. NN NN O
   
Hemorrhagic NN NN O
shock NN NN O
( NN NN O
HS NN NN O
) NN NN O
initiates NN NN O
an NN NN O
inflammatory NN NN O
cascade NN NN O
that NN NN O
includes NN NN O
the NN NN O
production NN NN O
of NN NN O
cytokines NN NN O
and NN NN O
recruitment NN NN O
of NN NN O
neutrophils NN NN O
( NN NN O
PMN NN NN O
) NN NN O
and NN NN O
may NN NN O
progress NN NN O
to NN NN O
organ NN NN O
failure NN NN O
, NN NN O
inducing NN NN O
acute NN NN O
respiratory NN NN O
distress NN NN O
syndrome NN NN O
( NN NN O
ARDS NN NN O
) NN NN O
. NN NN O
   
To NN NN O
examine NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
) NN NN O
contributes NN NN O
to NN NN O
PMN NN NN O
infiltration NN NN O
and NN NN O
lung NN NN O
damage NN NN O
in NN NN O
HS NN NN O
, NN NN O
we NN NN O
examined NN NN O
the NN NN O
lungs NN NN O
of NN NN O
rats NN NN O
subjected NN NN O
to NN NN O
unresuscitated NN NN O
and NN NN O
resuscitated NN NN O
HS NN NN O
for NN NN O
the NN NN O
production NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
and NN NN O
activation NN NN O
of NN NN O
Stat3 NN NN B-Protein
. NN NN O
   
Using NN NN O
semiquantitative NN NN O
RT NN NN O
- NN NN O
PCR NN NN O
, NN NN O
we NN NN O
found NN NN O
a NN NN O
striking NN NN O
increase NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
mRNA NN NN O
levels NN NN O
only NN NN O
in NN NN O
resuscitated NN NN O
HS NN NN O
, NN NN O
with NN NN O
peak NN NN O
levels NN NN O
observed NN NN O
1 NN NN O
h NN NN O
after NN NN O
initiation NN NN O
of NN NN O
resuscitation NN NN O
. NN NN O
   
Increased NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
protein NN NN O
expression NN NN O
was NN NN O
localized NN NN O
to NN NN O
bronchial NN NN O
and NN NN O
alveolar NN NN O
cells NN NN O
. NN NN O
   
Electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assay NN NN O
of NN NN O
protein NN NN O
extracts NN NN O
from NN NN O
shock NN NN O
lungs NN NN O
exhibited NN NN O
an NN NN O
increase NN NN O
in NN NN O
Stat3 NN NN B-Protein
activation NN NN O
with NN NN O
kinetics NN NN O
similar NN NN O
to NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
mRNA NN NN O
. NN NN O
   
In NN NN O
situ NN NN O
DNA NN NN O
binding NN NN O
assay NN NN O
determined NN NN O
Stat3 NN NN B-Protein
activation NN NN O
predominantly NN NN O
within NN NN O
alveoli NN NN O
. NN NN O
   
Intratracheal NN NN O
instillation NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
alone NN NN O
into NN NN O
normal NN NN O
rats NN NN O
resulted NN NN O
in NN NN O
PMN NN NN O
infiltration NN NN O
into NN NN O
lung NN NN O
interstitium NN NN O
and NN NN O
alveoli NN NN O
, NN NN O
marked NN NN O
elevation NN NN O
of NN NN O
bronchoalveolar NN NN O
lavage NN NN O
cellularity NN NN O
, NN NN O
and NN NN O
increased NN NN O
wet NN NN O
- NN NN O
to NN NN O
- NN NN O
dry NN NN O
ratio NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
indicate NN NN O
that NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
production NN NN O
and NN NN O
Stat3 NN NN B-Protein
activation NN NN O
occur NN NN O
early NN NN O
in NN NN O
HS NN NN O
and NN NN O
may NN NN O
contribute NN NN O
to NN NN O
PMN NN NN O
- NN NN O
mediated NN NN O
lung NN NN O
injury NN NN O
, NN NN O
including NN NN O
ARDS NN NN O
after NN NN O
HS NN NN O
. NN NN O
   
   
